,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"FY 2020 Sustainability ReportHeadline 60/60   FS Albert Thin In the extraordinary year of 2020, we saw a myriad of ways in  which the health of our communities, environment and  businesses are inextricably linked.
","('Human_Rights_And_Community_Relations', 0.5974915623664856)","('Ecological_Impacts', 0.1150062158703804)","('Business_Model_Resilience', 0.06620467454195023)","(['Community Relations'], 0.5974915623664856)","('NON-ESG', 0.1150062158703804)","('NON-ESG', 0.06620467454195023)"
Line 2,"Climate change stoked  record-breaking wildfires and hurricanes, while social justice  issues brought people out of their homes where they had been  living, working and quarantining to make their voices heard.
","('Physical_Impacts_Of_Climate_Change', 0.9470332860946655)","('Business_Model_Resilience', 0.006358789745718241)","('GHG_Emissions', 0.005398426204919815)","(['Climate Change'], 0.9470332860946655)","('NON-ESG', 0.006358789745718241)","('NON-ESG', 0.005398426204919815)"
Line 3,"At BD, we recognize that we have a responsibility to address  these issues head-on, using our scale and influence to drive  continuous improvement across our society’s biggest  challenges.
","('Human_Rights_And_Community_Relations', 0.5772112607955933)","('Business_Model_Resilience', 0.07120239734649658)","('Management_Of_Legal_And_Regulatory_Framework', 0.05494436249136925)","(['Community Relations'], 0.5772112607955933)","('NON-ESG', 0.07120239734649658)","('NON-ESG', 0.05494436249136925)"
Line 4,"Our Purpose— advancing the world of health ™— points to where that influence is most obvious: in responding  to the COVID-19 pandemic with solutions for diagnosis,  treatment and prevention.
","('Critical_Incident_Risk_Management', 0.29391956329345703)","('Physical_Impacts_Of_Climate_Change', 0.28052693605422974)","('Business_Model_Resilience', 0.04866710305213928)","('NON-ESG', 0.29391956329345703)","('NON-ESG', 0.28052693605422974)","('NON-ESG', 0.04866710305213928)"
Line 5,"However, we’re more than a med  tech innovator; we’re also an employer of more than 70,000  people around the world, a member of their communities and  a community of our own.
","('Human_Rights_And_Community_Relations', 0.3006300926208496)","('Employee_Engagement_Inclusion_And_Diversity', 0.2698831856250763)","('Access_And_Affordability', 0.07126402109861374)","('NON-ESG', 0.3006300926208496)","('NON-ESG', 0.2698831856250763)","('NON-ESG', 0.07126402109861374)"
Line 6,"Our manufacturing facilities produce  billions of life-enhancing devices each year, employing  thousands in high-quality jobs, and we seek to do it while  minimizing our environmental impact, supporting the  members of our global team, and standing up for what is right.
","('Product_Design_And_Lifecycle_Management', 0.8549869656562805)","('Supply_Chain_Management', 0.021341105923056602)","('Employee_Health_And_Safety', 0.01421031728386879)","(['Product Stewardship'], 0.8549869656562805)","('NON-ESG', 0.021341105923056602)","('NON-ESG', 0.01421031728386879)"
Line 7,"In 2015, we launched a broader, more integrated approach to  sustainability, with goals in four key issue areas that reflected  our ambitions for 2020.
","('Business_Model_Resilience', 0.3958072066307068)","('Product_Design_And_Lifecycle_Management', 0.12559284269809723)","('Physical_Impacts_Of_Climate_Change', 0.0805090069770813)","('NON-ESG', 0.3958072066307068)","('NON-ESG', 0.12559284269809723)","('NON-ESG', 0.0805090069770813)"
Line 8,"It is an approach that has enabled our  associates to rally around our purpose to develop innovative  diagnostic solutions for COVID-19 in record time, increase the  availability of products used in sample collection and the  treatment of critically ill patients, and work with governments  around the world to enable delivery of COVID-19 vaccinations.
","('Employee_Health_And_Safety', 0.271750807762146)","('Access_And_Affordability', 0.1948307752609253)","('Product_Quality_And_Safety', 0.11422977596521378)","('NON-ESG', 0.271750807762146)","('NON-ESG', 0.1948307752609253)","('NON-ESG', 0.11422977596521378)"
Line 9,"And it’s an approach that has enabled us to celebrate our  differences while challenging each other to continue  advancing our own culture of inclusion while also addressing  systemic inequities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9242644309997559)","('Human_Rights_And_Community_Relations', 0.017572512850165367)","('Business_Model_Resilience', 0.00587742542847991)","(['Human Capital Development'], 0.9242644309997559)","('NON-ESG', 0.017572512850165367)","('NON-ESG', 0.00587742542847991)"
Line 10,"I’m proud of how far we’ve come, and I  know we can make further progress in the years ahead.
","('Business_Model_Resilience', 0.5282168984413147)","('Human_Rights_And_Community_Relations', 0.0777612030506134)","('Employee_Engagement_Inclusion_And_Diversity', 0.04402720555663109)","(['Codes of Business Conduct'], 0.5282168984413147)","('NON-ESG', 0.0777612030506134)","('NON-ESG', 0.04402720555663109)"
Line 11,"The BD of 2020 is a very different company than the BD of  2015, having doubled in size through the successful  integrations of CareFusion and Bard.
","('Systemic_Risk_Management', 0.3593420088291168)","('Access_And_Affordability', 0.13257881999015808)","('Management_Of_Legal_And_Regulatory_Framework', 0.06953513622283936)","('NON-ESG', 0.3593420088291168)","('NON-ESG', 0.13257881999015808)","('NON-ESG', 0.06953513622283936)"
Line 12,"That’s why we’re rolling  out a new set of ambitions and commitments that will drive  improvements across our global organization through 2030.
","('Business_Model_Resilience', 0.37534090876579285)","('Management_Of_Legal_And_Regulatory_Framework', 0.16518931090831757)","('Human_Rights_And_Community_Relations', 0.10320183634757996)","('NON-ESG', 0.37534090876579285)","('NON-ESG', 0.16518931090831757)","('NON-ESG', 0.10320183634757996)"
Line 13,"First, we want to highlight what we’ve accomplished in our  2020 focus areas, because this is the foundation that we will  build upon over the next decade.
","('Business_Model_Resilience', 0.51085364818573)","('Employee_Engagement_Inclusion_And_Diversity', 0.06549324095249176)","('Ecological_Impacts', 0.05578344315290451)","(['Codes of Business Conduct'], 0.51085364818573)","('NON-ESG', 0.06549324095249176)","('NON-ESG', 0.05578344315290451)"
Line 14,"These focus areas support  priority health needs that are aligned with the UN Sustainable  Development Goals (SDGs) and shared value creation— meaning how we address unmet societal needs through  business models and initiatives that also contribute to the  commercial success of BD.
","('Human_Rights_And_Community_Relations', 0.48421552777290344)","('Business_Model_Resilience', 0.1651865392923355)","('Access_And_Affordability', 0.06014544516801834)","('NON-ESG', 0.48421552777290344)","('NON-ESG', 0.1651865392923355)","('NON-ESG', 0.06014544516801834)"
Line 15,"This has been the framework for how we manage, and make  an impact on, the most relevant social and environmental  issues for our company: Innovation We are building a strong portfolio of innovations that address  unmet clinical needs, developing solutions for both acute and  nonacute settings.
","('Human_Rights_And_Community_Relations', 0.5721672773361206)","('Access_And_Affordability', 0.09237790107727051)","('Business_Model_Resilience', 0.06035814434289932)","(['Community Relations'], 0.5721672773361206)","('NON-ESG', 0.09237790107727051)","('NON-ESG', 0.06035814434289932)"
Line 16,"We are also bringing to market products  that meet patients where they are—whether it’s in the  physician’s office, an outpatient surgery center, the hospital, a  local retail pharmacy or in the patient’s own home.
","('Product_Design_And_Lifecycle_Management', 0.37728962302207947)","('Customer_Welfare', 0.33605384826660156)","('Selling_Practices_And_Product_Labeling', 0.06567291915416718)","('NON-ESG', 0.37728962302207947)","('NON-ESG', 0.33605384826660156)","('NON-ESG', 0.06567291915416718)"
Line 17,"In 2020,  we leveraged our world-class manufacturing, research and  development, global scale, and deep capabilities in software  and informatics to respond with agility and urgency to the  COVID-19 pandemic.
","('Systemic_Risk_Management', 0.41030409932136536)","('Business_Model_Resilience', 0.25014322996139526)","('Physical_Impacts_Of_Climate_Change', 0.06468815356492996)","('NON-ESG', 0.41030409932136536)","('NON-ESG', 0.25014322996139526)","('NON-ESG', 0.06468815356492996)"
Line 18,"We launched a SARS-CoV-2 test on our  BD® Veritor Plus System, a rapid point-of-care  antigen test  system with a simple, digital display that returns results in   15 minutes.
","('Competitive_Behavior', 0.23308256268501282)","('Customer_Welfare', 0.16785161197185516)","('Product_Quality_And_Safety', 0.10785451531410217)","('NON-ESG', 0.23308256268501282)","('NON-ESG', 0.16785161197185516)","('NON-ESG', 0.10785451531410217)"
Line 19,"Moreover, we also produced the BD® SARS-CoV-2  Assay for the BD MAX™ Molecular Diagnostic System,   a real-time PCR test intended for the qualitative detection of  nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal and  oropharyngeal swab samples.
","('Customer_Welfare', 0.23776398599147797)","('GHG_Emissions', 0.08546410501003265)","('Employee_Engagement_Inclusion_And_Diversity', 0.07634035497903824)","('NON-ESG', 0.23776398599147797)","('NON-ESG', 0.08546410501003265)","('NON-ESG', 0.07634035497903824)"
Line 20,"Other healthcare challenges did not disappear with the onset  of the pandemic, however; the many innovations we  developed and launched in 2020 serve the entire healthcare  continuum, from discovery to diagnosis, to the process of care,  to the treatment of disease.
","('Employee_Health_And_Safety', 0.18733671307563782)","('Critical_Incident_Risk_Management', 0.1394600123167038)","('Access_And_Affordability', 0.1154334619641304)","('NON-ESG', 0.18733671307563782)","('NON-ESG', 0.1394600123167038)","('NON-ESG', 0.1154334619641304)"
Line 21,"Access Beyond the innovations we developed to expand COVID-19  diagnostic and vaccine delivery options globally, we continued  to partner and collaborate with governments and nonprofit  organizations around the world to address priority health needs.
","('Access_And_Affordability', 0.5068806409835815)","('Customer_Welfare', 0.08277974277734756)","('Product_Quality_And_Safety', 0.07768470048904419)","(['Health Outcome Contribution'], 0.5068806409835815)","('NON-ESG', 0.08277974277734756)","('NON-ESG', 0.07768470048904419)"
Line 22,"This encompasses our work with organizations like Project HOPE  to reduce infusion-related infections among healthcare workers  in China; with the U.S. Agency for International Development  and India’s National TB Elimination Program to improve access  to, and increase capacity for, liquid culture and drug- susceptibility testing; and the many partnerships we’ve forged  with leading health agencies and NGOs to raise awareness of  the threat of antimicrobial resistance and help reduce the risk   of infections globally.
","('Employee_Health_And_Safety', 0.6869998574256897)","('Product_Quality_And_Safety', 0.04049764573574066)","('Access_And_Affordability', 0.029062313959002495)","(['Operational Eco-Efficiency'], 0.6869998574256897)","('NON-ESG', 0.04049764573574066)","('NON-ESG', 0.029062313959002495)"
Line 23,"This encompasses our work with organizations like Project HOPE  to reduce infusion-related infections among healthcare workers  in China; with the U.S. Agency for International Development  and India’s National TB Elimination Program to improve access  to, and increase capacity for, liquid culture and drug- susceptibility testing; and the many partnerships we’ve forged  with leading health agencies and NGOs to raise awareness of  the threat of antimicrobial resistance and help reduce the risk   of infections globally.
","('Business_Model_Resilience', 0.15182790160179138)","('Systemic_Risk_Management', 0.14427563548088074)","('Competitive_Behavior', 0.09437666833400726)","('NON-ESG', 0.15182790160179138)","('NON-ESG', 0.14427563548088074)","('NON-ESG', 0.09437666833400726)"
Line 24,"BD was named to Corporate Responsibility Magazine’s    100 Best Corporate Citizens list for the fifth consecutive year  in 2020, and for the fourth time in the last six years, Fortune   magazine included BD on its annual list of companies that  “Change the World”—this time for fulfilling critical healthcare  needs during the COVID-19 pandemic.To our stakeholders Efficiency As I mentioned, BD is a vastly different organization than it was  in 2015, and the integration of two large organizations has  increased our complexity.
","('Business_Model_Resilience', 0.21445433795452118)","('Systemic_Risk_Management', 0.20382998883724213)","('Supply_Chain_Management', 0.1227143257856369)","('NON-ESG', 0.21445433795452118)","('NON-ESG', 0.20382998883724213)","('NON-ESG', 0.1227143257856369)"
Line 25,"BD was named to Corporate Responsibility Magazine’s    100 Best Corporate Citizens list for the fifth consecutive year  in 2020, and for the fourth time in the last six years, Fortune   magazine included BD on its annual list of companies that  “Change the World”—this time for fulfilling critical healthcare  needs during the COVID-19 pandemic.To our stakeholders Efficiency As I mentioned, BD is a vastly different organization than it was  in 2015, and the integration of two large organizations has  increased our complexity.
","('Competitive_Behavior', 0.5320066809654236)","('Systemic_Risk_Management', 0.05189640820026398)","('Business_Ethics', 0.04140555486083031)","(['Business Ethics'], 0.5320066809654236)","('NON-ESG', 0.05189640820026398)","('NON-ESG', 0.04140555486083031)"
Line 26,"That’s why one of the three pillars of  our BD 2025 strategic vision is “Simplify”—we seek continuous  improvement and efficiency across our global operations to  reduce our environmental impact, reduce cost and waste, and  enhance our customer and associate experiences.
","('Product_Design_And_Lifecycle_Management', 0.7664639353752136)","('Energy_Management', 0.09983640909194946)","('Business_Model_Resilience', 0.011841898784041405)","(['Product Stewardship'], 0.7664639353752136)","('NON-ESG', 0.09983640909194946)","('NON-ESG', 0.011841898784041405)"
Line 27,"In the years ahead, we are prioritizing climate change as a  significant area of focus.
","('Physical_Impacts_Of_Climate_Change', 0.9450045824050903)","('Business_Model_Resilience', 0.01240302249789238)","('GHG_Emissions', 0.006276752334088087)","(['Climate Change'], 0.9450045824050903)","('NON-ESG', 0.01240302249789238)","('NON-ESG', 0.006276752334088087)"
Line 28,"That’s why we have committed to  reduce Scope 1 and 2 GHG emissions 46% by 2030 (from a  2019 baseline) and to be carbon neutral across our direct  operations by 2040.
","('GHG_Emissions', 0.9662778973579407)","('Ecological_Impacts', 0.0037696415092796087)","('Air_Quality', 0.003621595213189721)","(['Climate Change'], 0.9662778973579407)","('NON-ESG', 0.0037696415092796087)","('NON-ESG', 0.003621595213189721)"
Line 29,"This science-based target is aligned with a  1.5 °C global emissions reduction pathway and is just the first  of several commitments we plan to align with our 2030  sustainability vision.
","('GHG_Emissions', 0.7068519592285156)","('Air_Quality', 0.11206065863370895)","('Energy_Management', 0.05421563237905502)","(['Climate Change'], 0.7068519592285156)","('NON-ESG', 0.11206065863370895)","('NON-ESG', 0.05421563237905502)"
Line 30,"Empowerment The BD WAY is a compilation of the values, leadership  commitments and mindsets that guide the behavior and  actions of every BD associate; it has been our North Star  throughout this extraordinary year.
","('Human_Rights_And_Community_Relations', 0.3309648633003235)","('Employee_Engagement_Inclusion_And_Diversity', 0.3220345079898834)","('Access_And_Affordability', 0.04151573404669762)","('NON-ESG', 0.3309648633003235)","('NON-ESG', 0.3220345079898834)","('NON-ESG', 0.04151573404669762)"
Line 31,"It helped empower our  teams to take bold actions, make decisions swiftly and  prioritize the things that matter the most.
","('Business_Model_Resilience', 0.21070261299610138)","('Management_Of_Legal_And_Regulatory_Framework', 0.2106078416109085)","('Human_Rights_And_Community_Relations', 0.10016074776649475)","('NON-ESG', 0.21070261299610138)","('NON-ESG', 0.2106078416109085)","('NON-ESG', 0.10016074776649475)"
Line 32,"Our associate resource groups (ARGs) are leaders in this  regard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3016282320022583)","('Human_Rights_And_Community_Relations', 0.14145533740520477)","('Ecological_Impacts', 0.0788482129573822)","('NON-ESG', 0.3016282320022583)","('NON-ESG', 0.14145533740520477)","('NON-ESG', 0.0788482129573822)"
Line 33,"The newest of these, Parents and Caregivers Together  (PACT), helped parents navigate the back-to-school process  during a global pandemic, while our African Americans at BD  (AABD) ARG organized a series of frank, open and timely  discussions with Black leaders at BD about social justice.
","('Human_Rights_And_Community_Relations', 0.7312148213386536)","('Access_And_Affordability', 0.13468030095100403)","('Employee_Engagement_Inclusion_And_Diversity', 0.020799461752176285)","(['Community Relations'], 0.7312148213386536)","('NON-ESG', 0.13468030095100403)","('NON-ESG', 0.020799461752176285)"
Line 34,"And the Women’s Initiative Network (WIN) was honored by  The Healthcare Businesswomen’s Association with a  prestigious 2020 ACE Award for their efforts to expand and  embed a culture of mentoring to BD sites around the globe.
","('Employee_Engagement_Inclusion_And_Diversity', 0.506257951259613)","('Access_And_Affordability', 0.1720622032880783)","('Human_Rights_And_Community_Relations', 0.05545370280742645)","(['Human Capital Development'], 0.506257951259613)","('NON-ESG', 0.1720622032880783)","('NON-ESG', 0.05545370280742645)"
Line 35,"We work to empower our communities as well.
","('Human_Rights_And_Community_Relations', 0.8929726481437683)","('Employee_Engagement_Inclusion_And_Diversity', 0.016818469390273094)","('Access_And_Affordability', 0.013837074860930443)","(['Community Relations'], 0.8929726481437683)","('NON-ESG', 0.016818469390273094)","('NON-ESG', 0.013837074860930443)"
Line 36,"For example,  BD and the BD Foundation committed $7.8 million in  monetary grants and product donations over the next three  years to support the continued expansion of the BD Helping  Build Healthy Communities ™ Initiative, which issues grants to  community health centers that are implementing innovative,  successful approaches to providing quality healthcare to  underserved populations in the United States.
","('Access_And_Affordability', 0.9459707140922546)","('Human_Rights_And_Community_Relations', 0.005276200361549854)","('Critical_Incident_Risk_Management', 0.005059303715825081)","(['Health Outcome Contribution'], 0.9459707140922546)","('NON-ESG', 0.005276200361549854)","('NON-ESG', 0.005059303715825081)"
Line 37,"Advancing toward a more  sustainable future We’re proud of the advancements we have made toward a   more sustainable future, even in a year in which our greatest  focus was on responding to the greatest healthcare challenge   in generations.
","('Product_Design_And_Lifecycle_Management', 0.39611947536468506)","('Business_Model_Resilience', 0.20619766414165497)","('Access_And_Affordability', 0.04547371715307236)","('NON-ESG', 0.39611947536468506)","('NON-ESG', 0.20619766414165497)","('NON-ESG', 0.04547371715307236)"
Line 38,"Our progress in advancing the world of health ™ is inseparable  from the way we treat our associates, our customers, our  communities and our environment.
","('Human_Rights_And_Community_Relations', 0.8924996852874756)","('Access_And_Affordability', 0.018728012219071388)","('Employee_Health_And_Safety', 0.014352717436850071)","(['Community Relations'], 0.8924996852874756)","('NON-ESG', 0.018728012219071388)","('NON-ESG', 0.014352717436850071)"
Line 39,"There will always be more  work to do, and as we roll out our 2030 sustainability vision,   we will strive to continue to be leaders in building an ethical and  sustainable business that continues to grow while supporting our  communities—and society—for generations to come.
","('Human_Rights_And_Community_Relations', 0.7549445033073425)","('Business_Model_Resilience', 0.06082319840788841)","('Employee_Engagement_Inclusion_And_Diversity', 0.029418081045150757)","(['Community Relations'], 0.7549445033073425)","('NON-ESG', 0.06082319840788841)","('NON-ESG', 0.029418081045150757)"
Line 40,"Sincerely, Tom Polen Chairman, CEO and President This report provides an update on our global environmental,  social and governance (ESG) performance against our 2020  goals, during fiscal year 2020 (October 1, 2019 to September  30, 2020) for Becton, Dickinson and Company (BD) and our  subsidiaries, unless otherwise stated.
","('Human_Rights_And_Community_Relations', 0.3560978174209595)","('Business_Model_Resilience', 0.2336273193359375)","('Management_Of_Legal_And_Regulatory_Framework', 0.08502862602472305)","('NON-ESG', 0.3560978174209595)","('NON-ESG', 0.2336273193359375)","('NON-ESG', 0.08502862602472305)"
Line 41,"We report annually on our sustainability performance, and  published our last report, which highlighted progress made in  fiscal year 2019, in July 2020.
","('Business_Model_Resilience', 0.459113210439682)","('Physical_Impacts_Of_Climate_Change', 0.09719095379114151)","('Systemic_Risk_Management', 0.09539268910884857)","('NON-ESG', 0.459113210439682)","('NON-ESG', 0.09719095379114151)","('NON-ESG', 0.09539268910884857)"
Line 42,"In December 2017, BD acquired C.
","('Systemic_Risk_Management', 0.22847045958042145)","('Business_Model_Resilience', 0.14789548516273499)","('Supply_Chain_Management', 0.08157195150852203)","('NON-ESG', 0.22847045958042145)","('NON-ESG', 0.14789548516273499)","('NON-ESG', 0.08157195150852203)"
Line 43,"R.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16864672303199768)","('Human_Rights_And_Community_Relations', 0.08567094802856445)","('Ecological_Impacts', 0.06714435666799545)","('NON-ESG', 0.16864672303199768)","('NON-ESG', 0.08567094802856445)","('NON-ESG', 0.06714435666799545)"
Line 44,"Bard, Inc.
","('Product_Design_And_Lifecycle_Management', 0.1618390828371048)","('Business_Ethics', 0.08434256166219711)","('Competitive_Behavior', 0.0712665319442749)","('NON-ESG', 0.1618390828371048)","('NON-ESG', 0.08434256166219711)","('NON-ESG', 0.0712665319442749)"
Line 45,"(Bard), a   leading multinational developer, manufacturer and marketer   of innovative, life-enhancing medical technologies in the fields  of vascular, urological, oncological and surgical specialty  products.
","('Product_Design_And_Lifecycle_Management', 0.5186997056007385)","('Customer_Welfare', 0.11835603415966034)","('Product_Quality_And_Safety', 0.05905935540795326)","(['Product Stewardship'], 0.5186997056007385)","('NON-ESG', 0.11835603415966034)","('NON-ESG', 0.05905935540795326)"
Line 46,"Bard data is integrated into all data provided  throughout this report, unless noted.
","('Customer_Privacy', 0.6653510332107544)","('Data_Security', 0.09242874383926392)","('Business_Model_Resilience', 0.024497246369719505)","(['Privacy Protection'], 0.6653510332107544)","('NON-ESG', 0.09242874383926392)","('NON-ESG', 0.024497246369719505)"
Line 47,"This report contains standard disclosures from the Global  Reporting Initiative ™ (GRI) Sustainability Reporting Guidelines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48797231912612915)","('Business_Model_Resilience', 0.08427170664072037)","('Systemic_Risk_Management', 0.05016849935054779)","('NON-ESG', 0.48797231912612915)","('NON-ESG', 0.08427170664072037)","('NON-ESG', 0.05016849935054779)"
Line 48,"While this report is not intended to meet the requirements of  the GRI Sustainability Reporting Guidelines, reference numbers for standard disclosures have been included where full or partial  information has been provided.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5489634275436401)","('Business_Model_Resilience', 0.0694955587387085)","('Product_Quality_And_Safety', 0.03635326400399208)","(['Corporate Governance'], 0.5489634275436401)","('NON-ESG', 0.0694955587387085)","('NON-ESG', 0.03635326400399208)"
Line 49,"This report contains standard disclosures from the Sustainability  Accounting Standards Board (SASB) Medical Equipment and  Supplies Sustainability Accounting Standard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.22350434958934784)","('Systemic_Risk_Management', 0.14497216045856476)","('Product_Quality_And_Safety', 0.11115451157093048)","('NON-ESG', 0.22350434958934784)","('NON-ESG', 0.14497216045856476)","('NON-ESG', 0.11115451157093048)"
Line 50,"While this report is  not intended to meet all the requirements of the SASB standard,  reference numbers for disclosures have been included where full  or partial information has been provided.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4207904040813446)","('Product_Quality_And_Safety', 0.07577693462371826)","('Selling_Practices_And_Product_Labeling', 0.06568791717290878)","('NON-ESG', 0.4207904040813446)","('NON-ESG', 0.07577693462371826)","('NON-ESG', 0.06568791717290878)"
Line 51,"Data in this report has not been externally assured.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3102823793888092)","('Customer_Privacy', 0.19210472702980042)","('Data_Security', 0.06999839097261429)","('NON-ESG', 0.3102823793888092)","('NON-ESG', 0.19210472702980042)","('NON-ESG', 0.06999839097261429)"
Line 52,"Reporting and performance data includes information on our  owned and operated facilities.
","('Energy_Management', 0.12772859632968903)","('Management_Of_Legal_And_Regulatory_Framework', 0.12142851203680038)","('Supply_Chain_Management', 0.11946418136358261)","('NON-ESG', 0.12772859632968903)","('NON-ESG', 0.12142851203680038)","('NON-ESG', 0.11946418136358261)"
Line 53,"We have processes in place to  ensure that reporting on key sustainability performance  indicators is as accurate and robust as possible, and we  continually work to improve them.
","('Business_Model_Resilience', 0.25674042105674744)","('Systemic_Risk_Management', 0.17791107296943665)","('Management_Of_Legal_And_Regulatory_Framework', 0.11644133925437927)","('NON-ESG', 0.25674042105674744)","('NON-ESG', 0.17791107296943665)","('NON-ESG', 0.11644133925437927)"
Line 54,"We seek feedback from stakeholders each year, which informs  our selection of content for sustainability reporting.
","('Business_Model_Resilience', 0.23847784101963043)","('Management_Of_Legal_And_Regulatory_Framework', 0.135081946849823)","('Product_Design_And_Lifecycle_Management', 0.07911022007465363)","('NON-ESG', 0.23847784101963043)","('NON-ESG', 0.135081946849823)","('NON-ESG', 0.07911022007465363)"
Line 55,"For contact  information, see the final page of this report.
","('Customer_Privacy', 0.6141272783279419)","('Business_Model_Resilience', 0.07191815972328186)","('Selling_Practices_And_Product_Labeling', 0.031185753643512726)","(['Privacy Protection'], 0.6141272783279419)","('NON-ESG', 0.07191815972328186)","('NON-ESG', 0.031185753643512726)"
Line 56,"Our previous sustainability report is available on our website .
","('Business_Model_Resilience', 0.16897065937519073)","('Supply_Chain_Management', 0.15555469691753387)","('Product_Design_And_Lifecycle_Management', 0.15208183228969574)","('NON-ESG', 0.16897065937519073)","('NON-ESG', 0.15555469691753387)","('NON-ESG', 0.15208183228969574)"
Line 57,"GRI disclosures: 102-1, 102-10, 102-50, 102-51, 102-52, 102-53, 102-54, 102-56About this report BD is one of the largest global medical technology companies in  the world and is advancing the world of health ™ by improving  medical discovery, diagnostics and the delivery of care.
","('Product_Design_And_Lifecycle_Management', 0.19893869757652283)","('Customer_Welfare', 0.18581965565681458)","('Access_And_Affordability', 0.1252780258655548)","('NON-ESG', 0.19893869757652283)","('NON-ESG', 0.18581965565681458)","('NON-ESG', 0.1252780258655548)"
Line 58,"The company supports the heroes on the front lines of healthcare  by developing innovative technologies, services and solutions that  help advance both clinical therapy for patients and the clinical  process for healthcare providers.
","('Access_And_Affordability', 0.43902143836021423)","('Customer_Welfare', 0.12015250325202942)","('Product_Design_And_Lifecycle_Management', 0.05249108374118805)","('NON-ESG', 0.43902143836021423)","('NON-ESG', 0.12015250325202942)","('NON-ESG', 0.05249108374118805)"
Line 59,"BD and its 70,000 associates  have a passion and commitment to help enhance the safety and  efficiency of clinicians’ care delivery processes.
","('Employee_Health_And_Safety', 0.32743147015571594)","('Product_Quality_And_Safety', 0.2981035113334656)","('Access_And_Affordability', 0.1371966153383255)","('NON-ESG', 0.32743147015571594)","('NON-ESG', 0.2981035113334656)","('NON-ESG', 0.1371966153383255)"
Line 60,"BD enables laboratory scientists to accurately detect disease  and advance researchers’ capabilities to develop the next  generation of diagnostics and therapeutics.
","('Customer_Welfare', 0.15150581300258636)","('Employee_Health_And_Safety', 0.10687559098005295)","('Access_And_Affordability', 0.10309693962335587)","('NON-ESG', 0.15150581300258636)","('NON-ESG', 0.10687559098005295)","('NON-ESG', 0.10309693962335587)"
Line 61,"BD has a presence  in virtually every country and partners with organizations  around the world to address some of the most challenging  global health issues.
","('Employee_Health_And_Safety', 0.4369007647037506)","('Access_And_Affordability', 0.13454896211624146)","('Critical_Incident_Risk_Management', 0.07138382643461227)","('NON-ESG', 0.4369007647037506)","('NON-ESG', 0.13454896211624146)","('NON-ESG', 0.07138382643461227)"
Line 62,"By working closely with customers,   BD can help enhance outcomes, lower costs, increase  efficiencies, improve safety and expand access to healthcare.
","('Product_Quality_And_Safety', 0.5242863297462463)","('Employee_Health_And_Safety', 0.3116113841533661)","('Access_And_Affordability', 0.025577127933502197)","(['Product Quality & Recall Management'], 0.5242863297462463)","('NON-ESG', 0.3116113841533661)","('NON-ESG', 0.025577127933502197)"
Line 63,"For more information on BD, please visit  bd.com .
","('Management_Of_Legal_And_Regulatory_Framework', 0.23154692351818085)","('Access_And_Affordability', 0.1600245237350464)","('Selling_Practices_And_Product_Labeling', 0.05396072939038277)","('NON-ESG', 0.23154692351818085)","('NON-ESG', 0.1600245237350464)","('NON-ESG', 0.05396072939038277)"
Line 64,"GRI disclosures: 102-1, 102-2, 102-3, 102-4, 102-5, 102-6,   102-7, 102-23, 102-24, 102-25, 201-1About BD The BD Medical segment  focuses on providing innovative  solutions to reduce the spread of infection, enhance diabetes  treatment, advance drug delivery, improve surgical procedures  and provide effective and safe medication management.
","('Employee_Health_And_Safety', 0.5640458464622498)","('Product_Quality_And_Safety', 0.0981135219335556)","('Access_And_Affordability', 0.04124968498945236)","(['Operational Eco-Efficiency'], 0.5640458464622498)","('NON-ESG', 0.0981135219335556)","('NON-ESG', 0.04124968498945236)"
Line 65,"Customers served include hospitals and clinics; physicians;  governmental and public health agencies; healthcare workers;  retail pharmacies; pharmaceutical and biotech companies;  and consumers.
","('Customer_Welfare', 0.25109702348709106)","('Access_And_Affordability', 0.16375558078289032)","('Competitive_Behavior', 0.07030601054430008)","('NON-ESG', 0.25109702348709106)","('NON-ESG', 0.16375558078289032)","('NON-ESG', 0.07030601054430008)"
Line 66,"The BD Life Sciences segment  delivers innovative solutions  from discovery to diagnosis, continually advancing science and  clinical outcomes across infectious disease and cancer.
","('Access_And_Affordability', 0.3330203890800476)","('Customer_Welfare', 0.15457266569137573)","('Product_Quality_And_Safety', 0.06643572449684143)","('NON-ESG', 0.3330203890800476)","('NON-ESG', 0.15457266569137573)","('NON-ESG', 0.06643572449684143)"
Line 67,"Offerings include preanalytical solutions for sample  management; immunology research solutions, including flow cytometry and multiomics tools; microbiology and molecular  diagnostics; lab automation and informatics solutions; and  differentiated reagents and assays.
","('Customer_Welfare', 0.25023889541625977)","('GHG_Emissions', 0.0732572078704834)","('Access_And_Affordability', 0.06647907197475433)","('NON-ESG', 0.25023889541625977)","('NON-ESG', 0.0732572078704834)","('NON-ESG', 0.06647907197475433)"
Line 68,"Customers served include  research institutions, industrial and reference laboratories; blood  banks; hospitals and clinics; alternate site healthcare; public  health agencies; academic and government institutions; and  pharmaceutical and biotech companies.
","('Access_And_Affordability', 0.37870675325393677)","('Customer_Welfare', 0.13693803548812866)","('Management_Of_Legal_And_Regulatory_Framework', 0.06029853969812393)","('NON-ESG', 0.37870675325393677)","('NON-ESG', 0.13693803548812866)","('NON-ESG', 0.06029853969812393)"
Line 69,"The BD Interventional segment  focuses on developing  innovative surgical, endovascular, urological and critical care  interventions that not only meet clinical needs but also deliver  value to health systems and improve patients’ lives.
","('Access_And_Affordability', 0.6548548936843872)","('Employee_Health_And_Safety', 0.05993196740746498)","('Critical_Incident_Risk_Management', 0.042570870369672775)","(['Health Outcome Contribution'], 0.6548548936843872)","('NON-ESG', 0.05993196740746498)","('NON-ESG', 0.042570870369672775)"
Line 70,"Customers  served include hospitals and clinics; physicians; ambulatory  surgery centers; nurses; and consumers.
","('Customer_Welfare', 0.23850753903388977)","('Access_And_Affordability', 0.12865591049194336)","('Selling_Practices_And_Product_Labeling', 0.0718412697315216)","('NON-ESG', 0.23850753903388977)","('NON-ESG', 0.12865591049194336)","('NON-ESG', 0.0718412697315216)"
Line 71,"GRI disclosures: 102-2, 102-6About our businesses BD is structured to serve customers by providing unique solutions.
","('Business_Model_Resilience', 0.3979302644729614)","('Customer_Welfare', 0.12826687097549438)","('Product_Design_And_Lifecycle_Management', 0.06504607945680618)","('NON-ESG', 0.3979302644729614)","('NON-ESG', 0.12826687097549438)","('NON-ESG', 0.06504607945680618)"
Line 72,"The data below represents the company structure for FY 2020.Company structure Revenue by geography Revenue by segment BD Medical  $8.
","('Systemic_Risk_Management', 0.3659043610095978)","('Business_Model_Resilience', 0.2557034492492676)","('Supply_Chain_Management', 0.06698720157146454)","('NON-ESG', 0.3659043610095978)","('NON-ESG', 0.2557034492492676)","('NON-ESG', 0.06698720157146454)"
Line 73,"Medication Delivery Systems  $3.
","('Customer_Welfare', 0.19154652953147888)","('Access_And_Affordability', 0.14872142672538757)","('Selling_Practices_And_Product_Labeling', 0.08271800726652145)","('NON-ESG', 0.19154652953147888)","('NON-ESG', 0.14872142672538757)","('NON-ESG', 0.08271800726652145)"
Line 74,"Medication Management Solutions  $2.
","('Customer_Welfare', 0.2714173197746277)","('Product_Design_And_Lifecycle_Management', 0.08975394070148468)","('Selling_Practices_And_Product_Labeling', 0.08585011959075928)","('NON-ESG', 0.2714173197746277)","('NON-ESG', 0.08975394070148468)","('NON-ESG', 0.08585011959075928)"
Line 75,"Diabetes Care  $1.
","('Access_And_Affordability', 0.4058818519115448)","('Customer_Welfare', 0.11200405657291412)","('Employee_Engagement_Inclusion_And_Diversity', 0.06851916015148163)","('NON-ESG', 0.4058818519115448)","('NON-ESG', 0.11200405657291412)","('NON-ESG', 0.06851916015148163)"
Line 76,"Pharmaceutical Systems  $1.BD Life Sciences  $4.
","('Product_Design_And_Lifecycle_Management', 0.18415634334087372)","('Supply_Chain_Management', 0.15843971073627472)","('Customer_Welfare', 0.1406298130750656)","('NON-ESG', 0.18415634334087372)","('NON-ESG', 0.15843971073627472)","('NON-ESG', 0.1406298130750656)"
Line 77,"Integrated Diagnostic Solutions *  $3.
","('Energy_Management', 0.20427396893501282)","('Product_Design_And_Lifecycle_Management', 0.17218348383903503)","('Product_Quality_And_Safety', 0.0896473303437233)","('NON-ESG', 0.20427396893501282)","('NON-ESG', 0.17218348383903503)","('NON-ESG', 0.0896473303437233)"
Line 78,"Biosciences  $1.BD Interventional  $3.
","('Access_And_Affordability', 0.18422234058380127)","('Competitive_Behavior', 0.09038790315389633)","('Systemic_Risk_Management', 0.08576809614896774)","('NON-ESG', 0.18422234058380127)","('NON-ESG', 0.09038790315389633)","('NON-ESG', 0.08576809614896774)"
Line 79,"Peripheral Intervention  $1.
","('Access_And_Affordability', 0.5618371963500977)","('Critical_Incident_Risk_Management', 0.04297435283660889)","('Ecological_Impacts', 0.04033862054347992)","(['Health Outcome Contribution'], 0.5618371963500977)","('NON-ESG', 0.04297435283660889)","('NON-ESG', 0.04033862054347992)"
Line 80,"Surgery  $1.
","('Employee_Health_And_Safety', 0.37021586298942566)","('Access_And_Affordability', 0.09299542754888535)","('Employee_Engagement_Inclusion_And_Diversity', 0.07859139889478683)","('NON-ESG', 0.37021586298942566)","('NON-ESG', 0.09299542754888535)","('NON-ESG', 0.07859139889478683)"
Line 81,"Urology and Critical Care  $1.Values in this exhibit reflect rounded numbers in billions of dollars.
","('Systemic_Risk_Management', 0.17882943153381348)","('Access_And_Affordability', 0.12830646336078644)","('Management_Of_Legal_And_Regulatory_Framework', 0.10917798429727554)","('NON-ESG', 0.17882943153381348)","('NON-ESG', 0.12830646336078644)","('NON-ESG', 0.10917798429727554)"
Line 82,"*Effective October 1, 2019, the Preanalytical Systems and Diagnostic Systems units were joined to create the new Integrated Diagnostic Solutions unit.BD Interventional BD MedicalBD Life Sciences$17.Total BD revenue GRI disclosures: 102-6, 102-(millions of dollars) United States (including Puerto Rico)  $9,716Europe   $3,Greater Asia  (including countries in Greater China,  Japan, South Asia, Southeast Asia,  Korea, Australia and New Zealand) $2,568Other  is comprised of Latin America (including Mexico,  Central America, the Carribean and South America), Canada,  and EMA (including the Commonwealth of Independent  States, the Middle East and Africa)  $1,(billions of dollars) BD has more than 800 critical to healthcare suppliers that  provide key materials, including plastics, glass, metals, textiles,  electronic and mechanical subassemblies, and various paper,  agricultural, biological, chemical and petrochemical products.BD manufactures and sells over 80,000 products worldwide.
","('Access_And_Affordability', 0.1897619217634201)","('Customer_Welfare', 0.10788010060787201)","('Systemic_Risk_Management', 0.0902465283870697)","('NON-ESG', 0.1897619217634201)","('NON-ESG', 0.10788010060787201)","('NON-ESG', 0.0902465283870697)"
Line 83,"*Effective October 1, 2019, the Preanalytical Systems and Diagnostic Systems units were joined to create the new Integrated Diagnostic Solutions unit.BD Interventional BD MedicalBD Life Sciences$17.Total BD revenue GRI disclosures: 102-6, 102-(millions of dollars) United States (including Puerto Rico)  $9,716Europe   $3,Greater Asia  (including countries in Greater China,  Japan, South Asia, Southeast Asia,  Korea, Australia and New Zealand) $2,568Other  is comprised of Latin America (including Mexico,  Central America, the Carribean and South America), Canada,  and EMA (including the Commonwealth of Independent  States, the Middle East and Africa)  $1,(billions of dollars) BD has more than 800 critical to healthcare suppliers that  provide key materials, including plastics, glass, metals, textiles,  electronic and mechanical subassemblies, and various paper,  agricultural, biological, chemical and petrochemical products.BD manufactures and sells over 80,000 products worldwide.
","('Product_Design_And_Lifecycle_Management', 0.9145060777664185)","('Supply_Chain_Management', 0.01992223598062992)","('Customer_Welfare', 0.00747752096503973)","(['Product Stewardship'], 0.9145060777664185)","('NON-ESG', 0.01992223598062992)","('NON-ESG', 0.00747752096503973)"
Line 84,"We market our products in the United States and internationally  through independent distribution channels and directly to   end users with company associates or independent   sales representatives.
","('Product_Design_And_Lifecycle_Management', 0.6751487255096436)","('Selling_Practices_And_Product_Labeling', 0.11828705668449402)","('Customer_Welfare', 0.06270736455917358)","(['Product Stewardship'], 0.6751487255096436)","('NON-ESG', 0.11828705668449402)","('NON-ESG', 0.06270736455917358)"
Line 85,"GRI disclosure: 102-6Value chain profile BD Medical BD Life Sciences BD Interventional Hospitals a a a Ambulatory surgical centers a a a Clinics a a a Laboratories a Physicians' office practices a a a Consumers and retail pharmacies a Government agencies* a a a Academic and government institutions a a a Public health agencies a a a Nonprofit public health agencies a a a Blood banks a Pharmaceutical companies a a Biotechnology companies a a Healthcare workers a a aPrimary customers served *Including prison system, military (DOD), VA.
","('Customer_Welfare', 0.22399839758872986)","('Access_And_Affordability', 0.1814374029636383)","('Competitive_Behavior', 0.09169597178697586)","('NON-ESG', 0.22399839758872986)","('NON-ESG', 0.1814374029636383)","('NON-ESG', 0.09169597178697586)"
Line 86,"GRI disclosure: 102-6Value chain profile BD Medical BD Life Sciences BD Interventional Hospitals a a a Ambulatory surgical centers a a a Clinics a a a Laboratories a Physicians' office practices a a a Consumers and retail pharmacies a Government agencies* a a a Academic and government institutions a a a Public health agencies a a a Nonprofit public health agencies a a a Blood banks a Pharmaceutical companies a a Biotechnology companies a a Healthcare workers a a aPrimary customers served *Including prison system, military (DOD), VA.
","('Management_Of_Legal_And_Regulatory_Framework', 0.20892685651779175)","('Critical_Incident_Risk_Management', 0.11364918202161789)","('Competitive_Behavior', 0.07396987825632095)","('NON-ESG', 0.20892685651779175)","('NON-ESG', 0.11364918202161789)","('NON-ESG', 0.07396987825632095)"
Line 87,"We center our sustainability strategy upon our Purpose— advancing the world of health ™—and integrally tie it to our  business strategy.
","('Business_Model_Resilience', 0.78475022315979)","('Product_Design_And_Lifecycle_Management', 0.039714645594358444)","('Supply_Chain_Management', 0.03222338855266571)","(['Codes of Business Conduct'], 0.78475022315979)","('NON-ESG', 0.039714645594358444)","('NON-ESG', 0.03222338855266571)"
Line 88,"Our sustainability strategy addresses a wide range of challenges in our industry while helping to make a difference on relevant  issues that affect society and the planet.
","('Business_Model_Resilience', 0.44323626160621643)","('Human_Rights_And_Community_Relations', 0.09046255797147751)","('Physical_Impacts_Of_Climate_Change', 0.08736000210046768)","('NON-ESG', 0.44323626160621643)","('NON-ESG', 0.09046255797147751)","('NON-ESG', 0.08736000210046768)"
Line 89,"We also actively evaluate how we can mobilize and contribute to the achievement of  the UN Sustainable Development Goals (SDGs) through our product and service offerings as well as collaborative efforts across  various sectors—most prominently around SDG 3, for good health and well-being.
","('Access_And_Affordability', 0.32891616225242615)","('Employee_Health_And_Safety', 0.3214482367038727)","('Human_Rights_And_Community_Relations', 0.05214812606573105)","('NON-ESG', 0.32891616225242615)","('NON-ESG', 0.3214482367038727)","('NON-ESG', 0.05214812606573105)"
Line 90,"In this section we outline our overall sustainability strategy and the mechanisms that help us support this work.
","('Business_Model_Resilience', 0.5056475400924683)","('Supply_Chain_Management', 0.055733997374773026)","('Product_Design_And_Lifecycle_Management', 0.05117872729897499)","(['Codes of Business Conduct'], 0.5056475400924683)","('NON-ESG', 0.055733997374773026)","('NON-ESG', 0.05117872729897499)"
Line 91,"We first detail the  governance of our sustainability program and stakeholder engagement.
","('Human_Rights_And_Community_Relations', 0.3549087643623352)","('Business_Model_Resilience', 0.1673736870288849)","('Management_Of_Legal_And_Regulatory_Framework', 0.11142099648714066)","('NON-ESG', 0.3549087643623352)","('NON-ESG', 0.1673736870288849)","('NON-ESG', 0.11142099648714066)"
Line 92,"This is followed by information about significant ESG  issues that formed the basis of the 2020 sustainability strategy and goals; performance against the goals are covered in the  following sections of this report.
","('Business_Model_Resilience', 0.7056451439857483)","('Human_Rights_And_Community_Relations', 0.036846090108156204)","('Systemic_Risk_Management', 0.03587548807263374)","(['Codes of Business Conduct'], 0.7056451439857483)","('NON-ESG', 0.036846090108156204)","('NON-ESG', 0.03587548807263374)"
Line 93,"This section concludes with a high-level outline of the development of our 2030+ sustainability  strategy and commitments.
","('Business_Model_Resilience', 0.5480344891548157)","('Human_Rights_And_Community_Relations', 0.07460661977529526)","('Physical_Impacts_Of_Climate_Change', 0.05193895474076271)","(['Codes of Business Conduct'], 0.5480344891548157)","('NON-ESG', 0.07460661977529526)","('NON-ESG', 0.05193895474076271)"
Line 94,"This will be the framework we will measure our performance against, and will report on in future  issues of our sustainability report.Sustainability strategy Solar panels installed at the BD European Headquarters in Eysins, Switzerland.
","('Energy_Management', 0.4713500738143921)","('Product_Design_And_Lifecycle_Management', 0.12578807771205902)","('Management_Of_Legal_And_Regulatory_Framework', 0.09768938273191452)","('NON-ESG', 0.4713500738143921)","('NON-ESG', 0.12578807771205902)","('NON-ESG', 0.09768938273191452)"
Line 95,"Sustainability governance The Environment, Health, Safety and Sustainability (EHS&S)  team manages our ESG reporting, as well as stakeholder  engagement activities relevant to our sustainability strategy.
","('Business_Model_Resilience', 0.2539116442203522)","('Human_Rights_And_Community_Relations', 0.18614213168621063)","('Ecological_Impacts', 0.13332116603851318)","('NON-ESG', 0.2539116442203522)","('NON-ESG', 0.18614213168621063)","('NON-ESG', 0.13332116603851318)"
Line 96,"This group is led by the VP EHS&S, who reports directly to the  executive vice president of Integrated Supply Chain.
","('Supply_Chain_Management', 0.9399055242538452)","('Product_Design_And_Lifecycle_Management', 0.007758736610412598)","('Labor_Practices', 0.00439706165343523)","(['Supply Chain Management'], 0.9399055242538452)","('NON-ESG', 0.007758736610412598)","('NON-ESG', 0.00439706165343523)"
Line 97,"This position reports to the CEO and is part of the company’s  Executive Leadership Team.
","('Director_Removal', 0.5997492074966431)","('Business_Model_Resilience', 0.06801282614469528)","('Employee_Engagement_Inclusion_And_Diversity', 0.06439246237277985)","(['Anti-Crime Policy & Measures'], 0.5997492074966431)","('NON-ESG', 0.06801282614469528)","('NON-ESG', 0.06439246237277985)"
Line 98,"The CEO is also Chairman  of the Board.
","('Director_Removal', 0.763886570930481)","('Management_Of_Legal_And_Regulatory_Framework', 0.022275350987911224)","('Employee_Engagement_Inclusion_And_Diversity', 0.019814152270555496)","(['Anti-Crime Policy & Measures'], 0.763886570930481)","('NON-ESG', 0.022275350987911224)","('NON-ESG', 0.019814152270555496)"
Line 99,"Our sustainability strategy is governed by the Executive  Leadership Team, which maintains a dialog with our  stakeholders, businesses and associates about issues relevant   to each group and monitors performance related to our  sustainability strategy.Our Board of Directors—as a board or through its  committees—also oversees several sustainability-related  issues, including: In addition, the Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen.
","('Business_Model_Resilience', 0.33056381344795227)","('Director_Removal', 0.2401944398880005)","('Human_Rights_And_Community_Relations', 0.05120273679494858)","('NON-ESG', 0.33056381344795227)","('NON-ESG', 0.2401944398880005)","('NON-ESG', 0.05120273679494858)"
Line 100,"Our sustainability strategy is governed by the Executive  Leadership Team, which maintains a dialog with our  stakeholders, businesses and associates about issues relevant   to each group and monitors performance related to our  sustainability strategy.Our Board of Directors—as a board or through its  committees—also oversees several sustainability-related  issues, including: In addition, the Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen.
","('Human_Rights_And_Community_Relations', 0.317954957485199)","('Business_Model_Resilience', 0.09772483259439468)","('Product_Design_And_Lifecycle_Management', 0.07248828560113907)","('NON-ESG', 0.317954957485199)","('NON-ESG', 0.09772483259439468)","('NON-ESG', 0.07248828560113907)"
Line 101,"This includes ESG issues and initiatives relating to sustainability,  access to healthcare and other social topics.
","('Human_Rights_And_Community_Relations', 0.7337736487388611)","('Access_And_Affordability', 0.06380235403776169)","('Business_Model_Resilience', 0.03029487654566765)","(['Community Relations'], 0.7337736487388611)","('NON-ESG', 0.06380235403776169)","('NON-ESG', 0.03029487654566765)"
Line 102,"The VP EHS&S  provides an update on activities related to our sustainability  strategy and performance on an annual basis.As I reflect on the work we have done over the past five years  toward our 2020 sustainability goals, I’m struck by the amount of  transformation that has taken place at BD, within healthcare and  throughout society in that short period of time.
","('Business_Model_Resilience', 0.5421810150146484)","('Human_Rights_And_Community_Relations', 0.06931112706661224)","('Physical_Impacts_Of_Climate_Change', 0.05292190983891487)","(['Codes of Business Conduct'], 0.5421810150146484)","('NON-ESG', 0.06931112706661224)","('NON-ESG', 0.05292190983891487)"
Line 103,"We successfully  leveraged the change and transformation that transpired to  advance work across each of the pillars of our strategy.
","('Business_Model_Resilience', 0.7448421716690063)","('Systemic_Risk_Management', 0.07038815319538116)","('Physical_Impacts_Of_Climate_Change', 0.03236285224556923)","(['Codes of Business Conduct'], 0.7448421716690063)","('NON-ESG', 0.07038815319538116)","('NON-ESG', 0.03236285224556923)"
Line 104,"The transformational acquisitions that BD made during this  period, combined with advancements in technology and  digitalization, enabled significant progress across our work on  Innovation  and Access .
","('Business_Model_Resilience', 0.4916588068008423)","('Systemic_Risk_Management', 0.1385081559419632)","('Competitive_Behavior', 0.0804532840847969)","('NON-ESG', 0.4916588068008423)","('NON-ESG', 0.1385081559419632)","('NON-ESG', 0.0804532840847969)"
Line 105,"During that same time, we strengthened  our capabilities and focus on addressing emerging social and  environmental issues, enabling many accomplishments across   our work on Efficiency  and Empowerment .
","('Human_Rights_And_Community_Relations', 0.9501240253448486)","('Management_Of_Legal_And_Regulatory_Framework', 0.00454678712412715)","('Ecological_Impacts', 0.003867925377562642)","(['Community Relations'], 0.9501240253448486)","('NON-ESG', 0.00454678712412715)","('NON-ESG', 0.003867925377562642)"
Line 106,"Most importantly,   we have many lessons learned that will be applied to our work  going forward.
","('Business_Model_Resilience', 0.279153972864151)","('Human_Rights_And_Community_Relations', 0.15455110371112823)","('Product_Design_And_Lifecycle_Management', 0.0775628313422203)","('NON-ESG', 0.279153972864151)","('NON-ESG', 0.15455110371112823)","('NON-ESG', 0.0775628313422203)"
Line 107,"Our 2020 goals created a platform to engage with our  stakeholders on many different issues that affect society at large.
","('Human_Rights_And_Community_Relations', 0.7613150477409363)","('Management_Of_Legal_And_Regulatory_Framework', 0.06857213377952576)","('Business_Model_Resilience', 0.020255502313375473)","(['Community Relations'], 0.7613150477409363)","('NON-ESG', 0.06857213377952576)","('NON-ESG', 0.020255502313375473)"
Line 108,"Those perspectives, and the important dialog we have created,  has informed the next phase of our work and will remain an  important part of how we shape our strategies going forward.
","('Business_Model_Resilience', 0.49655115604400635)","('Director_Removal', 0.05315053462982178)","('Human_Rights_And_Community_Relations', 0.05299210548400879)","('NON-ESG', 0.49655115604400635)","('NON-ESG', 0.05315053462982178)","('NON-ESG', 0.05299210548400879)"
Line 109,"As we embark on the next phase of work to advance the many  topics contained within our sustainability strategy, we remain  steadfast in our alignment to the BD Purpose— advancing the  world of health ™.
","('Business_Model_Resilience', 0.3198098838329315)","('Systemic_Risk_Management', 0.09178340435028076)","('Supply_Chain_Management', 0.07820098847150803)","('NON-ESG', 0.3198098838329315)","('NON-ESG', 0.09178340435028076)","('NON-ESG', 0.07820098847150803)"
Line 110,"Our 2030+ sustainability goals seek to address and further  advance how we manage risks and opportunities around our  most significant ESG issues.
","('Systemic_Risk_Management', 0.6266881823539734)","('Business_Model_Resilience', 0.2338053435087204)","('Physical_Impacts_Of_Climate_Change', 0.028157269582152367)","(['Risk & Crisis Management'], 0.6266881823539734)","('NON-ESG', 0.2338053435087204)","('NON-ESG', 0.028157269582152367)"
Line 111,"Our 2030+ sustainability strategy   is rooted in an understanding of the important role we play in  addressing social and environmental issues and setting an  example for responsibility in a rapidly changing world.
","('Human_Rights_And_Community_Relations', 0.9302486181259155)","('Business_Model_Resilience', 0.007191626355051994)","('Ecological_Impacts', 0.006661784369498491)","(['Community Relations'], 0.9302486181259155)","('NON-ESG', 0.007191626355051994)","('NON-ESG', 0.006661784369498491)"
Line 112,"With our 2030+ goals as the platform, we will seek to address climate  change through reducing emissions across our supply chain and  integrating climate impacts into various parts of our business  strategy and decisions, while at the same time addressing the  impact of our products and resiliency of our supply chain.
","('Supply_Chain_Management', 0.379120409488678)","('Physical_Impacts_Of_Climate_Change', 0.35601601004600525)","('Business_Model_Resilience', 0.06068062409758568)","('NON-ESG', 0.379120409488678)","('NON-ESG', 0.35601601004600525)","('NON-ESG', 0.06068062409758568)"
Line 113,"We will  also seek to strengthen the health of our workforce and  communities across the globe through the lens of well-being and  equality for all.
","('Human_Rights_And_Community_Relations', 0.8685664534568787)","('Employee_Engagement_Inclusion_And_Diversity', 0.03588277846574783)","('Access_And_Affordability', 0.02353588491678238)","(['Community Relations'], 0.8685664534568787)","('NON-ESG', 0.03588277846574783)","('NON-ESG', 0.02353588491678238)"
Line 114,"Lastly, we understand the importance of  communicating to all our stakeholders on these important issues  and will continue to evolve our ESG reporting.
","('Business_Model_Resilience', 0.38150352239608765)","('Human_Rights_And_Community_Relations', 0.16941450536251068)","('Systemic_Risk_Management', 0.09084229916334152)","('NON-ESG', 0.38150352239608765)","('NON-ESG', 0.16941450536251068)","('NON-ESG', 0.09084229916334152)"
Line 115,"We know that the work that lies ahead to pursue these goals is  challenging, yet I continue to be inspired each day by our more  than 70,000 associates globally who bring their innovative  thinking and passion for our Purpose to their work.
","('Business_Model_Resilience', 0.3034819960594177)","('Employee_Engagement_Inclusion_And_Diversity', 0.10177502036094666)","('Product_Design_And_Lifecycle_Management', 0.09641068428754807)","('NON-ESG', 0.3034819960594177)","('NON-ESG', 0.10177502036094666)","('NON-ESG', 0.09641068428754807)"
Line 116,"I know that  through the power and will of our associates, along with our  supply chain partners, customers and many other stakeholders,  we will make a meaningful and lasting impact through our 2030+  sustainability goals and strengthen the resilience of our business  in parallel.
","('Supply_Chain_Management', 0.8424714803695679)","('Product_Design_And_Lifecycle_Management', 0.04048356041312218)","('Business_Model_Resilience', 0.03959242254495621)","(['Supply Chain Management'], 0.8424714803695679)","('NON-ESG', 0.04048356041312218)","('NON-ESG', 0.03959242254495621)"
Line 117,"Thank you for your engagement and partnership in this  important work.To our stakeholders Ellen Kondracki VP, Sustainability and Environment,  Health and Safety GRI disclosures: 102-18, 102-26, 102-31• Community relations • Political engagement • Human capital  management practices • Environment,  health and safety• Ethics and  enterprise compliance • Innovation • Cybersecurity • Product quality and safety • Customers:  Our customers and patients are at the center of  everything that we do.
","('Product_Quality_And_Safety', 0.8572909235954285)","('Product_Design_And_Lifecycle_Management', 0.03143536299467087)","('Employee_Health_And_Safety', 0.017551615834236145)","(['Product Quality & Recall Management'], 0.8572909235954285)","('NON-ESG', 0.03143536299467087)","('NON-ESG', 0.017551615834236145)"
Line 118,"In a fast-changing environment, it is  vital for BD to understand what our customers value most to  develop solutions that will best meet their needs.
","('Business_Model_Resilience', 0.3277241289615631)","('Product_Design_And_Lifecycle_Management', 0.26403024792671204)","('Supply_Chain_Management', 0.1607278287410736)","('NON-ESG', 0.3277241289615631)","('NON-ESG', 0.26403024792671204)","('NON-ESG', 0.1607278287410736)"
Line 119,"We create a  deep understanding of the healthcare market and its  customers through a fact-based approach across regions and  strategically engage with customers to develop and deploy  our products and solutions.
","('Product_Design_And_Lifecycle_Management', 0.9466136693954468)","('Customer_Welfare', 0.00837845727801323)","('Business_Model_Resilience', 0.005733420141041279)","(['Product Stewardship'], 0.9466136693954468)","('NON-ESG', 0.00837845727801323)","('NON-ESG', 0.005733420141041279)"
Line 120,"• Shareholders:  Our focus on shareholders is to ensure   that the combination of our business and geographic  diversity—our balanced capital allocation and our drive   for efficiency—provides a long-term pathway toward  sustainable profit growth that returns capital to shareholders.
","('Business_Model_Resilience', 0.3207944929599762)","('Employee_Engagement_Inclusion_And_Diversity', 0.2595127522945404)","('Competitive_Behavior', 0.11955820769071579)","('NON-ESG', 0.3207944929599762)","('NON-ESG', 0.2595127522945404)","('NON-ESG', 0.11955820769071579)"
Line 121,"We engage with shareholders in a variety of forms, including  quarterly calls and in-person meetings, on specific topics that  range from our long-term growth and innovation strategy to  how we integrate ESG factors into our business.
","('Business_Model_Resilience', 0.8707330226898193)","('Systemic_Risk_Management', 0.02049919031560421)","('Supply_Chain_Management', 0.010667644441127777)","(['Codes of Business Conduct'], 0.8707330226898193)","('NON-ESG', 0.02049919031560421)","('NON-ESG', 0.010667644441127777)"
Line 122,"• BD associates:  BD has grown to over 70,000 associates.
","('Business_Model_Resilience', 0.17284932732582092)","('Business_Ethics', 0.11130601167678833)","('Systemic_Risk_Management', 0.10994092375040054)","('NON-ESG', 0.17284932732582092)","('NON-ESG', 0.11130601167678833)","('NON-ESG', 0.10994092375040054)"
Line 123,"The capabilities and dedication of these associates are  critical to achieving our strategy.
","('Business_Model_Resilience', 0.5308467149734497)","('Human_Rights_And_Community_Relations', 0.07995057851076126)","('Product_Design_And_Lifecycle_Management', 0.03937861695885658)","(['Codes of Business Conduct'], 0.5308467149734497)","('NON-ESG', 0.07995057851076126)","('NON-ESG', 0.03937861695885658)"
Line 124,"We engage and develop   our associates through a variety of mechanisms, including  internal social networks, town hall meetings, leadership   and mentoring programs, and associate resource groups.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5212344527244568)","('Human_Rights_And_Community_Relations', 0.1011313870549202)","('Access_And_Affordability', 0.057908158749341965)","(['Human Capital Development'], 0.5212344527244568)","('NON-ESG', 0.1011313870549202)","('NON-ESG', 0.057908158749341965)"
Line 125,"• Business partners:  Our suppliers, distributors and other  partners in the supply chain help us effectively serve our  customers.
","('Supply_Chain_Management', 0.9333253502845764)","('Product_Design_And_Lifecycle_Management', 0.008307474665343761)","('Labor_Practices', 0.006245133467018604)","(['Supply Chain Management'], 0.9333253502845764)","('NON-ESG', 0.008307474665343761)","('NON-ESG', 0.006245133467018604)"
Line 126,"We engage with them through a variety of  strategic programs, including through relationship managers  within our Integrated Supply Chain function.
","('Supply_Chain_Management', 0.9529046416282654)","('Product_Design_And_Lifecycle_Management', 0.0038739510346204042)","('Labor_Practices', 0.0035494256298989058)","(['Supply Chain Management'], 0.9529046416282654)","('NON-ESG', 0.0038739510346204042)","('NON-ESG', 0.0035494256298989058)"
Line 127,"• Communities:  At the country level, our general managers  engage with a variety of community stakeholders to  understand the health system’s priorities and align our  capabilities to them.
","('Human_Rights_And_Community_Relations', 0.939380943775177)","('Business_Model_Resilience', 0.005617077462375164)","('Access_And_Affordability', 0.00554502010345459)","(['Community Relations'], 0.939380943775177)","('NON-ESG', 0.005617077462375164)","('NON-ESG', 0.00554502010345459)"
Line 128,"In communities where we have  manufacturing operations, we engage with local government  officials and civic organizations, and often develop  relationships with teaching institutions to help develop the  skill sets we require in our operations.
","('Human_Rights_And_Community_Relations', 0.5953226089477539)","('Management_Of_Legal_And_Regulatory_Framework', 0.18981599807739258)","('Access_And_Affordability', 0.048146553337574005)","(['Community Relations'], 0.5953226089477539)","('NON-ESG', 0.18981599807739258)","('NON-ESG', 0.048146553337574005)"
Line 129,"In addition, our  associates engage in community-organized volunteer efforts  to support local programs.• Governments, policymakers and regulatory bodies:    We engage governments and policymakers through various  ways, primarily through our public affairs teams.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9586355090141296)","('Human_Rights_And_Community_Relations', 0.005956942681223154)","('Access_And_Affordability', 0.003521197009831667)","(['Corporate Governance'], 0.9586355090141296)","('NON-ESG', 0.005956942681223154)","('NON-ESG', 0.003521197009831667)"
Line 130,"We engage  at the agency and legislative levels in many countries to  enhance our understanding of the governments’ priorities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.95384281873703)","('Human_Rights_And_Community_Relations', 0.004977385047823191)","('Director_Removal', 0.004575237166136503)","(['Corporate Governance'], 0.95384281873703)","('NON-ESG', 0.004977385047823191)","('NON-ESG', 0.004575237166136503)"
Line 131,"From these engagements, we seek ways to deploy our  capabilities, products, and solutions to help support and  achieve national health objectives.
","('Product_Design_And_Lifecycle_Management', 0.9347160458564758)","('Product_Quality_And_Safety', 0.011306962929666042)","('Customer_Welfare', 0.008479827083647251)","(['Product Stewardship'], 0.9347160458564758)","('NON-ESG', 0.011306962929666042)","('NON-ESG', 0.008479827083647251)"
Line 132,"BD engages with our  global regulatory bodies directly and through participation in  public private partnerships and collaborative communities  supporting product safety, cybersecurity, and technical  standard initiatives to support the advancement of  innovation and how innovation is regulated to bring  technologies to market faster while prioritizing  product safety.
","('Product_Quality_And_Safety', 0.9077381491661072)","('Selling_Practices_And_Product_Labeling', 0.01165184285491705)","('Employee_Health_And_Safety', 0.009418167173862457)","(['Product Quality & Recall Management'], 0.9077381491661072)","('NON-ESG', 0.01165184285491705)","('NON-ESG', 0.009418167173862457)"
Line 133,"• International agencies and Nongovernmental  organizations (NGOs):  We engage with UN agencies such  as the World Health Organization (WHO), the United Nations  Interagency Coordination Group (UN IACG) on Antimicrobial  Resistance, UNICEF, the Joint United Nations Programme on  HIV/AIDS (UNAIDS) and other international and  intergovernmental organizations through collaborations that  aim to address pressing global health needs.
","('Access_And_Affordability', 0.5324827432632446)","('Critical_Incident_Risk_Management', 0.05858564376831055)","('Employee_Health_And_Safety', 0.051743071526288986)","(['Health Outcome Contribution'], 0.5324827432632446)","('NON-ESG', 0.05858564376831055)","('NON-ESG', 0.051743071526288986)"
Line 134,"We routinely  pursue these types of collaborations as an integral part of our  business model in countries throughout the world.
","('Business_Model_Resilience', 0.6163151860237122)","('Systemic_Risk_Management', 0.04991624504327774)","('Product_Design_And_Lifecycle_Management', 0.03753264993429184)","(['Codes of Business Conduct'], 0.6163151860237122)","('NON-ESG', 0.04991624504327774)","('NON-ESG', 0.03753264993429184)"
Line 135,"In many  cases, NGOs and relief organizations are strategic partners in  helping us meet unmet health needs.
","('Critical_Incident_Risk_Management', 0.566895604133606)","('Employee_Health_And_Safety', 0.2267889380455017)","('Access_And_Affordability', 0.06221639737486839)","(['Risk & Crisis Management'], 0.566895604133606)","('NON-ESG', 0.2267889380455017)","('NON-ESG', 0.06221639737486839)"
Line 136,"We engage with them  through in-person meetings, collaborative initiatives and site  visits to strengthen how we serve those in need.Stakeholder engagement GRI disclosure: 102-40Our stakeholdersBecause of our global reach and the nature of our work, we serve and rely on a wide range of stakeholders.
","('Human_Rights_And_Community_Relations', 0.6841916441917419)","('Business_Model_Resilience', 0.04022527113556862)","('Employee_Engagement_Inclusion_And_Diversity', 0.03672346472740173)","(['Community Relations'], 0.6841916441917419)","('NON-ESG', 0.04022527113556862)","('NON-ESG', 0.03672346472740173)"
Line 137,"Engaging with them  through a variety of channels across many parts of our organization is critical to how we apply the principle of shared value and  therefore essential to our business success.
","('Business_Model_Resilience', 0.6491931080818176)","('Human_Rights_And_Community_Relations', 0.04106450080871582)","('Product_Design_And_Lifecycle_Management', 0.038364578038454056)","(['Codes of Business Conduct'], 0.6491931080818176)","('NON-ESG', 0.04106450080871582)","('NON-ESG', 0.038364578038454056)"
Line 138,"Often, we work collaboratively with stakeholders who share our objectives and, in the  process, we gain a deep understanding of their work.
","('Human_Rights_And_Community_Relations', 0.7496626377105713)","('Business_Model_Resilience', 0.03586553782224655)","('Management_Of_Legal_And_Regulatory_Framework', 0.019896728917956352)","(['Community Relations'], 0.7496626377105713)","('NON-ESG', 0.03586553782224655)","('NON-ESG', 0.019896728917956352)"
Line 139,"We listen to our stakeholders’ views and suggestions, and use that feedback to  improve our products, services and business practices.
","('Product_Design_And_Lifecycle_Management', 0.7161786556243896)","('Business_Model_Resilience', 0.10604595392942429)","('Supply_Chain_Management', 0.020336773246526718)","(['Product Stewardship'], 0.7161786556243896)","('NON-ESG', 0.10604595392942429)","('NON-ESG', 0.020336773246526718)"
Line 140,"Access Innovation Efficiency Empowerment Governance We utilized a defined process to evaluate and prioritize the ESG  factors most relevant to our business and stakeholders.
","('Management_Of_Legal_And_Regulatory_Framework', 0.28214558959007263)","('Business_Model_Resilience', 0.27589836716651917)","('Systemic_Risk_Management', 0.08424513787031174)","('NON-ESG', 0.28214558959007263)","('NON-ESG', 0.27589836716651917)","('NON-ESG', 0.08424513787031174)"
Line 141,"By using  this process, we defined four areas of focus that provided the  framework for our 2020 sustainability goals: • Innovation—How we contribute to more sustainable  healthcare systems by improving outcomes, reducing system  costs and protecting patients and healthcare workers• Access—How we support health system leapfrogging in  emerging and developing economies, and reach vulnerable  populations globally • Efficiency—How we work across our value chain to minimize  environmental impact and create positive social impact • Empowerment—How we advance our purpose-driven culture  through workforce and community engagementsSignificant ESG issues2020 sustainability strategy For the development of our 2020 strategy, our ESG issues were: GRI disclosure: 102-47• Inclusion and diversity • Associate health   and safety• Attraction and  retention of talent • Transparent   and ethical   business practices• Data security • Informatics and innovationAccess • Planetary health  • Sustainable  supply chain • Product design and life  cycle management• Energy and  GHG management • Waste • WaterInnovation Efficiency• Collaborations and  partnerships • Value-based outcomes• Patient-centric care • Healthcare access   and affordability Empowerment Access Innovation Efficiency Empowerment Governance We launched our 2020 sustainability goals in July 2015,  reflecting a broader and more integrated agenda than previous  years.
","('Access_And_Affordability', 0.8347303867340088)","('Employee_Health_And_Safety', 0.029600661247968674)","('Human_Rights_And_Community_Relations', 0.020162617787718773)","(['Health Outcome Contribution'], 0.8347303867340088)","('NON-ESG', 0.029600661247968674)","('NON-ESG', 0.020162617787718773)"
Line 142,"By using  this process, we defined four areas of focus that provided the  framework for our 2020 sustainability goals: • Innovation—How we contribute to more sustainable  healthcare systems by improving outcomes, reducing system  costs and protecting patients and healthcare workers• Access—How we support health system leapfrogging in  emerging and developing economies, and reach vulnerable  populations globally • Efficiency—How we work across our value chain to minimize  environmental impact and create positive social impact • Empowerment—How we advance our purpose-driven culture  through workforce and community engagementsSignificant ESG issues2020 sustainability strategy For the development of our 2020 strategy, our ESG issues were: GRI disclosure: 102-47• Inclusion and diversity • Associate health   and safety• Attraction and  retention of talent • Transparent   and ethical   business practices• Data security • Informatics and innovationAccess • Planetary health  • Sustainable  supply chain • Product design and life  cycle management• Energy and  GHG management • Waste • WaterInnovation Efficiency• Collaborations and  partnerships • Value-based outcomes• Patient-centric care • Healthcare access   and affordability Empowerment Access Innovation Efficiency Empowerment Governance We launched our 2020 sustainability goals in July 2015,  reflecting a broader and more integrated agenda than previous  years.
","('Employee_Engagement_Inclusion_And_Diversity', 0.957819402217865)","('Human_Rights_And_Community_Relations', 0.004611098673194647)","('Employee_Health_And_Safety', 0.003944142255932093)","(['Human Capital Development'], 0.957819402217865)","('NON-ESG', 0.004611098673194647)","('NON-ESG', 0.003944142255932093)"
Line 143,"By using  this process, we defined four areas of focus that provided the  framework for our 2020 sustainability goals: • Innovation—How we contribute to more sustainable  healthcare systems by improving outcomes, reducing system  costs and protecting patients and healthcare workers• Access—How we support health system leapfrogging in  emerging and developing economies, and reach vulnerable  populations globally • Efficiency—How we work across our value chain to minimize  environmental impact and create positive social impact • Empowerment—How we advance our purpose-driven culture  through workforce and community engagementsSignificant ESG issues2020 sustainability strategy For the development of our 2020 strategy, our ESG issues were: GRI disclosure: 102-47• Inclusion and diversity • Associate health   and safety• Attraction and  retention of talent • Transparent   and ethical   business practices• Data security • Informatics and innovationAccess • Planetary health  • Sustainable  supply chain • Product design and life  cycle management• Energy and  GHG management • Waste • WaterInnovation Efficiency• Collaborations and  partnerships • Value-based outcomes• Patient-centric care • Healthcare access   and affordability Empowerment Access Innovation Efficiency Empowerment Governance We launched our 2020 sustainability goals in July 2015,  reflecting a broader and more integrated agenda than previous  years.
","('GHG_Emissions', 0.8078222274780273)","('Energy_Management', 0.07271780073642731)","('Water_And_Wastewater_Management', 0.02946891449391842)","(['Climate Change'], 0.8078222274780273)","('NON-ESG', 0.07271780073642731)","('NON-ESG', 0.02946891449391842)"
Line 144,"In our FY 2016 Sustainability Report, we outlined  alignment to our core activities and aligned the 2020 goal  framework against the 17 SDGs and associated 169 targets.
","('Business_Model_Resilience', 0.34228360652923584)","('Management_Of_Legal_And_Regulatory_Framework', 0.22181642055511475)","('Human_Rights_And_Community_Relations', 0.053155362606048584)","('NON-ESG', 0.34228360652923584)","('NON-ESG', 0.22181642055511475)","('NON-ESG', 0.053155362606048584)"
Line 145,"Our analysis reviewed the type of impact BD has on the SDG  target, the location of impacts within the value chain and our  degree of control and relevant ESG factors.
","('Business_Model_Resilience', 0.690041720867157)","('Systemic_Risk_Management', 0.1276557743549347)","('Supply_Chain_Management', 0.04253262281417847)","(['Codes of Business Conduct'], 0.690041720867157)","('NON-ESG', 0.1276557743549347)","('NON-ESG', 0.04253262281417847)"
Line 146,"We will update this  analysis against our new 2030 strategy and will publish the  results in subsequent reports.2020 sustainability goals Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safetyInnovation Access Efficiency EmpowermentDevelop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging markets Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs Access Innovation Efficiency Empowerment Governance Sustainability 2030+Our 2030+ sustainability strategy has been informed by a  stakeholder-driven assessment of a wide range of environmental,  social and governance issues, along with scenario analysis using  future factors.
","('Product_Quality_And_Safety', 0.29102715849876404)","('Access_And_Affordability', 0.16888336837291718)","('Employee_Health_And_Safety', 0.1580677628517151)","('NON-ESG', 0.29102715849876404)","('NON-ESG', 0.16888336837291718)","('NON-ESG', 0.1580677628517151)"
Line 147,"We will update this  analysis against our new 2030 strategy and will publish the  results in subsequent reports.2020 sustainability goals Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safetyInnovation Access Efficiency EmpowermentDevelop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging markets Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs Access Innovation Efficiency Empowerment Governance Sustainability 2030+Our 2030+ sustainability strategy has been informed by a  stakeholder-driven assessment of a wide range of environmental,  social and governance issues, along with scenario analysis using  future factors.
","('GHG_Emissions', 0.2452343851327896)","('Product_Design_And_Lifecycle_Management', 0.2173696607351303)","('Supply_Chain_Management', 0.08767592161893845)","('NON-ESG', 0.2452343851327896)","('NON-ESG', 0.2173696607351303)","('NON-ESG', 0.08767592161893845)"
Line 148,"We will update this  analysis against our new 2030 strategy and will publish the  results in subsequent reports.2020 sustainability goals Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safetyInnovation Access Efficiency EmpowermentDevelop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging markets Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs Access Innovation Efficiency Empowerment Governance Sustainability 2030+Our 2030+ sustainability strategy has been informed by a  stakeholder-driven assessment of a wide range of environmental,  social and governance issues, along with scenario analysis using  future factors.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9627267718315125)","('Business_Model_Resilience', 0.003546070773154497)","('Product_Design_And_Lifecycle_Management', 0.003106814343482256)","(['Human Capital Development'], 0.9627267718315125)","('NON-ESG', 0.003546070773154497)","('NON-ESG', 0.003106814343482256)"
Line 149,"We will update this  analysis against our new 2030 strategy and will publish the  results in subsequent reports.2020 sustainability goals Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safetyInnovation Access Efficiency EmpowermentDevelop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging markets Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs Access Innovation Efficiency Empowerment Governance Sustainability 2030+Our 2030+ sustainability strategy has been informed by a  stakeholder-driven assessment of a wide range of environmental,  social and governance issues, along with scenario analysis using  future factors.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6695608496665955)","('Physical_Impacts_Of_Climate_Change', 0.06347253173589706)","('Business_Model_Resilience', 0.04257623478770256)","(['Corporate Governance'], 0.6695608496665955)","('NON-ESG', 0.06347253173589706)","('NON-ESG', 0.04257623478770256)"
Line 150,"It will focus on five impact areas and will ensure we  remain focused on shared value creation  —meaning how we address unmet societal needs through business models and  initiatives that also contribute to the commercial success of BD.
","('Business_Model_Resilience', 0.5870192050933838)","('Human_Rights_And_Community_Relations', 0.12686476111412048)","('Supply_Chain_Management', 0.04093088209629059)","(['Codes of Business Conduct'], 0.5870192050933838)","('NON-ESG', 0.12686476111412048)","('NON-ESG', 0.04093088209629059)"
Line 151,"Our 2030+ sustainability strategy will be formally launched   in FY 2021.2030+ sustainability strategy Climate change Minimize our contribution to global  emissions and utilize our capabilities  to address unmet health needs for  climate-vulnerable populations.
","('Physical_Impacts_Of_Climate_Change', 0.9457340240478516)","('Business_Model_Resilience', 0.009918459691107273)","('GHG_Emissions', 0.00658389599993825)","(['Climate Change'], 0.9457340240478516)","('NON-ESG', 0.009918459691107273)","('NON-ESG', 0.00658389599993825)"
Line 152,"Transparency Invite trust across  stakeholder groups through  transparent performance  reporting on environmental,  social and governance issues  relevant to our business.
","('Business_Ethics', 0.9164524078369141)","('Management_Of_Legal_And_Regulatory_Framework', 0.02631395310163498)","('Human_Rights_And_Community_Relations', 0.00915430299937725)","(['Business Ethics'], 0.9164524078369141)","('NON-ESG', 0.02631395310163498)","('NON-ESG', 0.00915430299937725)"
Line 153,"Healthy workforce Maintain a healthy and  thriving workforce that  cultivates our culture of  inclusion, safety and  well-being.Supply chain resilience Create a supply chain adaptable   to disruption and able to contribute  to strong environmental and   social performance.Product impacts Reduce the environmental  impact of our portfolio and  address the sustainability  needs of our customers.
","('Supply_Chain_Management', 0.9241526126861572)","('Product_Design_And_Lifecycle_Management', 0.016400504857301712)","('Business_Model_Resilience', 0.008822396397590637)","(['Supply Chain Management'], 0.9241526126861572)","('NON-ESG', 0.016400504857301712)","('NON-ESG', 0.008822396397590637)"
Line 154,"Access Innovation Efficiency Empowerment Governance When  we analyze the various sustainability issues relevant to  our business and society, we recognize the significant impact  climate change will have on our operations, our supply chain  and, most urgently, on human health.
","('Physical_Impacts_Of_Climate_Change', 0.8077223896980286)","('Supply_Chain_Management', 0.08694765716791153)","('Business_Model_Resilience', 0.018630031496286392)","(['Climate Change'], 0.8077223896980286)","('NON-ESG', 0.08694765716791153)","('NON-ESG', 0.018630031496286392)"
Line 155,"The Intergovernmental  Panel on Climate Change has warned that global warming must  not exceed 1.5 °C to avoid the catastrophic impacts of climate  change.
","('Physical_Impacts_Of_Climate_Change', 0.9452964663505554)","('Business_Model_Resilience', 0.009462154470384121)","('GHG_Emissions', 0.009021363221108913)","(['Climate Change'], 0.9452964663505554)","('NON-ESG', 0.009462154470384121)","('NON-ESG', 0.009021363221108913)"
Line 156,"We therefore recognize that setting ambitious emission  reduction targets based on science must be part of our overall  strategy to manage and mitigate the impacts of  climate change.
","('Air_Quality', 0.663577139377594)","('Physical_Impacts_Of_Climate_Change', 0.11872325092554092)","('GHG_Emissions', 0.09359476715326309)","(['Operational Eco-Efficiency'], 0.663577139377594)","('NON-ESG', 0.11872325092554092)","('NON-ESG', 0.09359476715326309)"
Line 157,"At the end of 2020, we announced  our first set of targets under  the climate change impact area.
","('Physical_Impacts_Of_Climate_Change', 0.9250901341438293)","('GHG_Emissions', 0.01856454648077488)","('Business_Model_Resilience', 0.012436178512871265)","(['Climate Change'], 0.9250901341438293)","('NON-ESG', 0.01856454648077488)","('NON-ESG', 0.012436178512871265)"
Line 158,"These targets are aimed at reducing our contribution to global greenhouse gas emissions  from direct operations.
","('GHG_Emissions', 0.9688382148742676)","('Ecological_Impacts', 0.0037829435896128416)","('Air_Quality', 0.003757053753361106)","(['Climate Change'], 0.9688382148742676)","('NON-ESG', 0.0037829435896128416)","('NON-ESG', 0.003757053753361106)"
Line 159,"We have committed to reduce Scope 1  and 2 GHG emissions, 46% by 2030 (from a 2019 baseline)   and to be carbon neutral across our direct operations by 2040.
","('GHG_Emissions', 0.9669410586357117)","('Ecological_Impacts', 0.0038704336620867252)","('Air_Quality', 0.0037298989482223988)","(['Climate Change'], 0.9669410586357117)","('NON-ESG', 0.0038704336620867252)","('NON-ESG', 0.0037298989482223988)"
Line 160,"This science-based target is aligned with 1.5 °C global emissions  reduction pathway.
","('GHG_Emissions', 0.6401863098144531)","('Air_Quality', 0.1538928747177124)","('Energy_Management', 0.05944588780403137)","(['Climate Change'], 0.6401863098144531)","('NON-ESG', 0.1538928747177124)","('NON-ESG', 0.05944588780403137)"
Line 161,"Climate change will continue to shape our sustainability  programs and our business for years to come.
","('Physical_Impacts_Of_Climate_Change', 0.9481219053268433)","('Business_Model_Resilience', 0.010101129300892353)","('GHG_Emissions', 0.005440728273242712)","(['Climate Change'], 0.9481219053268433)","('NON-ESG', 0.010101129300892353)","('NON-ESG', 0.005440728273242712)"
Line 162,"We will announce  additional goals and targets in line with our 2030 sustainability  strategy during FY 2021.Climate change BD continues to follow all state, local and federal requirements  and ensures adherence to workplace health and safety  regulations for our essential workers.
","('Employee_Health_And_Safety', 0.9753031730651855)","('Employee_Engagement_Inclusion_And_Diversity', 0.0028194966726005077)","('Product_Quality_And_Safety', 0.0022812802344560623)","(['Operational Eco-Efficiency'], 0.9753031730651855)","('NON-ESG', 0.0028194966726005077)","('NON-ESG', 0.0022812802344560623)"
Line 163,"We have instituted  preventative measures at our facilities to help protect  associates, including: • Enhanced cleaning protocols and increasing  cleaning frequency • Implementing temperature screenings and symptom checks  for on-site associates • Deploying personal protective equipment (PPE) to on-site  associates and field workers • Implementing social distancing in our facilities • Supporting remote work for all associates who are able • Suspending travel and group meetings  • Limiting on-site visitors • Regularly educating associates about thorough health   and hygiene practices, including social distancing,   self-quarantining and handwashingChanges in demand across our portfolio did result in the need   to take temporary actions to reduce our costs so we could  continue to serve our customers during the height of the  pandemic and into the future.
","('Employee_Health_And_Safety', 0.904578685760498)","('Waste_And_Hazardous_Materials_Management', 0.016434254124760628)","('Critical_Incident_Risk_Management', 0.012183195911347866)","(['Operational Eco-Efficiency'], 0.904578685760498)","('NON-ESG', 0.016434254124760628)","('NON-ESG', 0.012183195911347866)"
Line 164,"We have instituted  preventative measures at our facilities to help protect  associates, including: • Enhanced cleaning protocols and increasing  cleaning frequency • Implementing temperature screenings and symptom checks  for on-site associates • Deploying personal protective equipment (PPE) to on-site  associates and field workers • Implementing social distancing in our facilities • Supporting remote work for all associates who are able • Suspending travel and group meetings  • Limiting on-site visitors • Regularly educating associates about thorough health   and hygiene practices, including social distancing,   self-quarantining and handwashingChanges in demand across our portfolio did result in the need   to take temporary actions to reduce our costs so we could  continue to serve our customers during the height of the  pandemic and into the future.
","('Employee_Health_And_Safety', 0.3031371235847473)","('Product_Quality_And_Safety', 0.21779359877109528)","('Customer_Welfare', 0.09683555364608765)","('NON-ESG', 0.3031371235847473)","('NON-ESG', 0.21779359877109528)","('NON-ESG', 0.09683555364608765)"
Line 165,"Steps included temporary work  reductions, by slowing or suspending production at select  manufacturing locations.
","('Labor_Practices', 0.41227954626083374)","('Supply_Chain_Management', 0.2364213913679123)","('Energy_Management', 0.0684075877070427)","('NON-ESG', 0.41227954626083374)","('NON-ESG', 0.2364213913679123)","('NON-ESG', 0.0684075877070427)"
Line 166,"This led to a limited number of furloughs, which allowed us to  retain BD associates as employees.
","('Labor_Practices', 0.890165388584137)","('Employee_Health_And_Safety', 0.019031912088394165)","('Management_Of_Legal_And_Regulatory_Framework', 0.018195437267422676)","(['Labor Practice Indicators'], 0.890165388584137)","('NON-ESG', 0.019031912088394165)","('NON-ESG', 0.018195437267422676)"
Line 167,"While pay was adjusted  accordingly,  we recognized the disruption this could cause to  our associates and their families and we wanted to do  everything we could to support and care for associates—this  included affected associates retaining their benefits, including  medical benefits, and establishing an employee assistance fund We also believe leaders in the company have the responsibility  to serve and act in the best interest of the company and our  associates, helping to ensure that we can emerge stronger.
","('Employee_Health_And_Safety', 0.5385413765907288)","('Labor_Practices', 0.1912282109260559)","('Employee_Engagement_Inclusion_And_Diversity', 0.09543308615684509)","(['Operational Eco-Efficiency'], 0.5385413765907288)","('NON-ESG', 0.1912282109260559)","('NON-ESG', 0.09543308615684509)"
Line 168,"While pay was adjusted  accordingly,  we recognized the disruption this could cause to  our associates and their families and we wanted to do  everything we could to support and care for associates—this  included affected associates retaining their benefits, including  medical benefits, and establishing an employee assistance fund We also believe leaders in the company have the responsibility  to serve and act in the best interest of the company and our  associates, helping to ensure that we can emerge stronger.
","('Data_Security', 0.2134476751089096)","('Customer_Privacy', 0.13334748148918152)","('Competitive_Behavior', 0.06774439662694931)","('NON-ESG', 0.2134476751089096)","('NON-ESG', 0.13334748148918152)","('NON-ESG', 0.06774439662694931)"
Line 169,"Therefore, all BD leaders globally, along with the chairman and  Board of Directors, were subject to a temporary reduction in  base pay in 2020.
","('Director_Removal', 0.7401653528213501)","('Labor_Practices', 0.05984530225396156)","('Management_Of_Legal_And_Regulatory_Framework', 0.04098235070705414)","(['Anti-Crime Policy & Measures'], 0.7401653528213501)","('NON-ESG', 0.05984530225396156)","('NON-ESG', 0.04098235070705414)"
Line 170,"*Protecting the health, safety and well-being of BD associatesOur response to COVID-BD continues to closely monitor COVID-19 (coronavirus) developments across the world as well as guidance from the U.S. Centers for  Disease Control and Prevention (CDC), the World Health Organization (WHO) and global health officials.
","('Product_Quality_And_Safety', 0.5621916055679321)","('Employee_Health_And_Safety', 0.222377747297287)","('Product_Design_And_Lifecycle_Management', 0.03358573094010353)","(['Product Quality & Recall Management'], 0.5621916055679321)","('NON-ESG', 0.222377747297287)","('NON-ESG', 0.03358573094010353)"
Line 171,"We are working vigilantly to  protect the health and safety of BD associates while also ensuring continued availability of our critical health preserving, lifesaving  and diagnostic medical devices during this challenging time.
","('Employee_Health_And_Safety', 0.7751165628433228)","('Product_Quality_And_Safety', 0.10951326042413712)","('Product_Design_And_Lifecycle_Management', 0.026476453989744186)","(['Operational Eco-Efficiency'], 0.7751165628433228)","('NON-ESG', 0.10951326042413712)","('NON-ESG', 0.026476453989744186)"
Line 172,"Content in this spotlight is current as of June 2021.
","('Management_Of_Legal_And_Regulatory_Framework', 0.23363476991653442)","('Data_Security', 0.09885987639427185)","('Business_Model_Resilience', 0.08520995825529099)","('NON-ESG', 0.23363476991653442)","('NON-ESG', 0.09885987639427185)","('NON-ESG', 0.08520995825529099)"
Line 173,"Spotlight—COVID-*Subject to any required consultation process and local law where applicable.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9595674872398376)","('Human_Rights_And_Community_Relations', 0.0036720046773552895)","('Director_Removal', 0.0032422468066215515)","(['Corporate Governance'], 0.9595674872398376)","('NON-ESG', 0.0036720046773552895)","('NON-ESG', 0.0032422468066215515)"
Line 174,"BD manufactures and sources products from multiple locations around the world.
","('Product_Design_And_Lifecycle_Management', 0.9445804357528687)","('Product_Quality_And_Safety', 0.008589022792875767)","('Customer_Welfare', 0.005604668520390987)","(['Product Stewardship'], 0.9445804357528687)","('NON-ESG', 0.008589022792875767)","('NON-ESG', 0.005604668520390987)"
Line 175,"All of our global manufacturing and distribution centers  are operational at this time, with the vast majority of critical-to-COVID sites operating at or near full capacity.
","('Supply_Chain_Management', 0.40548190474510193)","('Energy_Management', 0.19890625774860382)","('Product_Design_And_Lifecycle_Management', 0.14371448755264282)","('NON-ESG', 0.40548190474510193)","('NON-ESG', 0.19890625774860382)","('NON-ESG', 0.14371448755264282)"
Line 176,"In countries where local governments have imposed stricter “lockdown” measures to slow the spread of coronavirus, BD facilities continue to  operate with measures in place to ensure business continuity and minimize risk of disruption to our customers.BD operations Product availability: Supply and business continuity In addition, BD continues to work closely with our key suppliers  around the world that provide raw materials and components to  our manufacturing plants.
","('Supply_Chain_Management', 0.9100223779678345)","('Product_Design_And_Lifecycle_Management', 0.02261715941131115)","('Waste_And_Hazardous_Materials_Management', 0.005615996662527323)","(['Supply Chain Management'], 0.9100223779678345)","('NON-ESG', 0.02261715941131115)","('NON-ESG', 0.005615996662527323)"
Line 177,"We have implemented business  continuity measures to mitigate the risk of potential supplier  disruption, including partnering with local governments to seek  “essential business” exemptions for key suppliers  where necessary.
","('Supply_Chain_Management', 0.9480504393577576)","('Physical_Impacts_Of_Climate_Change', 0.0045518893748521805)","('Labor_Practices', 0.004129627253860235)","(['Supply Chain Management'], 0.9480504393577576)","('NON-ESG', 0.0045518893748521805)","('NON-ESG', 0.004129627253860235)"
Line 178,"BD continues to have sufficient raw material and component  inventory for the majority of products considered critical to  COVID-19.
","('Product_Design_And_Lifecycle_Management', 0.9395201206207275)","('Supply_Chain_Management', 0.011232889257371426)","('Waste_And_Hazardous_Materials_Management', 0.0051211146637797356)","(['Product Stewardship'], 0.9395201206207275)","('NON-ESG', 0.011232889257371426)","('NON-ESG', 0.0051211146637797356)"
Line 179,"If materials or components are deemed at risk, BD  activates any number of preapproved contingency plans,  including those for: • Seeking alternative suppliers • Redeploying raw materials and/or finished goods from other  parts of the BD network • Placing at-risk products on order review to prevent stockpilingDedicated teams continue to actively monitor our global  logistics and transportation network, taking action when  necessary to navigate global capacity limitations and border  constraints to minimize the risk of any customer delays.
","('Supply_Chain_Management', 0.4309815764427185)","('Product_Design_And_Lifecycle_Management', 0.374587744474411)","('Customer_Welfare', 0.030309997498989105)","('NON-ESG', 0.4309815764427185)","('NON-ESG', 0.374587744474411)","('NON-ESG', 0.030309997498989105)"
Line 180,"If materials or components are deemed at risk, BD  activates any number of preapproved contingency plans,  including those for: • Seeking alternative suppliers • Redeploying raw materials and/or finished goods from other  parts of the BD network • Placing at-risk products on order review to prevent stockpilingDedicated teams continue to actively monitor our global  logistics and transportation network, taking action when  necessary to navigate global capacity limitations and border  constraints to minimize the risk of any customer delays.
","('Critical_Incident_Risk_Management', 0.2584393322467804)","('Business_Ethics', 0.1270940750837326)","('Data_Security', 0.12293631583452225)","('NON-ESG', 0.2584393322467804)","('NON-ESG', 0.1270940750837326)","('NON-ESG', 0.12293631583452225)"
Line 181,"We are  making every effort to ensure the final product is transported to  distributors and customers as quickly and efficiently as possible.
","('Product_Design_And_Lifecycle_Management', 0.9542616605758667)","('Product_Quality_And_Safety', 0.006275918334722519)","('Selling_Practices_And_Product_Labeling', 0.006120655685663223)","(['Product Stewardship'], 0.9542616605758667)","('NON-ESG', 0.006275918334722519)","('NON-ESG', 0.006120655685663223)"
Line 182,"For U.S. customers, an up-to-date list of products on manual  inventory allocation can be found in the Allocation  section of  our website.
","('Product_Design_And_Lifecycle_Management', 0.8403041958808899)","('Selling_Practices_And_Product_Labeling', 0.0333184078335762)","('Customer_Welfare', 0.022243060171604156)","(['Product Stewardship'], 0.8403041958808899)","('NON-ESG', 0.0333184078335762)","('NON-ESG', 0.022243060171604156)"
Line 183,"Spotlight—COVID-Increasing access to testing The path forward out of COVID-19 relies on populations  worldwide having access to tests.
","('Access_And_Affordability', 0.8900122046470642)","('Product_Quality_And_Safety', 0.01351082231849432)","('Energy_Management', 0.008614669553935528)","(['Health Outcome Contribution'], 0.8900122046470642)","('NON-ESG', 0.01351082231849432)","('NON-ESG', 0.008614669553935528)"
Line 184,"BD is a critical supplier of swabs and other sample collection  products for COVID-19 and has launched multiple molecular  tests, enabling clinicians to know if a patient currently has  COVID-19.
","('Customer_Welfare', 0.335562527179718)","('Product_Design_And_Lifecycle_Management', 0.13369283080101013)","('Product_Quality_And_Safety', 0.09879329800605774)","('NON-ESG', 0.335562527179718)","('NON-ESG', 0.13369283080101013)","('NON-ESG', 0.09879329800605774)"
Line 185,"These molecular tests are primarily completed in a  hospital lab versus an offsite reference lab, so our results can be  seen in as little as two to three hours, not two to three days.
","('Competitive_Behavior', 0.19113358855247498)","('Customer_Welfare', 0.09790457040071487)","('Access_And_Affordability', 0.06919748336076736)","('NON-ESG', 0.19113358855247498)","('NON-ESG', 0.09790457040071487)","('NON-ESG', 0.06919748336076736)"
Line 186,"Our product teams are developing new testing options that can  be quickly deployed at scale, and we have already aggressively  increased production of our existing portfolio to help meet the  overwhelming global demand.Supporting COVID patient care On any given day, we estimate our products are part of the care  delivery for over 90% of U.S. hospital patients.
","('Product_Design_And_Lifecycle_Management', 0.9086133241653442)","('Customer_Welfare', 0.022717660292983055)","('Product_Quality_And_Safety', 0.010605921968817711)","(['Product Stewardship'], 0.9086133241653442)","('NON-ESG', 0.022717660292983055)","('NON-ESG', 0.010605921968817711)"
Line 187,"Our technologies and devices are on the front lines in the crisis,  helping physicians and nurses manage medications, safely  delivering drugs to patients and supporting advanced care  needs in ICUs. Advancing discovery Our solutions, instruments and data analysis platforms are  integral to helping researchers rapidly deepen our  understanding of COVID-19 at a cellular level, specifically in  clarifying our picture of the body’s immune system response.
","('Access_And_Affordability', 0.24459686875343323)","('Critical_Incident_Risk_Management', 0.13866235315799713)","('Customer_Welfare', 0.1010519340634346)","('NON-ESG', 0.24459686875343323)","('NON-ESG', 0.13866235315799713)","('NON-ESG', 0.1010519340634346)"
Line 188,"With a more detailed knowledge of immune responses,  researchers have a stronger foundation to develop more  effective therapies.What we are doing to address immediate needsOur products: Supporting a global response Enabling a return to the workplace In order to safely restart our economies, we need both  multifaceted testing capabilities and advanced disease  monitoring capabilities.
","('Employee_Health_And_Safety', 0.19864435493946075)","('Critical_Incident_Risk_Management', 0.13281643390655518)","('Access_And_Affordability', 0.12720231711864471)","('NON-ESG', 0.19864435493946075)","('NON-ESG', 0.13281643390655518)","('NON-ESG', 0.12720231711864471)"
Line 189,"Our information and data technologies help health systems  assess data on test results, drug inventory, hospital utilization  trends and more to help form a picture of risks and responses.
","('Access_And_Affordability', 0.1736111044883728)","('Systemic_Risk_Management', 0.13040372729301453)","('Selling_Practices_And_Product_Labeling', 0.10123227536678314)","('NON-ESG', 0.1736111044883728)","('NON-ESG', 0.13040372729301453)","('NON-ESG', 0.10123227536678314)"
Line 190,"And as we look ahead to cautiously returning to “normal,”   our technologies can help detect early warning signs of   re-emergence of the disease.Enabling the delivery of COVID-19 vaccinations BD has been by the side of vaccine developers and healthcare  providers for decades, ensuring the availability and safe  administration of vaccines from polio to the seasonal flu.
","('Employee_Health_And_Safety', 0.24358311295509338)","('Product_Quality_And_Safety', 0.1060013547539711)","('Critical_Incident_Risk_Management', 0.09691997617483139)","('NON-ESG', 0.24358311295509338)","('NON-ESG', 0.1060013547539711)","('NON-ESG', 0.09691997617483139)"
Line 191,"As COVID-19 vaccinations accelerate, and researchers continue  pursuing novel vaccines and treatments, BD has a full suite of  medication delivery devices to meet the needs of each potential  drug.
","('Access_And_Affordability', 0.11080227792263031)","('Customer_Welfare', 0.10814597457647324)","('Product_Quality_And_Safety', 0.10675545036792755)","('NON-ESG', 0.11080227792263031)","('NON-ESG', 0.10814597457647324)","('NON-ESG', 0.10675545036792755)"
Line 192,"We continue working with governments around the world  to understand their needs and scale up production.
","('Supply_Chain_Management', 0.2794944941997528)","('Energy_Management', 0.20381908118724823)","('Management_Of_Legal_And_Regulatory_Framework', 0.17012375593185425)","('NON-ESG', 0.2794944941997528)","('NON-ESG', 0.20381908118724823)","('NON-ESG', 0.17012375593185425)"
Line 193,"COVID-19 Insights  & Analytics Learn how test ing can helpCarving a path out of the crisis Spotlight—COVID-PREVENT TREAT BD Veritor ™ Rapid POC  COVID-19 Antigen TestAs one of the largest global medical technology companies in  the world, BD is deploying our capabilities, expertise and scale  to address critical health needs related to coronavirus—from our diagnostic offerings to detect SARS-CoV-2, to real-time  informatics and electronic surveillance technology, to essential  medical devices to support patient care.
","('Access_And_Affordability', 0.1798904836177826)","('Customer_Welfare', 0.12446664273738861)","('Product_Quality_And_Safety', 0.10448239743709564)","('NON-ESG', 0.1798904836177826)","('NON-ESG', 0.12446664273738861)","('NON-ESG', 0.10448239743709564)"
Line 194,"COVID-19 Insights  & Analytics Learn how test ing can helpCarving a path out of the crisis Spotlight—COVID-PREVENT TREAT BD Veritor ™ Rapid POC  COVID-19 Antigen TestAs one of the largest global medical technology companies in  the world, BD is deploying our capabilities, expertise and scale  to address critical health needs related to coronavirus—from our diagnostic offerings to detect SARS-CoV-2, to real-time  informatics and electronic surveillance technology, to essential  medical devices to support patient care.
","('Access_And_Affordability', 0.29221200942993164)","('Business_Ethics', 0.08322914689779282)","('Ecological_Impacts', 0.06462829560041428)","('NON-ESG', 0.29221200942993164)","('NON-ESG', 0.08322914689779282)","('NON-ESG', 0.06462829560041428)"
Line 195,"• Is offering a molecular diagnostic test  for both   SARS-CoV-2 and influenza A+B that can return results   using a single specimen in two to three hours;  • Is providing point-of-care antigen tests  that have the  potential to significantly change the public health  interventions needed to minimize the spread of COVID-19;  • Has delivered more than 900 million injection devices and  continues to deploy shipments of needles and syringes for  pandemic orders of more than 2 billion injection devices  to  support global COVID-19 vaccination planning efforts;  • Is enabling COVID-19 testing facilities , including labs,  hospitals and nursing homes, to provide timely, accurate data  reporting, empowering public health officials to more  precisely monitor the spread of COVID-19;  • Has leveraged its global manufacturing network and  scale  to increase production of SARS-CoV-2 antigen tests  from a rate of 8 million per month in October 2020, to a  capability of 12 million per month by March 2021;  • Is preparing for future pandemic efforts  by partnering  with the U.S. government on a $70 million capital project to  further expand our operations and manufacturing capacity  in Nebraska that, when complete, will provide the federal  government with priority access to hundreds of millions of  injection devices to support vaccination efforts for COVID-19  and future pandemics; and • Is investing approximately $1.2 billion  over a four-year  period to expand and upgrade manufacturing capacity and  technology for prefillable syringes and advanced drug  delivery systems.
","('Access_And_Affordability', 0.3421347141265869)","('Employee_Health_And_Safety', 0.17253060638904572)","('Critical_Incident_Risk_Management', 0.0786842629313469)","('NON-ESG', 0.3421347141265869)","('NON-ESG', 0.17253060638904572)","('NON-ESG', 0.0786842629313469)"
Line 196,"• Is offering a molecular diagnostic test  for both   SARS-CoV-2 and influenza A+B that can return results   using a single specimen in two to three hours;  • Is providing point-of-care antigen tests  that have the  potential to significantly change the public health  interventions needed to minimize the spread of COVID-19;  • Has delivered more than 900 million injection devices and  continues to deploy shipments of needles and syringes for  pandemic orders of more than 2 billion injection devices  to  support global COVID-19 vaccination planning efforts;  • Is enabling COVID-19 testing facilities , including labs,  hospitals and nursing homes, to provide timely, accurate data  reporting, empowering public health officials to more  precisely monitor the spread of COVID-19;  • Has leveraged its global manufacturing network and  scale  to increase production of SARS-CoV-2 antigen tests  from a rate of 8 million per month in October 2020, to a  capability of 12 million per month by March 2021;  • Is preparing for future pandemic efforts  by partnering  with the U.S. government on a $70 million capital project to  further expand our operations and manufacturing capacity  in Nebraska that, when complete, will provide the federal  government with priority access to hundreds of millions of  injection devices to support vaccination efforts for COVID-19  and future pandemics; and • Is investing approximately $1.2 billion  over a four-year  period to expand and upgrade manufacturing capacity and  technology for prefillable syringes and advanced drug  delivery systems.
","('Employee_Health_And_Safety', 0.35832661390304565)","('Access_And_Affordability', 0.12269078195095062)","('Product_Quality_And_Safety', 0.09772155433893204)","('NON-ESG', 0.35832661390304565)","('NON-ESG', 0.12269078195095062)","('NON-ESG', 0.09772155433893204)"
Line 197,"• Is offering a molecular diagnostic test  for both   SARS-CoV-2 and influenza A+B that can return results   using a single specimen in two to three hours;  • Is providing point-of-care antigen tests  that have the  potential to significantly change the public health  interventions needed to minimize the spread of COVID-19;  • Has delivered more than 900 million injection devices and  continues to deploy shipments of needles and syringes for  pandemic orders of more than 2 billion injection devices  to  support global COVID-19 vaccination planning efforts;  • Is enabling COVID-19 testing facilities , including labs,  hospitals and nursing homes, to provide timely, accurate data  reporting, empowering public health officials to more  precisely monitor the spread of COVID-19;  • Has leveraged its global manufacturing network and  scale  to increase production of SARS-CoV-2 antigen tests  from a rate of 8 million per month in October 2020, to a  capability of 12 million per month by March 2021;  • Is preparing for future pandemic efforts  by partnering  with the U.S. government on a $70 million capital project to  further expand our operations and manufacturing capacity  in Nebraska that, when complete, will provide the federal  government with priority access to hundreds of millions of  injection devices to support vaccination efforts for COVID-19  and future pandemics; and • Is investing approximately $1.2 billion  over a four-year  period to expand and upgrade manufacturing capacity and  technology for prefillable syringes and advanced drug  delivery systems.
","('Critical_Incident_Risk_Management', 0.23394475877285004)","('Access_And_Affordability', 0.11602463573217392)","('Employee_Health_And_Safety', 0.11046095192432404)","('NON-ESG', 0.23394475877285004)","('NON-ESG', 0.11602463573217392)","('NON-ESG', 0.11046095192432404)"
Line 198,"• Is offering a molecular diagnostic test  for both   SARS-CoV-2 and influenza A+B that can return results   using a single specimen in two to three hours;  • Is providing point-of-care antigen tests  that have the  potential to significantly change the public health  interventions needed to minimize the spread of COVID-19;  • Has delivered more than 900 million injection devices and  continues to deploy shipments of needles and syringes for  pandemic orders of more than 2 billion injection devices  to  support global COVID-19 vaccination planning efforts;  • Is enabling COVID-19 testing facilities , including labs,  hospitals and nursing homes, to provide timely, accurate data  reporting, empowering public health officials to more  precisely monitor the spread of COVID-19;  • Has leveraged its global manufacturing network and  scale  to increase production of SARS-CoV-2 antigen tests  from a rate of 8 million per month in October 2020, to a  capability of 12 million per month by March 2021;  • Is preparing for future pandemic efforts  by partnering  with the U.S. government on a $70 million capital project to  further expand our operations and manufacturing capacity  in Nebraska that, when complete, will provide the federal  government with priority access to hundreds of millions of  injection devices to support vaccination efforts for COVID-19  and future pandemics; and • Is investing approximately $1.2 billion  over a four-year  period to expand and upgrade manufacturing capacity and  technology for prefillable syringes and advanced drug  delivery systems.
","('Product_Design_And_Lifecycle_Management', 0.29163020849227905)","('Energy_Management', 0.14417634904384613)","('Customer_Welfare', 0.14397217333316803)","('NON-ESG', 0.29163020849227905)","('NON-ESG', 0.14417634904384613)","('NON-ESG', 0.14397217333316803)"
Line 199,"This allows for continued growth of new  injectable drugs and vaccines, and provides surge capacity  for increased prefillable syringe demand during times of  pandemic response.
","('Access_And_Affordability', 0.20619110763072968)","('Energy_Management', 0.16445988416671753)","('Critical_Incident_Risk_Management', 0.13859714567661285)","('NON-ESG', 0.20619110763072968)","('NON-ESG', 0.16445988416671753)","('NON-ESG', 0.13859714567661285)"
Line 200,"Cybersecurity and COVID-Over the past year, BD has: • Expanded secure connectivity options for the BD Veritor ™ Plus  System, a point-of-care device used to perform SARS-CoV-2  diagnostic testing;   • Enabled encrypted reporting capabilities for the BD Synapsys ™  Microbiology Informatics Solutions, which unifies instrument- read COVID-19 test results from the BD Veritor ™ and BD  MAX ™ Systems, simplifying the process of reporting accurate  results to public health authorities daily;  • Engaged with the U.S. Department of Homeland Security  Cybersecurity & Infrastructure Security Agency (CISA) to  strengthen our threat intel and bolster supply chain  cybersecurity; and   • Increased cybersecurity awareness training, especially  among associates who quickly transitioned to remote work  due to the COVID-19 pandemic.
","('Data_Security', 0.5196982026100159)","('Business_Ethics', 0.1142716333270073)","('Systemic_Risk_Management', 0.04372036084532738)","(['Information Security/Cybersecurity & System Availability'], 0.5196982026100159)","('NON-ESG', 0.1142716333270073)","('NON-ESG', 0.04372036084532738)"
Line 201,"Cybersecurity and COVID-Over the past year, BD has: • Expanded secure connectivity options for the BD Veritor ™ Plus  System, a point-of-care device used to perform SARS-CoV-2  diagnostic testing;   • Enabled encrypted reporting capabilities for the BD Synapsys ™  Microbiology Informatics Solutions, which unifies instrument- read COVID-19 test results from the BD Veritor ™ and BD  MAX ™ Systems, simplifying the process of reporting accurate  results to public health authorities daily;  • Engaged with the U.S. Department of Homeland Security  Cybersecurity & Infrastructure Security Agency (CISA) to  strengthen our threat intel and bolster supply chain  cybersecurity; and   • Increased cybersecurity awareness training, especially  among associates who quickly transitioned to remote work  due to the COVID-19 pandemic.
","('Data_Security', 0.9044333696365356)","('Systemic_Risk_Management', 0.021703124046325684)","('Supply_Chain_Management', 0.008158660493791103)","(['Information Security/Cybersecurity & System Availability'], 0.9044333696365356)","('NON-ESG', 0.021703124046325684)","('NON-ESG', 0.008158660493791103)"
Line 202,"BD MAX ™ Molecular  COVID-19 Tests and  Respiratory Panel  Swabs and UVT kits IV drug delivery in ICUs  and isolation extension sets Medication management  in field hospitals IV catheters and PICCs for  COVID-19 treatments Over 2 billion devices  committed for   COVID-19 vaccinations Partnering with pharma for  potential future prefilled  COVID-19 vaccine Note: Not all products are available in all countries/regions.DIAGNOSE BD HealthSight ™ Medication Management Platform with MedMined ™ Data Analytics for real-time   surveillance reporting and medication use reporting Specifically, BD:  Spotlight—COVID-BD and the BD Foundation have issued nearly $2.8 million in  philanthropic grants and product donations to trusted nonprofit  partners that are working to protect the most vulnerable  communities and individuals from the pandemic’s spread and  negative impacts.
","('Access_And_Affordability', 0.3085140585899353)","('Customer_Welfare', 0.12704768776893616)","('Product_Quality_And_Safety', 0.12002316862344742)","('NON-ESG', 0.3085140585899353)","('NON-ESG', 0.12704768776893616)","('NON-ESG', 0.12002316862344742)"
Line 203,"BD MAX ™ Molecular  COVID-19 Tests and  Respiratory Panel  Swabs and UVT kits IV drug delivery in ICUs  and isolation extension sets Medication management  in field hospitals IV catheters and PICCs for  COVID-19 treatments Over 2 billion devices  committed for   COVID-19 vaccinations Partnering with pharma for  potential future prefilled  COVID-19 vaccine Note: Not all products are available in all countries/regions.DIAGNOSE BD HealthSight ™ Medication Management Platform with MedMined ™ Data Analytics for real-time   surveillance reporting and medication use reporting Specifically, BD:  Spotlight—COVID-BD and the BD Foundation have issued nearly $2.8 million in  philanthropic grants and product donations to trusted nonprofit  partners that are working to protect the most vulnerable  communities and individuals from the pandemic’s spread and  negative impacts.
","('Critical_Incident_Risk_Management', 0.25867635011672974)","('Physical_Impacts_Of_Climate_Change', 0.2238171547651291)","('Human_Rights_And_Community_Relations', 0.1496257185935974)","('NON-ESG', 0.25867635011672974)","('NON-ESG', 0.2238171547651291)","('NON-ESG', 0.1496257185935974)"
Line 204,"BD volunteers are heeding the call too.
","('Access_And_Affordability', 0.42436063289642334)","('Human_Rights_And_Community_Relations', 0.07378049194812775)","('Employee_Health_And_Safety', 0.054170433431863785)","('NON-ESG', 0.42436063289642334)","('NON-ESG', 0.07378049194812775)","('NON-ESG', 0.054170433431863785)"
Line 205,"Clinically trained associates in BD sites around the world are  volunteering their time to augment hospital staff in communities hard-hit by COVID-19; and associates from a  broad range of disciplines are delivering virtual trainings to  teach community and nonprofit organizations how to contain  its spread.
","('Access_And_Affordability', 0.621779203414917)","('Employee_Engagement_Inclusion_And_Diversity', 0.08245155960321426)","('Employee_Health_And_Safety', 0.03568726405501366)","(['Health Outcome Contribution'], 0.621779203414917)","('NON-ESG', 0.08245155960321426)","('NON-ESG', 0.03568726405501366)"
Line 206,"Here, we share just a few examples of the local and global  impact of those philanthropic investments.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5864377617835999)","('Human_Rights_And_Community_Relations', 0.09793319553136826)","('Access_And_Affordability', 0.0687994435429573)","(['Corporate Governance'], 0.5864377617835999)","('NON-ESG', 0.09793319553136826)","('NON-ESG', 0.0687994435429573)"
Line 207,"Leveraging telehealth technology to provide care to New Jersey patients with urgent,  chronic or preventive health needsPhilanthropic investments in the fight against COVID-The Bergen Volunteer Medical  Initiative (BVMI)  is a free primary  care clinic serving working, low  income and uninsured residents of  Bergen County, NJ, where the BD  U.S. headquarters is located.
","('Access_And_Affordability', 0.8481049537658691)","('Employee_Health_And_Safety', 0.030116653069853783)","('Critical_Incident_Risk_Management', 0.014919651672244072)","(['Health Outcome Contribution'], 0.8481049537658691)","('NON-ESG', 0.030116653069853783)","('NON-ESG', 0.014919651672244072)"
Line 208,"When its healthcare center needed  to be temporarily closed during the onset of the pandemic,  BVMI leveraged its emergency COVID-19 grant funding from  BD to help launch an urgent telehealth program   to fill the gap.“Our online telehealth program ramped up quickly, providing  100 medical appointments each week for patients in need of  urgent, chronic, or preventive care, and ensuring that patients  with COVID-19 symptoms or concerns had immediate access to  medical care.
","('Critical_Incident_Risk_Management', 0.2788986265659332)","('Access_And_Affordability', 0.265310138463974)","('Employee_Health_And_Safety', 0.23585455119609833)","('NON-ESG', 0.2788986265659332)","('NON-ESG', 0.265310138463974)","('NON-ESG', 0.23585455119609833)"
Line 209,"This program is also facilitating patient access to a  case manager who assists our lowest income patients in  obtaining food, rental assistance and other vital services in  partnership with other community organizations,”  said Amanda  Missey, President & CEO.
","('Access_And_Affordability', 0.9225072264671326)","('Human_Rights_And_Community_Relations', 0.007853771559894085)","('Critical_Incident_Risk_Management', 0.00697877025231719)","(['Health Outcome Contribution'], 0.9225072264671326)","('NON-ESG', 0.007853771559894085)","('NON-ESG', 0.00697877025231719)"
Line 210,"Meeting the expanding needs of those facing homelessness and hunger in New Jersey An increasing number of families   across Northern New Jersey, where  the BD U.S. headquarters is located,  have experienced economic hardship as a result of COVID-19.
","('Employee_Health_And_Safety', 0.5023472905158997)","('Access_And_Affordability', 0.1327887326478958)","('Critical_Incident_Risk_Management', 0.07814754545688629)","(['Operational Eco-Efficiency'], 0.5023472905158997)","('NON-ESG', 0.1327887326478958)","('NON-ESG', 0.07814754545688629)"
Line 211,"Family Promise of Bergen County  has leveraged its COVID-19  emergency grant funding from BD to provide shelter and/or  support to 24 families through a combination of apartment or  hotel housing, rental assistance and post-shelter support.
","('Critical_Incident_Risk_Management', 0.9490635991096497)","('Employee_Health_And_Safety', 0.012042996473610401)","('Access_And_Affordability', 0.00841996818780899)","(['Risk & Crisis Management'], 0.9490635991096497)","('NON-ESG', 0.012042996473610401)","('NON-ESG', 0.00841996818780899)"
Line 212,"“Each of the families we’ve been able to support has also  received transformative case management, financial education,  job training, childcare, transportation support, meals and  enrichment for their children.
","('Access_And_Affordability', 0.9182133674621582)","('Employee_Engagement_Inclusion_And_Diversity', 0.007451748941093683)","('Human_Rights_And_Community_Relations', 0.007226495537906885)","(['Health Outcome Contribution'], 0.9182133674621582)","('NON-ESG', 0.007451748941093683)","('NON-ESG', 0.007226495537906885)"
Line 213,"We’ve also been able to address  the growing issue of food insecurity in Bergen County by  significantly expanding our meal program.
","('Systemic_Risk_Management', 0.2569243907928467)","('Supply_Chain_Management', 0.2552379369735718)","('Customer_Welfare', 0.06568694114685059)","('NON-ESG', 0.2569243907928467)","('NON-ESG', 0.2552379369735718)","('NON-ESG', 0.06568694114685059)"
Line 214,"Since March 2020,  with help from BD, this program has provided 85,000 meals and  more than 9,000 15-pound boxes of fresh produce to families,”   said Kate Duggan, Executive Director.
","('Customer_Welfare', 0.29408159852027893)","('Selling_Practices_And_Product_Labeling', 0.14980386197566986)","('Access_And_Affordability', 0.10512948036193848)","('NON-ESG', 0.29408159852027893)","('NON-ESG', 0.14980386197566986)","('NON-ESG', 0.10512948036193848)"
Line 215,"Providing urgent, lifesaving services to families in Port Elizabeth, South Africa For more than 21 years,   Ubuntu Pathways  has placed South  Africa’s most vulnerable children on  pathways out of poverty, from cradle  to career.
","('Access_And_Affordability', 0.8211961984634399)","('Human_Rights_And_Community_Relations', 0.06017723307013512)","('Employee_Health_And_Safety', 0.012391641736030579)","(['Health Outcome Contribution'], 0.8211961984634399)","('NON-ESG', 0.06017723307013512)","('NON-ESG', 0.012391641736030579)"
Line 216,"When the COVID-19  pandemic hit, the organization immediately mobilized an  emergency COVID-19 response to deliver urgent lifesaving  services in the city of Port Elizabeth.
","('Critical_Incident_Risk_Management', 0.9708223342895508)","('Air_Quality', 0.0037360205315053463)","('Physical_Impacts_Of_Climate_Change', 0.0031941495835781097)","(['Risk & Crisis Management'], 0.9708223342895508)","('NON-ESG', 0.0037360205315053463)","('NON-ESG', 0.0031941495835781097)"
Line 217,"“With the generous grant from BD, we are providing a  comprehensive support system to help families cope with this  crisis,”  said Jacob Lief, Founder & CEO.
","('Critical_Incident_Risk_Management', 0.3866618275642395)","('Access_And_Affordability', 0.27468398213386536)","('Human_Rights_And_Community_Relations', 0.07129007577896118)","('NON-ESG', 0.3866618275642395)","('NON-ESG', 0.27468398213386536)","('NON-ESG', 0.07129007577896118)"
Line 218,"“This includes delivering  food and safety packages to 4,000 households (nearly 30,000  people); supplying critical personal protective equipment to 27  local clinics, hospitals and social service institutions; providing  medical services to patients living with HIV and compromised  immune systems; and implementing a host of wraparound  services, including case management, remote education and job  skills training.” Spotlight—COVID-Working to reduce the impact of COVID-19 in 180+ countries UNICEF  has leveraged its emergency  COVID-19 grant funding from BD to support  its global efforts to reduce and address the  impact of COVID-19 on families in more  than 180 countries.
","('Product_Quality_And_Safety', 0.5076538920402527)","('Employee_Health_And_Safety', 0.3117697238922119)","('Access_And_Affordability', 0.03155767172574997)","(['Product Quality & Recall Management'], 0.5076538920402527)","('NON-ESG', 0.3117697238922119)","('NON-ESG', 0.03155767172574997)"
Line 219,"“This includes delivering  food and safety packages to 4,000 households (nearly 30,000  people); supplying critical personal protective equipment to 27  local clinics, hospitals and social service institutions; providing  medical services to patients living with HIV and compromised  immune systems; and implementing a host of wraparound  services, including case management, remote education and job  skills training.” Spotlight—COVID-Working to reduce the impact of COVID-19 in 180+ countries UNICEF  has leveraged its emergency  COVID-19 grant funding from BD to support  its global efforts to reduce and address the  impact of COVID-19 on families in more  than 180 countries.
","('Critical_Incident_Risk_Management', 0.9724768996238708)","('Employee_Health_And_Safety', 0.0030566025525331497)","('Air_Quality', 0.0029868220444768667)","(['Risk & Crisis Management'], 0.9724768996238708)","('NON-ESG', 0.0030566025525331497)","('NON-ESG', 0.0029868220444768667)"
Line 220,"UNICEF and its partners  have reached over 2.75 billion people with COVID-19 prevention messaging around handwashing and  hygiene; more than 63.5 million people have benefited from its  critical water, sanitation and hygiene supplies; and 49.4 million  women and children have continued to rely on UNICEF for  pre- and post-natal care and essential nutritional supplies.
","('Access_And_Affordability', 0.298477441072464)","('Employee_Health_And_Safety', 0.2534167766571045)","('Product_Quality_And_Safety', 0.05739033967256546)","('NON-ESG', 0.298477441072464)","('NON-ESG', 0.2534167766571045)","('NON-ESG', 0.05739033967256546)"
Line 221,"Supporting frontline health workers in four African nations “The donation from BD to  Last Mile Health   supported community and frontline health  workers in safely preventing, detecting and  responding to COVID-19 across four  countries in Africa,” said Lisha McCormick,  Chief Executive Officer, who explained that  Last Mile Health: • Supported Liberia’s Ministry of Health in designing and  delivering a comprehensive COVID-19 curriculum focused on  prevention measures, case detection and response and a  protocol for the “no touch” delivery of primary  healthcare services; • Distributed 2.4 million pieces of PPE across Liberia and  Malawi, to help health workers stay safe while continuing to  deliver essential primary care to patients living in remote  communities; and • Helped the Ministries of Health in Ethiopia and Uganda to  leverage digital tools to disseminate COVID-19 educational  and training resources to health workers and community  members, which have been viewed by more than 2,000  health sector professionals.Learn more about our philanthropic responses: • Our COVID-19 philanthropic response expands   to $2.8 million • Virtual COVID-19 trainings help HCPs in Papua   New Guinea • The impact of COVID-19 on community he alth centers • BD commits $1.1 million to global COVID-19   resp onse efforts • Reimagining community service in the age  of COVID-Throughout the pandemic, we will continue to create and deliver value to all our stakeholders, by  prioritizing the needs of our associates and customers around the world, while remaining focused on  our long-term strategy.
","('Employee_Health_And_Safety', 0.9745251536369324)","('Critical_Incident_Risk_Management', 0.00497169466689229)","('Access_And_Affordability', 0.0017764794174581766)","(['Operational Eco-Efficiency'], 0.9745251536369324)","('NON-ESG', 0.00497169466689229)","('NON-ESG', 0.0017764794174581766)"
Line 222,"Supporting frontline health workers in four African nations “The donation from BD to  Last Mile Health   supported community and frontline health  workers in safely preventing, detecting and  responding to COVID-19 across four  countries in Africa,” said Lisha McCormick,  Chief Executive Officer, who explained that  Last Mile Health: • Supported Liberia’s Ministry of Health in designing and  delivering a comprehensive COVID-19 curriculum focused on  prevention measures, case detection and response and a  protocol for the “no touch” delivery of primary  healthcare services; • Distributed 2.4 million pieces of PPE across Liberia and  Malawi, to help health workers stay safe while continuing to  deliver essential primary care to patients living in remote  communities; and • Helped the Ministries of Health in Ethiopia and Uganda to  leverage digital tools to disseminate COVID-19 educational  and training resources to health workers and community  members, which have been viewed by more than 2,000  health sector professionals.Learn more about our philanthropic responses: • Our COVID-19 philanthropic response expands   to $2.8 million • Virtual COVID-19 trainings help HCPs in Papua   New Guinea • The impact of COVID-19 on community he alth centers • BD commits $1.1 million to global COVID-19   resp onse efforts • Reimagining community service in the age  of COVID-Throughout the pandemic, we will continue to create and deliver value to all our stakeholders, by  prioritizing the needs of our associates and customers around the world, while remaining focused on  our long-term strategy.
","('Access_And_Affordability', 0.714930534362793)","('Employee_Health_And_Safety', 0.07595425099134445)","('Human_Rights_And_Community_Relations', 0.07201738655567169)","(['Health Outcome Contribution'], 0.714930534362793)","('NON-ESG', 0.07595425099134445)","('NON-ESG', 0.07201738655567169)"
Line 223,"Supporting frontline health workers in four African nations “The donation from BD to  Last Mile Health   supported community and frontline health  workers in safely preventing, detecting and  responding to COVID-19 across four  countries in Africa,” said Lisha McCormick,  Chief Executive Officer, who explained that  Last Mile Health: • Supported Liberia’s Ministry of Health in designing and  delivering a comprehensive COVID-19 curriculum focused on  prevention measures, case detection and response and a  protocol for the “no touch” delivery of primary  healthcare services; • Distributed 2.4 million pieces of PPE across Liberia and  Malawi, to help health workers stay safe while continuing to  deliver essential primary care to patients living in remote  communities; and • Helped the Ministries of Health in Ethiopia and Uganda to  leverage digital tools to disseminate COVID-19 educational  and training resources to health workers and community  members, which have been viewed by more than 2,000  health sector professionals.Learn more about our philanthropic responses: • Our COVID-19 philanthropic response expands   to $2.8 million • Virtual COVID-19 trainings help HCPs in Papua   New Guinea • The impact of COVID-19 on community he alth centers • BD commits $1.1 million to global COVID-19   resp onse efforts • Reimagining community service in the age  of COVID-Throughout the pandemic, we will continue to create and deliver value to all our stakeholders, by  prioritizing the needs of our associates and customers around the world, while remaining focused on  our long-term strategy.
","('Human_Rights_And_Community_Relations', 0.41968926787376404)","('Access_And_Affordability', 0.2482340931892395)","('Management_Of_Legal_And_Regulatory_Framework', 0.061234258115291595)","('NON-ESG', 0.41968926787376404)","('NON-ESG', 0.2482340931892395)","('NON-ESG', 0.061234258115291595)"
Line 224,"Supporting frontline health workers in four African nations “The donation from BD to  Last Mile Health   supported community and frontline health  workers in safely preventing, detecting and  responding to COVID-19 across four  countries in Africa,” said Lisha McCormick,  Chief Executive Officer, who explained that  Last Mile Health: • Supported Liberia’s Ministry of Health in designing and  delivering a comprehensive COVID-19 curriculum focused on  prevention measures, case detection and response and a  protocol for the “no touch” delivery of primary  healthcare services; • Distributed 2.4 million pieces of PPE across Liberia and  Malawi, to help health workers stay safe while continuing to  deliver essential primary care to patients living in remote  communities; and • Helped the Ministries of Health in Ethiopia and Uganda to  leverage digital tools to disseminate COVID-19 educational  and training resources to health workers and community  members, which have been viewed by more than 2,000  health sector professionals.Learn more about our philanthropic responses: • Our COVID-19 philanthropic response expands   to $2.8 million • Virtual COVID-19 trainings help HCPs in Papua   New Guinea • The impact of COVID-19 on community he alth centers • BD commits $1.1 million to global COVID-19   resp onse efforts • Reimagining community service in the age  of COVID-Throughout the pandemic, we will continue to create and deliver value to all our stakeholders, by  prioritizing the needs of our associates and customers around the world, while remaining focused on  our long-term strategy.
","('Business_Model_Resilience', 0.8477098941802979)","('Physical_Impacts_Of_Climate_Change', 0.025939980521798134)","('Systemic_Risk_Management', 0.01373742613941431)","(['Codes of Business Conduct'], 0.8477098941802979)","('NON-ESG', 0.025939980521798134)","('NON-ESG', 0.01373742613941431)"
Line 225,"Further details can be found at the BD COVID-19 response webpage  and our video library .
","('Management_Of_Legal_And_Regulatory_Framework', 0.33749330043792725)","('Access_And_Affordability', 0.09476414322853088)","('Energy_Management', 0.0530063696205616)","('NON-ESG', 0.33749330043792725)","('NON-ESG', 0.09476414322853088)","('NON-ESG', 0.0530063696205616)"
Line 226,"Spotlight—COVID-We are committed to a strong ethics and compliance culture.
","('Business_Ethics', 0.9586066007614136)","('Product_Quality_And_Safety', 0.003702318761497736)","('Management_Of_Legal_And_Regulatory_Framework', 0.0032840855419635773)","(['Business Ethics'], 0.9586066007614136)","('NON-ESG', 0.003702318761497736)","('NON-ESG', 0.0032840855419635773)"
Line 227,"We do not tolerate actions or behaviors that are inconsistent  with our values or violate the BD Code of Conduct or applicable  laws and regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7307474613189697)","('Business_Ethics', 0.1763094812631607)","('Competitive_Behavior', 0.011155868880450726)","(['Corporate Governance'], 0.7307474613189697)","('NON-ESG', 0.1763094812631607)","('NON-ESG', 0.011155868880450726)"
Line 228,"All BD associates are responsible for  reinforcing our ethics and compliance culture and sustaining our  reputation as a company dedicated to quality and integrity.
","('Business_Ethics', 0.9678337574005127)","('Product_Quality_And_Safety', 0.0024933088570833206)","('Customer_Privacy', 0.0024566466454416513)","(['Business Ethics'], 0.9678337574005127)","('NON-ESG', 0.0024933088570833206)","('NON-ESG', 0.0024566466454416513)"
Line 229,"We encourage and expect everyone at BD to speak up by asking  questions, raising concerns, seeking guidance and reporting  actual or suspected violations of laws, our Code of Conduct, our  policies or our high ethical standards.
","('Business_Ethics', 0.9603245854377747)","('Management_Of_Legal_And_Regulatory_Framework', 0.006024516653269529)","('Product_Quality_And_Safety', 0.005023536738008261)","(['Business Ethics'], 0.9603245854377747)","('NON-ESG', 0.006024516653269529)","('NON-ESG', 0.005023536738008261)"
Line 230,"This requirement extends  to all associates, vendors and other third parties working  on our behalf.The following BD Values further strengthen our culture of ethics  and compliance and guide how we hold ourselves accountable  to our shareholders and stakeholders.
","('Business_Ethics', 0.9709649682044983)","('Management_Of_Legal_And_Regulatory_Framework', 0.0028930213302373886)","('Competitive_Behavior', 0.002388887805864215)","(['Business Ethics'], 0.9709649682044983)","('NON-ESG', 0.0028930213302373886)","('NON-ESG', 0.002388887805864215)"
Line 231,"• We do what is right.
","('Human_Rights_And_Community_Relations', 0.23524053394794464)","('Business_Ethics', 0.08716137707233429)","('Management_Of_Legal_And_Regulatory_Framework', 0.06498222798109055)","('NON-ESG', 0.23524053394794464)","('NON-ESG', 0.08716137707233429)","('NON-ESG', 0.06498222798109055)"
Line 232,"• We thrive on innovation and demand quality.
","('Product_Design_And_Lifecycle_Management', 0.31479111313819885)","('Competitive_Behavior', 0.26795312762260437)","('Business_Model_Resilience', 0.10546170175075531)","('NON-ESG', 0.31479111313819885)","('NON-ESG', 0.26795312762260437)","('NON-ESG', 0.10546170175075531)"
Line 233,"• We are all accountable.
","('Business_Ethics', 0.6002901196479797)","('Management_Of_Legal_And_Regulatory_Framework', 0.14142952859401703)","('Competitive_Behavior', 0.049626246094703674)","(['Business Ethics'], 0.6002901196479797)","('NON-ESG', 0.14142952859401703)","('NON-ESG', 0.049626246094703674)"
Line 234,"• We learn and improve every day.
","('Access_And_Affordability', 0.26872801780700684)","('Employee_Engagement_Inclusion_And_Diversity', 0.23067523539066315)","('Human_Rights_And_Community_Relations', 0.07375331223011017)","('NON-ESG', 0.26872801780700684)","('NON-ESG', 0.23067523539066315)","('NON-ESG', 0.07375331223011017)"
Line 235,"• We help each other be great.
","('Human_Rights_And_Community_Relations', 0.3716264069080353)","('Access_And_Affordability', 0.09838979691267014)","('Management_Of_Legal_And_Regulatory_Framework', 0.09008834511041641)","('NON-ESG', 0.3716264069080353)","('NON-ESG', 0.09838979691267014)","('NON-ESG', 0.09008834511041641)"
Line 236,"These values are cascaded through all levels of the organization.
","('Business_Model_Resilience', 0.18405240774154663)","('Business_Ethics', 0.14286383986473083)","('Competitive_Behavior', 0.10703873634338379)","('NON-ESG', 0.18405240774154663)","('NON-ESG', 0.14286383986473083)","('NON-ESG', 0.10703873634338379)"
Line 237,"Read more about our commitment to ethics and compliance on  our website .Ethics and complianceHow we do business The BD Code of Conduct sets the foundation for how we  behave at BD.
","('Business_Ethics', 0.9708700180053711)","('Management_Of_Legal_And_Regulatory_Framework', 0.002916296711191535)","('Product_Quality_And_Safety', 0.002421615645289421)","(['Business Ethics'], 0.9708700180053711)","('NON-ESG', 0.002916296711191535)","('NON-ESG', 0.002421615645289421)"
Line 238,"Our value “We do what is right” is the cornerstone  of our Code.
","('Business_Ethics', 0.15285582840442657)","('Management_Of_Legal_And_Regulatory_Framework', 0.1441710889339447)","('Human_Rights_And_Community_Relations', 0.12683813273906708)","('NON-ESG', 0.15285582840442657)","('NON-ESG', 0.1441710889339447)","('NON-ESG', 0.12683813273906708)"
Line 239,"To do what is right, we follow the laws, rules and  company policies that apply to us.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9474550485610962)","('Business_Ethics', 0.007067467551678419)","('Human_Rights_And_Community_Relations', 0.006100552622228861)","(['Corporate Governance'], 0.9474550485610962)","('NON-ESG', 0.007067467551678419)","('NON-ESG', 0.006100552622228861)"
Line 240,"We also follow the highest  ethical standards, even when there’s no specific law or policy.
","('Business_Ethics', 0.9082727432250977)","('Competitive_Behavior', 0.015695063397288322)","('Management_Of_Legal_And_Regulatory_Framework', 0.013574366457760334)","(['Business Ethics'], 0.9082727432250977)","('NON-ESG', 0.015695063397288322)","('NON-ESG', 0.013574366457760334)"
Line 241,"Our Code provides guidance and resources to help us follow  through on these ethical standards and protect our reputation.
","('Business_Ethics', 0.9424352645874023)","('Management_Of_Legal_And_Regulatory_Framework', 0.00997082144021988)","('Product_Quality_And_Safety', 0.009649873711168766)","(['Business Ethics'], 0.9424352645874023)","('NON-ESG', 0.00997082144021988)","('NON-ESG', 0.009649873711168766)"
Line 242,"Everyone at BD, no matter their position or level, must follow our  Code.
","('Business_Ethics', 0.4162229001522064)","('Director_Removal', 0.1386396735906601)","('Employee_Engagement_Inclusion_And_Diversity', 0.07379092276096344)","('NON-ESG', 0.4162229001522064)","('NON-ESG', 0.1386396735906601)","('NON-ESG', 0.07379092276096344)"
Line 243,"This is a condition of employment at BD.
","('Labor_Practices', 0.9177292585372925)","('Employee_Engagement_Inclusion_And_Diversity', 0.02031286619603634)","('Employee_Health_And_Safety', 0.005260281264781952)","(['Labor Practice Indicators'], 0.9177292585372925)","('NON-ESG', 0.02031286619603634)","('NON-ESG', 0.005260281264781952)"
Line 244,"Our Code is  available in English and over 30 other languages.
","('Employee_Engagement_Inclusion_And_Diversity', 0.18976007401943207)","('Access_And_Affordability', 0.15903854370117188)","('Management_Of_Legal_And_Regulatory_Framework', 0.11052564531564713)","('NON-ESG', 0.18976007401943207)","('NON-ESG', 0.15903854370117188)","('NON-ESG', 0.11052564531564713)"
Line 245,"Every BD  associate is required to complete annual training on our Code.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17014597356319427)","('Access_And_Affordability', 0.15406914055347443)","('Product_Quality_And_Safety', 0.15295080840587616)","('NON-ESG', 0.17014597356319427)","('NON-ESG', 0.15406914055347443)","('NON-ESG', 0.15295080840587616)"
Line 246,"In addition to our Code, BD has a set of global policies and  standards, including our Global Standards for Interactions with Healthcare Providers, Health Care Organizations and  Government Officials, which are designed to ensure associates  have clear guidance on how to do what is right in the context of  their work for BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7889513373374939)","('Business_Ethics', 0.057954687625169754)","('Product_Quality_And_Safety', 0.04765519127249718)","(['Corporate Governance'], 0.7889513373374939)","('NON-ESG', 0.057954687625169754)","('NON-ESG', 0.04765519127249718)"
Line 247,"BD associates must comply with these global  standards, the Code, BD policies and procedures, applicable laws  and regulations and relevant industry codes (including  AdvaMed, APACMed, MedTech Europe, Mecomed and Abimed).
","('Management_Of_Legal_And_Regulatory_Framework', 0.8266880512237549)","('Business_Ethics', 0.05086085572838783)","('Product_Quality_And_Safety', 0.04096842184662819)","(['Corporate Governance'], 0.8266880512237549)","('NON-ESG', 0.05086085572838783)","('NON-ESG', 0.04096842184662819)"
Line 248,"BD associates receive information and training about the Code,  global standards and other policies in several ways, including  periodic communications and trainings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7842934131622314)","('Business_Ethics', 0.05188189446926117)","('Product_Quality_And_Safety', 0.05149724334478378)","(['Corporate Governance'], 0.7842934131622314)","('NON-ESG', 0.05188189446926117)","('NON-ESG', 0.05149724334478378)"
Line 249,"Associates can access  detailed information on our expectations through our intranet  and on our ethics and compliance mobile app.
","('Business_Ethics', 0.9545803666114807)","('Management_Of_Legal_And_Regulatory_Framework', 0.009524942375719547)","('Product_Quality_And_Safety', 0.004379520192742348)","(['Business Ethics'], 0.9545803666114807)","('NON-ESG', 0.009524942375719547)","('NON-ESG', 0.004379520192742348)"
Line 250,"Our Code of  Conduct is also available on our website .Code of ConductGRI disclosure: 102-GRI disclosure: 102-Except as prohibited by applicable law, BD associates are  obligated to report any suspected violations of laws, industry  codes, the BD Code of Conduct or BD policies in accordance  with the BD Global Speaking Up Policy.
","('Business_Ethics', 0.6075420379638672)","('Management_Of_Legal_And_Regulatory_Framework', 0.28966835141181946)","('Product_Quality_And_Safety', 0.01416951697319746)","(['Business Ethics'], 0.6075420379638672)","('NON-ESG', 0.28966835141181946)","('NON-ESG', 0.01416951697319746)"
Line 251,"BD takes all reports of  violations of laws, BD policies and ethical standards seriously  and will promptly, fairly and thoroughly investigate all such  reports.
","('Business_Ethics', 0.9556397795677185)","('Management_Of_Legal_And_Regulatory_Framework', 0.007539680227637291)","('Product_Quality_And_Safety', 0.005550045985728502)","(['Business Ethics'], 0.9556397795677185)","('NON-ESG', 0.007539680227637291)","('NON-ESG', 0.005550045985728502)"
Line 252,"BD does not tolerate any form of retaliation against any  person who in good faith reports an actual or suspected  violation.
","('Business_Ethics', 0.9268416166305542)","('Management_Of_Legal_And_Regulatory_Framework', 0.01765640266239643)","('Competitive_Behavior', 0.006226028315722942)","(['Business Ethics'], 0.9268416166305542)","('NON-ESG', 0.01765640266239643)","('NON-ESG', 0.006226028315722942)"
Line 253,"BD is committed to creating an environment in which  all associates feel comfortable raising concerns, seeking  guidance or asking questions without fear of retaliation  or discipline.
","('Business_Ethics', 0.9214946627616882)","('Employee_Health_And_Safety', 0.008549923077225685)","('Product_Quality_And_Safety', 0.008394897915422916)","(['Business Ethics'], 0.9214946627616882)","('NON-ESG', 0.008549923077225685)","('NON-ESG', 0.008394897915422916)"
Line 254,"Associates can report these in a number of ways, including via  the BD Ethics Helpline, which is independently operated and  available anywhere in the world 24 hours a day, 7 days a week.
","('Access_And_Affordability', 0.6154723763465881)","('Employee_Health_And_Safety', 0.05445938557386398)","('Product_Quality_And_Safety', 0.036206260323524475)","(['Health Outcome Contribution'], 0.6154723763465881)","('NON-ESG', 0.05445938557386398)","('NON-ESG', 0.036206260323524475)"
Line 255,"Alternatively, associates may use our online reporting tool   where associates worldwide can make a report in their native  language from any computer or mobile device with internet  access.
","('Human_Rights_And_Community_Relations', 0.12934839725494385)","('Management_Of_Legal_And_Regulatory_Framework', 0.12815721333026886)","('Customer_Privacy', 0.11829588562250137)","('NON-ESG', 0.12934839725494385)","('NON-ESG', 0.12815721333026886)","('NON-ESG', 0.11829588562250137)"
Line 256,"The helpline provides translation services as needed,   and reports can be made anonymously where permitted by law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21026960015296936)","('Access_And_Affordability', 0.18510259687900543)","('Customer_Privacy', 0.16180634498596191)","('NON-ESG', 0.21026960015296936)","('NON-ESG', 0.18510259687900543)","('NON-ESG', 0.16180634498596191)"
Line 257,"Associates can also report violations to their supervisor,  management, Human Resources, the Law Group or directly   to Ethics and Compliance.
","('Business_Ethics', 0.9621058702468872)","('Management_Of_Legal_And_Regulatory_Framework', 0.0043047345243394375)","('Product_Quality_And_Safety', 0.0033999888692051172)","(['Business Ethics'], 0.9621058702468872)","('NON-ESG', 0.0043047345243394375)","('NON-ESG', 0.0033999888692051172)"
Line 258,"In FY 2020, the Ethics Office received more than 850 contacts  from associates worldwide seeking guidance or reporting  concerns.
","('Business_Ethics', 0.9518070816993713)","('Management_Of_Legal_And_Regulatory_Framework', 0.010749722830951214)","('Product_Quality_And_Safety', 0.004597513936460018)","(['Business Ethics'], 0.9518070816993713)","('NON-ESG', 0.010749722830951214)","('NON-ESG', 0.004597513936460018)"
Line 259,"Depending on the findings of the investigation, we  may take corrective action, such as discipline up to and  including termination of employment or providing  nondisciplinary-based training and process improvements in  areas where a gap has been identified.Reporting ethics concerns GRI disclosure: 102-BD does not engage a third-party intermediary to do something  BD or its associates are prohibited from doing.
","('Business_Ethics', 0.9153318405151367)","('Labor_Practices', 0.011305426247417927)","('Management_Of_Legal_And_Regulatory_Framework', 0.010364647023379803)","(['Business Ethics'], 0.9153318405151367)","('NON-ESG', 0.011305426247417927)","('NON-ESG', 0.010364647023379803)"
Line 260,"The Ethics and  Compliance function provides resources to regional and local  country management to enhance their anticorruption and  compliance business practices.
","('Business_Ethics', 0.9555036425590515)","('Management_Of_Legal_And_Regulatory_Framework', 0.01110727246850729)","('Product_Quality_And_Safety', 0.0033846963196992874)","(['Business Ethics'], 0.9555036425590515)","('NON-ESG', 0.01110727246850729)","('NON-ESG', 0.0033846963196992874)"
Line 261,"This includes incorporating  compliance requirements into existing business practices   and advising local management on anticorruption   compliance-related issues.
","('Management_Of_Legal_And_Regulatory_Framework', 0.44042232632637024)","('Business_Ethics', 0.4353184401988983)","('Product_Quality_And_Safety', 0.014342552050948143)","('NON-ESG', 0.44042232632637024)","('NON-ESG', 0.4353184401988983)","('NON-ESG', 0.014342552050948143)"
Line 262,"A key focus for BD is driving compliance in our third-party  intermediary networks across the globe, resulting in stronger  business relationships while upholding our reputation.
","('Business_Ethics', 0.5220900177955627)","('Management_Of_Legal_And_Regulatory_Framework', 0.22911138832569122)","('Systemic_Risk_Management', 0.039238881319761276)","(['Business Ethics'], 0.5220900177955627)","('NON-ESG', 0.22911138832569122)","('NON-ESG', 0.039238881319761276)"
Line 263,"These efforts are advanced by fostering collaboration with  business leaders to deliver consistent and clear policies and  approval processes—along with enhanced third-party life cycle  management procedures—to help provide assurance that BD is “doing business the right way.” BD is committed to training all  associates via both in-person, scenario-based sessions and  learning management system courses that leverage policy  materials, such as the Global Anti Bribery and Anti Corruption  Policy and the Global Standards for Interactions with Healthcare  Professionals, Healthcare Organizations and  Government Officials.
","('Business_Ethics', 0.9744709134101868)","('Management_Of_Legal_And_Regulatory_Framework', 0.003464177018031478)","('Competitive_Behavior', 0.0018772018374875188)","(['Business Ethics'], 0.9744709134101868)","('NON-ESG', 0.003464177018031478)","('NON-ESG', 0.0018772018374875188)"
Line 264,"These efforts are advanced by fostering collaboration with  business leaders to deliver consistent and clear policies and  approval processes—along with enhanced third-party life cycle  management procedures—to help provide assurance that BD is “doing business the right way.” BD is committed to training all  associates via both in-person, scenario-based sessions and  learning management system courses that leverage policy  materials, such as the Global Anti Bribery and Anti Corruption  Policy and the Global Standards for Interactions with Healthcare  Professionals, Healthcare Organizations and  Government Officials.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3629707098007202)","('Business_Ethics', 0.2423529177904129)","('Product_Quality_And_Safety', 0.09545232355594635)","('NON-ESG', 0.3629707098007202)","('NON-ESG', 0.2423529177904129)","('NON-ESG', 0.09545232355594635)"
Line 265,"Risk-based training with third-party intermediaries is a core  component of the antibribery and anticorruption program.
","('Systemic_Risk_Management', 0.7315704226493835)","('Business_Ethics', 0.06763068586587906)","('Management_Of_Legal_And_Regulatory_Framework', 0.035325635224580765)","(['Risk & Crisis Management'], 0.7315704226493835)","('NON-ESG', 0.06763068586587906)","('NON-ESG', 0.035325635224580765)"
Line 266,"These sessions are focused on applicable antibribery and  anticorruption laws, including the Foreign Corrupt Practices Act  and relevant BD policies.Antibribery and anticorruption GRI disclosures: 102-16, 205-We comply with all applicable laws and regulations that govern  the interactions between medical technology companies and  healthcare professionals, healthcare organizations and  government officials in the many countries in which we do  business.
","('Business_Ethics', 0.9587545990943909)","('Management_Of_Legal_And_Regulatory_Framework', 0.0116098178550601)","('Competitive_Behavior', 0.004472522996366024)","(['Business Ethics'], 0.9587545990943909)","('NON-ESG', 0.0116098178550601)","('NON-ESG', 0.004472522996366024)"
Line 267,"To help ensure compliance, BD has adopted various  industry codes, including the Advanced Medical Technology  Association (AdvaMed) Code of Ethics in the United States and  MedTech Europe Code of Ethics.
","('Business_Ethics', 0.961340606212616)","('Management_Of_Legal_And_Regulatory_Framework', 0.006567089818418026)","('Systemic_Risk_Management', 0.0030411703046411276)","(['Business Ethics'], 0.961340606212616)","('NON-ESG', 0.006567089818418026)","('NON-ESG', 0.0030411703046411276)"
Line 268,"BD associates receive  information and training about these codes in a few ways, including periodic communications, and online and in-person  trainings.
","('Product_Quality_And_Safety', 0.24854816496372223)","('Business_Ethics', 0.15360137820243835)","('Employee_Engagement_Inclusion_And_Diversity', 0.11212119460105896)","('NON-ESG', 0.24854816496372223)","('NON-ESG', 0.15360137820243835)","('NON-ESG', 0.11212119460105896)"
Line 269,"Associates can access detailed information on our  expectations through our intranet and our Ethics and  Compliance mobile app.
","('Business_Ethics', 0.9568812847137451)","('Management_Of_Legal_And_Regulatory_Framework', 0.009285627864301205)","('Product_Quality_And_Safety', 0.0038337919395416975)","(['Business Ethics'], 0.9568812847137451)","('NON-ESG', 0.009285627864301205)","('NON-ESG', 0.0038337919395416975)"
Line 270,"Key provisions of applicable industry  codes are also incorporated into various global policies,  including the Global Standards for Interactions with  Healthcare Professionals, Healthcare Organizations and  Government Officials.Interactions with healthcare professionals GRI disclosure: 102-16   SASB disclosure: HC-MS-510a.At BD, we are committed to operating in a way that respects the  human rights of all associates, as well as the people in our  supply chains, the communities in which we operate and those  who are impacted by our products.
","('Human_Rights_And_Community_Relations', 0.5159046649932861)","('Supply_Chain_Management', 0.2058800607919693)","('Labor_Practices', 0.05204363912343979)","(['Community Relations'], 0.5159046649932861)","('NON-ESG', 0.2058800607919693)","('NON-ESG', 0.05204363912343979)"
Line 271,"Key provisions of applicable industry  codes are also incorporated into various global policies,  including the Global Standards for Interactions with  Healthcare Professionals, Healthcare Organizations and  Government Officials.Interactions with healthcare professionals GRI disclosure: 102-16   SASB disclosure: HC-MS-510a.At BD, we are committed to operating in a way that respects the  human rights of all associates, as well as the people in our  supply chains, the communities in which we operate and those  who are impacted by our products.
","('Product_Design_And_Lifecycle_Management', 0.9454041719436646)","('Selling_Practices_And_Product_Labeling', 0.008348899893462658)","('Product_Quality_And_Safety', 0.006801604758948088)","(['Product Stewardship'], 0.9454041719436646)","('NON-ESG', 0.008348899893462658)","('NON-ESG', 0.006801604758948088)"
Line 272,"Rather than doing the minimum required, BD is focused on  doing what is right.
","('Management_Of_Legal_And_Regulatory_Framework', 0.26052576303482056)","('Human_Rights_And_Community_Relations', 0.15896187722682953)","('Business_Ethics', 0.13491782546043396)","('NON-ESG', 0.26052576303482056)","('NON-ESG', 0.15896187722682953)","('NON-ESG', 0.13491782546043396)"
Line 273,"This value, along with the rest of our values,  guide our efforts on having a positive social impact across our  businesses and operations.
","('Human_Rights_And_Community_Relations', 0.9554004669189453)","('Access_And_Affordability', 0.0034248316660523415)","('Business_Model_Resilience', 0.0030652922578155994)","(['Community Relations'], 0.9554004669189453)","('NON-ESG', 0.0034248316660523415)","('NON-ESG', 0.0030652922578155994)"
Line 274,"Our commitment to human rights is guided by the principles  outlined in the UN Declaration of Human Rights and extends  beyond BD processes and practices to those in our supply  chains.
","('Supply_Chain_Management', 0.9115281701087952)","('Labor_Practices', 0.010635816492140293)","('Human_Rights_And_Community_Relations', 0.010371707379817963)","(['Supply Chain Management'], 0.9115281701087952)","('NON-ESG', 0.010635816492140293)","('NON-ESG', 0.010371707379817963)"
Line 275,"This commitment is detailed in our Global Human  Rights Policy .
","('Human_Rights_And_Community_Relations', 0.9480452537536621)","('Labor_Practices', 0.005604530218988657)","('Access_And_Affordability', 0.00484562898054719)","(['Community Relations'], 0.9480452537536621)","('NON-ESG', 0.005604530218988657)","('NON-ESG', 0.00484562898054719)"
Line 276,"We believe that all people should be treated with dignity and  respect, and we are committed to conducting our business in a  manner consistent with this principle.
","('Human_Rights_And_Community_Relations', 0.7882683873176575)","('Business_Ethics', 0.036270562559366226)","('Employee_Health_And_Safety', 0.023271098732948303)","(['Community Relations'], 0.7882683873176575)","('NON-ESG', 0.036270562559366226)","('NON-ESG', 0.023271098732948303)"
Line 277,"We comply with applicable employment and human rights laws  and regulations wherever we have operations; we expect our  suppliers to do the same.
","('Human_Rights_And_Community_Relations', 0.4958480894565582)","('Labor_Practices', 0.29430586099624634)","('Management_Of_Legal_And_Regulatory_Framework', 0.05430653318762779)","('NON-ESG', 0.4958480894565582)","('NON-ESG', 0.29430586099624634)","('NON-ESG', 0.05430653318762779)"
Line 278,"BD has programs in place to monitor and advance human rights  efforts throughout the company.
","('Human_Rights_And_Community_Relations', 0.9561470746994019)","('Access_And_Affordability', 0.003952051047235727)","('Labor_Practices', 0.0036138782743364573)","(['Community Relations'], 0.9561470746994019)","('NON-ESG', 0.003952051047235727)","('NON-ESG', 0.0036138782743364573)"
Line 279,"These include: • Additional policies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9416205883026123)","('Human_Rights_And_Community_Relations', 0.0057948436588048935)","('Director_Removal', 0.004590324126183987)","(['Corporate Governance'], 0.9416205883026123)","('NON-ESG', 0.0057948436588048935)","('NON-ESG', 0.004590324126183987)"
Line 280,"– BD Code of Conduct , which reinforces our commitment to     human rights and details how to report suspected violations     anywhere in our supply chain.
","('Supply_Chain_Management', 0.8396060466766357)","('Labor_Practices', 0.03586743026971817)","('Human_Rights_And_Community_Relations', 0.01582964137196541)","(['Supply Chain Management'], 0.8396060466766357)","('NON-ESG', 0.03586743026971817)","('NON-ESG', 0.01582964137196541)"
Line 281,"– BD Expectations for Suppliers , our Code of Conduct     designed for our thousands of suppliers.• Practices geared towards ensuring modern slavery and  human trafficking do not exist in our workforce and those of  our suppliers.
","('Labor_Practices', 0.31615525484085083)","('Employee_Health_And_Safety', 0.2264241874217987)","('Business_Ethics', 0.13357900083065033)","('NON-ESG', 0.31615525484085083)","('NON-ESG', 0.2264241874217987)","('NON-ESG', 0.13357900083065033)"
Line 282,"– We do not charge any of our associates recruitment fees,     and do not work with recruitment agencies that engage in     this practice.
","('Employee_Engagement_Inclusion_And_Diversity', 0.757716953754425)","('Labor_Practices', 0.06552497297525406)","('Competitive_Behavior', 0.02873568795621395)","(['Human Capital Development'], 0.757716953754425)","('NON-ESG', 0.06552497297525406)","('NON-ESG', 0.02873568795621395)"
Line 283,"– We do not withhold identity documents, immigration     documents or any other personal documentation of     our associates.
","('Customer_Privacy', 0.9361776113510132)","('Labor_Practices', 0.006907023023813963)","('Employee_Engagement_Inclusion_And_Diversity', 0.005528741516172886)","(['Privacy Protection'], 0.9361776113510132)","('NON-ESG', 0.006907023023813963)","('NON-ESG', 0.005528741516172886)"
Line 284,"– We encourage our associates to report, without fear of     retaliation, any matters related to human trafficking,     modern slavery or any other human rights violations.
","('Human_Rights_And_Community_Relations', 0.7759720087051392)","('Business_Ethics', 0.04442746564745903)","('Labor_Practices', 0.031209252774715424)","(['Community Relations'], 0.7759720087051392)","('NON-ESG', 0.04442746564745903)","('NON-ESG', 0.031209252774715424)"
Line 285,"º  We provide BD associates with forced labor and human      trafficking training, developed by a third party and      administered online, to associates each year.
","('Labor_Practices', 0.9157134294509888)","('Human_Rights_And_Community_Relations', 0.015810750424861908)","('Employee_Health_And_Safety', 0.01008431427180767)","(['Labor Practice Indicators'], 0.9157134294509888)","('NON-ESG', 0.015810750424861908)","('NON-ESG', 0.01008431427180767)"
Line 286,"This course      interacts directly and indirectly with sourcing, managing,      advising on or is otherwise involved with our suppliers.
","('Supply_Chain_Management', 0.9073808193206787)","('Product_Design_And_Lifecycle_Management', 0.017211807891726494)","('Selling_Practices_And_Product_Labeling', 0.006852921564131975)","(['Supply Chain Management'], 0.9073808193206787)","('NON-ESG', 0.017211807891726494)","('NON-ESG', 0.006852921564131975)"
Line 287,"• Due diligence, including initial assessments of suppliers  against 12 risk factors (including ESG risk and desktop audits  of prioritized suppliers).
","('Supply_Chain_Management', 0.9339585900306702)","('Systemic_Risk_Management', 0.013472090475261211)","('Physical_Impacts_Of_Climate_Change', 0.005125072319060564)","(['Supply Chain Management'], 0.9339585900306702)","('NON-ESG', 0.013472090475261211)","('NON-ESG', 0.005125072319060564)"
Line 288,"• Risk management efforts to ensure compliance against  related policies throughout our operations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9214072823524475)","('Business_Ethics', 0.0158944483846426)","('Systemic_Risk_Management', 0.006143526174128056)","(['Corporate Governance'], 0.9214072823524475)","('NON-ESG', 0.0158944483846426)","('NON-ESG', 0.006143526174128056)"
Line 289,"– For example, our Global Operations and Human Resources     teams work to ensure compliance with our policies     prohibiting forced labor, human trafficking and modern     slavery across all of our operations, including     manufacturing operations.
","('Labor_Practices', 0.943098783493042)","('Employee_Health_And_Safety', 0.009771651588380337)","('Employee_Engagement_Inclusion_And_Diversity', 0.007367463782429695)","(['Labor Practice Indicators'], 0.943098783493042)","('NON-ESG', 0.009771651588380337)","('NON-ESG', 0.007367463782429695)"
Line 290,"• Training and capacity building, both internally and for  key suppliers.
","('Supply_Chain_Management', 0.9035845398902893)","('Human_Rights_And_Community_Relations', 0.009132374078035355)","('Product_Design_And_Lifecycle_Management', 0.007877799682319164)","(['Supply Chain Management'], 0.9035845398902893)","('NON-ESG', 0.009132374078035355)","('NON-ESG', 0.007877799682319164)"
Line 291,"BD strives to continuously improve its programs to ensure  compliance with applicable laws and high ethical standards to  meet the expectations of our customers, shareholders,  associates, communities and other stakeholders.
","('Business_Ethics', 0.869583010673523)","('Management_Of_Legal_And_Regulatory_Framework', 0.0465378537774086)","('Product_Quality_And_Safety', 0.018951071426272392)","(['Business Ethics'], 0.869583010673523)","('NON-ESG', 0.0465378537774086)","('NON-ESG', 0.018951071426272392)"
Line 292,"More detail on our Supplier Human Rights Due Diligence process  can be found in the Efficiency  section of this report.Human rights In all of our operations:  • We provide a safe and healthy workplace for   our associates.
","('Human_Rights_And_Community_Relations', 0.9123625755310059)","('Employee_Health_And_Safety', 0.014603461138904095)","('Access_And_Affordability', 0.010715251788496971)","(['Community Relations'], 0.9123625755310059)","('NON-ESG', 0.014603461138904095)","('NON-ESG', 0.010715251788496971)"
Line 293,"• We do not use child labor.
","('Labor_Practices', 0.9705916047096252)","('Waste_And_Hazardous_Materials_Management', 0.002800801768898964)","('Director_Removal', 0.0024876969400793314)","(['Labor Practice Indicators'], 0.9705916047096252)","('NON-ESG', 0.002800801768898964)","('NON-ESG', 0.0024876969400793314)"
Line 294,"• We do not use forced, prison, indentured, bonded   or involuntary labor.
","('Labor_Practices', 0.9747187495231628)","('Director_Removal', 0.0024250245187431574)","('Waste_And_Hazardous_Materials_Management', 0.00191391259431839)","(['Labor Practice Indicators'], 0.9747187495231628)","('NON-ESG', 0.0024250245187431574)","('NON-ESG', 0.00191391259431839)"
Line 295,"• We prohibit discrimination in our hiring and  employment practices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9130445718765259)","('Labor_Practices', 0.03415606915950775)","('Employee_Health_And_Safety', 0.005434224847704172)","(['Human Capital Development'], 0.9130445718765259)","('NON-ESG', 0.03415606915950775)","('NON-ESG', 0.005434224847704172)"
Line 296,"• We prohibit physical abuse and harassment of  associates, as well as the threat of either.
","('Employee_Health_And_Safety', 0.34439295530319214)","('Business_Ethics', 0.2603631317615509)","('Labor_Practices', 0.10454301536083221)","('NON-ESG', 0.34439295530319214)","('NON-ESG', 0.2603631317615509)","('NON-ESG', 0.10454301536083221)"
Line 297,"• We support the freedom of association and the rights  of workers and employers to bargain collectively.
","('Labor_Practices', 0.9769103527069092)","('Director_Removal', 0.002712972229346633)","('Human_Rights_And_Community_Relations', 0.0017354023875668645)","(['Labor Practice Indicators'], 0.9769103527069092)","('NON-ESG', 0.002712972229346633)","('NON-ESG', 0.0017354023875668645)"
Line 298,"GRI disclosure: 412-For over 120 years, customers have relied on BD for safe,  effective products and services for patients around the world.
","('Product_Design_And_Lifecycle_Management', 0.7478895783424377)","('Product_Quality_And_Safety', 0.07177115976810455)","('Customer_Welfare', 0.049964237958192825)","(['Product Stewardship'], 0.7478895783424377)","('NON-ESG', 0.07177115976810455)","('NON-ESG', 0.049964237958192825)"
Line 299,"Our commitment to quality is at the core of what we do in  advancing the world of health ™ through innovation, instilling  confidence and trust in the reliability of what we bring to  market.
","('Product_Design_And_Lifecycle_Management', 0.41719186305999756)","('Business_Model_Resilience', 0.16868063807487488)","('Competitive_Behavior', 0.07858569175004959)","('NON-ESG', 0.41719186305999756)","('NON-ESG', 0.16868063807487488)","('NON-ESG', 0.07858569175004959)"
Line 300,"Quality is so integral to who we are at BD, it is  embedded in The BD WAY values, “We thrive on   innovation and demand quality.”  Inspire Quality is our renewed commitment to a culture of  quality that every BD associate shares around the world.
","('Business_Model_Resilience', 0.15934570133686066)","('Competitive_Behavior', 0.15764641761779785)","('Product_Design_And_Lifecycle_Management', 0.12721899151802063)","('NON-ESG', 0.15934570133686066)","('NON-ESG', 0.15764641761779785)","('NON-ESG', 0.12721899151802063)"
Line 301,"Inspire Quality brings to life our BD Quality Policy for our  associates, customers and shareholders through a multi-year  journey towards best-in-class quality.Inspire QualityEnsuring product safety At BD, we create value for our patients and customers through predictable delivery of differentiated, high-value products and  solutions.
","('Product_Quality_And_Safety', 0.6081660985946655)","('Product_Design_And_Lifecycle_Management', 0.23360972106456757)","('Customer_Welfare', 0.026155805215239525)","(['Product Quality & Recall Management'], 0.6081660985946655)","('NON-ESG', 0.23360972106456757)","('NON-ESG', 0.026155805215239525)"
Line 302,"We work relentlessly to develop solutions that advance healthcare and improve worker and patient safety.
","('Employee_Health_And_Safety', 0.9811697602272034)","('Critical_Incident_Risk_Management', 0.002583865774795413)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015237251063808799)","(['Operational Eco-Efficiency'], 0.9811697602272034)","('NON-ESG', 0.002583865774795413)","('NON-ESG', 0.0015237251063808799)"
Line 303,"Product safety is at the heart of how we design, manufacture and deliver products.
","('Product_Quality_And_Safety', 0.8017686605453491)","('Product_Design_And_Lifecycle_Management', 0.08389435708522797)","('Selling_Practices_And_Product_Labeling', 0.017426280304789543)","(['Product Quality & Recall Management'], 0.8017686605453491)","('NON-ESG', 0.08389435708522797)","('NON-ESG', 0.017426280304789543)"
Line 304,"This section details some of that work.
","('Management_Of_Legal_And_Regulatory_Framework', 0.14635568857192993)","('Ecological_Impacts', 0.10354364663362503)","('Business_Model_Resilience', 0.08300095051527023)","('NON-ESG', 0.14635568857192993)","('NON-ESG', 0.10354364663362503)","('NON-ESG', 0.08300095051527023)"
Line 305,"Inspire Quality focuses on growing customer relationships  through trust, reliability and compliance with all applicable laws  and regulations within the countries we operate and sell  products.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3411511480808258)","('Product_Quality_And_Safety', 0.246791809797287)","('Product_Design_And_Lifecycle_Management', 0.12940280139446259)","('NON-ESG', 0.3411511480808258)","('NON-ESG', 0.246791809797287)","('NON-ESG', 0.12940280139446259)"
Line 306,"With the acquisitions of Bard and CareFusion, we have  the opportunity to simplify our internal processes and  streamline our systems to enhance the customer experience,  reduce complexity and meet the expectations of regulatory and  oversight bodies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3746737837791443)","('Systemic_Risk_Management', 0.1374765932559967)","('Competitive_Behavior', 0.1243586540222168)","('NON-ESG', 0.3746737837791443)","('NON-ESG', 0.1374765932559967)","('NON-ESG', 0.1243586540222168)"
Line 307,"Our Quality Policy   “We will consistently provide superior     products and services in pursuit of our     Purpose of advancing the world of     health™.
","('Product_Design_And_Lifecycle_Management', 0.9284849166870117)","('Product_Quality_And_Safety', 0.016714878380298615)","('Customer_Welfare', 0.01090184599161148)","(['Product Stewardship'], 0.9284849166870117)","('NON-ESG', 0.016714878380298615)","('NON-ESG', 0.01090184599161148)"
Line 308,"This will be achieved through     customer-focused continuous     improvement and maintaining an     effective quality system which complies     with regulatory requirements.”      Tom Polen      Chairman, CEO and President “Quality is at the heart of everything     we do across BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7171914577484131)","('Business_Ethics', 0.11810188740491867)","('Product_Quality_And_Safety', 0.03169376403093338)","(['Corporate Governance'], 0.7171914577484131)","('NON-ESG', 0.11810188740491867)","('NON-ESG', 0.03169376403093338)"
Line 309,"It is everyone’s     responsibility and one we take     seriously—from manufacturing, to     marketing and everyone in-between.
","('Human_Rights_And_Community_Relations', 0.3986324369907379)","('Employee_Health_And_Safety', 0.16373281180858612)","('Business_Ethics', 0.060041673481464386)","('NON-ESG', 0.3986324369907379)","('NON-ESG', 0.16373281180858612)","('NON-ESG', 0.060041673481464386)"
Line 310,"It is that culture-shift and mindset that     quality is everyone’s responsibility that     is so important because at BD, we are     inspired by the customers who use our     products to treat patients and enhance     and save lives.”      David Shan      EVP, Chief Quality OfficerAs a first step, we established tiered governance forums for  improved oversight of key quality, regulatory affairs, and  medical matters.
","('Product_Quality_And_Safety', 0.33762145042419434)","('Business_Ethics', 0.10245829075574875)","('Product_Design_And_Lifecycle_Management', 0.09042850136756897)","('NON-ESG', 0.33762145042419434)","('NON-ESG', 0.10245829075574875)","('NON-ESG', 0.09042850136756897)"
Line 311,"These enhanced systems will empower us,  together with our customers and regulators, to be more  proactive and transparent with quality matters by harnessing  the power of data-driven insights to address potential quality  deviations sooner and with greater accuracy.
","('Business_Ethics', 0.4726918041706085)","('Management_Of_Legal_And_Regulatory_Framework', 0.2197224497795105)","('Competitive_Behavior', 0.08491155505180359)","('NON-ESG', 0.4726918041706085)","('NON-ESG', 0.2197224497795105)","('NON-ESG', 0.08491155505180359)"
Line 312,"This builds on our  philosophy of partnership, trust and transparency when it  comes to all product quality and patient safety matters.
","('Product_Quality_And_Safety', 0.8947250843048096)","('Business_Ethics', 0.019971061497926712)","('Selling_Practices_And_Product_Labeling', 0.010714953765273094)","(['Product Quality & Recall Management'], 0.8947250843048096)","('NON-ESG', 0.019971061497926712)","('NON-ESG', 0.010714953765273094)"
Line 313,"Inspiring Quality in product development  We understand that patient safety depends on us delivering  only the highest quality products and services.
","('Product_Design_And_Lifecycle_Management', 0.43328946828842163)","('Product_Quality_And_Safety', 0.4108256995677948)","('Customer_Welfare', 0.026323577389121056)","('NON-ESG', 0.43328946828842163)","('NON-ESG', 0.4108256995677948)","('NON-ESG', 0.026323577389121056)"
Line 314,"Quality at BD  starts with innovation and designing our products and services  with quality in mind.
","('Product_Design_And_Lifecycle_Management', 0.9580329060554504)","('Product_Quality_And_Safety', 0.007198957726359367)","('Business_Model_Resilience', 0.0029561331029981375)","(['Product Stewardship'], 0.9580329060554504)","('NON-ESG', 0.007198957726359367)","('NON-ESG', 0.0029561331029981375)"
Line 315,"Utilizing the Design for Six Sigma tools and  human factors engineering, we ingrain best practices within our  daily activities.
","('Human_Rights_And_Community_Relations', 0.15620248019695282)","('Employee_Engagement_Inclusion_And_Diversity', 0.1448553502559662)","('Employee_Health_And_Safety', 0.11190198361873627)","('NON-ESG', 0.15620248019695282)","('NON-ESG', 0.1448553502559662)","('NON-ESG', 0.11190198361873627)"
Line 316,"In FY 2020, we updated our risk management process to align  with ISO 14971:2019 to strengthen our product designs and  manufacturing processes to enable us to be more proactive and  predict potential product failures and implement controls to  prevent occurrences.
","('Product_Design_And_Lifecycle_Management', 0.6085779666900635)","('Product_Quality_And_Safety', 0.22204457223415375)","('Supply_Chain_Management', 0.01894611120223999)","(['Product Stewardship'], 0.6085779666900635)","('NON-ESG', 0.22204457223415375)","('NON-ESG', 0.01894611120223999)"
Line 317,"We performed design remediation activities on legacy products  to align with the changing global regulatory environment, such  as the E.U. MDR/IVDR, driving improvements in the safety and  efficacy of our older designs.
","('Product_Quality_And_Safety', 0.7978991270065308)","('Product_Design_And_Lifecycle_Management', 0.09403878450393677)","('Selling_Practices_And_Product_Labeling', 0.01622113585472107)","(['Product Quality & Recall Management'], 0.7978991270065308)","('NON-ESG', 0.09403878450393677)","('NON-ESG', 0.01622113585472107)"
Line 318,"We operate in a complex and evolving world of regulations,  standards, and guidance documents governing the  development and market access for our products and services.
","('Product_Quality_And_Safety', 0.4646010100841522)","('Product_Design_And_Lifecycle_Management', 0.17961207032203674)","('Management_Of_Legal_And_Regulatory_Framework', 0.08561546355485916)","('NON-ESG', 0.4646010100841522)","('NON-ESG', 0.17961207032203674)","('NON-ESG', 0.08561546355485916)"
Line 319,"As we continue to expand our portfolio, we must evolve to  ensure we have robust regulatory submissions that comply with  the most current standards and industry expectations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9052713513374329)","('Product_Quality_And_Safety', 0.0232273880392313)","('Business_Ethics', 0.007349121849983931)","(['Corporate Governance'], 0.9052713513374329)","('NON-ESG', 0.0232273880392313)","('NON-ESG', 0.007349121849983931)"
Line 320,"To that end, the Regulatory Affairs and Quality teams at BD  work together to ensure that our products and processes are  compliant with global laws, regulations, standards and policies.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8608254790306091)","('Product_Quality_And_Safety', 0.041967447847127914)","('Business_Ethics', 0.023022525012493134)","(['Corporate Governance'], 0.8608254790306091)","('NON-ESG', 0.041967447847127914)","('NON-ESG', 0.023022525012493134)"
Line 321,"The BD standards management process links our business units,  functional, and regional colleagues to monitor new and  updated regulations and standards worldwide that may impact  BD products and processes.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7070738077163696)","('Product_Quality_And_Safety', 0.11541556566953659)","('Business_Ethics', 0.0245259590446949)","(['Corporate Governance'], 0.7070738077163696)","('NON-ESG', 0.11541556566953659)","('NON-ESG', 0.0245259590446949)"
Line 322,"The global teams have expertise in  quality, regulatory affairs, research and development,  manufacturing, cybersecurity, sterilization, environmental health  and safety, and medical affairs.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7572605013847351)","('Business_Ethics', 0.09504692256450653)","('Product_Quality_And_Safety', 0.029425879940390587)","(['Corporate Governance'], 0.7572605013847351)","('NON-ESG', 0.09504692256450653)","('NON-ESG', 0.029425879940390587)"
Line 323,"When changes are identified, the cross functional and global  teams assess the impact of the new requirements against our  current processes.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5118927359580994)","('Business_Model_Resilience', 0.12679369747638702)","('Human_Rights_And_Community_Relations', 0.05011074244976044)","(['Corporate Governance'], 0.5118927359580994)","('NON-ESG', 0.12679369747638702)","('NON-ESG', 0.05011074244976044)"
Line 324,"Once gaps are identified, plans are put in  place to ensure necessary remediation can be made within a  defined time frame.
","('Critical_Incident_Risk_Management', 0.5787836909294128)","('Water_And_Wastewater_Management', 0.06693349033594131)","('Employee_Health_And_Safety', 0.0664757639169693)","(['Risk & Crisis Management'], 0.5787836909294128)","('NON-ESG', 0.06693349033594131)","('NON-ESG', 0.0664757639169693)"
Line 325,"Compliance plans are implemented across  BD facilities worldwide and built into our product life  cycle process.BD associates around the world engage in meaningful dialog  with regulators, standards development organizations,  collaborative communities, and trade associations to seek better  understanding, harmonization, and improvements in regulatory  requirements that impact BD, our customers and patients who  use our products.
","('Product_Quality_And_Safety', 0.4960383176803589)","('Management_Of_Legal_And_Regulatory_Framework', 0.13204406201839447)","('Product_Design_And_Lifecycle_Management', 0.12029110640287399)","('NON-ESG', 0.4960383176803589)","('NON-ESG', 0.13204406201839447)","('NON-ESG', 0.12029110640287399)"
Line 326,"At BD, we are also empowering cross functional teams within  each business unit and region to drive accountability for  incorporating new requirements from standards and regulations  into our new product development process as well as legacy  products, re-baselining historical regulatory submissions for  products that have evolved over time and enabling future  innovation by refreshing product data on file with regulatory  authorities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5369987487792969)","('Product_Quality_And_Safety', 0.20588642358779907)","('Product_Design_And_Lifecycle_Management', 0.06073490157723427)","(['Corporate Governance'], 0.5369987487792969)","('NON-ESG', 0.20588642358779907)","('NON-ESG', 0.06073490157723427)"
Line 327,"In addition to working on significant initiatives like  compliance with new E.U. regulations, we are also focusing on  countries that have seen significant changes to their  regulatory framework.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9753774404525757)","('Director_Removal', 0.0017999461852014065)","('Business_Ethics', 0.0017694593407213688)","(['Corporate Governance'], 0.9753774404525757)","('NON-ESG', 0.0017999461852014065)","('NON-ESG', 0.0017694593407213688)"
Line 328,"Through this effort we are driving registration excellence by  adopting a structured approach to conducting risk assessments,  identifying gaps, remediating, and ultimately updating our  regulatory filings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9288143515586853)","('Systemic_Risk_Management', 0.012637789361178875)","('Business_Ethics', 0.011313952505588531)","(['Corporate Governance'], 0.9288143515586853)","('NON-ESG', 0.012637789361178875)","('NON-ESG', 0.011313952505588531)"
Line 329,"We are also working toward digitizing our  registration processes and content management to enable  efficient global registrations that will impact public health.Inspiring Quality in registration excellence We are driven to manufacture high-quality products and to help  maintain safety for our customers.
","('Product_Quality_And_Safety', 0.8665885329246521)","('Employee_Health_And_Safety', 0.03995537757873535)","('Product_Design_And_Lifecycle_Management', 0.012276534922420979)","(['Product Quality & Recall Management'], 0.8665885329246521)","('NON-ESG', 0.03995537757873535)","('NON-ESG', 0.012276534922420979)"
Line 330,"BD monitors the quality of  our products using quality tools, including statistical trends of  quality control data, automated high-speed inspection and  manufacturing execution systems (MES) data monitoring.
","('Product_Design_And_Lifecycle_Management', 0.4557228088378906)","('Product_Quality_And_Safety', 0.39766043424606323)","('Selling_Practices_And_Product_Labeling', 0.01518955361098051)","('NON-ESG', 0.4557228088378906)","('NON-ESG', 0.39766043424606323)","('NON-ESG', 0.01518955361098051)"
Line 331,"We perform incoming, in-process and final inspections of our  products.
","('Product_Design_And_Lifecycle_Management', 0.8323291540145874)","('Product_Quality_And_Safety', 0.06830371916294098)","('Selling_Practices_And_Product_Labeling', 0.024805350229144096)","(['Product Stewardship'], 0.8323291540145874)","('NON-ESG', 0.06830371916294098)","('NON-ESG', 0.024805350229144096)"
Line 332,"Having real-time inspections and monitoring allows   us to monitor for potential issues and react quickly when  they occur.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31552618741989136)","('Critical_Incident_Risk_Management', 0.1528344452381134)","('Business_Ethics', 0.11721491068601608)","('NON-ESG', 0.31552618741989136)","('NON-ESG', 0.1528344452381134)","('NON-ESG', 0.11721491068601608)"
Line 333,"At BD, we believe quality is everyone’s responsibility, and our  approximately 48,000 global manufacturing associates take  that responsibility seriously.
","('Human_Rights_And_Community_Relations', 0.13459181785583496)","('Employee_Health_And_Safety', 0.11835796386003494)","('Business_Ethics', 0.10541877895593643)","('NON-ESG', 0.13459181785583496)","('NON-ESG', 0.11835796386003494)","('NON-ESG', 0.10541877895593643)"
Line 334,"Associates are empowered and  encouraged by management, as part of our “speak up/listen up”  culture, to stop production if they see anything off with a  product regardless of their role or the stage of product  production.
","('Product_Design_And_Lifecycle_Management', 0.9361644983291626)","('Product_Quality_And_Safety', 0.010005729272961617)","('Customer_Welfare', 0.009009584784507751)","(['Product Stewardship'], 0.9361644983291626)","('NON-ESG', 0.010005729272961617)","('NON-ESG', 0.009009584784507751)"
Line 335,"The product can be halted on the manufacturing  line or prior to distribution.
","('Product_Design_And_Lifecycle_Management', 0.8943681716918945)","('Selling_Practices_And_Product_Labeling', 0.03696506842970848)","('Product_Quality_And_Safety', 0.011498083360493183)","(['Product Stewardship'], 0.8943681716918945)","('NON-ESG', 0.03696506842970848)","('NON-ESG', 0.011498083360493183)"
Line 336,"This cultural mindset of associate  empowerment and having the mechanisms in place to stop the  product before it reaches a customer or patient, prioritizes  quality and safety.
","('Product_Quality_And_Safety', 0.8258917331695557)","('Product_Design_And_Lifecycle_Management', 0.04279700666666031)","('Selling_Practices_And_Product_Labeling', 0.03692709282040596)","(['Product Quality & Recall Management'], 0.8258917331695557)","('NON-ESG', 0.04279700666666031)","('NON-ESG', 0.03692709282040596)"
Line 337,"We are rolling out a single, unified operating system, the BD  Production System (BDPS), as a framework for global  operational excellence.
","('Business_Model_Resilience', 0.30390986800193787)","('Systemic_Risk_Management', 0.17701472342014313)","('Supply_Chain_Management', 0.04979328066110611)","('NON-ESG', 0.30390986800193787)","('NON-ESG', 0.17701472342014313)","('NON-ESG', 0.04979328066110611)"
Line 338,"This new way of working proactively  standardizes and systematizes daily operations, emphasizing   a Zero Loss mindset and culture: working safely every day to  effectively deliver high-quality products on time.
","('Product_Design_And_Lifecycle_Management', 0.9555372595787048)","('Product_Quality_And_Safety', 0.005418881773948669)","('Customer_Welfare', 0.004808556754142046)","(['Product Stewardship'], 0.9555372595787048)","('NON-ESG', 0.005418881773948669)","('NON-ESG', 0.004808556754142046)"
Line 339,"The BDPS  fosters goal alignment and drives performance accountability  across functions and at every level of the organization.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3830811083316803)","('Business_Ethics', 0.20983801782131195)","('Human_Rights_And_Community_Relations', 0.06372439116239548)","('NON-ESG', 0.3830811083316803)","('NON-ESG', 0.20983801782131195)","('NON-ESG', 0.06372439116239548)"
Line 340,"It engages the talents of all associates through highly  collaborative cross-functional teams that are focused on   solving the root cause of problems using a systemic approach.
","('Systemic_Risk_Management', 0.9158862829208374)","('Business_Ethics', 0.013172426261007786)","('Supply_Chain_Management', 0.007473403122276068)","(['Risk & Crisis Management'], 0.9158862829208374)","('NON-ESG', 0.013172426261007786)","('NON-ESG', 0.007473403122276068)"
Line 341,"The BDPS is active in nearly 90% of our worldwide manufacturing  sites with active expansion into the European and North American  distribution centers.
","('Product_Design_And_Lifecycle_Management', 0.42516234517097473)","('Supply_Chain_Management', 0.1537223905324936)","('Customer_Welfare', 0.08727449923753738)","('NON-ESG', 0.42516234517097473)","('NON-ESG', 0.1537223905324936)","('NON-ESG', 0.08727449923753738)"
Line 342,"In the midst of the global COVID-19 pandemic, quality  remained at the forefront as we continued to operate our global  manufacturing and distribution centers, with the vast majority  of the critical-to-COVID sites operating at or near full capacity.
","('Supply_Chain_Management', 0.5640249252319336)","('Product_Design_And_Lifecycle_Management', 0.10986452549695969)","('Energy_Management', 0.06265757232904434)","(['Supply Chain Management'], 0.5640249252319336)","('NON-ESG', 0.10986452549695969)","('NON-ESG', 0.06265757232904434)"
Line 343,"We instituted preventative pandemic precautions at facilities to protect employees, including increasing cleaning protocols,   implementing temperature screenings for on-site employees,  deploying PPE to on-site associates and field workers,  implementing social distancing in our facilities, supporting  remote work for all associates who are able, suspending travel  and group meetings, limiting on-site visitors, and regularly  educating associates about good hygiene and health practices.
","('Employee_Health_And_Safety', 0.9689816832542419)","('Waste_And_Hazardous_Materials_Management', 0.0039060181006789207)","('Critical_Incident_Risk_Management', 0.0032387494575232267)","(['Operational Eco-Efficiency'], 0.9689816832542419)","('NON-ESG', 0.0039060181006789207)","('NON-ESG', 0.0032387494575232267)"
Line 344,"We continue to enforce our pandemic protocols and measures  within our facilities to maintain the health and safety of our  associates, while ensuring business continuity and maintaining  a high level of quality for our customers.
","('Employee_Health_And_Safety', 0.9512962102890015)","('Critical_Incident_Risk_Management', 0.014633208513259888)","('Product_Quality_And_Safety', 0.004136624280363321)","(['Operational Eco-Efficiency'], 0.9512962102890015)","('NON-ESG', 0.014633208513259888)","('NON-ESG', 0.004136624280363321)"
Line 345,"Further details on our response to the pandemic can be found in  the COVID -19 section .Inspiring Quality in manufacturing “We understand the responsibility we     hold as the world’s largest     manufacturer of injection devices.
","('Critical_Incident_Risk_Management', 0.48521238565444946)","('Physical_Impacts_Of_Climate_Change', 0.1297883540391922)","('Air_Quality', 0.1123499944806099)","('NON-ESG', 0.48521238565444946)","('NON-ESG', 0.1297883540391922)","('NON-ESG', 0.1123499944806099)"
Line 346,"Our leadership position prompted our     early response to the COVID-19     crisis—rapidly scaling up our     manufacturing operations, without     sacrificing quality or associate safety.
","('Product_Quality_And_Safety', 0.7861521244049072)","('Employee_Health_And_Safety', 0.08094317466020584)","('Product_Design_And_Lifecycle_Management', 0.027514897286891937)","(['Product Quality & Recall Management'], 0.7861521244049072)","('NON-ESG', 0.08094317466020584)","('NON-ESG', 0.027514897286891937)"
Line 347,"We proactively took this initiative so     that once the COVID-19 vaccine     became available, BD syringes and     needles would be ready.
","('Product_Quality_And_Safety', 0.19382049143314362)","('Access_And_Affordability', 0.1823178082704544)","('Selling_Practices_And_Product_Labeling', 0.11378868669271469)","('NON-ESG', 0.19382049143314362)","('NON-ESG', 0.1823178082704544)","('NON-ESG', 0.11378868669271469)"
Line 348,"We are     committed to enabling healthcare     providers to deliver the best possible     patient care, which includes meeting     the critical need for vaccinations.”     Alexandre Conroy      EVP, Integrated Supply Chain Quality management systems In order to meet our customer needs and regulatory  requirements, we maintain Quality Management System (QMS)  Certifications across our BD facilities.
","('Supply_Chain_Management', 0.9214071035385132)","('Product_Design_And_Lifecycle_Management', 0.00970899872481823)","('Customer_Welfare', 0.005389141850173473)","(['Supply Chain Management'], 0.9214071035385132)","('NON-ESG', 0.00970899872481823)","('NON-ESG', 0.005389141850173473)"
Line 349,"In order to drive continuous improvement in our quality systems,  our corporate auditing program independently assesses  compliance to quality and regulatory standards and our internal  processes, including complaint management, production and  process controls, design controls, and corrective and preventive  actions (CAPA).
","('Business_Ethics', 0.4837937355041504)","('Management_Of_Legal_And_Regulatory_Framework', 0.33523303270339966)","('Product_Quality_And_Safety', 0.04659964516758919)","('NON-ESG', 0.4837937355041504)","('NON-ESG', 0.33523303270339966)","('NON-ESG', 0.04659964516758919)"
Line 350,"Each of our businesses and regional sites fulfill  local regulatory requirements for performing internal quality  audits and develop action plans to address all relevant audit  observations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9490814208984375)","('Business_Ethics', 0.014343108050525188)","('Product_Quality_And_Safety', 0.0045057181268930435)","(['Corporate Governance'], 0.9490814208984375)","('NON-ESG', 0.014343108050525188)","('NON-ESG', 0.0045057181268930435)"
Line 351,"We adapted this program in FY 2020 to perform  virtual audits as a result of the COVID-19 pandemic, enabling  continued compliance assessments and maintaining continuous  improvement momentum.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6684370040893555)","('Business_Ethics', 0.16951504349708557)","('Systemic_Risk_Management', 0.026578977704048157)","(['Corporate Governance'], 0.6684370040893555)","('NON-ESG', 0.16951504349708557)","('NON-ESG', 0.026578977704048157)"
Line 352,"Quality culture Our commitment to quality is driven by a culture of quality that  all associates across BD share through our BD Value, “We thrive  on innovation and demand quality.” Beginning in FY 2020, we  took steps to strengthen our culture of quality to ensure that all  associates, regardless of function, are trained on the importance  of quality in their daily activities.
","('Business_Ethics', 0.2678697109222412)","('Competitive_Behavior', 0.09097183495759964)","('Employee_Engagement_Inclusion_And_Diversity', 0.08220574259757996)","('NON-ESG', 0.2678697109222412)","('NON-ESG', 0.09097183495759964)","('NON-ESG', 0.08220574259757996)"
Line 353,"Annual training is provided via  our online compliance tool and supplemented by in-person  training.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7312591671943665)","('Business_Ethics', 0.1179230809211731)","('Product_Quality_And_Safety', 0.027118796482682228)","(['Corporate Governance'], 0.7312591671943665)","('NON-ESG', 0.1179230809211731)","('NON-ESG', 0.027118796482682228)"
Line 354,"We also introduced virtual customer contact messaging  at our manufacturing facilities, allowing associates to hear   stories from patients whose lives have been impacted by BD  products they manufacture.
","('Product_Design_And_Lifecycle_Management', 0.4244639575481415)","('Product_Quality_And_Safety', 0.1381130814552307)","('Access_And_Affordability', 0.10969352722167969)","('NON-ESG', 0.4244639575481415)","('NON-ESG', 0.1381130814552307)","('NON-ESG', 0.10969352722167969)"
Line 355,"In November 2020, we demonstrated this renewed  commitment to quality across BD by expanding our traditional  “Quality Day” with global events throughout the month of  November to a larger “Quality Week” with a series of global live  and virtual events, awards, engagement forums and  philanthropic opportunities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24805371463298798)","('Access_And_Affordability', 0.13642556965351105)","('Human_Rights_And_Community_Relations', 0.1249467134475708)","('NON-ESG', 0.24805371463298798)","('NON-ESG', 0.13642556965351105)","('NON-ESG', 0.1249467134475708)"
Line 356,"Our celebration of quality solidified  the organizational commitment we are making to quality and  the inspirational journey we are on to inspire quality through the  degree of excellence in everything we do.
","('Employee_Engagement_Inclusion_And_Diversity', 0.16335980594158173)","('Business_Model_Resilience', 0.15258750319480896)","('Business_Ethics', 0.1295265257358551)","('NON-ESG', 0.16335980594158173)","('NON-ESG', 0.15258750319480896)","('NON-ESG', 0.1295265257358551)"
Line 357,"A strong supplier quality program is key to ensuring that BD  products meet the highest standards of quality.
","('Product_Design_And_Lifecycle_Management', 0.7988737225532532)","('Product_Quality_And_Safety', 0.07678773999214172)","('Supply_Chain_Management', 0.031312670558691025)","(['Product Stewardship'], 0.7988737225532532)","('NON-ESG', 0.07678773999214172)","('NON-ESG', 0.031312670558691025)"
Line 358,"The Quality  function partners with Global Procurement to ensure that  appropriate systems and controls are in place to select, qualify  and monitor suppliers.
","('Supply_Chain_Management', 0.9170068502426147)","('Product_Design_And_Lifecycle_Management', 0.008632253855466843)","('Water_And_Wastewater_Management', 0.00599150825291872)","(['Supply Chain Management'], 0.9170068502426147)","('NON-ESG', 0.008632253855466843)","('NON-ESG', 0.00599150825291872)"
Line 359,"Key aspects of the program include  qualification of suppliers based on risk, auditing and monitoring supplier performance and managing supplier changes.
","('Supply_Chain_Management', 0.9432986974716187)","('Labor_Practices', 0.006922146305441856)","('Product_Design_And_Lifecycle_Management', 0.003993412014096975)","(['Supply Chain Management'], 0.9432986974716187)","('NON-ESG', 0.006922146305441856)","('NON-ESG', 0.003993412014096975)"
Line 360,"In 2020,  BD implemented a Supplier Change Portal that enables  suppliers to directly communicate potential changes to BD.
","('Supply_Chain_Management', 0.9475416541099548)","('Labor_Practices', 0.005217921454459429)","('Physical_Impacts_Of_Climate_Change', 0.0041513945907354355)","(['Supply Chain Management'], 0.9475416541099548)","('NON-ESG', 0.005217921454459429)","('NON-ESG', 0.0041513945907354355)"
Line 361,"This portal is also used as a means for BD to communicate back  to suppliers.
","('Supply_Chain_Management', 0.8673169612884521)","('GHG_Emissions', 0.010406021028757095)","('Management_Of_Legal_And_Regulatory_Framework', 0.009852608665823936)","(['Supply Chain Management'], 0.8673169612884521)","('NON-ESG', 0.010406021028757095)","('NON-ESG', 0.009852608665823936)"
Line 362,"This tool has greatly improved communication and  visibility of supplier changes.Inspiring Quality through our suppliers Inspiring Quality through continuous improvement “As part of our Inspire Quality journey,     we are focused on simplification and     reducing complexity of our Quality     Management Systems (QMS) by     consolidating and launching a unified     QMS.
","('Supply_Chain_Management', 0.8886350989341736)","('Systemic_Risk_Management', 0.014373458921909332)","('Business_Model_Resilience', 0.009463486261665821)","(['Supply Chain Management'], 0.8886350989341736)","('NON-ESG', 0.014373458921909332)","('NON-ESG', 0.009463486261665821)"
Line 363,"This change, which we are     deploying in FY 2021, will enable us to     function as One BD to our customers,     be more agile as a corporation and     [make it] easier for our customers to do     business with us.
","('Business_Model_Resilience', 0.6539698839187622)","('Systemic_Risk_Management', 0.07591640204191208)","('Product_Design_And_Lifecycle_Management', 0.04416372627019882)","(['Codes of Business Conduct'], 0.6539698839187622)","('NON-ESG', 0.07591640204191208)","('NON-ESG', 0.04416372627019882)"
Line 364,"Quality is the     foundation of customer and patient     trust and a unified QMS will take us one     step closer towards being a best-in-     class quality organization.”     Jerry Porreca      SVP, Quality, Interventional and Inspire Quality SponsorCertifications at manufacturing, design, distribution and shared service sites.ISO13485;   99 sitesISO 17025; 2 sitesISO 9001; 23 sites Inspiring Quality in industry We are committed to enabling healthcare providers to deliver  the best possible patient care.
","('Access_And_Affordability', 0.17248375713825226)","('Product_Quality_And_Safety', 0.16920988261699677)","('Business_Ethics', 0.07675442844629288)","('NON-ESG', 0.17248375713825226)","('NON-ESG', 0.16920988261699677)","('NON-ESG', 0.07675442844629288)"
Line 365,"We work closely with  organizations and trade associations outside of BD to   drive quality and shape the external environment through  industry-wide standards and initiatives consistent with our   Purpose of advancing with world of health ™.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4415624439716339)","('Business_Ethics', 0.17803393304347992)","('Product_Quality_And_Safety', 0.1306317150592804)","('NON-ESG', 0.4415624439716339)","('NON-ESG', 0.17803393304347992)","('NON-ESG', 0.1306317150592804)"
Line 366,"We actively support the creation and harmonization of  standards at both a national and international level.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7663158178329468)","('Product_Quality_And_Safety', 0.0470472052693367)","('Business_Ethics', 0.03700016438961029)","(['Corporate Governance'], 0.7663158178329468)","('NON-ESG', 0.0470472052693367)","('NON-ESG', 0.03700016438961029)"
Line 367,"Through  participation in standard development work groups, such as ISO  standard development through national organizations like the  Association for the Advancement of Medical   Instrumentation  (AAMI ), we help improve performance and  product compatibility around the world.
","('Product_Quality_And_Safety', 0.4034446179866791)","('Product_Design_And_Lifecycle_Management', 0.38504207134246826)","('Management_Of_Legal_And_Regulatory_Framework', 0.024931078776717186)","('NON-ESG', 0.4034446179866791)","('NON-ESG', 0.38504207134246826)","('NON-ESG', 0.024931078776717186)"
Line 368,"Our executive vice president, general counsel, public policy &  regulatory affairs serves on the Medical Device Innovation  Consortium (MDIC)  Board of Directors.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4850437641143799)","('Product_Quality_And_Safety', 0.04961760342121124)","('Business_Model_Resilience', 0.046991318464279175)","('NON-ESG', 0.4850437641143799)","('NON-ESG', 0.04961760342121124)","('NON-ESG', 0.046991318464279175)"
Line 369,"We are also involved in the MDIC Case for Quality Collaborative  Community (CfQcc), the National Evaluation System for Health  Technology Coordinating Center (NESTcc) and the  Cybersecurity Program.
","('Data_Security', 0.7833498120307922)","('Systemic_Risk_Management', 0.039285872131586075)","('Management_Of_Legal_And_Regulatory_Framework', 0.022364703938364983)","(['Information Security/Cybersecurity & System Availability'], 0.7833498120307922)","('NON-ESG', 0.039285872131586075)","('NON-ESG', 0.022364703938364983)"
Line 370,"Through an educational grant, BD provides funds and clinical  reviewers for the Infusion Nurses Society (INS)  development  update to the  Infusion Therapy Standard of Practice .
","('Access_And_Affordability', 0.6100488305091858)","('Customer_Welfare', 0.05760398879647255)","('Critical_Incident_Risk_Management', 0.05097227543592453)","(['Health Outcome Contribution'], 0.6100488305091858)","('NON-ESG', 0.05760398879647255)","('NON-ESG', 0.05097227543592453)"
Line 371,"This publication defines and develops organizational   infusion-based policies and procedures for all healthcare  practice settings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6872727870941162)","('Human_Rights_And_Community_Relations', 0.0700971707701683)","('Director_Removal', 0.02369379810988903)","(['Corporate Governance'], 0.6872727870941162)","('NON-ESG', 0.0700971707701683)","('NON-ESG', 0.02369379810988903)"
Line 372,"In collaboration with the Society for Healthcare Epidemiology of  America (SHEA), BD launched the Prevention Course in  Healthcare-Acquired Infections (HAI) Knowledge and Control.
","('Employee_Health_And_Safety', 0.3105977177619934)","('Access_And_Affordability', 0.11302947998046875)","('Product_Quality_And_Safety', 0.07055684924125671)","('NON-ESG', 0.3105977177619934)","('NON-ESG', 0.11302947998046875)","('NON-ESG', 0.07055684924125671)"
Line 373,"This online course was developed with frontline staff in mind  and allowed course participants to review the fundamentals of  infection prevention, review best practices for the prevention of  device-and pathogen-associated infections and improve  understanding of disinfection and sterilization procedures.“Behind each and every product and     service we deliver is an engaged BD     associate who is committed to doing     the right thing and delivering quality     each and every day.
","('Employee_Health_And_Safety', 0.32858505845069885)","('Product_Quality_And_Safety', 0.14118994772434235)","('Data_Security', 0.0693957656621933)","('NON-ESG', 0.32858505845069885)","('NON-ESG', 0.14118994772434235)","('NON-ESG', 0.0693957656621933)"
Line 374,"Our culture of     quality is essential for building the     foundation of customer and patient     trust and the reliability and consistency     expected of BD products.
","('Product_Design_And_Lifecycle_Management', 0.9002200961112976)","('Product_Quality_And_Safety', 0.029783891513943672)","('Customer_Welfare', 0.010489932261407375)","(['Product Stewardship'], 0.9002200961112976)","('NON-ESG', 0.029783891513943672)","('NON-ESG', 0.010489932261407375)"
Line 375,"We are so proud of our associates for     embracing our “speak up/listen up”     culture of quality and making their     voices heard when it comes to potential     quality matters.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2813410758972168)","('Human_Rights_And_Community_Relations', 0.2017778605222702)","('Business_Model_Resilience', 0.05985287204384804)","('NON-ESG', 0.2813410758972168)","('NON-ESG', 0.2017778605222702)","('NON-ESG', 0.05985287204384804)"
Line 376,"Thank you to all our     BD associates for putting quality first.”     Betty Larson      EVP, Chief Human Resources Officer “We at BD have a responsibility as a     leading manufacturer of quality     products to have a seat at the table in     the quality professional’s industry.
","('Product_Design_And_Lifecycle_Management', 0.908236026763916)","('Product_Quality_And_Safety', 0.032619379460811615)","('Supply_Chain_Management', 0.006102677900344133)","(['Product Stewardship'], 0.908236026763916)","('NON-ESG', 0.032619379460811615)","('NON-ESG', 0.006102677900344133)"
Line 377,"Our voice can be powerful and influential,     sharing best practices, driving     innovation in quality management,     educating and advancing awareness of     our industry and value to organizations.
","('Business_Model_Resilience', 0.33640944957733154)","('Systemic_Risk_Management', 0.13471591472625732)","('Product_Design_And_Lifecycle_Management', 0.08055460453033447)","('NON-ESG', 0.33640944957733154)","('NON-ESG', 0.13471591472625732)","('NON-ESG', 0.08055460453033447)"
Line 378,"The perception of the quality function     is changing thanks to the engaged     professionals who are moving us     collectively forward.”     Adrienne Brott      VP, Global Quality Management, Central Quality In order to ensure that we continue to provide high-quality  products and services, each BD business unit monitors product  performance, identifying early warning signs of potential quality  issues.
","('Product_Design_And_Lifecycle_Management', 0.7614805698394775)","('Product_Quality_And_Safety', 0.12909503281116486)","('Supply_Chain_Management', 0.012154280208051205)","(['Product Stewardship'], 0.7614805698394775)","('NON-ESG', 0.12909503281116486)","('NON-ESG', 0.012154280208051205)"
Line 379,"Under Inspire Quality, each business unit has established  plans to proactively eliminate the potential root causes of  internally identified nonconformances to continually improve  our processes and products.
","('Product_Design_And_Lifecycle_Management', 0.9483532309532166)","('Product_Quality_And_Safety', 0.009205610491335392)","('Customer_Welfare', 0.004808761645108461)","(['Product Stewardship'], 0.9483532309532166)","('NON-ESG', 0.009205610491335392)","('NON-ESG', 0.004808761645108461)"
Line 380,"Additionally, each business unit has  performed a “deep dive” into the root causes of our recalls and near misses to identify projects to reduce the recurrence of  recalls for similar issues across the company.
","('Critical_Incident_Risk_Management', 0.3163180649280548)","('Employee_Health_And_Safety', 0.12557587027549744)","('Product_Quality_And_Safety', 0.09734384715557098)","('NON-ESG', 0.3163180649280548)","('NON-ESG', 0.12557587027549744)","('NON-ESG', 0.09734384715557098)"
Line 381,"Each year, BD establishes business-wide key driver goals (KDGs)  shared across the company, by all functions.
","('Business_Model_Resilience', 0.38579514622688293)","('Supply_Chain_Management', 0.18383096158504486)","('Systemic_Risk_Management', 0.1029830276966095)","('NON-ESG', 0.38579514622688293)","('NON-ESG', 0.18383096158504486)","('NON-ESG', 0.1029830276966095)"
Line 382,"In FY 2020, BD  prioritized improving quality with multiple targeted KDGs   in the areas of customer experience, product quality  performance, complaint and adverse reporting and  compliance to regulations.
","('Product_Design_And_Lifecycle_Management', 0.5561598539352417)","('Product_Quality_And_Safety', 0.3025429844856262)","('Selling_Practices_And_Product_Labeling', 0.01905759610235691)","(['Product Stewardship'], 0.5561598539352417)","('NON-ESG', 0.3025429844856262)","('NON-ESG', 0.01905759610235691)"
Line 383,"Post-market surveillanceKey quality indicatorsProduct performance SASB disclosures: HC-MS-250a.2; HC-MS-250a.3; HC-MS-250a.4FY 2018 FY 2019 FY Number of inspections by worldwide regulatory agencies 27 34 Percentage with zero observations 74% 59% 81% Number of FDA inspections 18 15 6* Percentage with zero observations 72% 73% 50% Number of FDA Warning Letters received 2 0 Number of FDA Warning Letters resolved 0 1 Number of corporate audits 20 35 Number of FDA Class I recalls 1 4 10** * FDA Inspections were reduced due to the COIVD-19 Pandemic   ** Increase in FDA Class I recalls in FY 2020 (7 of 10) related to BD Alaris System.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3564748764038086)","('Business_Ethics', 0.23280233144760132)","('Product_Quality_And_Safety', 0.16313987970352173)","('NON-ESG', 0.3564748764038086)","('NON-ESG', 0.23280233144760132)","('NON-ESG', 0.16313987970352173)"
Line 384,"Post-market surveillanceKey quality indicatorsProduct performance SASB disclosures: HC-MS-250a.2; HC-MS-250a.3; HC-MS-250a.4FY 2018 FY 2019 FY Number of inspections by worldwide regulatory agencies 27 34 Percentage with zero observations 74% 59% 81% Number of FDA inspections 18 15 6* Percentage with zero observations 72% 73% 50% Number of FDA Warning Letters received 2 0 Number of FDA Warning Letters resolved 0 1 Number of corporate audits 20 35 Number of FDA Class I recalls 1 4 10** * FDA Inspections were reduced due to the COIVD-19 Pandemic   ** Increase in FDA Class I recalls in FY 2020 (7 of 10) related to BD Alaris System.
","('Systemic_Risk_Management', 0.1648460030555725)","('Management_Of_Legal_And_Regulatory_Framework', 0.15139645338058472)","('Product_Quality_And_Safety', 0.1205374076962471)","('NON-ESG', 0.1648460030555725)","('NON-ESG', 0.15139645338058472)","('NON-ESG', 0.1205374076962471)"
Line 385,"GRI disclosure: 416-2   SASB disclosures: HC-MS-250a.1; HC-MS-250a.“We do what is right” is one of our core values.
","('Human_Rights_And_Community_Relations', 0.2925003170967102)","('Management_Of_Legal_And_Regulatory_Framework', 0.21232837438583374)","('Director_Removal', 0.09062730520963669)","('NON-ESG', 0.2925003170967102)","('NON-ESG', 0.21232837438583374)","('NON-ESG', 0.09062730520963669)"
Line 386,"When an issue  has been identified, initiating a field action, such as recalling a  product from the marketplace, is the right thing to do for  patients and end users.
","('Product_Design_And_Lifecycle_Management', 0.5828494429588318)","('Selling_Practices_And_Product_Labeling', 0.18639765679836273)","('Product_Quality_And_Safety', 0.08545097708702087)","(['Product Stewardship'], 0.5828494429588318)","('NON-ESG', 0.18639765679836273)","('NON-ESG', 0.08545097708702087)"
Line 387,"Post Market Surveillance (PMS) is a key  Quality and Regulatory requirement for the medical device  industry.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7591043710708618)","('Competitive_Behavior', 0.1292022168636322)","('Systemic_Risk_Management', 0.014225021004676819)","(['Corporate Governance'], 0.7591043710708618)","('NON-ESG', 0.1292022168636322)","('NON-ESG', 0.014225021004676819)"
Line 388,"It provides how a medical device company becomes  aware and monitors actual device-related events (complaints)  associated with the commercialized product.
","('Product_Quality_And_Safety', 0.27023547887802124)","('Competitive_Behavior', 0.1746593415737152)","('Customer_Welfare', 0.08568070828914642)","('NON-ESG', 0.27023547887802124)","('NON-ESG', 0.1746593415737152)","('NON-ESG', 0.08568070828914642)"
Line 389,"Part of PMS  involves medical safety’s support to assess the level or severity  of harm that may have or could have occurred with the  particular event.
","('Employee_Health_And_Safety', 0.8290156722068787)","('Product_Quality_And_Safety', 0.09007979184389114)","('Access_And_Affordability', 0.008527836762368679)","(['Operational Eco-Efficiency'], 0.8290156722068787)","('NON-ESG', 0.09007979184389114)","('NON-ESG', 0.008527836762368679)"
Line 390,"Each business unit in BD has a Field Action Committee (FAC),  which convenes when necessary to evaluate concerns with the  quality, safety or regulatory compliance of a product in the market.
","('Product_Quality_And_Safety', 0.9199398756027222)","('Selling_Practices_And_Product_Labeling', 0.012120090425014496)","('Employee_Health_And_Safety', 0.007440314628183842)","(['Product Quality & Recall Management'], 0.9199398756027222)","('NON-ESG', 0.012120090425014496)","('NON-ESG', 0.007440314628183842)"
Line 391,"The FACs consist of leaders from Quality, Medical  Affairs and Regulatory Affairs who determine, independent of  commercial considerations, whether actions need to be taken to  correct or recall a product from the market.
","('Product_Quality_And_Safety', 0.6198458671569824)","('Selling_Practices_And_Product_Labeling', 0.18283575773239136)","('Product_Design_And_Lifecycle_Management', 0.031223246827721596)","(['Product Quality & Recall Management'], 0.6198458671569824)","('NON-ESG', 0.18283575773239136)","('NON-ESG', 0.031223246827721596)"
Line 392,"Patient safety takes  priority over any other factor in this decision-making process.
","('Employee_Health_And_Safety', 0.8958575129508972)","('Product_Quality_And_Safety', 0.026408502832055092)","('Critical_Incident_Risk_Management', 0.013456996530294418)","(['Operational Eco-Efficiency'], 0.8958575129508972)","('NON-ESG', 0.026408502832055092)","('NON-ESG', 0.013456996530294418)"
Line 393,"We continue to implement corrective actions to address recalls  on BD products .
","('Product_Quality_And_Safety', 0.6065110564231873)","('Selling_Practices_And_Product_Labeling', 0.12302254885435104)","('Product_Design_And_Lifecycle_Management', 0.08657824993133545)","(['Product Quality & Recall Management'], 0.6065110564231873)","('NON-ESG', 0.12302254885435104)","('NON-ESG', 0.08657824993133545)"
Line 394,"In line with its obligations to regulators, BD  reports all necessary data relating to cases where any of its  devices may have  caused or contributed to a death or serious  injury.
","('Employee_Health_And_Safety', 0.9801530838012695)","('Critical_Incident_Risk_Management', 0.002917208941653371)","('Product_Design_And_Lifecycle_Management', 0.00137906929012388)","(['Operational Eco-Efficiency'], 0.9801530838012695)","('NON-ESG', 0.002917208941653371)","('NON-ESG', 0.00137906929012388)"
Line 395,"This information is available in the FDA’s Manufacturer  and User Facility Device Experience database (MAUDE) .
","('Product_Quality_And_Safety', 0.2087761014699936)","('Selling_Practices_And_Product_Labeling', 0.17914849519729614)","('Customer_Privacy', 0.08000259846448898)","('NON-ESG', 0.2087761014699936)","('NON-ESG', 0.17914849519729614)","('NON-ESG', 0.08000259846448898)"
Line 396,"Additionally, a list of BD products in the FDA’s MedWatch   Safety Alerts for Human Medical Products is available on the  FDA website .
","('Product_Quality_And_Safety', 0.8818036913871765)","('Selling_Practices_And_Product_Labeling', 0.028945134952664375)","('Customer_Welfare', 0.009797593578696251)","(['Product Quality & Recall Management'], 0.8818036913871765)","('NON-ESG', 0.028945134952664375)","('NON-ESG', 0.009797593578696251)"
Line 397,"Medical Affairs is a human health focused organization serving as  the bridge between the clinical practice of medicine and BD.
","('Access_And_Affordability', 0.3629094660282135)","('Management_Of_Legal_And_Regulatory_Framework', 0.095182865858078)","('Employee_Engagement_Inclusion_And_Diversity', 0.06374028325080872)","('NON-ESG', 0.3629094660282135)","('NON-ESG', 0.095182865858078)","('NON-ESG', 0.06374028325080872)"
Line 398,"The  organization consists of a team of experts with hands-on clinical  experience across a range of medical areas and specialties.
","('Employee_Engagement_Inclusion_And_Diversity', 0.25400906801223755)","('Access_And_Affordability', 0.12953431904315948)","('Customer_Welfare', 0.07847429066896439)","('NON-ESG', 0.25400906801223755)","('NON-ESG', 0.12953431904315948)","('NON-ESG', 0.07847429066896439)"
Line 399,"This  clinical expertise is leveraged to understand and evaluate how our  products work in the clinical settings where they are used.
","('Product_Design_And_Lifecycle_Management', 0.5166814923286438)","('Customer_Welfare', 0.2022753357887268)","('Product_Quality_And_Safety', 0.05277974531054497)","(['Product Stewardship'], 0.5166814923286438)","('NON-ESG', 0.2022753357887268)","('NON-ESG', 0.05277974531054497)"
Line 400,"This  includes understanding unmet medical needs—translating these  insights into innovation—and determining the evidence needs  that define the clinical value of our products.
","('Product_Design_And_Lifecycle_Management', 0.7593974471092224)","('Customer_Welfare', 0.08941575884819031)","('Product_Quality_And_Safety', 0.024549394845962524)","(['Product Stewardship'], 0.7593974471092224)","('NON-ESG', 0.08941575884819031)","('NON-ESG', 0.024549394845962524)"
Line 401,"It also includes  communicating the evidence that defines our products through  conversations, publications and presentations.
","('Product_Design_And_Lifecycle_Management', 0.8334107398986816)","('Product_Quality_And_Safety', 0.045339182019233704)","('Selling_Practices_And_Product_Labeling', 0.037090811878442764)","(['Product Stewardship'], 0.8334107398986816)","('NON-ESG', 0.045339182019233704)","('NON-ESG', 0.037090811878442764)"
Line 402,"Being the only  organization at BD that consists of clinicians with a clinical remit,  the Medical Affairs organization is also responsible for oversight  of the safety of human subjects when conducting research and  evaluating any product issues that may threaten the health and  well-being of those who use our products.
","('Product_Quality_And_Safety', 0.7495948076248169)","('Selling_Practices_And_Product_Labeling', 0.0785016119480133)","('Product_Design_And_Lifecycle_Management', 0.047501400113105774)","(['Product Quality & Recall Management'], 0.7495948076248169)","('NON-ESG', 0.0785016119480133)","('NON-ESG', 0.047501400113105774)"
Line 403,"As part of the BD Inspire Quality initiative, Global Medical Safety  and Governance is involved in restructuring how Medical Affairs  will support Quality, specifically, product risk management file  review and approvals across BD.
","('Product_Quality_And_Safety', 0.9167872667312622)","('Employee_Health_And_Safety', 0.011427655816078186)","('Product_Design_And_Lifecycle_Management', 0.00896383821964264)","(['Product Quality & Recall Management'], 0.9167872667312622)","('NON-ESG', 0.011427655816078186)","('NON-ESG', 0.00896383821964264)"
Line 404,"This is fundamental to ensuring  consistent product benefit-risk assessments throughout the BD  portfolio of products.
","('Product_Design_And_Lifecycle_Management', 0.9513432383537292)","('Product_Quality_And_Safety', 0.007702363654971123)","('Customer_Welfare', 0.0056807431392371655)","(['Product Stewardship'], 0.9513432383537292)","('NON-ESG', 0.007702363654971123)","('NON-ESG', 0.0056807431392371655)"
Line 405,"The Global Medical Safety and Governance (GMS&G)  Organization is a dedicated and specialized independent medical  safety organization that maintains a constant and proactive  monitoring process that encourages a consistent and efficient  means for product safety and as well as Quality, Regulatory, and  Ethics & Compliance alignment.
","('Product_Quality_And_Safety', 0.8912976384162903)","('Employee_Health_And_Safety', 0.023434793576598167)","('Business_Ethics', 0.009402444586157799)","(['Product Quality & Recall Management'], 0.8912976384162903)","('NON-ESG', 0.023434793576598167)","('NON-ESG', 0.009402444586157799)"
Line 406,"It also provides a neutral and  independent assessment and objective means for escalation,  independent of the BD business unit.
","('Systemic_Risk_Management', 0.3693026006221771)","('Management_Of_Legal_And_Regulatory_Framework', 0.26940563321113586)","('Business_Model_Resilience', 0.0700632706284523)","('NON-ESG', 0.3693026006221771)","('NON-ESG', 0.26940563321113586)","('NON-ESG', 0.0700632706284523)"
Line 407,"Safety-signal detection has always been an important  “quantitative” element from a Quality perspective.
","('Employee_Health_And_Safety', 0.3924137353897095)","('Product_Quality_And_Safety', 0.32023951411247253)","('Critical_Incident_Risk_Management', 0.09438659250736237)","('NON-ESG', 0.3924137353897095)","('NON-ESG', 0.32023951411247253)","('NON-ESG', 0.09438659250736237)"
Line 408,"GMS&G  provides a “qualitative” medical assessment that adds another  layer of surveillance.
","('Product_Quality_And_Safety', 0.19231592118740082)","('Employee_Health_And_Safety', 0.1319424957036972)","('Access_And_Affordability', 0.10269875079393387)","('NON-ESG', 0.19231592118740082)","('NON-ESG', 0.1319424957036972)","('NON-ESG', 0.10269875079393387)"
Line 409,"This includes using tools that allow for  custom queries and reports, FDA MAUDE database reviews as  well as Natural Language Processing or “Word Cloud” technology  that allows for search and trending of key risk terms from within  the BD complaint database.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7390575408935547)","('Competitive_Behavior', 0.073234923183918)","('Systemic_Risk_Management', 0.024577680975198746)","(['Corporate Governance'], 0.7390575408935547)","('NON-ESG', 0.073234923183918)","('NON-ESG', 0.024577680975198746)"
Line 410,"The data analytics from these tools  are reviewed on a regular basis and are part of the Medical Safety  Review Board.
","('Product_Quality_And_Safety', 0.8874871730804443)","('Employee_Health_And_Safety', 0.02844018116593361)","('Access_And_Affordability', 0.007925331592559814)","(['Product Quality & Recall Management'], 0.8874871730804443)","('NON-ESG', 0.02844018116593361)","('NON-ESG', 0.007925331592559814)"
Line 411,"A Medical Affairs Safety Council (MASC) was established in   FY 2020 as a forum that could be used for specific issues that  would benefit from an independent medical review.
","('Product_Quality_And_Safety', 0.8904067277908325)","('Employee_Health_And_Safety', 0.017501847818493843)","('Access_And_Affordability', 0.00823763757944107)","(['Product Quality & Recall Management'], 0.8904067277908325)","('NON-ESG', 0.017501847818493843)","('NON-ESG', 0.00823763757944107)"
Line 412,"The MASC is  led by the VP of Global Medical Safety and Governance (GMS&G)  and includes the EVP and chief medical officer along with the VP  of Medical Affairs from each business unit.Medical Affairs While we have implemented, and continue to improve upon,  programs and management systems around product quality  and safety, we are, on occasion, subject to enforcement action.
","('Product_Quality_And_Safety', 0.9218959808349609)","('Employee_Health_And_Safety', 0.014403958804905415)","('Product_Design_And_Lifecycle_Management', 0.007740682922303677)","(['Product Quality & Recall Management'], 0.9218959808349609)","('NON-ESG', 0.014403958804905415)","('NON-ESG', 0.007740682922303677)"
Line 413,"For a description of certain enforcement matters see our Form  10-Q for the quarterly period ended March 31, 2021 and our  subsequent SEC filings .
","('Management_Of_Legal_And_Regulatory_Framework', 0.8859795928001404)","('Business_Ethics', 0.043347686529159546)","('Director_Removal', 0.008424554951488972)","(['Corporate Governance'], 0.8859795928001404)","('NON-ESG', 0.043347686529159546)","('NON-ESG', 0.008424554951488972)"
Line 414,"Enforcement action GRI disclosure: 416-2   SASB disclosure: HC-MS-250a.Quality and Regulatory compliance Our Quality and related Regulatory Compliance strategies are  based on principles of prevention, speak up culture and Find It  Once – Fix It Everywhere.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9243491291999817)","('Business_Ethics', 0.030083637684583664)","('Product_Quality_And_Safety', 0.004150854889303446)","(['Corporate Governance'], 0.9243491291999817)","('NON-ESG', 0.030083637684583664)","('NON-ESG', 0.004150854889303446)"
Line 415,"Any known non-compliances are  resolved through rigorous CAPA processes.
","('Business_Ethics', 0.7959182262420654)","('Management_Of_Legal_And_Regulatory_Framework', 0.06319334357976913)","('Product_Quality_And_Safety', 0.027128316462039948)","(['Business Ethics'], 0.7959182262420654)","('NON-ESG', 0.06319334357976913)","('NON-ESG', 0.027128316462039948)"
Line 416,"The Corporate Quality Audit (CQA) Program provides  independent assessment of BD entities to identify compliance  and product quality risk areas and drive holistic remediations.
","('Product_Quality_And_Safety', 0.3333059549331665)","('Business_Ethics', 0.20849470794200897)","('Management_Of_Legal_And_Regulatory_Framework', 0.2021106332540512)","('NON-ESG', 0.3333059549331665)","('NON-ESG', 0.20849470794200897)","('NON-ESG', 0.2021106332540512)"
Line 417,"The Corporate Quality Audit Program uses experienced BD  auditors as well as subject matter experts/consultants to ensure  robust reviews.
","('Business_Ethics', 0.5003155469894409)","('Management_Of_Legal_And_Regulatory_Framework', 0.3299163281917572)","('Systemic_Risk_Management', 0.0353439524769783)","(['Business Ethics'], 0.5003155469894409)","('NON-ESG', 0.3299163281917572)","('NON-ESG', 0.0353439524769783)"
Line 418,"The audit findings are shared across BD and  assessed for similar weakness in the Quality System.
","('Business_Ethics', 0.6974710822105408)","('Systemic_Risk_Management', 0.11810199171304703)","('Management_Of_Legal_And_Regulatory_Framework', 0.04047071933746338)","(['Business Ethics'], 0.6974710822105408)","('NON-ESG', 0.11810199171304703)","('NON-ESG', 0.04047071933746338)"
Line 419,"A Quality Audit Network (QAN) of all auditors across BD meets  regularly to share best practices and audit trends.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3138413727283478)","('Business_Ethics', 0.24782754480838776)","('Systemic_Risk_Management', 0.19716952741146088)","('NON-ESG', 0.3138413727283478)","('NON-ESG', 0.24782754480838776)","('NON-ESG', 0.19716952741146088)"
Line 420,"These  meetings also serve as a platform for educational programs to  continuously improve auditor skills.Good quality performance is rewarded through awards such as  Becton Award for continuous improvement, CAPA Award for  excellence in CAPA and First Pass Award for robust audit actions.
","('Business_Ethics', 0.4513164460659027)","('Management_Of_Legal_And_Regulatory_Framework', 0.26156672835350037)","('Product_Quality_And_Safety', 0.04634813964366913)","('NON-ESG', 0.4513164460659027)","('NON-ESG', 0.26156672835350037)","('NON-ESG', 0.04634813964366913)"
Line 421,"These awards are communicated through various channels,  including the BD intranet as well as town hall meetings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3015327453613281)","('Energy_Management', 0.10039620846509933)","('Customer_Privacy', 0.06643880158662796)","('NON-ESG', 0.3015327453613281)","('NON-ESG', 0.10039620846509933)","('NON-ESG', 0.06643880158662796)"
Line 422,"Quality  metrics and strategic milestones are included in the BD  incentive program.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5779954791069031)","('Business_Ethics', 0.17369982600212097)","('Systemic_Risk_Management', 0.06218263506889343)","(['Corporate Governance'], 0.5779954791069031)","('NON-ESG', 0.17369982600212097)","('NON-ESG', 0.06218263506889343)"
Line 423,"Quality and compliance metrics with target goals are instituted  at all sites, business units and regions and are monitored  routinely.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5423922538757324)","('Business_Ethics', 0.1255587339401245)","('Product_Quality_And_Safety', 0.08065564930438995)","(['Corporate Governance'], 0.5423922538757324)","('NON-ESG', 0.1255587339401245)","('NON-ESG', 0.08065564930438995)"
Line 424,"Any trends or missing goals are escalated to higher  levels of management so that timely actions can be taken to  bring performance metrics back to target levels.
","('Business_Model_Resilience', 0.43769192695617676)","('Systemic_Risk_Management', 0.3001205027103424)","('Physical_Impacts_Of_Climate_Change', 0.031802430748939514)","('NON-ESG', 0.43769192695617676)","('NON-ESG', 0.3001205027103424)","('NON-ESG', 0.031802430748939514)"
Line 425,"Quality Metrics  and trends are reviewed regularly at cross-functional forums  that ensure focus on regulatory compliance and product quality.
","('Product_Quality_And_Safety', 0.7360771298408508)","('Product_Design_And_Lifecycle_Management', 0.07000595331192017)","('Management_Of_Legal_And_Regulatory_Framework', 0.048146817833185196)","(['Product Quality & Recall Management'], 0.7360771298408508)","('NON-ESG', 0.07000595331192017)","('NON-ESG', 0.048146817833185196)"
Line 426,"Selecting materials A key part of our product development program is the selection  of the right materials that ensure patient safety, device  functional performance and continuity of the device to the  healthcare market.
","('Product_Design_And_Lifecycle_Management', 0.4549644887447357)","('Product_Quality_And_Safety', 0.39222148060798645)","('Employee_Health_And_Safety', 0.027275649830698967)","('NON-ESG', 0.4549644887447357)","('NON-ESG', 0.39222148060798645)","('NON-ESG', 0.027275649830698967)"
Line 427,"There are five criteria that are considered  when selecting materials for any of our devices: • What is critical to the function of the product?
","('Product_Design_And_Lifecycle_Management', 0.9412612915039062)","('Energy_Management', 0.006848787423223257)","('Supply_Chain_Management', 0.0068045370280742645)","(['Product Stewardship'], 0.9412612915039062)","('NON-ESG', 0.006848787423223257)","('NON-ESG', 0.0068045370280742645)"
Line 428,"• What is critical to the manufacturability of the product?
","('Product_Design_And_Lifecycle_Management', 0.9556736350059509)","('Product_Quality_And_Safety', 0.004345973953604698)","('Customer_Welfare', 0.0038555390201509)","(['Product Stewardship'], 0.9556736350059509)","('NON-ESG', 0.004345973953604698)","('NON-ESG', 0.0038555390201509)"
Line 429,"• What is critical to the quality of the product?
","('Product_Design_And_Lifecycle_Management', 0.9399282932281494)","('Product_Quality_And_Safety', 0.012992600910365582)","('Selling_Practices_And_Product_Labeling', 0.00498041370883584)","(['Product Stewardship'], 0.9399282932281494)","('NON-ESG', 0.012992600910365582)","('NON-ESG', 0.00498041370883584)"
Line 430,"• What is critical to compliance with regulation?
","('Management_Of_Legal_And_Regulatory_Framework', 0.9684648513793945)","('Energy_Management', 0.0026373371947556734)","('GHG_Emissions', 0.002467636950314045)","(['Corporate Governance'], 0.9684648513793945)","('NON-ESG', 0.0026373371947556734)","('NON-ESG', 0.002467636950314045)"
Line 431,"• What is critical to business requirements?
","('Supply_Chain_Management', 0.3139423131942749)","('Business_Model_Resilience', 0.22450518608093262)","('Product_Design_And_Lifecycle_Management', 0.09235890954732895)","('NON-ESG', 0.3139423131942749)","('NON-ESG', 0.22450518608093262)","('NON-ESG', 0.09235890954732895)"
Line 432,"Once required material properties have been established,  potential materials can be identified for feasibility studies.
","('Product_Design_And_Lifecycle_Management', 0.42779412865638733)","('Waste_And_Hazardous_Materials_Management', 0.1619405746459961)","('Supply_Chain_Management', 0.10250585526227951)","('NON-ESG', 0.42779412865638733)","('NON-ESG', 0.1619405746459961)","('NON-ESG', 0.10250585526227951)"
Line 433,"These studies evaluate characteristics that include chemical, toxicological, physical and mechanical properties.
","('Product_Quality_And_Safety', 0.4462726414203644)","('Waste_And_Hazardous_Materials_Management', 0.13955293595790863)","('Selling_Practices_And_Product_Labeling', 0.08439597487449646)","('NON-ESG', 0.4462726414203644)","('NON-ESG', 0.13955293595790863)","('NON-ESG', 0.08439597487449646)"
Line 434,"All materials  are rigorously evaluated for safety and suitability for their  intended clinical application.
","('Product_Quality_And_Safety', 0.8670331239700317)","('Customer_Welfare', 0.018427684903144836)","('Selling_Practices_And_Product_Labeling', 0.014117629267275333)","(['Product Quality & Recall Management'], 0.8670331239700317)","('NON-ESG', 0.018427684903144836)","('NON-ESG', 0.014117629267275333)"
Line 435,"This includes qualification against  national and international standards for biological safety (e.g.,  ISO 10993 and U.S. FDA guidance on same [2016]) and  compliance with U.S. and international regulations for biological  (patient) safety.
","('Product_Quality_And_Safety', 0.9177335500717163)","('Employee_Health_And_Safety', 0.007438339293003082)","('Product_Design_And_Lifecycle_Management', 0.00733980955556035)","(['Product Quality & Recall Management'], 0.9177335500717163)","('NON-ESG', 0.007438339293003082)","('NON-ESG', 0.00733980955556035)"
Line 436,"Materials are also subject to re-evaluation under conditions as  defined in these standards and regulations, for example, upon  any change in source or specification.
","('Product_Design_And_Lifecycle_Management', 0.3811485767364502)","('Supply_Chain_Management', 0.13104787468910217)","('Management_Of_Legal_And_Regulatory_Framework', 0.06849218904972076)","('NON-ESG', 0.3811485767364502)","('NON-ESG', 0.13104787468910217)","('NON-ESG', 0.06849218904972076)"
Line 437,"All materials are subject  to our established controls with respect to formulation  continuity and ongoing quality conformance.
","('Product_Design_And_Lifecycle_Management', 0.5603498220443726)","('Product_Quality_And_Safety', 0.1822309046983719)","('Supply_Chain_Management', 0.078547902405262)","(['Product Stewardship'], 0.5603498220443726)","('NON-ESG', 0.1822309046983719)","('NON-ESG', 0.078547902405262)"
Line 438,"For each of the critical areas, probing questions are  asked to develop the critical material property  requirements to ensure patient safety, functional  performance and continuity to the healthcare  market.
","('Employee_Health_And_Safety', 0.6349275708198547)","('Product_Quality_And_Safety', 0.23556001484394073)","('Product_Design_And_Lifecycle_Management', 0.027510160580277443)","(['Operational Eco-Efficiency'], 0.6349275708198547)","('NON-ESG', 0.23556001484394073)","('NON-ESG', 0.027510160580277443)"
Line 439,"For example: Critical to function:    Who is the end user?
","('Data_Security', 0.27548161149024963)","('Competitive_Behavior', 0.15114125609397888)","('Customer_Privacy', 0.08946950733661652)","('NON-ESG', 0.27548161149024963)","('NON-ESG', 0.15114125609397888)","('NON-ESG', 0.08946950733661652)"
Line 440,"What critical material properties will  enable function?
","('Supply_Chain_Management', 0.3035142123699188)","('Waste_And_Hazardous_Materials_Management', 0.23849694430828094)","('Product_Design_And_Lifecycle_Management', 0.1440502554178238)","('NON-ESG', 0.3035142123699188)","('NON-ESG', 0.23849694430828094)","('NON-ESG', 0.1440502554178238)"
Line 441,"Critical to manufacturability:    What manufacturing processes will be used?
","('Product_Design_And_Lifecycle_Management', 0.9022252559661865)","('Energy_Management', 0.01802729442715645)","('Supply_Chain_Management', 0.013259828090667725)","(['Product Stewardship'], 0.9022252559661865)","('NON-ESG', 0.01802729442715645)","('NON-ESG', 0.013259828090667725)"
Line 442,"What sterilization  method is necessary to ensure sterility?
","('Employee_Health_And_Safety', 0.4150806963443756)","('Access_And_Affordability', 0.16710424423217773)","('Product_Quality_And_Safety', 0.15117226541042328)","('NON-ESG', 0.4150806963443756)","('NON-ESG', 0.16710424423217773)","('NON-ESG', 0.15117226541042328)"
Line 443,"Critical to quality:    What properties need to be monitored/measured to ensure the  product performs consistently?
","('Product_Design_And_Lifecycle_Management', 0.8319932818412781)","('Product_Quality_And_Safety', 0.07448294013738632)","('Customer_Welfare', 0.014574771746993065)","(['Product Stewardship'], 0.8319932818412781)","('NON-ESG', 0.07448294013738632)","('NON-ESG', 0.014574771746993065)"
Line 444,"Critical to compliance :   What regulatory requirements must the product comply with?
","('Management_Of_Legal_And_Regulatory_Framework', 0.940643310546875)","('Business_Ethics', 0.009151234291493893)","('Product_Quality_And_Safety', 0.008671361953020096)","(['Corporate Governance'], 0.940643310546875)","('NON-ESG', 0.009151234291493893)","('NON-ESG', 0.008671361953020096)"
Line 445,"Critical to business requirements:    Are there constraints on cost or supplier?
","('Supply_Chain_Management', 0.9388482570648193)","('Water_And_Wastewater_Management', 0.005466347094625235)","('Labor_Practices', 0.004917678888887167)","(['Supply Chain Management'], 0.9388482570648193)","('NON-ESG', 0.005466347094625235)","('NON-ESG', 0.004917678888887167)"
Line 446,"What options are  available for second sources?
","('Access_And_Affordability', 0.25343701243400574)","('Management_Of_Legal_And_Regulatory_Framework', 0.13289330899715424)","('Selling_Practices_And_Product_Labeling', 0.10366693139076233)","('NON-ESG', 0.25343701243400574)","('NON-ESG', 0.13289330899715424)","('NON-ESG', 0.10366693139076233)"
Line 447,"Our Materials of Concern (MOC) list guides the way we address  the reduction of MOC across our portfolio.
","('Supply_Chain_Management', 0.3612448275089264)","('Product_Design_And_Lifecycle_Management', 0.21395568549633026)","('Energy_Management', 0.04900778830051422)","('NON-ESG', 0.3612448275089264)","('NON-ESG', 0.21395568549633026)","('NON-ESG', 0.04900778830051422)"
Line 448,"The list contains both  regulated and nonregulated substances that we consider to be  of concern and is updated twice a year.
","('Selling_Practices_And_Product_Labeling', 0.28835368156433105)","('Product_Quality_And_Safety', 0.13652881979942322)","('Customer_Welfare', 0.10858749598264694)","('NON-ESG', 0.28835368156433105)","('NON-ESG', 0.13652881979942322)","('NON-ESG', 0.10858749598264694)"
Line 449,"It includes substances  the company has put special emphasis on—for example, PVC  and phthalates—and those that BD has chosen to avoid and/or  reduce from its products and packaging.
","('Product_Design_And_Lifecycle_Management', 0.41559430956840515)","('Selling_Practices_And_Product_Labeling', 0.2001914083957672)","('Customer_Welfare', 0.11393836885690689)","('NON-ESG', 0.41559430956840515)","('NON-ESG', 0.2001914083957672)","('NON-ESG', 0.11393836885690689)"
Line 450,"BD carefully considers the potential impact of the materials we  use in our products and packaging and reviews customer  preferences related to chemicals of concern in finished goods.
","('Product_Design_And_Lifecycle_Management', 0.9412840008735657)","('Selling_Practices_And_Product_Labeling', 0.015233922749757767)","('Product_Quality_And_Safety', 0.005214514676481485)","(['Product Stewardship'], 0.9412840008735657)","('NON-ESG', 0.015233922749757767)","('NON-ESG', 0.005214514676481485)"
Line 451,"In order to monitor the changing landscape around chemicals  of high concern among customers, regulatory bodies and  advocacy groups, BD established a Chemical Review Board in  2013.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8295629024505615)","('Ecological_Impacts', 0.02467908337712288)","('Product_Quality_And_Safety', 0.016700712963938713)","(['Corporate Governance'], 0.8295629024505615)","('NON-ESG', 0.02467908337712288)","('NON-ESG', 0.016700712963938713)"
Line 452,"This internal board, led by our director of Global Product  Stewardship, includes representation from R&D for each of   our business units and functional expertise from toxicology   and procurement.
","('Product_Design_And_Lifecycle_Management', 0.6404026746749878)","('Product_Quality_And_Safety', 0.19002006947994232)","('Customer_Welfare', 0.031623657792806625)","(['Product Stewardship'], 0.6404026746749878)","('NON-ESG', 0.19002006947994232)","('NON-ESG', 0.031623657792806625)"
Line 453,"This group is equipped to evaluate the feasibility of alternative  materials, provide guidance to R&D within the company and  leverage material expertise across the organization to accelerate  our work to reduce priority MOC from the portfolio.
","('Supply_Chain_Management', 0.5747692584991455)","('Product_Design_And_Lifecycle_Management', 0.18556782603263855)","('Waste_And_Hazardous_Materials_Management', 0.037941984832286835)","(['Supply Chain Management'], 0.5747692584991455)","('NON-ESG', 0.18556782603263855)","('NON-ESG', 0.037941984832286835)"
Line 454,"At the corporate level, BD has a Global Product Stewardship  function, led by a director of Global Product Stewardship and  director of Global Product Stewardship Compliance.
","('Product_Design_And_Lifecycle_Management', 0.8843586444854736)","('Product_Quality_And_Safety', 0.03662591055035591)","('Selling_Practices_And_Product_Labeling', 0.01707059144973755)","(['Product Stewardship'], 0.8843586444854736)","('NON-ESG', 0.03662591055035591)","('NON-ESG', 0.01707059144973755)"
Line 455,"The Global Product Stewardship function reports to the VP of Environment,  Health & Safety and Sustainability (EHS&S); the VP EHS&S  reports to the company’s executive VP Integrated Supply Chain.
","('Product_Design_And_Lifecycle_Management', 0.661007821559906)","('Supply_Chain_Management', 0.11321057379245758)","('Product_Quality_And_Safety', 0.08301928639411926)","(['Product Stewardship'], 0.661007821559906)","('NON-ESG', 0.11321057379245758)","('NON-ESG', 0.08301928639411926)"
Line 456,"The Global Product Stewardship team is in place to monitor  changing global environmental regulations affecting our  product portfolio (including chemicals of high concern) and  provide governance over compliance activities carried out by our  business units.
","('Product_Design_And_Lifecycle_Management', 0.640282154083252)","('Product_Quality_And_Safety', 0.17796720564365387)","('Selling_Practices_And_Product_Labeling', 0.054181963205337524)","(['Product Stewardship'], 0.640282154083252)","('NON-ESG', 0.17796720564365387)","('NON-ESG', 0.054181963205337524)"
Line 457,"The Global Product Stewardship team also  administers our system of collecting information from suppliers  through a dedicated team of supply base compliance  associates.
","('Supply_Chain_Management', 0.7391027212142944)","('Product_Design_And_Lifecycle_Management', 0.09609939903020859)","('Waste_And_Hazardous_Materials_Management', 0.021593725308775902)","(['Supply Chain Management'], 0.7391027212142944)","('NON-ESG', 0.09609939903020859)","('NON-ESG', 0.021593725308775902)"
Line 458,"The team also maintains our MOC list and owns the  central database used to manage chemical information at the  product portfolio level.
","('Product_Design_And_Lifecycle_Management', 0.5881409645080566)","('Selling_Practices_And_Product_Labeling', 0.167564257979393)","('Customer_Welfare', 0.06883491575717926)","(['Product Stewardship'], 0.5881409645080566)","('NON-ESG', 0.167564257979393)","('NON-ESG', 0.06883491575717926)"
Line 459,"The Global Product Stewardship team, and in turn our EHS&S  function, is accountable for the company’s overall system of  chemicals management.
","('Product_Design_And_Lifecycle_Management', 0.8985492587089539)","('Product_Quality_And_Safety', 0.023050457239151)","('Selling_Practices_And_Product_Labeling', 0.012470528483390808)","(['Product Stewardship'], 0.8985492587089539)","('NON-ESG', 0.023050457239151)","('NON-ESG', 0.012470528483390808)"
Line 460,"They are responsible for governance  over compliance with product environmental regulations, such  as REACH and RoHS.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7317061424255371)","('Product_Quality_And_Safety', 0.06195593997836113)","('Product_Design_And_Lifecycle_Management', 0.053870365023612976)","(['Corporate Governance'], 0.7317061424255371)","('NON-ESG', 0.06195593997836113)","('NON-ESG', 0.053870365023612976)"
Line 461,"Our MOC list and materials for suppliers are available on the  Supplier Resources page on our website .
","('Supply_Chain_Management', 0.9336374998092651)","('Labor_Practices', 0.0060461233370006084)","('Product_Design_And_Lifecycle_Management', 0.005537873599678278)","(['Supply Chain Management'], 0.9336374998092651)","('NON-ESG', 0.0060461233370006084)","('NON-ESG', 0.005537873599678278)"
Line 462,"SASB disclosure: HC-MS-410a.1Management of Materials of Concern Laboratory animal welfare: Ensuring patient safety for human and veterinary patients BD continues to build its product portfolio that includes a  variety of medical devices, diagnostics, biotechnology and  pharmaceuticals.
","('Product_Quality_And_Safety', 0.819046676158905)","('Product_Design_And_Lifecycle_Management', 0.046017516404390335)","('Customer_Welfare', 0.02493762969970703)","(['Product Quality & Recall Management'], 0.819046676158905)","('NON-ESG', 0.046017516404390335)","('NON-ESG', 0.02493762969970703)"
Line 463,"Products in this sector must meet very  stringent requirements to demonstrate safety, efficacy and  suitability for their intended use.
","('Product_Quality_And_Safety', 0.8951186537742615)","('Product_Design_And_Lifecycle_Management', 0.021195802837610245)","('Selling_Practices_And_Product_Labeling', 0.012727758847177029)","(['Product Quality & Recall Management'], 0.8951186537742615)","('NON-ESG', 0.021195802837610245)","('NON-ESG', 0.012727758847177029)"
Line 464,"As part of this work of ensuring  ultimate patient safety, existing regulations and standards  require the use of laboratory animals in research and   product evaluation.
","('Product_Quality_And_Safety', 0.9204543828964233)","('Product_Design_And_Lifecycle_Management', 0.010923277586698532)","('Selling_Practices_And_Product_Labeling', 0.010534780099987984)","(['Product Quality & Recall Management'], 0.9204543828964233)","('NON-ESG', 0.010923277586698532)","('NON-ESG', 0.010534780099987984)"
Line 465,"BD is committed to animal welfare and uses recognized leading  standards to ensure best animal care practices.
","('Product_Quality_And_Safety', 0.13531610369682312)","('Waste_And_Hazardous_Materials_Management', 0.11205954849720001)","('Selling_Practices_And_Product_Labeling', 0.07833603024482727)","('NON-ESG', 0.13531610369682312)","('NON-ESG', 0.11205954849720001)","('NON-ESG', 0.07833603024482727)"
Line 466,"Good animal  welfare leads to good scientific data in support of product  safety.
","('Product_Quality_And_Safety', 0.8765769004821777)","('Selling_Practices_And_Product_Labeling', 0.029086874797940254)","('Customer_Welfare', 0.01196600403636694)","(['Product Quality & Recall Management'], 0.8765769004821777)","('NON-ESG', 0.029086874797940254)","('NON-ESG', 0.01196600403636694)"
Line 467,"Every required study must first be approved by an ethics  committee known as the Institutional Animal Care and Use  Committee (IACUC).
","('Management_Of_Legal_And_Regulatory_Framework', 0.4507821500301361)","('Business_Ethics', 0.3437942564487457)","('Director_Removal', 0.033871110528707504)","('NON-ESG', 0.4507821500301361)","('NON-ESG', 0.3437942564487457)","('NON-ESG', 0.033871110528707504)"
Line 468,"This ethics committee is comprised of  veterinarians, scientists, animal care teams and a member of  the community to represent general public opinion.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7633719444274902)","('Business_Ethics', 0.09743092954158783)","('Director_Removal', 0.02432924136519432)","(['Corporate Governance'], 0.7633719444274902)","('NON-ESG', 0.09743092954158783)","('NON-ESG', 0.02432924136519432)"
Line 469,"The IACUC  ensures responsible use of BD research animals in consideration  of the 4Rs: Replacement, Refinement, Reduction and  Retirement.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6922051310539246)","('Access_And_Affordability', 0.08821849524974823)","('GHG_Emissions', 0.036688484251499176)","(['Corporate Governance'], 0.6922051310539246)","('NON-ESG', 0.08821849524974823)","('NON-ESG', 0.036688484251499176)"
Line 470,"BD continues to support refinement by veterinary gold standard  practice across all animal studies; replacement by using in vitro  testing if and when possible; reduction of animal numbers by  extensive literature reviews of previous studies; and an active  retirement program that has provided adoption opportunities to  BD research animal heroes.
","('GHG_Emissions', 0.1805269569158554)","('Access_And_Affordability', 0.1522618532180786)","('Customer_Welfare', 0.1399601548910141)","('NON-ESG', 0.1805269569158554)","('NON-ESG', 0.1522618532180786)","('NON-ESG', 0.1399601548910141)"
Line 471,"BD continues to build transparency of the Research Animal  Programs under the BD corporate policy guidance on the  humane and responsible use of research animals signed by  senior management.
","('Business_Ethics', 0.9091889262199402)","('Management_Of_Legal_And_Regulatory_Framework', 0.015894848853349686)","('Labor_Practices', 0.006929480005055666)","(['Business Ethics'], 0.9091889262199402)","('NON-ESG', 0.015894848853349686)","('NON-ESG', 0.006929480005055666)"
Line 472,"The policy is available to the public   on bd.com .
","('Management_Of_Legal_And_Regulatory_Framework', 0.9214155077934265)","('Director_Removal', 0.00817995797842741)","('Business_Ethics', 0.007197240367531776)","(['Corporate Governance'], 0.9214155077934265)","('NON-ESG', 0.00817995797842741)","('NON-ESG', 0.007197240367531776)"
Line 473,"The Animal Welfare Policy and Oversight  Committee is defined within this policy and is comprised of  global members that work to support BD animal research.
","('Management_Of_Legal_And_Regulatory_Framework', 0.23235079646110535)","('Ecological_Impacts', 0.19761903584003448)","('Access_And_Affordability', 0.087098129093647)","('NON-ESG', 0.23235079646110535)","('NON-ESG', 0.19761903584003448)","('NON-ESG', 0.087098129093647)"
Line 474,"This group meets regularly to share best practices and examples  of the 4Rs across programs.
","('Management_Of_Legal_And_Regulatory_Framework', 0.28415003418922424)","('Business_Ethics', 0.1512197107076645)","('Human_Rights_And_Community_Relations', 0.10307316482067108)","('NON-ESG', 0.28415003418922424)","('NON-ESG', 0.1512197107076645)","('NON-ESG', 0.10307316482067108)"
Line 475,"BD supports membership to the National Association of  Biomedical Research and the European Animal Research  Association to help educate the public about the importance of  laboratory animal research and seek collaboration on best  practices.
","('Access_And_Affordability', 0.16518829762935638)","('Ecological_Impacts', 0.16019506752490997)","('GHG_Emissions', 0.15112628042697906)","('NON-ESG', 0.16518829762935638)","('NON-ESG', 0.16019506752490997)","('NON-ESG', 0.15112628042697906)"
Line 476,"The BD Biosciences facility in Tatabanya, Hungary is  one of the front runners to support animal research  transparency in Hungary.
","('Business_Ethics', 0.9014474153518677)","('Management_Of_Legal_And_Regulatory_Framework', 0.025706026703119278)","('Product_Quality_And_Safety', 0.006951988209038973)","(['Business Ethics'], 0.9014474153518677)","('NON-ESG', 0.025706026703119278)","('NON-ESG', 0.006951988209038973)"
Line 477,"The site has hosted local round table  discussions to share information about their operation and to  provide local teams the opportunity to visit its facility to learn  about their animal research program.
","('Ecological_Impacts', 0.22376199066638947)","('Management_Of_Legal_And_Regulatory_Framework', 0.16054785251617432)","('GHG_Emissions', 0.1253768354654312)","('NON-ESG', 0.22376199066638947)","('NON-ESG', 0.16054785251617432)","('NON-ESG', 0.1253768354654312)"
Line 478,"The BD Research Animal Program is supported by a team of  research animal care professionals that are highly committed to  animal welfare through daily welfare assessments, animal  training programs and novel environmental enrichment  opportunities.
","('Ecological_Impacts', 0.24226897954940796)","('Access_And_Affordability', 0.12372121959924698)","('Selling_Practices_And_Product_Labeling', 0.06623939424753189)","('NON-ESG', 0.24226897954940796)","('NON-ESG', 0.12372121959924698)","('NON-ESG', 0.06623939424753189)"
Line 479,"The BD Research Animal Program actively  publishes best practices and techniques in the global animal  research community.
","('Access_And_Affordability', 0.21559835970401764)","('GHG_Emissions', 0.15973058342933655)","('Ecological_Impacts', 0.1321336030960083)","('NON-ESG', 0.21559835970401764)","('NON-ESG', 0.15973058342933655)","('NON-ESG', 0.1321336030960083)"
Line 480,"We require that all third parties who carry out animal testing on  our behalf are covered by our Expectations for Suppliers (EFS) and  our company policy.
","('Selling_Practices_And_Product_Labeling', 0.19219349324703217)","('Product_Quality_And_Safety', 0.10019444674253464)","('Management_Of_Legal_And_Regulatory_Framework', 0.09757037460803986)","('NON-ESG', 0.19219349324703217)","('NON-ESG', 0.10019444674253464)","('NON-ESG', 0.09757037460803986)"
Line 481,"We preferentially use American Association  for Accreditation of Laboratory Animal Care (AAALAC)-accredited  third parties but have made exceptions when other qualification  information is considered sufficient and if unique expertise limits  options.
","('Management_Of_Legal_And_Regulatory_Framework', 0.331104576587677)","('Product_Quality_And_Safety', 0.20159752666950226)","('Access_And_Affordability', 0.11414351314306259)","('NON-ESG', 0.331104576587677)","('NON-ESG', 0.20159752666950226)","('NON-ESG', 0.11414351314306259)"
Line 482,"Even in the latter case, the BD Animal Research Program  performs full supplier animal welfare and care audits to ensure  sound animal welfare among animal vendors and suppliers, and  adherence to our EFS and content of our policy.
","('Ecological_Impacts', 0.23943734169006348)","('Selling_Practices_And_Product_Labeling', 0.1047736257314682)","('GHG_Emissions', 0.07331584393978119)","('NON-ESG', 0.23943734169006348)","('NON-ESG', 0.1047736257314682)","('NON-ESG', 0.07331584393978119)"
Line 483,"BD will continue to host a BRAD (Biomedical Research  Awareness Day) event each year as part of an international  effort to celebrate the contributions of research animals in  biomedical research.
","('Access_And_Affordability', 0.3584975004196167)","('Management_Of_Legal_And_Regulatory_Framework', 0.12159574776887894)","('Ecological_Impacts', 0.09292149543762207)","('NON-ESG', 0.3584975004196167)","('NON-ESG', 0.12159574776887894)","('NON-ESG', 0.09292149543762207)"
Line 484,"This effort helps to further educate the BD  community on the significant, lifesaving medical contributions  research animals have made to improve both human and  veterinary medicine.
","('Access_And_Affordability', 0.37308943271636963)","('Customer_Welfare', 0.08054254949092865)","('Ecological_Impacts', 0.07580666244029999)","('NON-ESG', 0.37308943271636963)","('NON-ESG', 0.08054254949092865)","('NON-ESG', 0.07580666244029999)"
Line 485,"BD is committed to honoring the  contributions of animal research and ensuring our medical  devices are safe for veterinary, as well as human use.
","('Product_Quality_And_Safety', 0.17683455348014832)","('Product_Design_And_Lifecycle_Management', 0.16383768618106842)","('Customer_Welfare', 0.1488095372915268)","('NON-ESG', 0.17683455348014832)","('NON-ESG', 0.16383768618106842)","('NON-ESG', 0.1488095372915268)"
Line 486,"Replacement ReﬁnementReduction Retirementby in vitro  testing, liter ature review use appr oaches that r educe or  eliminate the potential f or pain  and distr essuse minimal number  of animals to achie ve  scientiﬁc r esults utilizing an appr oved  program to adopt out  retired labor atory  animals with attending  veterinarian guidanc e4Rs Global Clinical Affairs Clinical studies are carried out by a central function within  Medical Affairs, serving all BD businesses and regions.
","('Access_And_Affordability', 0.17061404883861542)","('Employee_Health_And_Safety', 0.12965726852416992)","('Customer_Welfare', 0.10621194541454315)","('NON-ESG', 0.17061404883861542)","('NON-ESG', 0.12965726852416992)","('NON-ESG', 0.10621194541454315)"
Line 487,"The VP,  Global Clinical Affairs (GCA) reports directly to the company’s  Executive VP and Chief Medical Officer and has overall  responsibility for clinical studies.
","('Access_And_Affordability', 0.16717682778835297)","('Customer_Welfare', 0.09775262326002121)","('GHG_Emissions', 0.09083171933889389)","('NON-ESG', 0.16717682778835297)","('NON-ESG', 0.09775262326002121)","('NON-ESG', 0.09083171933889389)"
Line 488,"The VP GCA is responsible for ensuring clinical studies are  carried out in an ethical manner and in adherence to Good  Clinical Practice (GCP).
","('Access_And_Affordability', 0.4324162006378174)","('Management_Of_Legal_And_Regulatory_Framework', 0.08263867348432541)","('Product_Quality_And_Safety', 0.07240758836269379)","('NON-ESG', 0.4324162006378174)","('NON-ESG', 0.08263867348432541)","('NON-ESG', 0.07240758836269379)"
Line 489,"In addition, an independent Ethics  Committee/Institutional Review Board (EC/IRB) reviews all  studies and has the authority to approve, modify or stop a study  at any time.
","('Management_Of_Legal_And_Regulatory_Framework', 0.606292188167572)","('Business_Ethics', 0.12691518664360046)","('Director_Removal', 0.11215362697839737)","(['Corporate Governance'], 0.606292188167572)","('NON-ESG', 0.12691518664360046)","('NON-ESG', 0.11215362697839737)"
Line 490,"Prior to the start of each study, a risk assessment is carried out  by the GCA study team and representatives from the Medical  Affairs Quality team.
","('Systemic_Risk_Management', 0.2881939709186554)","('Physical_Impacts_Of_Climate_Change', 0.15626412630081177)","('Supply_Chain_Management', 0.06382068246603012)","('NON-ESG', 0.2881939709186554)","('NON-ESG', 0.15626412630081177)","('NON-ESG', 0.06382068246603012)"
Line 491,"The risk assessment is shared with the EC/ IRB and any oversight bodies, such as a clinical event  committee, and regulatory agencies where applicable.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9535143375396729)","('GHG_Emissions', 0.004535167943686247)","('Access_And_Affordability', 0.004123485181480646)","(['Corporate Governance'], 0.9535143375396729)","('NON-ESG', 0.004535167943686247)","('NON-ESG', 0.004123485181480646)"
Line 492,"Identified risks are assessed during the study on an ongoing  basis, by examination of adverse events or other factors.
","('Systemic_Risk_Management', 0.4980434775352478)","('Physical_Impacts_Of_Climate_Change', 0.09873974323272705)","('Critical_Incident_Risk_Management', 0.07008189707994461)","('NON-ESG', 0.4980434775352478)","('NON-ESG', 0.09873974323272705)","('NON-ESG', 0.07008189707994461)"
Line 493,"Free and informed consent is obtained from all study  participants prior to the start of each study.
","('Access_And_Affordability', 0.20588360726833344)","('Management_Of_Legal_And_Regulatory_Framework', 0.11823385953903198)","('Human_Rights_And_Community_Relations', 0.1150745078921318)","('NON-ESG', 0.20588360726833344)","('NON-ESG', 0.11823385953903198)","('NON-ESG', 0.1150745078921318)"
Line 494,"Consent is obtained  by the study site principal investigator and designees, as per site  procedures.
","('Ecological_Impacts', 0.6448790431022644)","('GHG_Emissions', 0.07162550091743469)","('Human_Rights_And_Community_Relations', 0.056837912648916245)","(['Natural Capital'], 0.6448790431022644)","('NON-ESG', 0.07162550091743469)","('NON-ESG', 0.056837912648916245)"
Line 495,"The names and contact information of the study  site’s principal investigator and the EC/IRB are provided to each  study participant in written form, usually by listing this  information in the subject’s Informed Consent.
","('Customer_Privacy', 0.9175620079040527)","('Selling_Practices_And_Product_Labeling', 0.011025374755263329)","('Data_Security', 0.007401207461953163)","(['Privacy Protection'], 0.9175620079040527)","('NON-ESG', 0.011025374755263329)","('NON-ESG', 0.007401207461953163)"
Line 496,"Participants are  encouraged to reach out to either of these contacts if they have  questions or concerns about the study.
","('Management_Of_Legal_And_Regulatory_Framework', 0.25281229615211487)","('Human_Rights_And_Community_Relations', 0.13261935114860535)","('Access_And_Affordability', 0.12894362211227417)","('NON-ESG', 0.25281229615211487)","('NON-ESG', 0.13261935114860535)","('NON-ESG', 0.12894362211227417)"
Line 497,"Extensive training in BD policies related to human subject  research and in GCA’s formal Quality System, consisting of  standard operating procedures (SOPs) and work instructions, is  required of all BD associates who engage in clinical study activities.
","('Access_And_Affordability', 0.2657115161418915)","('Management_Of_Legal_And_Regulatory_Framework', 0.2613561451435089)","('Product_Quality_And_Safety', 0.10917911678552628)","('NON-ESG', 0.2657115161418915)","('NON-ESG', 0.2613561451435089)","('NON-ESG', 0.10917911678552628)"
Line 498,"This training occurs via course and procedure review  via the BD online training system, as well as through direct  education during study team meetings.
","('Access_And_Affordability', 0.3652178943157196)","('Employee_Engagement_Inclusion_And_Diversity', 0.12528613209724426)","('Management_Of_Legal_And_Regulatory_Framework', 0.09229640662670135)","('NON-ESG', 0.3652178943157196)","('NON-ESG', 0.12528613209724426)","('NON-ESG', 0.09229640662670135)"
Line 499,"BD clinical studies are conducted in regions where ethical and  competent clinical research teams are located.
","('Access_And_Affordability', 0.26728570461273193)","('Customer_Welfare', 0.09002389758825302)","('Management_Of_Legal_And_Regulatory_Framework', 0.07465746253728867)","('NON-ESG', 0.26728570461273193)","('NON-ESG', 0.09002389758825302)","('NON-ESG', 0.07465746253728867)"
Line 500,"The Medical  Affairs and GCA teams have decision-making responsibilities in  this area.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8164166212081909)","('Human_Rights_And_Community_Relations', 0.02011551707983017)","('Director_Removal', 0.016611358150839806)","(['Corporate Governance'], 0.8164166212081909)","('NON-ESG', 0.02011551707983017)","('NON-ESG', 0.016611358150839806)"
Line 501,"However, the locations of the teams may vary from  where products are ultimately marketed.
","('Product_Design_And_Lifecycle_Management', 0.7188996076583862)","('Customer_Welfare', 0.07563461363315582)","('Selling_Practices_And_Product_Labeling', 0.07052463293075562)","(['Product Stewardship'], 0.7188996076583862)","('NON-ESG', 0.07563461363315582)","('NON-ESG', 0.07052463293075562)"
Line 502,"In accordance with the GCA’s SOPs, a formal Monitoring Plan is  written for each study.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8125981688499451)","('GHG_Emissions', 0.03112132102251053)","('Human_Rights_And_Community_Relations', 0.029556969180703163)","(['Corporate Governance'], 0.8125981688499451)","('NON-ESG', 0.03112132102251053)","('NON-ESG', 0.029556969180703163)"
Line 503,"This plan defines the method and timing  by which BD associates maintain oversight of each study site.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5926295518875122)","('Director_Removal', 0.069309763610363)","('Competitive_Behavior', 0.04401079937815666)","(['Corporate Governance'], 0.5926295518875122)","('NON-ESG', 0.069309763610363)","('NON-ESG', 0.04401079937815666)"
Line 504,"Clinical study monitoring may occur through frequent  communications via phone and email, and multiple visits to the  site.
","('Access_And_Affordability', 0.18530987203121185)","('Customer_Privacy', 0.15655972063541412)","('Selling_Practices_And_Product_Labeling', 0.10068053007125854)","('NON-ESG', 0.18530987203121185)","('NON-ESG', 0.15655972063541412)","('NON-ESG', 0.10068053007125854)"
Line 505,"The site and its principal investigator are qualified for  participation by GCA procedures.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5324853658676147)","('GHG_Emissions', 0.11023527383804321)","('Human_Rights_And_Community_Relations', 0.057501040399074554)","(['Corporate Governance'], 0.5324853658676147)","('NON-ESG', 0.11023527383804321)","('NON-ESG', 0.057501040399074554)"
Line 506,"Compliance to the study  protocol and GCP, especially related to safety issues, is reviewed  regularly by reviewing the medical record and study database  for each site participant.
","('Product_Quality_And_Safety', 0.8508874773979187)","('Employee_Health_And_Safety', 0.05359218642115593)","('Selling_Practices_And_Product_Labeling', 0.008885245770215988)","(['Product Quality & Recall Management'], 0.8508874773979187)","('NON-ESG', 0.05359218642115593)","('NON-ESG', 0.008885245770215988)"
Line 507,"In addition, external audits are conducted using selected  high-risk studies by BD auditors external to the GCA team.
","('Systemic_Risk_Management', 0.3138114809989929)","('Business_Ethics', 0.31065842509269714)","('Management_Of_Legal_And_Regulatory_Framework', 0.1897232085466385)","('NON-ESG', 0.3138114809989929)","('NON-ESG', 0.31065842509269714)","('NON-ESG', 0.1897232085466385)"
Line 508,"All studies are registered on public databases (such as  clinicaltrials.gov ), as required by U.S. Federal law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5015733242034912)","('Access_And_Affordability', 0.1005450114607811)","('Competitive_Behavior', 0.03296344354748726)","(['Corporate Governance'], 0.5015733242034912)","('NON-ESG', 0.1005450114607811)","('NON-ESG', 0.03296344354748726)"
Line 509,"This includes  information about the study protocol, clinical study sites, and  eventually, adverse events and other study results.
","('Product_Quality_And_Safety', 0.1898011714220047)","('Employee_Health_And_Safety', 0.12819607555866241)","('Selling_Practices_And_Product_Labeling', 0.09145693480968475)","('NON-ESG', 0.1898011714220047)","('NON-ESG', 0.12819607555866241)","('NON-ESG', 0.09145693480968475)"
Line 510,"Reporting on  significant problems discovered during monitoring, deviations to  the protocol and necessary corrective actions are reported to  the responsible EC/IRB and, when required, to the regulatory  agency (e.g., FDA) with jurisdiction.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9078369140625)","('Business_Ethics', 0.014833815395832062)","('Product_Quality_And_Safety', 0.01148364320397377)","(['Corporate Governance'], 0.9078369140625)","('NON-ESG', 0.014833815395832062)","('NON-ESG', 0.01148364320397377)"
Line 511,"View our clinical trial publication policy .
","('Access_And_Affordability', 0.13711445033550262)","('Competitive_Behavior', 0.13036024570465088)","('Management_Of_Legal_And_Regulatory_Framework', 0.11317449063062668)","('NON-ESG', 0.13711445033550262)","('NON-ESG', 0.13036024570465088)","('NON-ESG', 0.11317449063062668)"
Line 512,"Product marketing BD has policies and procedures to ensure the advertising and  promotion of our products, solutions and services comply with  applicable laws and regulations.
","('Selling_Practices_And_Product_Labeling', 0.8358416557312012)","('Product_Design_And_Lifecycle_Management', 0.029649637639522552)","('Product_Quality_And_Safety', 0.0248939897865057)","(['Marketing Practices'], 0.8358416557312012)","('NON-ESG', 0.029649637639522552)","('NON-ESG', 0.0248939897865057)"
Line 513,"Our advertising and promotions  programs serve to create a globally harmonized process for  generating, reviewing and approving advertising and  promotional communications.
","('Selling_Practices_And_Product_Labeling', 0.3600136935710907)","('Competitive_Behavior', 0.17224431037902832)","('Customer_Welfare', 0.1028480976819992)","('NON-ESG', 0.3600136935710907)","('NON-ESG', 0.17224431037902832)","('NON-ESG', 0.1028480976819992)"
Line 514,"This program ensures consistency  in definitions, rules, principles, governance and approval criteria  to enable consistent compliance across BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9473703503608704)","('Business_Ethics', 0.015411736443638802)","('Director_Removal', 0.004906708374619484)","(['Corporate Governance'], 0.9473703503608704)","('NON-ESG', 0.015411736443638802)","('NON-ESG', 0.004906708374619484)"
Line 515,"Our advertising and  promotion review and approval processes are overseen by a  steering committee consisting of cross-functional  representatives from each business unit, including Marketing,  Medical Affairs, Regulatory Affairs and Legal.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9540547132492065)","('Competitive_Behavior', 0.006163462530821562)","('Business_Ethics', 0.003899693489074707)","(['Corporate Governance'], 0.9540547132492065)","('NON-ESG', 0.006163462530821562)","('NON-ESG', 0.003899693489074707)"
Line 516,"Our global policy on advertising and promotion prohibits the  development and distribution of advertising and promotional  materials that have not been approved under the structure set  out in the policy.
","('Selling_Practices_And_Product_Labeling', 0.5756727457046509)","('Management_Of_Legal_And_Regulatory_Framework', 0.0985841453075409)","('Customer_Privacy', 0.056842006742954254)","(['Marketing Practices'], 0.5756727457046509)","('NON-ESG', 0.0985841453075409)","('NON-ESG', 0.056842006742954254)"
Line 517,"This policy is supported by procedures that outline how material is reviewed and approved, and systems  used to manage and track approvals.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9323326349258423)","('Director_Removal', 0.0058784824796020985)","('Ecological_Impacts', 0.005092540755867958)","(['Corporate Governance'], 0.9323326349258423)","('NON-ESG', 0.0058784824796020985)","('NON-ESG', 0.005092540755867958)"
Line 518,"All policies outline the obligation to report noncompliance, how  associates can do this, including via the BD Ethics Helpline, and  potential disciplinary action that could be taken for noncompliance.
","('Business_Ethics', 0.940125584602356)","('Management_Of_Legal_And_Regulatory_Framework', 0.018445774912834167)","('Product_Quality_And_Safety', 0.005351177416741848)","(['Business Ethics'], 0.940125584602356)","('NON-ESG', 0.018445774912834167)","('NON-ESG', 0.005351177416741848)"
Line 519,"Finally, expectations around the promotion of our products are  laid out in our Code of Conduct.
","('Product_Design_And_Lifecycle_Management', 0.8022168278694153)","('Selling_Practices_And_Product_Labeling', 0.06556908786296844)","('Product_Quality_And_Safety', 0.04080832004547119)","(['Product Stewardship'], 0.8022168278694153)","('NON-ESG', 0.06556908786296844)","('NON-ESG', 0.04080832004547119)"
Line 520,"All associates who are involved in the creation, review and  approval of advertising and promotional material are required  to complete annual training via the BD online training system.
","('Management_Of_Legal_And_Regulatory_Framework', 0.35627806186676025)","('Selling_Practices_And_Product_Labeling', 0.16868115961551666)","('Product_Quality_And_Safety', 0.056224118918180466)","('NON-ESG', 0.35627806186676025)","('NON-ESG', 0.16868115961551666)","('NON-ESG', 0.056224118918180466)"
Line 521,"Training covers BD policies and procedures, as well as our  systems used to manage and track approvals.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9334090948104858)","('Director_Removal', 0.008225950412452221)","('Business_Ethics', 0.0073850881308317184)","(['Corporate Governance'], 0.9334090948104858)","('NON-ESG', 0.008225950412452221)","('NON-ESG', 0.0073850881308317184)"
Line 522,"In addition,  topic-specific training is provided throughout the year.
","('Product_Quality_And_Safety', 0.14856146275997162)","('Employee_Engagement_Inclusion_And_Diversity', 0.13906888663768768)","('Access_And_Affordability', 0.136680468916893)","('NON-ESG', 0.14856146275997162)","('NON-ESG', 0.13906888663768768)","('NON-ESG', 0.136680468916893)"
Line 523,"Information regarding interactions with healthcare  professionals can be found in the How We Do Business    section of this report.
","('Access_And_Affordability', 0.24605143070220947)","('Employee_Engagement_Inclusion_And_Diversity', 0.14812014997005463)","('Human_Rights_And_Community_Relations', 0.09224797785282135)","('NON-ESG', 0.24605143070220947)","('NON-ESG', 0.14812014997005463)","('NON-ESG', 0.09224797785282135)"
Line 524,"SASB disclosure: HC-MS-270a.Cybersecurity Security   by design Security   in use Security   through  partnershipOur commitment to cybersecurity includes the protection and  resilience of our products, manufacturing and IT.
","('Data_Security', 0.7471118569374084)","('Business_Model_Resilience', 0.08570949733257294)","('Systemic_Risk_Management', 0.021940751001238823)","(['Information Security/Cybersecurity & System Availability'], 0.7471118569374084)","('NON-ESG', 0.08570949733257294)","('NON-ESG', 0.021940751001238823)"
Line 525,"We strive to  meet high security standards so our customers can focus on  what matters most: caring for patients.
","('Access_And_Affordability', 0.3276602327823639)","('Product_Quality_And_Safety', 0.14236214756965637)","('Employee_Health_And_Safety', 0.11021651327610016)","('NON-ESG', 0.3276602327823639)","('NON-ESG', 0.14236214756965637)","('NON-ESG', 0.11021651327610016)"
Line 526,"Cybersecurity program BD Information Security is part of the company’s Risk  Management organization and is responsible for global strategy across the company’s enterprise, IT, manufacturing systems and  product offerings.
","('Data_Security', 0.9557892680168152)","('Systemic_Risk_Management', 0.00676626805216074)","('Business_Ethics', 0.0033522762823849916)","(['Information Security/Cybersecurity & System Availability'], 0.9557892680168152)","('NON-ESG', 0.00676626805216074)","('NON-ESG', 0.0033522762823849916)"
Line 527,"This includes cybersecurity strategy and  governance (including cybersecurity policies, procedures and  compliance); security operations (including incident response,  investigations, monitoring and detection, as well as vulnerability  and threat intel); security engineering (including security  architecture, testing and research and solutions management);  product security; and regional cybersecurity.
","('Data_Security', 0.9592503905296326)","('Systemic_Risk_Management', 0.004432285204529762)","('Physical_Impacts_Of_Climate_Change', 0.0029467211570590734)","(['Information Security/Cybersecurity & System Availability'], 0.9592503905296326)","('NON-ESG', 0.004432285204529762)","('NON-ESG', 0.0029467211570590734)"
Line 528,"BD products and systems are designed to be secure and are developed  using industry-leading cybersecurity standards, including those from ISO  and NIST.
","('Data_Security', 0.9286975264549255)","('Business_Ethics', 0.011746852658689022)","('Systemic_Risk_Management', 0.00964315328747034)","(['Information Security/Cybersecurity & System Availability'], 0.9286975264549255)","('NON-ESG', 0.011746852658689022)","('NON-ESG', 0.00964315328747034)"
Line 529,"BD products and systems are secured and maintained throughout their  intended life cycle, across all technologies and sites.
","('Product_Design_And_Lifecycle_Management', 0.9106494784355164)","('Product_Quality_And_Safety', 0.008578553795814514)","('Data_Security', 0.008534489199519157)","(['Product Stewardship'], 0.9106494784355164)","('NON-ESG', 0.008578553795814514)","('NON-ESG', 0.008534489199519157)"
Line 530,"BD maintains a culture of transparency and collaboration with customers  and industry stakeholders to establish industry best practices.Our cybersecurity program incorporates: BD utilizes a framework to incorporate cybersecurity into our processes for product design, manufacturing, customer support and  enterprise systems.
","('Business_Ethics', 0.8525970578193665)","('Data_Security', 0.07576363533735275)","('Systemic_Risk_Management', 0.010239963419735432)","(['Business Ethics'], 0.8525970578193665)","('NON-ESG', 0.07576363533735275)","('NON-ESG', 0.010239963419735432)"
Line 531,"Our framework has been aligned to various industry work products including the HSCC Med Tech Joint Security  Plan, NIST Cybersecurity Framework, ISO 27001, UL 2900, and ISA 62443.
","('Data_Security', 0.8532474040985107)","('Systemic_Risk_Management', 0.02839333936572075)","('Management_Of_Legal_And_Regulatory_Framework', 0.013792518526315689)","(['Information Security/Cybersecurity & System Availability'], 0.8532474040985107)","('NON-ESG', 0.02839333936572075)","('NON-ESG', 0.013792518526315689)"
Line 532,"Our cybersecurity program includes regular internal and external  security audits and vulnerability assessments; penetration  testing of the company’s systems, products and practices;  threat intelligence investigations; and vulnerability and incident  management.
","('Data_Security', 0.9594330191612244)","('Systemic_Risk_Management', 0.0038169065956026316)","('Business_Ethics', 0.0033418380189687014)","(['Information Security/Cybersecurity & System Availability'], 0.9594330191612244)","('NON-ESG', 0.0038169065956026316)","('NON-ESG', 0.0033418380189687014)"
Line 533,"We also leverage threat modeling to uncover and  examine potential cybersecurity risks during the design process  and beyond.
","('Data_Security', 0.847321629524231)","('Systemic_Risk_Management', 0.06622355431318283)","('Physical_Impacts_Of_Climate_Change', 0.010687878355383873)","(['Information Security/Cybersecurity & System Availability'], 0.847321629524231)","('NON-ESG', 0.06622355431318283)","('NON-ESG', 0.010687878355383873)"
Line 534,"In addition, we provide cybersecurity awareness training to our  70,000 associates, comprised of online cybersecurity training  modules; in-person and virtual cybersecurity bootcamp classes;  contextual phishing simulation exercises; mock incident  response exercises; and intranet resources aimed at enhancing  associates’ ongoing cyber awareness.
","('Data_Security', 0.8892785310745239)","('Business_Ethics', 0.012678884901106358)","('Critical_Incident_Risk_Management', 0.011717421002686024)","(['Information Security/Cybersecurity & System Availability'], 0.8892785310745239)","('NON-ESG', 0.012678884901106358)","('NON-ESG', 0.011717421002686024)"
Line 535,"Transparency and collaboration with customers While we maintain robust security protocols, we also recognize  that new security threats in the healthcare industry emerge  continually.
","('Data_Security', 0.9426130056381226)","('Business_Ethics', 0.010584451258182526)","('Systemic_Risk_Management', 0.005776162259280682)","(['Information Security/Cybersecurity & System Availability'], 0.9426130056381226)","('NON-ESG', 0.010584451258182526)","('NON-ESG', 0.005776162259280682)"
Line 536,"That is why we believe transparency and  collaboration are essential.
","('Business_Ethics', 0.9542851448059082)","('Data_Security', 0.005861109122633934)","('Management_Of_Legal_And_Regulatory_Framework', 0.004761459305882454)","(['Business Ethics'], 0.9542851448059082)","('NON-ESG', 0.005861109122633934)","('NON-ESG', 0.004761459305882454)"
Line 537,"In 2020, we launched the BD Cybersecurity Trust Center   where customers can learn more about our cybersecurity  program and access product security bulletins and patches,  along with product security white papers, which include  Manufacturer Disclosure Statement for Medical Device   Security (MDS2) attestations.
","('Data_Security', 0.9607455134391785)","('Systemic_Risk_Management', 0.0041943988762795925)","('Director_Removal', 0.0029730619862675667)","(['Information Security/Cybersecurity & System Availability'], 0.9607455134391785)","('NON-ESG', 0.0041943988762795925)","('NON-ESG', 0.0029730619862675667)"
Line 538,"Customers, security researchers,  third-party component vendors and other external groups can  also report a product security concern, incident or vulnerability  to BD through the Cybersecurity Trust Center.
","('Data_Security', 0.9571568965911865)","('Systemic_Risk_Management', 0.005443977192044258)","('Supply_Chain_Management', 0.003139343811199069)","(['Information Security/Cybersecurity & System Availability'], 0.9571568965911865)","('NON-ESG', 0.005443977192044258)","('NON-ESG', 0.003139343811199069)"
Line 539,"We recognize that systems and threats evolve continuously,   and no system can be protected against all vulnerabilities.
","('Data_Security', 0.9380220174789429)","('Systemic_Risk_Management', 0.008237555623054504)","('Customer_Privacy', 0.004930074792355299)","(['Information Security/Cybersecurity & System Availability'], 0.9380220174789429)","('NON-ESG', 0.008237555623054504)","('NON-ESG', 0.004930074792355299)"
Line 540,"That’s why vulnerability disclosure is essential.
","('Data_Security', 0.8620684742927551)","('Systemic_Risk_Management', 0.033970605581998825)","('Physical_Impacts_Of_Climate_Change', 0.010879906825721264)","(['Information Security/Cybersecurity & System Availability'], 0.8620684742927551)","('NON-ESG', 0.033970605581998825)","('NON-ESG', 0.010879906825721264)"
Line 541,"When a potential  vulnerability or incident is uncovered or reported to BD, we work  to identify vulnerable IT systems and products, examine them,  develop and validate compensating controls and/or security updates (as needed), and disclose our findings publicly,  equipping customers with the information they need to manage  potential risks properly.
","('Data_Security', 0.9523141980171204)","('Systemic_Risk_Management', 0.006764282006770372)","('Physical_Impacts_Of_Climate_Change', 0.003660319373011589)","(['Information Security/Cybersecurity & System Availability'], 0.9523141980171204)","('NON-ESG', 0.006764282006770372)","('NON-ESG', 0.003660319373011589)"
Line 542,"For maximum awareness, BD voluntarily  reports coordinated vulnerability disclosures to the U.S. Food &  Drug Administration (FDA)  and Information Sharing Analysis  Organizations (ISAO) where BD participates—including the U.S.  Department of Homeland Security Cybersecurity &  Infrastructure Security Agency (CISA)  and the Health  Information Sharing and Analysis Center (H-ISAC) —and  publishes them to the BD Cybersecurity Trust Center.
","('Data_Security', 0.9629579782485962)","('Systemic_Risk_Management', 0.0038632710929960012)","('Customer_Privacy', 0.0031000999733805656)","(['Information Security/Cybersecurity & System Availability'], 0.9629579782485962)","('NON-ESG', 0.0038632710929960012)","('NON-ESG', 0.0031000999733805656)"
Line 543,"In addition to product security bulletins and patches, customers  can also access third-party certifications and attestations  through the BD Cybersecurity Trust Center.
","('Data_Security', 0.9486810564994812)","('Systemic_Risk_Management', 0.006340809632092714)","('Business_Ethics', 0.005221603438258171)","(['Information Security/Cybersecurity & System Availability'], 0.9486810564994812)","('NON-ESG', 0.006340809632092714)","('NON-ESG', 0.005221603438258171)"
Line 544,"Our cybersecurity  programs and policies for products have been evaluated by the  Underwriters Laboratories Cybersecurity Assurance Program (UL  CAP), affording BD an independently audited certification that  demonstrates the cybersecurity of medical device products  through a rigorous program of analysis.
","('Data_Security', 0.939433217048645)","('Systemic_Risk_Management', 0.00972446333616972)","('Business_Ethics', 0.007145361974835396)","(['Information Security/Cybersecurity & System Availability'], 0.939433217048645)","('NON-ESG', 0.00972446333616972)","('NON-ESG', 0.007145361974835396)"
Line 545,"UL CAP cybersecurity  testing is extensive and challenges BD products against known BD Cybersecurity framework cybersecurity vulnerabilities, malware, malformed input (fuzz  testing), structured penetration, static source code analysis,  static binary and bytecode analysis and verification of security  controls (access control, user authentication and authorization,  remote communication, cryptography and software updates).
","('Data_Security', 0.9627861976623535)","('Systemic_Risk_Management', 0.0035657298285514116)","('Business_Ethics', 0.003263000166043639)","(['Information Security/Cybersecurity & System Availability'], 0.9627861976623535)","('NON-ESG', 0.0035657298285514116)","('NON-ESG', 0.003263000166043639)"
Line 546,"Two BD products, the BD FACSLyric ™ Flow Cytometer and the BD  Synapsys ™ Microbiology Informatics Solution, were among the first  medical devices to earn UL CAP certification, with additional  evaluations underway.BD also maintains a SOC2+ program for multiple BD products  and systems that collect and process patient health information  in accordance with the Health Insurance Portability and  Accountability Act (HIPAA).
","('Customer_Privacy', 0.3816337287425995)","('Data_Security', 0.1585015207529068)","('Product_Quality_And_Safety', 0.07208073884248734)","('NON-ESG', 0.3816337287425995)","('NON-ESG', 0.1585015207529068)","('NON-ESG', 0.07208073884248734)"
Line 547,"These annual audits address the  Trust Principles for Security and (for our cloud-based products)  Availability.
","('Data_Security', 0.8476139307022095)","('Systemic_Risk_Management', 0.02658192068338394)","('Business_Ethics', 0.016579395160079002)","(['Information Security/Cybersecurity & System Availability'], 0.8476139307022095)","('NON-ESG', 0.02658192068338394)","('NON-ESG', 0.016579395160079002)"
Line 548,"SOC2+ reports are prepared by an independent  third party and provide assurance regarding the operational  effectiveness of BD internal controls and the security of BD  products.
","('Data_Security', 0.8249390721321106)","('Business_Ethics', 0.06217586621642113)","('Customer_Privacy', 0.016610169783234596)","(['Information Security/Cybersecurity & System Availability'], 0.8249390721321106)","('NON-ESG', 0.06217586621642113)","('NON-ESG', 0.016610169783234596)"
Line 549,"UL CAP and SOC2+ reports are available to customers  upon request via the BD Cybersecurity Trust Center.
","('Systemic_Risk_Management', 0.3655986785888672)","('Data_Security', 0.3234926760196686)","('Management_Of_Legal_And_Regulatory_Framework', 0.07723087072372437)","('NON-ESG', 0.3655986785888672)","('NON-ESG', 0.3234926760196686)","('NON-ESG', 0.07723087072372437)"
Line 550,"Cybersecurity and COVID-In 2020, our cybersecurity strategy helped to enable the company’s response to the COVID-19 pandemic.
","('Data_Security', 0.7958547472953796)","('Systemic_Risk_Management', 0.0863264799118042)","('Physical_Impacts_Of_Climate_Change', 0.020574901252985)","(['Information Security/Cybersecurity & System Availability'], 0.7958547472953796)","('NON-ESG', 0.0863264799118042)","('NON-ESG', 0.020574901252985)"
Line 551,"We expanded secure connectivity options for the BD Veritor ™ Plus System, which is an antigen-based  point-of-care device granted Emergency Use Authorization by the FDA to perform SARS-CoV-2 diagnostic  testing.
","('Critical_Incident_Risk_Management', 0.9704557657241821)","('Employee_Health_And_Safety', 0.004583586007356644)","('Air_Quality', 0.003285254817456007)","(['Risk & Crisis Management'], 0.9704557657241821)","('NON-ESG', 0.004583586007356644)","('NON-ESG', 0.003285254817456007)"
Line 552,"We also enabled encrypted reporting capabilities for BD Synapsys ™, an integrated informatics solution.
","('Data_Security', 0.8157678246498108)","('Customer_Privacy', 0.03882605582475662)","('Business_Ethics', 0.02549753338098526)","(['Information Security/Cybersecurity & System Availability'], 0.8157678246498108)","('NON-ESG', 0.03882605582475662)","('NON-ESG', 0.02549753338098526)"
Line 553,"The BD Synapsys ™ Solution unifies instrument-read COVID-19 test results from the BD Veritor ™ Plus System  and the BD MAX ™ System.
","('Energy_Management', 0.15283571183681488)","('Customer_Welfare', 0.102471262216568)","('Access_And_Affordability', 0.09059584140777588)","('NON-ESG', 0.15283571183681488)","('NON-ESG', 0.102471262216568)","('NON-ESG', 0.09059584140777588)"
Line 554,"The BD MAX ™ System is a fully integrated, automated PCR-based molecular  platform also granted Emergency Use Authorization by the FDA to perform SARS-CoV-2 diagnostic testing.
","('Critical_Incident_Risk_Management', 0.9705716371536255)","('Employee_Health_And_Safety', 0.004056097008287907)","('Air_Quality', 0.0036957820411771536)","(['Risk & Crisis Management'], 0.9705716371536255)","('NON-ESG', 0.004056097008287907)","('NON-ESG', 0.0036957820411771536)"
Line 555,"Once the data is aggregated in the BD Synapsys ™ Solution, customers who enable the solution’s optional  reporting capabilities can create encrypted reports, simplifying compliance requirements and reducing   the need for manual reporting.
","('Data_Security', 0.4899015724658966)","('Customer_Privacy', 0.19709348678588867)","('Business_Ethics', 0.07628791034221649)","('NON-ESG', 0.4899015724658966)","('NON-ESG', 0.19709348678588867)","('NON-ESG', 0.07628791034221649)"
Line 556,"Improving cybersecurity through partnership We believe industry collaboration makes us stronger and,  likewise, enhances healthcare cybersecurity.
","('Data_Security', 0.6811344027519226)","('Systemic_Risk_Management', 0.11058767884969711)","('Business_Model_Resilience', 0.04382471367716789)","(['Information Security/Cybersecurity & System Availability'], 0.6811344027519226)","('NON-ESG', 0.11058767884969711)","('NON-ESG', 0.04382471367716789)"
Line 557,"The partnerships  below exemplify industry engagements from 2020 that helped  us further improve our cybersecurity practices at BD while also  advancing cybersecurity maturity across the industry.
","('Data_Security', 0.6398078203201294)","('Systemic_Risk_Management', 0.1788480430841446)","('Business_Model_Resilience', 0.028164856135845184)","(['Information Security/Cybersecurity & System Availability'], 0.6398078203201294)","('NON-ESG', 0.1788480430841446)","('NON-ESG', 0.028164856135845184)"
Line 558,"Operation Warp Speed (OWS) —OWS was a public-private  partnership initiated by the U.S. government in 2020 for the  purpose of producing and delivering 300 million coronavirus  vaccine doses across the U.S. Our participation with this  multiagency initiative helped to strengthen our threat intel and  bolster manufacturing cybersecurity while also guarding against  increased cyberactivity related to the vaccine effort.
","('Data_Security', 0.8877750039100647)","('Systemic_Risk_Management', 0.010979789309203625)","('Physical_Impacts_Of_Climate_Change', 0.009778515435755253)","(['Information Security/Cybersecurity & System Availability'], 0.8877750039100647)","('NON-ESG', 0.010979789309203625)","('NON-ESG', 0.009778515435755253)"
Line 559,"U.S. Department of Homeland Security Cybersecurity &  Infrastructure Security Agency (CISA) —CISA offers in-depth  cybersecurity resources for U.S.-based organizations, including  those in the healthcare and public health sector.
","('Data_Security', 0.9462368488311768)","('Systemic_Risk_Management', 0.00821185577660799)","('Physical_Impacts_Of_Climate_Change', 0.005142137873917818)","(['Information Security/Cybersecurity & System Availability'], 0.9462368488311768)","('NON-ESG', 0.00821185577660799)","('NON-ESG', 0.005142137873917818)"
Line 560,"Following our  involvement with OWS, CISA engaged with BD on several  initiatives including assessments, reviews and preparedness  exercises.
","('Critical_Incident_Risk_Management', 0.6287034749984741)","('Physical_Impacts_Of_Climate_Change', 0.052097517997026443)","('Human_Rights_And_Community_Relations', 0.03380883112549782)","(['Risk & Crisis Management'], 0.6287034749984741)","('NON-ESG', 0.052097517997026443)","('NON-ESG', 0.03380883112549782)"
Line 561,"CISA also performed an evaluation of our phishing simulation program to help us assess our cybersecurity  awareness training for BD associates.
","('Data_Security', 0.9432626962661743)","('Systemic_Risk_Management', 0.00645343866199255)","('Business_Ethics', 0.006361139006912708)","(['Information Security/Cybersecurity & System Availability'], 0.9432626962661743)","('NON-ESG', 0.00645343866199255)","('NON-ESG', 0.006361139006912708)"
Line 562,"The International Medical Device Regulators’ Forum  (IMDRF) —The IMDRF published Principles and Practices for  Medical Device Cybersecurity  in March 2020.
","('Data_Security', 0.7784079313278198)","('Systemic_Risk_Management', 0.06768251210451126)","('Business_Ethics', 0.02668202854692936)","(['Information Security/Cybersecurity & System Availability'], 0.7784079313278198)","('NON-ESG', 0.06768251210451126)","('NON-ESG', 0.02668202854692936)"
Line 563,"BD is a member  of the IMDRF Cybersecurity Working Group, which calls for  greater transparency around third-party software labeling, as  well as device end of life (EoL) and end of support (EoS).
","('Data_Security', 0.7047842741012573)","('Business_Ethics', 0.16513527929782867)","('Systemic_Risk_Management', 0.024144073948264122)","(['Information Security/Cybersecurity & System Availability'], 0.7047842741012573)","('NON-ESG', 0.16513527929782867)","('NON-ESG', 0.024144073948264122)"
Line 564,"The Medical Device Innovation Consortium (MDIC) —The  MDIC Cybersecurity Steering Committee, chaired by BD Vice  President and Chief Information Security Officer, Rob Suárez, is  working to develop a maturity model benchmark based on the  Healthcare and Public Health Sector Coordinating Council  (HSCC) Med Tech Joint Security Plan (JSP) .
","('Data_Security', 0.9246045351028442)","('Systemic_Risk_Management', 0.013916712254285812)","('Management_Of_Legal_And_Regulatory_Framework', 0.004963727667927742)","(['Information Security/Cybersecurity & System Availability'], 0.9246045351028442)","('NON-ESG', 0.013916712254285812)","('NON-ESG', 0.004963727667927742)"
Line 565,"BD also  contributed to the development of the MDIC’s Threat Modeling  Playbook, authored by the MITRE Corporation, and helps  facilitate the MDIC’s Medical Device Cybersecurity Threat  Modeling Bootcamp .
","('Data_Security', 0.9310926198959351)","('Systemic_Risk_Management', 0.0124256182461977)","('Physical_Impacts_Of_Climate_Change', 0.006016670260578394)","(['Information Security/Cybersecurity & System Availability'], 0.9310926198959351)","('NON-ESG', 0.0124256182461977)","('NON-ESG', 0.006016670260578394)"
Line 566,"To learn more about our engagement with cybersecurity working groups in healthcare, read our inaugural Cybersecurity Annual  Report .
","('Data_Security', 0.8332347273826599)","('Systemic_Risk_Management', 0.05081493407487869)","('Physical_Impacts_Of_Climate_Change', 0.016017546877264977)","(['Information Security/Cybersecurity & System Availability'], 0.8332347273826599)","('NON-ESG', 0.05081493407487869)","('NON-ESG', 0.016017546877264977)"
Line 567,"Released in 2020, this report highlights our engagement with cybersecurity working groups in healthcare and updates  stakeholders on BD cybersecurity practices.
","('Data_Security', 0.86102294921875)","('Systemic_Risk_Management', 0.04318671301007271)","('Business_Ethics', 0.01183356810361147)","(['Information Security/Cybersecurity & System Availability'], 0.86102294921875)","('NON-ESG', 0.04318671301007271)","('NON-ESG', 0.01183356810361147)"
Line 568,"For more information about our cybersecurity program, visit the BD Cybersecurity Trust Center .
","('Data_Security', 0.8799704909324646)","('Systemic_Risk_Management', 0.029885442927479744)","('Business_Model_Resilience', 0.010779166594147682)","(['Information Security/Cybersecurity & System Availability'], 0.8799704909324646)","('NON-ESG', 0.029885442927479744)","('NON-ESG', 0.010779166594147682)"
Line 569,"Sterilization Medical device sterilization is essential to a functioning and  effective healthcare system.
","('Employee_Health_And_Safety', 0.7428522706031799)","('Access_And_Affordability', 0.05963139235973358)","('Product_Quality_And_Safety', 0.038415756076574326)","(['Operational Eco-Efficiency'], 0.7428522706031799)","('NON-ESG', 0.05963139235973358)","('NON-ESG', 0.038415756076574326)"
Line 570,"Sterilization protects patients from  the risks of infectious diseases caused by bacteria, viruses and  fungi.
","('Access_And_Affordability', 0.1860649436712265)","('Employee_Health_And_Safety', 0.1174396350979805)","('Product_Quality_And_Safety', 0.09242527931928635)","('NON-ESG', 0.1860649436712265)","('NON-ESG', 0.1174396350979805)","('NON-ESG', 0.09242527931928635)"
Line 571,"At BD, we use a variety of methods to safely sterilize our  products, including ethylene oxide (or “EtO”), gamma radiation,  e-beam and moist heat.
","('Product_Design_And_Lifecycle_Management', 0.25995728373527527)","('Waste_And_Hazardous_Materials_Management', 0.2061421275138855)","('Product_Quality_And_Safety', 0.19156640768051147)","('NON-ESG', 0.25995728373527527)","('NON-ESG', 0.2061421275138855)","('NON-ESG', 0.19156640768051147)"
Line 572,"The appropriate method of sterilization depends on a variety   of factors.
","('Employee_Health_And_Safety', 0.4960823059082031)","('Product_Quality_And_Safety', 0.10836425423622131)","('Customer_Welfare', 0.05801377072930336)","('NON-ESG', 0.4960823059082031)","('NON-ESG', 0.10836425423622131)","('NON-ESG', 0.05801377072930336)"
Line 573,"For example, a large number of devices can be  damaged by moist heat, radiation and other modes of  sterilization, making EtO the only practical sterilization option  for those devices.
","('Employee_Health_And_Safety', 0.3099365234375)","('Product_Quality_And_Safety', 0.2319524735212326)","('Product_Design_And_Lifecycle_Management', 0.09069565683603287)","('NON-ESG', 0.3099365234375)","('NON-ESG', 0.2319524735212326)","('NON-ESG', 0.09069565683603287)"
Line 574,"Further, viable sterilization methods must not  only ensure the safety of devices, but they must also provide the  ongoing capacity and scale required to process the billions of medical devices needed by patients in today’s modern  healthcare systems.
","('Product_Quality_And_Safety', 0.4452051520347595)","('Employee_Health_And_Safety', 0.3117426931858063)","('Product_Design_And_Lifecycle_Management', 0.03351680189371109)","('NON-ESG', 0.4452051520347595)","('NON-ESG', 0.3117426931858063)","('NON-ESG', 0.03351680189371109)"
Line 575,"For these reasons and others,   EtO sterilization is the method used for approximately 50%   of our company’s sterile devices.
","('Waste_And_Hazardous_Materials_Management', 0.3880048096179962)","('Employee_Health_And_Safety', 0.2139768898487091)","('Water_And_Wastewater_Management', 0.04964107647538185)","('NON-ESG', 0.3880048096179962)","('NON-ESG', 0.2139768898487091)","('NON-ESG', 0.04964107647538185)"
Line 576,"We recognize the responsibility we have to safely use all modes  of sterilization in our operations.
","('Employee_Health_And_Safety', 0.7778798937797546)","('Waste_And_Hazardous_Materials_Management', 0.03809811919927597)","('Access_And_Affordability', 0.032091401517391205)","(['Operational Eco-Efficiency'], 0.7778798937797546)","('NON-ESG', 0.03809811919927597)","('NON-ESG', 0.032091401517391205)"
Line 577,"That is why for decades,   BD has invested in emission control technologies, process safety  controls, as well as subject matter expertise in process safety  engineering, environmental engineering, radiation safety,  industrial hygiene, sterility assurance and other disciplines.
","('Employee_Health_And_Safety', 0.4654984474182129)","('Air_Quality', 0.18370512127876282)","('Critical_Incident_Risk_Management', 0.10116890072822571)","('NON-ESG', 0.4654984474182129)","('NON-ESG', 0.18370512127876282)","('NON-ESG', 0.10116890072822571)"
Line 578,"Our environmental health and safety (EHS) standards ensure  that all BD sterilization facilities are designed and operate with   a high level of process safety and environmental controls.
","('Employee_Health_And_Safety', 0.78474360704422)","('Product_Quality_And_Safety', 0.11156293004751205)","('Critical_Incident_Risk_Management', 0.012455173768103123)","(['Operational Eco-Efficiency'], 0.78474360704422)","('NON-ESG', 0.11156293004751205)","('NON-ESG', 0.012455173768103123)"
Line 579,"U.S. FDA Innovation Challenge In FY 2019, BD was selected as a participant in the U.S. FDA’s  two-part innovation challenge to: 1) identify new sterilization  methods and technologies as alternatives to EtO, and 2) reduce  EtO emissions.
","('Customer_Welfare', 0.26626506447792053)","('Product_Quality_And_Safety', 0.2082628458738327)","('Competitive_Behavior', 0.05920463427901268)","('NON-ESG', 0.26626506447792053)","('NON-ESG', 0.2082628458738327)","('NON-ESG', 0.05920463427901268)"
Line 580,"We were one of 12 accepted proposals out of 46  applicants, for our submission under part 2 of the challenge, to  reduce EtO emissions.
","('GHG_Emissions', 0.8433923721313477)","('Air_Quality', 0.06254502385854721)","('Energy_Management', 0.021988224238157272)","(['Climate Change'], 0.8433923721313477)","('NON-ESG', 0.06254502385854721)","('NON-ESG', 0.021988224238157272)"
Line 581,"The FDA’s selection of our proposal into  the program marks a critical step in our ongoing partnership  with the FDA.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9006824493408203)","('Competitive_Behavior', 0.01658187434077263)","('GHG_Emissions', 0.008114351890981197)","(['Corporate Governance'], 0.9006824493408203)","('NON-ESG', 0.01658187434077263)","('NON-ESG', 0.008114351890981197)"
Line 582,"It demonstrates the company’s commitment to improve upon  and ensure the continued safe use of EtO, and to investigate  alternative work practices that will provide the same sterility  assurance and result in the same device performance, at the  scale required.
","('Employee_Health_And_Safety', 0.9588669538497925)","('Product_Quality_And_Safety', 0.0049079046584665775)","('Access_And_Affordability', 0.00436512241140008)","(['Operational Eco-Efficiency'], 0.9588669538497925)","('NON-ESG', 0.0049079046584665775)","('NON-ESG', 0.00436512241140008)"
Line 583,"Under this program, BD has completed submissions to  regulatory agencies for an optimized sterilization cycle for our  sterilization facilities in Georgia in the U.S. We received FDA approval for use of this optimized cycle in a number of product  families in August 2020.
","('Product_Quality_And_Safety', 0.33374884724617004)","('Customer_Welfare', 0.23939435184001923)","('Selling_Practices_And_Product_Labeling', 0.11428849399089813)","('NON-ESG', 0.33374884724617004)","('NON-ESG', 0.23939435184001923)","('NON-ESG', 0.11428849399089813)"
Line 584,"We also completed the installation and  commissioning of additional emission control systems at our  Georgia sterilization facilities to control fugitive emissions from  the process.
","('Air_Quality', 0.9740018248558044)","('GHG_Emissions', 0.003752372693270445)","('Critical_Incident_Risk_Management', 0.002563649322837591)","(['Operational Eco-Efficiency'], 0.9740018248558044)","('NON-ESG', 0.003752372693270445)","('NON-ESG', 0.002563649322837591)"
Line 585,"This new application of emission control technology  makes them among the industry’s most effectively controlled  EtO sterilization facilities.
","('Air_Quality', 0.9659770131111145)","('Critical_Incident_Risk_Management', 0.005343302618712187)","('Energy_Management', 0.003790067508816719)","(['Operational Eco-Efficiency'], 0.9659770131111145)","('NON-ESG', 0.005343302618712187)","('NON-ESG', 0.003790067508816719)"
Line 586,"Until there is a safe and effective replacement for EtO, BD will  continue to pursue our goal to reduce the amount of EtO used  and minimize emissions from the process.
","('GHG_Emissions', 0.6958049535751343)","('Air_Quality', 0.19508855044841766)","('Energy_Management', 0.02128230221569538)","(['Climate Change'], 0.6958049535751343)","('NON-ESG', 0.19508855044841766)","('NON-ESG', 0.02128230221569538)"
Line 587,"Optimizing EtO  sterilization cycles, evaluating new device packaging  configurations and evaluating new approaches to validation are  examples of possible ways to minimize the amount of EtO used  in the sterilization process.
","('Product_Quality_And_Safety', 0.3021535575389862)","('Product_Design_And_Lifecycle_Management', 0.18918414413928986)","('Waste_And_Hazardous_Materials_Management', 0.10700388997793198)","('NON-ESG', 0.3021535575389862)","('NON-ESG', 0.18918414413928986)","('NON-ESG', 0.10700388997793198)"
Line 588,"We are also actively looking at  alternate sterilization modalities, taking into consideration  product performance, sterility assurance, regulatory compliance  and scalability.
","('Product_Quality_And_Safety', 0.46804720163345337)","('Product_Design_And_Lifecycle_Management', 0.2967008054256439)","('Selling_Practices_And_Product_Labeling', 0.04541879892349243)","('NON-ESG', 0.46804720163345337)","('NON-ESG', 0.2967008054256439)","('NON-ESG', 0.04541879892349243)"
Line 589,"Access Efficiency Empowerment Governance InnovationOur Corporate Governance Principles outline how we hold  ourselves accountable to shareholders and stakeholders.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7250247597694397)","('Business_Ethics', 0.1172112226486206)","('Competitive_Behavior', 0.03288469836115837)","(['Corporate Governance'], 0.7250247597694397)","('NON-ESG', 0.1172112226486206)","('NON-ESG', 0.03288469836115837)"
Line 590,"These principles address the operation of our Board and its  committees; strategic and succession planning; director  qualifications, independence, compensation and equity ownership; and the ability of shareholders and others to  communicate directly with Board members.
","('Director_Removal', 0.7614567875862122)","('Management_Of_Legal_And_Regulatory_Framework', 0.033863604068756104)","('Employee_Engagement_Inclusion_And_Diversity', 0.023663967847824097)","(['Anti-Crime Policy & Measures'], 0.7614567875862122)","('NON-ESG', 0.033863604068756104)","('NON-ESG', 0.023663967847824097)"
Line 591,"Further details can be found on the Corporate Governance  website .Corporate Governance PrinciplesCorporate governance BD is governed by a Board of Directors consisting of 12 members,  11 of whom are independent.
","('Director_Removal', 0.5052312612533569)","('Management_Of_Legal_And_Regulatory_Framework', 0.16362382471561432)","('Business_Ethics', 0.05621960759162903)","(['Anti-Crime Policy & Measures'], 0.5052312612533569)","('NON-ESG', 0.16362382471561432)","('NON-ESG', 0.05621960759162903)"
Line 592,"Our Board members have a  variety of backgrounds, which reflects our continuing efforts to  achieve a diversity of viewpoints, experiences and knowledge,   as well as ethnicities and genders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734119176864624)","('Human_Rights_And_Community_Relations', 0.0017346463864669204)","('Customer_Privacy', 0.001684514107182622)","(['Human Capital Development'], 0.9734119176864624)","('NON-ESG', 0.0017346463864669204)","('NON-ESG', 0.001684514107182622)"
Line 593,"Our Board is comprised of   four female directors and eight male directors, one of whom is  African American.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7035694122314453)","('Director_Removal', 0.10254183411598206)","('Labor_Practices', 0.023619184270501137)","(['Human Capital Development'], 0.7035694122314453)","('NON-ESG', 0.10254183411598206)","('NON-ESG', 0.023619184270501137)"
Line 594,"There are five operating Board committees (listed below) and  an executive committee that meets only as needed: • Audit • Compensation and Management Development • Corporate Governance and Nominating • Quality and Regulatory • Science, Marketing, Innovation and TechnologyA charter for each committee outlines its mission, the  qualifications required for membership and its members’ duties.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3928520083427429)","('Director_Removal', 0.32925382256507874)","('Business_Ethics', 0.03397855535149574)","('NON-ESG', 0.3928520083427429)","('NON-ESG', 0.32925382256507874)","('NON-ESG', 0.03397855535149574)"
Line 595,"See more about our Board of Directors on the Corporate  Governance website .Board compositionGRI disclosures: 102-18, 102-22, 102-23, 102-24, 102-25, 102-28, 102-Our goal is to provide an executive compensation program   that best serves the long-term interests of our shareholders.
","('Director_Removal', 0.6909054517745972)","('Employee_Engagement_Inclusion_And_Diversity', 0.047694459557533264)","('Management_Of_Legal_And_Regulatory_Framework', 0.03601159155368805)","(['Anti-Crime Policy & Measures'], 0.6909054517745972)","('NON-ESG', 0.047694459557533264)","('NON-ESG', 0.03601159155368805)"
Line 596,"We believe that attracting and retaining superior talent and  rewarding performance is key to delivering long-term shareholder returns, and that a competitive compensation  program is critical to that end.
","('Competitive_Behavior', 0.8856255412101746)","('Business_Model_Resilience', 0.019632278010249138)","('Employee_Engagement_Inclusion_And_Diversity', 0.015421230345964432)","(['Business Ethics'], 0.8856255412101746)","('NON-ESG', 0.019632278010249138)","('NON-ESG', 0.015421230345964432)"
Line 597,"For further details of executive  compensation, see our proxy statements .Executive compensation Access Efficiency Empowerment Governance InnovationStrong, long-term relationships with policymakers help us better  understand unmet public health needs around the world.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8522982001304626)","('Business_Ethics', 0.03866463154554367)","('Competitive_Behavior', 0.018439915031194687)","(['Corporate Governance'], 0.8522982001304626)","('NON-ESG', 0.03866463154554367)","('NON-ESG', 0.018439915031194687)"
Line 598,"BD engages in public policy advocacy through ongoing,  constructive and transparent interactions with government  officials and stakeholder groups.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9026817679405212)","('Human_Rights_And_Community_Relations', 0.029153093695640564)","('Access_And_Affordability', 0.008710997179150581)","(['Corporate Governance'], 0.9026817679405212)","('NON-ESG', 0.029153093695640564)","('NON-ESG', 0.008710997179150581)"
Line 599,"All advocacy activities are  directed toward furthering the company’s Purpose of  advancing  the world of health ™, without regard to the personal political  affiliations or views of any individual BD associates at any level  across the organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23022302985191345)","('Management_Of_Legal_And_Regulatory_Framework', 0.12620025873184204)","('Competitive_Behavior', 0.11860328167676926)","('NON-ESG', 0.23022302985191345)","('NON-ESG', 0.12620025873184204)","('NON-ESG', 0.11860328167676926)"
Line 600,"We employ public affairs professionals  who work closely with our country and business leaders to  make constructive contributions to policy discussions relevant   to the company and to the communities in which we operate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7466320395469666)","('Human_Rights_And_Community_Relations', 0.12143442034721375)","('Physical_Impacts_Of_Climate_Change', 0.01288974191993475)","(['Corporate Governance'], 0.7466320395469666)","('NON-ESG', 0.12143442034721375)","('NON-ESG', 0.01288974191993475)"
Line 601,"We leverage our diverse expertise, global reach and  collaborations with healthcare professionals, patients and  others to advance sound public policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.26876989006996155)","('Employee_Engagement_Inclusion_And_Diversity', 0.18240876495838165)","('Access_And_Affordability', 0.08935270458459854)","('NON-ESG', 0.26876989006996155)","('NON-ESG', 0.18240876495838165)","('NON-ESG', 0.08935270458459854)"
Line 602,"Our participation in the policymaking process, including  lobbying and the BD Political Action Committee, is governed   by the Board of Directors and the Executive Leadership Team.Participation in the policymaking process The Center for Political Accountability (CPA)  recognized BD  with a first-place rating of 100% on their 2020 corporate political  disclosure and accountability index.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8745459318161011)","('Director_Removal', 0.029049621894955635)","('Business_Ethics', 0.020124806091189384)","(['Corporate Governance'], 0.8745459318161011)","('NON-ESG', 0.029049621894955635)","('NON-ESG', 0.020124806091189384)"
Line 603,"The ranking benchmarks  Fortune 500 companies and is produced by CPA in conjunction  with the Zicklin Center for Business Ethics Research at the Wharton School at the University of Pennsylvania.
","('Business_Ethics', 0.6705375909805298)","('Systemic_Risk_Management', 0.1359570175409317)","('Competitive_Behavior', 0.07247965037822723)","(['Business Ethics'], 0.6705375909805298)","('NON-ESG', 0.1359570175409317)","('NON-ESG', 0.07247965037822723)"
Line 604,"This is the  fourth year in a row that the company has received a perfect  score for the transparency with which we conduct our political  engagement, and it is a designation that investors watch.Engaging with governments in a transparent manner In areas where BD has deep experience, the company develops  public policy positions that guide our advocacy efforts  worldwide.
","('Business_Ethics', 0.8829373121261597)","('Management_Of_Legal_And_Regulatory_Framework', 0.05086619406938553)","('Systemic_Risk_Management', 0.008791469968855381)","(['Business Ethics'], 0.8829373121261597)","('NON-ESG', 0.05086619406938553)","('NON-ESG', 0.008791469968855381)"
Line 605,"We currently have a range of global public policy  positions  available online.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8934966921806335)","('Human_Rights_And_Community_Relations', 0.013917071744799614)","('Competitive_Behavior', 0.009334568865597248)","(['Corporate Governance'], 0.8934966921806335)","('NON-ESG', 0.013917071744799614)","('NON-ESG', 0.009334568865597248)"
Line 606,"We also engage in policy dialog to advance regulatory and  reimbursement frameworks that ensure the safety and efficacy of medical technologies while enabling timely patient access to  them.
","('Product_Quality_And_Safety', 0.8614120483398438)","('Employee_Health_And_Safety', 0.01921006292104721)","('Selling_Practices_And_Product_Labeling', 0.01484617032110691)","(['Product Quality & Recall Management'], 0.8614120483398438)","('NON-ESG', 0.01921006292104721)","('NON-ESG', 0.01484617032110691)"
Line 607,"We promote sensible tax policies that enhance  competitiveness and innovation, support policies and programs  that advance biomedical research and seek to expand access to  care for all people.Public policy advocacy The company prohibits the use of corporate funds and assets to  support U.S. federal or state candidates, political parties, ballot  measures or referendum campaigns.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9273590445518494)","('Access_And_Affordability', 0.010967817157506943)","('Competitive_Behavior', 0.010918864980340004)","(['Corporate Governance'], 0.9273590445518494)","('NON-ESG', 0.010967817157506943)","('NON-ESG', 0.010918864980340004)"
Line 608,"Exceptions to this policy  require approval by the CEO, the general counsel and a  designated member of the Board of Directors Corporate Nominating and Governance Committee.
","('Director_Removal', 0.6434741020202637)","('Management_Of_Legal_And_Regulatory_Framework', 0.16185332834720612)","('Business_Ethics', 0.021495409309864044)","(['Anti-Crime Policy & Measures'], 0.6434741020202637)","('NON-ESG', 0.16185332834720612)","('NON-ESG', 0.021495409309864044)"
Line 609,"To date, no  exceptions have been sought or approved.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7158582806587219)","('Competitive_Behavior', 0.07855161279439926)","('GHG_Emissions', 0.020365891978144646)","(['Corporate Governance'], 0.7158582806587219)","('NON-ESG', 0.07855161279439926)","('NON-ESG', 0.020365891978144646)"
Line 610,"Certain conditions must also be met for any political  contributions outside of the United States.Process for corporate financial contributionsAs permitted under U.S. law, the company operates a PAC.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8410347104072571)","('Director_Removal', 0.025308983400464058)","('Labor_Practices', 0.015008221380412579)","(['Corporate Governance'], 0.8410347104072571)","('NON-ESG', 0.025308983400464058)","('NON-ESG', 0.015008221380412579)"
Line 611,"The BD PAC is a mechanism to enable eligible U.S. associates to  voluntarily support candidates for elected office who share our  perspectives and approaches to public policy issues.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8155152201652527)","('Competitive_Behavior', 0.025213731452822685)","('Human_Rights_And_Community_Relations', 0.024875199422240257)","(['Corporate Governance'], 0.8155152201652527)","('NON-ESG', 0.025213731452822685)","('NON-ESG', 0.024875199422240257)"
Line 612,"BD has not  authorized the establishment of any PACs operating on the  state or local level.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9352332949638367)","('Human_Rights_And_Community_Relations', 0.0078052617609500885)","('Director_Removal', 0.005823524668812752)","(['Corporate Governance'], 0.9352332949638367)","('NON-ESG', 0.0078052617609500885)","('NON-ESG', 0.005823524668812752)"
Line 613,"Contributions to the BD PAC are entirely  voluntary and are governed by the BD PAC Bylaws.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9040431976318359)","('Business_Ethics', 0.01332793664187193)","('Director_Removal', 0.012550760991871357)","(['Corporate Governance'], 0.9040431976318359)","('NON-ESG', 0.01332793664187193)","('NON-ESG', 0.012550760991871357)"
Line 614,"BD provides  administrative support to the PAC, as permitted under  federal law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9277307391166687)","('Business_Ethics', 0.02050384320318699)","('Competitive_Behavior', 0.007028114981949329)","(['Corporate Governance'], 0.9277307391166687)","('NON-ESG', 0.02050384320318699)","('NON-ESG', 0.007028114981949329)"
Line 615,"The BD PAC contributed a total of $64,000 to candidates in 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.538785994052887)","('Competitive_Behavior', 0.09168844670057297)","('Business_Ethics', 0.046391572803258896)","(['Corporate Governance'], 0.538785994052887)","('NON-ESG', 0.09168844670057297)","('NON-ESG', 0.046391572803258896)"
Line 616,"All contributions made by the BD PAC are also publicly reported.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8094926476478577)","('Director_Removal', 0.021455014124512672)","('Business_Ethics', 0.01932338997721672)","(['Corporate Governance'], 0.8094926476478577)","('NON-ESG', 0.021455014124512672)","('NON-ESG', 0.01932338997721672)"
Line 617,"For annual reporting of itemized PAC contributions and any  other corporate contributions, visit our website .
","('Management_Of_Legal_And_Regulatory_Framework', 0.7433722615242004)","('Labor_Practices', 0.03332948684692383)","('Director_Removal', 0.025860557332634926)","(['Corporate Governance'], 0.7433722615242004)","('NON-ESG', 0.03332948684692383)","('NON-ESG', 0.025860557332634926)"
Line 618,"For details on U.S. lobby expenditures by year, visit the   BD Sustainability Report archive .Political Action Committee: BD PAC Access Efficiency Empowerment Governance InnovationU.S. lobbying expenditures In addition to the work of our public affairs team, BD is able to  expand our reach by leveraging state and federal public policy  consultants; collaboratively engage on issues that impact our  industry through trade associations; and advance policy  proposals focused on key priorities through advocacy coalitions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9584196209907532)","('Competitive_Behavior', 0.003644662443548441)","('Director_Removal', 0.003444276051595807)","(['Corporate Governance'], 0.9584196209907532)","('NON-ESG', 0.003644662443548441)","('NON-ESG', 0.003444276051595807)"
Line 619,"For details on U.S. lobby expenditures by year, visit the   BD Sustainability Report archive .Political Action Committee: BD PAC Access Efficiency Empowerment Governance InnovationU.S. lobbying expenditures In addition to the work of our public affairs team, BD is able to  expand our reach by leveraging state and federal public policy  consultants; collaboratively engage on issues that impact our  industry through trade associations; and advance policy  proposals focused on key priorities through advocacy coalitions.
","('Competitive_Behavior', 0.403764933347702)","('Business_Ethics', 0.14340434968471527)","('Management_Of_Legal_And_Regulatory_Framework', 0.08201500028371811)","('NON-ESG', 0.403764933347702)","('NON-ESG', 0.14340434968471527)","('NON-ESG', 0.08201500028371811)"
Line 620,"For calendar year 2020, the company spent approximately   $1.8 million on salaries and expenses associated with lobbying  in the U.S., which was roughly the same as the company’s 2019  expenditure.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5217433571815491)","('Labor_Practices', 0.2019602358341217)","('Director_Removal', 0.07093873620033264)","(['Corporate Governance'], 0.5217433571815491)","('NON-ESG', 0.2019602358341217)","('NON-ESG', 0.07093873620033264)"
Line 621,"We file quarterly reports regarding our federal  lobbying activities with the Office of the Clerk of the House of  Representatives and the Secretary of the Senate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7678780555725098)","('Competitive_Behavior', 0.04298340529203415)","('Director_Removal', 0.020363427698612213)","(['Corporate Governance'], 0.7678780555725098)","('NON-ESG', 0.04298340529203415)","('NON-ESG', 0.020363427698612213)"
Line 622,"* Data represents calendar years.
","('Physical_Impacts_Of_Climate_Change', 0.18001127243041992)","('Business_Model_Resilience', 0.10168060660362244)","('Customer_Privacy', 0.0793747678399086)","('NON-ESG', 0.18001127243041992)","('NON-ESG', 0.10168060660362244)","('NON-ESG', 0.0793747678399086)"
Line 623,"References  1 Issue-based coalitions: Diagnostic Test Working Group, Medical Device Competitiveness Coalition, Physicians Fee Schedule Pathology Payment Coalition, United for Medical Research,  Corporate Friends of CDC, Inc.
","('Competitive_Behavior', 0.9382606744766235)","('Management_Of_Legal_And_Regulatory_Framework', 0.012251378037035465)","('Customer_Welfare', 0.005456872750073671)","(['Business Ethics'], 0.9382606744766235)","('NON-ESG', 0.012251378037035465)","('NON-ESG', 0.005456872750073671)"
Line 624,"2 Trade associations: AdvaMed, Healthcare Institute of New Jersey, California Life Sciences Association, North Carolina Biosciences Organization, Bio Nebraska.2019* 2020* GRI disclosure: 415-$848,008  Public policy consultant s$592,BD associates$112,Issue-based coalitions $193,Trade associations$991,516  Public policy consultant s$636,BD associates$89,Issue-based coalitions$135,Trade associations$1,851,950$1,746,Access Innovation Efficiency Empowerment Governance Introduction Our Purpose— advancing the world of health ™—and innovating  to solve major health problems are mutually reinforced goals.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4988274574279785)","('Competitive_Behavior', 0.1229543462395668)","('Business_Ethics', 0.07226313650608063)","('NON-ESG', 0.4988274574279785)","('NON-ESG', 0.1229543462395668)","('NON-ESG', 0.07226313650608063)"
Line 625,"2 Trade associations: AdvaMed, Healthcare Institute of New Jersey, California Life Sciences Association, North Carolina Biosciences Organization, Bio Nebraska.2019* 2020* GRI disclosure: 415-$848,008  Public policy consultant s$592,BD associates$112,Issue-based coalitions $193,Trade associations$991,516  Public policy consultant s$636,BD associates$89,Issue-based coalitions$135,Trade associations$1,851,950$1,746,Access Innovation Efficiency Empowerment Governance Introduction Our Purpose— advancing the world of health ™—and innovating  to solve major health problems are mutually reinforced goals.
","('Employee_Health_And_Safety', 0.849016547203064)","('Access_And_Affordability', 0.018054910004138947)","('Product_Quality_And_Safety', 0.016182471066713333)","(['Operational Eco-Efficiency'], 0.849016547203064)","('NON-ESG', 0.018054910004138947)","('NON-ESG', 0.016182471066713333)"
Line 626,"When we innovate to increase access to quality healthcare, it  benefits people and societies throughout the world and drives  our business performance.
","('Access_And_Affordability', 0.8894975185394287)","('Human_Rights_And_Community_Relations', 0.010687149129807949)","('Critical_Incident_Risk_Management', 0.01054481603205204)","(['Health Outcome Contribution'], 0.8894975185394287)","('NON-ESG', 0.010687149129807949)","('NON-ESG', 0.01054481603205204)"
Line 627,"BD conducts its R&D activities around the world.
","('Supply_Chain_Management', 0.26196861267089844)","('Business_Model_Resilience', 0.16773951053619385)","('Product_Design_And_Lifecycle_Management', 0.12214431166648865)","('NON-ESG', 0.26196861267089844)","('NON-ESG', 0.16773951053619385)","('NON-ESG', 0.12214431166648865)"
Line 628,"In North  America this work is done at its operating units and at BD  Technologies in Research Triangle Park, NC.
","('Access_And_Affordability', 0.12420210242271423)","('Product_Design_And_Lifecycle_Management', 0.11887121200561523)","('Supply_Chain_Management', 0.09872514754533768)","('NON-ESG', 0.12420210242271423)","('NON-ESG', 0.11887121200561523)","('NON-ESG', 0.09872514754533768)"
Line 629,"Outside North  America, BD primarily conducts R&D activities in China, France,  India, Ireland and Singapore.
","('Business_Model_Resilience', 0.29939156770706177)","('Supply_Chain_Management', 0.13244947791099548)","('Systemic_Risk_Management', 0.08592718094587326)","('NON-ESG', 0.29939156770706177)","('NON-ESG', 0.13244947791099548)","('NON-ESG', 0.08592718094587326)"
Line 630,"BD also collaborates with certain  universities, medical centers and other entities on R&D  programs and retains individual consultants and partners to  support its efforts in specialized fields.
","('Access_And_Affordability', 0.3789554536342621)","('Employee_Engagement_Inclusion_And_Diversity', 0.08224660158157349)","('Management_Of_Legal_And_Regulatory_Framework', 0.07004082202911377)","('NON-ESG', 0.3789554536342621)","('NON-ESG', 0.08224660158157349)","('NON-ESG', 0.07004082202911377)"
Line 631,"Our investments in research and development led to a number  of product launches in FY 2020, including: • The BD Veritor ™ Assay for rapid detection of SARS-CoV-2, a  digitally read immunoassay for the direct and qualitative  detection of SARS-CoV-2 antigens in nasal swabs from  patients with signs and symptoms who are suspected  of COVID-19;  • The BD® SARS-CoV-2 Assay for the BD MAX ™ System, a  real-time PCR test intended for the qualitative detection of  nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal and  oropharyngeal swab samples; • The BD ™ Intraosseous Vascular Access System, providing a  solution for immediate vascular access via the bone marrow  in emergent situations;  • The BD Onclarity ™ HPV Assay, the only FDA-approved HPV  assay to individually identify and report genotypes beyond  16, 18 and 45;  • The Caterpillar ™ and Caterpillar ™ Micro Arterial Embolization  Devices, self-expanding arterial occlusion plugs intended for  use in the peripheral vasculature—our first venture into  interventional oncology; and  • The Arctic Sun ™ Stat Temperature Management System, with  an updated ergonomic design, integrated analytics  capabilities and interoperability with hospitals’ electronic  medical records.R&D investmentsInnovation Healthcare safety, outcomes and cost  BD is on the forefront of helping healthcare systems balance four key priorities: increasing access, improving  outcomes, mitigating healthcare system cost pressures and protecting patients and healthcare workers.
","('Customer_Welfare', 0.35938775539398193)","('Selling_Practices_And_Product_Labeling', 0.11835358291864395)","('Competitive_Behavior', 0.06146278977394104)","('NON-ESG', 0.35938775539398193)","('NON-ESG', 0.11835358291864395)","('NON-ESG', 0.06146278977394104)"
Line 632,"Our investments in research and development led to a number  of product launches in FY 2020, including: • The BD Veritor ™ Assay for rapid detection of SARS-CoV-2, a  digitally read immunoassay for the direct and qualitative  detection of SARS-CoV-2 antigens in nasal swabs from  patients with signs and symptoms who are suspected  of COVID-19;  • The BD® SARS-CoV-2 Assay for the BD MAX ™ System, a  real-time PCR test intended for the qualitative detection of  nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal and  oropharyngeal swab samples; • The BD ™ Intraosseous Vascular Access System, providing a  solution for immediate vascular access via the bone marrow  in emergent situations;  • The BD Onclarity ™ HPV Assay, the only FDA-approved HPV  assay to individually identify and report genotypes beyond  16, 18 and 45;  • The Caterpillar ™ and Caterpillar ™ Micro Arterial Embolization  Devices, self-expanding arterial occlusion plugs intended for  use in the peripheral vasculature—our first venture into  interventional oncology; and  • The Arctic Sun ™ Stat Temperature Management System, with  an updated ergonomic design, integrated analytics  capabilities and interoperability with hospitals’ electronic  medical records.R&D investmentsInnovation Healthcare safety, outcomes and cost  BD is on the forefront of helping healthcare systems balance four key priorities: increasing access, improving  outcomes, mitigating healthcare system cost pressures and protecting patients and healthcare workers.
","('Access_And_Affordability', 0.31881290674209595)","('Employee_Health_And_Safety', 0.24140913784503937)","('Customer_Welfare', 0.06068866699934006)","('NON-ESG', 0.31881290674209595)","('NON-ESG', 0.24140913784503937)","('NON-ESG', 0.06068866699934006)"
Line 633,"Our investments in research and development led to a number  of product launches in FY 2020, including: • The BD Veritor ™ Assay for rapid detection of SARS-CoV-2, a  digitally read immunoassay for the direct and qualitative  detection of SARS-CoV-2 antigens in nasal swabs from  patients with signs and symptoms who are suspected  of COVID-19;  • The BD® SARS-CoV-2 Assay for the BD MAX ™ System, a  real-time PCR test intended for the qualitative detection of  nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal and  oropharyngeal swab samples; • The BD ™ Intraosseous Vascular Access System, providing a  solution for immediate vascular access via the bone marrow  in emergent situations;  • The BD Onclarity ™ HPV Assay, the only FDA-approved HPV  assay to individually identify and report genotypes beyond  16, 18 and 45;  • The Caterpillar ™ and Caterpillar ™ Micro Arterial Embolization  Devices, self-expanding arterial occlusion plugs intended for  use in the peripheral vasculature—our first venture into  interventional oncology; and  • The Arctic Sun ™ Stat Temperature Management System, with  an updated ergonomic design, integrated analytics  capabilities and interoperability with hospitals’ electronic  medical records.R&D investmentsInnovation Healthcare safety, outcomes and cost  BD is on the forefront of helping healthcare systems balance four key priorities: increasing access, improving  outcomes, mitigating healthcare system cost pressures and protecting patients and healthcare workers.
","('Access_And_Affordability', 0.49886462092399597)","('Employee_Health_And_Safety', 0.0625246986746788)","('Product_Quality_And_Safety', 0.05597252771258354)","('NON-ESG', 0.49886462092399597)","('NON-ESG', 0.0625246986746788)","('NON-ESG', 0.05597252771258354)"
Line 634,"A sustainable innovation system needs investment, discipline and leadership to succeed.
","('Product_Design_And_Lifecycle_Management', 0.2778349220752716)","('Business_Model_Resilience', 0.1988561898469925)","('Competitive_Behavior', 0.06880734115839005)","('NON-ESG', 0.2778349220752716)","('NON-ESG', 0.1988561898469925)","('NON-ESG', 0.06880734115839005)"
Line 635,"Innovation requires diligence and partnering, and our capabilities span ideation through market  development.
","('Competitive_Behavior', 0.4087298810482025)","('Business_Model_Resilience', 0.3027053475379944)","('Systemic_Risk_Management', 0.05037642642855644)","('NON-ESG', 0.4087298810482025)","('NON-ESG', 0.3027053475379944)","('NON-ESG', 0.05037642642855644)"
Line 636,"Along this continuum, we can increase our impact through selective partnerships.
","('Human_Rights_And_Community_Relations', 0.14794465899467468)","('Access_And_Affordability', 0.11738084256649017)","('Business_Model_Resilience', 0.1066485196352005)","('NON-ESG', 0.14794465899467468)","('NON-ESG', 0.11738084256649017)","('NON-ESG', 0.1066485196352005)"
Line 637,"We think a broad definition of the term “innovation” is the best way to advance healthcare.
","('Business_Model_Resilience', 0.38855454325675964)","('Product_Design_And_Lifecycle_Management', 0.10096300393342972)","('Competitive_Behavior', 0.06837061047554016)","('NON-ESG', 0.38855454325675964)","('NON-ESG', 0.10096300393342972)","('NON-ESG', 0.06837061047554016)"
Line 638,"Whether it is  technology, processes, systems partnerships or any dimension of business, we pioneer new, relevant ways to  address healthcare’s most pressing problems.
","('Systemic_Risk_Management', 0.2280769944190979)","('Supply_Chain_Management', 0.17977018654346466)","('Business_Model_Resilience', 0.15462440252304077)","('NON-ESG', 0.2280769944190979)","('NON-ESG', 0.17977018654346466)","('NON-ESG', 0.15462440252304077)"
Line 639,"Our technologies and execution capabilities allow BD to make  a profound impact on the quality of care.
","('Access_And_Affordability', 0.4104657769203186)","('Product_Design_And_Lifecycle_Management', 0.10290601849555969)","('Product_Quality_And_Safety', 0.07740877568721771)","('NON-ESG', 0.4104657769203186)","('NON-ESG', 0.10290601849555969)","('NON-ESG', 0.07740877568721771)"
Line 640,"R&D expense FY 2016 FY 2017 FY 2018 FY 2019 FY USD,  millions$828 $770 $1,004 $1,062 $1,Access Innovation Efficiency Empowerment Governance Innovation is not a buzzword at BD.
","('Business_Model_Resilience', 0.24503040313720703)","('Competitive_Behavior', 0.19769848883152008)","('Product_Design_And_Lifecycle_Management', 0.08305288106203079)","('NON-ESG', 0.24503040313720703)","('NON-ESG', 0.19769848883152008)","('NON-ESG', 0.08305288106203079)"
Line 641,"It’s the heart of the  company.
","('Business_Model_Resilience', 0.1696239411830902)","('Product_Design_And_Lifecycle_Management', 0.12569698691368103)","('Business_Ethics', 0.10933748632669449)","('NON-ESG', 0.1696239411830902)","('NON-ESG', 0.12569698691368103)","('NON-ESG', 0.10933748632669449)"
Line 642,"Each year, we invest more than a billion dollars in  innovation, knowing that behind every advance we make,  there’s a patient who could get a more accurate result, a faster  or better treatment, a better quality of life and, ideally, more  time.
","('Access_And_Affordability', 0.37546291947364807)","('Customer_Welfare', 0.09478692710399628)","('Product_Quality_And_Safety', 0.0716073289513588)","('NON-ESG', 0.37546291947364807)","('NON-ESG', 0.09478692710399628)","('NON-ESG', 0.0716073289513588)"
Line 643,"Given that impact, it’s vital that we continue to cultivate a  culture where innovation can thrive.
","('Business_Model_Resilience', 0.31673771142959595)","('Product_Design_And_Lifecycle_Management', 0.20670336484909058)","('Employee_Engagement_Inclusion_And_Diversity', 0.09099805355072021)","('NON-ESG', 0.31673771142959595)","('NON-ESG', 0.20670336484909058)","('NON-ESG', 0.09099805355072021)"
Line 644,"For the sixth year running, BD was included in the Clarivate   Top 100 Global Innovators list in recognition, in part, of this  innovation-focused culture.
","('Business_Model_Resilience', 0.48439639806747437)","('Product_Design_And_Lifecycle_Management', 0.10959718376398087)","('Supply_Chain_Management', 0.08726445585489273)","('NON-ESG', 0.48439639806747437)","('NON-ESG', 0.10959718376398087)","('NON-ESG', 0.08726445585489273)"
Line 645,"Since 2012, Clarivate has published the Top 100 Global  Innovators report to honor the most innovative companies   and institutions in the world.
","('Business_Model_Resilience', 0.4516706168651581)","('Systemic_Risk_Management', 0.21222417056560516)","('Supply_Chain_Management', 0.04734060913324356)","('NON-ESG', 0.4516706168651581)","('NON-ESG', 0.21222417056560516)","('NON-ESG', 0.04734060913324356)"
Line 646,"Through robust analysis of  Clarivate’s unique and proprietary data, including patent  volume, patent grant success rates, global reach and invention  influence, Clarivate is able to identify, without bias, the world’s  most innovative organizations.At the start of 2021, BD had approximately 27,000 active, issued  patents worldwide and 4,500 in the United States alone.
","('Competitive_Behavior', 0.9378307461738586)","('Management_Of_Legal_And_Regulatory_Framework', 0.006312918849289417)","('Business_Model_Resilience', 0.006190249230712652)","(['Business Ethics'], 0.9378307461738586)","('NON-ESG', 0.006312918849289417)","('NON-ESG', 0.006190249230712652)"
Line 647,"Based solely on volume, for 2020, the Intellectual Property  Owners Association ranked BD 120th for number of granted  U.S. patents, and the European Patent Office ranked BD 70th in  number of patent applications filed—reflecting a significant  input to the analysis performed by Clarivate that pushed us into  the top 100 category.
","('Competitive_Behavior', 0.9069673418998718)","('Management_Of_Legal_And_Regulatory_Framework', 0.017661958932876587)","('Business_Ethics', 0.0063955290243029594)","(['Business Ethics'], 0.9069673418998718)","('NON-ESG', 0.017661958932876587)","('NON-ESG', 0.0063955290243029594)"
Line 648,"We’re proud to be recognized on   Clarivate’s Top 100 Global Innovators list.
","('Business_Model_Resilience', 0.6283631324768066)","('Product_Design_And_Lifecycle_Management', 0.06584098935127258)","('Supply_Chain_Management', 0.045611411333084106)","(['Codes of Business Conduct'], 0.6283631324768066)","('NON-ESG', 0.06584098935127258)","('NON-ESG', 0.045611411333084106)"
Line 649,"Innovation always has been and always  will be vital as we continue to look for   new and better ways of advancing the  world of health ™.Innovation awards  Innovation strategy Discovery Providing tools and technologies  to the research community that  facilitate the understanding of the  cell, cellular diagnostics, cell therapy   and immunologyDiagnostics Driving diagnostic stewardship   with end-to-end solutions that   improve lab performance and   impact clinical outcomes Medication   management Enabling safer, simpler and more  effective parenteral drug deliveryTherapy   management Enhancing disease management   with our product offeringsOur strategy focuses on four specific areas within healthcare and life sciences:BD remains focused on delivering sustainable growth and  shareholder value, while making appropriate investments for the  future.
","('Access_And_Affordability', 0.19920600950717926)","('Customer_Welfare', 0.1218387633562088)","('Product_Design_And_Lifecycle_Management', 0.11647681891918182)","('NON-ESG', 0.19920600950717926)","('NON-ESG', 0.1218387633562088)","('NON-ESG', 0.11647681891918182)"
Line 650,"Innovation always has been and always  will be vital as we continue to look for   new and better ways of advancing the  world of health ™.Innovation awards  Innovation strategy Discovery Providing tools and technologies  to the research community that  facilitate the understanding of the  cell, cellular diagnostics, cell therapy   and immunologyDiagnostics Driving diagnostic stewardship   with end-to-end solutions that   improve lab performance and   impact clinical outcomes Medication   management Enabling safer, simpler and more  effective parenteral drug deliveryTherapy   management Enhancing disease management   with our product offeringsOur strategy focuses on four specific areas within healthcare and life sciences:BD remains focused on delivering sustainable growth and  shareholder value, while making appropriate investments for the  future.
","('Product_Design_And_Lifecycle_Management', 0.844907283782959)","('Customer_Welfare', 0.05281670019030571)","('Selling_Practices_And_Product_Labeling', 0.017275849357247353)","(['Product Stewardship'], 0.844907283782959)","('NON-ESG', 0.05281670019030571)","('NON-ESG', 0.017275849357247353)"
Line 651,"We operate the business in a manner consistent with  various core strategies, including: • Increasing revenue growth by focusing on our core products,  services and solutions that deliver greater benefits to  patients, healthcare workers and researchers;• Supplementing our internal growth through strategic  acquisitions; • Continuing investment in research and development for  platform extensions and innovative new products; and • Making investments in growing our operations in emerging  markets.
","('Product_Design_And_Lifecycle_Management', 0.9548235535621643)","('Customer_Welfare', 0.006996702402830124)","('Product_Quality_And_Safety', 0.005379476584494114)","(['Product Stewardship'], 0.9548235535621643)","('NON-ESG', 0.006996702402830124)","('NON-ESG', 0.005379476584494114)"
Line 652,"Access Innovation Efficiency Empowerment Governance In the five years since we set our 2020 goals, BD has been  relentlessly focused on helping healthcare systems balance four  key priorities: increasing access, improving outcomes, mitigating  healthcare costs and protecting patients and healthcare  workers.
","('Access_And_Affordability', 0.9028900861740112)","('Critical_Incident_Risk_Management', 0.00906309299170971)","('Employee_Engagement_Inclusion_And_Diversity', 0.008070500567555428)","(['Health Outcome Contribution'], 0.9028900861740112)","('NON-ESG', 0.00906309299170971)","('NON-ESG', 0.008070500567555428)"
Line 653,"Through sustained, disciplined investments in  innovation, strategic partnerships and two transformative  acquisitions—of CareFusion in 2015 and Bard in 2017—BD has  continued to evolve and expand our product and solution  offerings to address healthcare’s most pressing problems.
","('Product_Design_And_Lifecycle_Management', 0.9102982878684998)","('Customer_Welfare', 0.018391652032732964)","('Selling_Practices_And_Product_Labeling', 0.009573574177920818)","(['Product Stewardship'], 0.9102982878684998)","('NON-ESG', 0.018391652032732964)","('NON-ESG', 0.009573574177920818)"
Line 654,"• In 2015, our acquisition of CareFusion significantly  accelerated our strategy and enhanced the scale and depth  of our medication management and patient safety solutions.
","('Product_Quality_And_Safety', 0.8469823598861694)","('Product_Design_And_Lifecycle_Management', 0.025710834190249443)","('Customer_Welfare', 0.021271562203764915)","(['Product Quality & Recall Management'], 0.8469823598861694)","('NON-ESG', 0.025710834190249443)","('NON-ESG', 0.021271562203764915)"
Line 655,"This transformative acquisition was instrumental in BD  becoming one of the largest global leaders in medical  technology, significantly strengthening our ability to partner  with healthcare providers around the world to provide safer,  more economical care.
","('Access_And_Affordability', 0.5413945317268372)","('Customer_Welfare', 0.06696531921625137)","('Energy_Management', 0.06611534208059311)","(['Health Outcome Contribution'], 0.5413945317268372)","('NON-ESG', 0.06696531921625137)","('NON-ESG', 0.06611534208059311)"
Line 656,"The combination of our  complementary product portfolios enabled BD to offer  medication management solutions and smart devices, from drug preparation in the pharmacy, to dispensing on the  hospital floor, to patient administration and subsequent  medication monitoring.
","('Product_Design_And_Lifecycle_Management', 0.6704492568969727)","('Customer_Welfare', 0.12842151522636414)","('Selling_Practices_And_Product_Labeling', 0.049324873834848404)","(['Product Stewardship'], 0.6704492568969727)","('NON-ESG', 0.12842151522636414)","('NON-ESG', 0.049324873834848404)"
Line 657,"• Just two years later, in 2017, we further expanded  opportunities to innovate in fast-growing clinical areas,  including vascular, urology, oncology and surgical specialty  products, with the acquisition of Bard.
","('Customer_Welfare', 0.21889521181583405)","('Employee_Engagement_Inclusion_And_Diversity', 0.11707944422960281)","('Business_Model_Resilience', 0.1019190326333046)","('NON-ESG', 0.21889521181583405)","('NON-ESG', 0.11707944422960281)","('NON-ESG', 0.1019190326333046)"
Line 658,"This acquisition enabled  BD to expand its leadership position in medication  management and in infection prevention, with offerings  positioned to address 75% of the most costly and frequent  healthcare-associated infections.
","('Employee_Health_And_Safety', 0.8297588229179382)","('Critical_Incident_Risk_Management', 0.016303058713674545)","('Product_Quality_And_Safety', 0.015768442302942276)","(['Operational Eco-Efficiency'], 0.8297588229179382)","('NON-ESG', 0.016303058713674545)","('NON-ESG', 0.015768442302942276)"
Line 659,"Today, we estimate approximately 90% of all U.S. hospital  inpatients receive care using a BD device; and approximately  70% of all U.S. acute hospitals have connectivity to a BD  data platform.
","('Access_And_Affordability', 0.3937770426273346)","('Energy_Management', 0.15018002688884735)","('Customer_Welfare', 0.050581373274326324)","('NON-ESG', 0.3937770426273346)","('NON-ESG', 0.15018002688884735)","('NON-ESG', 0.050581373274326324)"
Line 660,"Innovation in review Over the course of the last five years, BD has launched numerous products that contribute towards our four sustainability goals that  relate to innovation.
","('Product_Design_And_Lifecycle_Management', 0.964301586151123)","('Product_Quality_And_Safety', 0.004180818796157837)","('Customer_Welfare', 0.003534287214279175)","(['Product Stewardship'], 0.964301586151123)","('NON-ESG', 0.004180818796157837)","('NON-ESG', 0.003534287214279175)"
Line 661,"In this five-year lookback, we’ll highlight some of the key products we launched across our four innovation goals.Applying smart devices,   robotics and analytics   and artificial intelligence to improve care processes Enabling new care settings to enhance the patient experience Better diagnosis and treatment   of chronic disease to improve outcomesLooking towards FY 2021 and beyond, our expanding innovation pipeline will leverage our core strengths to focus on lowering  healthcare costs by addressing shifting industry trends, which include:  Access Innovation Efficiency Empowerment Governance FY BD Cato ™  Medication  Workflow  Solution FY BD MAX ™  Extended  Enteric Bacterial  Panel 2020 goal Innovate  key healthcare processes such as medication management and lab automation BD innovations in lab automation and medication management have enabled the seamless unification of complex work   systems.
","('Access_And_Affordability', 0.3314839005470276)","('Employee_Health_And_Safety', 0.10782286524772644)","('Customer_Welfare', 0.09569843858480453)","('NON-ESG', 0.3314839005470276)","('NON-ESG', 0.10782286524772644)","('NON-ESG', 0.09569843858480453)"
Line 662,"In this five-year lookback, we’ll highlight some of the key products we launched across our four innovation goals.Applying smart devices,   robotics and analytics   and artificial intelligence to improve care processes Enabling new care settings to enhance the patient experience Better diagnosis and treatment   of chronic disease to improve outcomesLooking towards FY 2021 and beyond, our expanding innovation pipeline will leverage our core strengths to focus on lowering  healthcare costs by addressing shifting industry trends, which include:  Access Innovation Efficiency Empowerment Governance FY BD Cato ™  Medication  Workflow  Solution FY BD MAX ™  Extended  Enteric Bacterial  Panel 2020 goal Innovate  key healthcare processes such as medication management and lab automation BD innovations in lab automation and medication management have enabled the seamless unification of complex work   systems.
","('Energy_Management', 0.21527579426765442)","('Product_Design_And_Lifecycle_Management', 0.21406289935112)","('Customer_Welfare', 0.11684519797563553)","('NON-ESG', 0.21527579426765442)","('NON-ESG', 0.21406289935112)","('NON-ESG', 0.11684519797563553)"
Line 663,"Over the past five years, we have continuously built upon successful models like the BD Kiestra ™ Lab Automation Solution   and BD HealthSight ™ System.
","('Access_And_Affordability', 0.18296712636947632)","('Energy_Management', 0.154961958527565)","('Product_Design_And_Lifecycle_Management', 0.11249150335788727)","('NON-ESG', 0.18296712636947632)","('NON-ESG', 0.154961958527565)","('NON-ESG', 0.11249150335788727)"
Line 664,"Notable launches that helped to innovate key processes include:  Pyxis ™ ES  SystemBD Alaris ™  Infusion  System BD Totalys ™  Automated  Cervical Cancer  Screening  System BD MAX ™  Vaginal Panel BD™ U-500  Insulin  Syringe  BD MAX ™   CT/GC/TV Assay The BD HealthSight ™ Platform for enterprise medication management is our unique  combination of connective technologies, analytics and expert services that close gaps  and create seamless visibility across BD medication management solutions, such as  BD Pyxis ™ Dispensing System and BD Alaris ™ Infusion Solutions.
","('Access_And_Affordability', 0.2775689363479614)","('Customer_Welfare', 0.19547833502292633)","('Product_Quality_And_Safety', 0.0971807986497879)","('NON-ESG', 0.2775689363479614)","('NON-ESG', 0.19547833502292633)","('NON-ESG', 0.0971807986497879)"
Line 665,"Notable launches that helped to innovate key processes include:  Pyxis ™ ES  SystemBD Alaris ™  Infusion  System BD Totalys ™  Automated  Cervical Cancer  Screening  System BD MAX ™  Vaginal Panel BD™ U-500  Insulin  Syringe  BD MAX ™   CT/GC/TV Assay The BD HealthSight ™ Platform for enterprise medication management is our unique  combination of connective technologies, analytics and expert services that close gaps  and create seamless visibility across BD medication management solutions, such as  BD Pyxis ™ Dispensing System and BD Alaris ™ Infusion Solutions.
","('Customer_Welfare', 0.3089713156223297)","('Selling_Practices_And_Product_Labeling', 0.1356666535139084)","('Energy_Management', 0.09986857324838638)","('NON-ESG', 0.3089713156223297)","('NON-ESG', 0.1356666535139084)","('NON-ESG', 0.09986857324838638)"
Line 666,"The BD HealthSight ™  Platform connects systems and processes to help hospitals and health systems drive a  safer, more efficient medication management process.
","('Access_And_Affordability', 0.3816477656364441)","('Employee_Health_And_Safety', 0.11226490885019302)","('Customer_Welfare', 0.08641388267278671)","('NON-ESG', 0.3816477656364441)","('NON-ESG', 0.11226490885019302)","('NON-ESG', 0.08641388267278671)"
Line 667,"We continue to develop the  capabilities of the BD HealthSight ™ Platform.FY BD Phoenix ™  M50 System BD Phoenix ™  CPO Detect  Test Access Innovation Efficiency Empowerment Governance BD MAX ™  MDR-TB PanelFY BD MAX ™  Enteric Viral  PanelBD Onclarity ™  HPV Assay PAXgene®  Blood ccfDNA  Tube (CE-IVD) FY BD Pyxis ™  SupplyStation ™  RF Cabinet BD COR ™  Automated  Molecular  Diagnostic  SystemBD Pyxis ™  Kanban RF  System BD COR ™   GX/PX with  BD Onclarity ™  HPV Assay  (E.U. only)FY BD Kiestra ™  ReadA  CompactBD Synapsys ™  3.1 Solution FY BD  Intelliport ™  Medication  Management  System BD  FlowSmart ™  TechnologyTechnology is advancing capabilities for how clinicians and patients manage disease across the care continuum.
","('Access_And_Affordability', 0.2300814539194107)","('Customer_Welfare', 0.16867989301681519)","('Competitive_Behavior', 0.08524397015571594)","('NON-ESG', 0.2300814539194107)","('NON-ESG', 0.16867989301681519)","('NON-ESG', 0.08524397015571594)"
Line 668,"We continue to develop the  capabilities of the BD HealthSight ™ Platform.FY BD Phoenix ™  M50 System BD Phoenix ™  CPO Detect  Test Access Innovation Efficiency Empowerment Governance BD MAX ™  MDR-TB PanelFY BD MAX ™  Enteric Viral  PanelBD Onclarity ™  HPV Assay PAXgene®  Blood ccfDNA  Tube (CE-IVD) FY BD Pyxis ™  SupplyStation ™  RF Cabinet BD COR ™  Automated  Molecular  Diagnostic  SystemBD Pyxis ™  Kanban RF  System BD COR ™   GX/PX with  BD Onclarity ™  HPV Assay  (E.U. only)FY BD Kiestra ™  ReadA  CompactBD Synapsys ™  3.1 Solution FY BD  Intelliport ™  Medication  Management  System BD  FlowSmart ™  TechnologyTechnology is advancing capabilities for how clinicians and patients manage disease across the care continuum.
","('Access_And_Affordability', 0.4613182842731476)","('Customer_Welfare', 0.06397344172000885)","('Critical_Incident_Risk_Management', 0.05016408860683441)","('NON-ESG', 0.4613182842731476)","('NON-ESG', 0.06397344172000885)","('NON-ESG', 0.05016408860683441)"
Line 669,"We work closely with  healthcare systems to improve safety, costs and outcomes.
","('Employee_Health_And_Safety', 0.941157877445221)","('Product_Quality_And_Safety', 0.01789148710668087)","('Access_And_Affordability', 0.004768573213368654)","(['Operational Eco-Efficiency'], 0.941157877445221)","('NON-ESG', 0.01789148710668087)","('NON-ESG', 0.004768573213368654)"
Line 670,"We continue to invest in new technologies under development to provide  more advanced “wearable” drug delivery devices and diabetes disease management applications.
","('Product_Design_And_Lifecycle_Management', 0.3510386645793915)","('Customer_Welfare', 0.14516492187976837)","('Access_And_Affordability', 0.11431055516004562)","('NON-ESG', 0.3510386645793915)","('NON-ESG', 0.14516492187976837)","('NON-ESG', 0.11431055516004562)"
Line 671,"As we pursue new digital  technologies, we are committed to providing secure products to our customers.Develop  innovations and informatics to enable disease management across the care continuum Access Innovation Efficiency Empowerment Governance FY BD Veritor ™ Plus System The wireless BD Veritor Plus ™ System provides healthcare providers and laboratorians   in physicians’ offices, clinics, hospitals and integrated delivery networks (IDNs)   with objective, lab-quality immunoassay test results within minutes.
","('Customer_Welfare', 0.23642954230308533)","('Product_Design_And_Lifecycle_Management', 0.14952923357486725)","('Access_And_Affordability', 0.12963366508483887)","('NON-ESG', 0.23642954230308533)","('NON-ESG', 0.14952923357486725)","('NON-ESG', 0.12963366508483887)"
Line 672,"As we pursue new digital  technologies, we are committed to providing secure products to our customers.Develop  innovations and informatics to enable disease management across the care continuum Access Innovation Efficiency Empowerment Governance FY BD Veritor ™ Plus System The wireless BD Veritor Plus ™ System provides healthcare providers and laboratorians   in physicians’ offices, clinics, hospitals and integrated delivery networks (IDNs)   with objective, lab-quality immunoassay test results within minutes.
","('Product_Design_And_Lifecycle_Management', 0.11591445654630661)","('Waste_And_Hazardous_Materials_Management', 0.10108833014965057)","('Ecological_Impacts', 0.08083184063434601)","('NON-ESG', 0.11591445654630661)","('NON-ESG', 0.10108833014965057)","('NON-ESG', 0.08083184063434601)"
Line 673,"This rapid and  accurate solution streamlines the point-of-care (POC) diagnostic workflow and  enables providers to quickly review patient results to assist in determining the  appropriate treatment in a single consultation.
","('Access_And_Affordability', 0.4634156823158264)","('Customer_Welfare', 0.09923861175775528)","('Selling_Practices_And_Product_Labeling', 0.06548424810171127)","('NON-ESG', 0.4634156823158264)","('NON-ESG', 0.09923861175775528)","('NON-ESG', 0.06548424810171127)"
Line 674,"The system can help detect results   for a variety of tests while the patient is still on site, which enables faster decision  making for earlier intervention.
","('Access_And_Affordability', 0.30085524916648865)","('Product_Quality_And_Safety', 0.11575118452310562)","('Management_Of_Legal_And_Regulatory_Framework', 0.0963897556066513)","('NON-ESG', 0.30085524916648865)","('NON-ESG', 0.11575118452310562)","('NON-ESG', 0.0963897556066513)"
Line 675,"In FY 2020, BD was able to develop a SARS-CoV-2 (the novel or new coronavirus strain that causes COVID-19) assay for use   on the BD Veritor ™ Plus System.
","('Ecological_Impacts', 0.2580533027648926)","('Access_And_Affordability', 0.1054721474647522)","('Customer_Welfare', 0.0616469644010067)","('NON-ESG', 0.2580533027648926)","('NON-ESG', 0.1054721474647522)","('NON-ESG', 0.0616469644010067)"
Line 676,"At this time, the BD Veritor ™ System, which is slightly larger than a cell phone, was in use at   more than 25,000 hospitals, clinician offices, urgent care centers and retail pharmacies in all 50 U.S. states.
","('Access_And_Affordability', 0.5378109812736511)","('Critical_Incident_Risk_Management', 0.10542779415845871)","('Employee_Health_And_Safety', 0.04174518957734108)","(['Health Outcome Contribution'], 0.5378109812736511)","('NON-ESG', 0.10542779415845871)","('NON-ESG', 0.04174518957734108)"
Line 677,"Its one-button  functionality, workflow flexibility and ease-of-use made it an ideal solution for settings without laboratory personnel.
","('Product_Design_And_Lifecycle_Management', 0.5724504590034485)","('Energy_Management', 0.07678434252738953)","('Customer_Welfare', 0.04259687662124634)","(['Product Stewardship'], 0.5724504590034485)","('NON-ESG', 0.07678434252738953)","('NON-ESG', 0.04259687662124634)"
Line 678,"It also  offers customers real-time reporting capabilities through the BD Synapsys ™ Informatics Solution, providing them with the   ability to easily report data for disease monitoring and surveillance purposes.
","('Systemic_Risk_Management', 0.13229720294475555)","('Access_And_Affordability', 0.1273794025182724)","('Employee_Health_And_Safety', 0.10343077778816223)","('NON-ESG', 0.13229720294475555)","('NON-ESG', 0.1273794025182724)","('NON-ESG', 0.10343077778816223)"
Line 679,"Used as part of a comprehensive coronavirus mitigation program, this fast, easy-to-use testing system for SARS-CoV-2   provides virus detection for healthcare providers, therefore helping to decrease the spread of the virus.
","('Data_Security', 0.5111880302429199)","('Systemic_Risk_Management', 0.06721127778291702)","('Physical_Impacts_Of_Climate_Change', 0.06109544262290001)","(['Information Security/Cybersecurity & System Availability'], 0.5111880302429199)","('NON-ESG', 0.06721127778291702)","('NON-ESG', 0.06109544262290001)"
Line 680,"BD Provena ™  PICCFY BD Rowa ™ VMax  Automated  Storage and  Dispensing  System FY BD Rowa ™  VMax 210  System Covera ™ Stent  Graft   (fistula  indication) BD HealthSight ™ Diversion Management Analytics  Addiction to prescription narcotics in the U.S. has reached epidemic proportions,  contributing to the opioid crisis and becoming a major driver of drug diversion   within healthcare settings.
","('Critical_Incident_Risk_Management', 0.18525756895542145)","('Access_And_Affordability', 0.14132854342460632)","('Business_Ethics', 0.11985386162996292)","('NON-ESG', 0.18525756895542145)","('NON-ESG', 0.14132854342460632)","('NON-ESG', 0.11985386162996292)"
Line 681,"Diversion of drugs, for personal use or illegal distribution,   can cause significant financial loss and potentially impact care to patients and  staff safety.
","('Business_Ethics', 0.829089343547821)","('Product_Quality_And_Safety', 0.033099107444286346)","('Waste_And_Hazardous_Materials_Management', 0.01651984080672264)","(['Business Ethics'], 0.829089343547821)","('NON-ESG', 0.033099107444286346)","('NON-ESG', 0.01651984080672264)"
Line 682,"As part of the BD HealthSight ™ Platform that is designed to support enterprise-wide  medication management, the BD HealthSight ™ Diversion Management Analytics  application assists with opioid drug diversion investigations by creating an investigation workflow to monitor, triage and assign  potential diversion cases to specific investigators.
","('Business_Ethics', 0.8188515305519104)","('Competitive_Behavior', 0.015509594231843948)","('Management_Of_Legal_And_Regulatory_Framework', 0.014796105213463306)","(['Business Ethics'], 0.8188515305519104)","('NON-ESG', 0.015509594231843948)","('NON-ESG', 0.014796105213463306)"
Line 683,"Compared to traditional, statistically based analytical tools that only look at  opioid amounts dispensed to identify potential diversion, BD utilizes machine learning algorithms and multiple dispensing  behaviors—such as overrides, canceled transactions, delays in dispense, administration or waste—to identify clinicians whose  behavior indicates higher risk for diversion.
","('Waste_And_Hazardous_Materials_Management', 0.827793300151825)","('Business_Ethics', 0.023761386051774025)","('Water_And_Wastewater_Management', 0.01962745562195778)","(['Operational Eco-Efficiency'], 0.827793300151825)","('NON-ESG', 0.023761386051774025)","('NON-ESG', 0.01962745562195778)"
Line 684,"FY Access Innovation Efficiency Empowerment Governance FY BD Veritor ™  COVID-19  POC   Antigen Test BD MAX ™  COVID-19  AssaysBD EleVation ™  Breast Biopsy  Device BD Intevia ™   1 mL   Handheld  Autoinjector Enable  the transition from research to clinical practice The ability for healthcare providers to advance their understanding of disease states and then quickly and accurately diagnose and  treat patients is critical to reducing overall system costs and improving patient outcomes.
","('Access_And_Affordability', 0.4087204039096832)","('Employee_Health_And_Safety', 0.10594236850738525)","('Customer_Welfare', 0.07187004387378693)","('NON-ESG', 0.4087204039096832)","('NON-ESG', 0.10594236850738525)","('NON-ESG', 0.07187004387378693)"
Line 685,"Since 2015, BD introduced the following  products to aid researchers and clinicians: FY BD  FACSCelesta ™  Flow  Cytometer BD CLiC ™ LP  SystemBD   FACSymphony ™  Cell Analyzer FY BD  FACSCelesta ™  System BD Horizon  Brilliant ™  ReagentBD  FACSMelody ™  Cell Sorter BD FACSLyric ™  Cell Analyzer Access Innovation Efficiency Empowerment Governance BD FACSDuet ™ System   BD FACSDuet ™ Sample Preparation System is the first fully automated   sample-to-answer solution when integrated with the BD FACSLyric ™ Flow Cytometer.
","('Customer_Welfare', 0.2734591066837311)","('Access_And_Affordability', 0.14028656482696533)","('GHG_Emissions', 0.061573777347803116)","('NON-ESG', 0.2734591066837311)","('NON-ESG', 0.14028656482696533)","('NON-ESG', 0.061573777347803116)"
Line 686,"Since 2015, BD introduced the following  products to aid researchers and clinicians: FY BD  FACSCelesta ™  Flow  Cytometer BD CLiC ™ LP  SystemBD   FACSymphony ™  Cell Analyzer FY BD  FACSCelesta ™  System BD Horizon  Brilliant ™  ReagentBD  FACSMelody ™  Cell Sorter BD FACSLyric ™  Cell Analyzer Access Innovation Efficiency Empowerment Governance BD FACSDuet ™ System   BD FACSDuet ™ Sample Preparation System is the first fully automated   sample-to-answer solution when integrated with the BD FACSLyric ™ Flow Cytometer.
","('Energy_Management', 0.42212387919425964)","('Product_Design_And_Lifecycle_Management', 0.09425219893455505)","('Water_And_Wastewater_Management', 0.06150937080383301)","('NON-ESG', 0.42212387919425964)","('NON-ESG', 0.09425219893455505)","('NON-ESG', 0.06150937080383301)"
Line 687,"The new integrated system enables clinical laboratories to fully automate the   sample-to-answer process and improve their efficiency by reducing errors and   limiting the manual user interactions required to run assays on the BD FACSLyric ™   Flow Cytometer.
","('Competitive_Behavior', 0.4010145962238312)","('Customer_Welfare', 0.15192094445228577)","('Management_Of_Legal_And_Regulatory_Framework', 0.056901462376117706)","('NON-ESG', 0.4010145962238312)","('NON-ESG', 0.15192094445228577)","('NON-ESG', 0.056901462376117706)"
Line 688,"The BD FACSDuet ™ Sample Preparation System builds new capabilities into the   BD portfolio of clinical flow cytometry solutions offering a preanalytical system.
","('Customer_Welfare', 0.3081229627132416)","('Access_And_Affordability', 0.09769079834222794)","('Competitive_Behavior', 0.09171982854604721)","('NON-ESG', 0.3081229627132416)","('NON-ESG', 0.09769079834222794)","('NON-ESG', 0.09171982854604721)"
Line 689,"When combined with the BD FACSLyric ™ Flow Cytometer, the BD FACSDuet ™ System   is the first truly walkaway sample-to-answer solution for clinical labs.
","('Customer_Welfare', 0.22271233797073364)","('Access_And_Affordability', 0.14483869075775146)","('Competitive_Behavior', 0.08990541845560074)","('NON-ESG', 0.22271233797073364)","('NON-ESG', 0.14483869075775146)","('NON-ESG', 0.08990541845560074)"
Line 690,"BD Precise ™  WTA  Reagents BD  Rhapsody ™  Single Cell  Analysis  PlatformBD FACSLyric ™  Flow   Cytometer  System FY FY BD AbSeq ™  Antibody- Oligonucleotide  Conjugates BD OptiBuild ™  Reagents FY FY BD  FACSymphony ™  S6 Sorter BD  FACSMelody ™  Cell Sorter BD FACSLyric ™  Clinical   Flow Cytometer Access Innovation Efficiency Empowerment Governance Provide  solutions that improve healthcare worker and patient safety BD is dedicated to enhancing safety for patients and healthcare workers.
","('Employee_Health_And_Safety', 0.9107826948165894)","('Product_Quality_And_Safety', 0.02641195058822632)","('Critical_Incident_Risk_Management', 0.0064469329081475735)","(['Operational Eco-Efficiency'], 0.9107826948165894)","('NON-ESG', 0.02641195058822632)","('NON-ESG', 0.0064469329081475735)"
Line 691,"Hospitals and clinics pose an inherently risky environment  due, in part, to the high percentage of patients with communicable diseases.
","('Access_And_Affordability', 0.4988447427749634)","('Employee_Health_And_Safety', 0.15336187183856964)","('Product_Quality_And_Safety', 0.050587281584739685)","('NON-ESG', 0.4988447427749634)","('NON-ESG', 0.15336187183856964)","('NON-ESG', 0.050587281584739685)"
Line 692,"With the increase in antimicrobial resistance (AMR), the  need for infection prevention and control in the healthcare environment is paramount, in addition to protecting healthcare workers  from needlestick injuries and exposure to hazardous drugs.
","('Employee_Health_And_Safety', 0.9820797443389893)","('Critical_Incident_Risk_Management', 0.002483314834535122)","('Employee_Engagement_Inclusion_And_Diversity', 0.0012179865734651685)","(['Operational Eco-Efficiency'], 0.9820797443389893)","('NON-ESG', 0.002483314834535122)","('NON-ESG', 0.0012179865734651685)"
Line 693,"Key examples of this work over the past five years include: FY BD  ChloraShield ™  IV DressingFY BD Cato®  Medication  Workflow FY BD Phoenix ™  CPO Detect  Test BD Nano ™  PRO 4mm Pen  Needles AccuCath  Ace ™   Intravascular  CatheterFY BD® HD Check  SystemBD PhaSeal ™  Optima  System LifeStent ™ 5F  Vascular Stent  System AllPoints ™  Port Access  System BD Vacutainer® UltraTouch ™ Push Button Blood Collection Set  BD Vacutainer® UltraTouch ™ Push Button Blood Collection Set with Preattached Holder.
","('Customer_Welfare', 0.17878122627735138)","('Access_And_Affordability', 0.15419919788837433)","('Critical_Incident_Risk_Management', 0.07153574377298355)","('NON-ESG', 0.17878122627735138)","('NON-ESG', 0.15419919788837433)","('NON-ESG', 0.07153574377298355)"
Line 694,"The one-handed safety activation of the push button allows clinicians to activate   the safety mechanism while still attending to the patient and venipuncture site.
","('Product_Quality_And_Safety', 0.6909410357475281)","('Employee_Health_And_Safety', 0.14902924001216888)","('Product_Design_And_Lifecycle_Management', 0.02074279449880123)","(['Product Quality & Recall Management'], 0.6909410357475281)","('NON-ESG', 0.14902924001216888)","('NON-ESG', 0.02074279449880123)"
Line 695,"The preattached holder is designed to protect against accidental needlestick injury   from the nonpatient (tube side) needle and to help ensure OSHA single-use holder  compliance.
","('Employee_Health_And_Safety', 0.9624753594398499)","('Business_Ethics', 0.0032199921552091837)","('Waste_And_Hazardous_Materials_Management', 0.0031810931395739317)","(['Operational Eco-Efficiency'], 0.9624753594398499)","('NON-ESG', 0.0032199921552091837)","('NON-ESG', 0.0031810931395739317)"
Line 696,"The wing set with preassembled holder is provided as one sterile unit.
","('Waste_And_Hazardous_Materials_Management', 0.48809319734573364)","('Employee_Health_And_Safety', 0.07854735851287842)","('Water_And_Wastewater_Management', 0.07011548429727554)","('NON-ESG', 0.48809319734573364)","('NON-ESG', 0.07854735851287842)","('NON-ESG', 0.07011548429727554)"
Line 697,"Access Innovation Efficiency Empowerment Governance Venovo ™  Venous Stent  SystemFY OptiFix ™ AT  Absorbable   Fixation  SystemPureWick ™  Female  External   Catheter Kit WavelinQ ™ 4F  EndoAVF  System BD PurPrep ™ Patient Preoperative Skin Preparation In FY 2020, BD launched the BD PurPrep ™ Patient Preoperative Skin Preparation with  sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol  single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl  alcohol) commercially available in the U.S.  BD PurPrep ™ Skin Preparation joins BD ChloraPrep ™ Patient Preoperative Skin Preparation  as the only fully sterile skin preparations available on the market that use a single-use  applicator specifically designed to prevent cross-contamination and promote aseptic  nontouch technique.
","('Employee_Health_And_Safety', 0.3168971538543701)","('Product_Quality_And_Safety', 0.15641777217388153)","('Customer_Welfare', 0.09614041447639465)","('NON-ESG', 0.3168971538543701)","('NON-ESG', 0.15641777217388153)","('NON-ESG', 0.09614041447639465)"
Line 698,"Access Innovation Efficiency Empowerment Governance Venovo ™  Venous Stent  SystemFY OptiFix ™ AT  Absorbable   Fixation  SystemPureWick ™  Female  External   Catheter Kit WavelinQ ™ 4F  EndoAVF  System BD PurPrep ™ Patient Preoperative Skin Preparation In FY 2020, BD launched the BD PurPrep ™ Patient Preoperative Skin Preparation with  sterile solution, the first and only fully sterile povidone-iodine plus isopropyl alcohol  single-use antiseptic skin preparation (PVP-I; 0.83% available iodine and 72.5% isopropyl  alcohol) commercially available in the U.S.  BD PurPrep ™ Skin Preparation joins BD ChloraPrep ™ Patient Preoperative Skin Preparation  as the only fully sterile skin preparations available on the market that use a single-use  applicator specifically designed to prevent cross-contamination and promote aseptic  nontouch technique.
","('Product_Quality_And_Safety', 0.17484551668167114)","('Waste_And_Hazardous_Materials_Management', 0.13398633897304535)","('Employee_Health_And_Safety', 0.119682177901268)","('NON-ESG', 0.17484551668167114)","('NON-ESG', 0.13398633897304535)","('NON-ESG', 0.119682177901268)"
Line 699,"The BD PurPrep ™ Patient Preoperative Skin Preparation is an  effective skin preparation alternative  when the use of a chlorhexidine gluconate   (CHG/IPA) is contraindicated, or the patient is sensitive to CHG.
","('Customer_Welfare', 0.21443042159080505)","('Product_Quality_And_Safety', 0.16963699460029602)","('Employee_Health_And_Safety', 0.15724921226501465)","('NON-ESG', 0.21443042159080505)","('NON-ESG', 0.16963699460029602)","('NON-ESG', 0.15724921226501465)"
Line 700,"“Though progress has been made, healthcare-associated infections remain a problem,”  said Donald E.
","('Employee_Health_And_Safety', 0.5898454785346985)","('Product_Quality_And_Safety', 0.061474356800317764)","('Business_Ethics', 0.03420943394303322)","(['Operational Eco-Efficiency'], 0.5898454785346985)","('NON-ESG', 0.061474356800317764)","('NON-ESG', 0.03420943394303322)"
Line 701,"Fry, MD, a nationally  recognized expert in infection prevention.
","('Employee_Health_And_Safety', 0.7729476690292358)","('Critical_Incident_Risk_Management', 0.025173261761665344)","('Product_Quality_And_Safety', 0.019374601542949677)","(['Operational Eco-Efficiency'], 0.7729476690292358)","('NON-ESG', 0.025173261761665344)","('NON-ESG', 0.019374601542949677)"
Line 702,"“Sterile, single-use products have been shown to reduce the risk of outbreaks linked to  microbial contamination of antiseptic products.
","('Waste_And_Hazardous_Materials_Management', 0.6374346017837524)","('Product_Design_And_Lifecycle_Management', 0.09039098024368286)","('Product_Quality_And_Safety', 0.07424633204936981)","(['Operational Eco-Efficiency'], 0.6374346017837524)","('NON-ESG', 0.09039098024368286)","('NON-ESG', 0.07424633204936981)"
Line 703,"By developing fully sterile BD PurPrep ™ and ChloraPrep ™ Patient Preoperative  Skin Preparations, BD is providing healthcare professionals with a more complete set of tools to reduce the risk of intrinsic  contamination in antiseptic solutions.” BD Provena ™  Midline  Catheter with  Max Barrier+  Kits BD Provena ™  Solo CatheterFY Lutonix® AV  Low ProfileBD Insyte ™  Autoguard ™  BC Pro  Shielded IV  Catheter BD  PowerMidline ™  Catheter with  Max Barrier+  Kits BD UltraSafe  Plus ™ 2.25 mL  Passive  Needle Guard Access Innovation Efficiency Empowerment Governance While our 2020 sustainability goals have concluded, BD will continue to provide innovative solutions across the care continuum.
","('Waste_And_Hazardous_Materials_Management', 0.3023293912410736)","('Employee_Health_And_Safety', 0.169407919049263)","('Product_Quality_And_Safety', 0.11381494253873825)","('NON-ESG', 0.3023293912410736)","('NON-ESG', 0.169407919049263)","('NON-ESG', 0.11381494253873825)"
Line 704,"By developing fully sterile BD PurPrep ™ and ChloraPrep ™ Patient Preoperative  Skin Preparations, BD is providing healthcare professionals with a more complete set of tools to reduce the risk of intrinsic  contamination in antiseptic solutions.” BD Provena ™  Midline  Catheter with  Max Barrier+  Kits BD Provena ™  Solo CatheterFY Lutonix® AV  Low ProfileBD Insyte ™  Autoguard ™  BC Pro  Shielded IV  Catheter BD  PowerMidline ™  Catheter with  Max Barrier+  Kits BD UltraSafe  Plus ™ 2.25 mL  Passive  Needle Guard Access Innovation Efficiency Empowerment Governance While our 2020 sustainability goals have concluded, BD will continue to provide innovative solutions across the care continuum.
","('Access_And_Affordability', 0.24507035315036774)","('Product_Design_And_Lifecycle_Management', 0.1409141570329666)","('Management_Of_Legal_And_Regulatory_Framework', 0.1274542212486267)","('NON-ESG', 0.24507035315036774)","('NON-ESG', 0.1409141570329666)","('NON-ESG', 0.1274542212486267)"
Line 705,"This innovation will not be focused solely on the products we deliver, but also on how we deliver them.Looking forward—innovation beyond Exponential technologies While these products themselves enable this transition from  research to clinical practice, BD has also been innovating on  how we showcase our comprehensive BD solutions across   three business segments (BD Medical, BD Interventional and   BD Life Sciences).
","('Product_Design_And_Lifecycle_Management', 0.8129261136054993)","('Customer_Welfare', 0.055306918919086456)","('Product_Quality_And_Safety', 0.024476638063788414)","(['Product Stewardship'], 0.8129261136054993)","('NON-ESG', 0.055306918919086456)","('NON-ESG', 0.024476638063788414)"
Line 706,"BD has begun to utilize cutting-edge  visualization techniques to create experiences that better  demonstrate product solutions, educate healthcare  professionals in proper product use and engage with  stakeholders—from potential and current associates to  customers and patients.
","('Product_Design_And_Lifecycle_Management', 0.9304751753807068)","('Customer_Welfare', 0.014518825337290764)","('Selling_Practices_And_Product_Labeling', 0.010754327289760113)","(['Product Stewardship'], 0.9304751753807068)","('NON-ESG', 0.014518825337290764)","('NON-ESG', 0.010754327289760113)"
Line 707,"The BD Computer-Aided Engineering (CAE) Exponential  Technologies Group drives this work through immersive   and interactive experiences.
","('Product_Design_And_Lifecycle_Management', 0.24761517345905304)","('Energy_Management', 0.15423206984996796)","('Access_And_Affordability', 0.07070787250995636)","('NON-ESG', 0.24761517345905304)","('NON-ESG', 0.15423206984996796)","('NON-ESG', 0.07070787250995636)"
Line 708,"They utilize virtual reality (VR),  augmented reality (AR) and virtual tours (VT) to better  support the rollout of products—easing their transition from  research to clinical practice.
","('Product_Design_And_Lifecycle_Management', 0.29858630895614624)","('Customer_Welfare', 0.14382144808769226)","('Competitive_Behavior', 0.08443628251552582)","('NON-ESG', 0.29858630895614624)","('NON-ESG', 0.14382144808769226)","('NON-ESG', 0.08443628251552582)"
Line 709,"Our VR technology puts users in  the driver seat to interact with BD products, enabling them to  understand seamless workflows and helping drive better  healthcare outcomes.
","('Product_Design_And_Lifecycle_Management', 0.583896815776825)","('Access_And_Affordability', 0.061945296823978424)","('Customer_Welfare', 0.05642849579453468)","(['Product Stewardship'], 0.583896815776825)","('NON-ESG', 0.061945296823978424)","('NON-ESG', 0.05642849579453468)"
Line 710,"AR allows users to engage with BD  products and concepts in a new way by placing them within  their own real-world environment, creating a next-level  visualization experience.
","('Product_Design_And_Lifecycle_Management', 0.9500081539154053)","('Customer_Welfare', 0.005157310515642166)","('Business_Model_Resilience', 0.004546837415546179)","(['Product Stewardship'], 0.9500081539154053)","('NON-ESG', 0.005157310515642166)","('NON-ESG', 0.004546837415546179)"
Line 711,"One such solution, our virtual tour, leverages scans of   real-world environments to create portable, web-based  experiences (viewed on a phone, tablet or computer) to  highlight our solutions and key messages for customers   and talent recruitment.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6227225661277771)","('Business_Model_Resilience', 0.07657145708799362)","('Product_Design_And_Lifecycle_Management', 0.03143228217959404)","(['Human Capital Development'], 0.6227225661277771)","('NON-ESG', 0.07657145708799362)","('NON-ESG', 0.03143228217959404)"
Line 712,"These experiences help users learn  about the broad portfolio of BD products, follow a patient  journey from diagnosis to cure, highlight new market  opportunities through visualization and storytelling, and plan  optimal layout solutions for customer environments and  measure customer environments for optimal layout solutions.
","('Product_Design_And_Lifecycle_Management', 0.7920141816139221)","('Customer_Welfare', 0.058898650109767914)","('Business_Model_Resilience', 0.02590121142566204)","(['Product Stewardship'], 0.7920141816139221)","('NON-ESG', 0.058898650109767914)","('NON-ESG', 0.02590121142566204)"
Line 713,"Users can view two of the BD virtual tours from their own  computer at  BD Innovation and Engagement Center   (based out of Eysins, Switzerland) and the   Shanghai Customer Experience Center .
","('Product_Design_And_Lifecycle_Management', 0.5601484775543213)","('Business_Model_Resilience', 0.12916716933250427)","('Competitive_Behavior', 0.03650263696908951)","(['Product Stewardship'], 0.5601484775543213)","('NON-ESG', 0.12916716933250427)","('NON-ESG', 0.03650263696908951)"
Line 714,"Antimicrobial resistance, or AMR for short, is among the greatest threats to the health and well-being of  the world’s population.
","('Employee_Health_And_Safety', 0.16206973791122437)","('Access_And_Affordability', 0.08025716990232468)","('Water_And_Wastewater_Management', 0.07916749268770218)","('NON-ESG', 0.16206973791122437)","('NON-ESG', 0.08025716990232468)","('NON-ESG', 0.07916749268770218)"
Line 715,"If present trends continue, by 2050 AMR will become a greater cause of  mortality than heart disease or cancer.1 As the bacteria that cause infections become increasingly drug  resistant, even common medical procedures—such as surgery, childbirth and chemotherapy—will  become increasingly life-threatening.
","('Employee_Health_And_Safety', 0.6613573431968689)","('Access_And_Affordability', 0.04704806208610535)","('Product_Quality_And_Safety', 0.042482227087020874)","(['Operational Eco-Efficiency'], 0.6613573431968689)","('NON-ESG', 0.04704806208610535)","('NON-ESG', 0.042482227087020874)"
Line 716,"This is not a theoretical future risk; it is already happening.
","('Systemic_Risk_Management', 0.8070610761642456)","('Business_Model_Resilience', 0.04336448758840561)","('Physical_Impacts_Of_Climate_Change', 0.04008650407195091)","(['Risk & Crisis Management'], 0.8070610761642456)","('NON-ESG', 0.04336448758840561)","('NON-ESG', 0.04008650407195091)"
Line 717,"In 2019, the CDC released updated estimates for the toll of drug-resistant infections in the United  States, demonstrating that the risk is greater than previously believed, affecting over 2.8 million   patients annually.
","('Employee_Health_And_Safety', 0.1368919312953949)","('Systemic_Risk_Management', 0.1315866857767105)","('Data_Security', 0.08917870372533798)","('NON-ESG', 0.1368919312953949)","('NON-ESG', 0.1315866857767105)","('NON-ESG', 0.08917870372533798)"
Line 718,"And while the COVID-19 pandemic quickly became the focus of the world’s attention,  AMR continues to increase, threatening the lives of millions every year.
","('Critical_Incident_Risk_Management', 0.3192097544670105)","('Physical_Impacts_Of_Climate_Change', 0.28415149450302124)","('Air_Quality', 0.1287643313407898)","('NON-ESG', 0.3192097544670105)","('NON-ESG', 0.28415149450302124)","('NON-ESG', 0.1287643313407898)"
Line 719,"To mobilize action, in 2016 the United Nations identified AMR as a global health threat and called on  countries to enact national programs to combat AMR and to reduce the risk of drug-resistant infections.
","('Employee_Health_And_Safety', 0.2262410968542099)","('Product_Quality_And_Safety', 0.11051972955465317)","('Access_And_Affordability', 0.09640782326459885)","('NON-ESG', 0.2262410968542099)","('NON-ESG', 0.11051972955465317)","('NON-ESG', 0.09640782326459885)"
Line 720,"A continued rise in resistance   by 2050 would lead to 10 million deaths   and a reduction of    2% to 3.5%  in GDP1–3.4 trillion   U.S. dollars in estimated  losses annuallyAntimicrobial resistance (AMR) There is usually a small  number of bacteria that   are resistant to antibiotics.Eventually, the drug-resistant  bacteria becomes dominant  and spreads.The drug-resistant bacteria  survive and multiply.When taken, antibiotics kill bacteria  causing the illness—but they also kill   the good bacteria that protects the   body from infection.AMR is the ability of microorganisms (such as bacteria, fungi, viruses or protozoa) to nullify the effects of antimicrobial drugs,  resulting in these drugs becoming ineffective.2,3 AMR can affect anyone, of any age, in any country.
","('Product_Quality_And_Safety', 0.13403229415416718)","('Selling_Practices_And_Product_Labeling', 0.12589699029922485)","('Systemic_Risk_Management', 0.10192076116800308)","('NON-ESG', 0.13403229415416718)","('NON-ESG', 0.12589699029922485)","('NON-ESG', 0.10192076116800308)"
Line 721,"A continued rise in resistance   by 2050 would lead to 10 million deaths   and a reduction of    2% to 3.5%  in GDP1–3.4 trillion   U.S. dollars in estimated  losses annuallyAntimicrobial resistance (AMR) There is usually a small  number of bacteria that   are resistant to antibiotics.Eventually, the drug-resistant  bacteria becomes dominant  and spreads.The drug-resistant bacteria  survive and multiply.When taken, antibiotics kill bacteria  causing the illness—but they also kill   the good bacteria that protects the   body from infection.AMR is the ability of microorganisms (such as bacteria, fungi, viruses or protozoa) to nullify the effects of antimicrobial drugs,  resulting in these drugs becoming ineffective.2,3 AMR can affect anyone, of any age, in any country.
","('Systemic_Risk_Management', 0.16150443255901337)","('Customer_Welfare', 0.11294984072446823)","('Competitive_Behavior', 0.0838441252708435)","('NON-ESG', 0.16150443255901337)","('NON-ESG', 0.11294984072446823)","('NON-ESG', 0.0838441252708435)"
Line 722,"How does it happen?
","('Systemic_Risk_Management', 0.13212309777736664)","('Competitive_Behavior', 0.0762995257973671)","('Physical_Impacts_Of_Climate_Change', 0.06438490003347397)","('NON-ESG', 0.13212309777736664)","('NON-ESG', 0.0762995257973671)","('NON-ESG', 0.06438490003347397)"
Line 723,"700,000  preventable   deaths worldwide annually References 1 O’Neill J.
","('Employee_Health_And_Safety', 0.7426798343658447)","('Critical_Incident_Risk_Management', 0.15487071871757507)","('Access_And_Affordability', 0.017669454216957092)","(['Operational Eco-Efficiency'], 0.7426798343658447)","('NON-ESG', 0.15487071871757507)","('NON-ESG', 0.017669454216957092)"
Line 724,"Tackling drug-resistant infections globally: final report and recommendations.
","('Product_Quality_And_Safety', 0.12719738483428955)","('Access_And_Affordability', 0.10885042697191238)","('Employee_Health_And_Safety', 0.09051090478897095)","('NON-ESG', 0.12719738483428955)","('NON-ESG', 0.10885042697191238)","('NON-ESG', 0.09051090478897095)"
Line 725,"Review on Antimicrobial Resistance.
","('Customer_Welfare', 0.1724257916212082)","('Selling_Practices_And_Product_Labeling', 0.15181778371334076)","('Systemic_Risk_Management', 0.06339551508426666)","('NON-ESG', 0.1724257916212082)","('NON-ESG', 0.15181778371334076)","('NON-ESG', 0.06339551508426666)"
Line 726,"May 2016.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16443732380867004)","('Director_Removal', 0.10743921995162964)","('Business_Ethics', 0.08699965476989746)","('NON-ESG', 0.16443732380867004)","('NON-ESG', 0.10743921995162964)","('NON-ESG', 0.08699965476989746)"
Line 727,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 728,"https://amr-review.org/sites/ default/files/160525_Final%20paper_with%20cover.pdf 2 Antibiotic threats in the United States.
","('Systemic_Risk_Management', 0.20012889802455902)","('Competitive_Behavior', 0.14222928881645203)","('Product_Quality_And_Safety', 0.11840280145406723)","('NON-ESG', 0.20012889802455902)","('NON-ESG', 0.14222928881645203)","('NON-ESG', 0.11840280145406723)"
Line 729,"Centers for Disease Control and Prevention.
","('Access_And_Affordability', 0.187618687748909)","('Systemic_Risk_Management', 0.10559262335300446)","('Physical_Impacts_Of_Climate_Change', 0.08274717628955841)","('NON-ESG', 0.187618687748909)","('NON-ESG', 0.10559262335300446)","('NON-ESG', 0.08274717628955841)"
Line 730,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 731,"https://www.cdc.gov/drugresistance/threat-report-2013/index.html    3 O’Neill J.
","('Systemic_Risk_Management', 0.3823704123497009)","('Data_Security', 0.1329224705696106)","('Business_Ethics', 0.05050107464194298)","('NON-ESG', 0.3823704123497009)","('NON-ESG', 0.1329224705696106)","('NON-ESG', 0.05050107464194298)"
Line 732,"Antimicrobial resistance: tackling a crisis for the health and wealth of nations.
","('Systemic_Risk_Management', 0.18126240372657776)","('Customer_Welfare', 0.17984770238399506)","('Selling_Practices_And_Product_Labeling', 0.0579073466360569)","('NON-ESG', 0.18126240372657776)","('NON-ESG', 0.17984770238399506)","('NON-ESG', 0.0579073466360569)"
Line 733,"December 2014.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16583408415317535)","('Director_Removal', 0.08407029509544373)","('Business_Ethics', 0.07874836027622223)","('NON-ESG', 0.16583408415317535)","('NON-ESG', 0.08407029509544373)","('NON-ESG', 0.07874836027622223)"
Line 734,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 735,"https://amr-review.org/sites/default/files/AMR%Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdfCost2Impact1ProjectionsIn response to this threat, in 2016 the United Nations called on  countries to enact national programs to combat AMR, and  focused on five key strategic focal areas identified by the  Interagency Coordinating Group (IACG): • Raising awareness of AMR among clinicians and the   public at large • Funding education, research and surveillance programs   to understand the growing threat of AMR •  Reducing incidence of infection through hygiene and   prevention efforts •  Optimizing the use of antibiotics, many of which are   prescribed inappropriately •  Investing in R&D and innovation to develop novel drugs,   vaccines and diagnosticsBD is leveraging its extensive global capabilities to meaningfully  engage around each of the five key strategies outlined in the  WHO’s Global Action Plan on AMR.
","('Business_Ethics', 0.23405933380126953)","('Systemic_Risk_Management', 0.15290182828903198)","('Data_Security', 0.07590801268815994)","('NON-ESG', 0.23405933380126953)","('NON-ESG', 0.15290182828903198)","('NON-ESG', 0.07590801268815994)"
Line 736,"https://amr-review.org/sites/default/files/AMR%Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdfCost2Impact1ProjectionsIn response to this threat, in 2016 the United Nations called on  countries to enact national programs to combat AMR, and  focused on five key strategic focal areas identified by the  Interagency Coordinating Group (IACG): • Raising awareness of AMR among clinicians and the   public at large • Funding education, research and surveillance programs   to understand the growing threat of AMR •  Reducing incidence of infection through hygiene and   prevention efforts •  Optimizing the use of antibiotics, many of which are   prescribed inappropriately •  Investing in R&D and innovation to develop novel drugs,   vaccines and diagnosticsBD is leveraging its extensive global capabilities to meaningfully  engage around each of the five key strategies outlined in the  WHO’s Global Action Plan on AMR.
","('Employee_Health_And_Safety', 0.6251372694969177)","('Access_And_Affordability', 0.060557685792446136)","('Critical_Incident_Risk_Management', 0.047480508685112)","(['Operational Eco-Efficiency'], 0.6251372694969177)","('NON-ESG', 0.060557685792446136)","('NON-ESG', 0.047480508685112)"
Line 737,"BD possesses important  capabilities that are instrumental in containing AMR.
","('Access_And_Affordability', 0.18828856945037842)","('Management_Of_Legal_And_Regulatory_Framework', 0.13935761153697968)","('GHG_Emissions', 0.13737289607524872)","('NON-ESG', 0.18828856945037842)","('NON-ESG', 0.13935761153697968)","('NON-ESG', 0.13737289607524872)"
Line 738,"We offer a  wide range of medical products utilized to prevent the spread of  infection in healthcare facilities.
","('Employee_Health_And_Safety', 0.6188381314277649)","('Product_Quality_And_Safety', 0.08142825216054916)","('Selling_Practices_And_Product_Labeling', 0.030758759006857872)","(['Operational Eco-Efficiency'], 0.6188381314277649)","('NON-ESG', 0.08142825216054916)","('NON-ESG', 0.030758759006857872)"
Line 739,"In addition, we also offer  diagnostic systems to screen, test and diagnose infection,  including drug-resistant strains, and state-of-the-art  surveillance and reporting capabilities to monitor, track and  predict AMR outbreaks.
","('Employee_Health_And_Safety', 0.3130372166633606)","('Systemic_Risk_Management', 0.09103333204984665)","('Critical_Incident_Risk_Management', 0.08779004216194153)","('NON-ESG', 0.3130372166633606)","('NON-ESG', 0.09103333204984665)","('NON-ESG', 0.08779004216194153)"
Line 740,"Support infection control guidelines Comprehensive product and service offerings from BD to  help clinicians improve patient outcomes through the  standardization of care and adherence to best practices.
","('Employee_Health_And_Safety', 0.2147008329629898)","('Access_And_Affordability', 0.19319163262844086)","('Product_Quality_And_Safety', 0.18672171235084534)","('NON-ESG', 0.2147008329629898)","('NON-ESG', 0.19319163262844086)","('NON-ESG', 0.18672171235084534)"
Line 741,"Expand diagnostic testing Diagnostic tests classify infections and guide therapies,  enabling clinicians to implement effective antimicrobial  stewardship interventions.
","('Product_Quality_And_Safety', 0.15301723778247833)","('Employee_Health_And_Safety', 0.14343668520450592)","('Selling_Practices_And_Product_Labeling', 0.07542845606803894)","('NON-ESG', 0.15301723778247833)","('NON-ESG', 0.14343668520450592)","('NON-ESG', 0.07542845606803894)"
Line 742,"Advance medication management A connected medication management system comprised of  technologies, analytics and surveillance tools can help ensure  that medications are available and utilized appropriately.
","('Customer_Welfare', 0.3286648988723755)","('Access_And_Affordability', 0.11717662960290909)","('Selling_Practices_And_Product_Labeling', 0.09461678564548492)","('NON-ESG', 0.3286648988723755)","('NON-ESG', 0.11717662960290909)","('NON-ESG', 0.09461678564548492)"
Line 743,"The Antimicrobial Resistance Fighter Coalition (ARFC),  mobilized by BD in 2017, aims to raise awareness and emphasize  the need for a broad array of stakeholders to take personal  responsibility in combating AMR.
","('Human_Rights_And_Community_Relations', 0.2712289094924927)","('Access_And_Affordability', 0.14541494846343994)","('Ecological_Impacts', 0.06766924262046814)","('NON-ESG', 0.2712289094924927)","('NON-ESG', 0.14541494846343994)","('NON-ESG', 0.06766924262046814)"
Line 744,"The ARFC is comprised of a  broad stakeholder group of global organizations, patient  advocacy groups and individuals from over 50 countries,  including health agency officials, professional societies, clinicians, patients who recovered from resistant infections and  family members of patients who died from AMR-related causes.
","('Employee_Health_And_Safety', 0.5080115795135498)","('Access_And_Affordability', 0.141949862241745)","('Critical_Incident_Risk_Management', 0.05602016672492027)","(['Operational Eco-Efficiency'], 0.5080115795135498)","('NON-ESG', 0.141949862241745)","('NON-ESG', 0.05602016672492027)"
Line 745,"The ARFC utilizes digital and social media to advance awareness  and mobilization around AMR, including a dedicated website ,  social media channels, and more recently, a webinar and  podcast series featuring many of the world’s leading authorities  on AMR.Strategy 1: Improve awareness, education and training Improving awareness and education remain a critical component to combating AMR AMR in the Light of COVID-19 is a recent series of four  webinars mobilized by the ARFC that aired live from September  to November 2020.
","('Access_And_Affordability', 0.30496302247047424)","('Human_Rights_And_Community_Relations', 0.16853070259094238)","('Employee_Health_And_Safety', 0.072004534304142)","('NON-ESG', 0.30496302247047424)","('NON-ESG', 0.16853070259094238)","('NON-ESG', 0.072004534304142)"
Line 746,"The ARFC utilizes digital and social media to advance awareness  and mobilization around AMR, including a dedicated website ,  social media channels, and more recently, a webinar and  podcast series featuring many of the world’s leading authorities  on AMR.Strategy 1: Improve awareness, education and training Improving awareness and education remain a critical component to combating AMR AMR in the Light of COVID-19 is a recent series of four  webinars mobilized by the ARFC that aired live from September  to November 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3276703953742981)","('Physical_Impacts_Of_Climate_Change', 0.0871555432677269)","('Director_Removal', 0.08188419789075851)","('NON-ESG', 0.3276703953742981)","('NON-ESG', 0.0871555432677269)","('NON-ESG', 0.08188419789075851)"
Line 747,"In these webinars, global AMR experts  discussed how the COVID-19 pandemic could reshape strategies  for combating drug-resistant infections around the world.
","('Physical_Impacts_Of_Climate_Change', 0.20794834196567535)","('Systemic_Risk_Management', 0.12457066774368286)","('Data_Security', 0.11149466037750244)","('NON-ESG', 0.20794834196567535)","('NON-ESG', 0.12457066774368286)","('NON-ESG', 0.11149466037750244)"
Line 748,"This webinar series had 20,467 registrants from 167 countries.
","('Competitive_Behavior', 0.40431973338127136)","('Management_Of_Legal_And_Regulatory_Framework', 0.13057363033294678)","('Business_Ethics', 0.04782436788082123)","('NON-ESG', 0.40431973338127136)","('NON-ESG', 0.13057363033294678)","('NON-ESG', 0.04782436788082123)"
Line 749,"Superbugs and You: True Stories from Scientists and Patients  Around the World  is a podcast series co-created by the ARFC and  CIDRAP (Center for Infectious Disease Research and Policy).
","('Access_And_Affordability', 0.2323283702135086)","('Customer_Welfare', 0.10953901708126068)","('Product_Quality_And_Safety', 0.08032258599996567)","('NON-ESG', 0.2323283702135086)","('NON-ESG', 0.10953901708126068)","('NON-ESG', 0.08032258599996567)"
Line 750,"In each podcast, a patient, a clinician and a researcher tell their  stories about how they each have suffered, treated and researched  (respectively) drug-resistant infections (“superbugs”).
","('Employee_Health_And_Safety', 0.3859213590621948)","('Product_Quality_And_Safety', 0.07237398624420166)","('Data_Security', 0.04920956864953041)","('NON-ESG', 0.3859213590621948)","('NON-ESG', 0.07237398624420166)","('NON-ESG', 0.04920956864953041)"
Line 751,"They also  describe ways that listeners can change their behaviors to improve  the use of antibiotics.
","('Access_And_Affordability', 0.43222424387931824)","('Customer_Welfare', 0.09785262495279312)","('Selling_Practices_And_Product_Labeling', 0.08559232950210571)","('NON-ESG', 0.43222424387931824)","('NON-ESG', 0.09785262495279312)","('NON-ESG', 0.08559232950210571)"
Line 752,"From hypothetical to reality:   how COVID-19 foretells a world   without antibioticsAMR in the Light   of COVID-Drug-resistant infections can happen  when least expected Tatiana Vargas,1 was a healthy, recently married newlywed  living in California.
","('Employee_Health_And_Safety', 0.20284374058246613)","('Product_Quality_And_Safety', 0.13355909287929535)","('Access_And_Affordability', 0.12219129502773285)","('NON-ESG', 0.20284374058246613)","('NON-ESG', 0.13355909287929535)","('NON-ESG', 0.12219129502773285)"
Line 753,"After returning home from her  honeymoon, she began to feel unwell.
","('Employee_Health_And_Safety', 0.30360355973243713)","('Waste_And_Hazardous_Materials_Management', 0.10398925095796585)","('Critical_Incident_Risk_Management', 0.07784175872802734)","('NON-ESG', 0.30360355973243713)","('NON-ESG', 0.10398925095796585)","('NON-ESG', 0.07784175872802734)"
Line 754,"After a doctor visit  and a misdiagnosis, the infection moved to her lungs and  Tatiana landed in the ICU.
","('Employee_Health_And_Safety', 0.7176041007041931)","('Product_Quality_And_Safety', 0.0343102402985096)","('Employee_Engagement_Inclusion_And_Diversity', 0.02263779565691948)","(['Operational Eco-Efficiency'], 0.7176041007041931)","('NON-ESG', 0.0343102402985096)","('NON-ESG', 0.02263779565691948)"
Line 755,"She was then diagnosed with a  methicillin-resistant Staphylococcus aureus  (MRSA)  infection for which the initial antibiotic no longer worked.
","('Product_Quality_And_Safety', 0.15577992796897888)","('Selling_Practices_And_Product_Labeling', 0.11503354460000992)","('Access_And_Affordability', 0.09920821338891983)","('NON-ESG', 0.15577992796897888)","('NON-ESG', 0.11503354460000992)","('NON-ESG', 0.09920821338891983)"
Line 756,"After quarantine and many weeks of treatment, she was  released.
","('Waste_And_Hazardous_Materials_Management', 0.1852404624223709)","('Employee_Health_And_Safety', 0.17780829966068268)","('Access_And_Affordability', 0.1552479863166809)","('NON-ESG', 0.1852404624223709)","('NON-ESG', 0.17780829966068268)","('NON-ESG', 0.1552479863166809)"
Line 757,"Today, Tatiana lives with a chronic cough and the  reality that the infection might return.
","('Employee_Health_And_Safety', 0.4143475890159607)","('Waste_And_Hazardous_Materials_Management', 0.09039894491434097)","('Product_Quality_And_Safety', 0.046537626534700394)","('NON-ESG', 0.4143475890159607)","('NON-ESG', 0.09039894491434097)","('NON-ESG', 0.046537626534700394)"
Line 758,"Reference 1 Tatiana Vargas, Antimicrobial Resistance Fighter Coalition message.
","('Customer_Welfare', 0.19872471690177917)","('Competitive_Behavior', 0.08708672225475311)","('Selling_Practices_And_Product_Labeling', 0.08536621928215027)","('NON-ESG', 0.19872471690177917)","('NON-ESG', 0.08708672225475311)","('NON-ESG', 0.08536621928215027)"
Line 759,"https://antimicrobialresistancefighters.org/stories/story-tatiana-chiprez-vargas Strengthening surveillance and reporting are necessary to better  understand the scale of the challenge and develop an  appropriate response.
","('Systemic_Risk_Management', 0.1499720960855484)","('Competitive_Behavior', 0.10661669075489044)","('Critical_Incident_Risk_Management', 0.09618176519870758)","('NON-ESG', 0.1499720960855484)","('NON-ESG', 0.10661669075489044)","('NON-ESG', 0.09618176519870758)"
Line 760,"Lessons from COVID highlight the need  for improved surveillance of drug-resistant infections.
","('Data_Security', 0.17690669000148773)","('Systemic_Risk_Management', 0.10267376154661179)","('Selling_Practices_And_Product_Labeling', 0.07235997170209885)","('NON-ESG', 0.17690669000148773)","('NON-ESG', 0.10267376154661179)","('NON-ESG', 0.07235997170209885)"
Line 761,"BD has  contributed data to global organizations, such as the CDC; the  Institute for Health Metrics and Evaluation (IMHE); and the  Center for Disease Dynamics, Economics and Policy (CDDEP) to  evaluate and report the burden of AMR.
","('Access_And_Affordability', 0.22939229011535645)","('Systemic_Risk_Management', 0.21908557415008545)","('Management_Of_Legal_And_Regulatory_Framework', 0.06978732347488403)","('NON-ESG', 0.22939229011535645)","('NON-ESG', 0.21908557415008545)","('NON-ESG', 0.06978732347488403)"
Line 762,"In 2019, BD provided  extensive data and analytics to the CDC utilizing insights from  our proprietary hospital surveillance and analytics platforms.
","('Data_Security', 0.4512973129749298)","('Customer_Privacy', 0.16612884402275085)","('Energy_Management', 0.04838952794671059)","('NON-ESG', 0.4512973129749298)","('NON-ESG', 0.16612884402275085)","('NON-ESG', 0.04838952794671059)"
Line 763,"These data were integrated into the CDC’s  Antibiotic Resistance  Threats Report1 highlighting the prevalence and impact of antibiotic-resistant bacteria and fungi on patients in the  United States.
","('Selling_Practices_And_Product_Labeling', 0.36637642979621887)","('Customer_Welfare', 0.11564532667398453)","('Systemic_Risk_Management', 0.05204378813505173)","('NON-ESG', 0.36637642979621887)","('NON-ESG', 0.11564532667398453)","('NON-ESG', 0.05204378813505173)"
Line 764,"Healthcare systems and governments often do not understand  the economic impact that AMR can have—today and in the  future.
","('Access_And_Affordability', 0.1979070007801056)","('Systemic_Risk_Management', 0.19689075648784637)","('Management_Of_Legal_And_Regulatory_Framework', 0.16977880895137787)","('NON-ESG', 0.1979070007801056)","('NON-ESG', 0.19689075648784637)","('NON-ESG', 0.16977880895137787)"
Line 765,"The BD Health and Economic Outcomes Research  (HEOR) team developed an AMR Burden of Disease Tool that  illustrates current and anticipated future clinical and economic  impact of AMR across various system levels.
","('Access_And_Affordability', 0.2925547957420349)","('Employee_Health_And_Safety', 0.08052783459424973)","('Product_Quality_And_Safety', 0.07646098732948303)","('NON-ESG', 0.2925547957420349)","('NON-ESG', 0.08052783459424973)","('NON-ESG', 0.07646098732948303)"
Line 766,"BD has facilitated  the use of this new tool with health systems and facilities in  Canada, Southeast Asia and China.
","('Access_And_Affordability', 0.6453438997268677)","('Employee_Health_And_Safety', 0.10397061705589294)","('Critical_Incident_Risk_Management', 0.05089027062058449)","(['Health Outcome Contribution'], 0.6453438997268677)","('NON-ESG', 0.10397061705589294)","('NON-ESG', 0.05089027062058449)"
Line 767,"The tool is automated and  available online  for public use.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3477683365345001)","('Access_And_Affordability', 0.17416012287139893)","('Ecological_Impacts', 0.11347051709890366)","('NON-ESG', 0.3477683365345001)","('NON-ESG', 0.17416012287139893)","('NON-ESG', 0.11347051709890366)"
Line 768,"Strategy 2: Strengthen evidence via surveillance Reducing risk of infection is an essential component of the  global effort to combat AMR.
","('Employee_Health_And_Safety', 0.7369076609611511)","('Critical_Incident_Risk_Management', 0.029615500941872597)","('Product_Quality_And_Safety', 0.027184240520000458)","(['Operational Eco-Efficiency'], 0.7369076609611511)","('NON-ESG', 0.029615500941872597)","('NON-ESG', 0.027184240520000458)"
Line 769,"When selecting, placing and  maintaining medical devices, proper hand hygiene, aseptic  technique and compliance to guidelines are necessary to reduce  HAI risk to patients.
","('Employee_Health_And_Safety', 0.36801230907440186)","('Product_Quality_And_Safety', 0.1998564451932907)","('Product_Design_And_Lifecycle_Management', 0.0683179497718811)","('NON-ESG', 0.36801230907440186)","('NON-ESG', 0.1998564451932907)","('NON-ESG', 0.0683179497718811)"
Line 770,"And since resistant infections spread easily  among patients in healthcare facilities, patient screening and  universal precautions may reduce transmission of infections.
","('Employee_Health_And_Safety', 0.37420758605003357)","('Critical_Incident_Risk_Management', 0.0808216780424118)","('Data_Security', 0.07194487005472183)","('NON-ESG', 0.37420758605003357)","('NON-ESG', 0.0808216780424118)","('NON-ESG', 0.07194487005472183)"
Line 771,"BD is leveraging its expertise in diagnostics, vascular access,  surgical preparation and critical care to support hospitals’  infection prevention and control programs.
","('Employee_Health_And_Safety', 0.6737203598022461)","('Access_And_Affordability', 0.07608307898044586)","('Product_Quality_And_Safety', 0.03762204945087433)","(['Operational Eco-Efficiency'], 0.6737203598022461)","('NON-ESG', 0.07608307898044586)","('NON-ESG', 0.03762204945087433)"
Line 772,"In addition to deploying these programs at an individual health  facility level, BD has worked in collaboration with national  governments in multiple countries, including the U.S., China,  Kenya, Cambodia and India, via public-private partnerships   to improve infection prevention and control capabilities  in hospitals.In 2020, The Society for Healthcare Epidemiology of America  (SHEA) launched a new best practices training course in  infection prevention and control for hospital clinicians with  direct patient care responsibilities.
","('Employee_Health_And_Safety', 0.7362082004547119)","('Access_And_Affordability', 0.03928038850426674)","('Product_Quality_And_Safety', 0.03765428066253662)","(['Operational Eco-Efficiency'], 0.7362082004547119)","('NON-ESG', 0.03928038850426674)","('NON-ESG', 0.03765428066253662)"
Line 773,"In addition to deploying these programs at an individual health  facility level, BD has worked in collaboration with national  governments in multiple countries, including the U.S., China,  Kenya, Cambodia and India, via public-private partnerships   to improve infection prevention and control capabilities  in hospitals.In 2020, The Society for Healthcare Epidemiology of America  (SHEA) launched a new best practices training course in  infection prevention and control for hospital clinicians with  direct patient care responsibilities.
","('Access_And_Affordability', 0.4505278468132019)","('Management_Of_Legal_And_Regulatory_Framework', 0.07182391732931137)","('Critical_Incident_Risk_Management', 0.04282831400632858)","('NON-ESG', 0.4505278468132019)","('NON-ESG', 0.07182391732931137)","('NON-ESG', 0.04282831400632858)"
Line 774,"The online program,  Prevention Course in HAI Knowledge and Control (Prevention  CHKC), was supported by an educational grant from BD and is  available for free throughout the COVID-19 pandemic to  support infection prevention awareness and education.
","('Employee_Health_And_Safety', 0.16879568994045258)","('Access_And_Affordability', 0.15300510823726654)","('Critical_Incident_Risk_Management', 0.13663466274738312)","('NON-ESG', 0.16879568994045258)","('NON-ESG', 0.15300510823726654)","('NON-ESG', 0.13663466274738312)"
Line 775,"“With many healthcare facilities stretched to or beyond their limits  and others preparing to be, this course provides critical  information and skills to keep frontline providers, their families  and patients safe in this crisis,”  said Hilary Babcock, MD,  MPH, Chair of the SHEA Education and Research Foundation.
","('Employee_Health_And_Safety', 0.407691091299057)","('Critical_Incident_Risk_Management', 0.21450389921665192)","('Access_And_Affordability', 0.16126252710819244)","('NON-ESG', 0.407691091299057)","('NON-ESG', 0.21450389921665192)","('NON-ESG', 0.16126252710819244)"
Line 776,"“These prevention processes are not necessarily intuitive, and the  need for refreshing these skills among healthcare workers is high  in normal times and critical during this global pandemic.”Strategy 3: Reduce incidence of infection Diagnostic tests classify infections and guide therapies,  enabling clinicians to implement effective antimicrobial  stewardship interventions.
","('Employee_Health_And_Safety', 0.6071875095367432)","('Critical_Incident_Risk_Management', 0.12255091965198517)","('Access_And_Affordability', 0.02966517210006714)","(['Operational Eco-Efficiency'], 0.6071875095367432)","('NON-ESG', 0.12255091965198517)","('NON-ESG', 0.02966517210006714)"
Line 777,"Our focus in this area has been in   three areas: delivering updated and new diagnostic tools to  laboratories globally, deploying software to move data from the  lab to the patient, and co-developing training tools for optimal  use of the technologies.
","('Access_And_Affordability', 0.22987082600593567)","('Customer_Welfare', 0.16615906357765198)","('Energy_Management', 0.05400907248258591)","('NON-ESG', 0.22987082600593567)","('NON-ESG', 0.16615906357765198)","('NON-ESG', 0.05400907248258591)"
Line 778,"BD announced a collaboration with the Fleming Fund in 2019 to  equip labs in developing and emerging countries.
","('Management_Of_Legal_And_Regulatory_Framework', 0.20323911309242249)","('Access_And_Affordability', 0.14364032447338104)","('Business_Model_Resilience', 0.11153078824281693)","('NON-ESG', 0.20323911309242249)","('NON-ESG', 0.14364032447338104)","('NON-ESG', 0.11153078824281693)"
Line 779,"More on this  partnership can be found in the Access  section of this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6813665628433228)","('Access_And_Affordability', 0.08420504629611969)","('Ecological_Impacts', 0.03991136699914932)","(['Corporate Governance'], 0.6813665628433228)","('NON-ESG', 0.08420504629611969)","('NON-ESG', 0.03991136699914932)"
Line 780,"In 2020, a successful rollout of equipment, reagents and  training has improved lab capabilities across several countries.
","('Access_And_Affordability', 0.26703187823295593)","('Product_Quality_And_Safety', 0.11046823859214783)","('Customer_Welfare', 0.0824737399816513)","('NON-ESG', 0.26703187823295593)","('NON-ESG', 0.11046823859214783)","('NON-ESG', 0.0824737399816513)"
Line 781,"In the U.K., BD partnered with a community pharmacy chain to  demonstrate the effective use of point-of-care tests to diagnose  patients with viral infections, resulting in a reduction in the  number of unnecessary antibiotic prescriptions.
","('Selling_Practices_And_Product_Labeling', 0.20836257934570312)","('Customer_Welfare', 0.14147767424583435)","('Product_Quality_And_Safety', 0.12209450453519821)","('NON-ESG', 0.20836257934570312)","('NON-ESG', 0.14147767424583435)","('NON-ESG', 0.12209450453519821)"
Line 782,"Patients and  pharmacists surveyed expressed satisfaction with the survey  and even a willingness to pay if the service was not reimbursed  by the NHS.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7008861899375916)","('Labor_Practices', 0.058829497545957565)","('Business_Ethics', 0.05579641833901405)","(['Corporate Governance'], 0.7008861899375916)","('NON-ESG', 0.058829497545957565)","('NON-ESG', 0.05579641833901405)"
Line 783,"In the U.S. and other industrialized countries, BD introduced the  BD HealthSight ™ Clinical Advisor Platform to identify when an  inappropriate and potentially ineffective antibiotic has been  prescribed.
","('Customer_Welfare', 0.3027113080024719)","('Selling_Practices_And_Product_Labeling', 0.2725372910499573)","('Product_Quality_And_Safety', 0.08152198791503906)","('NON-ESG', 0.3027113080024719)","('NON-ESG', 0.2725372910499573)","('NON-ESG', 0.08152198791503906)"
Line 784,"Actionable alerts are delivered to clinicians involved  in the medication management process to assist with selection  of antibiotics to help avoid waste of resources associated with  compounding unnecessary medications.To support the understanding of the role of diagnostics in the  appropriate use of antimicrobials, BD partnered to create and  launch new training and assessment tools.
","('Customer_Welfare', 0.3730015456676483)","('Selling_Practices_And_Product_Labeling', 0.17910489439964294)","('Product_Quality_And_Safety', 0.05338462069630623)","('NON-ESG', 0.3730015456676483)","('NON-ESG', 0.17910489439964294)","('NON-ESG', 0.05338462069630623)"
Line 785,"Read more about the  massive online open course on AMR diagnostics and AMR  scorecard in the Access  section of this report.Strategy 4: Optimize the use of antimicrobials Antibiotics can cause harm and should  be used judicially The Peggy Lillis Foundation shares the story of Peggy Lillis,1  a healthy, vibrant, 56-year-old kindergarten teacher and  mother from New York who was prescribed a strong  antibiotic for prophylaxis.
","('Access_And_Affordability', 0.30630671977996826)","('Customer_Welfare', 0.14069409668445587)","('Selling_Practices_And_Product_Labeling', 0.1153913289308548)","('NON-ESG', 0.30630671977996826)","('NON-ESG', 0.14069409668445587)","('NON-ESG', 0.1153913289308548)"
Line 786,"She developed diarrhea and was  diagnosed with a Clostridioides difficile  infection.
","('Employee_Health_And_Safety', 0.7523006796836853)","('Product_Quality_And_Safety', 0.031282879412174225)","('Systemic_Risk_Management', 0.02620835043489933)","(['Operational Eco-Efficiency'], 0.7523006796836853)","('NON-ESG', 0.031282879412174225)","('NON-ESG', 0.02620835043489933)"
Line 787,"C.
","('Management_Of_Legal_And_Regulatory_Framework', 0.35686638951301575)","('Business_Ethics', 0.09611602127552032)","('Competitive_Behavior', 0.05494384095072746)","('NON-ESG', 0.35686638951301575)","('NON-ESG', 0.09611602127552032)","('NON-ESG', 0.05494384095072746)"
Line 788,"difficile  infections can occur when antibiotics disrupt the microflora  of “good” bacteria in your gut, resulting in overgrowth and  infection by the C.
","('Employee_Health_And_Safety', 0.22595345973968506)","('Ecological_Impacts', 0.0960507020354271)","('Water_And_Wastewater_Management', 0.0938263013958931)","('NON-ESG', 0.22595345973968506)","('NON-ESG', 0.0960507020354271)","('NON-ESG', 0.0938263013958931)"
Line 789,"difficile  bacteria.
","('Water_And_Wastewater_Management', 0.16906149685382843)","('Waste_And_Hazardous_Materials_Management', 0.11746842414140701)","('Customer_Welfare', 0.07108721882104874)","('NON-ESG', 0.16906149685382843)","('NON-ESG', 0.11746842414140701)","('NON-ESG', 0.07108721882104874)"
Line 790,"Despite the best efforts  of the medical team using the strongest antibiotics they  had, 36 hours later Peggy died from the infection.Resistance can spread through the air;  one-third of AMR deaths are due to   drug-resistant tuberculosis Saurabh Rane2 is an XDR-TB (extensively drug-resistant  tuberculosis) survivor.
","('Employee_Health_And_Safety', 0.1707036793231964)","('Product_Quality_And_Safety', 0.13320602476596832)","('Systemic_Risk_Management', 0.10498008131980896)","('NON-ESG', 0.1707036793231964)","('NON-ESG', 0.13320602476596832)","('NON-ESG', 0.10498008131980896)"
Line 791,"This means most TB drugs did not  work to cure his infection.
","('Employee_Health_And_Safety', 0.192884162068367)","('Product_Quality_And_Safety', 0.11203811317682266)","('Business_Ethics', 0.08469433337450027)","('NON-ESG', 0.192884162068367)","('NON-ESG', 0.11203811317682266)","('NON-ESG', 0.08469433337450027)"
Line 792,"He was initially misdiagnosed  with susceptible TB, and when he was correctly diagnosed,  he had to take over 20 pills a day for over 2.5 years,  including 6 months of daily injections.
","('Access_And_Affordability', 0.35866260528564453)","('Employee_Health_And_Safety', 0.15868201851844788)","('Product_Quality_And_Safety', 0.12811481952667236)","('NON-ESG', 0.35866260528564453)","('NON-ESG', 0.15868201851844788)","('NON-ESG', 0.12811481952667236)"
Line 793,"These medications  have terrible side effects, as they are very toxic.
","('Selling_Practices_And_Product_Labeling', 0.3758929669857025)","('Product_Quality_And_Safety', 0.15922485291957855)","('Customer_Welfare', 0.13972409069538116)","('NON-ESG', 0.3758929669857025)","('NON-ESG', 0.15922485291957855)","('NON-ESG', 0.13972409069538116)"
Line 794,"Today, he is  an advocate for fighting drug-resistant TB and fighting to  mandate drug susceptibility testing.
","('Product_Quality_And_Safety', 0.31903907656669617)","('Customer_Welfare', 0.13489936292171478)","('Access_And_Affordability', 0.06743935495615005)","('NON-ESG', 0.31903907656669617)","('NON-ESG', 0.13489936292171478)","('NON-ESG', 0.06743935495615005)"
Line 795,"References 1 Christian and Liam Lillis, Antimicrobial Resistance Fighter Coalition message.
","('Customer_Welfare', 0.24956469237804413)","('GHG_Emissions', 0.12399749457836151)","('Selling_Practices_And_Product_Labeling', 0.11053705960512161)","('NON-ESG', 0.24956469237804413)","('NON-ESG', 0.12399749457836151)","('NON-ESG', 0.11053705960512161)"
Line 796,"https://antimicrobialresistancefighters.org/stories/story-christian-and-liam-lillis 2 Saurabh Rane,  Antimicrobial Resistance Fighter Coalition message.
","('Competitive_Behavior', 0.16689224541187286)","('Customer_Welfare', 0.09006921201944351)","('Air_Quality', 0.08161114156246185)","('NON-ESG', 0.16689224541187286)","('NON-ESG', 0.09006921201944351)","('NON-ESG', 0.08161114156246185)"
Line 797,"https://antimicrobialresistancefighters.org/stories/story-saurabh-rane BD remains committed to investing in innovations to combat AMR through the development of new diagnostics, devices and  information systems that can help in clinical decision-making and reduce risks.Strategy 5: Innovations to help combat AMR Launched in 2016, BD ChloraShield ™ IV Dressing is a thin, transparent vascular dressing featuring BeneHold ™ Adhesive Technology  formulated with CHG (chlorhexidine gluconate) that provides sustained antimicrobial activity against skin flora for up to even days.
","('Customer_Welfare', 0.32076358795166016)","('Product_Quality_And_Safety', 0.10739471018314362)","('Selling_Practices_And_Product_Labeling', 0.09935596585273743)","('NON-ESG', 0.32076358795166016)","('NON-ESG', 0.10739471018314362)","('NON-ESG', 0.09935596585273743)"
Line 798,"https://antimicrobialresistancefighters.org/stories/story-saurabh-rane BD remains committed to investing in innovations to combat AMR through the development of new diagnostics, devices and  information systems that can help in clinical decision-making and reduce risks.Strategy 5: Innovations to help combat AMR Launched in 2016, BD ChloraShield ™ IV Dressing is a thin, transparent vascular dressing featuring BeneHold ™ Adhesive Technology  formulated with CHG (chlorhexidine gluconate) that provides sustained antimicrobial activity against skin flora for up to even days.
","('Customer_Welfare', 0.17910461127758026)","('Selling_Practices_And_Product_Labeling', 0.136416956782341)","('Ecological_Impacts', 0.10410729795694351)","('NON-ESG', 0.17910461127758026)","('NON-ESG', 0.136416956782341)","('NON-ESG', 0.10410729795694351)"
Line 799,"Designed to enhance patient care, the dressing stays in place, secures the vascular access device and is easy to remove.Support infection  control guidelines In 2016, BD expanded its efforts to combat antimicrobial resistance by introducing its next generation diagnostic instrument for  the rapid identification of bacteria and detection of antimicrobial resistance.
","('Selling_Practices_And_Product_Labeling', 0.14283588528633118)","('Product_Quality_And_Safety', 0.1303928792476654)","('Customer_Welfare', 0.0953090712428093)","('NON-ESG', 0.14283588528633118)","('NON-ESG', 0.1303928792476654)","('NON-ESG', 0.0953090712428093)"
Line 800,"The new BD Phoenix ™ M50 ID/AST System helps  deliver the same rapid, accurate and cost-effectiveness within a smaller footprint.Expand   diagnostic testing In 2019, BD announced the latest advancement in combating antimicrobial resistance with new analytics integrated into the  company’s connected medication management platform.
","('Customer_Welfare', 0.22907906770706177)","('Product_Quality_And_Safety', 0.15269926190376282)","('Selling_Practices_And_Product_Labeling', 0.13465574383735657)","('NON-ESG', 0.22907906770706177)","('NON-ESG', 0.15269926190376282)","('NON-ESG', 0.13465574383735657)"
Line 801,"It identifies when an inappropriate and potentially ineffective  antibiotic has been prescribed, based on a patient’s specific infection diagnosis.
","('Employee_Health_And_Safety', 0.38229939341545105)","('Product_Quality_And_Safety', 0.11215145140886307)","('Selling_Practices_And_Product_Labeling', 0.0649704560637474)","('NON-ESG', 0.38229939341545105)","('NON-ESG', 0.11215145140886307)","('NON-ESG', 0.0649704560637474)"
Line 802,"BD HealthSight ™ Clinical Advisor is a new  functionality within the BD HealthSight ™ Connected Medication Management Platform that aggregates disparate patient data  to provide clinicians with the ability to receive near real-time medication stewardship alerts within the pharmacy workflow.
","('Customer_Welfare', 0.19685834646224976)","('Access_And_Affordability', 0.1586753875017166)","('Energy_Management', 0.09212285280227661)","('NON-ESG', 0.19685834646224976)","('NON-ESG', 0.1586753875017166)","('NON-ESG', 0.09212285280227661)"
Line 803,"Advance medication  management In response to the global threat of antimicrobial resistance and  under the guidance of the UN AMR Interagency Coordination  Group, most countries throughout the world have established  AMR national action plans.
","('Systemic_Risk_Management', 0.1263863444328308)","('Customer_Welfare', 0.10987398773431778)","('Business_Model_Resilience', 0.10983912646770477)","('NON-ESG', 0.1263863444328308)","('NON-ESG', 0.10987398773431778)","('NON-ESG', 0.10983912646770477)"
Line 804,"BD is engaging with ministries of  health, international agencies and other partners to integrate  our AMR capabilities and initiatives within these country-level  plans.
","('Access_And_Affordability', 0.5180690288543701)","('Management_Of_Legal_And_Regulatory_Framework', 0.10269202291965485)","('Human_Rights_And_Community_Relations', 0.07358346879482269)","(['Health Outcome Contribution'], 0.5180690288543701)","('NON-ESG', 0.10269202291965485)","('NON-ESG', 0.07358346879482269)"
Line 805,"We are doing so in a manner that appropriately aligns our  actions to the stage of development of the countries and the  hospitals we are working in.
","('Management_Of_Legal_And_Regulatory_Framework', 0.25334471464157104)","('Human_Rights_And_Community_Relations', 0.18508753180503845)","('Access_And_Affordability', 0.16536346077919006)","('NON-ESG', 0.25334471464157104)","('NON-ESG', 0.18508753180503845)","('NON-ESG', 0.16536346077919006)"
Line 806,"These actions and activities reflect our company’s strong commitment to combating the global  risk of AMR.
","('Systemic_Risk_Management', 0.662104070186615)","('Physical_Impacts_Of_Climate_Change', 0.07682942599058151)","('Business_Model_Resilience', 0.07541216909885406)","(['Risk & Crisis Management'], 0.662104070186615)","('NON-ESG', 0.07682942599058151)","('NON-ESG', 0.07541216909885406)"
Line 807,"Halting and reversing this massive challenge will require the  combined resources and efforts of both public and private  sectors.
","('Management_Of_Legal_And_Regulatory_Framework', 0.752787709236145)","('Systemic_Risk_Management', 0.041342560201883316)","('Access_And_Affordability', 0.026626965031027794)","(['Corporate Governance'], 0.752787709236145)","('NON-ESG', 0.041342560201883316)","('NON-ESG', 0.026626965031027794)"
Line 808,"AMR has no single solution, and the challenges cannot  be solved without multiple players working collectively on a  common AMR agenda.
","('Systemic_Risk_Management', 0.27287599444389343)","('Competitive_Behavior', 0.11591798812150955)","('Management_Of_Legal_And_Regulatory_Framework', 0.0647820308804512)","('NON-ESG', 0.27287599444389343)","('NON-ESG', 0.11591798812150955)","('NON-ESG', 0.0647820308804512)"
Line 809,"BD will continue to collaborate with  global leaders around the world to address this urgent global  health concern.Starting in 2016, the PureWick® Female External Catheter has allowed for simple, noninvasive urine output management in  female patients in over 2,000 hospitals and rehabilitation facilities.Support infection  control guidelines In 2019, BD announced it received FDA approval for BD ChloraPrep ™ Skin Preparation with sterile solution, the only fully sterile  chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the U.S.Support infection  control guidelinesIn 2017, BD launched the first automated phenotypic test to detect and classify CPOs. Available as part of the BD Phoenix ™  Automated Microbiology System in Europe, the new BD Phoenix ™ CPO Detect Test will help hospitals identify and contain  infections caused by CPO, while potentially combating an increase in AMR.Expand   diagnostic testing In 2018, BD introduced the BD MAX ™ MDR-TB Panel, an in vitro diagnostic with CE-mark available in Europe and other regions.
","('Employee_Health_And_Safety', 0.5525466799736023)","('Product_Quality_And_Safety', 0.06602472066879272)","('Access_And_Affordability', 0.052799519151449203)","(['Operational Eco-Efficiency'], 0.5525466799736023)","('NON-ESG', 0.06602472066879272)","('NON-ESG', 0.052799519151449203)"
Line 810,"BD will continue to collaborate with  global leaders around the world to address this urgent global  health concern.Starting in 2016, the PureWick® Female External Catheter has allowed for simple, noninvasive urine output management in  female patients in over 2,000 hospitals and rehabilitation facilities.Support infection  control guidelines In 2019, BD announced it received FDA approval for BD ChloraPrep ™ Skin Preparation with sterile solution, the only fully sterile  chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the U.S.Support infection  control guidelinesIn 2017, BD launched the first automated phenotypic test to detect and classify CPOs. Available as part of the BD Phoenix ™  Automated Microbiology System in Europe, the new BD Phoenix ™ CPO Detect Test will help hospitals identify and contain  infections caused by CPO, while potentially combating an increase in AMR.Expand   diagnostic testing In 2018, BD introduced the BD MAX ™ MDR-TB Panel, an in vitro diagnostic with CE-mark available in Europe and other regions.
","('Employee_Health_And_Safety', 0.5423701405525208)","('Product_Quality_And_Safety', 0.08672331273555756)","('Access_And_Affordability', 0.040267374366521835)","(['Operational Eco-Efficiency'], 0.5423701405525208)","('NON-ESG', 0.08672331273555756)","('NON-ESG', 0.040267374366521835)"
Line 811,"BD will continue to collaborate with  global leaders around the world to address this urgent global  health concern.Starting in 2016, the PureWick® Female External Catheter has allowed for simple, noninvasive urine output management in  female patients in over 2,000 hospitals and rehabilitation facilities.Support infection  control guidelines In 2019, BD announced it received FDA approval for BD ChloraPrep ™ Skin Preparation with sterile solution, the only fully sterile  chlorhexidine gluconate (CHG) antiseptic skin preparation commercially available in the U.S.Support infection  control guidelinesIn 2017, BD launched the first automated phenotypic test to detect and classify CPOs. Available as part of the BD Phoenix ™  Automated Microbiology System in Europe, the new BD Phoenix ™ CPO Detect Test will help hospitals identify and contain  infections caused by CPO, while potentially combating an increase in AMR.Expand   diagnostic testing In 2018, BD introduced the BD MAX ™ MDR-TB Panel, an in vitro diagnostic with CE-mark available in Europe and other regions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6544506549835205)","('Product_Quality_And_Safety', 0.04353931173682213)","('Business_Model_Resilience', 0.024240298196673393)","(['Corporate Governance'], 0.6544506549835205)","('NON-ESG', 0.04353931173682213)","('NON-ESG', 0.024240298196673393)"
Line 812,"The single, PCR-based molecular diagnostic test is an integrated diagnostic test that can simultaneously detect bacteria that  cause TB.
","('Selling_Practices_And_Product_Labeling', 0.24640028178691864)","('Customer_Welfare', 0.16730940341949463)","('Product_Quality_And_Safety', 0.08719147741794586)","('NON-ESG', 0.24640028178691864)","('NON-ESG', 0.16730940341949463)","('NON-ESG', 0.08719147741794586)"
Line 813,"It determines if the bacteria contains mutations associated with resistance to the two important first-line drugs, INH  and RIF, enhancing the information for clinicians to direct the optimal treatment for their patients.Expand   diagnostic testing In 2020, BD announced availability in Europe (CE marked) of the new BD Kiestra ™ InoqulA System powered by BD Synapsys ™  Informatics Solution.
","('Customer_Welfare', 0.30681920051574707)","('Selling_Practices_And_Product_Labeling', 0.11255555599927902)","('Competitive_Behavior', 0.07816261053085327)","('NON-ESG', 0.30681920051574707)","('NON-ESG', 0.11255555599927902)","('NON-ESG', 0.07816261053085327)"
Line 814,"The BD Kiestra ™ InoqulA System allows the user to prioritize urgent samples immediately for on-demand  processing, minimizing workflow interruption.
","('Data_Security', 0.26004838943481445)","('Supply_Chain_Management', 0.16727571189403534)","('Energy_Management', 0.09403160214424133)","('NON-ESG', 0.26004838943481445)","('NON-ESG', 0.16727571189403534)","('NON-ESG', 0.09403160214424133)"
Line 815,"In addition, it also reduces the need for subculture, which may shorten the time  for microbial identification and antibiotic susceptibility testing, allowing earlier result reporting.Expand   diagnostic testing AccessInnovation Efficiency Empowerment Governance In July 2020, BD was granted Emergency Use Authorization  (EUA) from the FDA for a rapid, point-of-care SARS-CoV-2  diagnostic test for use with our broadly available BD Veritor ™  Plus System.
","('Critical_Incident_Risk_Management', 0.38406121730804443)","('Product_Quality_And_Safety', 0.0857197567820549)","('Access_And_Affordability', 0.08384115993976593)","('NON-ESG', 0.38406121730804443)","('NON-ESG', 0.0857197567820549)","('NON-ESG', 0.08384115993976593)"
Line 816,"The launch of this new assay that delivers results in  15 minutes on an easy-to-use, highly portable instrument was  critical for improving access to COVID-19 diagnostics because it  enabled real-time results and decision-making while the patient  was still on site.2020 goal Develop  low-cost innovations to address leading causes of mortality and morbidityBD believes in the vision of a world free of disease and needless suffering.
","('Employee_Health_And_Safety', 0.6552817821502686)","('Access_And_Affordability', 0.1342037469148636)","('Critical_Incident_Risk_Management', 0.06036952883005142)","(['Operational Eco-Efficiency'], 0.6552817821502686)","('NON-ESG', 0.1342037469148636)","('NON-ESG', 0.06036952883005142)"
Line 817,"We think access to high quality  healthcare is so fundamental that it can create more productive, educated and equitable societies.
","('Access_And_Affordability', 0.9189296364784241)","('Product_Quality_And_Safety', 0.008413510397076607)","('Human_Rights_And_Community_Relations', 0.007876025512814522)","(['Health Outcome Contribution'], 0.9189296364784241)","('NON-ESG', 0.008413510397076607)","('NON-ESG', 0.007876025512814522)"
Line 818,"BD’s global public health efforts seek to expand access and drive capacity building through partnerships  with leading organizations and governments.
","('Access_And_Affordability', 0.869429886341095)","('Human_Rights_And_Community_Relations', 0.0170321986079216)","('Critical_Incident_Risk_Management', 0.012380462139844894)","(['Health Outcome Contribution'], 0.869429886341095)","('NON-ESG', 0.0170321986079216)","('NON-ESG', 0.012380462139844894)"
Line 819,"We engage in advocacy with governments, funders and  health agencies to advance innovations to address the world’s leading public health needs, which are  highly aligned with the UN SDGs. The business model for emerging markets encourages our country’s leaders to understand the health  system priorities in their country and engage with key opinion leaders responsible for health policies and  practices.
","('Access_And_Affordability', 0.5243532061576843)","('Employee_Health_And_Safety', 0.09961266070604324)","('Critical_Incident_Risk_Management', 0.058555394411087036)","(['Health Outcome Contribution'], 0.5243532061576843)","('NON-ESG', 0.09961266070604324)","('NON-ESG', 0.058555394411087036)"
Line 820,"This enables BD to engage at earlier stages in the healthcare decision-making process and  adapt our strategic plans for product array, manufacturing and talent accordingly.Access Healthcare in resource-limited populations The BD Veritor ™ System, which is slightly larger than a cell  phone, is currently in use in hospitals, clinician offices, urgent  care centers and retail pharmacies.
","('Product_Design_And_Lifecycle_Management', 0.25417548418045044)","('Access_And_Affordability', 0.20672106742858887)","('Customer_Welfare', 0.1944669485092163)","('NON-ESG', 0.25417548418045044)","('NON-ESG', 0.20672106742858887)","('NON-ESG', 0.1944669485092163)"
Line 821,"Its one-button functionality,  workflow flexibility and ease of use make it an ideal solution for  settings without laboratory personnel.
","('Product_Design_And_Lifecycle_Management', 0.3832170069217682)","('Customer_Welfare', 0.08387238532304764)","('Energy_Management', 0.06699123978614807)","('NON-ESG', 0.3832170069217682)","('NON-ESG', 0.08387238532304764)","('NON-ESG', 0.06699123978614807)"
Line 822,"It also offers customers  real-time reporting capabilities through the BD Synapsys ™  Informatics Solution, which provides them with the ability to  easily report data for disease monitoring and  surveillance purposes.
","('Access_And_Affordability', 0.14068755507469177)","('Systemic_Risk_Management', 0.13703858852386475)","('Employee_Health_And_Safety', 0.08346005529165268)","('NON-ESG', 0.14068755507469177)","('NON-ESG', 0.13703858852386475)","('NON-ESG', 0.08346005529165268)"
Line 823,"“This will be a game changer for frontline healthcare workers  and their patients to be able to access a quick diagnostic test for  COVID-19, offering results in real time at convenient locations  like retail pharmacies, urgent care centers and doctors’ offices,”   said Dave Hickey, President of Integrated Diagnostic Solutions  for BD at the time of launch.
","('Access_And_Affordability', 0.4379628300666809)","('Customer_Welfare', 0.099279023706913)","('Employee_Health_And_Safety', 0.06481604278087616)","('NON-ESG', 0.4379628300666809)","('NON-ESG', 0.099279023706913)","('NON-ESG', 0.06481604278087616)"
Line 824,"“Such tests will also help  communities be more informed and better prepared to help  prevent new spikes and additional waves of COVID-19 by  enabling public health workers to quickly identify infectious  individuals and trace their contacts.
","('Employee_Health_And_Safety', 0.7950411438941956)","('Critical_Incident_Risk_Management', 0.05815467983484268)","('Access_And_Affordability', 0.01886318251490593)","(['Operational Eco-Efficiency'], 0.7950411438941956)","('NON-ESG', 0.05815467983484268)","('NON-ESG', 0.01886318251490593)"
Line 825,"The highly portable,  easy-to-use, point-of-care format of this test, large quantity of  test kits available and existing, expansive footprint of BD  Veritor ™ Plus Instruments will help bring widespread access to  COVID-19 testing in the United States and around the world as  additional country-specific regulatory requirements are met.” BD Veritor ™ Plus System AccessInnovation Efficiency Empowerment Governance BD has established a series of partnerships with PEPFAR (U.S. President’s Emergency Plan for AIDS Relief) and the U.S. CDC.
","('Critical_Incident_Risk_Management', 0.9595093131065369)","('Access_And_Affordability', 0.0047079939395189285)","('Air_Quality', 0.004600102081894875)","(['Risk & Crisis Management'], 0.9595093131065369)","('NON-ESG', 0.0047079939395189285)","('NON-ESG', 0.004600102081894875)"
Line 826,"The highly portable,  easy-to-use, point-of-care format of this test, large quantity of  test kits available and existing, expansive footprint of BD  Veritor ™ Plus Instruments will help bring widespread access to  COVID-19 testing in the United States and around the world as  additional country-specific regulatory requirements are met.” BD Veritor ™ Plus System AccessInnovation Efficiency Empowerment Governance BD has established a series of partnerships with PEPFAR (U.S. President’s Emergency Plan for AIDS Relief) and the U.S. CDC.
","('Critical_Incident_Risk_Management', 0.3079964518547058)","('Management_Of_Legal_And_Regulatory_Framework', 0.13365191221237183)","('Access_And_Affordability', 0.0717456191778183)","('NON-ESG', 0.3079964518547058)","('NON-ESG', 0.13365191221237183)","('NON-ESG', 0.0717456191778183)"
Line 827,"These  partnerships helps us strengthen laboratory systems and upgrade clinical practices in phlebotomy, infusion and injection.
","('Access_And_Affordability', 0.3431553840637207)","('Customer_Welfare', 0.16444538533687592)","('Product_Quality_And_Safety', 0.06207845360040665)","('NON-ESG', 0.3431553840637207)","('NON-ESG', 0.16444538533687592)","('NON-ESG', 0.06207845360040665)"
Line 828,"Labs for Life 2020 goal Collaborate  on strengthening health systems with leading agencies and NGOs BD, PEPFAR and CDC public-private partnerships PEPFAR, CDC and BD have a long-standing public-private  partnership (“Labs for Life”) focused on laboratory systems  strengthening toward achieving the UNAIDS 95:95:95 targets.
","('Access_And_Affordability', 0.784530758857727)","('Product_Quality_And_Safety', 0.025321410968899727)","('Customer_Welfare', 0.016610439866781235)","(['Health Outcome Contribution'], 0.784530758857727)","('NON-ESG', 0.025321410968899727)","('NON-ESG', 0.016610439866781235)"
Line 829,"Launched in 2007, Labs for Life provides frontline training for  laboratory staff in six countries heavily burdened with HIV.
","('Access_And_Affordability', 0.7712036967277527)","('Product_Quality_And_Safety', 0.030716197565197945)","('Employee_Engagement_Inclusion_And_Diversity', 0.024944569915533066)","(['Health Outcome Contribution'], 0.7712036967277527)","('NON-ESG', 0.030716197565197945)","('NON-ESG', 0.024944569915533066)"
Line 830,"In 2016, The Journal of Infectious Diseases highlighted the  successes of the partnership, such as reduced turnaround times  for test results, improved laboratory quality results and  standardization of safe specimen transport practices  and networks.
","('Product_Quality_And_Safety', 0.2337469905614853)","('Systemic_Risk_Management', 0.08815464377403259)","('Access_And_Affordability', 0.08439798653125763)","('NON-ESG', 0.2337469905614853)","('NON-ESG', 0.08815464377403259)","('NON-ESG', 0.08439798653125763)"
Line 831,"Renewed in 2012, phase 2 expanded to 41 laboratories across  five countries in sub-Saharan Africa and India.
","('Access_And_Affordability', 0.3192523717880249)","('GHG_Emissions', 0.07773397117853165)","('Ecological_Impacts', 0.07241738587617874)","('NON-ESG', 0.3192523717880249)","('NON-ESG', 0.07773397117853165)","('NON-ESG', 0.07241738587617874)"
Line 832,"Several labs were  successfully accredited in phase 2.
","('Access_And_Affordability', 0.3512965440750122)","('Management_Of_Legal_And_Regulatory_Framework', 0.15315541625022888)","('Product_Quality_And_Safety', 0.09463631361722946)","('NON-ESG', 0.3512965440750122)","('NON-ESG', 0.15315541625022888)","('NON-ESG', 0.09463631361722946)"
Line 833,"Based on the success of the  first two phases, the partnership was renewed in 2018 for  another three years.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6919946074485779)","('Access_And_Affordability', 0.058653928339481354)","('Human_Rights_And_Community_Relations', 0.03256465494632721)","(['Corporate Governance'], 0.6919946074485779)","('NON-ESG', 0.058653928339481354)","('NON-ESG', 0.03256465494632721)"
Line 834,"As part of this partnership, the U.S. Department of State brings  strategic guidance, HIV/AIDS technical expertise and in-kind  resources.
","('Access_And_Affordability', 0.47167056798934937)","('Product_Quality_And_Safety', 0.08349429070949554)","('Employee_Health_And_Safety', 0.07748129963874817)","('NON-ESG', 0.47167056798934937)","('NON-ESG', 0.08349429070949554)","('NON-ESG', 0.07748129963874817)"
Line 835,"CDC provides oversight and technical guidance and  serves as the primary implementing agency through CDC  country offices and local partners.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8634368181228638)","('Human_Rights_And_Community_Relations', 0.01582983322441578)","('Access_And_Affordability', 0.014629337005317211)","(['Corporate Governance'], 0.8634368181228638)","('NON-ESG', 0.01582983322441578)","('NON-ESG', 0.014629337005317211)"
Line 836,"BD contributes personnel  time through trainers, mentors, and subject matter experts and  has deployed more than 300 BD Global Health Fellows to  short-term, in-country assignments.
","('Access_And_Affordability', 0.616528332233429)","('Employee_Engagement_Inclusion_And_Diversity', 0.07764973491430283)","('Product_Quality_And_Safety', 0.029946742579340935)","(['Health Outcome Contribution'], 0.616528332233429)","('NON-ESG', 0.07764973491430283)","('NON-ESG', 0.029946742579340935)"
Line 837,"In the current phase, which  launched in 2018, the partnership is working in 39 laboratories  across six countries where, to date, BD fellows have conducted  28 mentorships, resulting in improved laboratory quality  assessment scores.
","('Product_Quality_And_Safety', 0.2513156235218048)","('Access_And_Affordability', 0.16315868496894836)","('Management_Of_Legal_And_Regulatory_Framework', 0.11039368808269501)","('NON-ESG', 0.2513156235218048)","('NON-ESG', 0.16315868496894836)","('NON-ESG', 0.11039368808269501)"
Line 838,"Through the program, lab assessment scores    across participating labs increased by at least 46% and as  high as 196%.
","('Access_And_Affordability', 0.357991099357605)","('Management_Of_Legal_And_Regulatory_Framework', 0.12950357794761658)","('Employee_Engagement_Inclusion_And_Diversity', 0.08672834932804108)","('NON-ESG', 0.357991099357605)","('NON-ESG', 0.12950357794761658)","('NON-ESG', 0.08672834932804108)"
Line 839,"In one country in Africa, the partnership established a Center of  Excellence (COE) in phlebotomy and equipment maintenance  (EM) in a region with high prevalence of HIV.
","('Employee_Health_And_Safety', 0.2220202535390854)","('Employee_Engagement_Inclusion_And_Diversity', 0.10394581407308578)","('Data_Security', 0.07611004263162613)","('NON-ESG', 0.2220202535390854)","('NON-ESG', 0.10394581407308578)","('NON-ESG', 0.07611004263162613)"
Line 840,"In India, the Labs for Life partnership also established a COE  in phlebotomy and EM at Government Medical College  (GMC) Aurangabad.
","('Access_And_Affordability', 0.665147602558136)","('Customer_Welfare', 0.031903691589832306)","('Employee_Engagement_Inclusion_And_Diversity', 0.02606513351202011)","(['Health Outcome Contribution'], 0.665147602558136)","('NON-ESG', 0.031903691589832306)","('NON-ESG', 0.02606513351202011)"
Line 841,"By FY 2020 about 220 lab personnel  and medical officers were trained on phlebotomy.
","('Employee_Health_And_Safety', 0.5438213348388672)","('Access_And_Affordability', 0.09360591322183609)","('Product_Quality_And_Safety', 0.043041013181209564)","(['Operational Eco-Efficiency'], 0.5438213348388672)","('NON-ESG', 0.09360591322183609)","('NON-ESG', 0.043041013181209564)"
Line 842,"Additionally, online educational content has been developed,  which has over 500,000 views from 91 countries.
","('Access_And_Affordability', 0.6288976669311523)","('Management_Of_Legal_And_Regulatory_Framework', 0.06551309674978256)","('Energy_Management', 0.03146880492568016)","(['Health Outcome Contribution'], 0.6288976669311523)","('NON-ESG', 0.06551309674978256)","('NON-ESG', 0.03146880492568016)"
Line 843,"BD has partnered with the William Davidson Institute (WDI) of  the University of Michigan to conduct our monitoring and  evaluation (M&E) of the program.“I could have never imagined that I    would be a BD Global Health Fellow in    Kenya, but BD made my wildest dream    come true! We helped a laboratory    operate more efficiently by improving    good documentation practices, building    a reliable inventory system and    emphasizing the importance of audits    and identifying nonconformities.
","('Business_Ethics', 0.26409244537353516)","('Systemic_Risk_Management', 0.19068394601345062)","('Management_Of_Legal_And_Regulatory_Framework', 0.13724254071712494)","('NON-ESG', 0.26409244537353516)","('NON-ESG', 0.19068394601345062)","('NON-ESG', 0.13724254071712494)"
Line 844,"BD, CDC and PEPFAR’s collaboration is    exceptional and makes the world    better one lab at a time.
","('Access_And_Affordability', 0.4276849031448364)","('Ecological_Impacts', 0.057973820716142654)","('Human_Rights_And_Community_Relations', 0.050911467522382736)","('NON-ESG', 0.4276849031448364)","('NON-ESG', 0.057973820716142654)","('NON-ESG', 0.050911467522382736)"
Line 845,"It was the    greatest experience.”       Gábor Oláh      (Quality Control Operations Supervisor, Kornye,      BD Hungary) Kenya, AccessInnovation Efficiency Empowerment Governance Laboratory leadership training in low- and middle-income countries At a time when clinical laboratories are under increased pressure  due to the COVID-19 pandemic, having strong leadership within  labs has become even more essential.
","('Employee_Engagement_Inclusion_And_Diversity', 0.17132800817489624)","('Access_And_Affordability', 0.11920993775129318)","('Systemic_Risk_Management', 0.09733480960130692)","('NON-ESG', 0.17132800817489624)","('NON-ESG', 0.11920993775129318)","('NON-ESG', 0.09733480960130692)"
Line 846,"In 2020, as part of the  Labs for Life partnership, BD and the Association of Public  Health Laboratories (APHL), together with WDI, collaborated to  develop and offer an online laboratory leadership and management essentials training based on a curriculum  developed by APHL.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3409760296344757)","('Access_And_Affordability', 0.30844545364379883)","('Employee_Health_And_Safety', 0.042253557592630386)","('NON-ESG', 0.3409760296344757)","('NON-ESG', 0.30844545364379883)","('NON-ESG', 0.042253557592630386)"
Line 847,"This virtual eight-week course will be  offered via the ExtendEd platform in Q1 FY 2021 and aims to  strengthen laboratory managers’ skills and knowledge to  manage and lead clinical laboratories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.48676443099975586)","('Access_And_Affordability', 0.14664845168590546)","('Product_Quality_And_Safety', 0.03691471740603447)","('NON-ESG', 0.48676443099975586)","('NON-ESG', 0.14664845168590546)","('NON-ESG', 0.03691471740603447)"
Line 848,"Infection prevention in Kenya Needlestick injuries put both patients and healthcare workers  worldwide at increased risk of bloodborne pathogen exposure.
","('Employee_Health_And_Safety', 0.9758408665657043)","('Critical_Incident_Risk_Management', 0.004505650140345097)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015368866734206676)","(['Operational Eco-Efficiency'], 0.9758408665657043)","('NON-ESG', 0.004505650140345097)","('NON-ESG', 0.0015368866734206676)"
Line 849,"In Kenya, more than 20% of needlestick injuries occur from  starting IVs or connecting a syringe into an IV line.
","('Employee_Health_And_Safety', 0.9712591767311096)","('Critical_Incident_Risk_Management', 0.005115628708153963)","('Employee_Engagement_Inclusion_And_Diversity', 0.0025714535731822252)","(['Operational Eco-Efficiency'], 0.9712591767311096)","('NON-ESG', 0.005115628708153963)","('NON-ESG', 0.0025714535731822252)"
Line 850,"To address  this safety issue, BD in collaboration with PEPFAR, CDC and the  Kenya Ministry of Health (MOH) signed a memorandum of  understanding (MOU) in 2018 for an infection prevention  partnership.
","('Product_Quality_And_Safety', 0.4190004765987396)","('Employee_Health_And_Safety', 0.3557988405227661)","('Access_And_Affordability', 0.028294477611780167)","('NON-ESG', 0.4190004765987396)","('NON-ESG', 0.3557988405227661)","('NON-ESG', 0.028294477611780167)"
Line 851,"The objective of the Kenya Infection Prevention  Global Collaboration for Advancement (KINGA) partnership is  to improve the safety of both patients and healthcare workers  during injections, infusion and blood collection procedures.
","('Employee_Health_And_Safety', 0.8806157112121582)","('Product_Quality_And_Safety', 0.01428201049566269)","('Critical_Incident_Risk_Management', 0.011277503333985806)","(['Operational Eco-Efficiency'], 0.8806157112121582)","('NON-ESG', 0.01428201049566269)","('NON-ESG', 0.011277503333985806)"
Line 852,"Program activities commenced in 2019 with observational  assessments at nine hospitals to understand injection and  infusion practices.
","('Access_And_Affordability', 0.20067758858203888)","('Employee_Health_And_Safety', 0.15793442726135254)","('Customer_Welfare', 0.11990396678447723)","('NON-ESG', 0.20067758858203888)","('NON-ESG', 0.15793442726135254)","('NON-ESG', 0.11990396678447723)"
Line 853,"BD Global Health trained 29 BD associates  from around the world to serve as BD Global Health Fellows to  perform key in-country activities, including the assessments.
","('Access_And_Affordability', 0.3248293995857239)","('Employee_Health_And_Safety', 0.10015315562486649)","('Systemic_Risk_Management', 0.06501501798629761)","('NON-ESG', 0.3248293995857239)","('NON-ESG', 0.10015315562486649)","('NON-ESG', 0.06501501798629761)"
Line 854,"Fellows and local KINGA staff followed hundreds of patients to  complete over 2,500 observations of injections, peripheral IV  insertions and starts, medication administration, as well as care  and maintenance of the peripheral IV lines.
","('Access_And_Affordability', 0.27149298787117004)","('Employee_Health_And_Safety', 0.1617777794599533)","('Customer_Welfare', 0.09120956063270569)","('NON-ESG', 0.27149298787117004)","('NON-ESG', 0.1617777794599533)","('NON-ESG', 0.09120956063270569)"
Line 855,"Following the  observations, BD and partners developed a training curriculum   that addresses the gaps identified and emphasizes best practices.
","('Access_And_Affordability', 0.5225211381912231)","('Employee_Engagement_Inclusion_And_Diversity', 0.08740249276161194)","('Product_Quality_And_Safety', 0.06456518918275833)","(['Health Outcome Contribution'], 0.5225211381912231)","('NON-ESG', 0.08740249276161194)","('NON-ESG', 0.06456518918275833)"
Line 856,"In 2021, Kenyan healthcare workers at the target facilities will  receive an adapted training that incorporates both virtual and  in-person content to account for the COVID-19 pandemic.
","('Employee_Health_And_Safety', 0.6230856776237488)","('Labor_Practices', 0.07407335191965103)","('Critical_Incident_Risk_Management', 0.05023326352238655)","(['Operational Eco-Efficiency'], 0.6230856776237488)","('NON-ESG', 0.07407335191965103)","('NON-ESG', 0.05023326352238655)"
Line 857,"BD Global Health Fellows based in their home countries will  support the train-the-trainer training sessions virtually, and local  KINGA and BD associates will lead the hands-on skills practice in  Kenya.
","('Access_And_Affordability', 0.6848065853118896)","('Employee_Health_And_Safety', 0.05431932210922241)","('Product_Quality_And_Safety', 0.0432601198554039)","(['Health Outcome Contribution'], 0.6848065853118896)","('NON-ESG', 0.05431932210922241)","('NON-ESG', 0.0432601198554039)"
Line 858,"This train-the-trainer session will be followed by in-facility  sessions and mentoring support to educate more healthcare  workers, thus expanding the program’s reach throughout the  nine facilities in Kenya.
","('Access_And_Affordability', 0.7787846326828003)","('Employee_Health_And_Safety', 0.048664893954992294)","('Employee_Engagement_Inclusion_And_Diversity', 0.0303655955940485)","(['Health Outcome Contribution'], 0.7787846326828003)","('NON-ESG', 0.048664893954992294)","('NON-ESG', 0.0303655955940485)"
Line 859,"In addition, the quality improvement project  of the KINGA partnership will introduce safety-engineered   BD Venflon ™ Pro Safety IV Catheter at all the target hospitals.
","('Product_Quality_And_Safety', 0.692804217338562)","('Employee_Health_And_Safety', 0.1310858130455017)","('Access_And_Affordability', 0.02834486775100231)","(['Product Quality & Recall Management'], 0.692804217338562)","('NON-ESG', 0.1310858130455017)","('NON-ESG', 0.02834486775100231)"
Line 860,"Recognizing the risks that healthcare workers face as a result of  needlestick injuries and exposure to blood, the partnership has  further supported the testing and vaccination of 3,000  healthcare workers against hepatitis B in the selected facilities.
","('Employee_Health_And_Safety', 0.9821987748146057)","('Employee_Engagement_Inclusion_And_Diversity', 0.001822350313887)","('Critical_Incident_Risk_Management', 0.001652565086260438)","(['Operational Eco-Efficiency'], 0.9821987748146057)","('NON-ESG', 0.001822350313887)","('NON-ESG', 0.001652565086260438)"
Line 861,"Endline   assessmentsQuality    improvement   observationFacility-based   mentoringTrain-the-   trainer sessionsBaseline   assessments1 2 3 4 AccessInnovation Efficiency Empowerment Governance Healthcare worker and patient safety in western China Over the last four years, BD and Project HOPE, an international  nonprofit for global health and disaster recovery, have  collaborated to reduce infusion-related infections among  healthcare workers and patients in four provinces in western  China.
","('Employee_Health_And_Safety', 0.9723473787307739)","('Critical_Incident_Risk_Management', 0.007314632646739483)","('Product_Quality_And_Safety', 0.0019037852762266994)","(['Operational Eco-Efficiency'], 0.9723473787307739)","('NON-ESG', 0.007314632646739483)","('NON-ESG', 0.0019037852762266994)"
Line 862,"A total of 16 hospitals are included in the partnership  that targets outpatient, ICU, obstetrics, surgery, oncology,  pediatrics and endocrinology units.
","('Access_And_Affordability', 0.638931930065155)","('Employee_Engagement_Inclusion_And_Diversity', 0.0641082227230072)","('Employee_Health_And_Safety', 0.037693433463573456)","(['Health Outcome Contribution'], 0.638931930065155)","('NON-ESG', 0.0641082227230072)","('NON-ESG', 0.037693433463573456)"
Line 863,"At the start of the program,  over 2,000 observations of peripheral IV catheter insertions and  practices of care and maintenance were conducted to assess  practices at baseline.
","('Employee_Health_And_Safety', 0.39776021242141724)","('Access_And_Affordability', 0.298476904630661)","('Employee_Engagement_Inclusion_And_Diversity', 0.03642651066184044)","('NON-ESG', 0.39776021242141724)","('NON-ESG', 0.298476904630661)","('NON-ESG', 0.03642651066184044)"
Line 864,"Based on the insights made during the  observations, a training curriculum was developed to address  gaps in peripheral IV practice and maintenance while  reinforcing best practices.
","('Access_And_Affordability', 0.3367992341518402)","('Product_Quality_And_Safety', 0.10384513437747955)","('Employee_Engagement_Inclusion_And_Diversity', 0.08349709212779999)","('NON-ESG', 0.3367992341518402)","('NON-ESG', 0.10384513437747955)","('NON-ESG', 0.08349709212779999)"
Line 865,"Over 2,200 nurses and 30 nursing  students were trained through the partnership’s train-the-trainer  model in the first two years of the program.
","('Access_And_Affordability', 0.6751421093940735)","('Employee_Health_And_Safety', 0.06488379836082458)","('Employee_Engagement_Inclusion_And_Diversity', 0.05313359573483467)","(['Health Outcome Contribution'], 0.6751421093940735)","('NON-ESG', 0.06488379836082458)","('NON-ESG', 0.05313359573483467)"
Line 866,"Year three of the partnership commenced in 2020 at the start  of the COVID-19 pandemic.
","('Physical_Impacts_Of_Climate_Change', 0.4793626666069031)","('Air_Quality', 0.059744928032159805)","('Critical_Incident_Risk_Management', 0.05860181897878647)","('NON-ESG', 0.4793626666069031)","('NON-ESG', 0.059744928032159805)","('NON-ESG', 0.05860181897878647)"
Line 867,"To assure continuity of program  activities during the pandemic, trainings transitioned to an  online platform.
","('Access_And_Affordability', 0.23681221902370453)","('Critical_Incident_Risk_Management', 0.23043224215507507)","('Systemic_Risk_Management', 0.09218917042016983)","('NON-ESG', 0.23681221902370453)","('NON-ESG', 0.23043224215507507)","('NON-ESG', 0.09218917042016983)"
Line 868,"BD and Project HOPE invited local faculty to  record nine online videos that mirrored the curriculum for the in-person training workshops.
","('Access_And_Affordability', 0.35885241627693176)","('Employee_Engagement_Inclusion_And_Diversity', 0.2637396454811096)","('Product_Quality_And_Safety', 0.03313666582107544)","('NON-ESG', 0.35885241627693176)","('NON-ESG', 0.2637396454811096)","('NON-ESG', 0.03313666582107544)"
Line 869,"Each facility managed the rollout  of the training.
","('Access_And_Affordability', 0.1760474145412445)","('Employee_Engagement_Inclusion_And_Diversity', 0.109477698802948)","('Product_Quality_And_Safety', 0.07278081774711609)","('NON-ESG', 0.1760474145412445)","('NON-ESG', 0.109477698802948)","('NON-ESG', 0.07278081774711609)"
Line 870,"The nurses watched the online courses, and then  the local faculty led the practice session on site afterwards.
","('Access_And_Affordability', 0.22014501690864563)","('Management_Of_Legal_And_Regulatory_Framework', 0.1442326307296753)","('Employee_Engagement_Inclusion_And_Diversity', 0.1341194361448288)","('NON-ESG', 0.22014501690864563)","('NON-ESG', 0.1442326307296753)","('NON-ESG', 0.1341194361448288)"
Line 871,"The new online structure expanded the reach of the program,  resulting in an additional 1,827 nurses trained.
","('Access_And_Affordability', 0.5393086671829224)","('Employee_Engagement_Inclusion_And_Diversity', 0.11519256234169006)","('Employee_Health_And_Safety', 0.03573282063007355)","(['Health Outcome Contribution'], 0.5393086671829224)","('NON-ESG', 0.11519256234169006)","('NON-ESG', 0.03573282063007355)"
Line 872,"To date, over  4,000 nurses have been trained since the program’s inception.
","('Access_And_Affordability', 0.36228325963020325)","('Employee_Health_And_Safety', 0.12366922199726105)","('Employee_Engagement_Inclusion_And_Diversity', 0.10036980360746384)","('NON-ESG', 0.36228325963020325)","('NON-ESG', 0.12366922199726105)","('NON-ESG', 0.10036980360746384)"
Line 873,"Additional nurses will be trained as the partnership concludes  in 2021.
","('Access_And_Affordability', 0.41980674862861633)","('Employee_Health_And_Safety', 0.17903846502304077)","('Critical_Incident_Risk_Management', 0.06138728931546211)","('NON-ESG', 0.41980674862861633)","('NON-ESG', 0.17903846502304077)","('NON-ESG', 0.06138728931546211)"
Line 874,"Devex Content Series   —BD and Devex, a global development  media platform, have collaborated on two dedicated digital  platforms that draw awareness to important global health  issues.
","('Employee_Health_And_Safety', 0.5148035287857056)","('Access_And_Affordability', 0.13825549185276031)","('Critical_Incident_Risk_Management', 0.07358068972826004)","(['Operational Eco-Efficiency'], 0.5148035287857056)","('NON-ESG', 0.13825549185276031)","('NON-ESG', 0.07358068972826004)"
Line 875,"The first called “Safety First” explores the challenges at  the heart of needlestick and sharps safety and highlights  promising efforts to ensure patient and healthcare worker  safety in hospitals and clinics around the world.Advanced HIV Disease: Know Your Count  is the second  digital platform by BD and Devex.
","('Employee_Health_And_Safety', 0.9575135707855225)","('Product_Quality_And_Safety', 0.010829477570950985)","('Critical_Incident_Risk_Management', 0.003198685124516487)","(['Operational Eco-Efficiency'], 0.9575135707855225)","('NON-ESG', 0.010829477570950985)","('NON-ESG', 0.003198685124516487)"
Line 876,"The partnership explores the  reasons why mortality from advanced HIV disease (AHD)  persists when diagnostic services and treatments are available.
","('Employee_Health_And_Safety', 0.33759716153144836)","('Access_And_Affordability', 0.24390794336795807)","('Product_Quality_And_Safety', 0.08837627619504929)","('NON-ESG', 0.33759716153144836)","('NON-ESG', 0.24390794336795807)","('NON-ESG', 0.08837627619504929)"
Line 877,"It calls on leaders in the HIV/AIDS field, like policymakers,  practitioners and people living with AHD, to share insights on  how to address AHD.
","('Access_And_Affordability', 0.610756516456604)","('Employee_Health_And_Safety', 0.1015787348151207)","('Human_Rights_And_Community_Relations', 0.041420478373765945)","(['Health Outcome Contribution'], 0.610756516456604)","('NON-ESG', 0.1015787348151207)","('NON-ESG', 0.041420478373765945)"
Line 878,"Early diagnosis, treatment and access to  services are just some of the ways.
","('Access_And_Affordability', 0.8839432597160339)","('Product_Quality_And_Safety', 0.015739720314741135)","('Employee_Health_And_Safety', 0.012037377804517746)","(['Health Outcome Contribution'], 0.8839432597160339)","('NON-ESG', 0.015739720314741135)","('NON-ESG', 0.012037377804517746)"
Line 879,"AccessInnovation Efficiency Empowerment Governance Making STRIDES against drug-resistant TB in high-burden countries Dr. Richard Pfelz, BD–Baltimore, undertaking the assessment.Lack of access to reliable drug-susceptibility testing (DST) is a critical public health challenge posed by drug-resistant forms of  tuberculosis.
","('Access_And_Affordability', 0.3248539865016937)","('Product_Quality_And_Safety', 0.2005903720855713)","('Systemic_Risk_Management', 0.0669148787856102)","('NON-ESG', 0.3248539865016937)","('NON-ESG', 0.2005903720855713)","('NON-ESG', 0.0669148787856102)"
Line 880,"On average, it is estimated that 50% of those in need of second-line drug-susceptibility testing in high-burden countries  do not receive it.
","('Product_Quality_And_Safety', 0.38014712929725647)","('Customer_Welfare', 0.0983203873038292)","('Access_And_Affordability', 0.08396679162979126)","('NON-ESG', 0.38014712929725647)","('NON-ESG', 0.0983203873038292)","('NON-ESG', 0.08396679162979126)"
Line 881,"To better understand the barriers that stand in the way of patient access to this life-saving test, BD and the U.S. Agency for  International Development (USAID) formed a partnership in 2018, called STRIDES (Strengthening TB Resistance Testing and  Diagnostic Systems).
","('Access_And_Affordability', 0.7412680983543396)","('Product_Quality_And_Safety', 0.04734007641673088)","('Employee_Health_And_Safety', 0.03275367617607117)","(['Health Outcome Contribution'], 0.7412680983543396)","('NON-ESG', 0.04734007641673088)","('NON-ESG', 0.03275367617607117)"
Line 882,"As part of the partnership, BD and USAID are working in India in collaboration with the National TB Elimination  Program (NTEP) to improve access to and increase capacity for liquid culture and drug-susceptibility testing (LC/DST) across 55 public  sector labs.
","('Product_Quality_And_Safety', 0.20003624260425568)","('Access_And_Affordability', 0.17391172051429749)","('Customer_Welfare', 0.10572652518749237)","('NON-ESG', 0.20003624260425568)","('NON-ESG', 0.17391172051429749)","('NON-ESG', 0.10572652518749237)"
Line 883,"Key highlights of this partnership achieved by end of FY 2020 include:  Assessment of liquid culture (LC) and drug susceptibility  testing (DST) labs:  Ten key public sector labs across different  cities have been assessed by BD experts on various aspects of  lab and quality management, including processes followed   (i.e., testing, sample management), documentation practices  and availability of adequate infrastructure.
","('Product_Quality_And_Safety', 0.4052088260650635)","('Business_Ethics', 0.07676650583744049)","('Management_Of_Legal_And_Regulatory_Framework', 0.0636071041226387)","('NON-ESG', 0.4052088260650635)","('NON-ESG', 0.07676650583744049)","('NON-ESG', 0.0636071041226387)"
Line 884,"BD developed a standardized checklist, which was approved by NTEP, WHO and  national experts for use during lab assessments.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5634922385215759)","('Competitive_Behavior', 0.07658469676971436)","('Business_Ethics', 0.05443041771650314)","(['Corporate Governance'], 0.5634922385215759)","('NON-ESG', 0.07658469676971436)","('NON-ESG', 0.05443041771650314)"
Line 885,"Results from  these assessments were shared with all labs in debriefing  meetings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6856518387794495)","('Access_And_Affordability', 0.04083358123898506)","('Business_Ethics', 0.03450489416718483)","(['Corporate Governance'], 0.6856518387794495)","('NON-ESG', 0.04083358123898506)","('NON-ESG', 0.03450489416718483)"
Line 886,"Based on the discussions, BD developed specific  action plans for each lab containing short-, medium- and  long-term action items.
","('Management_Of_Legal_And_Regulatory_Framework', 0.45453426241874695)","('Business_Model_Resilience', 0.1111757904291153)","('Human_Rights_And_Community_Relations', 0.0641125813126564)","('NON-ESG', 0.45453426241874695)","('NON-ESG', 0.1111757904291153)","('NON-ESG', 0.0641125813126564)"
Line 887,"Training and capacity building:  BD trained microbiologists  from 31 public sector labs on best practices in LC/DST, which   led to a 25% to 40% increase in knowledge and skill levels.
","('Employee_Engagement_Inclusion_And_Diversity', 0.707495927810669)","('Access_And_Affordability', 0.08453378081321716)","('Employee_Health_And_Safety', 0.035575952380895615)","(['Human Capital Development'], 0.707495927810669)","('NON-ESG', 0.08453378081321716)","('NON-ESG', 0.035575952380895615)"
Line 888,"A follow-up skill assessment was conducted at a subset of ten labs  wherein 94 laboratory personnel were interviewed.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8138779997825623)","('Labor_Practices', 0.04769019037485123)","('Employee_Health_And_Safety', 0.019313523545861244)","(['Human Capital Development'], 0.8138779997825623)","('NON-ESG', 0.04769019037485123)","('NON-ESG', 0.019313523545861244)"
Line 889,"During this  assessment, it was found that overall knowledge scores from the  original training were retained, highlighting the effectiveness of  the training.
","('Access_And_Affordability', 0.2166454941034317)","('Product_Quality_And_Safety', 0.15311235189437866)","('Employee_Engagement_Inclusion_And_Diversity', 0.10499269515275955)","('NON-ESG', 0.2166454941034317)","('NON-ESG', 0.15311235189437866)","('NON-ESG', 0.10499269515275955)"
Line 890,"Based on the findings from the skill assessment,  targeted classroom and hands-on training was organized at the  ten labs to train 63 lab personnel on gaps observed.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8089135885238647)","('Access_And_Affordability', 0.035095371305942535)","('Employee_Health_And_Safety', 0.03144194185733795)","(['Human Capital Development'], 0.8089135885238647)","('NON-ESG', 0.035095371305942535)","('NON-ESG', 0.03144194185733795)"
Line 891,"AccessInnovation Efficiency Empowerment Governance BD and USAID also partnered with  an award-winning documentary  filmmaker in India to launch “TB  Talk Unmasked,”  a platform  through which policymakers, TB survivors and treating  physicians can share their unique stories and  perspectives.
","('Access_And_Affordability', 0.2645314037799835)","('Employee_Health_And_Safety', 0.09739411622285843)","('Systemic_Risk_Management', 0.08037695288658142)","('NON-ESG', 0.2645314037799835)","('NON-ESG', 0.09739411622285843)","('NON-ESG', 0.08037695288658142)"
Line 892,"At the 50th Union World Conference on Lung Health in  Hyderabad, USAID honored BD for its commitment to  strengthening the national TB program in India.
","('Employee_Health_And_Safety', 0.5705129504203796)","('Access_And_Affordability', 0.15552161633968353)","('Product_Quality_And_Safety', 0.029755525290966034)","(['Operational Eco-Efficiency'], 0.5705129504203796)","('NON-ESG', 0.15552161633968353)","('NON-ESG', 0.029755525290966034)"
Line 893,"In FY 2019, BD signed a memorandum of  understanding with USAID to expand the STRIDES  program to Indonesia with the goal of working across  four national labs and 15 labs that are part of   the country’s TB diagnostics network.Strengthening Specimen Referral System:  BD conducted  field assessments to identify gaps in TB diagnostics management  and observed suboptimal visibility in specimen movement as one  of the key gaps impacting patient outcomes.
","('Employee_Health_And_Safety', 0.24592304229736328)","('Access_And_Affordability', 0.22434435784816742)","('Product_Quality_And_Safety', 0.0699349120259285)","('NON-ESG', 0.24592304229736328)","('NON-ESG', 0.22434435784816742)","('NON-ESG', 0.0699349120259285)"
Line 894,"BD worked to  develop a solution framework for addressing this gap.
","('Management_Of_Legal_And_Regulatory_Framework', 0.18221476674079895)","('Systemic_Risk_Management', 0.14977170526981354)","('Access_And_Affordability', 0.13624489307403564)","('NON-ESG', 0.18221476674079895)","('NON-ESG', 0.14977170526981354)","('NON-ESG', 0.13624489307403564)"
Line 895,"Currently, in collaboration with NTEP, BD is supporting development of an  integrated module in the Nikshay application (used by NTEP for  end-to-end management of patients) to track the movement of a  sample and help reduce turnaround time from sample collection  to diagnosis and treatment.
","('Access_And_Affordability', 0.3574254512786865)","('Customer_Welfare', 0.1273861974477768)","('Selling_Practices_And_Product_Labeling', 0.07039957493543625)","('NON-ESG', 0.3574254512786865)","('NON-ESG', 0.1273861974477768)","('NON-ESG', 0.07039957493543625)"
Line 896,"“Under BD-USAID partnership     STRIDES, we have been able to     conduct lab assessments and     laboratory staff’s trainings at our     public sector Liquid Culture and Drug     Susceptibility Testing laboratories,     which is critical to the National     Tuberculosis Elimination Program.
","('Product_Quality_And_Safety', 0.24898682534694672)","('Customer_Welfare', 0.12551867961883545)","('Competitive_Behavior', 0.08804605901241302)","('NON-ESG', 0.24898682534694672)","('NON-ESG', 0.12551867961883545)","('NON-ESG', 0.08804605901241302)"
Line 897,"STRIDES team brings niche skills and     technical expertise to the table.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5288457870483398)","('Business_Model_Resilience', 0.06370322406291962)","('Supply_Chain_Management', 0.05927593261003494)","(['Human Capital Development'], 0.5288457870483398)","('NON-ESG', 0.06370322406291962)","('NON-ESG', 0.05927593261003494)"
Line 898,"We  look forward to continuing the     collaboration with STRIDES team to     achieve the goal of eliminating TB     from India by 2025.”           Dr. Nishant      Central TB Division      Ministry of Health, IndiaTM AccessInnovation Efficiency Empowerment Governance Innovative partnerships to strengthen lab systems and combat AMR BD has formed several innovative partnerships with leading health agencies and NGOs, each of which aims to raise awareness of this  growing global threat; better understand the scale and scope of the challenge; help reduce the risk of infection and drive optimal  antimicrobial use—particularly in low- and middle-income countries.AMR Educating and advocating for AMR Global experts have identified several challenges that low- and  middle-income countries face when addressing AMR.
","('Employee_Health_And_Safety', 0.21701650321483612)","('Access_And_Affordability', 0.13353142142295837)","('Systemic_Risk_Management', 0.0936594307422638)","('NON-ESG', 0.21701650321483612)","('NON-ESG', 0.13353142142295837)","('NON-ESG', 0.0936594307422638)"
Line 899,"We  look forward to continuing the     collaboration with STRIDES team to     achieve the goal of eliminating TB     from India by 2025.”           Dr. Nishant      Central TB Division      Ministry of Health, IndiaTM AccessInnovation Efficiency Empowerment Governance Innovative partnerships to strengthen lab systems and combat AMR BD has formed several innovative partnerships with leading health agencies and NGOs, each of which aims to raise awareness of this  growing global threat; better understand the scale and scope of the challenge; help reduce the risk of infection and drive optimal  antimicrobial use—particularly in low- and middle-income countries.AMR Educating and advocating for AMR Global experts have identified several challenges that low- and  middle-income countries face when addressing AMR.
","('Access_And_Affordability', 0.20488031208515167)","('Employee_Health_And_Safety', 0.1748792976140976)","('Systemic_Risk_Management', 0.08743695169687271)","('NON-ESG', 0.20488031208515167)","('NON-ESG', 0.1748792976140976)","('NON-ESG', 0.08743695169687271)"
Line 900,"There are  too few trained microbiologists, few health facilities that  routinely undertake bacterial culture and still fewer facilities that  meet the requirements for accreditation.
","('Product_Quality_And_Safety', 0.12401029467582703)","('Ecological_Impacts', 0.1165437400341034)","('Customer_Welfare', 0.11408606916666031)","('NON-ESG', 0.12401029467582703)","('NON-ESG', 0.1165437400341034)","('NON-ESG', 0.11408606916666031)"
Line 901,"To respond to these challenges, BD and The London School of  Hygiene & Tropical Medicine, together with a global advisory  group of experts, partnered to create the Massive Open Online  Course (MOOC) that educates participants about how  diagnostics can be leveraged to reduce the inappropriate use of  antibiotics, screen patients with resistant bacteria in healthcare  settings, and monitor AMR trends and the effectiveness of  antibiotic stewardship strategies.
","('Customer_Welfare', 0.26773473620414734)","('Selling_Practices_And_Product_Labeling', 0.17634478211402893)","('Access_And_Affordability', 0.09252224862575531)","('NON-ESG', 0.26773473620414734)","('NON-ESG', 0.17634478211402893)","('NON-ESG', 0.09252224862575531)"
Line 902,"The course was publicly available and offered in collaboration  with leading regional organizations to assure learning is widely  scaled.
","('Access_And_Affordability', 0.26437613368034363)","('Employee_Engagement_Inclusion_And_Diversity', 0.11774885654449463)","('Management_Of_Legal_And_Regulatory_Framework', 0.11636938154697418)","('NON-ESG', 0.26437613368034363)","('NON-ESG', 0.11774885654449463)","('NON-ESG', 0.11636938154697418)"
Line 903,"These organizations include: the Indian Council of  Medical Research (ICMR), ALADDiV (Latin American Alliance  for the Development of In Vitro Diagnostics); the Philippine  Society of Microbiology and Infectious Diseases (PSMID);   the Interregional Association for Clinical Microbiology and  Antimicrobial Chemotherapy (IACMAC) of the Russian  Federation; and the Chinese Academy of Laboratory Medicine  Education (CALME).
","('Access_And_Affordability', 0.27785125374794006)","('Customer_Welfare', 0.10234851390123367)","('Ecological_Impacts', 0.10049407929182053)","('NON-ESG', 0.27785125374794006)","('NON-ESG', 0.10234851390123367)","('NON-ESG', 0.10049407929182053)"
Line 904,"This course, which launched in 2019 and is available in six  languages, has since reached 13,000 participants in over  100 countries.Expanding capacity for AMR diagnostics in low- and  middle-income countries.
","('Access_And_Affordability', 0.7215790152549744)","('Human_Rights_And_Community_Relations', 0.04141489788889885)","('Management_Of_Legal_And_Regulatory_Framework', 0.034839604049921036)","(['Health Outcome Contribution'], 0.7215790152549744)","('NON-ESG', 0.04141489788889885)","('NON-ESG', 0.034839604049921036)"
Line 905,"The Fleming Fund, a U.K. aid program, provides grants to  improve the surveillance of AMR and generates relevant data  that is shared nationally and globally.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7392146587371826)","('Access_And_Affordability', 0.03928585350513458)","('Human_Rights_And_Community_Relations', 0.021081628277897835)","(['Corporate Governance'], 0.7392146587371826)","('NON-ESG', 0.03928585350513458)","('NON-ESG', 0.021081628277897835)"
Line 906,"In 2019, The Fleming  Fund awarded grants to diagnostic sector companies for  strengthening laboratory systems in 24 countries in sub-Saharan  Africa and Asia.
","('Access_And_Affordability', 0.37556254863739014)","('Management_Of_Legal_And_Regulatory_Framework', 0.08028716593980789)","('GHG_Emissions', 0.0717373788356781)","('NON-ESG', 0.37556254863739014)","('NON-ESG', 0.08028716593980789)","('NON-ESG', 0.0717373788356781)"
Line 907,"BD was awarded grants to expand its  automated blood culture and identification and antimicrobial  susceptibility testing (ID/AST) technologies to help strengthen  laboratory systems for combating AMR in 19 of the 24 countries.
","('Selling_Practices_And_Product_Labeling', 0.16310887038707733)","('Customer_Welfare', 0.14443500339984894)","('Product_Quality_And_Safety', 0.12958082556724548)","('NON-ESG', 0.16310887038707733)","('NON-ESG', 0.14443500339984894)","('NON-ESG', 0.12958082556724548)"
Line 908,"Since the award, our AMR solutions continue to be placed in  countries with limited or no prior experience of using diagnostics  to address AMR.
","('Access_And_Affordability', 0.24729947745800018)","('Product_Quality_And_Safety', 0.11933016777038574)","('Customer_Welfare', 0.11093102395534515)","('NON-ESG', 0.24729947745800018)","('NON-ESG', 0.11933016777038574)","('NON-ESG', 0.11093102395534515)"
Line 909,"In 2020, instruments were rolled out in nine  countries in sub-Saharan Africa and Asia.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3980671465396881)","('Business_Model_Resilience', 0.12751801311969757)","('Competitive_Behavior', 0.06191764771938324)","('NON-ESG', 0.3980671465396881)","('NON-ESG', 0.12751801311969757)","('NON-ESG', 0.06191764771938324)"
Line 910,"The additional  countries will be rolled out in 2021.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5827277302742004)","('Competitive_Behavior', 0.11160384118556976)","('Systemic_Risk_Management', 0.03099028579890728)","(['Corporate Governance'], 0.5827277302742004)","('NON-ESG', 0.11160384118556976)","('NON-ESG', 0.03099028579890728)"
Line 911,"Strengthening laboratory systems for performing   AMR-related laboratory tests.
","('Access_And_Affordability', 0.16564899682998657)","('Management_Of_Legal_And_Regulatory_Framework', 0.1456807404756546)","('Competitive_Behavior', 0.09751978516578674)","('NON-ESG', 0.16564899682998657)","('NON-ESG', 0.1456807404756546)","('NON-ESG', 0.09751978516578674)"
Line 912,"To further strengthen capacities to combat AMR at both an  individual laboratory level and across national laboratory  systems, in FY 2019 BD partnered with the Foundation for  Innovative New Diagnostics (FIND), a Geneva-based NGO, to  develop the new AMR scorecard for lab quality improvement.
","('Product_Quality_And_Safety', 0.43442869186401367)","('Employee_Health_And_Safety', 0.06388269364833832)","('Access_And_Affordability', 0.06217736005783081)","('NON-ESG', 0.43442869186401367)","('NON-ESG', 0.06388269364833832)","('NON-ESG', 0.06217736005783081)"
Line 913,"BD piloted this new AMR tool in collaboration with FIND in five  countries—Vietnam, Cameroon, Kenya, Ethiopia and Uganda.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5117105841636658)","('Human_Rights_And_Community_Relations', 0.1435738205909729)","('Ecological_Impacts', 0.05139659717679024)","(['Corporate Governance'], 0.5117105841636658)","('NON-ESG', 0.1435738205909729)","('NON-ESG', 0.05139659717679024)"
Line 914,"The final version will be launched in FY 2021 in collaboration  with the African Society for Laboratory Medicine (ASLM) and  Africa CDC.
","('Access_And_Affordability', 0.18408259749412537)","('Management_Of_Legal_And_Regulatory_Framework', 0.16123665869235992)","('Ecological_Impacts', 0.13263212144374847)","('NON-ESG', 0.18408259749412537)","('NON-ESG', 0.16123665869235992)","('NON-ESG', 0.13263212144374847)"
Line 915,"An awareness and education campaign will begin in  FY 2021 in collaboration with all partners to include training  assessors on how to best utilize the scorecard.
","('Access_And_Affordability', 0.5703315138816833)","('Management_Of_Legal_And_Regulatory_Framework', 0.12464984506368637)","('Product_Quality_And_Safety', 0.05832350254058838)","(['Health Outcome Contribution'], 0.5703315138816833)","('NON-ESG', 0.12464984506368637)","('NON-ESG', 0.05832350254058838)"
Line 916,"In India, BD has been in discussions with government  stakeholders and relevant partners for rollout of the scorecard at  several public sector facilities, but experienced delays in FY 2020  due to COVID-19 pandemic-related issues.
","('Physical_Impacts_Of_Climate_Change', 0.42337051033973694)","('Systemic_Risk_Management', 0.12735514342784882)","('Critical_Incident_Risk_Management', 0.06393621116876602)","('NON-ESG', 0.42337051033973694)","('NON-ESG', 0.12735514342784882)","('NON-ESG', 0.06393621116876602)"
Line 917,"AccessInnovation Efficiency Empowerment Governance Reference 1 Sreemathy BB, Menon SPS, Kumari ARPV, et al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.33059683442115784)","('Business_Model_Resilience', 0.09968923032283783)","('Competitive_Behavior', 0.09528099000453949)","('NON-ESG', 0.33059683442115784)","('NON-ESG', 0.09968923032283783)","('NON-ESG', 0.09528099000453949)"
Line 918,"Impact of sepsis management project on rational use of antibiotics in presumed  and probable neonatal sepsis - a retrospective comparative study.
","('Employee_Health_And_Safety', 0.4072011411190033)","('Access_And_Affordability', 0.21381577849388123)","('Product_Quality_And_Safety', 0.07391051203012466)","('NON-ESG', 0.4072011411190033)","('NON-ESG', 0.21381577849388123)","('NON-ESG', 0.07391051203012466)"
Line 919,"J Evid Based Med Healthc.
","('Access_And_Affordability', 0.2945191562175751)","('Management_Of_Legal_And_Regulatory_Framework', 0.2331608682870865)","('Systemic_Risk_Management', 0.06349243223667145)","('NON-ESG', 0.2945191562175751)","('NON-ESG', 0.2331608682870865)","('NON-ESG', 0.06349243223667145)"
Line 920,"2020;7(36):1970-1975.The results showed that rational use of antibiotics increased  significantly after the project implementation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2043026238679886)","('Access_And_Affordability', 0.19769644737243652)","('Customer_Welfare', 0.12020950019359589)","('NON-ESG', 0.2043026238679886)","('NON-ESG', 0.19769644737243652)","('NON-ESG', 0.12020950019359589)"
Line 921,"Use of ampicillin  and amikacin as first-line antibiotic increased from 80% to 91%  and use of cefotaxime as first-line decreased from 18% to 7%.
","('Customer_Welfare', 0.37380409240722656)","('Selling_Practices_And_Product_Labeling', 0.19207367300987244)","('Competitive_Behavior', 0.0794406309723854)","('NON-ESG', 0.37380409240722656)","('NON-ESG', 0.19207367300987244)","('NON-ESG', 0.0794406309723854)"
Line 922,"At the same time, average length of stay in the hospital for the  patients decreased from 7.2 to 5.4 days after implementation of  the project.
","('Access_And_Affordability', 0.6199626326560974)","('Employee_Health_And_Safety', 0.04460453987121582)","('Energy_Management', 0.039659541100263596)","(['Health Outcome Contribution'], 0.6199626326560974)","('NON-ESG', 0.04460453987121582)","('NON-ESG', 0.039659541100263596)"
Line 923,"Number of days for which antibiotics were given to  neonates were also reduced significantly.1  Based on the success of this initiative, the MOH decided to  expand access to these technologies to 13 surrounding primary  and secondary hospitals through an innovative Hub and Spoke  model wherein samples are moved to GH Ernakulum for testing.
","('Access_And_Affordability', 0.7689380645751953)","('Product_Quality_And_Safety', 0.02908693253993988)","('Customer_Welfare', 0.028254296630620956)","(['Health Outcome Contribution'], 0.7689380645751953)","('NON-ESG', 0.02908693253993988)","('NON-ESG', 0.028254296630620956)"
Line 924,"Sepsis Management Program, Kerala In India, BD partnered with the Ministry of Health (MOH) in  Kerala to increase access to automated blood culture and  identification and antibiotic susceptibility technologies (ID/AST)  at a secondary public sector hospital—Government Hospital  (GH), Ernakulum.
","('Access_And_Affordability', 0.20076607167720795)","('Selling_Practices_And_Product_Labeling', 0.12422804534435272)","('Customer_Welfare', 0.12368616461753845)","('NON-ESG', 0.20076607167720795)","('NON-ESG', 0.12422804534435272)","('NON-ESG', 0.12368616461753845)"
Line 925,"Bacterial sepsis is the leading cause of  neonatal deaths.
","('Employee_Health_And_Safety', 0.6061522960662842)","('Access_And_Affordability', 0.06604207307100296)","('Product_Quality_And_Safety', 0.043785665184259415)","(['Operational Eco-Efficiency'], 0.6061522960662842)","('NON-ESG', 0.06604207307100296)","('NON-ESG', 0.043785665184259415)"
Line 926,"With 3.8% incidence of neonatal sepsis and  neonatal mortality rate of 28/1,000 lives births, India accounts  for 30% of the neonatal deaths globally.
","('Employee_Health_And_Safety', 0.558716356754303)","('Access_And_Affordability', 0.22423961758613586)","('Critical_Incident_Risk_Management', 0.03152903914451599)","(['Operational Eco-Efficiency'], 0.558716356754303)","('NON-ESG', 0.22423961758613586)","('NON-ESG', 0.03152903914451599)"
Line 927,"The objective of the  project was to: 1) enable early diagnosis of sepsis to reduce  sepsis-related morbidity and mortality, while 2) providing  rational antimicrobial therapy to reduce AMR.
","('Employee_Health_And_Safety', 0.8915368914604187)","('Access_And_Affordability', 0.022767232730984688)","('Product_Quality_And_Safety', 0.01030194852501154)","(['Operational Eco-Efficiency'], 0.8915368914604187)","('NON-ESG', 0.022767232730984688)","('NON-ESG', 0.01030194852501154)"
Line 928,"7 days Others5 days6 daysProject impact on number of days antibiotics were given Baseline Endline 50%20% 21%9% 35%5% 9% 51% AccessInnovation Efficiency Empowerment Governance As part of this effort in emerging markets, BD increased the number of facilities (new facilities, a move to larger facilities or product  line expansions) and in employment in some key locations, detailed in the map below.Expansion in emerging manufacturing employment and facilities*,†2020 goal Further expand  BD manufacturing, product array and employment in emerging markets In the period of FY 2015 to FY 2020, BD saw emerging market revenue growth of over $600 million.
","('Product_Design_And_Lifecycle_Management', 0.6451170444488525)","('Supply_Chain_Management', 0.06764944642782211)","('Customer_Welfare', 0.04705885425209999)","(['Product Stewardship'], 0.6451170444488525)","('NON-ESG', 0.06764944642782211)","('NON-ESG', 0.04705885425209999)"
Line 929,"7 days Others5 days6 daysProject impact on number of days antibiotics were given Baseline Endline 50%20% 21%9% 35%5% 9% 51% AccessInnovation Efficiency Empowerment Governance As part of this effort in emerging markets, BD increased the number of facilities (new facilities, a move to larger facilities or product  line expansions) and in employment in some key locations, detailed in the map below.Expansion in emerging manufacturing employment and facilities*,†2020 goal Further expand  BD manufacturing, product array and employment in emerging markets In the period of FY 2015 to FY 2020, BD saw emerging market revenue growth of over $600 million.
","('Systemic_Risk_Management', 0.14193080365657806)","('Employee_Engagement_Inclusion_And_Diversity', 0.12649454176425934)","('Business_Model_Resilience', 0.11984502524137497)","('NON-ESG', 0.14193080365657806)","('NON-ESG', 0.12649454176425934)","('NON-ESG', 0.11984502524137497)"
Line 930,"Throughout this time, we  continued to pursue growth opportunities in emerging markets, which includes certain countries in Eastern Europe, the Middle East,  Africa, Latin America and Asia Pacific.Emerging market revenue growth Emerging market revenues (in billions) Malaysia    1,790 additional associate s 1 office location added 1 manufacturing location acquiredChile    140 additional associate s 1 office facility acquiredChinaChina    850 additional associate s 1 R&D center added 3 locations added or expired 4 manufacturing locations added,       acquired or expandedHungary    480 additional associate s 1 manufacturing location expanded India    650 additional associate s 2 R&D locations expanded 1 office location added 1 manufacturing location expandedIsraelIsrael    460 additional associate s 2 manufacturing locations acquired 1 office location acquiredPoland   660 additional associate s 2 office locations acquired or expanded South Africa    90 additional associate s 1 office location acquiredMexico    6,940 additional associate s 4 manufacturing locations       added, acquired or expanded * Associate numbers are rounded to the nearest ten.
","('Business_Model_Resilience', 0.4106833040714264)","('Systemic_Risk_Management', 0.2465837597846985)","('Competitive_Behavior', 0.09306415170431137)","('NON-ESG', 0.4106833040714264)","('NON-ESG', 0.2465837597846985)","('NON-ESG', 0.09306415170431137)"
Line 931,"Throughout this time, we  continued to pursue growth opportunities in emerging markets, which includes certain countries in Eastern Europe, the Middle East,  Africa, Latin America and Asia Pacific.Emerging market revenue growth Emerging market revenues (in billions) Malaysia    1,790 additional associate s 1 office location added 1 manufacturing location acquiredChile    140 additional associate s 1 office facility acquiredChinaChina    850 additional associate s 1 R&D center added 3 locations added or expired 4 manufacturing locations added,       acquired or expandedHungary    480 additional associate s 1 manufacturing location expanded India    650 additional associate s 2 R&D locations expanded 1 office location added 1 manufacturing location expandedIsraelIsrael    460 additional associate s 2 manufacturing locations acquired 1 office location acquiredPoland   660 additional associate s 2 office locations acquired or expanded South Africa    90 additional associate s 1 office location acquiredMexico    6,940 additional associate s 4 manufacturing locations       added, acquired or expanded * Associate numbers are rounded to the nearest ten.
","('Business_Model_Resilience', 0.27100151777267456)","('Employee_Engagement_Inclusion_And_Diversity', 0.1382037252187729)","('Systemic_Risk_Management', 0.11463438719511032)","('NON-ESG', 0.27100151777267456)","('NON-ESG', 0.1382037252187729)","('NON-ESG', 0.11463438719511032)"
Line 932,"Throughout this time, we  continued to pursue growth opportunities in emerging markets, which includes certain countries in Eastern Europe, the Middle East,  Africa, Latin America and Asia Pacific.Emerging market revenue growth Emerging market revenues (in billions) Malaysia    1,790 additional associate s 1 office location added 1 manufacturing location acquiredChile    140 additional associate s 1 office facility acquiredChinaChina    850 additional associate s 1 R&D center added 3 locations added or expired 4 manufacturing locations added,       acquired or expandedHungary    480 additional associate s 1 manufacturing location expanded India    650 additional associate s 2 R&D locations expanded 1 office location added 1 manufacturing location expandedIsraelIsrael    460 additional associate s 2 manufacturing locations acquired 1 office location acquiredPoland   660 additional associate s 2 office locations acquired or expanded South Africa    90 additional associate s 1 office location acquiredMexico    6,940 additional associate s 4 manufacturing locations       added, acquired or expanded * Associate numbers are rounded to the nearest ten.
","('Business_Model_Resilience', 0.27048832178115845)","('Systemic_Risk_Management', 0.17904022336006165)","('Employee_Engagement_Inclusion_And_Diversity', 0.09626197069883347)","('NON-ESG', 0.27048832178115845)","('NON-ESG', 0.17904022336006165)","('NON-ESG', 0.09626197069883347)"
Line 933,"† Increased employment is defined as adding over 75 associates to the total headcount in these countries from FY 2015 to FY 2020.2015 2016 2017 2018 2019 $1.8 $1.9 $1.95 $2.53 $2.71 $2.Foreign currency translation unfavorably impacted emerging market revenues in 2020 and 2019 by an estimated $100 million and $155 million, respectively.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23261070251464844)","('Systemic_Risk_Management', 0.1377505362033844)","('Labor_Practices', 0.10800237953662872)","('NON-ESG', 0.23261070251464844)","('NON-ESG', 0.1377505362033844)","('NON-ESG', 0.10800237953662872)"
Line 934,"Revenues in emerging markets in 2020 were unfavorably impacted by a decline in healthcare utilization as a result of the COVID-19 pandemic.
","('Systemic_Risk_Management', 0.5650812983512878)","('Supply_Chain_Management', 0.07698681950569153)","('Access_And_Affordability', 0.07599454373121262)","(['Risk & Crisis Management'], 0.5650812983512878)","('NON-ESG', 0.07698681950569153)","('NON-ESG', 0.07599454373121262)"
Line 935,"Revenues in   our BD Medical–Medication Delivery Solutions unit were also unfavorably impacted by a new volume-based procurement process which has been adopted   by several of China’s provinces.
","('Supply_Chain_Management', 0.15892599523067474)","('Customer_Welfare', 0.14865748584270477)","('Management_Of_Legal_And_Regulatory_Framework', 0.12818585336208344)","('NON-ESG', 0.15892599523067474)","('NON-ESG', 0.14865748584270477)","('NON-ESG', 0.12818585336208344)"
Line 936,"To date, the impact of these procurement initiatives to our revenues in China has been limited to our BD Medical–Medication  Delivery Solutions unit.
","('Product_Design_And_Lifecycle_Management', 0.3356642425060272)","('Customer_Welfare', 0.1978801190853119)","('Selling_Practices_And_Product_Labeling', 0.07382209599018097)","('NON-ESG', 0.3356642425060272)","('NON-ESG', 0.1978801190853119)","('NON-ESG', 0.07382209599018097)"
Line 937,"Emerging market revenue growth in 2019 was favorably impacted by the inclusion of revenues associated with Bard products in our  results for the first quarter of FY 2019, as noted above.
","('Product_Design_And_Lifecycle_Management', 0.9260386228561401)","('Customer_Welfare', 0.012502213008701801)","('Business_Model_Resilience', 0.008448994718492031)","(['Product Stewardship'], 0.9260386228561401)","('NON-ESG', 0.012502213008701801)","('NON-ESG', 0.008448994718492031)"
Line 938,"Underlying growth in 2019 was particularly driven by sales in China and EMA.
","('Business_Model_Resilience', 0.31415316462516785)","('Systemic_Risk_Management', 0.1529984474182129)","('Customer_Welfare', 0.0779261365532875)","('NON-ESG', 0.31415316462516785)","('NON-ESG', 0.1529984474182129)","('NON-ESG', 0.0779261365532875)"
Line 939,"Emerging market revenues in 2016 related to divested businesses, primarily the Respiratory Solutions business, were approximately $105 million.
","('Business_Model_Resilience', 0.4187583029270172)","('Systemic_Risk_Management', 0.17819568514823914)","('Supply_Chain_Management', 0.0724240317940712)","('NON-ESG', 0.4187583029270172)","('NON-ESG', 0.17819568514823914)","('NON-ESG', 0.0724240317940712)"
Line 940,"Unfavorable foreign currency translation impacted emerging market revenues in 2017 and 2016 by an estimated $29 million and $156 million, respectively.
","('Systemic_Risk_Management', 0.4273677170276642)","('Competitive_Behavior', 0.2269289493560791)","('Management_Of_Legal_And_Regulatory_Framework', 0.14668415486812592)","('NON-ESG', 0.4273677170276642)","('NON-ESG', 0.2269289493560791)","('NON-ESG', 0.14668415486812592)"
Line 941,"Emerging market revenue growth in 2017 was driven by sales in Greater Asia, including China, and Latin America.
","('Business_Model_Resilience', 0.48292621970176697)","('Systemic_Risk_Management', 0.12032996118068695)","('Competitive_Behavior', 0.11239499598741531)","('NON-ESG', 0.48292621970176697)","('NON-ESG', 0.12032996118068695)","('NON-ESG', 0.11239499598741531)"
Line 942,"Emerging market revenue growth in 2016  reflected the inclusion of CareFusion’s sales for the full fiscal year, as well as growth in China and Latin America, partially offset by declines in the Middle East   and Africa.
","('Systemic_Risk_Management', 0.40465906262397766)","('Business_Model_Resilience', 0.33056798577308655)","('Competitive_Behavior', 0.0661480501294136)","('NON-ESG', 0.40465906262397766)","('NON-ESG', 0.33056798577308655)","('NON-ESG', 0.0661480501294136)"
Line 943,"Access Innovation Efficiency Empowerment Governance We understand that the health of the planet is linked to the health of people, and reducing our impact  on the environment supports our Purpose of advancing the world of health™.
","('Human_Rights_And_Community_Relations', 0.5660584568977356)","('Access_And_Affordability', 0.18226227164268494)","('Ecological_Impacts', 0.0468854196369648)","(['Community Relations'], 0.5660584568977356)","('NON-ESG', 0.18226227164268494)","('NON-ESG', 0.0468854196369648)"
Line 944,"With continuing pressure  on natural resources and the predicted impacts of climate change, it is imperative that we continue to  increase the resilience of our operations and explore opportunities for environmental improvements  across our value chain.
","('Physical_Impacts_Of_Climate_Change', 0.5619404911994934)","('Business_Model_Resilience', 0.28684118390083313)","('Ecological_Impacts', 0.031597595661878586)","(['Climate Change'], 0.5619404911994934)","('NON-ESG', 0.28684118390083313)","('NON-ESG', 0.031597595661878586)"
Line 945,"By partnering more closely with suppliers, customers and peers, we can address  some of the world’s most pressing environmental issues more broadly than we could on our own.
","('Supply_Chain_Management', 0.8384873270988464)","('Physical_Impacts_Of_Climate_Change', 0.025136135518550873)","('Product_Design_And_Lifecycle_Management', 0.024193868041038513)","(['Supply Chain Management'], 0.8384873270988464)","('NON-ESG', 0.025136135518550873)","('NON-ESG', 0.024193868041038513)"
Line 946,"Efficiency Environmentally sound products and  resilient operations Status of performance against 2020 goals Since the launch of our 2020 goals in FY 2015, our business has  grown significantly through acquisition.
","('Product_Design_And_Lifecycle_Management', 0.8169664144515991)","('Business_Model_Resilience', 0.07739555090665817)","('Supply_Chain_Management', 0.018242230638861656)","(['Product Stewardship'], 0.8169664144515991)","('NON-ESG', 0.07739555090665817)","('NON-ESG', 0.018242230638861656)"
Line 947,"While these acquisitions  have impacted absolute emissions, we have continued to make progress in reducing our environmental footprint on a per unit  basis, through investments and continuous improvement.
","('GHG_Emissions', 0.5841308832168579)","('Air_Quality', 0.1801079362630844)","('Energy_Management', 0.09572603553533554)","(['Climate Change'], 0.5841308832168579)","('NON-ESG', 0.1801079362630844)","('NON-ESG', 0.09572603553533554)"
Line 948,"Over the period from FY 2015 to FY 2020: 13 acquisitions incorporated  into environmental disclosures,  including major acquisitions of  CareFusion and Bard Over 650  projects related to energy, water  and waste efficiency improvements saving  $25.6 million$47.5 million  invested from a   dedicated capital fund for energy, water   and waste reduction projects1 fuel cell energy  storage upgradeSan Jose, CA4 combined  heat and power  (CHP) facilitiesFraga, Spain   Heidelberg, Germany  Cuautitlán, Mexico   Drogheda, Ireland8 solar  installationsBawal, India   Four Oaks, NC   Suzhou, China   Canaan, CT (Phase I)  Cayey, Puerto Rico   Eysins, Switzerland   Franklin Lakes, NJ   Canaan, CT (Phase II) Access Innovation Efficiency Empowerment Governance We have achieved the following against our 2020 targets:* Reduce water  consumption by 40%.
","('Energy_Management', 0.7512073516845703)","('Waste_And_Hazardous_Materials_Management', 0.07085283100605011)","('Water_And_Wastewater_Management', 0.06859073787927628)","(['Operational Eco-Efficiency'], 0.7512073516845703)","('NON-ESG', 0.07085283100605011)","('NON-ESG', 0.06859073787927628)"
Line 949,"Over the period from FY 2015 to FY 2020: 13 acquisitions incorporated  into environmental disclosures,  including major acquisitions of  CareFusion and Bard Over 650  projects related to energy, water  and waste efficiency improvements saving  $25.6 million$47.5 million  invested from a   dedicated capital fund for energy, water   and waste reduction projects1 fuel cell energy  storage upgradeSan Jose, CA4 combined  heat and power  (CHP) facilitiesFraga, Spain   Heidelberg, Germany  Cuautitlán, Mexico   Drogheda, Ireland8 solar  installationsBawal, India   Four Oaks, NC   Suzhou, China   Canaan, CT (Phase I)  Cayey, Puerto Rico   Eysins, Switzerland   Franklin Lakes, NJ   Canaan, CT (Phase II) Access Innovation Efficiency Empowerment Governance We have achieved the following against our 2020 targets:* Reduce water  consumption by 40%.
","('Water_And_Wastewater_Management', 0.9052640795707703)","('Energy_Management', 0.04788481071591377)","('GHG_Emissions', 0.0054794782772660255)","(['Operational Eco-Efficiency'], 0.9052640795707703)","('NON-ESG', 0.04788481071591377)","('NON-ESG', 0.0054794782772660255)"
Line 950,"Current status FY 2020   Reduced  by 53%   TARGET ACHIEVED .Reduce ozone-depleting  substance emissions by 95%.
","('GHG_Emissions', 0.8292246460914612)","('Air_Quality', 0.059870049357414246)","('Energy_Management', 0.015100359916687012)","(['Climate Change'], 0.8292246460914612)","('NON-ESG', 0.059870049357414246)","('NON-ESG', 0.015100359916687012)"
Line 951,"Current status FY 2020   Reduced  by 95%   TARGET ACHIEVED.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5502241253852844)","('Business_Model_Resilience', 0.07083368301391602)","('Systemic_Risk_Management', 0.04827068746089935)","(['Corporate Governance'], 0.5502241253852844)","('NON-ESG', 0.07083368301391602)","('NON-ESG', 0.04827068746089935)"
Line 952,"Reduce energy  consumption by 40%.
","('Energy_Management', 0.9794837236404419)","('Management_Of_Legal_And_Regulatory_Framework', 0.001674760365858674)","('Critical_Incident_Risk_Management', 0.0015773284249007702)","(['Operational Eco-Efficiency'], 0.9794837236404419)","('NON-ESG', 0.001674760365858674)","('NON-ESG', 0.0015773284249007702)"
Line 953,"Current status FY 2020   Reduced  by 30%  Increase recycling rate   to over 70%.
","('Energy_Management', 0.3217984139919281)","('Product_Design_And_Lifecycle_Management', 0.2650927007198334)","('Management_Of_Legal_And_Regulatory_Framework', 0.13679859042167664)","('NON-ESG', 0.3217984139919281)","('NON-ESG', 0.2650927007198334)","('NON-ESG', 0.13679859042167664)"
Line 954,"Current status FY 2020   Increased  by 63% Increase diversion rate  to over 85%.
","('Business_Ethics', 0.22013318538665771)","('Management_Of_Legal_And_Regulatory_Framework', 0.12198386341333389)","('Air_Quality', 0.09202809631824493)","('NON-ESG', 0.22013318538665771)","('NON-ESG', 0.12198386341333389)","('NON-ESG', 0.09202809631824493)"
Line 955,"Current status FY 2020   Increased  by 79%  Our strategy has directly contributed to more efficient  operations and reduced energy consumption.
","('Energy_Management', 0.9810011982917786)","('Management_Of_Legal_And_Regulatory_Framework', 0.002129599219188094)","('Product_Design_And_Lifecycle_Management', 0.001517790136858821)","(['Operational Eco-Efficiency'], 0.9810011982917786)","('NON-ESG', 0.002129599219188094)","('NON-ESG', 0.001517790136858821)"
Line 956,"Diversification of  energy supply through the installation of CHP and sourcing of  renewable energy has enabled us to protect against volatility in  the energy market that could result in increased operational costs.
","('Energy_Management', 0.9599828720092773)","('Management_Of_Legal_And_Regulatory_Framework', 0.006636565085500479)","('Supply_Chain_Management', 0.0046581388451159)","(['Operational Eco-Efficiency'], 0.9599828720092773)","('NON-ESG', 0.006636565085500479)","('NON-ESG', 0.0046581388451159)"
Line 957,"A heavy focus on material efficiencies (such as packaging  optimization, product density optimization for shipping, greater recycled content and material optimization/reduction) has   been another strategy to help maintain cost competitiveness.
","('Product_Design_And_Lifecycle_Management', 0.9423167109489441)","('Customer_Welfare', 0.00858541950583458)","('Energy_Management', 0.006590889301151037)","(['Product Stewardship'], 0.9423167109489441)","('NON-ESG', 0.00858541950583458)","('NON-ESG', 0.006590889301151037)"
Line 958,"Our work to communicate GHG emissions avoidance to key  customers has also enabled a new dialog with these stakeholders.
","('GHG_Emissions', 0.9643555879592896)","('Air_Quality', 0.0057736895978450775)","('Physical_Impacts_Of_Climate_Change', 0.003399708541110158)","(['Climate Change'], 0.9643555879592896)","('NON-ESG', 0.0057736895978450775)","('NON-ESG', 0.003399708541110158)"
Line 959,"In some cases, this has led to opportunities to collaborate to  make further environmental improvements.Emissions Energy Waste Recycling Water consumptionReduce Scope 1 and 2 GHG  emissions by 50%.
","('GHG_Emissions', 0.9309167265892029)","('Energy_Management', 0.012675131671130657)","('Air_Quality', 0.010747246444225311)","(['Climate Change'], 0.9309167265892029)","('NON-ESG', 0.012675131671130657)","('NON-ESG', 0.010747246444225311)"
Line 960,"Current status FY Reduced  by 58%   TARGET ACHIEVED.Reduce volatile organic  compound (VOC) and  hazardous air pollution  (HAP) emissions by 65%.
","('Air_Quality', 0.9776114225387573)","('GHG_Emissions', 0.0025596751365810633)","('Critical_Incident_Risk_Management', 0.001600937219336629)","(['Operational Eco-Efficiency'], 0.9776114225387573)","('NON-ESG', 0.0025596751365810633)","('NON-ESG', 0.001600937219336629)"
Line 961,"Current status FY 2020   Increased  by 38%   Increase use of renewable  energy to 50% of  total energy.
","('Energy_Management', 0.9779828786849976)","('Management_Of_Legal_And_Regulatory_Framework', 0.004044794477522373)","('Air_Quality', 0.0013988424325361848)","(['Operational Eco-Efficiency'], 0.9779828786849976)","('NON-ESG', 0.004044794477522373)","('NON-ESG', 0.0013988424325361848)"
Line 962,"Current status FY 2020   Increased  by 21%   Reduce total waste   by 50%.
","('Waste_And_Hazardous_Materials_Management', 0.9825125932693481)","('Water_And_Wastewater_Management', 0.0017435966292396188)","('Air_Quality', 0.0013423956697806716)","(['Operational Eco-Efficiency'], 0.9825125932693481)","('NON-ESG', 0.0017435966292396188)","('NON-ESG', 0.0013423956697806716)"
Line 963,"Current status FY 2020   Reduced  by 14% Reduce hazardous waste by  more than 60%.
","('Waste_And_Hazardous_Materials_Management', 0.9845784902572632)","('Water_And_Wastewater_Management', 0.0011030121240764856)","('Data_Security', 0.0010863153729587793)","(['Operational Eco-Efficiency'], 0.9845784902572632)","('NON-ESG', 0.0011030121240764856)","('NON-ESG', 0.0010863153729587793)"
Line 964,"Current status FY 2020   Reduced  by 42%   *From baseline year of FY Access Innovation Efficiency Empowerment Governance Data collection and governance Environmental data from our global locations are collected   via a third-party data collection and analysis platform.
","('Management_Of_Legal_And_Regulatory_Framework', 0.298813134431839)","('Customer_Privacy', 0.21496281027793884)","('Data_Security', 0.08037316054105759)","('NON-ESG', 0.298813134431839)","('NON-ESG', 0.21496281027793884)","('NON-ESG', 0.08037316054105759)"
Line 965,"Our environmental inventory management plan (IMP)  documents key governance and measurement processes for  energy, greenhouse gas emissions, water and waste.
","('GHG_Emissions', 0.9626806974411011)","('Ecological_Impacts', 0.0058202785439789295)","('Air_Quality', 0.0037965618539601564)","(['Climate Change'], 0.9626806974411011)","('NON-ESG', 0.0058202785439789295)","('NON-ESG', 0.0037965618539601564)"
Line 966,"It also  defines roles, responsibilities and processes, including triggers  for recalculation and restatement (for example, merger,  acquisition or divestiture that results in a significant structural  change to the data).Improvements in our operational practices and improved  visibility to environmental performance metrics have  encouraged emissions reduction.
","('GHG_Emissions', 0.4710719883441925)","('Air_Quality', 0.2673271596431732)","('Energy_Management', 0.09673280268907547)","('NON-ESG', 0.4710719883441925)","('NON-ESG', 0.2673271596431732)","('NON-ESG', 0.09673280268907547)"
Line 967,"Operations leaders review  progress against our targets on a regular frequency.
","('Business_Model_Resilience', 0.2657185196876526)","('Systemic_Risk_Management', 0.15019124746322632)","('Human_Rights_And_Community_Relations', 0.0705808624625206)","('NON-ESG', 0.2657185196876526)","('NON-ESG', 0.15019124746322632)","('NON-ESG', 0.0705808624625206)"
Line 968,"At the  company level, progress on overall sustainability performance is  reviewed with the Executive Leadership Team.
","('Business_Model_Resilience', 0.4892801344394684)","('Director_Removal', 0.0837981104850769)","('Human_Rights_And_Community_Relations', 0.05637205392122269)","('NON-ESG', 0.4892801344394684)","('NON-ESG', 0.0837981104850769)","('NON-ESG', 0.05637205392122269)"
Line 969,"The IMP ensures confidence of information to support decision  making, and consistent and transparent reporting.
","('Business_Ethics', 0.4430200755596161)","('Management_Of_Legal_And_Regulatory_Framework', 0.3347001373767853)","('Customer_Privacy', 0.040365710854530334)","('NON-ESG', 0.4430200755596161)","('NON-ESG', 0.3347001373767853)","('NON-ESG', 0.040365710854530334)"
Line 970,"Funding We previously established a dedicated carbon capital fund for  projects that may fall outside of traditional funding models but  have a sustainability benefit.
","('Management_Of_Legal_And_Regulatory_Framework', 0.906495988368988)","('Access_And_Affordability', 0.01194564439356327)","('GHG_Emissions', 0.009794390760362148)","(['Corporate Governance'], 0.906495988368988)","('NON-ESG', 0.01194564439356327)","('NON-ESG', 0.009794390760362148)"
Line 971,"The fund has been used for  projects that include HVAC replacements, chiller upgrades,  compressed air upgrades and LED installations—each of which  has improved the resilience and efficiency of our operations.
","('Business_Model_Resilience', 0.36662042140960693)","('Energy_Management', 0.2258484661579132)","('Physical_Impacts_Of_Climate_Change', 0.08966687321662903)","('NON-ESG', 0.36662042140960693)","('NON-ESG', 0.2258484661579132)","('NON-ESG', 0.08966687321662903)"
Line 972,"In addition, the fund was able to match our traditional capital funding for a co-generation facility at our Fraga, Spain facility.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7420505881309509)","('GHG_Emissions', 0.041241370141506195)","('Business_Model_Resilience', 0.030543910339474678)","(['Corporate Governance'], 0.7420505881309509)","('NON-ESG', 0.041241370141506195)","('NON-ESG', 0.030543910339474678)"
Line 973,"Other projects included upgrades to our fuel cell energy storage  in San Jose, California, and various major solar installation  projects.
","('Energy_Management', 0.9753766655921936)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033383893314749002)","('Product_Design_And_Lifecycle_Management', 0.0020572408102452755)","(['Operational Eco-Efficiency'], 0.9753766655921936)","('NON-ESG', 0.0033383893314749002)","('NON-ESG', 0.0020572408102452755)"
Line 974,"Capital funding will continue to be identified and  allocated for projects that support achievement of our 2030+  Sustainability goals.
","('Management_Of_Legal_And_Regulatory_Framework', 0.719918429851532)","('Business_Model_Resilience', 0.046306438744068146)","('GHG_Emissions', 0.030882008373737335)","(['Corporate Governance'], 0.719918429851532)","('NON-ESG', 0.046306438744068146)","('NON-ESG', 0.030882008373737335)"
Line 975,"Best practice sharing The ATLAS initiative was implemented in 2008 to drive  environmental improvement projects within the BD Medical  segment, by reviewing performance and sharing best practices.
","('Access_And_Affordability', 0.26684805750846863)","('Human_Rights_And_Community_Relations', 0.13467317819595337)","('Product_Quality_And_Safety', 0.10484319925308228)","('NON-ESG', 0.26684805750846863)","('NON-ESG', 0.13467317819595337)","('NON-ESG', 0.10484319925308228)"
Line 976,"The initiative is now being expanded across BD with monthly  calls held by region.
","('Management_Of_Legal_And_Regulatory_Framework', 0.47022488713264465)","('Access_And_Affordability', 0.13599379360675812)","('Employee_Engagement_Inclusion_And_Diversity', 0.03797344118356705)","('NON-ESG', 0.47022488713264465)","('NON-ESG', 0.13599379360675812)","('NON-ESG', 0.03797344118356705)"
Line 977,"In FY 2020, the Sustainability Council was established,  consisting of representatives from each business unit and  sponsored by the VP EHS&S.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2929409444332123)","('Director_Removal', 0.17942994832992554)","('Business_Model_Resilience', 0.07980167865753174)","('NON-ESG', 0.2929409444332123)","('NON-ESG', 0.17942994832992554)","('NON-ESG', 0.07980167865753174)"
Line 978,"Covering manufacturing locations,  distribution centers and large campuses, the group is responsible  for developing and deploying site level targets resulting from our new 2030 sustainability strategy; developing a multiyear   project pipeline and leveraging the BD network (such as the  ATLAS initiative) to standardize sharing best practices.
","('Supply_Chain_Management', 0.3370179831981659)","('Business_Model_Resilience', 0.23638811707496643)","('Product_Design_And_Lifecycle_Management', 0.17293667793273926)","('NON-ESG', 0.3370179831981659)","('NON-ESG', 0.23638811707496643)","('NON-ESG', 0.17293667793273926)"
Line 979,"We utilize a number of programs to identify opportunities at our  locations, ranging from associate suggestions to more formal  on-site audits.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2854295074939728)","('Business_Ethics', 0.15381483733654022)","('Access_And_Affordability', 0.0859668105840683)","('NON-ESG', 0.2854295074939728)","('NON-ESG', 0.15381483733654022)","('NON-ESG', 0.0859668105840683)"
Line 980,"As part of the integration of the legacy Bard  manufacturing facilities, we have continued a program of  on-site audits to identify opportunities for emissions reductions.
","('Air_Quality', 0.4112102687358856)","('GHG_Emissions', 0.3896467983722687)","('Energy_Management', 0.07874283939599991)","('NON-ESG', 0.4112102687358856)","('NON-ESG', 0.3896467983722687)","('NON-ESG', 0.07874283939599991)"
Line 981,"All data relating to our performance can be found in the  Efficiency data tables section .
","('Energy_Management', 0.8581647276878357)","('Management_Of_Legal_And_Regulatory_Framework', 0.017991138622164726)","('Business_Model_Resilience', 0.01443248800933361)","(['Operational Eco-Efficiency'], 0.8581647276878357)","('NON-ESG', 0.017991138622164726)","('NON-ESG', 0.01443248800933361)"
Line 982,"Access Innovation Efficiency Empowerment Governance 2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain GHG emissions Our absolute Scope 1 and 2 GHG emissions  continued to decline, despite an increase in  revenues; this is largely due a reduction in our  Scope 2 emissions.
","('GHG_Emissions', 0.9670790433883667)","('Air_Quality', 0.003940905909985304)","('Ecological_Impacts', 0.003313193330541253)","(['Climate Change'], 0.9670790433883667)","('NON-ESG', 0.003940905909985304)","('NON-ESG', 0.003313193330541253)"
Line 983,"In previous years we have  purchased additional unbundled Renewable Energy Credits  (RECs) to offset carbon emissions at our US facilities.
","('Energy_Management', 0.4110654592514038)","('Management_Of_Legal_And_Regulatory_Framework', 0.20937229692935944)","('GHG_Emissions', 0.20725370943546295)","('NON-ESG', 0.4110654592514038)","('NON-ESG', 0.20937229692935944)","('NON-ESG', 0.20725370943546295)"
Line 984,"However  due to the significant increase in the market price for RECs, we are  evaluating alternative strategies, including the purchase of  carbon offsets.
","('Management_Of_Legal_And_Regulatory_Framework', 0.524743914604187)","('Systemic_Risk_Management', 0.15924832224845886)","('Competitive_Behavior', 0.07390991598367691)","(['Corporate Governance'], 0.524743914604187)","('NON-ESG', 0.15924832224845886)","('NON-ESG', 0.07390991598367691)"
Line 985,"After normalization, we have reduced emissions  by 58% from our baseline year of FY 2008.
","('GHG_Emissions', 0.6915624141693115)","('Air_Quality', 0.13144327700138092)","('Energy_Management', 0.06657291948795319)","(['Climate Change'], 0.6915624141693115)","('NON-ESG', 0.13144327700138092)","('NON-ESG', 0.06657291948795319)"
Line 986,"Facilities continue to  identify carbon reduction opportunities as we continue working  toward newly announced 2030 climate targets for scope 1 and 2  emissions.
","('GHG_Emissions', 0.8376040458679199)","('Physical_Impacts_Of_Climate_Change', 0.034569039940834045)","('Ecological_Impacts', 0.024296987801790237)","(['Climate Change'], 0.8376040458679199)","('NON-ESG', 0.034569039940834045)","('NON-ESG', 0.024296987801790237)"
Line 987,"We also continued our commitment to increasing our use of  on-site generation and renewable energy sources, where feasible.
","('Energy_Management', 0.9762459397315979)","('Product_Design_And_Lifecycle_Management', 0.0032787795644253492)","('Management_Of_Legal_And_Regulatory_Framework', 0.002041210187599063)","(['Operational Eco-Efficiency'], 0.9762459397315979)","('NON-ESG', 0.0032787795644253492)","('NON-ESG', 0.002041210187599063)"
Line 988,"We provided limited reporting of Scope 3 emissions in previous  years, and in FY 2019 we continued to work with external partners  to establish baseline Scope 3 emissions across all relevant  categories.
","('GHG_Emissions', 0.8474371433258057)","('Air_Quality', 0.07917752861976624)","('Management_Of_Legal_And_Regulatory_Framework', 0.010747067630290985)","(['Climate Change'], 0.8474371433258057)","('NON-ESG', 0.07917752861976624)","('NON-ESG', 0.010747067630290985)"
Line 989,"Our largest sources of Scope 3 emissions are  estimated to be from purchased goods, distribution and the use  and disposal of products.
","('Product_Design_And_Lifecycle_Management', 0.9593837857246399)","('Energy_Management', 0.004547306336462498)","('Product_Quality_And_Safety', 0.004534172359853983)","(['Product Stewardship'], 0.9593837857246399)","('NON-ESG', 0.004547306336462498)","('NON-ESG', 0.004534172359853983)"
Line 990,"Therefore, these sources represent the  largest areas for opportunity and will be the subject of focus in  our future sustainability strategy.
","('Business_Model_Resilience', 0.522769570350647)","('Systemic_Risk_Management', 0.10463748127222061)","('Supply_Chain_Management', 0.06821239739656448)","(['Codes of Business Conduct'], 0.522769570350647)","('NON-ESG', 0.10463748127222061)","('NON-ESG', 0.06821239739656448)"
Line 991,"Further information about our climate change strategy   and programs to reduce GHG emissions can be found in our   Climate Change Management Report , as well as in our  responses to the CDP  (formerly the Carbon Disclosure Project).
","('GHG_Emissions', 0.9296182990074158)","('Physical_Impacts_Of_Climate_Change', 0.02223251573741436)","('Ecological_Impacts', 0.006562643684446812)","(['Climate Change'], 0.9296182990074158)","('NON-ESG', 0.02223251573741436)","('NON-ESG', 0.006562643684446812)"
Line 992,"BD  has reported to the CDP since its inception in 2003.
","('Management_Of_Legal_And_Regulatory_Framework', 0.39219558238983154)","('Access_And_Affordability', 0.10834136605262756)","('Systemic_Risk_Management', 0.09819518774747849)","('NON-ESG', 0.39219558238983154)","('NON-ESG', 0.10834136605262756)","('NON-ESG', 0.09819518774747849)"
Line 993,"2020 goal Minimize  our environmental footprint and conserve natural resources  For FY 2020, we continued to invest in on-site  power generation and assessing opportunities to  reduce our environmental footprint across all sites.
","('Ecological_Impacts', 0.9606075286865234)","('GHG_Emissions', 0.0052480208687484264)","('Product_Design_And_Lifecycle_Management', 0.003754148492589593)","(['Natural Capital'], 0.9606075286865234)","('NON-ESG', 0.0052480208687484264)","('NON-ESG', 0.003754148492589593)"
Line 994,"Our energy consumption continued to decrease in  absolute terms and normalized terms in FY 2020.
","('Energy_Management', 0.9812213778495789)","('Management_Of_Legal_And_Regulatory_Framework', 0.0018334835767745972)","('Water_And_Wastewater_Management', 0.0015609664842486382)","(['Operational Eco-Efficiency'], 0.9812213778495789)","('NON-ESG', 0.0018334835767745972)","('NON-ESG', 0.0015609664842486382)"
Line 995,"A number of opportunities were identified including: • Replacement of HVAC units and other upgrades to more  energy efficient equipment• Process optimization resulting in the reduction of  compressed air usage • LED lighting upgrades Going forward, we are continuing to build a robust pipeline of  energy reduction projects that will reduce energy consumption  in addition to GHG emissions.
","('Energy_Management', 0.8992637395858765)","('GHG_Emissions', 0.03815348073840141)","('Air_Quality', 0.01869249902665615)","(['Operational Eco-Efficiency'], 0.8992637395858765)","('NON-ESG', 0.03815348073840141)","('NON-ESG', 0.01869249902665615)"
Line 996,"Click here to view the Energy data tables .EnergyIn FY 2020, we completed 109 projects that contributed to lowering our environmental footprint and to conserve natural resources.GRI disclosure: 201-EPA Green Power Partnership As an EPA Green Power Partner since 2008, we report our use of  renewable energy in the U.S. on an annual basis.
","('Energy_Management', 0.9658826589584351)","('Management_Of_Legal_And_Regulatory_Framework', 0.006179667543619871)","('GHG_Emissions', 0.004033926874399185)","(['Operational Eco-Efficiency'], 0.9658826589584351)","('NON-ESG', 0.006179667543619871)","('NON-ESG', 0.004033926874399185)"
Line 997,"Details of the  Green Power Partnership and our current ranking can be found at  epa.gov /greenpower .
","('Management_Of_Legal_And_Regulatory_Framework', 0.5674513578414917)","('Human_Rights_And_Community_Relations', 0.06581546366214752)","('Ecological_Impacts', 0.06001117452979088)","(['Corporate Governance'], 0.5674513578414917)","('NON-ESG', 0.06581546366214752)","('NON-ESG', 0.06001117452979088)"
Line 998,"Access Innovation Efficiency Empowerment Governance The latest on-site solar installation was completed for our  headquarters in Franklin Lakes, NJ.
","('Energy_Management', 0.9682542085647583)","('Management_Of_Legal_And_Regulatory_Framework', 0.004274476785212755)","('Product_Design_And_Lifecycle_Management', 0.00406862935051322)","(['Operational Eco-Efficiency'], 0.9682542085647583)","('NON-ESG', 0.004274476785212755)","('NON-ESG', 0.00406862935051322)"
Line 999,"The project saves roughly   7% of the annual power consumption, which equates to roughly  1,000,000 kilowatt hours annually.
","('Energy_Management', 0.9764695763587952)","('Management_Of_Legal_And_Regulatory_Framework', 0.002213051076978445)","('Water_And_Wastewater_Management', 0.0019401763565838337)","(['Operational Eco-Efficiency'], 0.9764695763587952)","('NON-ESG', 0.002213051076978445)","('NON-ESG', 0.0019401763565838337)"
Line 1000,"That is enough to power 50  U.S. homes for a year.
","('Energy_Management', 0.8748325109481812)","('Management_Of_Legal_And_Regulatory_Framework', 0.028661340475082397)","('Competitive_Behavior', 0.00918252021074295)","(['Operational Eco-Efficiency'], 0.8748325109481812)","('NON-ESG', 0.028661340475082397)","('NON-ESG', 0.00918252021074295)"
Line 1001,"It also reduces 700 metric tonnes of  carbon dioxide, the equivalent to removing 140 cars from the road.
","('GHG_Emissions', 0.7784255743026733)","('Air_Quality', 0.03982385993003845)","('Energy_Management', 0.03975383937358856)","(['Climate Change'], 0.7784255743026733)","('NON-ESG', 0.03982385993003845)","('NON-ESG', 0.03975383937358856)"
Line 1002,"The 1,500 solar panel project is one of our largest solar  projects to date.
","('Energy_Management', 0.8981242179870605)","('GHG_Emissions', 0.011961737647652626)","('Product_Design_And_Lifecycle_Management', 0.01131400465965271)","(['Operational Eco-Efficiency'], 0.8981242179870605)","('NON-ESG', 0.011961737647652626)","('NON-ESG', 0.01131400465965271)"
Line 1003,"We continue to identify and implement solar opportunities.
","('Systemic_Risk_Management', 0.14493389427661896)","('Business_Model_Resilience', 0.1375660002231598)","('Employee_Engagement_Inclusion_And_Diversity', 0.08405411243438721)","('NON-ESG', 0.14493389427661896)","('NON-ESG', 0.1375660002231598)","('NON-ESG', 0.08405411243438721)"
Line 1004,"The next solar installation to come online will be at our   San Diego, CA facility.Solar Access Innovation Efficiency Empowerment Governance Water management Water is vital for sustaining healthy lives and   the planet.
","('Water_And_Wastewater_Management', 0.9756821990013123)","('GHG_Emissions', 0.002400838304311037)","('Energy_Management', 0.0022707409225404263)","(['Operational Eco-Efficiency'], 0.9756821990013123)","('NON-ESG', 0.002400838304311037)","('NON-ESG', 0.0022707409225404263)"
Line 1005,"Having access to clean and sufficient  supply is critical for our operations and the  communities where we live, work and do business.
","('Supply_Chain_Management', 0.8602160811424255)","('Water_And_Wastewater_Management', 0.02191351167857647)","('Labor_Practices', 0.01223487127572298)","(['Supply Chain Management'], 0.8602160811424255)","('NON-ESG', 0.02191351167857647)","('NON-ESG', 0.01223487127572298)"
Line 1006,"Water quality and quantity is fundamental to ensure that the  highest healthcare product safety standards are met.
","('Product_Quality_And_Safety', 0.9259748458862305)","('Employee_Health_And_Safety', 0.008906885050237179)","('Product_Design_And_Lifecycle_Management', 0.006876061670482159)","(['Product Quality & Recall Management'], 0.9259748458862305)","('NON-ESG', 0.008906885050237179)","('NON-ESG', 0.006876061670482159)"
Line 1007,"Water  conservation is an important operational strategy, especially for  products that contain purified water.
","('Water_And_Wastewater_Management', 0.9645766019821167)","('Ecological_Impacts', 0.006760342977941036)","('GHG_Emissions', 0.0036268183030188084)","(['Operational Eco-Efficiency'], 0.9645766019821167)","('NON-ESG', 0.006760342977941036)","('NON-ESG', 0.0036268183030188084)"
Line 1008,"Freshwater is used in  manufacturing, sanitation, sterilization, processing and cooling  for our direct operations.
","('Water_And_Wastewater_Management', 0.9741137623786926)","('Waste_And_Hazardous_Materials_Management', 0.0028081159107387066)","('GHG_Emissions', 0.0026786276139318943)","(['Operational Eco-Efficiency'], 0.9741137623786926)","('NON-ESG', 0.0028081159107387066)","('NON-ESG', 0.0026786276139318943)"
Line 1009,"Indirect water is used in the  manufacturing and/or processing of many raw materials used in  our products, such as resins, steel, and packaging and electrical  components.
","('Product_Design_And_Lifecycle_Management', 0.7273144721984863)","('Water_And_Wastewater_Management', 0.06117894500494003)","('Waste_And_Hazardous_Materials_Management', 0.05685637891292572)","(['Product Stewardship'], 0.7273144721984863)","('NON-ESG', 0.06117894500494003)","('NON-ESG', 0.05685637891292572)"
Line 1010,"Recycled/brackish water is used in ancillary operations, such as  cooling towers, because it does not meet quality standards for  most other uses.
","('Water_And_Wastewater_Management', 0.9697186946868896)","('GHG_Emissions', 0.0036687864921987057)","('Ecological_Impacts', 0.0029839470516890287)","(['Operational Eco-Efficiency'], 0.9697186946868896)","('NON-ESG', 0.0036687864921987057)","('NON-ESG', 0.0029839470516890287)"
Line 1011,"Operating in accordance with local regulations that protect  people and the environment, approximately 96% of water used  at our facilities comes from, and is discharged to, third-party  sources (such as local municipal water sources).
","('Water_And_Wastewater_Management', 0.9766468405723572)","('GHG_Emissions', 0.0021294993348419666)","('Waste_And_Hazardous_Materials_Management', 0.0021123159676790237)","(['Operational Eco-Efficiency'], 0.9766468405723572)","('NON-ESG', 0.0021294993348419666)","('NON-ESG', 0.0021123159676790237)"
Line 1012,"We collect  water-related data for total withdrawals from our sites worldwide  through an online system.
","('Water_And_Wastewater_Management', 0.9720472097396851)","('Energy_Management', 0.0035640045534819365)","('GHG_Emissions', 0.0026514914352446795)","(['Operational Eco-Efficiency'], 0.9720472097396851)","('NON-ESG', 0.0035640045534819365)","('NON-ESG', 0.0026514914352446795)"
Line 1013,"This data is monitored and reviewed  on an ongoing basis.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3019430339336395)","('Access_And_Affordability', 0.09513375163078308)","('Customer_Privacy', 0.07279512286186218)","('NON-ESG', 0.3019430339336395)","('NON-ESG', 0.09513375163078308)","('NON-ESG', 0.07279512286186218)"
Line 1014,"We are committed to responsible and sustainable use of water  and strive to include water sustainability considerations in  business decisions.
","('Water_And_Wastewater_Management', 0.975741982460022)","('GHG_Emissions', 0.0027963353786617517)","('Energy_Management', 0.0022402866743505)","(['Operational Eco-Efficiency'], 0.975741982460022)","('NON-ESG', 0.0027963353786617517)","('NON-ESG', 0.0022402866743505)"
Line 1015,"We seek to achieve efficient use of water  resources at our operational locations by investing in and using  new technologies when feasible and implementing water  conservation and water management practices.
","('Water_And_Wastewater_Management', 0.9756465554237366)","('Ecological_Impacts', 0.002946726977825165)","('GHG_Emissions', 0.00241179415024817)","(['Operational Eco-Efficiency'], 0.9756465554237366)","('NON-ESG', 0.002946726977825165)","('NON-ESG', 0.00241179415024817)"
Line 1016,"Water risk is considered part of business continuity planning.
","('Water_And_Wastewater_Management', 0.9747023582458496)","('Waste_And_Hazardous_Materials_Management', 0.0021319270599633455)","('GHG_Emissions', 0.0019225974101573229)","(['Operational Eco-Efficiency'], 0.9747023582458496)","('NON-ESG', 0.0021319270599633455)","('NON-ESG', 0.0019225974101573229)"
Line 1017,"Water-related risks within operations are identified, assessed and  addressed through the general enterprise risk management (ERM) process.
","('Water_And_Wastewater_Management', 0.9681596755981445)","('GHG_Emissions', 0.00292663904838264)","('Energy_Management', 0.0028756288811564445)","(['Operational Eco-Efficiency'], 0.9681596755981445)","('NON-ESG', 0.00292663904838264)","('NON-ESG', 0.0028756288811564445)"
Line 1018,"We use established water risk tools to evaluate  the basin risk and operational risk at the corporate level.
","('Water_And_Wastewater_Management', 0.9732711911201477)","('Waste_And_Hazardous_Materials_Management', 0.0028289170004427433)","('GHG_Emissions', 0.0024951393716037273)","(['Operational Eco-Efficiency'], 0.9732711911201477)","('NON-ESG', 0.0028289170004427433)","('NON-ESG', 0.0024951393716037273)"
Line 1019,"Efficiency audits are conducted at the site level to identify  opportunities for reduction of water usage and consumption.
","('Water_And_Wastewater_Management', 0.9654006958007812)","('Energy_Management', 0.008730988949537277)","('GHG_Emissions', 0.0033031783532351255)","(['Operational Eco-Efficiency'], 0.9654006958007812)","('NON-ESG', 0.008730988949537277)","('NON-ESG', 0.0033031783532351255)"
Line 1020,"These local site efficiency audits also include energy, waste and  emissions to provide prioritization for conservation projects.
","('Energy_Management', 0.9705069661140442)","('Air_Quality', 0.004276196472346783)","('Management_Of_Legal_And_Regulatory_Framework', 0.0030679316259920597)","(['Operational Eco-Efficiency'], 0.9705069661140442)","('NON-ESG', 0.004276196472346783)","('NON-ESG', 0.0030679316259920597)"
Line 1021,"These are projects that may reduce energy consumption along  with having a significant water reduction associated with it.
","('Energy_Management', 0.5557140707969666)","('Water_And_Wastewater_Management', 0.3561243414878845)","('GHG_Emissions', 0.011214793659746647)","(['Operational Eco-Efficiency'], 0.5557140707969666)","('NON-ESG', 0.3561243414878845)","('NON-ESG', 0.011214793659746647)"
Line 1022,"Water-related issues (such as resilience from water scarcity and  internal water efficiencies) are integrated into our long-term  business objectives.
","('Water_And_Wastewater_Management', 0.9731844663619995)","('Energy_Management', 0.0028168284334242344)","('GHG_Emissions', 0.002116488292813301)","(['Operational Eco-Efficiency'], 0.9731844663619995)","('NON-ESG', 0.0028168284334242344)","('NON-ESG', 0.002116488292813301)"
Line 1023,"We see opportunities to continue to improve  operational efficiencies.
","('Energy_Management', 0.305921345949173)","('Business_Model_Resilience', 0.12885873019695282)","('Supply_Chain_Management', 0.11278699338436127)","('NON-ESG', 0.305921345949173)","('NON-ESG', 0.12885873019695282)","('NON-ESG', 0.11278699338436127)"
Line 1024,"Further information about our water management strategy and  programs can be found in our responses to the CDP (formerly the  Carbon Disclosure Project).
","('Water_And_Wastewater_Management', 0.9721633791923523)","('Ecological_Impacts', 0.003179759718477726)","('GHG_Emissions', 0.0026488006114959717)","(['Operational Eco-Efficiency'], 0.9721633791923523)","('NON-ESG', 0.003179759718477726)","('NON-ESG', 0.0026488006114959717)"
Line 1025,"BD has reported to the CDP since its  inception in 2003.
","('Management_Of_Legal_And_Regulatory_Framework', 0.39219558238983154)","('Access_And_Affordability', 0.10834136605262756)","('Systemic_Risk_Management', 0.09819518774747849)","('NON-ESG', 0.39219558238983154)","('NON-ESG', 0.10834136605262756)","('NON-ESG', 0.09819518774747849)"
Line 1026,"Clean water plays a role in global health.
","('Water_And_Wastewater_Management', 0.973884642124176)","('GHG_Emissions', 0.002892732387408614)","('Ecological_Impacts', 0.0028265404980629683)","(['Operational Eco-Efficiency'], 0.973884642124176)","('NON-ESG', 0.002892732387408614)","('NON-ESG', 0.0028265404980629683)"
Line 1027,"Damaged ecosystems  affect the quantity and quality of water available for human  consumption.
","('Water_And_Wastewater_Management', 0.9524697661399841)","('Ecological_Impacts', 0.01479022391140461)","('GHG_Emissions', 0.005270843859761953)","(['Operational Eco-Efficiency'], 0.9524697661399841)","('NON-ESG', 0.01479022391140461)","('NON-ESG', 0.005270843859761953)"
Line 1028,"Extreme weather events are impacting water  availability and quality.
","('Water_And_Wastewater_Management', 0.9690715670585632)","('Ecological_Impacts', 0.004500418435782194)","('GHG_Emissions', 0.0035491727758198977)","(['Operational Eco-Efficiency'], 0.9690715670585632)","('NON-ESG', 0.004500418435782194)","('NON-ESG', 0.0035491727758198977)"
Line 1029,"While water covers a significant amount of the planet, only 3% is  freshwater and two-thirds is locked in glaciers or otherwise  inaccessible for use.
","('Water_And_Wastewater_Management', 0.9757643342018127)","('Waste_And_Hazardous_Materials_Management', 0.0023439209908246994)","('GHG_Emissions', 0.002006279304623604)","(['Operational Eco-Efficiency'], 0.9757643342018127)","('NON-ESG', 0.0023439209908246994)","('NON-ESG', 0.002006279304623604)"
Line 1030,"This results in 1.1 billion people lacking  access to water, with 2.7 billion experiencing water scarcity for at  least one month of the year.
","('Water_And_Wastewater_Management', 0.9752534031867981)","('Energy_Management', 0.002276633633300662)","('GHG_Emissions', 0.002025444759055972)","(['Operational Eco-Efficiency'], 0.9752534031867981)","('NON-ESG', 0.002276633633300662)","('NON-ESG', 0.002025444759055972)"
Line 1031,"In addition, 2.4 billion people  experience inadequate sanitation, exposing them to disease and  water-borne illnesses.BD has partnered with Charity: Water  and Planet Water  in  previous years to provide clean drinking water to communities  around the world.
","('Water_And_Wastewater_Management', 0.9717005491256714)","('Energy_Management', 0.0026179614942520857)","('Critical_Incident_Risk_Management', 0.0020503485575318336)","(['Operational Eco-Efficiency'], 0.9717005491256714)","('NON-ESG', 0.0026179614942520857)","('NON-ESG', 0.0020503485575318336)"
Line 1032,"You can read more about our work with Planet  Water in 2020 in the Empowerment section of this report.Water Water consumption decreased in FY 2020 as a result of  continued water conservation efforts, exceeding our target of  40% reduction of water use (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9773693680763245)","('Waste_And_Hazardous_Materials_Management', 0.0020220009610056877)","('GHG_Emissions', 0.0019363552564755082)","(['Operational Eco-Efficiency'], 0.9773693680763245)","('NON-ESG', 0.0020220009610056877)","('NON-ESG', 0.0019363552564755082)"
Line 1033,"Production  decreases at certain plants due to the pandemic allowed us to  carry out maintenance and upgrades to equipment, such as pumps, also contributed to reduction in water consumption.
","('Water_And_Wastewater_Management', 0.9361914992332458)","('Energy_Management', 0.02167823351919651)","('GHG_Emissions', 0.006981047336012125)","(['Operational Eco-Efficiency'], 0.9361914992332458)","('NON-ESG', 0.02167823351919651)","('NON-ESG', 0.006981047336012125)"
Line 1034,"We will continue to identify and implement viable water  reduction projects.
","('Water_And_Wastewater_Management', 0.9740366339683533)","('GHG_Emissions', 0.003209501039236784)","('Ecological_Impacts', 0.0025678419042378664)","(['Operational Eco-Efficiency'], 0.9740366339683533)","('NON-ESG', 0.003209501039236784)","('NON-ESG', 0.0025678419042378664)"
Line 1035,"Click here to view the Water data table .GRI disclosure: 303-Water use Reference 1 Water scarcity.
","('Water_And_Wastewater_Management', 0.9767835140228271)","('GHG_Emissions', 0.0020429291762411594)","('Ecological_Impacts', 0.0018860548734664917)","(['Operational Eco-Efficiency'], 0.9767835140228271)","('NON-ESG', 0.0020429291762411594)","('NON-ESG', 0.0018860548734664917)"
Line 1036,"World Wildlife Fund.
","('Ecological_Impacts', 0.9138303399085999)","('GHG_Emissions', 0.027063751593232155)","('Water_And_Wastewater_Management', 0.0075578815303742886)","(['Natural Capital'], 0.9138303399085999)","('NON-ESG', 0.027063751593232155)","('NON-ESG', 0.0075578815303742886)"
Line 1037,"Accessed March 9, 2021.
","('Management_Of_Legal_And_Regulatory_Framework', 0.19880585372447968)","('Ecological_Impacts', 0.08863341063261032)","('Competitive_Behavior', 0.0771370455622673)","('NON-ESG', 0.19880585372447968)","('NON-ESG', 0.08863341063261032)","('NON-ESG', 0.0771370455622673)"
Line 1038,"https://www.worldwildlife.org/threats/water-scarcit y.
","('Water_And_Wastewater_Management', 0.9443681836128235)","('Ecological_Impacts', 0.012683792039752007)","('GHG_Emissions', 0.007861175574362278)","(['Operational Eco-Efficiency'], 0.9443681836128235)","('NON-ESG', 0.012683792039752007)","('NON-ESG', 0.007861175574362278)"
Line 1039,"Access Innovation Efficiency Empowerment Governance Waste management Effective waste prevention and management  practices are critical for protecting human health  and the environment.
","('Waste_And_Hazardous_Materials_Management', 0.9841880798339844)","('Water_And_Wastewater_Management', 0.0011431510793045163)","('Data_Security', 0.001044297474436462)","(['Operational Eco-Efficiency'], 0.9841880798339844)","('NON-ESG', 0.0011431510793045163)","('NON-ESG', 0.001044297474436462)"
Line 1040,"BD acknowledges the  importance of responsible end disposal management for the  various types of waste generated from our operations.
","('Waste_And_Hazardous_Materials_Management', 0.9840286374092102)","('Water_And_Wastewater_Management', 0.0014774483861401677)","('Data_Security', 0.0011163655435666442)","(['Operational Eco-Efficiency'], 0.9840286374092102)","('NON-ESG', 0.0014774483861401677)","('NON-ESG', 0.0011163655435666442)"
Line 1041,"Recognizing the current and future potential liabilities associated  with waste disposal is necessary to safeguard our company,  communities and planet.
","('Waste_And_Hazardous_Materials_Management', 0.9844693541526794)","('Water_And_Wastewater_Management', 0.0013878562022000551)","('Data_Security', 0.0010429196991026402)","(['Operational Eco-Efficiency'], 0.9844693541526794)","('NON-ESG', 0.0013878562022000551)","('NON-ESG', 0.0010429196991026402)"
Line 1042,"We are committed to reducing nonhazard and hazardous waste  generated.
","('Waste_And_Hazardous_Materials_Management', 0.9843810796737671)","('Data_Security', 0.0011440879898145795)","('Air_Quality', 0.001057460787706077)","(['Operational Eco-Efficiency'], 0.9843810796737671)","('NON-ESG', 0.0011440879898145795)","('NON-ESG', 0.001057460787706077)"
Line 1043,"We are examining ways to move beyond the  traditional hierarchy of waste management by focusing on  opportunities to prevent waste from occurring and proactively  planning how to extend the life of materials that would  otherwise become waste.
","('Waste_And_Hazardous_Materials_Management', 0.9846742153167725)","('Data_Security', 0.0011014242190867662)","('Water_And_Wastewater_Management', 0.0010516500333324075)","(['Operational Eco-Efficiency'], 0.9846742153167725)","('NON-ESG', 0.0011014242190867662)","('NON-ESG', 0.0010516500333324075)"
Line 1044,"Through management of change  processes, our manufacturing locations are required to review  and assess what waste would be generated by process changes  and design transfers.
","('Waste_And_Hazardous_Materials_Management', 0.9840717911720276)","('Water_And_Wastewater_Management', 0.0017226490890607238)","('Air_Quality', 0.0012368394527584314)","(['Operational Eco-Efficiency'], 0.9840717911720276)","('NON-ESG', 0.0017226490890607238)","('NON-ESG', 0.0012368394527584314)"
Line 1045,"Cross-functional teams will also evaluate source reduction and  waste minimization opportunities and will partner with our waste  disposal vendors to evaluate areas for waste reduction, reuse,  redesign and recycle.
","('Waste_And_Hazardous_Materials_Management', 0.9832506775856018)","('Water_And_Wastewater_Management', 0.0013390232343226671)","('Product_Design_And_Lifecycle_Management', 0.001215880154632032)","(['Operational Eco-Efficiency'], 0.9832506775856018)","('NON-ESG', 0.0013390232343226671)","('NON-ESG', 0.001215880154632032)"
Line 1046,"Data associated with the generation of waste is reported by  each of our locations via an online system, and this data is  reviewed and monitored on an ongoing basis.
","('Waste_And_Hazardous_Materials_Management', 0.9820340871810913)","('Water_And_Wastewater_Management', 0.0022592071909457445)","('Air_Quality', 0.0015292938333004713)","(['Operational Eco-Efficiency'], 0.9820340871810913)","('NON-ESG', 0.0022592071909457445)","('NON-ESG', 0.0015292938333004713)"
Line 1047,"This enables us to  assess the type and amount of material that is being generated  and to identify opportunities for improvement that can occur on  a local or regional level.
","('Product_Design_And_Lifecycle_Management', 0.5623660683631897)","('Supply_Chain_Management', 0.09208876639604568)","('Waste_And_Hazardous_Materials_Management', 0.07576720416545868)","(['Product Stewardship'], 0.5623660683631897)","('NON-ESG', 0.09208876639604568)","('NON-ESG', 0.07576720416545868)"
Line 1048,"Risks associated with the transportation, storage and disposal of  waste are identified, managed and mitigated through a series of  mechanisms, such as internal governance protocols, end disposal  selection approval process, vendor management and end  disposal site audits.
","('Waste_And_Hazardous_Materials_Management', 0.9827378392219543)","('Water_And_Wastewater_Management', 0.0019633397459983826)","('Product_Design_And_Lifecycle_Management', 0.0011257847072556615)","(['Operational Eco-Efficiency'], 0.9827378392219543)","('NON-ESG', 0.0019633397459983826)","('NON-ESG', 0.0011257847072556615)"
Line 1049,"Waste performance While we continue to assess and implement waste reduction  projects, we have more work to do to improve total waste  reduction from our operations.
","('Waste_And_Hazardous_Materials_Management', 0.9835813045501709)","('Air_Quality', 0.0014611936639994383)","('Data_Security', 0.0011453918414190412)","(['Operational Eco-Efficiency'], 0.9835813045501709)","('NON-ESG', 0.0014611936639994383)","('NON-ESG', 0.0011453918414190412)"
Line 1050,"Disposal methods have remained  largely static, and we continue to face challenges with recycling  waste streams.
","('Waste_And_Hazardous_Materials_Management', 0.980726420879364)","('Water_And_Wastewater_Management', 0.0019499040208756924)","('Product_Design_And_Lifecycle_Management', 0.001396654173731804)","(['Operational Eco-Efficiency'], 0.980726420879364)","('NON-ESG', 0.0019499040208756924)","('NON-ESG', 0.001396654173731804)"
Line 1051,"However, hazardous waste generation saw a  decrease due to operational improvements.
","('Waste_And_Hazardous_Materials_Management', 0.9841728210449219)","('Water_And_Wastewater_Management', 0.0012535930145531893)","('Data_Security', 0.0011843107640743256)","(['Operational Eco-Efficiency'], 0.9841728210449219)","('NON-ESG', 0.0012535930145531893)","('NON-ESG', 0.0011843107640743256)"
Line 1052,"There were a few unique factors in FY 2020 that contributed to  our waste performance.
","('Waste_And_Hazardous_Materials_Management', 0.9792294502258301)","('Water_And_Wastewater_Management', 0.0017970901681110263)","('Air_Quality', 0.0017402272205799818)","(['Operational Eco-Efficiency'], 0.9792294502258301)","('NON-ESG', 0.0017970901681110263)","('NON-ESG', 0.0017402272205799818)"
Line 1053,"• Cleaning protocols introduced in response to the pandemic  contributed to increases in the hazardous and regulated  waste streams • Increased production at manufacturing facilities used for the  testing and treatment of, and vaccination against, COVID-• One-time waste generation associated with development and  start-up of new production lines • One-time disposal of expired products and product recalls Click here to view the Waste data tables .Waste  Air emissions While our facilities continued to make absolute  reductions in HAP emissions, VOC emissions have risen.
","('Waste_And_Hazardous_Materials_Management', 0.9845015406608582)","('Water_And_Wastewater_Management', 0.0011712732957676053)","('Air_Quality', 0.0011542646680027246)","(['Operational Eco-Efficiency'], 0.9845015406608582)","('NON-ESG', 0.0011712732957676053)","('NON-ESG', 0.0011542646680027246)"
Line 1054,"• Cleaning protocols introduced in response to the pandemic  contributed to increases in the hazardous and regulated  waste streams • Increased production at manufacturing facilities used for the  testing and treatment of, and vaccination against, COVID-• One-time waste generation associated with development and  start-up of new production lines • One-time disposal of expired products and product recalls Click here to view the Waste data tables .Waste  Air emissions While our facilities continued to make absolute  reductions in HAP emissions, VOC emissions have risen.
","('GHG_Emissions', 0.8142622709274292)","('Air_Quality', 0.0857279896736145)","('Energy_Management', 0.022950362414121628)","(['Climate Change'], 0.8142622709274292)","('NON-ESG', 0.0857279896736145)","('NON-ESG', 0.022950362414121628)"
Line 1055,"Data demonstrates areas for opportunity remain and  we will continue to reduce emissions through process  improvement projects and installation of emissions  control equipment.We continue to make progress on the reduction of  ozone-depleting substances, which are used at several  of our BD Medical facilities.
","('Air_Quality', 0.7979881167411804)","('GHG_Emissions', 0.12847229838371277)","('Energy_Management', 0.012361130677163601)","(['Operational Eco-Efficiency'], 0.7979881167411804)","('NON-ESG', 0.12847229838371277)","('NON-ESG', 0.012361130677163601)"
Line 1056,"Conversion plans to  eliminate the use of HCFC141b remain in progress and  are expected to be completed as scheduled.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48002365231513977)","('GHG_Emissions', 0.11735590547323227)","('Energy_Management', 0.11653394997119904)","('NON-ESG', 0.48002365231513977)","('NON-ESG', 0.11735590547323227)","('NON-ESG', 0.11653394997119904)"
Line 1057,"Click here to view the Air emissions data tables .
","('Air_Quality', 0.9753995537757874)","('Waste_And_Hazardous_Materials_Management', 0.002099535660818219)","('GHG_Emissions', 0.002076941542327404)","(['Operational Eco-Efficiency'], 0.9753995537757874)","('NON-ESG', 0.002099535660818219)","('NON-ESG', 0.002076941542327404)"
Line 1058,"Access Innovation Efficiency Empowerment Governance Environment, Health and Safety (EHS) management  We set expectations of environmental, health and safety  management via three key documents: • Our EHS policy • Our Code of Conduct  • Our Expectation for Suppliers At the corporate level, BD has an EHS team, led by the VP of  Environment, Health & Safety and Sustainability (EHS&S); the VP  EHS&S reports to the company’s Executive VP Integrated Supply  Chain (EVP ISC).
","('Supply_Chain_Management', 0.8877872824668884)","('Employee_Health_And_Safety', 0.020065302029252052)","('Waste_And_Hazardous_Materials_Management', 0.010043147951364517)","(['Supply Chain Management'], 0.8877872824668884)","('NON-ESG', 0.020065302029252052)","('NON-ESG', 0.010043147951364517)"
Line 1059,"Reporting to the VP EHS&S are the following  individuals with responsibility for EHS activities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7086873650550842)","('Human_Rights_And_Community_Relations', 0.04409833997488022)","('Director_Removal', 0.02592250518500805)","(['Corporate Governance'], 0.7086873650550842)","('NON-ESG', 0.04409833997488022)","('NON-ESG', 0.02592250518500805)"
Line 1060,"• Senior Director, EHS Governance & Compliance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.555802047252655)","('Business_Model_Resilience', 0.08190708607435226)","('Business_Ethics', 0.05834423005580902)","(['Corporate Governance'], 0.555802047252655)","('NON-ESG', 0.08190708607435226)","('NON-ESG', 0.05834423005580902)"
Line 1061,"This individual  is responsible for governance and compliance activities,  including our company’s internal EHS audit program, EHS  standards and training programs and communicating EHS  matters to relevant stakeholders throughout the organization.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5782464742660522)","('Business_Ethics', 0.2754310071468353)","('Product_Quality_And_Safety', 0.03231438621878624)","(['Corporate Governance'], 0.5782464742660522)","('NON-ESG', 0.2754310071468353)","('NON-ESG', 0.03231438621878624)"
Line 1062,"This individual also oversees the Global EHS Advisory Council  (see the Empowerment section for further information).
","('Management_Of_Legal_And_Regulatory_Framework', 0.8659992218017578)","('Director_Removal', 0.017517687752842903)","('Business_Ethics', 0.012878227978944778)","(['Corporate Governance'], 0.8659992218017578)","('NON-ESG', 0.017517687752842903)","('NON-ESG', 0.012878227978944778)"
Line 1063,"• Director, Sustainability.
","('Product_Design_And_Lifecycle_Management', 0.15307851135730743)","('Business_Model_Resilience', 0.14870105683803558)","('Supply_Chain_Management', 0.10639584064483643)","('NON-ESG', 0.15307851135730743)","('NON-ESG', 0.14870105683803558)","('NON-ESG', 0.10639584064483643)"
Line 1064,"In addition to stakeholder  engagement and development of our sustainability strategy,  this individual is responsible for the development of our water  stewardship and waste management programs; and  management of our EHS information management systems.
","('Water_And_Wastewater_Management', 0.9465089440345764)","('Ecological_Impacts', 0.012303666211664677)","('GHG_Emissions', 0.005624392069876194)","(['Operational Eco-Efficiency'], 0.9465089440345764)","('NON-ESG', 0.012303666211664677)","('NON-ESG', 0.005624392069876194)"
Line 1065,"The VP EHS&S engages directly with the Executive Leadership  Team and provides a report on EHS activities to the Board on an  annual basis.
","('Director_Removal', 0.6824329495429993)","('Management_Of_Legal_And_Regulatory_Framework', 0.04421653971076012)","('Business_Model_Resilience', 0.04144256189465523)","(['Anti-Crime Policy & Measures'], 0.6824329495429993)","('NON-ESG', 0.04421653971076012)","('NON-ESG', 0.04144256189465523)"
Line 1066,"The Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen;  this includes EHS matters.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7378113269805908)","('Director_Removal', 0.06564266979694366)","('Business_Ethics', 0.04555574432015419)","(['Corporate Governance'], 0.7378113269805908)","('NON-ESG', 0.06564266979694366)","('NON-ESG', 0.04555574432015419)"
Line 1067,"Training At a corporate level, we provide various training to our associates,  including new hire orientation to EHS professionals; training on  new or revised corporate EHS standards, and ongoing training for  our EHS management of information systems.
","('Product_Quality_And_Safety', 0.3289068639278412)","('Management_Of_Legal_And_Regulatory_Framework', 0.1708098202943802)","('Access_And_Affordability', 0.08906444162130356)","('NON-ESG', 0.3289068639278412)","('NON-ESG', 0.1708098202943802)","('NON-ESG', 0.08906444162130356)"
Line 1068,"We use a variety  of training mediums, including classroom training, webinars and  on-demand compliance training via our company’s online  training system.
","('Product_Quality_And_Safety', 0.1677895486354828)","('Management_Of_Legal_And_Regulatory_Framework', 0.15483061969280243)","('Access_And_Affordability', 0.14476202428340912)","('NON-ESG', 0.1677895486354828)","('NON-ESG', 0.15483061969280243)","('NON-ESG', 0.14476202428340912)"
Line 1069,"Individual sites are responsible for identifying site-specific EHS  training needs and implementing training programs on a variety  of EHS topics, taking into consideration the risks that are present  and any local regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9619016647338867)","('Product_Quality_And_Safety', 0.004087002016603947)","('Access_And_Affordability', 0.002848547650501132)","(['Corporate Governance'], 0.9619016647338867)","('NON-ESG', 0.004087002016603947)","('NON-ESG', 0.002848547650501132)"
Line 1070,"EHS management information systems We use global EHS management of information systems that  are provided by third-party vendors to collect and manage EHS  data, such as:• EHS incident reporting (including near misses) and corrective  action tracking • EHS performance metric reporting and tracking • Safety data sheet management In FY 2020, we identified and selected a new platform to  manage EHS incidence reporting and corrective action tracking.
","('Employee_Health_And_Safety', 0.5345085859298706)","('Critical_Incident_Risk_Management', 0.3819286525249481)","('Air_Quality', 0.007385051343590021)","(['Operational Eco-Efficiency'], 0.5345085859298706)","('NON-ESG', 0.3819286525249481)","('NON-ESG', 0.007385051343590021)"
Line 1071,"This new system will eliminate multiple instances in the existing  platform, simplifying reporting and improving governance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9270735383033752)","('Systemic_Risk_Management', 0.00865304283797741)","('Business_Ethics', 0.007932201959192753)","(['Corporate Governance'], 0.9270735383033752)","('NON-ESG', 0.00865304283797741)","('NON-ESG', 0.007932201959192753)"
Line 1072,"The new platform will go live in FY 2021.
","('Business_Model_Resilience', 0.255276620388031)","('Data_Security', 0.11601052433252335)","('Physical_Impacts_Of_Climate_Change', 0.092500701546669)","('NON-ESG', 0.255276620388031)","('NON-ESG', 0.11601052433252335)","('NON-ESG', 0.092500701546669)"
Line 1073,"Internal audits We have a global internal audit program covering all BD locations.
","('Business_Ethics', 0.8875155448913574)","('Systemic_Risk_Management', 0.021604081615805626)","('Management_Of_Legal_And_Regulatory_Framework', 0.01800544001162052)","(['Business Ethics'], 0.8875155448913574)","('NON-ESG', 0.021604081615805626)","('NON-ESG', 0.01800544001162052)"
Line 1074,"Audits are typically carried out by a third party and a  representative from the corporate EHS&S team who leads and  monitors audit performance and outcomes.
","('Business_Ethics', 0.3506816327571869)","('Management_Of_Legal_And_Regulatory_Framework', 0.3421150743961334)","('Systemic_Risk_Management', 0.10252749919891357)","('NON-ESG', 0.3506816327571869)","('NON-ESG', 0.3421150743961334)","('NON-ESG', 0.10252749919891357)"
Line 1075,"In FY 2020, the BD  EHS team implemented a new risk-based audit model which  gauges facilities on three main components: inherit risk, changes  and performance.
","('Systemic_Risk_Management', 0.8861632347106934)","('Business_Ethics', 0.017686961218714714)","('Business_Model_Resilience', 0.016500240191817284)","(['Risk & Crisis Management'], 0.8861632347106934)","('NON-ESG', 0.017686961218714714)","('NON-ESG', 0.016500240191817284)"
Line 1076,"This enabled a more deliberate focus for  selection of sites to be audited during the year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38281649351119995)","('Competitive_Behavior', 0.16207388043403625)","('Business_Ethics', 0.13952358067035675)","('NON-ESG', 0.38281649351119995)","('NON-ESG', 0.16207388043403625)","('NON-ESG', 0.13952358067035675)"
Line 1077,"Executive summaries  from each initial and follow-up audit are provided to site  management, operational leaders, EHS Business unit leaders,  EVP ISC and the CEO.
","('Director_Removal', 0.3837064504623413)","('Business_Model_Resilience', 0.2170449197292328)","('Employee_Engagement_Inclusion_And_Diversity', 0.06998037546873093)","('NON-ESG', 0.3837064504623413)","('NON-ESG', 0.2170449197292328)","('NON-ESG', 0.06998037546873093)"
Line 1078,"All corrective actions are tracked to closure  with a follow-up audit carried out approximately six and 12  months later to verify completion.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5166219472885132)","('Business_Ethics', 0.2599031329154968)","('Systemic_Risk_Management', 0.04059891775250435)","(['Corporate Governance'], 0.5166219472885132)","('NON-ESG', 0.2599031329154968)","('NON-ESG', 0.04059891775250435)"
Line 1079,"EHS management systems To ensure continuous improvement of environmental  performance at a facility level, BD is implementing ISO  14001-certified environmental management systems at our  manufacturing sites around the world.
","('Product_Design_And_Lifecycle_Management', 0.6482076048851013)","('Energy_Management', 0.0727972760796547)","('Supply_Chain_Management', 0.03376920148730278)","(['Product Stewardship'], 0.6482076048851013)","('NON-ESG', 0.0727972760796547)","('NON-ESG', 0.03376920148730278)"
Line 1080,"Currently, 46 BD sites  have ISO 14001-certified environmental management systems;  most of these sites are manufacturing locations, but also  includes HQ offices and some sales offices in Europe.
","('Product_Design_And_Lifecycle_Management', 0.4104142189025879)","('Product_Quality_And_Safety', 0.22226566076278687)","('Supply_Chain_Management', 0.04781441017985344)","('NON-ESG', 0.4104142189025879)","('NON-ESG', 0.22226566076278687)","('NON-ESG', 0.04781441017985344)"
Line 1081,"Around two-thirds of these certified locations are part of a group  certificate, where we have established standardized procedures  and methods for program implementation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48568496108055115)","('Product_Quality_And_Safety', 0.14489391446113586)","('Human_Rights_And_Community_Relations', 0.0647311881184578)","('NON-ESG', 0.48568496108055115)","('NON-ESG', 0.14489391446113586)","('NON-ESG', 0.0647311881184578)"
Line 1082,"This standardized  approach allows sites to work together in a collaborative way  with extensive sharing and interaction to enhance program  effectiveness.
","('Access_And_Affordability', 0.39337578415870667)","('Management_Of_Legal_And_Regulatory_Framework', 0.22261810302734375)","('Human_Rights_And_Community_Relations', 0.10423155128955841)","('NON-ESG', 0.39337578415870667)","('NON-ESG', 0.22261810302734375)","('NON-ESG', 0.10423155128955841)"
Line 1083,"For example, all corrective actions are logged and  shared with all sites in the respective group certificates to  facilitate learning from each other’s experience and to take  proactive actions to prevent similar issues from happening at  other sites.
","('Business_Ethics', 0.34746798872947693)","('Management_Of_Legal_And_Regulatory_Framework', 0.19254662096500397)","('Human_Rights_And_Community_Relations', 0.07299992442131042)","('NON-ESG', 0.34746798872947693)","('NON-ESG', 0.19254662096500397)","('NON-ESG', 0.07299992442131042)"
Line 1084,"Furthermore, every EMS-certified site sets  environmental improvement objectives on an annual basis and  they are reviewed for progress quarterly.
","('Product_Design_And_Lifecycle_Management', 0.18720102310180664)","('Ecological_Impacts', 0.15080931782722473)","('Human_Rights_And_Community_Relations', 0.10777932405471802)","('NON-ESG', 0.18720102310180664)","('NON-ESG', 0.15080931782722473)","('NON-ESG', 0.10777932405471802)"
Line 1085,"Our plan is to continue ISO 14001 certification of remaining BD  manufacturing plants over the coming years.
","('Product_Quality_And_Safety', 0.42622697353363037)","('Product_Design_And_Lifecycle_Management', 0.28931209444999695)","('Management_Of_Legal_And_Regulatory_Framework', 0.026488138362765312)","('NON-ESG', 0.42622697353363037)","('NON-ESG', 0.28931209444999695)","('NON-ESG', 0.026488138362765312)"
Line 1086,"Access Innovation Efficiency Empowerment Governance GRI disclosures: 403-1, 403-5The ISO 50001 energy management standard provides a  framework of requirements to measure and use data for better  understanding of energy use, set objectives for energy use  reduction and continually improve energy management.
","('Energy_Management', 0.9805431962013245)","('Management_Of_Legal_And_Regulatory_Framework', 0.0018842126009985805)","('Product_Design_And_Lifecycle_Management', 0.0018230744171887636)","(['Operational Eco-Efficiency'], 0.9805431962013245)","('NON-ESG', 0.0018842126009985805)","('NON-ESG', 0.0018230744171887636)"
Line 1087,"Many BD facilities have a strong focus on energy management  and reduction and are pursuing many aspects of a responsible  energy management program.
","('Energy_Management', 0.9798905849456787)","('Air_Quality', 0.002157552633434534)","('Critical_Incident_Risk_Management', 0.001936158281750977)","(['Operational Eco-Efficiency'], 0.9798905849456787)","('NON-ESG', 0.002157552633434534)","('NON-ESG', 0.001936158281750977)"
Line 1088,"We currently have two facilities  in Spain and Hungary that have implemented energy  management systems which are certified to ISO 50001.
","('Energy_Management', 0.9559239149093628)","('Product_Design_And_Lifecycle_Management', 0.006976784206926823)","('Management_Of_Legal_And_Regulatory_Framework', 0.003568216459825635)","(['Operational Eco-Efficiency'], 0.9559239149093628)","('NON-ESG', 0.006976784206926823)","('NON-ESG', 0.003568216459825635)"
Line 1089,"All BD manufacturing locations have a strong focus on  occupational health and safety (OHS) management for injury  reduction and prevention.
","('Employee_Health_And_Safety', 0.9847753643989563)","('Employee_Engagement_Inclusion_And_Diversity', 0.0017760635819286108)","('Critical_Incident_Risk_Management', 0.0012124800123274326)","(['Operational Eco-Efficiency'], 0.9847753643989563)","('NON-ESG', 0.0017760635819286108)","('NON-ESG', 0.0012124800123274326)"
Line 1090,"Significant OHS risks associated with  our activities are identified and reviewed for elimination and/or  control to minimize their potential effects on our employees.
","('Systemic_Risk_Management', 0.6387709379196167)","('Employee_Health_And_Safety', 0.10514277964830399)","('Supply_Chain_Management', 0.06784985214471817)","(['Risk & Crisis Management'], 0.6387709379196167)","('NON-ESG', 0.10514277964830399)","('NON-ESG', 0.06784985214471817)"
Line 1091,"The most accepted OHS management system in the past has  been the OHSAS-18001 standard, and two BD sites in Spain and  China are certified in this standard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3710722029209137)","('Systemic_Risk_Management', 0.10396196693181992)","('Product_Quality_And_Safety', 0.08761931955814362)","('NON-ESG', 0.3710722029209137)","('NON-ESG', 0.10396196693181992)","('NON-ESG', 0.08761931955814362)"
Line 1092,"The OHSAS-18001 standard  is currently being replaced by ISO-45001 and both of our sites  have converted to this new standard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4321702718734741)","('Product_Quality_And_Safety', 0.22077924013137817)","('Product_Design_And_Lifecycle_Management', 0.02870684675872326)","('NON-ESG', 0.4321702718734741)","('NON-ESG', 0.22077924013137817)","('NON-ESG', 0.02870684675872326)"
Line 1093,"Although our other sites  are currently not formally certified in any OHS standard, their  site safety programs follow many of the elements included in  the OHSAS-18001/ISO-45001 standards.
","('Product_Quality_And_Safety', 0.6205521821975708)","('Employee_Health_And_Safety', 0.21340572834014893)","('Business_Ethics', 0.031633976846933365)","(['Product Quality & Recall Management'], 0.6205521821975708)","('NON-ESG', 0.21340572834014893)","('NON-ESG', 0.031633976846933365)"
Line 1094,"For additional details on work carried out in FY 2020 related   to associate safety, please see our goals around achieving   best-in-class associate safety performance in the  Empowerment  section of this report.
","('Product_Quality_And_Safety', 0.808458685874939)","('Employee_Health_And_Safety', 0.08095036447048187)","('Access_And_Affordability', 0.013205542229115963)","(['Product Quality & Recall Management'], 0.808458685874939)","('NON-ESG', 0.08095036447048187)","('NON-ESG', 0.013205542229115963)"
Line 1095,"Access Innovation Efficiency Empowerment Governance Supplier risk management is a major focus area for BD.
","('Supply_Chain_Management', 0.9257557392120361)","('Product_Design_And_Lifecycle_Management', 0.014847285114228725)","('Labor_Practices', 0.004876961465924978)","(['Supply Chain Management'], 0.9257557392120361)","('NON-ESG', 0.014847285114228725)","('NON-ESG', 0.004876961465924978)"
Line 1096,"The overarching strategy of the risk program is to enable  processes and procedures that reduce or eliminate the likelihood  of a supplier event affecting our continuity of supply.
","('Supply_Chain_Management', 0.9545343518257141)","('Labor_Practices', 0.0039816685020923615)","('Water_And_Wastewater_Management', 0.003397855442017317)","(['Supply Chain Management'], 0.9545343518257141)","('NON-ESG', 0.0039816685020923615)","('NON-ESG', 0.003397855442017317)"
Line 1097,"We have  developed a robust assessment process to identify our “critical  to healthcare” products.
","('Product_Design_And_Lifecycle_Management', 0.957791805267334)","('Supply_Chain_Management', 0.004617077764123678)","('Product_Quality_And_Safety', 0.0045331805013120174)","(['Product Stewardship'], 0.957791805267334)","('NON-ESG', 0.004617077764123678)","('NON-ESG', 0.0045331805013120174)"
Line 1098,"This has allowed us to prioritize risk  management best practices for not only our strategic products  but also those critical to the healthcare market.
","('Business_Model_Resilience', 0.6134169101715088)","('Systemic_Risk_Management', 0.18143099546432495)","('Supply_Chain_Management', 0.05389200896024704)","(['Codes of Business Conduct'], 0.6134169101715088)","('NON-ESG', 0.18143099546432495)","('NON-ESG', 0.05389200896024704)"
Line 1099,"With a   top-down directive on risk management, we have implemented  an enhanced risk model with a consistent framework across all  our business units to assess, identify, prioritize, mitigate and  monitor top risks.
","('Systemic_Risk_Management', 0.9471973776817322)","('Business_Model_Resilience', 0.012295812368392944)","('Physical_Impacts_Of_Climate_Change', 0.005815837532281876)","(['Risk & Crisis Management'], 0.9471973776817322)","('NON-ESG', 0.012295812368392944)","('NON-ESG', 0.005815837532281876)"
Line 1100,"The program takes a quantifiable approach to assess   multiple risk factors, including direct supplier-driven risks,   such as operational and financial risk, as well as indirect or  market-driven risks, such as natural disasters and geopolitical risks.
","('Supply_Chain_Management', 0.5656440854072571)","('Systemic_Risk_Management', 0.30521684885025024)","('Physical_Impacts_Of_Climate_Change', 0.03445185348391533)","(['Supply Chain Management'], 0.5656440854072571)","('NON-ESG', 0.30521684885025024)","('NON-ESG', 0.03445185348391533)"
Line 1101,"We continue to build our capabilities to include the identification  and monitoring of our tier-n supply chain by leveraging supplier  surveys and AI discovery services.
","('Supply_Chain_Management', 0.9521431922912598)","('Labor_Practices', 0.0044652316719293594)","('Product_Design_And_Lifecycle_Management', 0.0033666417002677917)","(['Supply Chain Management'], 0.9521431922912598)","('NON-ESG', 0.0044652316719293594)","('NON-ESG', 0.0033666417002677917)"
Line 1102,"Additionally, we have formed  a cross-business, cross-functional and cross-regional crisis  management team to proactively monitor and respond to  events around the world that may impact our supply chain.
","('Supply_Chain_Management', 0.9564056396484375)","('Physical_Impacts_Of_Climate_Change', 0.0036711806897073984)","('Systemic_Risk_Management', 0.0036336113698780537)","(['Supply Chain Management'], 0.9564056396484375)","('NON-ESG', 0.0036711806897073984)","('NON-ESG', 0.0036336113698780537)"
Line 1103,"The program will continue to evolve as we leverage sophisticated  technologies to aid us in our journey to resiliency.2020 goal Establish  supplier responsibility evaluation methodology  BD is committed to partnering with suppliers to actively work  towards eliminating human rights abuses across our supply chain.
","('Supply_Chain_Management', 0.953296959400177)","('Labor_Practices', 0.004151670727878809)","('Physical_Impacts_Of_Climate_Change', 0.004034421406686306)","(['Supply Chain Management'], 0.953296959400177)","('NON-ESG', 0.004151670727878809)","('NON-ESG', 0.004034421406686306)"
Line 1104,"Our Expectations for Suppliers (EFS) document details the  minimum standards that all our suppliers must meet with regards  to human rights.
","('Human_Rights_And_Community_Relations', 0.5994790196418762)","('Labor_Practices', 0.16028350591659546)","('Supply_Chain_Management', 0.033915404230356216)","(['Community Relations'], 0.5994790196418762)","('NON-ESG', 0.16028350591659546)","('NON-ESG', 0.033915404230356216)"
Line 1105,"More information on this document is provided in  the following section.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5779505372047424)","('Ecological_Impacts', 0.041383255273103714)","('Access_And_Affordability', 0.039850205183029175)","(['Corporate Governance'], 0.5779505372047424)","('NON-ESG', 0.041383255273103714)","('NON-ESG', 0.039850205183029175)"
Line 1106,"On an ongoing basis, BD suppliers are analyzed annually, via a third  party, against two focus areas: industry-specific risk and geographic  or location risk.
","('Supply_Chain_Management', 0.9462622404098511)","('Water_And_Wastewater_Management', 0.004423149395734072)","('Energy_Management', 0.004232434555888176)","(['Supply Chain Management'], 0.9462622404098511)","('NON-ESG', 0.004423149395734072)","('NON-ESG', 0.004232434555888176)"
Line 1107,"* BD recognizes that our highest risk suppliers are  likely to be found in countries cited for having the highest  prevalence of modern slavery and human trafficking rights  violations.
","('Employee_Health_And_Safety', 0.2974027693271637)","('Business_Ethics', 0.19682666659355164)","('Human_Rights_And_Community_Relations', 0.17733284831047058)","('NON-ESG', 0.2974027693271637)","('NON-ESG', 0.19682666659355164)","('NON-ESG', 0.17733284831047058)"
Line 1108,"Suppliers with the highest risk profiles are prioritized for  further evaluation.
","('Supply_Chain_Management', 0.9140307903289795)","('Systemic_Risk_Management', 0.018492935225367546)","('Physical_Impacts_Of_Climate_Change', 0.008990862406790257)","(['Supply Chain Management'], 0.9140307903289795)","('NON-ESG', 0.018492935225367546)","('NON-ESG', 0.008990862406790257)"
Line 1109,"Those suppliers identified as high priority and/or providing “critical  to healthcare” materials will be asked to complete an in-depth  desktop audit led by a third party, the results of which may trigger  site inspections and/or in-person audits or guide corrective actions  if deemed necessary.
","('Supply_Chain_Management', 0.9180237054824829)","('Systemic_Risk_Management', 0.009169789031147957)","('Waste_And_Hazardous_Materials_Management', 0.008517125621438026)","(['Supply Chain Management'], 0.9180237054824829)","('NON-ESG', 0.009169789031147957)","('NON-ESG', 0.008517125621438026)"
Line 1110,"BD also maintains several policies, mechanisms and trainings that  support our work in this area.
","('Management_Of_Legal_And_Regulatory_Framework', 0.806049108505249)","('Human_Rights_And_Community_Relations', 0.06412894278764725)","('Access_And_Affordability', 0.019074559211730957)","(['Corporate Governance'], 0.806049108505249)","('NON-ESG', 0.06412894278764725)","('NON-ESG', 0.019074559211730957)"
Line 1111,"These include;  • The BD Global Human Rights Policy which prohibits the use of  forced, prison, indentured, bonded or involuntary labor in all of  BD operations, among other human rights issues; • The BD Code of Conduct that reaffirms the human rights  commitments outlined in the above policy; • The BD Global Speaking Up Policy, which encourages and  expects all associates and agents to speak up about any actual  or suspected violations of laws, regulations, the BD Code of  Conduct, BD policies or relevant industry codes, except as  prohibited by law.
","('Labor_Practices', 0.8708760142326355)","('Human_Rights_And_Community_Relations', 0.056833136826753616)","('Employee_Engagement_Inclusion_And_Diversity', 0.007724371738731861)","(['Labor Practice Indicators'], 0.8708760142326355)","('NON-ESG', 0.056833136826753616)","('NON-ESG', 0.007724371738731861)"
Line 1112,"These include;  • The BD Global Human Rights Policy which prohibits the use of  forced, prison, indentured, bonded or involuntary labor in all of  BD operations, among other human rights issues; • The BD Code of Conduct that reaffirms the human rights  commitments outlined in the above policy; • The BD Global Speaking Up Policy, which encourages and  expects all associates and agents to speak up about any actual  or suspected violations of laws, regulations, the BD Code of  Conduct, BD policies or relevant industry codes, except as  prohibited by law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9179813265800476)","('Business_Ethics', 0.010142972692847252)","('Director_Removal', 0.007661996874958277)","(['Corporate Governance'], 0.9179813265800476)","('NON-ESG', 0.010142972692847252)","('NON-ESG', 0.007661996874958277)"
Line 1113,"Those that speak up in good faith are  protected against any form of retaliation or discipline; • The BD Ethics Helpline which allows for anonymous (where  permitted by law) and/or confidential reporting of all matters of  ethics concerns, including known or suspected human rights  abuses, both within BD and in our wider supply chain.
","('Business_Ethics', 0.9695632457733154)","('Data_Security', 0.0034350536298006773)","('Systemic_Risk_Management', 0.0025485046207904816)","(['Business Ethics'], 0.9695632457733154)","('NON-ESG', 0.0034350536298006773)","('NON-ESG', 0.0025485046207904816)"
Line 1114,"It is available online or via telephone in a number of  languages; and • Forced labor and human trafficking training developed by a  third party and administered annually to BD associates online.
","('Labor_Practices', 0.9077177047729492)","('Human_Rights_And_Community_Relations', 0.015620997175574303)","('Employee_Health_And_Safety', 0.012429756112396717)","(['Labor Practice Indicators'], 0.9077177047729492)","('NON-ESG', 0.015620997175574303)","('NON-ESG', 0.012429756112396717)"
Line 1115,"This course explains that forced labor, also known as modern  slavery, still exists in the world and prompts the learner to  consider ways of identifying, preventing and stopping it in the  supply chain.
","('Labor_Practices', 0.95572829246521)","('Supply_Chain_Management', 0.006236179731786251)","('Employee_Health_And_Safety', 0.005337633658200502)","(['Labor Practice Indicators'], 0.95572829246521)","('NON-ESG', 0.006236179731786251)","('NON-ESG', 0.005337633658200502)"
Line 1116,"It also trains BD associates on how to report known  or suspected human rights abuses via our Ethics Helpline.
","('Business_Ethics', 0.7844582200050354)","('Human_Rights_And_Community_Relations', 0.0704377144575119)","('Management_Of_Legal_And_Regulatory_Framework', 0.02269311249256134)","(['Business Ethics'], 0.7844582200050354)","('NON-ESG', 0.0704377144575119)","('NON-ESG', 0.02269311249256134)"
Line 1117,"This course is delivered to BD associates that interact directly  and indirectly in sourcing, managing, advising on, or are  otherwise involved with our suppliers, including but not limited to  our leaders and our associates in the following departments:  Environment, Health and Safety, Procurement, Supply Chain,  Quality, R&D, Operations, Human Resources, and our Law Group.
","('Supply_Chain_Management', 0.9444695115089417)","('Product_Design_And_Lifecycle_Management', 0.006489002611488104)","('Labor_Practices', 0.004259764216840267)","(['Supply Chain Management'], 0.9444695115089417)","('NON-ESG', 0.006489002611488104)","('NON-ESG', 0.004259764216840267)"
Line 1118,"More details on our human rights due diligence efforts in our supply  chain are provided in our compliance documents, which can be  found on the Sustainability page of bd.com .
","('Supply_Chain_Management', 0.9363808631896973)","('Product_Design_And_Lifecycle_Management', 0.007268472574651241)","('Labor_Practices', 0.004949843976646662)","(['Supply Chain Management'], 0.9363808631896973)","('NON-ESG', 0.007268472574651241)","('NON-ESG', 0.004949843976646662)"
Line 1119,"BD Expectations for Suppliers As mentioned above, the BD Expectations for Suppliers (EFS)  document details the minimum standards that suppliers must  meet—these cover human rights standards, as well as  environmental and governance standards and ethical practices.
","('Business_Ethics', 0.8375269770622253)","('Labor_Practices', 0.032131604850292206)","('Human_Rights_And_Community_Relations', 0.021105598658323288)","(['Business Ethics'], 0.8375269770622253)","('NON-ESG', 0.032131604850292206)","('NON-ESG', 0.021105598658323288)"
Line 1120,"BD includes language that requires its suppliers represent, warrant,  and/or certify to comply with the EFS and all relevant laws in our  contracts, purchase orders and supplier terms and conditions,  among others, where failure to comply could be a breach of  contract and result in contract termination, payment of damages  and other consequences and/or remedies depending on the terms  of the agreement.
","('Supply_Chain_Management', 0.8188417553901672)","('Labor_Practices', 0.06095137819647789)","('Human_Rights_And_Community_Relations', 0.01089670043438673)","(['Supply Chain Management'], 0.8188417553901672)","('NON-ESG', 0.06095137819647789)","('NON-ESG', 0.01089670043438673)"
Line 1121,"Our desktop audit program is designed, in part,  to verify compliance with the expectations laid out in  this document.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6882616877555847)","('Business_Ethics', 0.16732636094093323)","('Product_Quality_And_Safety', 0.02928781695663929)","(['Corporate Governance'], 0.6882616877555847)","('NON-ESG', 0.16732636094093323)","('NON-ESG', 0.02928781695663929)"
Line 1122,"The BD Expectations for Suppliers document is available  online  in a number of languages and is updated periodically   to reflect the high standards by which BD operates.Human rights due diligence in our supply chain * Risk, in this case, is specific to human rights risk.
","('Human_Rights_And_Community_Relations', 0.4126961827278137)","('Supply_Chain_Management', 0.33590757846832275)","('Labor_Practices', 0.05675308033823967)","('NON-ESG', 0.4126961827278137)","('NON-ESG', 0.33590757846832275)","('NON-ESG', 0.05675308033823967)"
Line 1123,"Access Innovation Efficiency Empowerment Governance Supplier diversity encompasses more than simply tracking  spending or “doing the right thing”—it supports our business  values and objectives.
","('Supply_Chain_Management', 0.5121381878852844)","('Employee_Engagement_Inclusion_And_Diversity', 0.15595628321170807)","('Labor_Practices', 0.03984817862510681)","(['Supply Chain Management'], 0.5121381878852844)","('NON-ESG', 0.15595628321170807)","('NON-ESG', 0.03984817862510681)"
Line 1124,"Being committed to supplier diversity  entails developing and implementing strategies that ensure our  supply base aligns with the diverse customers, communities and  patients we serve, as well as the diverse markets we seek.
","('Supply_Chain_Management', 0.7239128351211548)","('Employee_Engagement_Inclusion_And_Diversity', 0.07916168123483658)","('Labor_Practices', 0.03412473574280739)","(['Supply Chain Management'], 0.7239128351211548)","('NON-ESG', 0.07916168123483658)","('NON-ESG', 0.03412473574280739)"
Line 1125,"Having a successful supplier diversity program not only supports  sustainable procurement efforts, but it is integral in how we  support the economic empowerment of underutilized and  underserved communities.
","('Access_And_Affordability', 0.9371619820594788)","('Product_Quality_And_Safety', 0.0065542664378881454)","('Human_Rights_And_Community_Relations', 0.006519523914903402)","(['Health Outcome Contribution'], 0.9371619820594788)","('NON-ESG', 0.0065542664378881454)","('NON-ESG', 0.006519523914903402)"
Line 1126,"Further details on our Supplier Diversity Program can be found  on our website .
","('Employee_Engagement_Inclusion_And_Diversity', 0.885101318359375)","('Supply_Chain_Management', 0.015128434635698795)","('Human_Rights_And_Community_Relations', 0.008765670470893383)","(['Human Capital Development'], 0.885101318359375)","('NON-ESG', 0.015128434635698795)","('NON-ESG', 0.008765670470893383)"
Line 1127,"We remain committed to increasing the number of small and  diverse-owned businesses in our supply chain.
","('Supply_Chain_Management', 0.9426596760749817)","('Product_Design_And_Lifecycle_Management', 0.005824613384902477)","('Labor_Practices', 0.00519780907779932)","(['Supply Chain Management'], 0.9426596760749817)","('NON-ESG', 0.005824613384902477)","('NON-ESG', 0.00519780907779932)"
Line 1128,"After our supplier  diversity performance was negatively impacted in FY 2019 due  to a number of merger-related data alignment factors, we have  made concerted efforts to resolve these challenges.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6736378073692322)","('Supply_Chain_Management', 0.07645189017057419)","('Business_Model_Resilience', 0.045168060809373856)","(['Human Capital Development'], 0.6736378073692322)","('NON-ESG', 0.07645189017057419)","('NON-ESG', 0.045168060809373856)"
Line 1129,"Through focused revision of our data tracking and management  systems, we have improved the way we capture, track and report  spend with small and diverse-owned businesses who are tier 1  and tier 2 suppliers.
","('Supply_Chain_Management', 0.8885107040405273)","('Customer_Welfare', 0.01190997939556837)","('Systemic_Risk_Management', 0.008242916315793991)","(['Supply Chain Management'], 0.8885107040405273)","('NON-ESG', 0.01190997939556837)","('NON-ESG', 0.008242916315793991)"
Line 1130,"With respect to the challenges small and  diverse-owned businesses face during the COVID-19 pandemic,  we have made concerted efforts to extend net terms  considerations to small business suppliers, both diverse and  non-diverse owned.
","('Supply_Chain_Management', 0.8679316639900208)","('Customer_Welfare', 0.013888223096728325)","('Product_Design_And_Lifecycle_Management', 0.013314231298863888)","(['Supply Chain Management'], 0.8679316639900208)","('NON-ESG', 0.013888223096728325)","('NON-ESG', 0.013314231298863888)"
Line 1131,"Both efforts have resulted in identifying  small and diverse-owned suppliers more accurately and in  higher quantity, thus helping to provide a more accurate picture  of our accomplishments and remaining opportunities.
","('Supply_Chain_Management', 0.9005612134933472)","('Product_Design_And_Lifecycle_Management', 0.009602115489542484)","('Customer_Welfare', 0.009540107101202011)","(['Supply Chain Management'], 0.9005612134933472)","('NON-ESG', 0.009602115489542484)","('NON-ESG', 0.009540107101202011)"
Line 1132,"Further information on how our program supports our  communities will be provided in our FY 2021 report with the  addition of our newly established annual economic   impact study.
","('Human_Rights_And_Community_Relations', 0.5969882011413574)","('Access_And_Affordability', 0.10633648931980133)","('Management_Of_Legal_And_Regulatory_Framework', 0.06914961338043213)","(['Community Relations'], 0.5969882011413574)","('NON-ESG', 0.10633648931980133)","('NON-ESG', 0.06914961338043213)"
Line 1133,"50% 0%40% 30% 20% 10% FY 2013 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014Total div erse spen d Disability owne d Veteran owned Woman ownedMinority/W oman owned Minority owne d90% 80% 70% 60%100% FY 2020 FY 2012Supplier Diversity Program: Percent of spend by designationSupplier diversity Access Innovation Efficiency Empowerment Governance 2020 goal Reduce  priority materials of concern in specified product categories BD actively engages in dialog with our customers and advocacy  groups to understand their position on the use of safer chemicals  for consideration in our work to reduce priority MOC.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9581670761108398)","('Competitive_Behavior', 0.003916220739483833)","('Business_Model_Resilience', 0.0036288718692958355)","(['Human Capital Development'], 0.9581670761108398)","('NON-ESG', 0.003916220739483833)","('NON-ESG', 0.0036288718692958355)"
Line 1134,"50% 0%40% 30% 20% 10% FY 2013 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014Total div erse spen d Disability owne d Veteran owned Woman ownedMinority/W oman owned Minority owne d90% 80% 70% 60%100% FY 2020 FY 2012Supplier Diversity Program: Percent of spend by designationSupplier diversity Access Innovation Efficiency Empowerment Governance 2020 goal Reduce  priority materials of concern in specified product categories BD actively engages in dialog with our customers and advocacy  groups to understand their position on the use of safer chemicals  for consideration in our work to reduce priority MOC.
","('Product_Quality_And_Safety', 0.3161354064941406)","('Product_Design_And_Lifecycle_Management', 0.29048746824264526)","('Waste_And_Hazardous_Materials_Management', 0.09310496598482132)","('NON-ESG', 0.3161354064941406)","('NON-ESG', 0.29048746824264526)","('NON-ESG', 0.09310496598482132)"
Line 1135,"This engagement includes our continued response to the  Chemical Footprint Project  (CFP).
","('GHG_Emissions', 0.5673546195030212)","('Business_Model_Resilience', 0.061074189841747284)","('Supply_Chain_Management', 0.05658202990889549)","(['Climate Change'], 0.5673546195030212)","('NON-ESG', 0.061074189841747284)","('NON-ESG', 0.05658202990889549)"
Line 1136,"The mission of the CFP is to  transform global chemical use by measuring and disclosing data on business progress to safer chemicals.
","('Product_Quality_And_Safety', 0.25606629252433777)","('Selling_Practices_And_Product_Labeling', 0.2276051938533783)","('Customer_Welfare', 0.13480190932750702)","('NON-ESG', 0.25606629252433777)","('NON-ESG', 0.2276051938533783)","('NON-ESG', 0.13480190932750702)"
Line 1137,"It provides a tool for  benchmarking companies as they select safer alternatives and  reduce their use of chemicals of high concern.
","('Product_Quality_And_Safety', 0.2760327160358429)","('Customer_Welfare', 0.19458262622356415)","('Product_Design_And_Lifecycle_Management', 0.1930207759141922)","('NON-ESG', 0.2760327160358429)","('NON-ESG', 0.19458262622356415)","('NON-ESG', 0.1930207759141922)"
Line 1138,"As in previous  years, we have chosen to make our response public and, as such,  have been recognized as a CFP 2020 Disclosure Leader.Chemical Footprint Project PVC is used in medical devices for a number of reasons,  including its ease of processing and the ability to tailor its  properties to a range of applications.
","('Product_Design_And_Lifecycle_Management', 0.3029847741127014)","('Customer_Welfare', 0.2438184916973114)","('Selling_Practices_And_Product_Labeling', 0.1553974151611328)","('NON-ESG', 0.3029847741127014)","('NON-ESG', 0.2438184916973114)","('NON-ESG', 0.1553974151611328)"
Line 1139,"It has allowed for the  development of single-use devices, reducing the risk of infection  due to multiuse devices.
","('Employee_Health_And_Safety', 0.7751604318618774)","('Access_And_Affordability', 0.02863144502043724)","('Critical_Incident_Risk_Management', 0.02029189094901085)","(['Operational Eco-Efficiency'], 0.7751604318618774)","('NON-ESG', 0.02863144502043724)","('NON-ESG', 0.02029189094901085)"
Line 1140,"PVC comes in two forms; un-plasticized  PVC which is rigid, and plasticized PVC, where additives are  introduced to change the properties of the material.
","('Product_Design_And_Lifecycle_Management', 0.43399590253829956)","('Energy_Management', 0.1609363555908203)","('Waste_And_Hazardous_Materials_Management', 0.12903927266597748)","('NON-ESG', 0.43399590253829956)","('NON-ESG', 0.1609363555908203)","('NON-ESG', 0.12903927266597748)"
Line 1141,"Plasticized PVC has a number of favorable properties, such as  flexibility (allowing for ease of use for healthcare professionals  and comfort to the patient); kink resistance, providing  confidence that fluids and gases will flow unhindered and stay  resilient against potential damage.
","('Product_Design_And_Lifecycle_Management', 0.8232319951057434)","('Customer_Welfare', 0.02160695008933544)","('Energy_Management', 0.018990250304341316)","(['Product Stewardship'], 0.8232319951057434)","('NON-ESG', 0.02160695008933544)","('NON-ESG', 0.018990250304341316)"
Line 1142,"There are a number of challenges to replacing PVC in existing  product lines.
","('Product_Design_And_Lifecycle_Management', 0.8468572497367859)","('Energy_Management', 0.048484668135643005)","('Product_Quality_And_Safety', 0.020660724490880966)","(['Product Stewardship'], 0.8468572497367859)","('NON-ESG', 0.048484668135643005)","('NON-ESG', 0.020660724490880966)"
Line 1143,"It requires conversion to non-like materials, which  can impact performance (such as the favorable properties  noted above), manufacturability and the ability to meet  functional requirements.
","('Product_Design_And_Lifecycle_Management', 0.9135567545890808)","('Supply_Chain_Management', 0.01366480067372322)","('Energy_Management', 0.012918653897941113)","(['Product Stewardship'], 0.9135567545890808)","('NON-ESG', 0.01366480067372322)","('NON-ESG', 0.012918653897941113)"
Line 1144,"DEHP is a common plasticizer, used most often in PVC to make  it flexible.
","('Product_Design_And_Lifecycle_Management', 0.6531440019607544)","('Energy_Management', 0.12859003245830536)","('Waste_And_Hazardous_Materials_Management', 0.0465879961848259)","(['Product Stewardship'], 0.6531440019607544)","('NON-ESG', 0.12859003245830536)","('NON-ESG', 0.0465879961848259)"
Line 1145,"DEHP is one of several phthalates that are heavily  regulated and, in some cases, restricted for use in certain  medical devices due to known health impacts for certain classes  of patients.
","('Employee_Health_And_Safety', 0.7719840407371521)","('Product_Quality_And_Safety', 0.05256552994251251)","('Customer_Welfare', 0.022030165418982506)","(['Operational Eco-Efficiency'], 0.7719840407371521)","('NON-ESG', 0.05256552994251251)","('NON-ESG', 0.022030165418982506)"
Line 1146,"In Europe, the Medical Device Regulation1 SCHEER  Guidelines2 require phthalates to undergo more complex   benefit/risk/alternative assessments than other MOCs. In addition to the increasing regulatory restrictions and health  impacts of DEHP, we recognized the environmental concerns  that our stakeholders—particularly customers—have about  PVC.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9738178253173828)","('Energy_Management', 0.001998221268877387)","('Competitive_Behavior', 0.0018866682657971978)","(['Corporate Governance'], 0.9738178253173828)","('NON-ESG', 0.001998221268877387)","('NON-ESG', 0.0018866682657971978)"
Line 1147,"This prompted our efforts to reduce the use of PVC and  DEHP in our products as part of our 2020 sustainability strategy.
","('Product_Design_And_Lifecycle_Management', 0.9552041888237)","('Product_Quality_And_Safety', 0.007954597473144531)","('Selling_Practices_And_Product_Labeling', 0.0056899250485002995)","(['Product Stewardship'], 0.9552041888237)","('NON-ESG', 0.007954597473144531)","('NON-ESG', 0.0056899250485002995)"
Line 1148,"Using knowledge gained from the development of the   BD Nexiva ™ Closed IV Catheter System, a PVC-free product which  uses thermoplastic urethane tubing, * further products were developed and launched, including peripheral IV catheters, IV  extension sets and catheter extension sets, such as: • BD™ Gravity IV Sets, launched in FY 2017 in the CSA, Europe  and Japan regions.
","('Access_And_Affordability', 0.3171156942844391)","('Energy_Management', 0.11570912599563599)","('Employee_Health_And_Safety', 0.08628077059984207)","('NON-ESG', 0.3171156942844391)","('NON-ESG', 0.11570912599563599)","('NON-ESG', 0.08628077059984207)"
Line 1149,"These advanced gravity IV sets contain  features such as anti-run dry technology, autoprime caps,  needle-free injection ports and non-DEHP materials.
","('Energy_Management', 0.2204071581363678)","('Product_Design_And_Lifecycle_Management', 0.19543588161468506)","('Waste_And_Hazardous_Materials_Management', 0.08322353661060333)","('NON-ESG', 0.2204071581363678)","('NON-ESG', 0.19543588161468506)","('NON-ESG', 0.08322353661060333)"
Line 1150,"These products have non-PVC material options made   from thermoplastic elastomers (TPE).
","('Product_Design_And_Lifecycle_Management', 0.8972240686416626)","('Energy_Management', 0.0247859638184309)","('Product_Quality_And_Safety', 0.009948099963366985)","(['Product Stewardship'], 0.8972240686416626)","('NON-ESG', 0.0247859638184309)","('NON-ESG', 0.009948099963366985)"
Line 1151,"• BD Pegasus Plus ™, a closed IV catheter with features for  preventing needlestick injuries.
","('Employee_Health_And_Safety', 0.965385377407074)","('Critical_Incident_Risk_Management', 0.0052886540070176125)","('Employee_Engagement_Inclusion_And_Diversity', 0.003452145028859377)","(['Operational Eco-Efficiency'], 0.965385377407074)","('NON-ESG', 0.0052886540070176125)","('NON-ESG', 0.003452145028859377)"
Line 1152,"It was launched in the  Chinese market in February 2016.
","('Business_Model_Resilience', 0.2722221314907074)","('Product_Design_And_Lifecycle_Management', 0.15476001799106598)","('Competitive_Behavior', 0.08766768127679825)","('NON-ESG', 0.2722221314907074)","('NON-ESG', 0.15476001799106598)","('NON-ESG', 0.08766768127679825)"
Line 1153,"The product contains  extension tubing made from polyurethane, replacing DEHP- plasticized PVC that was used in the previous version of  the product.
","('Product_Design_And_Lifecycle_Management', 0.835105836391449)","('Energy_Management', 0.05257193371653557)","('Waste_And_Hazardous_Materials_Management', 0.02386034093797207)","(['Product Stewardship'], 0.835105836391449)","('NON-ESG', 0.05257193371653557)","('NON-ESG', 0.02386034093797207)"
Line 1154,"• BD Intima II PLUS ™ was launched for the Chinese market in  2015.
","('Business_Model_Resilience', 0.19541631639003754)","('Product_Design_And_Lifecycle_Management', 0.19415976107120514)","('Management_Of_Legal_And_Regulatory_Framework', 0.090250663459301)","('NON-ESG', 0.19541631639003754)","('NON-ESG', 0.19415976107120514)","('NON-ESG', 0.090250663459301)"
Line 1155,"It meets basic requirements for infusion and meets  additional requirements for pediatric, gynecology, oncology,  CT and specialty infusion processes.
","('Customer_Welfare', 0.19818100333213806)","('Access_And_Affordability', 0.18619346618652344)","('Critical_Incident_Risk_Management', 0.06813915073871613)","('NON-ESG', 0.19818100333213806)","('NON-ESG', 0.18619346618652344)","('NON-ESG', 0.06813915073871613)"
Line 1156,"The new product is  made from polyurethane, replacing DEHP-plasticized PVC  that was used in the previous version of the product.DevicesDetails of how we manage materials of concern (MOC) can be found in the Product Safety  section of this report.
","('Product_Quality_And_Safety', 0.846006453037262)","('Product_Design_And_Lifecycle_Management', 0.04545921832323074)","('Employee_Health_And_Safety', 0.015671638771891594)","(['Product Quality & Recall Management'], 0.846006453037262)","('NON-ESG', 0.04545921832323074)","('NON-ESG', 0.015671638771891594)"
Line 1157,"* Launched in the USA in FY References 1 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation  (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R2 Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or  have endocrine-disurpting (ED) propertiesPerformance BD is working to reduce priority MOC *   in each of the following product categories: Devices:    PVC and phthalates Instruments:    Phthalates, brominated flame retardants (BFRs)   and heavy metals Packaging: PVC and expanded polystyrene *Intentionally added Access Innovation Efficiency Empowerment Governance We are accelerating the pace of qualifying alternatives to DEHP  and, in some instances, assessing substitute materials to replace  plasticized PVC or designing out components that contain  plasticized PVC.
","('Selling_Practices_And_Product_Labeling', 0.19733655452728271)","('Waste_And_Hazardous_Materials_Management', 0.1881387084722519)","('Product_Quality_And_Safety', 0.16685406863689423)","('NON-ESG', 0.19733655452728271)","('NON-ESG', 0.1881387084722519)","('NON-ESG', 0.16685406863689423)"
Line 1158,"* Launched in the USA in FY References 1 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation  (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R2 Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or  have endocrine-disurpting (ED) propertiesPerformance BD is working to reduce priority MOC *   in each of the following product categories: Devices:    PVC and phthalates Instruments:    Phthalates, brominated flame retardants (BFRs)   and heavy metals Packaging: PVC and expanded polystyrene *Intentionally added Access Innovation Efficiency Empowerment Governance We are accelerating the pace of qualifying alternatives to DEHP  and, in some instances, assessing substitute materials to replace  plasticized PVC or designing out components that contain  plasticized PVC.
","('Product_Design_And_Lifecycle_Management', 0.7818319201469421)","('Customer_Welfare', 0.0523378811776638)","('Product_Quality_And_Safety', 0.046749651432037354)","(['Product Stewardship'], 0.7818319201469421)","('NON-ESG', 0.0523378811776638)","('NON-ESG', 0.046749651432037354)"
Line 1159,"* Launched in the USA in FY References 1 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation  (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R2 Guidelines on the benefit-risk assessment of the presence of phthalates in certain medical devices covering phthalates which are carcinogenic, mutagenic, toxic to reproduction (CMR) or  have endocrine-disurpting (ED) propertiesPerformance BD is working to reduce priority MOC *   in each of the following product categories: Devices:    PVC and phthalates Instruments:    Phthalates, brominated flame retardants (BFRs)   and heavy metals Packaging: PVC and expanded polystyrene *Intentionally added Access Innovation Efficiency Empowerment Governance We are accelerating the pace of qualifying alternatives to DEHP  and, in some instances, assessing substitute materials to replace  plasticized PVC or designing out components that contain  plasticized PVC.
","('Product_Design_And_Lifecycle_Management', 0.5107464790344238)","('Energy_Management', 0.2572435140609741)","('Waste_And_Hazardous_Materials_Management', 0.07098211348056793)","(['Product Stewardship'], 0.5107464790344238)","('NON-ESG', 0.2572435140609741)","('NON-ESG', 0.07098211348056793)"
Line 1160,"While removal of DEHP and/or PVC is not always  possible, strategies have included development of products  without DEHP and/or PVC in certain product categories,  providing an alternative choice for our customers.
","('Product_Design_And_Lifecycle_Management', 0.9156400561332703)","('Product_Quality_And_Safety', 0.015414130873978138)","('Customer_Welfare', 0.012800523079931736)","(['Product Stewardship'], 0.9156400561332703)","('NON-ESG', 0.015414130873978138)","('NON-ESG', 0.012800523079931736)"
Line 1161,"With a large portfolio of products, conversion away from DEHP  and plasticized PVC—where feasible—will take time.
","('Product_Design_And_Lifecycle_Management', 0.916316568851471)","('Energy_Management', 0.018580716103315353)","('Waste_And_Hazardous_Materials_Management', 0.011238074861466885)","(['Product Stewardship'], 0.916316568851471)","('NON-ESG', 0.018580716103315353)","('NON-ESG', 0.011238074861466885)"
Line 1162,"In addition,  we face regulatory complexities in certain regions of the world  which still prefer DEHP and don’t yet allow alternatives due to  potential safety concerns.
","('Product_Quality_And_Safety', 0.895993173122406)","('Employee_Health_And_Safety', 0.01977093704044819)","('Product_Design_And_Lifecycle_Management', 0.010389787144958973)","(['Product Quality & Recall Management'], 0.895993173122406)","('NON-ESG', 0.01977093704044819)","('NON-ESG', 0.010389787144958973)"
Line 1163,"Instruments In 2017, we completed product changes that eliminate certain  heavy metals and flame retardants and brought impacted  monitoring and control instruments into compliance with the  E.U. RoHS Directive.1 Subsequent inclusion of certain phthalates  in the directive2 impacted only a small number of products.
","('Product_Design_And_Lifecycle_Management', 0.903223991394043)","('Product_Quality_And_Safety', 0.02461005188524723)","('Selling_Practices_And_Product_Labeling', 0.015336534939706326)","(['Product Stewardship'], 0.903223991394043)","('NON-ESG', 0.02461005188524723)","('NON-ESG', 0.015336534939706326)"
Line 1164,"Products have been redesigned to remove the  restricted substances.Packaging We continue to utilize PVC and expanded polystyrene (EPS) in  certain packaging systems, such as trays.
","('Selling_Practices_And_Product_Labeling', 0.3345542550086975)","('Product_Design_And_Lifecycle_Management', 0.2432447075843811)","('Waste_And_Hazardous_Materials_Management', 0.13543523848056793)","('NON-ESG', 0.3345542550086975)","('NON-ESG', 0.2432447075843811)","('NON-ESG', 0.13543523848056793)"
Line 1165,"While alternative  materials are being assessed, they do not always offer the same  functional properties.
","('Product_Design_And_Lifecycle_Management', 0.7146990895271301)","('Supply_Chain_Management', 0.07798314094543457)","('Energy_Management', 0.03497281298041344)","(['Product Stewardship'], 0.7146990895271301)","('NON-ESG', 0.07798314094543457)","('NON-ESG', 0.03497281298041344)"
Line 1166,"For example, EPS packaging is required to  withstand significant weights.
","('Product_Design_And_Lifecycle_Management', 0.7943729162216187)","('Energy_Management', 0.031998682767152786)","('Waste_And_Hazardous_Materials_Management', 0.02614942379295826)","(['Product Stewardship'], 0.7943729162216187)","('NON-ESG', 0.031998682767152786)","('NON-ESG', 0.02614942379295826)"
Line 1167,"Its light weight is also an  important factor when considering the significant impact  transportation and distribution can have over the life cycle of our  products.
","('Product_Design_And_Lifecycle_Management', 0.9662916660308838)","('Product_Quality_And_Safety', 0.0029230196960270405)","('Business_Model_Resilience', 0.0028945114463567734)","(['Product Stewardship'], 0.9662916660308838)","('NON-ESG', 0.0029230196960270405)","('NON-ESG', 0.0028945114463567734)"
Line 1168,"Taking a life cycle assessment approach to assessing  current materials used in packaging applications will allow us to  identify hotspots and areas for opportunity.
","('Product_Design_And_Lifecycle_Management', 0.9044978618621826)","('Supply_Chain_Management', 0.020230548456311226)","('Energy_Management', 0.009760934859514236)","(['Product Stewardship'], 0.9044978618621826)","('NON-ESG', 0.020230548456311226)","('NON-ESG', 0.009760934859514236)"
Line 1169,"In addition to  assessing alternative materials, areas for opportunity may  include light-weighting, or extending the useful life of packaging  materials through reuse or recycling.
","('Product_Design_And_Lifecycle_Management', 0.9361035227775574)","('Supply_Chain_Management', 0.007934884168207645)","('Waste_And_Hazardous_Materials_Management', 0.006838243454694748)","(['Product Stewardship'], 0.9361035227775574)","('NON-ESG', 0.007934884168207645)","('NON-ESG', 0.006838243454694748)"
Line 1170,"References 1 Directive 2011/65/E.U. of the European Parliament and of the Council of 8 June 2011 on the restriction of the use of certain hazardous substances in  electrical and electronic equipment.
","('Waste_And_Hazardous_Materials_Management', 0.9631367325782776)","('Air_Quality', 0.0038363945204764605)","('Selling_Practices_And_Product_Labeling', 0.0035714551340788603)","(['Operational Eco-Efficiency'], 0.9631367325782776)","('NON-ESG', 0.0038363945204764605)","('NON-ESG', 0.0035714551340788603)"
Line 1171,"2 Commission Delegated Directive (EU) 2015/863 of 31 March 2015 amending Annex II to Directive 2011/65/EU of the European Parliament and of the  Council as regards the list of restricted substances.
","('Selling_Practices_And_Product_Labeling', 0.45214030146598816)","('Product_Quality_And_Safety', 0.08585861325263977)","('Customer_Welfare', 0.07518340647220612)","('NON-ESG', 0.45214030146598816)","('NON-ESG', 0.08585861325263977)","('NON-ESG', 0.07518340647220612)"
Line 1172,"Access Innovation Efficiency Empowerment Governance 2020 goal Improve  life cycle impacts of current and future products Transportation and distribution activities are a significant  contributor to our Scope 3 emissions and, in some cases, a  significant contributor to the individual footprint of products.
","('Product_Design_And_Lifecycle_Management', 0.9697229862213135)","('Product_Quality_And_Safety', 0.0030065535102039576)","('Energy_Management', 0.002868631388992071)","(['Product Stewardship'], 0.9697229862213135)","('NON-ESG', 0.0030065535102039576)","('NON-ESG', 0.002868631388992071)"
Line 1173,"Utilizing electric vehicles for  deliveries in Brazil In FY 2020, our Supply Chain team in Brazil began using two  electric vehicles (EVs) to deliver products to key accounts inside  the metropolitan area of Sao Paulo.
","('Product_Design_And_Lifecycle_Management', 0.7782691121101379)","('Supply_Chain_Management', 0.09618842601776123)","('Energy_Management', 0.029458994045853615)","(['Product Stewardship'], 0.7782691121101379)","('NON-ESG', 0.09618842601776123)","('NON-ESG', 0.029458994045853615)"
Line 1174,"BD is the first company in  the healthcare segment to use EVs to make deliveries in Brazil.
","('Energy_Management', 0.6918949484825134)","('Product_Design_And_Lifecycle_Management', 0.09995201230049133)","('Customer_Welfare', 0.021313317120075226)","(['Operational Eco-Efficiency'], 0.6918949484825134)","('NON-ESG', 0.09995201230049133)","('NON-ESG', 0.021313317120075226)"
Line 1175,"Many hospitals and labs do not carry inventory, therefore reliable  deliveries are critical.
","('Supply_Chain_Management', 0.2075902819633484)","('Waste_And_Hazardous_Materials_Management', 0.1579723358154297)","('Energy_Management', 0.1458951234817505)","('NON-ESG', 0.2075902819633484)","('NON-ESG', 0.1579723358154297)","('NON-ESG', 0.1458951234817505)"
Line 1176,"Use of EVs helps to ensure business  continuity, for example when availability of gasoline and   diesel is limited (as experienced during the strikes in 2018).
","('Energy_Management', 0.29397234320640564)","('Supply_Chain_Management', 0.18586039543151855)","('Systemic_Risk_Management', 0.1098031997680664)","('NON-ESG', 0.29397234320640564)","('NON-ESG', 0.18586039543151855)","('NON-ESG', 0.1098031997680664)"
Line 1177,"Additionally, EVs are exempt from rules in place in Sao Paulo  aimed at reducing emissions from vehicles.
","('Air_Quality', 0.7621821761131287)","('Energy_Management', 0.07962744683027267)","('GHG_Emissions', 0.05764741078019142)","(['Operational Eco-Efficiency'], 0.7621821761131287)","('NON-ESG', 0.07962744683027267)","('NON-ESG', 0.05764741078019142)"
Line 1178,"Routing procedures were adapted to consider the size of the  vehicle and maximum distance of travel between charges.
","('Management_Of_Legal_And_Regulatory_Framework', 0.422572523355484)","('Energy_Management', 0.07358931005001068)","('Customer_Privacy', 0.0699796974658966)","('NON-ESG', 0.422572523355484)","('NON-ESG', 0.07358931005001068)","('NON-ESG', 0.0699796974658966)"
Line 1179,"The EVs are able to make deliveries in two cycles each day,  charging in between.
","('Energy_Management', 0.4286923408508301)","('Product_Design_And_Lifecycle_Management', 0.3624086380004883)","('Supply_Chain_Management', 0.033394161611795425)","('NON-ESG', 0.4286923408508301)","('NON-ESG', 0.3624086380004883)","('NON-ESG', 0.033394161611795425)"
Line 1180,"In the first 6 months of use, it is estimated  that nearly 1,800 deliveries were made, covering 34,800 km,  preventing around 8,400 kg CO2-e of emissions.Due to the success of this program, we are looking to expand to  other countries in Latin America, specifically large metro cities  which have vehicle restrictions in place aimed at reducing  CO2 emissions.
","('GHG_Emissions', 0.7601743340492249)","('Air_Quality', 0.14404433965682983)","('Energy_Management', 0.020323529839515686)","(['Climate Change'], 0.7601743340492249)","('NON-ESG', 0.14404433965682983)","('NON-ESG', 0.020323529839515686)"
Line 1181,"SmartWay BD has been a U.S. EPA Transport SmartWay® partner since 2010.
","('Business_Model_Resilience', 0.26534393429756165)","('Product_Design_And_Lifecycle_Management', 0.1206473857164383)","('Energy_Management', 0.06366124749183655)","('NON-ESG', 0.26534393429756165)","('NON-ESG', 0.1206473857164383)","('NON-ESG', 0.06366124749183655)"
Line 1182,"The SmartWay  transport partnership provides a framework to  assess the environmental and energy efficiency of goods  movement supply chains.LogisticsBD continues to focus efforts on improving the life cycle impacts of our products.
","('Product_Design_And_Lifecycle_Management', 0.9601033329963684)","('Energy_Management', 0.005406187381595373)","('Supply_Chain_Management', 0.004776097368448973)","(['Product Stewardship'], 0.9601033329963684)","('NON-ESG', 0.005406187381595373)","('NON-ESG', 0.004776097368448973)"
Line 1183,"In 2020, we continued our engagement with the Healthcare  Plastics Recycling Council (HPRC) both in the United States and  the European Union, and the Sustainable Healthcare Coalition  (SHC) in Europe.
","('Product_Design_And_Lifecycle_Management', 0.628813624382019)","('Energy_Management', 0.05962175130844116)","('Waste_And_Hazardous_Materials_Management', 0.04172986373305321)","(['Product Stewardship'], 0.628813624382019)","('NON-ESG', 0.05962175130844116)","('NON-ESG', 0.04172986373305321)"
Line 1184,"The activities we undertake as part of our  engagement with these entities support, among other projects,  our efforts to limit and minimize waste produced during the life  cycle of our products.
","('Waste_And_Hazardous_Materials_Management', 0.7911936044692993)","('Product_Design_And_Lifecycle_Management', 0.1207590401172638)","('Product_Quality_And_Safety', 0.00963145587593317)","(['Operational Eco-Efficiency'], 0.7911936044692993)","('NON-ESG', 0.1207590401172638)","('NON-ESG', 0.00963145587593317)"
Line 1185,"Reducing end-of-life impacts of syringes  used for vaccinations As noted in the COVID-19 section of this report, BD is supplying a  significant number of syringes to support vaccination programs  around the world.
","('Employee_Health_And_Safety', 0.36518576741218567)","('Access_And_Affordability', 0.20438072085380554)","('Product_Quality_And_Safety', 0.07606629282236099)","('NON-ESG', 0.36518576741218567)","('NON-ESG', 0.20438072085380554)","('NON-ESG', 0.07606629282236099)"
Line 1186,"Due to the presence of sharps and patient  contact, end-of-life disposal options for syringes are limited due  to technical and regulatory challenges.
","('Product_Design_And_Lifecycle_Management', 0.3128705322742462)","('Waste_And_Hazardous_Materials_Management', 0.2831594944000244)","('Selling_Practices_And_Product_Labeling', 0.05997219681739807)","('NON-ESG', 0.3128705322742462)","('NON-ESG', 0.2831594944000244)","('NON-ESG', 0.05997219681739807)"
Line 1187,"However, there are certain components, such as needle shields and packaging that  may be recycled where facilities exist.
","('Product_Design_And_Lifecycle_Management', 0.7312344908714294)","('Waste_And_Hazardous_Materials_Management', 0.08391423523426056)","('Energy_Management', 0.035259686410427094)","(['Product Stewardship'], 0.7312344908714294)","('NON-ESG', 0.08391423523426056)","('NON-ESG', 0.035259686410427094)"
Line 1188,"Information to enable end  users to properly dispose of or recycle products and packaging  components, consistent with applicable regulatory requirements,  is available on bd.com .
","('Product_Design_And_Lifecycle_Management', 0.9421936273574829)","('Product_Quality_And_Safety', 0.00969068706035614)","('Selling_Practices_And_Product_Labeling', 0.009335089474916458)","(['Product Stewardship'], 0.9421936273574829)","('NON-ESG', 0.00969068706035614)","('NON-ESG', 0.009335089474916458)"
Line 1189,"Product takeback Where required by law, we participate in compliance schemes to  ensure responsible collection, management and disposal  (including recycling) of packaging, batteries and waste electrical  and electronic equipment.
","('Waste_And_Hazardous_Materials_Management', 0.7151663899421692)","('Product_Design_And_Lifecycle_Management', 0.17633694410324097)","('Selling_Practices_And_Product_Labeling', 0.014872659929096699)","(['Operational Eco-Efficiency'], 0.7151663899421692)","('NON-ESG', 0.17633694410324097)","('NON-ESG', 0.014872659929096699)"
Line 1190,"For details regarding product donations, please refer to the  Empowerment  section of this report.Supporting reduction of end-of-life impacts Access Innovation Efficiency Empowerment Governance GRI disclosure: 301-3   SASB disclosure: HC-MS-410a.We continue to manage the end-of-life disposal of products from  the BD Pyxis ™ Portfolio at our San Diego, CA facility by recovering  materials and components for refurbishment or recycling.
","('Product_Design_And_Lifecycle_Management', 0.9648029804229736)","('Product_Quality_And_Safety', 0.003518370445817709)","('Selling_Practices_And_Product_Labeling', 0.0027404064312577248)","(['Product Stewardship'], 0.9648029804229736)","('NON-ESG', 0.003518370445817709)","('NON-ESG', 0.0027404064312577248)"
Line 1191,"In FY 2020, 18,746 units were processed through our facility,  representing 3,529 metric tonnes of materials that were either  refurbished, reused or recycled.
","('Product_Design_And_Lifecycle_Management', 0.5704981088638306)","('Energy_Management', 0.15061889588832855)","('Waste_And_Hazardous_Materials_Management', 0.08739396929740906)","(['Product Stewardship'], 0.5704981088638306)","('NON-ESG', 0.15061889588832855)","('NON-ESG', 0.08739396929740906)"
Line 1192,"No materials were disposed of  via landfill.While there have been challenges due to recycled commodity  pricing, we will continue to explore opportunities to improve the  end-of-life disposal options for products through programs such  as this.
","('Product_Design_And_Lifecycle_Management', 0.8667335510253906)","('Waste_And_Hazardous_Materials_Management', 0.05733448266983032)","('Customer_Welfare', 0.009108180180191994)","(['Product Stewardship'], 0.8667335510253906)","('NON-ESG', 0.05733448266983032)","('NON-ESG', 0.009108180180191994)"
Line 1193,"Where product take-back is not appropriate or viable, we  will look to alternatives, such as cross-industry partnerships found  in HPRC.
","('Product_Design_And_Lifecycle_Management', 0.8997432589530945)","('Customer_Welfare', 0.02158038318157196)","('Product_Quality_And_Safety', 0.01455099880695343)","(['Product Stewardship'], 0.8997432589530945)","('NON-ESG', 0.02158038318157196)","('NON-ESG', 0.01455099880695343)"
Line 1194,"These programs will be just one element of our 2030  sustainability strategy to improve the product impacts.
","('Product_Design_And_Lifecycle_Management', 0.9580973386764526)","('Product_Quality_And_Safety', 0.006995818577706814)","('Business_Model_Resilience', 0.0032711627427488565)","(['Product Stewardship'], 0.9580973386764526)","('NON-ESG', 0.006995818577706814)","('NON-ESG', 0.0032711627427488565)"
Line 1195,"Access Innovation Efficiency Empowerment Governance FY 2020 efficiency targets— performance data tables Solar panels installed at Canaan, CT site.
","('Energy_Management', 0.9689838886260986)","('Management_Of_Legal_And_Regulatory_Framework', 0.004568065516650677)","('Product_Design_And_Lifecycle_Management', 0.003527048509567976)","(['Operational Eco-Efficiency'], 0.9689838886260986)","('NON-ESG', 0.004568065516650677)","('NON-ESG', 0.003527048509567976)"
Line 1196,"A total of 2.9 mega-watts are generated from solar panels at this site.
","('Energy_Management', 0.9637007117271423)","('Management_Of_Legal_And_Regulatory_Framework', 0.007780542131513357)","('GHG_Emissions', 0.002647659508511424)","(['Operational Eco-Efficiency'], 0.9637007117271423)","('NON-ESG', 0.007780542131513357)","('NON-ESG', 0.002647659508511424)"
Line 1197,"Restatement of data In FY 2020, we reviewed our reporting boundary and excluded 20  sites that were divested between 2010 and 2018.
","('Business_Model_Resilience', 0.3072899281978607)","('Systemic_Risk_Management', 0.29477986693382263)","('Director_Removal', 0.045593585819005966)","('NON-ESG', 0.3072899281978607)","('NON-ESG', 0.29477986693382263)","('NON-ESG', 0.045593585819005966)"
Line 1198,"Therefore, data  from these divested sites were removed back to the baseline  year 2008.
","('Management_Of_Legal_And_Regulatory_Framework', 0.15982036292552948)","('Business_Model_Resilience', 0.11606044322252274)","('Systemic_Risk_Management', 0.11006995290517807)","('NON-ESG', 0.15982036292552948)","('NON-ESG', 0.11606044322252274)","('NON-ESG', 0.11006995290517807)"
Line 1199,"We have included data for 11 new sites, two of  which were acquisitions in FY 2019.
","('Business_Model_Resilience', 0.2617834210395813)","('Systemic_Risk_Management', 0.23374032974243164)","('Competitive_Behavior', 0.09455665946006775)","('NON-ESG', 0.2617834210395813)","('NON-ESG', 0.23374032974243164)","('NON-ESG', 0.09455665946006775)"
Line 1200,"Energy usage for the two  acquired sites have been back casted to the baseline year 2008.
","('Energy_Management', 0.9789230823516846)","('Management_Of_Legal_And_Regulatory_Framework', 0.0025405329652130604)","('Air_Quality', 0.002147858729586005)","(['Operational Eco-Efficiency'], 0.9789230823516846)","('NON-ESG', 0.0025405329652130604)","('NON-ESG', 0.002147858729586005)"
Line 1201,"The overall impact from the boundary update has led to a  general decrease in utility and emissions from all historical  years, including the baseline FY 2008, compared to what   was reported last year.Notes on data Bard For most performance indicators, we have included data for  Bard back to our baseline year of FY 2008; however, in   a few instances, no historical data was available.
","('GHG_Emissions', 0.7731949090957642)","('Air_Quality', 0.07677199691534042)","('Physical_Impacts_Of_Climate_Change', 0.0249740369617939)","(['Climate Change'], 0.7731949090957642)","('NON-ESG', 0.07677199691534042)","('NON-ESG', 0.0249740369617939)"
Line 1202,"This is noted  where applicable.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7064068913459778)","('Competitive_Behavior', 0.04938843101263046)","('Business_Ethics', 0.038861338049173355)","(['Corporate Governance'], 0.7064068913459778)","('NON-ESG', 0.04938843101263046)","('NON-ESG', 0.038861338049173355)"
Line 1203,"To allow for year-on-year comparability and transparency, we  are reporting performance data separately for both legacy BD  and Bard organizations across all performance indicators, in  addition to combined performance data.
","('Business_Ethics', 0.8611953258514404)","('Systemic_Risk_Management', 0.03643890842795372)","('Management_Of_Legal_And_Regulatory_Framework', 0.01763583905994892)","(['Business Ethics'], 0.8611953258514404)","('NON-ESG', 0.03643890842795372)","('NON-ESG', 0.01763583905994892)"
Line 1204,"In previous years, we used COPs to normalize data for legacy   Bard.
","('Customer_Privacy', 0.4396072328090668)","('Data_Security', 0.389707088470459)","('Waste_And_Hazardous_Materials_Management', 0.017562618479132652)","('NON-ESG', 0.4396072328090668)","('NON-ESG', 0.389707088470459)","('NON-ESG', 0.017562618479132652)"
Line 1205,"As Bard is now fully integrated into BD, we have used  GAAP COPs for BD Interventional as a proxy to normalize   FY 2020 data from legacy Bard locations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.20155052840709686)","('Access_And_Affordability', 0.19737392663955688)","('Systemic_Risk_Management', 0.17687638103961945)","('NON-ESG', 0.20155052840709686)","('NON-ESG', 0.19737392663955688)","('NON-ESG', 0.17687638103961945)"
Line 1206,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.9643124341964722)","('Air_Quality', 0.006508934777230024)","('Ecological_Impacts', 0.003527762135490775)","(['Climate Change'], 0.9643124341964722)","('NON-ESG', 0.006508934777230024)","('NON-ESG', 0.003527762135490775)"
Line 1207,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.6743005514144897)","('Air_Quality', 0.038132403045892715)","('Customer_Welfare', 0.03045685403048992)","(['Climate Change'], 0.6743005514144897)","('NON-ESG', 0.038132403045892715)","('NON-ESG', 0.03045685403048992)"
Line 1208,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.6377569437026978)","('Customer_Welfare', 0.03568022698163986)","('Waste_And_Hazardous_Materials_Management', 0.03234339505434036)","(['Climate Change'], 0.6377569437026978)","('NON-ESG', 0.03568022698163986)","('NON-ESG', 0.03234339505434036)"
Line 1209,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.6761113405227661)","('Energy_Management', 0.03065616637468338)","('Waste_And_Hazardous_Materials_Management', 0.028129760175943375)","(['Climate Change'], 0.6761113405227661)","('NON-ESG', 0.03065616637468338)","('NON-ESG', 0.028129760175943375)"
Line 1210,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.5906240344047546)","('Energy_Management', 0.059629157185554504)","('Customer_Welfare', 0.03338819742202759)","(['Climate Change'], 0.5906240344047546)","('NON-ESG', 0.059629157185554504)","('NON-ESG', 0.03338819742202759)"
Line 1211,"Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope 1 and Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,093 11,093 11,093 11,067 14,680 16,618 20,506 17,297 16,247 23,702 36,621 16,291 15,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 16 13 12 16 36 12 Scope 1 absolute (metric tonnes  CO2-e), legacy BD85,240 86,078 84,441 78,232 78,059 75,532 72,654 72,097 72,361 87,092 97,994 101,421 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 18 17 15 14 13 12 13 11 14 13 13 Scope 1 absolute (metric tonnes  CO2-e), combined96,333 97,171 95,534 89,299 92,739 92,150 93,160 89,394 88,607 110,794 134,615 117,712 116,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 17 16 14 14 14 13 13 11 15 15 13 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard62,328 59,127 60,943 59,513 59,742 58,656 60,257 68,769 67,226 73,472 65,467 69,990 69,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard67 62 60 55 53 50 48 53 50 51 64 51 Scope 2 absolute (metric tonnes  CO2-e), legacy BD452,473 403,250 341,460 314,034 264,553 223,997 230,363 195,246 145,879 126,597 135,199 170,103 247,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD95 85 67 59 48 40 38 35 22 21 18 22 Scope 2 absolute (metric tonnes  CO2-e), combined514,801 462,377 402,403 373,547 324,295 282,654 290,620 264,015 213,105 200,069 200,666 240,093 316,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined91 81 66 58 49 41 40 38 27 26 23 27 Total absolute (metric tonnes CO2-e),  legacy Bard73,421 70,220 72,036 70,580 74,422 75,274 80,763 86,065 83,472 97,174 102,087 86,281 84,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard79 74 71 65 66 64 65 66 62 67 100 62 % reduction from baseline 21% Total absolute (metric tonnes CO2-e),  legacy BD537,714 489,329 425,901 392,266 342,612 299,530 303,016 267,343 218,240 213,689 233,193 271,524 348,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD113 103 83 74 62 53 50 48 34 35 30 36 % reduction from baseline 62% Total absolute (metric tonnes CO2-e),  combined611,134 559,549 497,937 462,846 417,034 374,804 383,780 353,409 301,712 310,863 335,281 357,805 433,Total normalized (metric tonnes  CO2-e per $M COPS), combined108 98 81 72 63 55 52 51 39 41 38 40 % reduction from baseline 58% 2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.9633058309555054)","('Air_Quality', 0.005565395578742027)","('Physical_Impacts_Of_Climate_Change', 0.003100838279351592)","(['Climate Change'], 0.9633058309555054)","('NON-ESG', 0.005565395578742027)","('NON-ESG', 0.003100838279351592)"
Line 1212,"Current status: Reduced by 58% TARGET ACHIEVED   Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.
","('Energy_Management', 0.9786801338195801)","('Management_Of_Legal_And_Regulatory_Framework', 0.0027619304601103067)","('Water_And_Wastewater_Management', 0.002006345661357045)","(['Operational Eco-Efficiency'], 0.9786801338195801)","('NON-ESG', 0.0027619304601103067)","('NON-ESG', 0.002006345661357045)"
Line 1213,"BD uses emission factors that are temporally, geographically and technologically accurate for each site and source within its operational boundary as specified by the WRI/WBCSD GHG Protocol.
","('GHG_Emissions', 0.9346151351928711)","('Air_Quality', 0.025699397549033165)","('Energy_Management', 0.004813638981431723)","(['Climate Change'], 0.9346151351928711)","('NON-ESG', 0.025699397549033165)","('NON-ESG', 0.004813638981431723)"
Line 1214,"This includes updating electric power emission factors to reflect changes in the  grid mix for areas in which BD operates.
","('Air_Quality', 0.9431355595588684)","('Energy_Management', 0.013641816563904285)","('Critical_Incident_Risk_Management', 0.005777369253337383)","(['Operational Eco-Efficiency'], 0.9431355595588684)","('NON-ESG', 0.013641816563904285)","('NON-ESG', 0.005777369253337383)"
Line 1215,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard  combined GRI disclosures: 305-1, 305-2, 305-4, 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,55211,147,Capital goods  42,728 37,691 39,602 21,516221,Fuel-and-energy-related activities (not included in Scope 1 or 2)3106,340 103,995 106,451 106,360 101,856 105,617 111,946 101,392 91,Upstream transportation and distribution  72,640 125,904 280,636 286,0511258,Waste generated in operations115,266 15,302 13,789 13,071 15,465 15,380 19,239 19,359 19,Business travel435,273 38,230 41,171 68,259 107,049 95,612 117,116 147,795 88,Employee commuting 1,743 9,157 13,061 4,888 102,232 73,195 83,829 138,010152,Upstream leased assets 27,094 47,011 32,299 1,35951,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,8821435,End-of-life treatment of sold products 87,558 97,082 191,821 192,440 7132,Downstream leased assets Not relevant6Not relevant6Not relevant61,52451,Franchises Not relevant6Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('GHG_Emissions', 0.959970235824585)","('Air_Quality', 0.011406071484088898)","('Physical_Impacts_Of_Climate_Change', 0.003095184452831745)","(['Climate Change'], 0.959970235824585)","('NON-ESG', 0.011406071484088898)","('NON-ESG', 0.003095184452831745)"
Line 1216,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard  combined GRI disclosures: 305-1, 305-2, 305-4, 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,55211,147,Capital goods  42,728 37,691 39,602 21,516221,Fuel-and-energy-related activities (not included in Scope 1 or 2)3106,340 103,995 106,451 106,360 101,856 105,617 111,946 101,392 91,Upstream transportation and distribution  72,640 125,904 280,636 286,0511258,Waste generated in operations115,266 15,302 13,789 13,071 15,465 15,380 19,239 19,359 19,Business travel435,273 38,230 41,171 68,259 107,049 95,612 117,116 147,795 88,Employee commuting 1,743 9,157 13,061 4,888 102,232 73,195 83,829 138,010152,Upstream leased assets 27,094 47,011 32,299 1,35951,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,8821435,End-of-life treatment of sold products 87,558 97,082 191,821 192,440 7132,Downstream leased assets Not relevant6Not relevant6Not relevant61,52451,Franchises Not relevant6Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('Waste_And_Hazardous_Materials_Management', 0.8703019618988037)","('Energy_Management', 0.02971392683684826)","('Water_And_Wastewater_Management', 0.022845791652798653)","(['Operational Eco-Efficiency'], 0.8703019618988037)","('NON-ESG', 0.02971392683684826)","('NON-ESG', 0.022845791652798653)"
Line 1217,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard  combined GRI disclosures: 305-1, 305-2, 305-4, 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,55211,147,Capital goods  42,728 37,691 39,602 21,516221,Fuel-and-energy-related activities (not included in Scope 1 or 2)3106,340 103,995 106,451 106,360 101,856 105,617 111,946 101,392 91,Upstream transportation and distribution  72,640 125,904 280,636 286,0511258,Waste generated in operations115,266 15,302 13,789 13,071 15,465 15,380 19,239 19,359 19,Business travel435,273 38,230 41,171 68,259 107,049 95,612 117,116 147,795 88,Employee commuting 1,743 9,157 13,061 4,888 102,232 73,195 83,829 138,010152,Upstream leased assets 27,094 47,011 32,299 1,35951,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,8821435,End-of-life treatment of sold products 87,558 97,082 191,821 192,440 7132,Downstream leased assets Not relevant6Not relevant6Not relevant61,52451,Franchises Not relevant6Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('Product_Design_And_Lifecycle_Management', 0.9130783677101135)","('Selling_Practices_And_Product_Labeling', 0.020070934668183327)","('Customer_Welfare', 0.01164576318114996)","(['Product Stewardship'], 0.9130783677101135)","('NON-ESG', 0.020070934668183327)","('NON-ESG', 0.01164576318114996)"
Line 1218,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard  combined GRI disclosures: 305-1, 305-2, 305-4, 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,55211,147,Capital goods  42,728 37,691 39,602 21,516221,Fuel-and-energy-related activities (not included in Scope 1 or 2)3106,340 103,995 106,451 106,360 101,856 105,617 111,946 101,392 91,Upstream transportation and distribution  72,640 125,904 280,636 286,0511258,Waste generated in operations115,266 15,302 13,789 13,071 15,465 15,380 19,239 19,359 19,Business travel435,273 38,230 41,171 68,259 107,049 95,612 117,116 147,795 88,Employee commuting 1,743 9,157 13,061 4,888 102,232 73,195 83,829 138,010152,Upstream leased assets 27,094 47,011 32,299 1,35951,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,8821435,End-of-life treatment of sold products 87,558 97,082 191,821 192,440 7132,Downstream leased assets Not relevant6Not relevant6Not relevant61,52451,Franchises Not relevant6Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('GHG_Emissions', 0.9461788535118103)","('Air_Quality', 0.018782803788781166)","('Physical_Impacts_Of_Climate_Change', 0.003961886744946241)","(['Climate Change'], 0.9461788535118103)","('NON-ESG', 0.018782803788781166)","('NON-ESG', 0.003961886744946241)"
Line 1219,"Current status: We provided limited reporting of Scope 3 emissions in previous years, and in FY 2020 we continued to work with external partners to  establish baseline Scope 3 emissions across all categories.
","('GHG_Emissions', 0.8480314016342163)","('Air_Quality', 0.0819825530052185)","('Management_Of_Legal_And_Regulatory_Framework', 0.009671650826931)","(['Climate Change'], 0.8480314016342163)","('NON-ESG', 0.0819825530052185)","('NON-ESG', 0.009671650826931)"
Line 1220,"This information is being used to inform future strategy and to establish targets for reduction.
","('Management_Of_Legal_And_Regulatory_Framework', 0.30771780014038086)","('Human_Rights_And_Community_Relations', 0.10932481288909912)","('Business_Model_Resilience', 0.09475313872098923)","('NON-ESG', 0.30771780014038086)","('NON-ESG', 0.10932481288909912)","('NON-ESG', 0.09475313872098923)"
Line 1221,"2020 goal: Initiate climate resilience planning for BD facilities.
","('Business_Model_Resilience', 0.8625092506408691)","('Physical_Impacts_Of_Climate_Change', 0.03531722351908684)","('Supply_Chain_Management', 0.01560039073228836)","(['Codes of Business Conduct'], 0.8625092506408691)","('NON-ESG', 0.03531722351908684)","('NON-ESG', 0.01560039073228836)"
Line 1222,"Current status: As the devastating hurricanes across the U.S. in 2017 demonstrated, resilience planning for extreme weather events is essential to ensure operations are  restored as quickly as possible.
","('Business_Model_Resilience', 0.8068100214004517)","('Physical_Impacts_Of_Climate_Change', 0.08828447759151459)","('Systemic_Risk_Management', 0.01106006558984518)","(['Codes of Business Conduct'], 0.8068100214004517)","('NON-ESG', 0.08828447759151459)","('NON-ESG', 0.01106006558984518)"
Line 1223,"Work continues to be carried to deepen our understanding of potential risks to our supply chain and operations, to ensure potential impacts are mitigated or reduced.
","('Supply_Chain_Management', 0.9525874257087708)","('Physical_Impacts_Of_Climate_Change', 0.004702269099652767)","('Systemic_Risk_Management', 0.0038284724578261375)","(['Supply Chain Management'], 0.9525874257087708)","('NON-ESG', 0.004702269099652767)","('NON-ESG', 0.0038284724578261375)"
Line 1224,"Further information can be found in  our Climate Change Management Report.
","('Physical_Impacts_Of_Climate_Change', 0.9425768852233887)","('GHG_Emissions', 0.009615585207939148)","('Business_Model_Resilience', 0.009141995571553707)","(['Climate Change'], 0.9425768852233887)","('NON-ESG', 0.009615585207939148)","('NON-ESG', 0.009141995571553707)"
Line 1225,"1 Includes Bard.
","('Data_Security', 0.09129183739423752)","('Competitive_Behavior', 0.08813836425542831)","('Customer_Welfare', 0.0780898779630661)","('NON-ESG', 0.09129183739423752)","('NON-ESG', 0.08813836425542831)","('NON-ESG', 0.0780898779630661)"
Line 1226,"2 Includes Bard.
","('Customer_Welfare', 0.10174619406461716)","('Competitive_Behavior', 0.08950380235910416)","('Product_Design_And_Lifecycle_Management', 0.07292187213897705)","('NON-ESG', 0.10174619406461716)","('NON-ESG', 0.08950380235910416)","('NON-ESG', 0.07292187213897705)"
Line 1227,"Reduction is driven by change in sector classification, which have lower capital goods emission intensities.
","('GHG_Emissions', 0.42597585916519165)","('Air_Quality', 0.2025928646326065)","('Systemic_Risk_Management', 0.06559787690639496)","('NON-ESG', 0.42597585916519165)","('NON-ESG', 0.2025928646326065)","('NON-ESG', 0.06559787690639496)"
Line 1228,"3 Data for all years reported has been recalculated to include Bard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31079721450805664)","('Energy_Management', 0.09713467210531235)","('Access_And_Affordability', 0.09233058989048004)","('NON-ESG', 0.31079721450805664)","('NON-ESG', 0.09713467210531235)","('NON-ESG', 0.09233058989048004)"
Line 1229,"Data for all years also now includes emissions related to transmission and distribution losses and well to tank emissions from all energy sources, not just electric power.
","('Air_Quality', 0.8807607293128967)","('Energy_Management', 0.03637471795082092)","('GHG_Emissions', 0.03210925683379173)","(['Operational Eco-Efficiency'], 0.8807607293128967)","('NON-ESG', 0.03637471795082092)","('NON-ESG', 0.03210925683379173)"
Line 1230,"(In prior years we disclosed emissions related to  transmission and distribution losses from electric power only.)   4 FY 2019 and FY 2020 includes Bard.
","('Air_Quality', 0.7326431274414062)","('GHG_Emissions', 0.15977440774440765)","('Energy_Management', 0.033014751970767975)","(['Operational Eco-Efficiency'], 0.7326431274414062)","('NON-ESG', 0.15977440774440765)","('NON-ESG', 0.033014751970767975)"
Line 1231,"FY 2016 and FY 2017 have been restated due to error in earlier calculations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24710704386234283)","('Business_Model_Resilience', 0.10994674265384674)","('Systemic_Risk_Management', 0.09995220601558685)","('NON-ESG', 0.24710704386234283)","('NON-ESG', 0.10994674265384674)","('NON-ESG', 0.09995220601558685)"
Line 1232,"5 Includes Bard.
","('Customer_Welfare', 0.1104169636964798)","('Product_Design_And_Lifecycle_Management', 0.09633488208055496)","('Competitive_Behavior', 0.09223975241184235)","('NON-ESG', 0.1104169636964798)","('NON-ESG', 0.09633488208055496)","('NON-ESG', 0.09223975241184235)"
Line 1233,"Significant decrease due to more accurate data used in calculations.
","('Customer_Privacy', 0.24698230624198914)","('Management_Of_Legal_And_Regulatory_Framework', 0.1181187555193901)","('Data_Security', 0.08335629105567932)","('NON-ESG', 0.24698230624198914)","('NON-ESG', 0.1181187555193901)","('NON-ESG', 0.08335629105567932)"
Line 1234,"6 Relevance based on 1% threshold relative to total Scope 3 emissions inventory.
","('Air_Quality', 0.47932422161102295)","('GHG_Emissions', 0.3245503306388855)","('Energy_Management', 0.0694194957613945)","('NON-ESG', 0.47932422161102295)","('NON-ESG', 0.3245503306388855)","('NON-ESG', 0.0694194957613945)"
Line 1235,"Determined this category to be not relevant to the company’s business activities and did not estimate the associated GHG emissions.
","('GHG_Emissions', 0.9688921570777893)","('Ecological_Impacts', 0.004027440678328276)","('Air_Quality', 0.0027539548464119434)","(['Climate Change'], 0.9688921570777893)","('NON-ESG', 0.004027440678328276)","('NON-ESG', 0.0027539548464119434)"
Line 1236,"7 Emissions are for a subset of our company’s portfolio only.
","('GHG_Emissions', 0.4667408764362335)","('Air_Quality', 0.3941652476787567)","('Energy_Management', 0.04379449039697647)","('NON-ESG', 0.4667408764362335)","('NON-ESG', 0.3941652476787567)","('NON-ESG', 0.04379449039697647)"
Line 1237,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Energy_Management', 0.9793603420257568)","('Air_Quality', 0.0018209628760814667)","('Water_And_Wastewater_Management', 0.0017207037890329957)","(['Operational Eco-Efficiency'], 0.9793603420257568)","('NON-ESG', 0.0018209628760814667)","('NON-ESG', 0.0017207037890329957)"
Line 1238,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.271823912858963)","('Competitive_Behavior', 0.137677401304245)","('Management_Of_Legal_And_Regulatory_Framework', 0.12801842391490936)","('NON-ESG', 0.271823912858963)","('NON-ESG', 0.137677401304245)","('NON-ESG', 0.12801842391490936)"
Line 1239,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.3377023935317993)","('Competitive_Behavior', 0.16734249889850616)","('Management_Of_Legal_And_Regulatory_Framework', 0.07443427294492722)","('NON-ESG', 0.3377023935317993)","('NON-ESG', 0.16734249889850616)","('NON-ESG', 0.07443427294492722)"
Line 1240,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.24774672091007233)","('Management_Of_Legal_And_Regulatory_Framework', 0.16009168326854706)","('Competitive_Behavior', 0.10709846764802933)","('NON-ESG', 0.24774672091007233)","('NON-ESG', 0.16009168326854706)","('NON-ESG', 0.10709846764802933)"
Line 1241,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.24135489761829376)","('Management_Of_Legal_And_Regulatory_Framework', 0.17093798518180847)","('Competitive_Behavior', 0.12464010715484619)","('NON-ESG', 0.24135489761829376)","('NON-ESG', 0.17093798518180847)","('NON-ESG', 0.12464010715484619)"
Line 1242,"GRI disclosure: 305-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 215,241 215,241 215,241 215,241 266,085 297,752 376,921 329,117 312,945 410,851 617,098 309,637 289,Scope 1 normalized (GJ per $M COPS),  legacy Bard231 227 213 200 238 254 302 253 233 285 607 224 Scope 1 absolute (GJ), legacy BD 1,595,001 1,614,825 1,584,194 1,473,342 1,452,446 1,351,514 1,365,597 1,356,050 1,361,896 1,663,909 1,875,420 1,945,456 1,951,Scope 1 normalized (GJ per $M COPS),  legacy BD336 341 310 277 263 240 225 243 210 272 244 255 Scope 1 absolute (GJ), combined 1,810,242 1,830,066 1,799,435 1,688,583 1,718,531 1,649,265 1,742,518 1,685,167 1,674,841 2,074,759 2,492,518 2,255,092 2,240,Scope 1 normalized (GJ per $M COPS),  combined318 322 294 264 259 242 238 245 214 274 286 251 Scope 2 absolute (GJ), legacy Bard 428,405 429,481 429,578 429,578 443,139 454,612 475,974 541,190 556,285 604,081 595,166 579,184 565,Scope 2 normalized (GJ per $M COPS),  legacy Bard460 454 425 398 396 388 381 416 414 419 586 418 Scope 2 absolute (GJ), legacy BD 3,284,961 3,239,706 3,335,681 3,353,830 3,332,961 3,429,182 3,507,524 3,456,404 3,498,860 3,552,016 3,637,374 3,709,835 3,683,Scope 2 normalized (GJ per $M COPS),  legacy BD691 683 653 629 603 608 577 619 539 580 473 487 Scope 2 absolute (GJ), combined 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,248,Scope 2 normalized (GJ per $M COPS),  combined653 645 615 591 568 570 544 580 518 549 486 476 Total absolute (GJ), legacy Bard  643,646 644,722 644,818 644,818 709,224 752,363 852,895 870,307 869,231 1,014,932 1,212,264 888,821 854,Total normalized (GJ per $M COPS),  legacy Bard690 681 637 598 633 642 682 669 647 703 1,193 642 % reduction from baseline 9% Total absolute (GJ), legacy BD 4,879,962 4,854,532 4,919,875 4,827,173 4,785,408 4,780,696 4,873,121 4,812,455 4,860,756 5,215,924 5,512,793 5,655,290 5,634,Total normalized (GJ per $M COPS),  legacy BD1,027 1,024 962 906 866 847 802 861 749 851 716 742 % reduction from baseline 33% Total absolute (GJ), combined 5,523,608 5,499,254 5,564,693 5,471,991 5,494,632 5,533,059 5,726,017 5,682,762 5,729,986 6,230,856 6,725,057 6,544,112 6,489,Total normalized (GJ per $M COPS),  combined972 967 909 854 827 812 781 825 731 823 772 727 % reduction from baseline 30% 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Energy_Management', 0.980728268623352)","('Water_And_Wastewater_Management', 0.0015973125118762255)","('Critical_Incident_Risk_Management', 0.0015777889639139175)","(['Operational Eco-Efficiency'], 0.980728268623352)","('NON-ESG', 0.0015973125118762255)","('NON-ESG', 0.0015777889639139175)"
Line 1243,"Current stat: Reducedced by 30% Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.2020 goal Minimize  our environmental footprint and conserve natural resources GRI disclosures: 302-1, 302-3, 302- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Renewable energy (RECs, green power)—combined Electric power (GJ) 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,237,Green energy (GJ) 104,745 161,475 181,361 264,315 202,821 170,913 99,492 97,626 246,777 448,020 345,797 580,285 608,Renewable energy credit (REC)  purchased (GJ)18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,817,926 2,020,847 1,896,194 1,476,279 678,Renewable energy offsite—direct  (physical) PPA (GJ)50,Renewable power - on site (GJ) 1,218 1,203 1,344 2,667 1,099 1,229 1,131 1,Total green power 123,293 294,890 752,176 935,030 1,215,517 1,490,347 1,427,051 1,591,160 2,067,370 2,469,966 2,243,220 2,057,695 1,337,As part of electric power consumption: % from REC purchases 0.5% 4% 15% 18% 27% 34% 33% 37% 45% 49% 45% 34% 16% % from green energy 3% 4% 5% 7% 5% 4% 2% 2% 6% 11% 8% 14% 14% % from direct PPA 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1% % from on-site generation 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% % of all green power 3% 8% 20% 25% 32% 38% 36% 40% 51% 59% 53% 48% 32% As part of total energy: % from RECs 0.3% 2% 10% 12% 18% 24% 23% 26% 32% 32% 28% 23% 10% % of all renewable energy sourced  and generated2% 5% 14% 17% 22% 27% 25% 28% 36% 40% 33% 31% 21% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9801038503646851)","('Product_Design_And_Lifecycle_Management', 0.0020550128538161516)","('Management_Of_Legal_And_Regulatory_Framework', 0.001720226719044149)","(['Operational Eco-Efficiency'], 0.9801038503646851)","('NON-ESG', 0.0020550128538161516)","('NON-ESG', 0.001720226719044149)"
Line 1244,"Current stat: Reducedced by 30% Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.2020 goal Minimize  our environmental footprint and conserve natural resources GRI disclosures: 302-1, 302-3, 302- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Renewable energy (RECs, green power)—combined Electric power (GJ) 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,237,Green energy (GJ) 104,745 161,475 181,361 264,315 202,821 170,913 99,492 97,626 246,777 448,020 345,797 580,285 608,Renewable energy credit (REC)  purchased (GJ)18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,817,926 2,020,847 1,896,194 1,476,279 678,Renewable energy offsite—direct  (physical) PPA (GJ)50,Renewable power - on site (GJ) 1,218 1,203 1,344 2,667 1,099 1,229 1,131 1,Total green power 123,293 294,890 752,176 935,030 1,215,517 1,490,347 1,427,051 1,591,160 2,067,370 2,469,966 2,243,220 2,057,695 1,337,As part of electric power consumption: % from REC purchases 0.5% 4% 15% 18% 27% 34% 33% 37% 45% 49% 45% 34% 16% % from green energy 3% 4% 5% 7% 5% 4% 2% 2% 6% 11% 8% 14% 14% % from direct PPA 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1% % from on-site generation 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% % of all green power 3% 8% 20% 25% 32% 38% 36% 40% 51% 59% 53% 48% 32% As part of total energy: % from RECs 0.3% 2% 10% 12% 18% 24% 23% 26% 32% 32% 28% 23% 10% % of all renewable energy sourced  and generated2% 5% 14% 17% 22% 27% 25% 28% 36% 40% 33% 31% 21% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9740707874298096)","('Management_Of_Legal_And_Regulatory_Framework', 0.0046551465056836605)","('GHG_Emissions', 0.0021710889413952827)","(['Operational Eco-Efficiency'], 0.9740707874298096)","('NON-ESG', 0.0046551465056836605)","('NON-ESG', 0.0021710889413952827)"
Line 1245,"Current stat: Reducedced by 30% Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.2020 goal Minimize  our environmental footprint and conserve natural resources GRI disclosures: 302-1, 302-3, 302- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Renewable energy (RECs, green power)—combined Electric power (GJ) 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,237,Green energy (GJ) 104,745 161,475 181,361 264,315 202,821 170,913 99,492 97,626 246,777 448,020 345,797 580,285 608,Renewable energy credit (REC)  purchased (GJ)18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,817,926 2,020,847 1,896,194 1,476,279 678,Renewable energy offsite—direct  (physical) PPA (GJ)50,Renewable power - on site (GJ) 1,218 1,203 1,344 2,667 1,099 1,229 1,131 1,Total green power 123,293 294,890 752,176 935,030 1,215,517 1,490,347 1,427,051 1,591,160 2,067,370 2,469,966 2,243,220 2,057,695 1,337,As part of electric power consumption: % from REC purchases 0.5% 4% 15% 18% 27% 34% 33% 37% 45% 49% 45% 34% 16% % from green energy 3% 4% 5% 7% 5% 4% 2% 2% 6% 11% 8% 14% 14% % from direct PPA 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1% % from on-site generation 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% % of all green power 3% 8% 20% 25% 32% 38% 36% 40% 51% 59% 53% 48% 32% As part of total energy: % from RECs 0.3% 2% 10% 12% 18% 24% 23% 26% 32% 32% 28% 23% 10% % of all renewable energy sourced  and generated2% 5% 14% 17% 22% 27% 25% 28% 36% 40% 33% 31% 21% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9729867577552795)","('Critical_Incident_Risk_Management', 0.002742731710895896)","('Access_And_Affordability', 0.0022442329209297895)","(['Operational Eco-Efficiency'], 0.9729867577552795)","('NON-ESG', 0.002742731710895896)","('NON-ESG', 0.0022442329209297895)"
Line 1246,"Current stat: Reducedced by 30% Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.2020 goal Minimize  our environmental footprint and conserve natural resources GRI disclosures: 302-1, 302-3, 302- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Renewable energy (RECs, green power)—combined Electric power (GJ) 3,713,366 3,669,188 3,765,258 3,783,408 3,776,100 3,883,794 3,983,498 3,997,594 4,055,145 4,156,097 4,232,540 4,289,019 4,237,Green energy (GJ) 104,745 161,475 181,361 264,315 202,821 170,913 99,492 97,626 246,777 448,020 345,797 580,285 608,Renewable energy credit (REC)  purchased (GJ)18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,817,926 2,020,847 1,896,194 1,476,279 678,Renewable energy offsite—direct  (physical) PPA (GJ)50,Renewable power - on site (GJ) 1,218 1,203 1,344 2,667 1,099 1,229 1,131 1,Total green power 123,293 294,890 752,176 935,030 1,215,517 1,490,347 1,427,051 1,591,160 2,067,370 2,469,966 2,243,220 2,057,695 1,337,As part of electric power consumption: % from REC purchases 0.5% 4% 15% 18% 27% 34% 33% 37% 45% 49% 45% 34% 16% % from green energy 3% 4% 5% 7% 5% 4% 2% 2% 6% 11% 8% 14% 14% % from direct PPA 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 1% % from on-site generation 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% % of all green power 3% 8% 20% 25% 32% 38% 36% 40% 51% 59% 53% 48% 32% As part of total energy: % from RECs 0.3% 2% 10% 12% 18% 24% 23% 26% 32% 32% 28% 23% 10% % of all renewable energy sourced  and generated2% 5% 14% 17% 22% 27% 25% 28% 36% 40% 33% 31% 21% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9779114127159119)","('Management_Of_Legal_And_Regulatory_Framework', 0.0020946036092936993)","('Air_Quality', 0.001880871132016182)","(['Operational Eco-Efficiency'], 0.9779114127159119)","('NON-ESG', 0.0020946036092936993)","('NON-ESG', 0.001880871132016182)"
Line 1247,"Current status:  Increased to 21% GRI disclosure: 302-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Water consumption Water (cubic meters), legacy Bard 919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 938,842 686,256 505,Water - Groundwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 275,757 266,040 285,Water - Rainwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Recycled (cubic meters),   legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Surface water (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 1,239 0 Absolute (cubic meters),   legacy Bard919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 1,215,838 952,296 791,Normalized (cubic meters per $M  COPS), legacy Bard986 980 917 860 836 771 724 699 683 620 1,197 688 % reduction from baseline,   legacy Bard41% Water (cubic meters), legacy BD 4,583,955 4,220,395 3,809,810 3,834,116 3,889,155 4,020,578 4,221,694 4,450,833 4,399,485 3,902,538 3,835,244 3,696,898 3,465,Water - Groundwater (cubic meters),  legacy BD71,878 76,400 73,188 81,361 72,860 64,179 53,377 33,988 40,747 34,398 11,369 18,979 20,Water - Rainwater (cubic meters),  legacy BD0 0 45 60 60 60 1,297 1,851 1,660 1,340 1,285 1,629 Water - Recycled (cubic meters),  legacy BD42,885 27,052 56,220 47,851 31,167 24,043 25,349 6,522 11,954 3,582 3,061 3,174 3,Water - Surface water (cubic meters),  legacy BD0 0 33,869 61,955 74,218 56,445 80,132 86,135 84,446 85,700 103,870 129,714 154,Absolute (cubic meters), legacy BD 4,698,717 4,323,846 3,973,133 4,025,344 4,067,460 4,165,305 4,381,849 4,579,329 4,538,292 4,027,558 3,954,830 3,850,394 3,643,Normalized (cubic meters per $M  COPS), legacy BD989 912 777 756 736 738 721 820 699 657 514 505 % reduction from baseline, legacy BD 55% Absolute (cubic meters), combined 5,618,193 5,251,522 4,900,808 4,953,020 5,003,229 5,068,694 5,286,495 5,489,116 5,456,416 4,922,740 5,170,668 4,802,690 4,435,Normalized (cubic meters per $M  COPS), combined988 924 800 773 753 744 721 797 696 650 593 534 % reduction from baseline, combined 53% 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9739933013916016)","('Energy_Management', 0.003443632973358035)","('GHG_Emissions', 0.0020465620327740908)","(['Operational Eco-Efficiency'], 0.9739933013916016)","('NON-ESG', 0.003443632973358035)","('NON-ESG', 0.0020465620327740908)"
Line 1248,"Current status:  Increased to 21% GRI disclosure: 302-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Water consumption Water (cubic meters), legacy Bard 919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 938,842 686,256 505,Water - Groundwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 275,757 266,040 285,Water - Rainwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Recycled (cubic meters),   legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Surface water (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 1,239 0 Absolute (cubic meters),   legacy Bard919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 1,215,838 952,296 791,Normalized (cubic meters per $M  COPS), legacy Bard986 980 917 860 836 771 724 699 683 620 1,197 688 % reduction from baseline,   legacy Bard41% Water (cubic meters), legacy BD 4,583,955 4,220,395 3,809,810 3,834,116 3,889,155 4,020,578 4,221,694 4,450,833 4,399,485 3,902,538 3,835,244 3,696,898 3,465,Water - Groundwater (cubic meters),  legacy BD71,878 76,400 73,188 81,361 72,860 64,179 53,377 33,988 40,747 34,398 11,369 18,979 20,Water - Rainwater (cubic meters),  legacy BD0 0 45 60 60 60 1,297 1,851 1,660 1,340 1,285 1,629 Water - Recycled (cubic meters),  legacy BD42,885 27,052 56,220 47,851 31,167 24,043 25,349 6,522 11,954 3,582 3,061 3,174 3,Water - Surface water (cubic meters),  legacy BD0 0 33,869 61,955 74,218 56,445 80,132 86,135 84,446 85,700 103,870 129,714 154,Absolute (cubic meters), legacy BD 4,698,717 4,323,846 3,973,133 4,025,344 4,067,460 4,165,305 4,381,849 4,579,329 4,538,292 4,027,558 3,954,830 3,850,394 3,643,Normalized (cubic meters per $M  COPS), legacy BD989 912 777 756 736 738 721 820 699 657 514 505 % reduction from baseline, legacy BD 55% Absolute (cubic meters), combined 5,618,193 5,251,522 4,900,808 4,953,020 5,003,229 5,068,694 5,286,495 5,489,116 5,456,416 4,922,740 5,170,668 4,802,690 4,435,Normalized (cubic meters per $M  COPS), combined988 924 800 773 753 744 721 797 696 650 593 534 % reduction from baseline, combined 53% 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9733358025550842)","('Waste_And_Hazardous_Materials_Management', 0.003189633134752512)","('GHG_Emissions', 0.002797431778162718)","(['Operational Eco-Efficiency'], 0.9733358025550842)","('NON-ESG', 0.003189633134752512)","('NON-ESG', 0.002797431778162718)"
Line 1249,"Current status:  Increased to 21% GRI disclosure: 302-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Water consumption Water (cubic meters), legacy Bard 919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 938,842 686,256 505,Water - Groundwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 275,757 266,040 285,Water - Rainwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Recycled (cubic meters),   legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Surface water (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 1,239 0 Absolute (cubic meters),   legacy Bard919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 1,215,838 952,296 791,Normalized (cubic meters per $M  COPS), legacy Bard986 980 917 860 836 771 724 699 683 620 1,197 688 % reduction from baseline,   legacy Bard41% Water (cubic meters), legacy BD 4,583,955 4,220,395 3,809,810 3,834,116 3,889,155 4,020,578 4,221,694 4,450,833 4,399,485 3,902,538 3,835,244 3,696,898 3,465,Water - Groundwater (cubic meters),  legacy BD71,878 76,400 73,188 81,361 72,860 64,179 53,377 33,988 40,747 34,398 11,369 18,979 20,Water - Rainwater (cubic meters),  legacy BD0 0 45 60 60 60 1,297 1,851 1,660 1,340 1,285 1,629 Water - Recycled (cubic meters),  legacy BD42,885 27,052 56,220 47,851 31,167 24,043 25,349 6,522 11,954 3,582 3,061 3,174 3,Water - Surface water (cubic meters),  legacy BD0 0 33,869 61,955 74,218 56,445 80,132 86,135 84,446 85,700 103,870 129,714 154,Absolute (cubic meters), legacy BD 4,698,717 4,323,846 3,973,133 4,025,344 4,067,460 4,165,305 4,381,849 4,579,329 4,538,292 4,027,558 3,954,830 3,850,394 3,643,Normalized (cubic meters per $M  COPS), legacy BD989 912 777 756 736 738 721 820 699 657 514 505 % reduction from baseline, legacy BD 55% Absolute (cubic meters), combined 5,618,193 5,251,522 4,900,808 4,953,020 5,003,229 5,068,694 5,286,495 5,489,116 5,456,416 4,922,740 5,170,668 4,802,690 4,435,Normalized (cubic meters per $M  COPS), combined988 924 800 773 753 744 721 797 696 650 593 534 % reduction from baseline, combined 53% 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9663868546485901)","('Waste_And_Hazardous_Materials_Management', 0.005014270544052124)","('Energy_Management', 0.002693871036171913)","(['Operational Eco-Efficiency'], 0.9663868546485901)","('NON-ESG', 0.005014270544052124)","('NON-ESG', 0.002693871036171913)"
Line 1250,"Current status:  Increased to 21% GRI disclosure: 302-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Water consumption Water (cubic meters), legacy Bard 919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 938,842 686,256 505,Water - Groundwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 275,757 266,040 285,Water - Rainwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Recycled (cubic meters),   legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Surface water (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 1,239 0 Absolute (cubic meters),   legacy Bard919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 1,215,838 952,296 791,Normalized (cubic meters per $M  COPS), legacy Bard986 980 917 860 836 771 724 699 683 620 1,197 688 % reduction from baseline,   legacy Bard41% Water (cubic meters), legacy BD 4,583,955 4,220,395 3,809,810 3,834,116 3,889,155 4,020,578 4,221,694 4,450,833 4,399,485 3,902,538 3,835,244 3,696,898 3,465,Water - Groundwater (cubic meters),  legacy BD71,878 76,400 73,188 81,361 72,860 64,179 53,377 33,988 40,747 34,398 11,369 18,979 20,Water - Rainwater (cubic meters),  legacy BD0 0 45 60 60 60 1,297 1,851 1,660 1,340 1,285 1,629 Water - Recycled (cubic meters),  legacy BD42,885 27,052 56,220 47,851 31,167 24,043 25,349 6,522 11,954 3,582 3,061 3,174 3,Water - Surface water (cubic meters),  legacy BD0 0 33,869 61,955 74,218 56,445 80,132 86,135 84,446 85,700 103,870 129,714 154,Absolute (cubic meters), legacy BD 4,698,717 4,323,846 3,973,133 4,025,344 4,067,460 4,165,305 4,381,849 4,579,329 4,538,292 4,027,558 3,954,830 3,850,394 3,643,Normalized (cubic meters per $M  COPS), legacy BD989 912 777 756 736 738 721 820 699 657 514 505 % reduction from baseline, legacy BD 55% Absolute (cubic meters), combined 5,618,193 5,251,522 4,900,808 4,953,020 5,003,229 5,068,694 5,286,495 5,489,116 5,456,416 4,922,740 5,170,668 4,802,690 4,435,Normalized (cubic meters per $M  COPS), combined988 924 800 773 753 744 721 797 696 650 593 534 % reduction from baseline, combined 53% 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9294806122779846)","('Energy_Management', 0.01388723123818636)","('GHG_Emissions', 0.009003625251352787)","(['Operational Eco-Efficiency'], 0.9294806122779846)","('NON-ESG', 0.01388723123818636)","('NON-ESG', 0.009003625251352787)"
Line 1251,"Current status:  Increased to 21% GRI disclosure: 302-Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Water consumption Water (cubic meters), legacy Bard 919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 938,842 686,256 505,Water - Groundwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 275,757 266,040 285,Water - Rainwater (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Recycled (cubic meters),   legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Water - Surface water (cubic meters),  legacy Bard0 0 0 0 0 0 0 0 0 0 1,239 0 Absolute (cubic meters),   legacy Bard919,476 927,676 927,676 927,676 935,769 903,390 904,646 909,787 918,124 895,182 1,215,838 952,296 791,Normalized (cubic meters per $M  COPS), legacy Bard986 980 917 860 836 771 724 699 683 620 1,197 688 % reduction from baseline,   legacy Bard41% Water (cubic meters), legacy BD 4,583,955 4,220,395 3,809,810 3,834,116 3,889,155 4,020,578 4,221,694 4,450,833 4,399,485 3,902,538 3,835,244 3,696,898 3,465,Water - Groundwater (cubic meters),  legacy BD71,878 76,400 73,188 81,361 72,860 64,179 53,377 33,988 40,747 34,398 11,369 18,979 20,Water - Rainwater (cubic meters),  legacy BD0 0 45 60 60 60 1,297 1,851 1,660 1,340 1,285 1,629 Water - Recycled (cubic meters),  legacy BD42,885 27,052 56,220 47,851 31,167 24,043 25,349 6,522 11,954 3,582 3,061 3,174 3,Water - Surface water (cubic meters),  legacy BD0 0 33,869 61,955 74,218 56,445 80,132 86,135 84,446 85,700 103,870 129,714 154,Absolute (cubic meters), legacy BD 4,698,717 4,323,846 3,973,133 4,025,344 4,067,460 4,165,305 4,381,849 4,579,329 4,538,292 4,027,558 3,954,830 3,850,394 3,643,Normalized (cubic meters per $M  COPS), legacy BD989 912 777 756 736 738 721 820 699 657 514 505 % reduction from baseline, legacy BD 55% Absolute (cubic meters), combined 5,618,193 5,251,522 4,900,808 4,953,020 5,003,229 5,068,694 5,286,495 5,489,116 5,456,416 4,922,740 5,170,668 4,802,690 4,435,Normalized (cubic meters per $M  COPS), combined988 924 800 773 753 744 721 797 696 650 593 534 % reduction from baseline, combined 53% 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9343253970146179)","('Energy_Management', 0.025439448654651642)","('Waste_And_Hazardous_Materials_Management', 0.003481905208900571)","(['Operational Eco-Efficiency'], 0.9343253970146179)","('NON-ESG', 0.025439448654651642)","('NON-ESG', 0.003481905208900571)"
Line 1252,"Current status:  Reduced by 53%.
","('Management_Of_Legal_And_Regulatory_Framework', 0.19540855288505554)","('Director_Removal', 0.1371087282896042)","('Systemic_Risk_Management', 0.12061841785907745)","('NON-ESG', 0.19540855288505554)","('NON-ESG', 0.1371087282896042)","('NON-ESG', 0.12061841785907745)"
Line 1253,"TARGET ACHIEVED GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Waste water discharge Absolute (cubic meters),   legacy Bard0 0 0 0 0 185,028 242,905 242,536 248,418 350,708 787,000 837,735 806,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 243 775 605 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 27% 27% 27% 39% 65% 88% 102% Absolute (cubic meters), legacy BD 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 2,996,344 3,232,445 3,165,895 3,156,006 2,926,977 3,151,365 3,412,453 3,069,Normalized (cubic meters per $M  COPS), legacy BD715 679 523 518 543 531 532 567 486 478 409 448 % discharge, legacy BD 72% 74% 67% 69% 74% 72% 74% 69% 70% 73% 80% 89% 84% Absolute (cubic meters), combined 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 3,181,372 3,475,350 3,408,431 3,404,423 3,277,684 3,938,365 4,250,188 3,876,Normalized (cubic meters per $M  COPS), combined1598 566 436 430 452 467 474 495 434 433 452 472 % discharge, combined 61% 61% 55% 56% 60% 63% 66% 62% 62% 67% 76% 88% 87% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Water_And_Wastewater_Management', 0.6964178085327148)","('Waste_And_Hazardous_Materials_Management', 0.15555205941200256)","('Energy_Management', 0.043282944709062576)","(['Operational Eco-Efficiency'], 0.6964178085327148)","('NON-ESG', 0.15555205941200256)","('NON-ESG', 0.043282944709062576)"
Line 1254,"TARGET ACHIEVED GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Waste water discharge Absolute (cubic meters),   legacy Bard0 0 0 0 0 185,028 242,905 242,536 248,418 350,708 787,000 837,735 806,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 243 775 605 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 27% 27% 27% 39% 65% 88% 102% Absolute (cubic meters), legacy BD 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 2,996,344 3,232,445 3,165,895 3,156,006 2,926,977 3,151,365 3,412,453 3,069,Normalized (cubic meters per $M  COPS), legacy BD715 679 523 518 543 531 532 567 486 478 409 448 % discharge, legacy BD 72% 74% 67% 69% 74% 72% 74% 69% 70% 73% 80% 89% 84% Absolute (cubic meters), combined 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 3,181,372 3,475,350 3,408,431 3,404,423 3,277,684 3,938,365 4,250,188 3,876,Normalized (cubic meters per $M  COPS), combined1598 566 436 430 452 467 474 495 434 433 452 472 % discharge, combined 61% 61% 55% 56% 60% 63% 66% 62% 62% 67% 76% 88% 87% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Energy_Management', 0.2972876727581024)","('Water_And_Wastewater_Management', 0.11872733384370804)","('Customer_Welfare', 0.06317313015460968)","('NON-ESG', 0.2972876727581024)","('NON-ESG', 0.11872733384370804)","('NON-ESG', 0.06317313015460968)"
Line 1255,"TARGET ACHIEVED GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Waste water discharge Absolute (cubic meters),   legacy Bard0 0 0 0 0 185,028 242,905 242,536 248,418 350,708 787,000 837,735 806,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 243 775 605 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 27% 27% 27% 39% 65% 88% 102% Absolute (cubic meters), legacy BD 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 2,996,344 3,232,445 3,165,895 3,156,006 2,926,977 3,151,365 3,412,453 3,069,Normalized (cubic meters per $M  COPS), legacy BD715 679 523 518 543 531 532 567 486 478 409 448 % discharge, legacy BD 72% 74% 67% 69% 74% 72% 74% 69% 70% 73% 80% 89% 84% Absolute (cubic meters), combined 3,399,366 3,220,323 2,671,884 2,757,745 3,000,525 3,181,372 3,475,350 3,408,431 3,404,423 3,277,684 3,938,365 4,250,188 3,876,Normalized (cubic meters per $M  COPS), combined1598 566 436 430 452 467 474 495 434 433 452 472 % discharge, combined 61% 61% 55% 56% 60% 63% 66% 62% 62% 67% 76% 88% 87% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.2376413643360138)","('Energy_Management', 0.12993839383125305)","('GHG_Emissions', 0.06450165808200836)","('NON-ESG', 0.2376413643360138)","('NON-ESG', 0.12993839383125305)","('NON-ESG', 0.06450165808200836)"
Line 1256,"GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total nonhazardous waste generated Absolute (metric tonnes), legacy Bard 4,673 4,673 4,673 4,673 4,673 5,145 5,737 7,156 7,581 8,692 12,327 9,379 11,Normalized (metric tonnes per $M COPS),  including regulated waste,   legacy Bard5.01 4.94 4.62 4.33 4.17 4.39 4.59 5.50 5.64 6.02 12.13 6.78 8.% reduction from baseline,   legacy Bard-64% Absolute (metric tonnes), legacy BD 43,232 42,161 43,804 42,742 42,884 43,578 42,114 40,842 45,211 46,189 54,690 58,085 57,Normalized (metric tonnes per $M COPS),  including regulated waste, legacy BD9.10 8.89 8.57 8.02 7.76 7.72 6.93 7.31 6.96 7.54 7.10 7.62 7.% reduction from baseline, legacy BD 22% Absolute (metric tonnes), combined 47,904 46,834 48,477 47,414 47,557 48,724 47,851 47,998 52,792 54,881 67,018 67,464 69,Normalized (metric tonnes per $M COPS),  including regulated waste, combined8.43 8.24 7.92 7.40 7.16 7.15 6.53 6.97 6.74 7.25 7.69 7.49 7.% reduction from baseline, combined 14% 2020 goal:  Reduce total waste by 50% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9835265278816223)","('Water_And_Wastewater_Management', 0.001583867589943111)","('Air_Quality', 0.0013069813139736652)","(['Operational Eco-Efficiency'], 0.9835265278816223)","('NON-ESG', 0.001583867589943111)","('NON-ESG', 0.0013069813139736652)"
Line 1257,"GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total nonhazardous waste generated Absolute (metric tonnes), legacy Bard 4,673 4,673 4,673 4,673 4,673 5,145 5,737 7,156 7,581 8,692 12,327 9,379 11,Normalized (metric tonnes per $M COPS),  including regulated waste,   legacy Bard5.01 4.94 4.62 4.33 4.17 4.39 4.59 5.50 5.64 6.02 12.13 6.78 8.% reduction from baseline,   legacy Bard-64% Absolute (metric tonnes), legacy BD 43,232 42,161 43,804 42,742 42,884 43,578 42,114 40,842 45,211 46,189 54,690 58,085 57,Normalized (metric tonnes per $M COPS),  including regulated waste, legacy BD9.10 8.89 8.57 8.02 7.76 7.72 6.93 7.31 6.96 7.54 7.10 7.62 7.% reduction from baseline, legacy BD 22% Absolute (metric tonnes), combined 47,904 46,834 48,477 47,414 47,557 48,724 47,851 47,998 52,792 54,881 67,018 67,464 69,Normalized (metric tonnes per $M COPS),  including regulated waste, combined8.43 8.24 7.92 7.40 7.16 7.15 6.53 6.97 6.74 7.25 7.69 7.49 7.% reduction from baseline, combined 14% 2020 goal:  Reduce total waste by 50% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9757823944091797)","('Water_And_Wastewater_Management', 0.003033679910004139)","('Air_Quality', 0.001743246684782207)","(['Operational Eco-Efficiency'], 0.9757823944091797)","('NON-ESG', 0.003033679910004139)","('NON-ESG', 0.001743246684782207)"
Line 1258,"GRI disclosure: 303- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Total nonhazardous waste generated Absolute (metric tonnes), legacy Bard 4,673 4,673 4,673 4,673 4,673 5,145 5,737 7,156 7,581 8,692 12,327 9,379 11,Normalized (metric tonnes per $M COPS),  including regulated waste,   legacy Bard5.01 4.94 4.62 4.33 4.17 4.39 4.59 5.50 5.64 6.02 12.13 6.78 8.% reduction from baseline,   legacy Bard-64% Absolute (metric tonnes), legacy BD 43,232 42,161 43,804 42,742 42,884 43,578 42,114 40,842 45,211 46,189 54,690 58,085 57,Normalized (metric tonnes per $M COPS),  including regulated waste, legacy BD9.10 8.89 8.57 8.02 7.76 7.72 6.93 7.31 6.96 7.54 7.10 7.62 7.% reduction from baseline, legacy BD 22% Absolute (metric tonnes), combined 47,904 46,834 48,477 47,414 47,557 48,724 47,851 47,998 52,792 54,881 67,018 67,464 69,Normalized (metric tonnes per $M COPS),  including regulated waste, combined8.43 8.24 7.92 7.40 7.16 7.15 6.53 6.97 6.74 7.25 7.69 7.49 7.% reduction from baseline, combined 14% 2020 goal:  Reduce total waste by 50% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9835842847824097)","('Water_And_Wastewater_Management', 0.0015265129040926695)","('Air_Quality', 0.0013965258840471506)","(['Operational Eco-Efficiency'], 0.9835842847824097)","('NON-ESG', 0.0015265129040926695)","('NON-ESG', 0.0013965258840471506)"
Line 1259,"Current status:  Reduced by 14% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste landfilled Absolute (metric tonnes), legacy Bard 1,647 1,647 1,647 1,647 1,647 1,905 2,329 2,612 2,668 2,935 3,489 3,524 2,Normalized (metric tonnes per $M COPS),  legacy Bard1.77 1.74 1.63 1.53 1.47 1.63 1.86 2.01 1.99 2.03 3.43 2.55 2.% landfilled, legacy Bard 35% 35% 35% 35% 35% 37% 41% 36% 35% 34% 28% 38% 25% % diversion, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 72% 62% 75% Absolute (metric tonnes), legacy BD 23,347 22,191 18,777 14,046 12,342 11,726 8,897 7,855 9,405 9,341 11,963 12,248 11,Normalized (metric tonnes per $M COPS),  legacy BD4.91 4.68 3.67 2.64 2.23 2.08 1.46 1.41 1.45 1.52 1.55 1.61 1.% landfilled, legacy BD 54% 53% 43% 33% 29% 27% 21% 19% 21% 20% 22% 21% 20% % diversion, legacy BD 46% 47% 57% 67% 71% 73% 79% 81% 79% 80% 78% 79% 80% Absolute (metric tonnes), combined 24,994 23,838 20,424 15,693 13,989 13,631 11,226 10,467 12,074 12,276 15,452 15,772 14,Normalized (metric tonnes per $M COPS),  combined4.40 4.19 3.34 2.45 2.10 2.00 1.53 1.52 1.54 1.62 1.77 1.75 1.% landfilled, combined 52% 51% 42% 33% 29% 28% 23% 22% 23% 22% 23% 23% 21% % diversion, combined 48% 49% 58% 67% 71% 72% 77% 78% 77% 78% 77% 77% 79% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9811252355575562)","('Water_And_Wastewater_Management', 0.0022167277056723833)","('Air_Quality', 0.0014391818549484015)","(['Operational Eco-Efficiency'], 0.9811252355575562)","('NON-ESG', 0.0022167277056723833)","('NON-ESG', 0.0014391818549484015)"
Line 1260,"Current status:  Reduced by 14% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste landfilled Absolute (metric tonnes), legacy Bard 1,647 1,647 1,647 1,647 1,647 1,905 2,329 2,612 2,668 2,935 3,489 3,524 2,Normalized (metric tonnes per $M COPS),  legacy Bard1.77 1.74 1.63 1.53 1.47 1.63 1.86 2.01 1.99 2.03 3.43 2.55 2.% landfilled, legacy Bard 35% 35% 35% 35% 35% 37% 41% 36% 35% 34% 28% 38% 25% % diversion, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 72% 62% 75% Absolute (metric tonnes), legacy BD 23,347 22,191 18,777 14,046 12,342 11,726 8,897 7,855 9,405 9,341 11,963 12,248 11,Normalized (metric tonnes per $M COPS),  legacy BD4.91 4.68 3.67 2.64 2.23 2.08 1.46 1.41 1.45 1.52 1.55 1.61 1.% landfilled, legacy BD 54% 53% 43% 33% 29% 27% 21% 19% 21% 20% 22% 21% 20% % diversion, legacy BD 46% 47% 57% 67% 71% 73% 79% 81% 79% 80% 78% 79% 80% Absolute (metric tonnes), combined 24,994 23,838 20,424 15,693 13,989 13,631 11,226 10,467 12,074 12,276 15,452 15,772 14,Normalized (metric tonnes per $M COPS),  combined4.40 4.19 3.34 2.45 2.10 2.00 1.53 1.52 1.54 1.62 1.77 1.75 1.% landfilled, combined 52% 51% 42% 33% 29% 28% 23% 22% 23% 22% 23% 23% 21% % diversion, combined 48% 49% 58% 67% 71% 72% 77% 78% 77% 78% 77% 77% 79% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Energy_Management', 0.11206945776939392)","('Management_Of_Legal_And_Regulatory_Framework', 0.10944415628910065)","('Supply_Chain_Management', 0.09492982178926468)","('NON-ESG', 0.11206945776939392)","('NON-ESG', 0.10944415628910065)","('NON-ESG', 0.09492982178926468)"
Line 1261,"Current status:  Reduced by 14% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste landfilled Absolute (metric tonnes), legacy Bard 1,647 1,647 1,647 1,647 1,647 1,905 2,329 2,612 2,668 2,935 3,489 3,524 2,Normalized (metric tonnes per $M COPS),  legacy Bard1.77 1.74 1.63 1.53 1.47 1.63 1.86 2.01 1.99 2.03 3.43 2.55 2.% landfilled, legacy Bard 35% 35% 35% 35% 35% 37% 41% 36% 35% 34% 28% 38% 25% % diversion, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 72% 62% 75% Absolute (metric tonnes), legacy BD 23,347 22,191 18,777 14,046 12,342 11,726 8,897 7,855 9,405 9,341 11,963 12,248 11,Normalized (metric tonnes per $M COPS),  legacy BD4.91 4.68 3.67 2.64 2.23 2.08 1.46 1.41 1.45 1.52 1.55 1.61 1.% landfilled, legacy BD 54% 53% 43% 33% 29% 27% 21% 19% 21% 20% 22% 21% 20% % diversion, legacy BD 46% 47% 57% 67% 71% 73% 79% 81% 79% 80% 78% 79% 80% Absolute (metric tonnes), combined 24,994 23,838 20,424 15,693 13,989 13,631 11,226 10,467 12,074 12,276 15,452 15,772 14,Normalized (metric tonnes per $M COPS),  combined4.40 4.19 3.34 2.45 2.10 2.00 1.53 1.52 1.54 1.62 1.77 1.75 1.% landfilled, combined 52% 51% 42% 33% 29% 28% 23% 22% 23% 22% 23% 23% 21% % diversion, combined 48% 49% 58% 67% 71% 72% 77% 78% 77% 78% 77% 77% 79% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9813764691352844)","('Water_And_Wastewater_Management', 0.00236723804846406)","('Air_Quality', 0.0013610963942483068)","(['Operational Eco-Efficiency'], 0.9813764691352844)","('NON-ESG', 0.00236723804846406)","('NON-ESG', 0.0013610963942483068)"
Line 1262,"Current status:  Increased to 79% GRI disclosure: 306-5GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste incinerated Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 22 212 203 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.15 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 2% 2% Absolute (metric tonnes), legacy BD 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,232 8,156 9,712 10,Normalized (metric tonnes per $M  COPS), legacy BD0.58 0.56 0.54 0.43 0.50 0.72 0.68 0.62 0.91 1.02 1.06 1.27 1.% incinerated, legacy BD 6% 6% 6% 5% 6% 9% 10% 9% 13% 13% 15% 17% 19% Absolute (metric tonnes), combined 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,254 8,368 9,915 11,Normalized (metric tonnes per $M  COPS), combined10.49 0.47 0.45 0.36 0.42 0.60 0.56 0.51 0.76 0.83 0.96 1.10 1.% incinerated, combined 6% 6% 6% 5% 6% 8% 9% 7% 11% 11% 12% 15% 16% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.9793537855148315)","('Water_And_Wastewater_Management', 0.0025527244433760643)","('Air_Quality', 0.0018528599757701159)","(['Operational Eco-Efficiency'], 0.9793537855148315)","('NON-ESG', 0.0025527244433760643)","('NON-ESG', 0.0018528599757701159)"
Line 1263,"Current status:  Increased to 79% GRI disclosure: 306-5GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste incinerated Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 22 212 203 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.15 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 2% 2% Absolute (metric tonnes), legacy BD 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,232 8,156 9,712 10,Normalized (metric tonnes per $M  COPS), legacy BD0.58 0.56 0.54 0.43 0.50 0.72 0.68 0.62 0.91 1.02 1.06 1.27 1.% incinerated, legacy BD 6% 6% 6% 5% 6% 9% 10% 9% 13% 13% 15% 17% 19% Absolute (metric tonnes), combined 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,254 8,368 9,915 11,Normalized (metric tonnes per $M  COPS), combined10.49 0.47 0.45 0.36 0.42 0.60 0.56 0.51 0.76 0.83 0.96 1.10 1.% incinerated, combined 6% 6% 6% 5% 6% 8% 9% 7% 11% 11% 12% 15% 16% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.6939631700515747)","('Air_Quality', 0.04785690829157829)","('Energy_Management', 0.04483905807137489)","(['Operational Eco-Efficiency'], 0.6939631700515747)","('NON-ESG', 0.04785690829157829)","('NON-ESG', 0.04483905807137489)"
Line 1264,"Current status:  Increased to 79% GRI disclosure: 306-5GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste incinerated Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 22 212 203 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.15 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 2% 2% Absolute (metric tonnes), legacy BD 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,232 8,156 9,712 10,Normalized (metric tonnes per $M  COPS), legacy BD0.58 0.56 0.54 0.43 0.50 0.72 0.68 0.62 0.91 1.02 1.06 1.27 1.% incinerated, legacy BD 6% 6% 6% 5% 6% 9% 10% 9% 13% 13% 15% 17% 19% Absolute (metric tonnes), combined 2,770 2,667 2,759 2,275 2,778 4,073 4,123 3,485 5,928 6,254 8,368 9,915 11,Normalized (metric tonnes per $M  COPS), combined10.49 0.47 0.45 0.36 0.42 0.60 0.56 0.51 0.76 0.83 0.96 1.10 1.% incinerated, combined 6% 6% 6% 5% 6% 8% 9% 7% 11% 11% 12% 15% 16% 1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.2920140326023102)","('Energy_Management', 0.23883354663848877)","('Water_And_Wastewater_Management', 0.1308317631483078)","('NON-ESG', 0.2920140326023102)","('NON-ESG', 0.23883354663848877)","('NON-ESG', 0.1308317631483078)"
Line 1265,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste recycled Absolute (metric tonnes),   legacy Bard3,026 3,026 3,026 3,026 3,026 3,240 3,408 4,545 4,913 5,735 8,626 5,652 8,Normalized (metric tonnes per $M  COPS), legacy Bard3.25 3.20 2.99 2.80 2.70 2.77 2.73 3.49 3.66 3.97 8.49 4.08 5.% recycled, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 70% 60% 73% Absolute (metric tonnes), legacy BD 17,114 17,303 22,268 26,421 27,764 27,779 29,094 29,501 29,878 30,617 34,572 36,125 35,Normalized (metric tonnes per $M  COPS), legacy BD3.60 3.65 4.36 4.96 5.02 4.92 4.79 5.28 4.60 5.00 4.49 4.74 4.% recycled, legacy BD 40% 41% 51% 62% 65% 64% 69% 72% 66% 66% 63% 62% 61% Absolute (metric tonnes), combined 20,140 20,329 25,294 29,446 30,790 31,019 32,503 34,046 34,791 36,351 43,198 41,777 43,Normalized (metric tonnes per $M  COPS), combined3.54 3.57 4.13 4.60 4.63 4.55 4.44 4.94 4.44 4.80 4.96 4.64 4.% recycled, combined 42% 43% 52% 62% 65% 64% 68% 71% 66% 66% 64% 62% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9781092405319214)","('Water_And_Wastewater_Management', 0.002878358820453286)","('Product_Design_And_Lifecycle_Management', 0.0015467384364455938)","(['Operational Eco-Efficiency'], 0.9781092405319214)","('NON-ESG', 0.002878358820453286)","('NON-ESG', 0.0015467384364455938)"
Line 1266,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste recycled Absolute (metric tonnes),   legacy Bard3,026 3,026 3,026 3,026 3,026 3,240 3,408 4,545 4,913 5,735 8,626 5,652 8,Normalized (metric tonnes per $M  COPS), legacy Bard3.25 3.20 2.99 2.80 2.70 2.77 2.73 3.49 3.66 3.97 8.49 4.08 5.% recycled, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 70% 60% 73% Absolute (metric tonnes), legacy BD 17,114 17,303 22,268 26,421 27,764 27,779 29,094 29,501 29,878 30,617 34,572 36,125 35,Normalized (metric tonnes per $M  COPS), legacy BD3.60 3.65 4.36 4.96 5.02 4.92 4.79 5.28 4.60 5.00 4.49 4.74 4.% recycled, legacy BD 40% 41% 51% 62% 65% 64% 69% 72% 66% 66% 63% 62% 61% Absolute (metric tonnes), combined 20,140 20,329 25,294 29,446 30,790 31,019 32,503 34,046 34,791 36,351 43,198 41,777 43,Normalized (metric tonnes per $M  COPS), combined3.54 3.57 4.13 4.60 4.63 4.55 4.44 4.94 4.44 4.80 4.96 4.64 4.% recycled, combined 42% 43% 52% 62% 65% 64% 68% 71% 66% 66% 64% 62% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Product_Design_And_Lifecycle_Management', 0.22559407353401184)","('Energy_Management', 0.21082803606987)","('Supply_Chain_Management', 0.10933013260364532)","('NON-ESG', 0.22559407353401184)","('NON-ESG', 0.21082803606987)","('NON-ESG', 0.10933013260364532)"
Line 1267,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Nonhazardous waste recycled Absolute (metric tonnes),   legacy Bard3,026 3,026 3,026 3,026 3,026 3,240 3,408 4,545 4,913 5,735 8,626 5,652 8,Normalized (metric tonnes per $M  COPS), legacy Bard3.25 3.20 2.99 2.80 2.70 2.77 2.73 3.49 3.66 3.97 8.49 4.08 5.% recycled, legacy Bard 65% 65% 65% 65% 65% 63% 59% 64% 65% 66% 70% 60% 73% Absolute (metric tonnes), legacy BD 17,114 17,303 22,268 26,421 27,764 27,779 29,094 29,501 29,878 30,617 34,572 36,125 35,Normalized (metric tonnes per $M  COPS), legacy BD3.60 3.65 4.36 4.96 5.02 4.92 4.79 5.28 4.60 5.00 4.49 4.74 4.% recycled, legacy BD 40% 41% 51% 62% 65% 64% 69% 72% 66% 66% 63% 62% 61% Absolute (metric tonnes), combined 20,140 20,329 25,294 29,446 30,790 31,019 32,503 34,046 34,791 36,351 43,198 41,777 43,Normalized (metric tonnes per $M  COPS), combined3.54 3.57 4.13 4.60 4.63 4.55 4.44 4.94 4.44 4.80 4.96 4.64 4.% recycled, combined 42% 43% 52% 62% 65% 64% 68% 71% 66% 66% 64% 62% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.978011965751648)","('Water_And_Wastewater_Management', 0.002853523241356015)","('Product_Design_And_Lifecycle_Management', 0.0017919979291036725)","(['Operational Eco-Efficiency'], 0.978011965751648)","('NON-ESG', 0.002853523241356015)","('NON-ESG', 0.0017919979291036725)"
Line 1268,"Current status:  Increased to 63% GRI disclosures: 306-4GRI disclosures: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Regulated waste (biohazardous and controlled waste) Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 5 187 276 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.20 0.Absolute (metric tonnes), legacy BD 196 181 693 923 840 680 995 1,206 1,079 1,094 934 1,052 1,Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.17 0.15 0.12 0.16 0.22 0.17 0.18 0.12 0.14 0.Absolute (metric tonnes), combined 196 181 693 923 840 680 995 1,206 1,079 1,099 1,121 1,329 1,Normalized (metric tonnes per $M  COPS), combined10.03 0.03 0.11 0.14 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.15 0.1 Combined COPS were used to calculate normalized performance back to FY 2,008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.9830400347709656)","('Water_And_Wastewater_Management', 0.0017450267914682627)","('Air_Quality', 0.001406187075190246)","(['Operational Eco-Efficiency'], 0.9830400347709656)","('NON-ESG', 0.0017450267914682627)","('NON-ESG', 0.001406187075190246)"
Line 1269,"Current status:  Increased to 63% GRI disclosures: 306-4GRI disclosures: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Regulated waste (biohazardous and controlled waste) Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 5 187 276 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.20 0.Absolute (metric tonnes), legacy BD 196 181 693 923 840 680 995 1,206 1,079 1,094 934 1,052 1,Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.17 0.15 0.12 0.16 0.22 0.17 0.18 0.12 0.14 0.Absolute (metric tonnes), combined 196 181 693 923 840 680 995 1,206 1,079 1,099 1,121 1,329 1,Normalized (metric tonnes per $M  COPS), combined10.03 0.03 0.11 0.14 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.15 0.1 Combined COPS were used to calculate normalized performance back to FY 2,008 baseline.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2960200607776642)","('Energy_Management', 0.11338245123624802)","('Systemic_Risk_Management', 0.06082851067185402)","('NON-ESG', 0.2960200607776642)","('NON-ESG', 0.11338245123624802)","('NON-ESG', 0.06082851067185402)"
Line 1270,"Current status:  Increased to 63% GRI disclosures: 306-4GRI disclosures: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Regulated waste (biohazardous and controlled waste) Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 5 187 276 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.20 0.Absolute (metric tonnes), legacy BD 196 181 693 923 840 680 995 1,206 1,079 1,094 934 1,052 1,Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.17 0.15 0.12 0.16 0.22 0.17 0.18 0.12 0.14 0.Absolute (metric tonnes), combined 196 181 693 923 840 680 995 1,206 1,079 1,099 1,121 1,329 1,Normalized (metric tonnes per $M  COPS), combined10.03 0.03 0.11 0.14 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.15 0.1 Combined COPS were used to calculate normalized performance back to FY 2,008 baseline.
","('Physical_Impacts_Of_Climate_Change', 0.20593896508216858)","('Business_Model_Resilience', 0.18110992014408112)","('GHG_Emissions', 0.14378505945205688)","('NON-ESG', 0.20593896508216858)","('NON-ESG', 0.18110992014408112)","('NON-ESG', 0.14378505945205688)"
Line 1271,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Hazardous waste generation Absolute (metric tonnes),   legacy Bard324 324 324 324 333 439 1,057 1,142 1,053 1,182 1,153 903 Normalized (metric tonnes per $M  COPS), legacy Bard0.35 0.34 0.32 0.30 0.30 0.37 0.85 0.88 0.78 0.82 1.14 0.65 0.% reduction, legacy Bard -90% Absolute (metric tonnes), legacy BD 2,718 2,103 2,523 2,043 1,854 1,826 1,646 1,739 1,866 1,753 2,088 1,786 2,Normalized (metric tonnes per $M  COPS), legacy BD0.57 0.44 0.49 0.38 0.34 0.32 0.27 0.31 0.29 0.29 0.27 0.23 0.% reduction, legacy BD 56% Absolute (metric tonnes), combined 3,041 2,427 2,846 2,367 2,187 2,264 2,704 2,881 2,919 2,935 3,241 2,688 2,Normalized (metric tonnes per $M  COPS), combined0.54 0.43 0.46 0.37 0.33 0.33 0.37 0.42 0.37 0.39 0.37 0.30 0.% reduction, combined 42% 2020 goal:  Reduce hazardous waste by more than 60% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9822338223457336)","('Water_And_Wastewater_Management', 0.0017111829947680235)","('Air_Quality', 0.0014966281596571207)","(['Operational Eco-Efficiency'], 0.9822338223457336)","('NON-ESG', 0.0017111829947680235)","('NON-ESG', 0.0014966281596571207)"
Line 1272,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Hazardous waste generation Absolute (metric tonnes),   legacy Bard324 324 324 324 333 439 1,057 1,142 1,053 1,182 1,153 903 Normalized (metric tonnes per $M  COPS), legacy Bard0.35 0.34 0.32 0.30 0.30 0.37 0.85 0.88 0.78 0.82 1.14 0.65 0.% reduction, legacy Bard -90% Absolute (metric tonnes), legacy BD 2,718 2,103 2,523 2,043 1,854 1,826 1,646 1,739 1,866 1,753 2,088 1,786 2,Normalized (metric tonnes per $M  COPS), legacy BD0.57 0.44 0.49 0.38 0.34 0.32 0.27 0.31 0.29 0.29 0.27 0.23 0.% reduction, legacy BD 56% Absolute (metric tonnes), combined 3,041 2,427 2,846 2,367 2,187 2,264 2,704 2,881 2,919 2,935 3,241 2,688 2,Normalized (metric tonnes per $M  COPS), combined0.54 0.43 0.46 0.37 0.33 0.33 0.37 0.42 0.37 0.39 0.37 0.30 0.% reduction, combined 42% 2020 goal:  Reduce hazardous waste by more than 60% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9812053442001343)","('Water_And_Wastewater_Management', 0.0014926035655662417)","('Employee_Health_And_Safety', 0.0013002223568037152)","(['Operational Eco-Efficiency'], 0.9812053442001343)","('NON-ESG', 0.0014926035655662417)","('NON-ESG', 0.0013002223568037152)"
Line 1273,"Current status:  Reduced by 42%Waste—hazardous GRI disclosure: 306-3GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentVOC emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY VOC emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 182 155 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.11 0.Absolute (metric tonnes), legacy BD1189 136 106 104 132 123 139 138 148 183 212 200 Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.Absolute (metric tonnes), combined 189 136 106 104 132 123 139 138 148 183 394 355 Normalized (metric tonnes per $M  COPS), combined20.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.05 0.04 0.1 Absolute legacy BD restated back to FY 2008 baseline,  due to removal of duplicate VOC data.
","('Waste_And_Hazardous_Materials_Management', 0.937797486782074)","('Air_Quality', 0.019368451088666916)","('Water_And_Wastewater_Management', 0.006540291476994753)","(['Operational Eco-Efficiency'], 0.937797486782074)","('NON-ESG', 0.019368451088666916)","('NON-ESG', 0.006540291476994753)"
Line 1274,"Current status:  Reduced by 42%Waste—hazardous GRI disclosure: 306-3GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentVOC emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY VOC emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 182 155 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.11 0.Absolute (metric tonnes), legacy BD1189 136 106 104 132 123 139 138 148 183 212 200 Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.Absolute (metric tonnes), combined 189 136 106 104 132 123 139 138 148 183 394 355 Normalized (metric tonnes per $M  COPS), combined20.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.05 0.04 0.1 Absolute legacy BD restated back to FY 2008 baseline,  due to removal of duplicate VOC data.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3073132336139679)","('Energy_Management', 0.07140692323446274)","('Systemic_Risk_Management', 0.06434503942728043)","('NON-ESG', 0.3073132336139679)","('NON-ESG', 0.07140692323446274)","('NON-ESG', 0.06434503942728043)"
Line 1275,"2 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.32311415672302246)","('Business_Model_Resilience', 0.20431917905807495)","('Competitive_Behavior', 0.08891726285219193)","('NON-ESG', 0.32311415672302246)","('NON-ESG', 0.20431917905807495)","('NON-ESG', 0.08891726285219193)"
Line 1276,"HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY HAPs emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 82 79 Normalized (metric tonnes per $M COPS),  legacy Bard0 0 0 0 0 0 0 0 0 0 0.08 0.06 0.Absolute (metric tonnes), legacy BD 15 13 23 23 18 17 14 12 16 23 26 21 Normalized (metric tonnes per $M COPS),  legacy BD0.003 0.003 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.004 0.003 0.003 0.Absolute (metric tonnes), combined 15 13 23 23 18 17 14 12 16 23 107 100 Normalized (metric tonnes per $M COPS),  combined10.003 0.002 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.003 0.012 0.011 0.1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('GHG_Emissions', 0.5011544823646545)","('Air_Quality', 0.3610757887363434)","('Energy_Management', 0.02407197095453739)","(['Climate Change'], 0.5011544823646545)","('NON-ESG', 0.3610757887363434)","('NON-ESG', 0.02407197095453739)"
Line 1277,"HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY HAPs emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 82 79 Normalized (metric tonnes per $M COPS),  legacy Bard0 0 0 0 0 0 0 0 0 0 0.08 0.06 0.Absolute (metric tonnes), legacy BD 15 13 23 23 18 17 14 12 16 23 26 21 Normalized (metric tonnes per $M COPS),  legacy BD0.003 0.003 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.004 0.003 0.003 0.Absolute (metric tonnes), combined 15 13 23 23 18 17 14 12 16 23 107 100 Normalized (metric tonnes per $M COPS),  combined10.003 0.002 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.003 0.012 0.011 0.1 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Management_Of_Legal_And_Regulatory_Framework', 0.22534191608428955)","('Energy_Management', 0.12627153098583221)","('Systemic_Risk_Management', 0.0736054927110672)","('NON-ESG', 0.22534191608428955)","('NON-ESG', 0.12627153098583221)","('NON-ESG', 0.0736054927110672)"
Line 1278,"GRI disclosures: 305- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentVOC + HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY VOC + HAPs emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 264 235 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.26 0.17 0.% reduction, legacy Bard 45% Absolute (metric tonnes), legacy BD1204 149 128 127 150 141 153 150 164 207 237 220 Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.03 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.% reduction, legacy BD 21% Absolute (metric tonnes), combined 204 149 128 127 150 141 153 150 164 207 501 455 Normalized (metric tonnes per $M  COPS), combined20.04 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.06 0.05 0.% reduction, combined -38% 2020 goal:  Reduce VOC and HAPs emissions by 65% (normalized by COPS).
","('Air_Quality', 0.8489165306091309)","('GHG_Emissions', 0.06392140686511993)","('Energy_Management', 0.027656061574816704)","(['Operational Eco-Efficiency'], 0.8489165306091309)","('NON-ESG', 0.06392140686511993)","('NON-ESG', 0.027656061574816704)"
Line 1279,"GRI disclosures: 305- Legacy Bard  Legacy BD BD + Bard  combined Efficiency data tablesAccess Innovation Governance Efficiency EmpowermentVOC + HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY VOC + HAPs emissions Absolute (metric tonnes),   legacy Bard0 0 0 0 0 0 0 0 0 0 264 235 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.26 0.17 0.% reduction, legacy Bard 45% Absolute (metric tonnes), legacy BD1204 149 128 127 150 141 153 150 164 207 237 220 Normalized (metric tonnes per $M  COPS), legacy BD0.04 0.03 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.% reduction, legacy BD 21% Absolute (metric tonnes), combined 204 149 128 127 150 141 153 150 164 207 501 455 Normalized (metric tonnes per $M  COPS), combined20.04 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.06 0.05 0.% reduction, combined -38% 2020 goal:  Reduce VOC and HAPs emissions by 65% (normalized by COPS).
","('Air_Quality', 0.5364315509796143)","('GHG_Emissions', 0.28732702136039734)","('Energy_Management', 0.0581003874540329)","(['Operational Eco-Efficiency'], 0.5364315509796143)","('NON-ESG', 0.28732702136039734)","('NON-ESG', 0.0581003874540329)"
Line 1280,"Current status:  Increased by 38% 1 Absolute legacy BD restated back to FY 2008 baseline,  due to removal of duplicate VOC data.
","('Data_Security', 0.4214317798614502)","('Systemic_Risk_Management', 0.11712339520454407)","('Customer_Privacy', 0.10288657993078232)","('NON-ESG', 0.4214317798614502)","('NON-ESG', 0.11712339520454407)","('NON-ESG', 0.10288657993078232)"
Line 1281,"2 Combined COPS were used to calculate normalized  performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.32311415672302246)","('Business_Model_Resilience', 0.20431917905807495)","('Competitive_Behavior', 0.08891726285219193)","('NON-ESG', 0.32311415672302246)","('NON-ESG', 0.20431917905807495)","('NON-ESG', 0.08891726285219193)"
Line 1282,"Ozone-depleting substances emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Ozone-depleting substances emissions Absolute (metric tonnes), legacy   Bard0 0 0 0 0 0 0 0 0 0 0 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Absolute (metric tonnes), legacy BD 323 274 249 254 235 236 228 218 192 185 172 103 Normalized (metric tonnes per $M  COPS), legacy BD0.07 0.06 0.05 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.02 0.01 0.Absolute (metric tonnes), combined 323 274 249 254 235 236 228 218 192 185 172 103 Normalized (metric tonnes per $M  COPS), combined20.06 0.05 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.02 0.02 0.01 0.% reduction, combined 95% 2020 goal:  Reduce ozone-depleting substance emissions by 95% (normalized by COPS).
","('GHG_Emissions', 0.6086550354957581)","('Air_Quality', 0.23062783479690552)","('Waste_And_Hazardous_Materials_Management', 0.022370804101228714)","(['Climate Change'], 0.6086550354957581)","('NON-ESG', 0.23062783479690552)","('NON-ESG', 0.022370804101228714)"
Line 1283,"Ozone-depleting substances emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY 2019 FY Ozone-depleting substances emissions Absolute (metric tonnes), legacy   Bard0 0 0 0 0 0 0 0 0 0 0 Normalized (metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0 0 Absolute (metric tonnes), legacy BD 323 274 249 254 235 236 228 218 192 185 172 103 Normalized (metric tonnes per $M  COPS), legacy BD0.07 0.06 0.05 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.02 0.01 0.Absolute (metric tonnes), combined 323 274 249 254 235 236 228 218 192 185 172 103 Normalized (metric tonnes per $M  COPS), combined20.06 0.05 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.02 0.02 0.01 0.% reduction, combined 95% 2020 goal:  Reduce ozone-depleting substance emissions by 95% (normalized by COPS).
","('GHG_Emissions', 0.5318426489830017)","('Air_Quality', 0.1974698007106781)","('Energy_Management', 0.06547538191080093)","(['Climate Change'], 0.5318426489830017)","('NON-ESG', 0.1974698007106781)","('NON-ESG', 0.06547538191080093)"
Line 1284,"Current status:  Reduced by 95% TARGET ACHIEVED 2020 goal:  100% elimination of use of HCFC141b in manufacturing.
","('Customer_Welfare', 0.20202112197875977)","('Product_Design_And_Lifecycle_Management', 0.14285975694656372)","('Supply_Chain_Management', 0.0887322872877121)","('NON-ESG', 0.20202112197875977)","('NON-ESG', 0.14285975694656372)","('NON-ESG', 0.0887322872877121)"
Line 1285,"Current status:  While a number of our facilities have completed conversion plans and eliminated the use of hydrochlorofluorocarbon (HCFC), we continue to make  progress implementing conversion plans at remaining facilities and expect to complete all conversions as scheduled.
","('Energy_Management', 0.463260293006897)","('Customer_Welfare', 0.13600687682628632)","('GHG_Emissions', 0.09522730112075806)","('NON-ESG', 0.463260293006897)","('NON-ESG', 0.13600687682628632)","('NON-ESG', 0.09522730112075806)"
Line 1286,"1 Absolute legacy Bard data for FY 2019  restated due to data error.
","('Data_Security', 0.7146586179733276)","('Customer_Privacy', 0.09177892655134201)","('Systemic_Risk_Management', 0.04135582223534584)","(['Information Security/Cybersecurity & System Availability'], 0.7146586179733276)","('NON-ESG', 0.09177892655134201)","('NON-ESG', 0.04135582223534584)"
Line 1287,"2 Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.32311415672302246)","('Business_Model_Resilience', 0.20431917905807495)","('Competitive_Behavior', 0.08891726285219193)","('NON-ESG', 0.32311415672302246)","('NON-ESG', 0.20431917905807495)","('NON-ESG', 0.08891726285219193)"
Line 1288,"GRI disclosures: 305-6GRI disclosures: 305- Legacy Bard  Legacy BD BD + Bard  combined Access Innovation Efficiency Empowerment Governance Our Purpose is a promise.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3342925012111664)","('Access_And_Affordability', 0.24549414217472076)","('Product_Quality_And_Safety', 0.05715274065732956)","('NON-ESG', 0.3342925012111664)","('NON-ESG', 0.24549414217472076)","('NON-ESG', 0.05715274065732956)"
Line 1289,"Those words truly capture the culture  that is BD.
","('Employee_Engagement_Inclusion_And_Diversity', 0.211220845580101)","('Business_Ethics', 0.13129188120365143)","('Competitive_Behavior', 0.12891995906829834)","('NON-ESG', 0.211220845580101)","('NON-ESG', 0.13129188120365143)","('NON-ESG', 0.12891995906829834)"
Line 1290,"With our Purpose of advancing the world of health ™  driving everything we do, the role of inclusion and diversity at  BD is clear.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734931588172913)","('Employee_Health_And_Safety', 0.0025490138214081526)","('Human_Rights_And_Community_Relations', 0.001969660399481654)","(['Human Capital Development'], 0.9734931588172913)","('NON-ESG', 0.0025490138214081526)","('NON-ESG', 0.001969660399481654)"
Line 1291,"Following the acquisitions of CareFusion and Bard within   a three-year span, we had a very unique opportunity to create a  culture that was authentic to the new organization and position  inclusion and diversity as a top priority.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9717431664466858)","('Employee_Health_And_Safety', 0.002578540239483118)","('Human_Rights_And_Community_Relations', 0.002518653403967619)","(['Human Capital Development'], 0.9717431664466858)","('NON-ESG', 0.002578540239483118)","('NON-ESG', 0.002518653403967619)"
Line 1292,"We lead with “inclusion”  intentionally because we recognized the need to bring three  distinct cultures together, and we could only do that successfully  if we developed a new, inclusive culture.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9627829194068909)","('Human_Rights_And_Community_Relations', 0.0047183833085000515)","('Business_Model_Resilience', 0.0028885952197015285)","(['Human Capital Development'], 0.9627829194068909)","('NON-ESG', 0.0047183833085000515)","('NON-ESG', 0.0028885952197015285)"
Line 1293,"We took the “best of  the best” of the three to ensure each organization truly felt a  part of the new whole.
","('Employee_Engagement_Inclusion_And_Diversity', 0.19129151105880737)","('Business_Model_Resilience', 0.11743044853210449)","('Business_Ethics', 0.07165337353944778)","('NON-ESG', 0.19129151105880737)","('NON-ESG', 0.11743044853210449)","('NON-ESG', 0.07165337353944778)"
Line 1294,"As the new BD, we recognized that to best serve our diverse  patients and customers, and in order to attract and retain the  best talent, we must be committed to building and engaging  inclusive and diverse teams.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9628813862800598)","('Employee_Health_And_Safety', 0.0032192100770771503)","('Customer_Welfare', 0.002493061125278473)","(['Human Capital Development'], 0.9628813862800598)","('NON-ESG', 0.0032192100770771503)","('NON-ESG', 0.002493061125278473)"
Line 1295,"In addition, appreciating  individuals, and leveraging their unique ideas, backgrounds and  experiences would deliver better outcomes for our global  marketplace and our customers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8896161317825317)","('Business_Model_Resilience', 0.020109163597226143)","('Product_Design_And_Lifecycle_Management', 0.012494351714849472)","(['Human Capital Development'], 0.8896161317825317)","('NON-ESG', 0.020109163597226143)","('NON-ESG', 0.012494351714849472)"
Line 1296,"We’ve realized this vision by actively developing systems,  processes and tools, and we’re very proud of the progress we’ve  made.
","('Business_Model_Resilience', 0.2576020658016205)","('Product_Design_And_Lifecycle_Management', 0.15958307683467865)","('Human_Rights_And_Community_Relations', 0.09969186782836914)","('NON-ESG', 0.2576020658016205)","('NON-ESG', 0.15958307683467865)","('NON-ESG', 0.09969186782836914)"
Line 1297,"The steps we are taking ensure we are fair and that our  associates, no matter where they come from or where they are,  feel valued and comfortable being themselves at work, and  have an opportunity to contribute, succeed and realize  their potential.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5203495025634766)","('Business_Model_Resilience', 0.08186645805835724)","('Human_Rights_And_Community_Relations', 0.06988021731376648)","(['Human Capital Development'], 0.5203495025634766)","('NON-ESG', 0.08186645805835724)","('NON-ESG', 0.06988021731376648)"
Line 1298,"Our commitment to inclusion and diversity has never been more  important and valuable than during the challenges we were all  presented in 2020.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9742953777313232)","('Employee_Health_And_Safety', 0.0021157118026167154)","('Human_Rights_And_Community_Relations', 0.0019072502618655562)","(['Human Capital Development'], 0.9742953777313232)","('NON-ESG', 0.0021157118026167154)","('NON-ESG', 0.0019072502618655562)"
Line 1299,"With broad feelings of uncertainty,   a need to feel connected to the organization and each other,  and racial injustice, it was necessary that we did not shy away from the difficult conversations and demonstrate ours is a  culture where we can address the tough topics head on to  provide associates the outlet they needed.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4269667863845825)","('Human_Rights_And_Community_Relations', 0.25082364678382874)","('Business_Ethics', 0.0753868892788887)","('NON-ESG', 0.4269667863845825)","('NON-ESG', 0.25082364678382874)","('NON-ESG', 0.0753868892788887)"
Line 1300,"While we’re proud of the foundation we’ve built and the  progress we’ve made to support associates and our  communities, we still have much more work to do.
","('Human_Rights_And_Community_Relations', 0.8376725912094116)","('Access_And_Affordability', 0.016226833686232567)","('Ecological_Impacts', 0.015555203892290592)","(['Community Relations'], 0.8376725912094116)","('NON-ESG', 0.016226833686232567)","('NON-ESG', 0.015555203892290592)"
Line 1301,"FY 2021  marks the beginning of a three-year strategy that will further  advance inclusion and diversity within BD, our communities and  industry, and bring about a more equitable and just world.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734892249107361)","('Human_Rights_And_Community_Relations', 0.0026043648831546307)","('Employee_Health_And_Safety', 0.002230259822681546)","(['Human Capital Development'], 0.9734892249107361)","('NON-ESG', 0.0026043648831546307)","('NON-ESG', 0.002230259822681546)"
Line 1302,"At BD, our Purpose is a promise and is central to our culture,   The BD WAY.
","('Human_Rights_And_Community_Relations', 0.28882554173469543)","('Employee_Engagement_Inclusion_And_Diversity', 0.23628352582454681)","('Business_Model_Resilience', 0.07789411395788193)","('NON-ESG', 0.28882554173469543)","('NON-ESG', 0.23628352582454681)","('NON-ESG', 0.07789411395788193)"
Line 1303,"We live our values and improve every day our  individual and collective sense of belonging, our commitment   to helping each other be great, and the firm belief that inclusion  and diversity make us a stronger team as we work together  advancing the world of health ™.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734453558921814)","('Employee_Health_And_Safety', 0.0026374205481261015)","('Human_Rights_And_Community_Relations', 0.0025131150614470243)","(['Human Capital Development'], 0.9734453558921814)","('NON-ESG', 0.0026374205481261015)","('NON-ESG', 0.0025131150614470243)"
Line 1304,"Johnel Evans   Vice President, Global Inclusion Diversity & EquityIntroduction We profoundly respect that what we do is for the good of people.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9725604057312012)","('Human_Rights_And_Community_Relations', 0.0025557351764291525)","('Employee_Health_And_Safety', 0.002538674045354128)","(['Human Capital Development'], 0.9725604057312012)","('NON-ESG', 0.0025557351764291525)","('NON-ESG', 0.002538674045354128)"
Line 1305,"That’s why BD associates work with  humanity and kindness across cultures, regions and relationships.
","('Human_Rights_And_Community_Relations', 0.7209609746932983)","('Employee_Engagement_Inclusion_And_Diversity', 0.09700347483158112)","('Employee_Health_And_Safety', 0.016185341402888298)","(['Community Relations'], 0.7209609746932983)","('NON-ESG', 0.09700347483158112)","('NON-ESG', 0.016185341402888298)"
Line 1306,"It is the behavior that is necessary to  be responsible global citizens.
","('Business_Ethics', 0.5378378033638)","('Competitive_Behavior', 0.12208263576030731)","('Management_Of_Legal_And_Regulatory_Framework', 0.07134158164262772)","(['Business Ethics'], 0.5378378033638)","('NON-ESG', 0.12208263576030731)","('NON-ESG', 0.07134158164262772)"
Line 1307,"It is what it means to care.Empowerment Positive workforce and community impacts Letter from our Inclusion Diversity and Equity office Access Innovation Efficiency Empowerment Governance Inclusion, diversity and equity are a prominent and lived piece  of our culture as we firmly believe that inclusion and diversity  makes us a stronger team while enabling us to better deliver on  our Purpose of advancing the world of health ™.
","('Employee_Engagement_Inclusion_And_Diversity', 0.975784420967102)","('Employee_Health_And_Safety', 0.0022892511915415525)","('Human_Rights_And_Community_Relations', 0.001827617292292416)","(['Human Capital Development'], 0.975784420967102)","('NON-ESG', 0.0022892511915415525)","('NON-ESG', 0.001827617292292416)"
Line 1308,"Over the past five years, we’ve established and continually  invested in teams, processes, policies and programs to embed  inclusion and diversity in everything that we do, and we’re  committed to making sure that all BD associates, regardless of  where they come from, have a chance to succeed and realize  their full potential.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9727705717086792)","('Employee_Health_And_Safety', 0.0022773221135139465)","('Human_Rights_And_Community_Relations', 0.0022446620278060436)","(['Human Capital Development'], 0.9727705717086792)","('NON-ESG', 0.0022773221135139465)","('NON-ESG', 0.0022446620278060436)"
Line 1309,"We’re building an inclusive environment  where people feel valued, have no fears speaking up and are  empowered to give their best.
","('Human_Rights_And_Community_Relations', 0.5755261778831482)","('Employee_Engagement_Inclusion_And_Diversity', 0.23018713295459747)","('Access_And_Affordability', 0.023522542789578438)","(['Community Relations'], 0.5755261778831482)","('NON-ESG', 0.23018713295459747)","('NON-ESG', 0.023522542789578438)"
Line 1310,"Our associates come from all backgrounds, perspectives and  experiences.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9560329914093018)","('Human_Rights_And_Community_Relations', 0.004395344760268927)","('Customer_Privacy', 0.003981429152190685)","(['Human Capital Development'], 0.9560329914093018)","('NON-ESG', 0.004395344760268927)","('NON-ESG', 0.003981429152190685)"
Line 1311,"The diversity of the teams working at BD  across the globe allows us to successfully meet the needs of   the ever-expanding global marketplace.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9520758390426636)","('Business_Model_Resilience', 0.004826482385396957)","('Customer_Welfare', 0.003505030646920204)","(['Human Capital Development'], 0.9520758390426636)","('NON-ESG', 0.004826482385396957)","('NON-ESG', 0.003505030646920204)"
Line 1312,"Additionally, our work and commitment to inclusion, diversity  and equity extends beyond the walls of our organization to  make an impact in the healthcare industry and communities  where we work and live.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9748924374580383)","('Human_Rights_And_Community_Relations', 0.0020953076891601086)","('Employee_Health_And_Safety', 0.0019881222397089005)","(['Human Capital Development'], 0.9748924374580383)","('NON-ESG', 0.0020953076891601086)","('NON-ESG', 0.0019881222397089005)"
Line 1313,"We also influence and advocate for  more inclusive and equitable practices through global public  policy changes.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4444727599620819)","('Human_Rights_And_Community_Relations', 0.19173802435398102)","('Access_And_Affordability', 0.06811804324388504)","('NON-ESG', 0.4444727599620819)","('NON-ESG', 0.19173802435398102)","('NON-ESG', 0.06811804324388504)"
Line 1314,"Because we foster inclusion and diversity within our company,  industry and communities, we’ve made significant progress  towards fulfilling our Purpose of advancing the world of health ™ —for all.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9715296030044556)","('Employee_Health_And_Safety', 0.0028512701392173767)","('Human_Rights_And_Community_Relations', 0.0028261623810976744)","(['Human Capital Development'], 0.9715296030044556)","('NON-ESG', 0.0028512701392173767)","('NON-ESG', 0.0028261623810976744)"
Line 1315,"Key programs and achievements  We foster an inclusive environment where every associate has a  chance to succeed and realize their full potential, and we seek  out diverse perspectives because it drives innovation and is core  to our purpose and strategy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9386496543884277)","('Human_Rights_And_Community_Relations', 0.006690142676234245)","('Business_Model_Resilience', 0.005851805675774813)","(['Human Capital Development'], 0.9386496543884277)","('NON-ESG', 0.006690142676234245)","('NON-ESG', 0.005851805675774813)"
Line 1316,"• Nine associate resource groups (ARGs) provide professional  development opportunities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5884659290313721)","('Access_And_Affordability', 0.17142103612422943)","('Employee_Health_And_Safety', 0.021693071350455284)","(['Human Capital Development'], 0.5884659290313721)","('NON-ESG', 0.17142103612422943)","('NON-ESG', 0.021693071350455284)"
Line 1317,"• ARG-led global mentorship program was recognized by the  Healthcare Businesswomen’s Association as a 2020 winner of  its ACE Award.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3172789216041565)","('Access_And_Affordability', 0.205689936876297)","('Human_Rights_And_Community_Relations', 0.06189201772212982)","('NON-ESG', 0.3172789216041565)","('NON-ESG', 0.205689936876297)","('NON-ESG', 0.06189201772212982)"
Line 1318,"• Our learning and development program, BD University,  provides career development resources, including accelerator  programs and career mapping guides.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6419076919555664)","('Access_And_Affordability', 0.1082049235701561)","('Employee_Health_And_Safety', 0.02653644233942032)","(['Human Capital Development'], 0.6419076919555664)","('NON-ESG', 0.1082049235701561)","('NON-ESG', 0.02653644233942032)"
Line 1319,"• We facilitate ongoing dialog sessions to foster a speak-up  culture and provide educational resources.
","('Access_And_Affordability', 0.3280799686908722)","('Employee_Engagement_Inclusion_And_Diversity', 0.25255492329597473)","('Human_Rights_And_Community_Relations', 0.10513485968112946)","('NON-ESG', 0.3280799686908722)","('NON-ESG', 0.25255492329597473)","('NON-ESG', 0.10513485968112946)"
Line 1320,"Past discussions  have focused on timely topics, including racial injustice and  toxic masculinity.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9021191000938416)","('Human_Rights_And_Community_Relations', 0.017082106322050095)","('Labor_Practices', 0.011242459528148174)","(['Human Capital Development'], 0.9021191000938416)","('NON-ESG', 0.017082106322050095)","('NON-ESG', 0.011242459528148174)"
Line 1321,"• Leadership engagement through the Global Inclusion  Council, local inclusion and diversity champions and  ambassadors, and ARG sponsorships.• We drive accountability and monitor progress through  corporate-level goals, executive inclusion plans and Voice of  Associate surveys, among other methods.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9721094965934753)","('Human_Rights_And_Community_Relations', 0.0026576980017125607)","('Employee_Health_And_Safety', 0.00252422783523798)","(['Human Capital Development'], 0.9721094965934753)","('NON-ESG', 0.0026576980017125607)","('NON-ESG', 0.00252422783523798)"
Line 1322,"• To bring the best talent and diverse perspectives to BD, we  initiate diversity recruiting efforts through the National Black  MBA Association, Society of Women Engineers, National  Sales Network, MVPvets, Skillbridge internships and Hiring  Our Heroes fellowships.Associate impact2020 goal Increase the diversity of our workplace, particularly in leadership roles Access Innovation Efficiency Empowerment Governance We advance inclusion and diversity within our marketplace,  industry and global communities to create opportunities for all.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9765908718109131)","('Employee_Health_And_Safety', 0.002105513820424676)","('Human_Rights_And_Community_Relations', 0.00151336332783103)","(['Human Capital Development'], 0.9765908718109131)","('NON-ESG', 0.002105513820424676)","('NON-ESG', 0.00151336332783103)"
Line 1323,"• To bring the best talent and diverse perspectives to BD, we  initiate diversity recruiting efforts through the National Black  MBA Association, Society of Women Engineers, National  Sales Network, MVPvets, Skillbridge internships and Hiring  Our Heroes fellowships.Associate impact2020 goal Increase the diversity of our workplace, particularly in leadership roles Access Innovation Efficiency Empowerment Governance We advance inclusion and diversity within our marketplace,  industry and global communities to create opportunities for all.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5532708168029785)","('Access_And_Affordability', 0.11660455167293549)","('Human_Rights_And_Community_Relations', 0.05959315970540047)","(['Human Capital Development'], 0.5532708168029785)","('NON-ESG', 0.11660455167293549)","('NON-ESG', 0.05959315970540047)"
Line 1324,"• Membership in the AdvaMed Board’s Inclusion and Diversity  Committee and subcommittee • Collaborate with the Healthcare Businesswoman’s  Association and Society of Women Engineers to advocate for  women in the business of healthcare and in engineering  and technology• Implemented a supplier diversity program that ensures our  supply base aligns with the diverse customers and  communities we serve, as well as the diverse markets we seek • Annual participation in PRIDE events around the worldCommunity and industry impact We strive to be catalysts for change to bring about a more  equitable and just world.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9681934118270874)","('Business_Model_Resilience', 0.0022861198522150517)","('Human_Rights_And_Community_Relations', 0.0022163474932312965)","(['Human Capital Development'], 0.9681934118270874)","('NON-ESG', 0.0022861198522150517)","('NON-ESG', 0.0022163474932312965)"
Line 1325,"• Membership in the AdvaMed Board’s Inclusion and Diversity  Committee and subcommittee • Collaborate with the Healthcare Businesswoman’s  Association and Society of Women Engineers to advocate for  women in the business of healthcare and in engineering  and technology• Implemented a supplier diversity program that ensures our  supply base aligns with the diverse customers and  communities we serve, as well as the diverse markets we seek • Annual participation in PRIDE events around the worldCommunity and industry impact We strive to be catalysts for change to bring about a more  equitable and just world.
","('Human_Rights_And_Community_Relations', 0.5825662016868591)","('Business_Model_Resilience', 0.08734448254108429)","('Employee_Engagement_Inclusion_And_Diversity', 0.053654130548238754)","(['Community Relations'], 0.5825662016868591)","('NON-ESG', 0.08734448254108429)","('NON-ESG', 0.053654130548238754)"
Line 1326,"• Members of Chief Executive for Corporate Purpose and The  New Jersey CEO Council • Advocate for LGBTQ+ inclusion through membership in the  Human Rights Campaign’s Business Coalition for the Equality  Act and OPEN for Business, and we endorsed the UN  Standards of Conduct to support LGBT+ individuals • Celebrated the landmark Supreme Court Title VII ruling that  protects LGBT workers in the U.S. from workplace discrimination  • Philanthropic contributions to nonprofits that:  – Broaden healthcare access among vulnerable populations,     including the BD Helping Build Healthy     Communities ™ Initiative  – Expand access to food, shelter, healthcare services, job     and skills training among diverse populations that are     being disproportionately impacted by COVID-19Societal impact Access Innovation Efficiency Empowerment Governance BD condemns the acts of racism and violence that have  occurred in the communities we call home.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9564899206161499)","('Employee_Health_And_Safety', 0.005980437155812979)","('Human_Rights_And_Community_Relations', 0.004967869725078344)","(['Human Capital Development'], 0.9564899206161499)","('NON-ESG', 0.005980437155812979)","('NON-ESG', 0.004967869725078344)"
Line 1327,"• Members of Chief Executive for Corporate Purpose and The  New Jersey CEO Council • Advocate for LGBTQ+ inclusion through membership in the  Human Rights Campaign’s Business Coalition for the Equality  Act and OPEN for Business, and we endorsed the UN  Standards of Conduct to support LGBT+ individuals • Celebrated the landmark Supreme Court Title VII ruling that  protects LGBT workers in the U.S. from workplace discrimination  • Philanthropic contributions to nonprofits that:  – Broaden healthcare access among vulnerable populations,     including the BD Helping Build Healthy     Communities ™ Initiative  – Expand access to food, shelter, healthcare services, job     and skills training among diverse populations that are     being disproportionately impacted by COVID-19Societal impact Access Innovation Efficiency Empowerment Governance BD condemns the acts of racism and violence that have  occurred in the communities we call home.
","('Access_And_Affordability', 0.4124184548854828)","('Human_Rights_And_Community_Relations', 0.3842867612838745)","('Employee_Engagement_Inclusion_And_Diversity', 0.04305124655365944)","('NON-ESG', 0.4124184548854828)","('NON-ESG', 0.3842867612838745)","('NON-ESG', 0.04305124655365944)"
Line 1328,"The racial inequality  and injustice that’s taken place across the U.S. are inexplicable  as they are unacceptable.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4096302092075348)","('Business_Ethics', 0.2934280037879944)","('Labor_Practices', 0.06963080912828445)","('NON-ESG', 0.4096302092075348)","('NON-ESG', 0.2934280037879944)","('NON-ESG', 0.06963080912828445)"
Line 1329,"Our commitment to our values—and our fundamental belief  that inclusion and diversity are essential to our purpose and our  strategy—compel us to speak up against racism, divisiveness  and hate, and to stand up as one BD in support of justice and  equity for all.The BD Purpose— advancing the world of health ™—reflects our  commitment to help everyone, everywhere in their pursuit for  better health and a better life.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9673306345939636)","('Employee_Health_And_Safety', 0.003441769629716873)","('Access_And_Affordability', 0.00288190389983356)","(['Human Capital Development'], 0.9673306345939636)","('NON-ESG', 0.003441769629716873)","('NON-ESG', 0.00288190389983356)"
Line 1330,"We are proud that BD associates  come from all backgrounds and experiences, and firmly believe  BD is better because of this.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9212254285812378)","('Access_And_Affordability', 0.014477679505944252)","('Employee_Health_And_Safety', 0.008376693353056908)","(['Human Capital Development'], 0.9212254285812378)","('NON-ESG', 0.014477679505944252)","('NON-ESG', 0.008376693353056908)"
Line 1331,"The summer of 2020 was a turning point for long overdue  change, and it was an opportunity for BD to learn, grow and to  come together.
","('Employee_Engagement_Inclusion_And_Diversity', 0.22597742080688477)","('Business_Model_Resilience', 0.20364032685756683)","('Access_And_Affordability', 0.07616990804672241)","('NON-ESG', 0.22597742080688477)","('NON-ESG', 0.20364032685756683)","('NON-ESG', 0.07616990804672241)"
Line 1332,"This spotlight details a selection of our initiatives  in FY 2020 and through February 2021.Our commitment to racial justice, inclusion and diversity Spotlight—racial justice Fostering dialog: AABD fireside chat Following the senseless deaths of George Floyd and Breonna  Taylor, our Executive Leadership Team encouraged associates  not to shy away from conversations about what we all saw  happening.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9728796482086182)","('Human_Rights_And_Community_Relations', 0.002819385379552841)","('Employee_Health_And_Safety', 0.0024355656933039427)","(['Human Capital Development'], 0.9728796482086182)","('NON-ESG', 0.002819385379552841)","('NON-ESG', 0.0024355656933039427)"
Line 1333,"Instead, associates were encouraged to ask  questions about diversity, belonging, inclusion and equity so we  can grow and learn from each other.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9730729460716248)","('Employee_Health_And_Safety', 0.0020658855792135)","('Human_Rights_And_Community_Relations', 0.0020127217285335064)","(['Human Capital Development'], 0.9730729460716248)","('NON-ESG', 0.0020658855792135)","('NON-ESG', 0.0020127217285335064)"
Line 1334,"We began with a virtual discussion with Black senior leaders,  who spoke openly and candidly about their personal feelings,  emotions and experiences.
","('Employee_Engagement_Inclusion_And_Diversity', 0.35824891924858093)","('Customer_Privacy', 0.14305934309959412)","('Human_Rights_And_Community_Relations', 0.11056121438741684)","('NON-ESG', 0.35824891924858093)","('NON-ESG', 0.14305934309959412)","('NON-ESG', 0.11056121438741684)"
Line 1335,"The event was a catalyst for a series of open dialog sessions on racial equity and justice to further  build our learning and growth together, and to drive better  awareness internally on these critical issues.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5266350507736206)","('Human_Rights_And_Community_Relations', 0.277993768453598)","('Access_And_Affordability', 0.037736933678388596)","(['Human Capital Development'], 0.5266350507736206)","('NON-ESG', 0.277993768453598)","('NON-ESG', 0.037736933678388596)"
Line 1336,"Subsequent discussions focused on topics such as combating  COVID-19-related racial bias against the Asian community,  exploring disparities and health impacts of COVID-19 in Black  and brown communities, and moving from intent to action  through allyship and advocacy, among others.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9659096002578735)","('Employee_Health_And_Safety', 0.004661617334932089)","('Human_Rights_And_Community_Relations', 0.002961361315101385)","(['Human Capital Development'], 0.9659096002578735)","('NON-ESG', 0.004661617334932089)","('NON-ESG', 0.002961361315101385)"
Line 1337,"Encouraging learning: 21-day challenge In 2021, our African Americans at BD (AABD) ARG and Social  Investing team partnered to create an innovative and  educational way to raise awareness and understanding of social  and racial justice issues and continue advancing our culture  of inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9003111720085144)","('Human_Rights_And_Community_Relations', 0.03982935845851898)","('Access_And_Affordability', 0.0062399194575846195)","(['Human Capital Development'], 0.9003111720085144)","('NON-ESG', 0.03982935845851898)","('NON-ESG', 0.0062399194575846195)"
Line 1338,"Beginning on January 18, in celebration of Dr. Martin Luther  King Jr’s birthday, and running until February 15, in honor of  Black History Month, our associates could opt into a 21-day  Racial Equity and Social Justice Challenge.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8551355600357056)","('Human_Rights_And_Community_Relations', 0.0589684434235096)","('Access_And_Affordability', 0.010471056215465069)","(['Human Capital Development'], 0.8551355600357056)","('NON-ESG', 0.0589684434235096)","('NON-ESG', 0.010471056215465069)"
Line 1339,"Each day participants  would receive an email with articles, videos and interactive  content about racial inequities in areas including criminal justice  reform, education, healthcare and civic engagement.
","('Human_Rights_And_Community_Relations', 0.4483044743537903)","('Management_Of_Legal_And_Regulatory_Framework', 0.14752644300460815)","('Employee_Engagement_Inclusion_And_Diversity', 0.099599689245224)","('NON-ESG', 0.4483044743537903)","('NON-ESG', 0.14752644300460815)","('NON-ESG', 0.099599689245224)"
Line 1340,"The idea behind the challenge is that it takes 21 days to make a real  change in habits, and we saw it as an opportunity for associates  to begin what we hope will be a lifetime of learning.
","('Employee_Engagement_Inclusion_And_Diversity', 0.27973905205726624)","('Access_And_Affordability', 0.09678566455841064)","('Business_Model_Resilience', 0.08707693219184875)","('NON-ESG', 0.27973905205726624)","('NON-ESG', 0.09678566455841064)","('NON-ESG', 0.08707693219184875)"
Line 1341,"We also hosted an online exchange featuring videos and posts  from associates as they participated in the challenge and  captured some of the pivotal moments of their awareness  building.
","('Human_Rights_And_Community_Relations', 0.3234789967536926)","('Access_And_Affordability', 0.2396012544631958)","('Employee_Engagement_Inclusion_And_Diversity', 0.0430576428771019)","('NON-ESG', 0.3234789967536926)","('NON-ESG', 0.2396012544631958)","('NON-ESG', 0.0430576428771019)"
Line 1342,"Associates could also share their personal stories and  learnings with the broader BD community.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5511564016342163)","('Human_Rights_And_Community_Relations', 0.0915827751159668)","('Employee_Health_And_Safety', 0.07314138114452362)","(['Human Capital Development'], 0.5511564016342163)","('NON-ESG', 0.0915827751159668)","('NON-ESG', 0.07314138114452362)"
Line 1343,"This stimulated  conversations across BD and increased our collective  understanding of the challenges and barriers faced by many  of our colleagues and that we must all work together to  eliminate them.Standing united as one BD Access Innovation Efficiency Empowerment Governance  Spotlight—racial justice Virtual event series  BD has also hosted a number of virtual events and sessions for  associates.
","('Human_Rights_And_Community_Relations', 0.28586345911026)","('Management_Of_Legal_And_Regulatory_Framework', 0.16749177873134613)","('Business_Ethics', 0.1633893996477127)","('NON-ESG', 0.28586345911026)","('NON-ESG', 0.16749177873134613)","('NON-ESG', 0.1633893996477127)"
Line 1344,"During the U.S. election season, we hosted a free  screening of the documentary John Lewis: Good Trouble   focusing on the life of John Lewis and his lifelong work  advocating for voting rights for underserved and  underrepresented communities.
","('Access_And_Affordability', 0.9391376972198486)","('Human_Rights_And_Community_Relations', 0.006343095097690821)","('Product_Quality_And_Safety', 0.005974747706204653)","(['Health Outcome Contribution'], 0.9391376972198486)","('NON-ESG', 0.006343095097690821)","('NON-ESG', 0.005974747706204653)"
Line 1345,"Guest speakers at our events included: • Dr. Gershom Williams, professor emeritus of African American  and United States history at Mesa Community College • Rep.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9626495242118835)","('Human_Rights_And_Community_Relations', 0.003978791180998087)","('Business_Model_Resilience', 0.002294643083587289)","(['Human Capital Development'], 0.9626495242118835)","('NON-ESG', 0.003978791180998087)","('NON-ESG', 0.002294643083587289)"
Line 1346,"E.
","('Management_Of_Legal_And_Regulatory_Framework', 0.10841184854507446)","('Product_Design_And_Lifecycle_Management', 0.09176333993673325)","('Competitive_Behavior', 0.08798782527446747)","('NON-ESG', 0.10841184854507446)","('NON-ESG', 0.09176333993673325)","('NON-ESG', 0.08798782527446747)"
Line 1347,"G.
","('Competitive_Behavior', 0.09812983870506287)","('Access_And_Affordability', 0.08103787153959274)","('Energy_Management', 0.08059953898191452)","('NON-ESG', 0.09812983870506287)","('NON-ESG', 0.08103787153959274)","('NON-ESG', 0.08059953898191452)"
Line 1348,"Butterfield (D-NC), House of Representatives  member representing eastern North Carolina and long-time  champion of the underprivileged• Dr. T.
","('Access_And_Affordability', 0.661375880241394)","('Employee_Engagement_Inclusion_And_Diversity', 0.09606647491455078)","('Customer_Welfare', 0.025254489853978157)","(['Health Outcome Contribution'], 0.661375880241394)","('NON-ESG', 0.09606647491455078)","('NON-ESG', 0.025254489853978157)"
Line 1349,"Anthony Spearman, president of North Carolina NAACP • DeRay McKesson, acclaimed civil rights activist, podcaster,  and author of the critically acclaimed memoir, On the Other  Side of Freedom: The Case for Hope .
","('Human_Rights_And_Community_Relations', 0.7135055065155029)","('Employee_Engagement_Inclusion_And_Diversity', 0.06404268741607666)","('Labor_Practices', 0.03607542812824249)","(['Community Relations'], 0.7135055065155029)","('NON-ESG', 0.06404268741607666)","('NON-ESG', 0.03607542812824249)"
Line 1350,"He is the co-founder of  Campaign Zero and host of the award-winning weekly  podcast Pod Save the People • Reverend Kenneth Clayton, president of the Paterson, New  Jersey chapter of NAACP • Helen Archontou, CEO of the YWCA Northern New Jersey Enacting change in our communities Because we expect unity, respect, fairness and inclusiveness in  our own organization, we also aspire to these same values in all  the countries and communities we operate in throughout the  world.
","('Human_Rights_And_Community_Relations', 0.8268069624900818)","('Employee_Engagement_Inclusion_And_Diversity', 0.057905249297618866)","('Access_And_Affordability', 0.017707277089357376)","(['Community Relations'], 0.8268069624900818)","('NON-ESG', 0.057905249297618866)","('NON-ESG', 0.017707277089357376)"
Line 1351,"Recent efforts and charitable contributions include:  • Donating $10 for each participating associate in our 21-day  Racial Equity and Social Justice Challenge to nonprofit  organizations selected in partnership with the AABD ARG.
","('Human_Rights_And_Community_Relations', 0.7824921011924744)","('Access_And_Affordability', 0.07584059238433838)","('Employee_Engagement_Inclusion_And_Diversity', 0.04212629795074463)","(['Community Relations'], 0.7824921011924744)","('NON-ESG', 0.07584059238433838)","('NON-ESG', 0.04212629795074463)"
Line 1352,"With the support of the nearly 6,000 associates around the  world who participated, BD donated a total of $60,000 to  Americares, the National Association for the  Advancement of Colored People (NAACP) , the Equal  Justice Initiative  and the UNCF ; • Participating in the “Stop Hate for Profit” campaign, pausing  advertising spend in July 2020; • Contributing more than $450,000 to nonprofit organizations  focused on inclusion, diversity, equity and justice, including a  $100,000 donation to the Equal Justice Initiative ;  • Committing $22.6 million through the year 2022 as part of  the BD Helping Build Healthy Communities ™ Initiative.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9622318148612976)","('Human_Rights_And_Community_Relations', 0.004724577069282532)","('Access_And_Affordability', 0.0033578509464859962)","(['Human Capital Development'], 0.9622318148612976)","('NON-ESG', 0.004724577069282532)","('NON-ESG', 0.0033578509464859962)"
Line 1353,"With the support of the nearly 6,000 associates around the  world who participated, BD donated a total of $60,000 to  Americares, the National Association for the  Advancement of Colored People (NAACP) , the Equal  Justice Initiative  and the UNCF ; • Participating in the “Stop Hate for Profit” campaign, pausing  advertising spend in July 2020; • Contributing more than $450,000 to nonprofit organizations  focused on inclusion, diversity, equity and justice, including a  $100,000 donation to the Equal Justice Initiative ;  • Committing $22.6 million through the year 2022 as part of  the BD Helping Build Healthy Communities ™ Initiative.
","('Human_Rights_And_Community_Relations', 0.643860936164856)","('Access_And_Affordability', 0.10719531774520874)","('Business_Model_Resilience', 0.03347207233309746)","(['Community Relations'], 0.643860936164856)","('NON-ESG', 0.10719531774520874)","('NON-ESG', 0.03347207233309746)"
Line 1354,"The contributions support Direct  Relief  and the  National  Association of Community Health Centers  in expanding  the innovative practices of U.S. community health centers, which collectively serve more than 30 million U.S. patients,  the majority of which are uninsured or underinsured.
","('Access_And_Affordability', 0.6324567198753357)","('Employee_Health_And_Safety', 0.08673237264156342)","('Employee_Engagement_Inclusion_And_Diversity', 0.0593075230717659)","(['Health Outcome Contribution'], 0.6324567198753357)","('NON-ESG', 0.08673237264156342)","('NON-ESG', 0.0593075230717659)"
Line 1355,"This program targets its support on patients with  hypertension and diabetes, two health conditions that  disproportionately impact the Black community, based on  the social determinants of health; • Partnering with the UNCF to sponsor three scholarships for  the 2020–2021 academic year; • Supporting the expansion of evidence-based racial bias  training programs that educate parents, business owners and  community owners throughout New Jersey about key issues  that can help eliminate racism through a two-year donation  to the YWCA of Northern New Jersey ; and • Participating in the Chief Executives for Corporate  Purpose’s Diversity, Equity, and Inclusion (DEI)  Accelerate Community , which hosts conversations about  philanthropic giving with an equity lens, and how to recruit  and retain diverse talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9589926600456238)","('Human_Rights_And_Community_Relations', 0.0055669452995061874)","('Employee_Health_And_Safety', 0.0037762827705591917)","(['Human Capital Development'], 0.9589926600456238)","('NON-ESG', 0.0055669452995061874)","('NON-ESG', 0.0037762827705591917)"
Line 1356,"This program targets its support on patients with  hypertension and diabetes, two health conditions that  disproportionately impact the Black community, based on  the social determinants of health; • Partnering with the UNCF to sponsor three scholarships for  the 2020–2021 academic year; • Supporting the expansion of evidence-based racial bias  training programs that educate parents, business owners and  community owners throughout New Jersey about key issues  that can help eliminate racism through a two-year donation  to the YWCA of Northern New Jersey ; and • Participating in the Chief Executives for Corporate  Purpose’s Diversity, Equity, and Inclusion (DEI)  Accelerate Community , which hosts conversations about  philanthropic giving with an equity lens, and how to recruit  and retain diverse talent.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9745067954063416)","('Employee_Health_And_Safety', 0.0020677403081208467)","('Human_Rights_And_Community_Relations', 0.0017764036310836673)","(['Human Capital Development'], 0.9745067954063416)","('NON-ESG', 0.0020677403081208467)","('NON-ESG', 0.0017764036310836673)"
Line 1357,"Access Innovation Efficiency Empowerment Governance In this section of the report, the total number of associates  being reported for FY 2020 is 72,077, which includes Bard  associates.
","('Competitive_Behavior', 0.16211320459842682)","('Management_Of_Legal_And_Regulatory_Framework', 0.15420909225940704)","('Access_And_Affordability', 0.10620176047086716)","('NON-ESG', 0.16211320459842682)","('NON-ESG', 0.15420909225940704)","('NON-ESG', 0.10620176047086716)"
Line 1358,"As part of the integration activities following the  acquisition of Bard, BD worked to incorporate Bard associates  into our single HR IT system.
","('Systemic_Risk_Management', 0.3387190103530884)","('Data_Security', 0.11730629205703735)","('Business_Model_Resilience', 0.11279450356960297)","('NON-ESG', 0.3387190103530884)","('NON-ESG', 0.11730629205703735)","('NON-ESG', 0.11279450356960297)"
Line 1359,"FY 2019 is the first reporting year  to reflect this change in data.
","('Physical_Impacts_Of_Climate_Change', 0.22788643836975098)","('Business_Model_Resilience', 0.22368736565113068)","('Systemic_Risk_Management', 0.13353821635246277)","('NON-ESG', 0.22788643836975098)","('NON-ESG', 0.22368736565113068)","('NON-ESG', 0.13353821635246277)"
Line 1360,"All reporting data for years before  FY 2019 does not include Bard associates.In the chart below, “Other” is defined as people who do not  identify as those ethnicities listed below, or who identify as  more than one ethnicity, and “Unknown” indicates that   the associate chose not to answer.Demographic data FY 2020 worldwide associates by gender 49% Women51% Men 72,Total associates  FY 2020 Board of Directors—ethnicity Asian/Indian Black or African American Hispanic/Latino Other White Unknown 0Gender breakdown of the Board of Directors and executive officers Board of DirectorsWomen Executive Officers Officers 6Men 9* 10* *Includes Vincent A.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9719518423080444)","('Customer_Privacy', 0.002507021650671959)","('Human_Rights_And_Community_Relations', 0.001790921320207417)","(['Human Capital Development'], 0.9719518423080444)","('NON-ESG', 0.002507021650671959)","('NON-ESG', 0.001790921320207417)"
Line 1361,"All reporting data for years before  FY 2019 does not include Bard associates.In the chart below, “Other” is defined as people who do not  identify as those ethnicities listed below, or who identify as  more than one ethnicity, and “Unknown” indicates that   the associate chose not to answer.Demographic data FY 2020 worldwide associates by gender 49% Women51% Men 72,Total associates  FY 2020 Board of Directors—ethnicity Asian/Indian Black or African American Hispanic/Latino Other White Unknown 0Gender breakdown of the Board of Directors and executive officers Board of DirectorsWomen Executive Officers Officers 6Men 9* 10* *Includes Vincent A.
","('Director_Removal', 0.7980068922042847)","('Business_Ethics', 0.0176173597574234)","('Management_Of_Legal_And_Regulatory_Framework', 0.017324673011898994)","(['Anti-Crime Policy & Measures'], 0.7980068922042847)","('NON-ESG', 0.0176173597574234)","('NON-ESG', 0.017324673011898994)"
Line 1362,"Forlenza, Chairman of the Board and former CEO.
","('Director_Removal', 0.573853611946106)","('Business_Model_Resilience', 0.07899457961320877)","('Business_Ethics', 0.03907723352313042)","(['Anti-Crime Policy & Measures'], 0.573853611946106)","('NON-ESG', 0.07899457961320877)","('NON-ESG', 0.03907723352313042)"
Line 1363,"GRI disclosure: 405-Access Innovation Efficiency Empowerment Governance For the following tables, the total number of associates for each disclosure in executive and management positions is noted  in the corresponding table.
","('Management_Of_Legal_And_Regulatory_Framework', 0.25961002707481384)","('Business_Model_Resilience', 0.1497332602739334)","('Competitive_Behavior', 0.14612606167793274)","('NON-ESG', 0.25961002707481384)","('NON-ESG', 0.1497332602739334)","('NON-ESG', 0.14612606167793274)"
Line 1364,"Bard associates are included in FY 2019 and FY 2020 data.
","('Business_Model_Resilience', 0.31292781233787537)","('Management_Of_Legal_And_Regulatory_Framework', 0.09749589115381241)","('Physical_Impacts_Of_Climate_Change', 0.0867595449090004)","('NON-ESG', 0.31292781233787537)","('NON-ESG', 0.09749589115381241)","('NON-ESG', 0.0867595449090004)"
Line 1365,"Data in previous years has been restated due to improvements in data collection systems.
","('Customer_Privacy', 0.45055705308914185)","('Data_Security', 0.261385977268219)","('Energy_Management', 0.029134444892406464)","('NON-ESG', 0.45055705308914185)","('NON-ESG', 0.261385977268219)","('NON-ESG', 0.029134444892406464)"
Line 1366,"BD defines executives as those in VP, SVP or EVP roles.
","('Director_Removal', 0.5816554427146912)","('Employee_Engagement_Inclusion_And_Diversity', 0.09759250283241272)","('Business_Model_Resilience', 0.03505197539925575)","(['Anti-Crime Policy & Measures'], 0.5816554427146912)","('NON-ESG', 0.09759250283241272)","('NON-ESG', 0.03505197539925575)"
Line 1367,"Management positions are defined as those in manager, director or  equivalent roles.Executive and management positions Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 22% 21% 23% 25% 27% Male 78% 79% 77% 75% 73% Total 303 280 283 354 364Executives and management positions by gender (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 37% 38% 39% 39% 39% Male 63% 62% 61% 61% 61% Total 7,271 7,364 7,736 10,086 10,Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 0% 1% 0% 0% 0% 35–54 72% 70% 68% 72% 70% 55 and older 28% 29% 32% 28% 30% Total 303 280 283 354 364Executive and management positions by age (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 11% 11% 11% 11% 11% 35–54 72% 72% 72% 72% 72% 55 and older 17% 17% 17% 17% 17% Total 7,271 7,364 7,736 10,086 10,GRI disclosure: 405-Access Innovation Efficiency Empowerment Governance Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 9% 11% 10% 10% 11% Black or African  American2% 3% 2% 3% 4% Hispanic/Latino 2% 3% 4% 4% 5% Not disclosed 5% 2% 3% 3% 5% Other 0% 1% 1% 1% 1% White 82% 81% 80% 78% 75% Total 243 225 225 291 293Executive and management positions by ethnicity (U.S. only) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 14% 15% 15% 14% 14% Black or African  American3% 4% 4% 3% 4% Hispanic/Latino 5% 7% 7% 8% 8% Not disclosed 4% 2% 4% 4% 5% Other 3% 2% 2% 2% 2% White 71% 71% 69% 69% 67% Total 4,578 4,558 4,704 6,028 6,GRI disclosure: 405-1Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7054288983345032)","('Director_Removal', 0.09831693768501282)","('Business_Model_Resilience', 0.024831214919686317)","(['Human Capital Development'], 0.7054288983345032)","('NON-ESG', 0.09831693768501282)","('NON-ESG', 0.024831214919686317)"
Line 1368,"Management positions are defined as those in manager, director or  equivalent roles.Executive and management positions Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 22% 21% 23% 25% 27% Male 78% 79% 77% 75% 73% Total 303 280 283 354 364Executives and management positions by gender (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 37% 38% 39% 39% 39% Male 63% 62% 61% 61% 61% Total 7,271 7,364 7,736 10,086 10,Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 0% 1% 0% 0% 0% 35–54 72% 70% 68% 72% 70% 55 and older 28% 29% 32% 28% 30% Total 303 280 283 354 364Executive and management positions by age (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 11% 11% 11% 11% 11% 35–54 72% 72% 72% 72% 72% 55 and older 17% 17% 17% 17% 17% Total 7,271 7,364 7,736 10,086 10,GRI disclosure: 405-Access Innovation Efficiency Empowerment Governance Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 9% 11% 10% 10% 11% Black or African  American2% 3% 2% 3% 4% Hispanic/Latino 2% 3% 4% 4% 5% Not disclosed 5% 2% 3% 3% 5% Other 0% 1% 1% 1% 1% White 82% 81% 80% 78% 75% Total 243 225 225 291 293Executive and management positions by ethnicity (U.S. only) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 14% 15% 15% 14% 14% Black or African  American3% 4% 4% 3% 4% Hispanic/Latino 5% 7% 7% 8% 8% Not disclosed 4% 2% 4% 4% 5% Other 3% 2% 2% 2% 2% White 71% 71% 69% 69% 67% Total 4,578 4,558 4,704 6,028 6,GRI disclosure: 405-1Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.
","('Business_Model_Resilience', 0.14334362745285034)","('Product_Design_And_Lifecycle_Management', 0.13471296429634094)","('Employee_Engagement_Inclusion_And_Diversity', 0.08779555559158325)","('NON-ESG', 0.14334362745285034)","('NON-ESG', 0.13471296429634094)","('NON-ESG', 0.08779555559158325)"
Line 1369,"Management positions are defined as those in manager, director or  equivalent roles.Executive and management positions Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 22% 21% 23% 25% 27% Male 78% 79% 77% 75% 73% Total 303 280 283 354 364Executives and management positions by gender (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 37% 38% 39% 39% 39% Male 63% 62% 61% 61% 61% Total 7,271 7,364 7,736 10,086 10,Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 0% 1% 0% 0% 0% 35–54 72% 70% 68% 72% 70% 55 and older 28% 29% 32% 28% 30% Total 303 280 283 354 364Executive and management positions by age (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 11% 11% 11% 11% 11% 35–54 72% 72% 72% 72% 72% 55 and older 17% 17% 17% 17% 17% Total 7,271 7,364 7,736 10,086 10,GRI disclosure: 405-Access Innovation Efficiency Empowerment Governance Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 9% 11% 10% 10% 11% Black or African  American2% 3% 2% 3% 4% Hispanic/Latino 2% 3% 4% 4% 5% Not disclosed 5% 2% 3% 3% 5% Other 0% 1% 1% 1% 1% White 82% 81% 80% 78% 75% Total 243 225 225 291 293Executive and management positions by ethnicity (U.S. only) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 14% 15% 15% 14% 14% Black or African  American3% 4% 4% 3% 4% Hispanic/Latino 5% 7% 7% 8% 8% Not disclosed 4% 2% 4% 4% 5% Other 3% 2% 2% 2% 2% White 71% 71% 69% 69% 67% Total 4,578 4,558 4,704 6,028 6,GRI disclosure: 405-1Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9658604264259338)","('Customer_Privacy', 0.0022924081422388554)","('Business_Model_Resilience', 0.0022920933552086353)","(['Human Capital Development'], 0.9658604264259338)","('NON-ESG', 0.0022924081422388554)","('NON-ESG', 0.0022920933552086353)"
Line 1370,"Management positions are defined as those in manager, director or  equivalent roles.Executive and management positions Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 22% 21% 23% 25% 27% Male 78% 79% 77% 75% 73% Total 303 280 283 354 364Executives and management positions by gender (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 37% 38% 39% 39% 39% Male 63% 62% 61% 61% 61% Total 7,271 7,364 7,736 10,086 10,Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 0% 1% 0% 0% 0% 35–54 72% 70% 68% 72% 70% 55 and older 28% 29% 32% 28% 30% Total 303 280 283 354 364Executive and management positions by age (worldwide) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 11% 11% 11% 11% 11% 35–54 72% 72% 72% 72% 72% 55 and older 17% 17% 17% 17% 17% Total 7,271 7,364 7,736 10,086 10,GRI disclosure: 405-Access Innovation Efficiency Empowerment Governance Executive FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 9% 11% 10% 10% 11% Black or African  American2% 3% 2% 3% 4% Hispanic/Latino 2% 3% 4% 4% 5% Not disclosed 5% 2% 3% 3% 5% Other 0% 1% 1% 1% 1% White 82% 81% 80% 78% 75% Total 243 225 225 291 293Executive and management positions by ethnicity (U.S. only) Management FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 14% 15% 15% 14% 14% Black or African  American3% 4% 4% 3% 4% Hispanic/Latino 5% 7% 7% 8% 8% Not disclosed 4% 2% 4% 4% 5% Other 3% 2% 2% 2% 2% White 71% 71% 69% 69% 67% Total 4,578 4,558 4,704 6,028 6,GRI disclosure: 405-1Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24762316048145294)","('Employee_Engagement_Inclusion_And_Diversity', 0.24381370842456818)","('Competitive_Behavior', 0.08651503175497055)","('NON-ESG', 0.24762316048145294)","('NON-ESG', 0.24381370842456818)","('NON-ESG', 0.08651503175497055)"
Line 1371,"Access Innovation Efficiency Empowerment Governance FY 2016 * FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 33% 34% 35% 38% 37% 35–54 48% 52% 52% 50% 50% 55 and older 12% 13% 13% 12% 13% Total 50,920 46,641 48,473 70,200 72,*In FY 2016, age was not disclosed for 7% of the dataset.Associates by age (worldwide) FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 13% 13% 13% 11% 11% Black or African  American7% 8% 8% 9% 9% Hispanic/Latino 13% 16% 16% 16% 16% Not disclosed 4% 3% 7% 8% 9% Other 3% 2% 2% 2% 2% White 59% 58% 55% 55% 53% Total 18,392 22,944 23,790 24,220 24,Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.Associates by ethnicity (U.S. only)For the following tables, the total number of associates for each disclosure is noted in the corresponding table.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9599602818489075)","('Business_Model_Resilience', 0.0032992546912282705)","('Access_And_Affordability', 0.0026873305905610323)","(['Human Capital Development'], 0.9599602818489075)","('NON-ESG', 0.0032992546912282705)","('NON-ESG', 0.0026873305905610323)"
Line 1372,"Access Innovation Efficiency Empowerment Governance FY 2016 * FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 33% 34% 35% 38% 37% 35–54 48% 52% 52% 50% 50% 55 and older 12% 13% 13% 12% 13% Total 50,920 46,641 48,473 70,200 72,*In FY 2016, age was not disclosed for 7% of the dataset.Associates by age (worldwide) FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Asian/Indian 13% 13% 13% 11% 11% Black or African  American7% 8% 8% 9% 9% Hispanic/Latino 13% 16% 16% 16% 16% Not disclosed 4% 3% 7% 8% 9% Other 3% 2% 2% 2% 2% White 59% 58% 55% 55% 53% Total 18,392 22,944 23,790 24,220 24,Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, and Puerto Rico but excludes any other U.S. territories.Associates by ethnicity (U.S. only)For the following tables, the total number of associates for each disclosure is noted in the corresponding table.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9625630378723145)","('Customer_Privacy', 0.004649353213608265)","('Business_Model_Resilience', 0.0025093054864555597)","(['Human Capital Development'], 0.9625630378723145)","('NON-ESG', 0.004649353213608265)","('NON-ESG', 0.0025093054864555597)"
Line 1373,"Bard  associates are included in FY 2019 and FY 2020 data.
","('Business_Model_Resilience', 0.31292781233787537)","('Management_Of_Legal_And_Regulatory_Framework', 0.09749589115381241)","('Physical_Impacts_Of_Climate_Change', 0.0867595449090004)","('NON-ESG', 0.31292781233787537)","('NON-ESG', 0.09749589115381241)","('NON-ESG', 0.0867595449090004)"
Line 1374,"Data in previous years has been restated due to improvements in data collection systems.
","('Customer_Privacy', 0.45055705308914185)","('Data_Security', 0.261385977268219)","('Energy_Management', 0.029134444892406464)","('NON-ESG', 0.45055705308914185)","('NON-ESG', 0.261385977268219)","('NON-ESG', 0.029134444892406464)"
Line 1375,"Workforce includes all associates, both management and non-management.Associate positions Access Innovation Efficiency Empowerment Governance FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 36% 14% 13% 26% 27% Male 23% 13% 12% 23% 26% The way BD reports this metric has changed.
","('Employee_Engagement_Inclusion_And_Diversity', 0.470935583114624)","('Business_Model_Resilience', 0.111883245408535)","('Systemic_Risk_Management', 0.04616081342101097)","('NON-ESG', 0.470935583114624)","('NON-ESG', 0.111883245408535)","('NON-ESG', 0.04616081342101097)"
Line 1376,"The new metric calculates the rate at which employee start working for the organization as a percentage of average  headcount, during the period (e.g. Female new hire rate = Female new hire count/Avg headcount of female employees).
","('Labor_Practices', 0.3882569372653961)","('Employee_Engagement_Inclusion_And_Diversity', 0.3809060752391815)","('Director_Removal', 0.045344024896621704)","('NON-ESG', 0.3882569372653961)","('NON-ESG', 0.3809060752391815)","('NON-ESG', 0.045344024896621704)"
Line 1377,"In the past, this metric was reported as  count of new hires (by category)/total headcount.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1362626850605011)","('Systemic_Risk_Management', 0.12886865437030792)","('Labor_Practices', 0.11326246708631516)","('NON-ESG', 0.1362626850605011)","('NON-ESG', 0.12886865437030792)","('NON-ESG', 0.11326246708631516)"
Line 1378,"As a result, all data has been restated to reflect this new metric.
","('Systemic_Risk_Management', 0.20385801792144775)","('Customer_Privacy', 0.13833323121070862)","('Business_Model_Resilience', 0.11740312725305557)","('NON-ESG', 0.20385801792144775)","('NON-ESG', 0.13833323121070862)","('NON-ESG', 0.11740312725305557)"
Line 1379,"New hire rate by gender (worldwide) FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 36% 28% 19% 32% 43% 35–54 14% 14% 8% 11% 13% 55 and older 16% 19% 11% 11% 13% By turnover we mean the percentage of employees who exited voluntarily or involuntarily during the period.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8126213550567627)","('Labor_Practices', 0.04871039837598801)","('Director_Removal', 0.02071298100054264)","(['Human Capital Development'], 0.8126213550567627)","('NON-ESG', 0.04871039837598801)","('NON-ESG', 0.02071298100054264)"
Line 1380,"The way BD reports this metric has changed.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31740686297416687)","('Systemic_Risk_Management', 0.24178126454353333)","('Supply_Chain_Management', 0.050463881343603134)","('NON-ESG', 0.31740686297416687)","('NON-ESG', 0.24178126454353333)","('NON-ESG', 0.050463881343603134)"
Line 1381,"This new  metric is calculated using the number of employees who exited divided by the Average Headcount for the analysis period (e.g. Under 35 Turnover rate = count of  Under 35 who exited/average headcount).
","('Employee_Engagement_Inclusion_And_Diversity', 0.39568081498146057)","('Labor_Practices', 0.2072998732328415)","('Director_Removal', 0.10368663817644119)","('NON-ESG', 0.39568081498146057)","('NON-ESG', 0.2072998732328415)","('NON-ESG', 0.10368663817644119)"
Line 1382,"As a result, all data has been restated to reflect this new metric.Turnover rate by age (worldwide)FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Under 35 49% 26% 24% 48% 50% 35–54 13% 8% 7% 12% 13% 55 and older 6% 3% 3% 5% 6% The way BD reports this metric has changed.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8623708486557007)","('Labor_Practices', 0.015338977798819542)","('Business_Model_Resilience', 0.012456758879125118)","(['Human Capital Development'], 0.8623708486557007)","('NON-ESG', 0.015338977798819542)","('NON-ESG', 0.012456758879125118)"
Line 1383,"The new metric calculates the rate at which employee start working for the organization as a percentage of average  headcount, during the period (e.g. Under 35 new hire rate = Under 35 new hire count/Avg headcount of Under 35 employees).
","('Employee_Engagement_Inclusion_And_Diversity', 0.47643059492111206)","('Labor_Practices', 0.33132070302963257)","('Director_Removal', 0.02903272770345211)","('NON-ESG', 0.47643059492111206)","('NON-ESG', 0.33132070302963257)","('NON-ESG', 0.02903272770345211)"
Line 1384,"In the past, this metric was  reported as count of new hires (by category)/total headcount.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1362626850605011)","('Systemic_Risk_Management', 0.12886865437030792)","('Labor_Practices', 0.11326246708631516)","('NON-ESG', 0.1362626850605011)","('NON-ESG', 0.12886865437030792)","('NON-ESG', 0.11326246708631516)"
Line 1385,"As a result, all data has been restated to reflect this new metric.
","('Systemic_Risk_Management', 0.20385801792144775)","('Customer_Privacy', 0.13833323121070862)","('Business_Model_Resilience', 0.11740312725305557)","('NON-ESG', 0.20385801792144775)","('NON-ESG', 0.13833323121070862)","('NON-ESG', 0.11740312725305557)"
Line 1386,"New hire rate by age (worldwide) GRI disclosures: 401-1, 405-FY 2016 FY 2017 FY 2018 FY 2019 BD + Bard FY 2020 BD + Bard Female 33% 32% 15% 21% 26% Male 21% 21% 11% 17% 23% By turnover we mean the percentage of employees who exited voluntarily or involuntarily during the period.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6570215821266174)","('Labor_Practices', 0.1178213506937027)","('Director_Removal', 0.045287493616342545)","(['Human Capital Development'], 0.6570215821266174)","('NON-ESG', 0.1178213506937027)","('NON-ESG', 0.045287493616342545)"
Line 1387,"The way BD reports this metric has changed.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31740686297416687)","('Systemic_Risk_Management', 0.24178126454353333)","('Supply_Chain_Management', 0.050463881343603134)","('NON-ESG', 0.31740686297416687)","('NON-ESG', 0.24178126454353333)","('NON-ESG', 0.050463881343603134)"
Line 1388,"This new  metric is calculated using the number of employees who exited divided by the Average Headcount for the analysis period (e.g. Female Turnover rate = count of  Females who exited / average headcount).
","('Labor_Practices', 0.40416938066482544)","('Employee_Engagement_Inclusion_And_Diversity', 0.24784721434116364)","('Director_Removal', 0.08488393574953079)","('NON-ESG', 0.40416938066482544)","('NON-ESG', 0.24784721434116364)","('NON-ESG', 0.08488393574953079)"
Line 1389,"As a result, all data has been restated to reflect this new metric.Turnover rate by gender (worldwide) GRI disclosure: 401-Access Innovation Efficiency Empowerment Governance At BD, we continuously drive the implementation and execution  of programs that will keep our associates safe.
","('Management_Of_Legal_And_Regulatory_Framework', 0.31320953369140625)","('Access_And_Affordability', 0.09797849506139755)","('Systemic_Risk_Management', 0.08964525908231735)","('NON-ESG', 0.31320953369140625)","('NON-ESG', 0.09797849506139755)","('NON-ESG', 0.08964525908231735)"
Line 1390,"During the COVID-19 pandemic, we redoubled our efforts to  ensure the safety of our associates and business continuity.
","('Employee_Health_And_Safety', 0.8485848307609558)","('Critical_Incident_Risk_Management', 0.06968864798545837)","('Air_Quality', 0.014203865081071854)","(['Operational Eco-Efficiency'], 0.8485848307609558)","('NON-ESG', 0.06968864798545837)","('NON-ESG', 0.014203865081071854)"
Line 1391,"This work meant undertaking major new initiatives, such as:  • Institutionalizing the use of additional layers of PPE while  simultaneously ensuring we have access to a continuous  supply of PPE; • Redesigning our facilities and process flows to minimize  transmission of the virus; • Conducting effective contact tracing and investigations  through systematic methodologies; • Rolling out educational campaigns to modify behavior inside  and outside facilities to reduce transmission; and • Conducting COVID-19 testing in locations where community  spikes have impacted our facilities.
","('Access_And_Affordability', 0.222029909491539)","('Air_Quality', 0.11622416973114014)","('Systemic_Risk_Management', 0.07703272253274918)","('NON-ESG', 0.222029909491539)","('NON-ESG', 0.11622416973114014)","('NON-ESG', 0.07703272253274918)"
Line 1392,"This work meant undertaking major new initiatives, such as:  • Institutionalizing the use of additional layers of PPE while  simultaneously ensuring we have access to a continuous  supply of PPE; • Redesigning our facilities and process flows to minimize  transmission of the virus; • Conducting effective contact tracing and investigations  through systematic methodologies; • Rolling out educational campaigns to modify behavior inside  and outside facilities to reduce transmission; and • Conducting COVID-19 testing in locations where community  spikes have impacted our facilities.
","('Human_Rights_And_Community_Relations', 0.2568054497241974)","('Access_And_Affordability', 0.24783706665039062)","('Critical_Incident_Risk_Management', 0.05684273689985275)","('NON-ESG', 0.2568054497241974)","('NON-ESG', 0.24783706665039062)","('NON-ESG', 0.05684273689985275)"
Line 1393,"Although maintaining the safety of our associates during the  pandemic has been our priority, our planned improvements also  moved forward, strengthening our organization and assisting in  keeping our workforce safe.
","('Employee_Health_And_Safety', 0.9548102617263794)","('Critical_Incident_Risk_Management', 0.017859624698758125)","('Air_Quality', 0.0021368435118347406)","(['Operational Eco-Efficiency'], 0.9548102617263794)","('NON-ESG', 0.017859624698758125)","('NON-ESG', 0.0021368435118347406)"
Line 1394,"In FY 2020, we continued to solidify  and streamline our standards and practices across 80+ facilities  with focus on sites gained through recent acquisitions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5146881341934204)","('Product_Quality_And_Safety', 0.12912212312221527)","('Business_Ethics', 0.10311027616262436)","(['Corporate Governance'], 0.5146881341934204)","('NON-ESG', 0.12912212312221527)","('NON-ESG', 0.10311027616262436)"
Line 1395,"The continued establishment of governance platforms drove  this work.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8573406338691711)","('Human_Rights_And_Community_Relations', 0.02484874054789543)","('Systemic_Risk_Management', 0.013450218364596367)","(['Corporate Governance'], 0.8573406338691711)","('NON-ESG', 0.02484874054789543)","('NON-ESG', 0.013450218364596367)"
Line 1396,"The Global EHS Advisory Council, with representation  from all BD businesses, provided a unified direction in establishing global objectives and strong collaboration efforts  across the organization to streamline efforts and work  as one team.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6585061550140381)","('Human_Rights_And_Community_Relations', 0.04904251918196678)","('Director_Removal', 0.04214059188961983)","(['Corporate Governance'], 0.6585061550140381)","('NON-ESG', 0.04904251918196678)","('NON-ESG', 0.04214059188961983)"
Line 1397,"Furthermore, in FY 2020, the BD EHS team implemented its   new risk-based audit model, which gauges facilities on three  main components: inherit risk, changes and performance.
","('Systemic_Risk_Management', 0.8938297033309937)","('Business_Model_Resilience', 0.01811409555375576)","('Business_Ethics', 0.013821642845869064)","(['Risk & Crisis Management'], 0.8938297033309937)","('NON-ESG', 0.01811409555375576)","('NON-ESG', 0.013821642845869064)"
Line 1398,"This enabled a more deliberate focus for selection of sites to be  audited during the year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38281649351119995)","('Competitive_Behavior', 0.16207388043403625)","('Business_Ethics', 0.13952358067035675)","('NON-ESG', 0.38281649351119995)","('NON-ESG', 0.16207388043403625)","('NON-ESG', 0.13952358067035675)"
Line 1399,"This new model was launched during  the pandemic, which added a layer of complexity by shifting the  audit model to a virtual one.
","('Systemic_Risk_Management', 0.8288303017616272)","('Business_Ethics', 0.03616398200392723)","('Competitive_Behavior', 0.02882753312587738)","(['Risk & Crisis Management'], 0.8288303017616272)","('NON-ESG', 0.03616398200392723)","('NON-ESG', 0.02882753312587738)"
Line 1400,"With a shift to virtual audits and a  transformation of methodologies to address this new platform,  we were able to continue to audit facilities to ensure an effective  level of governance oversight and address these new challenges  during these unprecedented times.
","('Management_Of_Legal_And_Regulatory_Framework', 0.619389533996582)","('Business_Ethics', 0.19145537912845612)","('Systemic_Risk_Management', 0.06311717629432678)","(['Corporate Governance'], 0.619389533996582)","('NON-ESG', 0.19145537912845612)","('NON-ESG', 0.06311717629432678)"
Line 1401,"BD continues to reinforce systems that strengthen our goal to  drive a culture in which the health and well-being of our  associates, visitors and contractors are an integral part of every  decision we make.
","('Employee_Health_And_Safety', 0.8732808232307434)","('Access_And_Affordability', 0.03068540059030056)","('Human_Rights_And_Community_Relations', 0.010416611097753048)","(['Operational Eco-Efficiency'], 0.8732808232307434)","('NON-ESG', 0.03068540059030056)","('NON-ESG', 0.010416611097753048)"
Line 1402,"Instrumental in this vision is the continuation  of programs that drive management and leadership  engagement, peer-to-peer coaching, and education  and training.
","('Employee_Engagement_Inclusion_And_Diversity', 0.565101683139801)","('Access_And_Affordability', 0.1505568027496338)","('Human_Rights_And_Community_Relations', 0.06894807517528534)","(['Human Capital Development'], 0.565101683139801)","('NON-ESG', 0.1505568027496338)","('NON-ESG', 0.06894807517528534)"
Line 1403,"For further details about our EHS management programs,  please see EHS management in the Efficiency  section of  this report.
","('Energy_Management', 0.9412770867347717)","('Management_Of_Legal_And_Regulatory_Framework', 0.014279021881520748)","('Access_And_Affordability', 0.004521651193499565)","(['Operational Eco-Efficiency'], 0.9412770867347717)","('NON-ESG', 0.014279021881520748)","('NON-ESG', 0.004521651193499565)"
Line 1404,"In FY 2020, there were no fatalities.2020 goal Achieve best-in-class safety performance GRI disclosure: 403-9FY 2016 FY 2017 FY 2018 FY 2019 FY LTIFR* per 200,000 hours worked 0.29 0.32 0.26 0.24 0.OIFR† per 200,000 hours worked 0.004 0.03 0.00 0.00 0.Occupational IIR‡ rate per 200,000 hours worked 0.7 0.7 0.6 0.51 0.Data provided reflects manufacturing sites only.
","('Employee_Health_And_Safety', 0.9654008150100708)","('Product_Quality_And_Safety', 0.0055005247704684734)","('Labor_Practices', 0.0033943934831768274)","(['Operational Eco-Efficiency'], 0.9654008150100708)","('NON-ESG', 0.0055005247704684734)","('NON-ESG', 0.0033943934831768274)"
Line 1405,"FY 2008 to FY 2017, excludes Bard.
","('Business_Model_Resilience', 0.14626500010490417)","('Physical_Impacts_Of_Climate_Change', 0.1401544213294983)","('Management_Of_Legal_And_Regulatory_Framework', 0.13284781575202942)","('NON-ESG', 0.14626500010490417)","('NON-ESG', 0.1401544213294983)","('NON-ESG', 0.13284781575202942)"
Line 1406,"*Lost time injury frequency rate (LTIFR) †Occupational illness frequency rate (OIFR) ‡Injury and illness rate (IIR) There have been no fatalities since FY 2014.
","('Employee_Health_And_Safety', 0.9845653176307678)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015319261001423001)","('Critical_Incident_Risk_Management', 0.0012704093242064118)","(['Operational Eco-Efficiency'], 0.9845653176307678)","('NON-ESG', 0.0015319261001423001)","('NON-ESG', 0.0012704093242064118)"
Line 1407,"Access Innovation Efficiency Empowerment Governance Charitable giving summary, by the numbers: FY 2020Social Investing First grants issued by BD Foundation The BD Foundation was established in 2016 as a private 501(c)3 organization, with the goal of expanding and strengthening  the consistency of our ability to make strategic, multiyear, global philanthropic investments in initiatives that expand  healthcare access, advance human potential and support resilient communities.
","('Access_And_Affordability', 0.5934665203094482)","('Human_Rights_And_Community_Relations', 0.07345293462276459)","('Business_Model_Resilience', 0.05588454008102417)","(['Health Outcome Contribution'], 0.5934665203094482)","('NON-ESG', 0.07345293462276459)","('NON-ESG', 0.05588454008102417)"
Line 1408,"The BD Foundation issued its first grants in  2020 to Direct Relief in support of the BD Helping Build Healthy Communities ™ Initiative and to multiple philanthropic  partners in support of global COVID-19 relief efforts.
","('Human_Rights_And_Community_Relations', 0.5421687960624695)","('Access_And_Affordability', 0.24884626269340515)","('Critical_Incident_Risk_Management', 0.044069401919841766)","(['Community Relations'], 0.5421687960624695)","('NON-ESG', 0.24884626269340515)","('NON-ESG', 0.044069401919841766)"
Line 1409,"Total cash donations $9.9 million Total product donations $12.6 million Value of company match to associate donations $1.8 million Number of grants issued, worldwide Number of nonprofit beneficiaries Number of matching gifts distributed 26,FY 2020 cash contributionsFY 2020 charitable giving summary *Includes matching gifts and contributions from individual BD locations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6204957962036133)","('Access_And_Affordability', 0.05682719498872757)","('Human_Rights_And_Community_Relations', 0.037478238344192505)","(['Corporate Governance'], 0.6204957962036133)","('NON-ESG', 0.05682719498872757)","('NON-ESG', 0.037478238344192505)"
Line 1410,"†Includes $540,000 for COVID-19 emergency relief.
","('Critical_Incident_Risk_Management', 0.9745240807533264)","('Air_Quality', 0.0028103385120630264)","('Employee_Health_And_Safety', 0.002733194502070546)","(['Risk & Crisis Management'], 0.9745240807533264)","('NON-ESG', 0.0028103385120630264)","('NON-ESG', 0.002733194502070546)"
Line 1411,"‡Includes basic needs/hometown giving.
","('Access_And_Affordability', 0.8364962935447693)","('Human_Rights_And_Community_Relations', 0.01989039219915867)","('Employee_Health_And_Safety', 0.018805215135216713)","(['Health Outcome Contribution'], 0.8364962935447693)","('NON-ESG', 0.01989039219915867)","('NON-ESG', 0.018805215135216713)"
Line 1412,"§Includes care for the uninsured/underinsured, diabetes and prevention, global health, infection prevention, maternal and newborn health, vaccine preventable    diseases, women’s health, cancer and other health.$12.6 million   Product donations$338,000   Volunteering – pro bono   hours donated$32,000   Skills-based volunteering $9.9 million   Cash donations * $22.6 million Total contributions   (cash and product) $310,000   Arts and culture $4.2 million   Health and human services  §$1.5 million   Civic and social welfare‡$400,000   Disaster relief $2 million   Education$1.4 million   Other† $9.9 million   Total cash contributions Access Innovation Efficiency Empowerment Governance Community health centers are on the front lines, every day,  providing lifesaving care to more than 30 million people in  vulnerable rural and urban communities across the  United States.
","('Access_And_Affordability', 0.5936322212219238)","('Employee_Health_And_Safety', 0.14850741624832153)","('Employee_Engagement_Inclusion_And_Diversity', 0.03596549481153488)","(['Health Outcome Contribution'], 0.5936322212219238)","('NON-ESG', 0.14850741624832153)","('NON-ESG', 0.03596549481153488)"
Line 1413,"§Includes care for the uninsured/underinsured, diabetes and prevention, global health, infection prevention, maternal and newborn health, vaccine preventable    diseases, women’s health, cancer and other health.$12.6 million   Product donations$338,000   Volunteering – pro bono   hours donated$32,000   Skills-based volunteering $9.9 million   Cash donations * $22.6 million Total contributions   (cash and product) $310,000   Arts and culture $4.2 million   Health and human services  §$1.5 million   Civic and social welfare‡$400,000   Disaster relief $2 million   Education$1.4 million   Other† $9.9 million   Total cash contributions Access Innovation Efficiency Empowerment Governance Community health centers are on the front lines, every day,  providing lifesaving care to more than 30 million people in  vulnerable rural and urban communities across the  United States.
","('Critical_Incident_Risk_Management', 0.4529898464679718)","('Access_And_Affordability', 0.2528381645679474)","('Human_Rights_And_Community_Relations', 0.10210279375314713)","('NON-ESG', 0.4529898464679718)","('NON-ESG', 0.2528381645679474)","('NON-ESG', 0.10210279375314713)"
Line 1414,"Without these community-based “family doctors,”   millions of uninsured and underinsured patients would go   without healthcare.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1948786973953247)","('Access_And_Affordability', 0.18241232633590698)","('Labor_Practices', 0.1481604427099228)","('NON-ESG', 0.1948786973953247)","('NON-ESG', 0.18241232633590698)","('NON-ESG', 0.1481604427099228)"
Line 1415,"Implemented in partnership with Direct Relief and the National  Association of Community Health Centers, the BD Helping Build  Healthy Communities ™ Initiative awards grants to community health centers, to support the implementation of innovative  approaches to meeting the unique healthcare needs of local,  underserved and vulnerable populations.
","('Access_And_Affordability', 0.942011833190918)","('Human_Rights_And_Community_Relations', 0.00671808049082756)","('Critical_Incident_Risk_Management', 0.005487704183906317)","(['Health Outcome Contribution'], 0.942011833190918)","('NON-ESG', 0.00671808049082756)","('NON-ESG', 0.005487704183906317)"
Line 1416,"Since this program’s inception in 2013, and through 2022,   BD and the BD Foundation have together committed to invest  $22.6 million in this initiative, which clinical data predicts will  have a meaningful impact on the grant winners’ ability to  expand access to quality patient care, particularly among  patients experiencing diabetes, hypertension, depression and  difficulty with medication compliance.
","('Access_And_Affordability', 0.7471747994422913)","('Employee_Health_And_Safety', 0.03851554915308952)","('Product_Quality_And_Safety', 0.03768023103475571)","(['Health Outcome Contribution'], 0.7471747994422913)","('NON-ESG', 0.03851554915308952)","('NON-ESG', 0.03768023103475571)"
Line 1417,"Expanding healthcare access in the United States2020 goal Partner with nonprofits to address unmet healthcare needs, locally and globally BD Helping Build Healthy Communities ™ Initiative BD Helping Build Healthy Communities ™ Initiative, by the numbers Product donations have  reached 400,000 patients .
","('Access_And_Affordability', 0.8565948605537415)","('Human_Rights_And_Community_Relations', 0.018738526850938797)","('Critical_Incident_Risk_Management', 0.017873918637633324)","(['Health Outcome Contribution'], 0.8565948605537415)","('NON-ESG', 0.018738526850938797)","('NON-ESG', 0.017873918637633324)"
Line 1418,"Health outcomes of 65,000 patients  have  been improved through our cash support.BD has provided Direct Relief with more than 38 million insulin  syringes  and 743,000 pen needles , valued at $11.2 million .
","('Access_And_Affordability', 0.5297384858131409)","('Employee_Health_And_Safety', 0.20888452231884003)","('Product_Quality_And_Safety', 0.05117311328649521)","(['Health Outcome Contribution'], 0.5297384858131409)","('NON-ESG', 0.20888452231884003)","('NON-ESG', 0.05117311328649521)"
Line 1419,"48 grants , totaling $6.7 million , have been issued  to community health centers in 20 states .These items have been distributed to  1,400 community health centers,  free clinics and community clinics in  all 50 states and Puerto Rico .
","('Access_And_Affordability', 0.8618804216384888)","('Human_Rights_And_Community_Relations', 0.016989268362522125)","('Critical_Incident_Risk_Management', 0.014723381958901882)","(['Health Outcome Contribution'], 0.8618804216384888)","('NON-ESG', 0.016989268362522125)","('NON-ESG', 0.014723381958901882)"
Line 1420,"BD investment, 2013 to 2022   $22.6 million Access Innovation Efficiency Empowerment Governance In response to the success of the BD Helping Build Healthy  Communities ™ Initiative, and to reach an even broader at-risk  population, BD worked with the National Association of Free  and Charitable Clinics (NAFC) to introduce three companion  programs in 2017, which support free and charitable clinics.
","('Access_And_Affordability', 0.5642061829566956)","('Human_Rights_And_Community_Relations', 0.262308806180954)","('Employee_Engagement_Inclusion_And_Diversity', 0.02176697365939617)","(['Health Outcome Contribution'], 0.5642061829566956)","('NON-ESG', 0.262308806180954)","('NON-ESG', 0.02176697365939617)"
Line 1421,"The BD Continuity of Care Mini-Grant  Program , implemented in partnership with  Direct Relief  and  NAFC , provides member  organizations with cash grants to support  critically needed healthcare programs for medically underserved  patients.
","('Access_And_Affordability', 0.9455233812332153)","('Critical_Incident_Risk_Management', 0.005539172329008579)","('Energy_Management', 0.004710647277534008)","(['Health Outcome Contribution'], 0.9455233812332153)","('NON-ESG', 0.005539172329008579)","('NON-ESG', 0.004710647277534008)"
Line 1422,"From FY 2018 to FY 2021, BD and Direct Relief  committed $515,000 in grants to 24 NAFC member  organizations in 14 states.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9046266078948975)","('Access_And_Affordability', 0.02328375354409218)","('GHG_Emissions', 0.010198559612035751)","(['Corporate Governance'], 0.9046266078948975)","('NON-ESG', 0.02328375354409218)","('NON-ESG', 0.010198559612035751)"
Line 1423,"The BD Advancing Community Health: Driving  Quality Outcomes—Patient-Centered Medical  Home (PCMH) Program , co-developed with  Americares , provides grant funding to help free  clinics achieve the National Committee for Quality  Assurance (NCQA) quality standard for a patient-centered  medical home.
","('Access_And_Affordability', 0.3185952305793762)","('Product_Quality_And_Safety', 0.16884386539459229)","('Employee_Health_And_Safety', 0.06678846478462219)","('NON-ESG', 0.3185952305793762)","('NON-ESG', 0.16884386539459229)","('NON-ESG', 0.06678846478462219)"
Line 1424,"Since 2017, BD has invested $760,000 to support  six free, charitable and hybrid clinics in five states in their efforts  to work toward NCQA certification; and has donated $5 million  worth of diabetes care products to Americares for distribution to  the U.S. free clinics.
","('Access_And_Affordability', 0.40341049432754517)","('Product_Quality_And_Safety', 0.15145595371723175)","('Customer_Welfare', 0.12360764294862747)","('NON-ESG', 0.40341049432754517)","('NON-ESG', 0.15145595371723175)","('NON-ESG', 0.12360764294862747)"
Line 1425,"The Advancing Community Health—   Point-of-Care (POC) Enhancing Clinical  Effectiveness Award,  co-developed with  Heart to Heart International  and NAFC ,  provides essential, diagnostic point-of-care testing equipment,  supplies and quality controls to help free clinics effectively  administer and share the results of diagnostic tests during a  single medical visit.
","('Access_And_Affordability', 0.18665464222431183)","('Product_Quality_And_Safety', 0.17637842893600464)","('Customer_Welfare', 0.17337937653064728)","('NON-ESG', 0.18665464222431183)","('NON-ESG', 0.17637842893600464)","('NON-ESG', 0.17337937653064728)"
Line 1426,"Since FY 2017, BD has committed $1.8  million to this program and deployed 12 associate volunteers   to provide free lab training to 15 free clinics.Expanding on program success In recognition of our centennial anniversary in 1997,  BD co-founded its first signature philanthropic  program, supporting UNICEF’s Maternal and  Neonatal Tetanus Elimination (MNTE) Initiative   worldwide.
","('Access_And_Affordability', 0.7805553674697876)","('Employee_Health_And_Safety', 0.042913395911455154)","('Employee_Engagement_Inclusion_And_Diversity', 0.03713535889983177)","(['Health Outcome Contribution'], 0.7805553674697876)","('NON-ESG', 0.042913395911455154)","('NON-ESG', 0.03713535889983177)"
Line 1427,"The initiative seeks to reduce annual neonatal tetanus  incidence through vaccinating pregnant women and women of  reproductive age, promoting clean delivery practices, such as  umbilical cord cutting, and utilizing surveillance to enhance health  professionals’ understanding of the circumstances under which  cases can occur.
","('Employee_Health_And_Safety', 0.5365678668022156)","('Access_And_Affordability', 0.17732591927051544)","('Employee_Engagement_Inclusion_And_Diversity', 0.0718914270401001)","(['Operational Eco-Efficiency'], 0.5365678668022156)","('NON-ESG', 0.17732591927051544)","('NON-ESG', 0.0718914270401001)"
Line 1428,"Between 2000 and 2018, the World Health  Organization estimates deaths from neonatal tetanus had  dropped by 88%.
","('Employee_Health_And_Safety', 0.8703649640083313)","('Access_And_Affordability', 0.025171782821416855)","('Critical_Incident_Risk_Management', 0.015477714128792286)","(['Operational Eco-Efficiency'], 0.8703649640083313)","('NON-ESG', 0.025171782821416855)","('NON-ESG', 0.015477714128792286)"
Line 1429,"BD has committed $14.8 million in cash and  products to this initiative, through 2025.
","('Product_Design_And_Lifecycle_Management', 0.8843873143196106)","('Product_Quality_And_Safety', 0.02068948559463024)","('Customer_Welfare', 0.011014231480658054)","(['Product Stewardship'], 0.8843873143196106)","('NON-ESG', 0.02068948559463024)","('NON-ESG', 0.011014231480658054)"
Line 1430,"Reducing maternal mortality and delivery  complications in Zambia Since 2014, BD has committed more than  $675,000 in cash to support CMMB’s Children   and Mothers Partnership Program  in delivering  high-impact interventions to address the high  rates of maternal mortality, HIV infection and delivery  complications in Zambia.
","('Employee_Health_And_Safety', 0.7924325466156006)","('Critical_Incident_Risk_Management', 0.062446631491184235)","('Access_And_Affordability', 0.044399429112672806)","(['Operational Eco-Efficiency'], 0.7924325466156006)","('NON-ESG', 0.062446631491184235)","('NON-ESG', 0.044399429112672806)"
Line 1431,"This program has enabled CMMB to  continue to deliver healthcare interventions, including safe  motherhood, community-led total sanitation, integrated  community case management, maternal, adolescent and young  child nutrition, and community-based growth monitoring  and promotion.
","('Access_And_Affordability', 0.7378839254379272)","('Human_Rights_And_Community_Relations', 0.1082010492682457)","('Employee_Health_And_Safety', 0.02299817092716694)","(['Health Outcome Contribution'], 0.7378839254379272)","('NON-ESG', 0.1082010492682457)","('NON-ESG', 0.02299817092716694)"
Line 1432,"Bringing free, safe surgery to those in need Each year, 18.6 million people die due to lack of access to surgical  care, 93% of whom are in Africa.
","('Access_And_Affordability', 0.7984699010848999)","('Employee_Health_And_Safety', 0.05434643477201462)","('Critical_Incident_Risk_Management', 0.02937372215092182)","(['Health Outcome Contribution'], 0.7984699010848999)","('NON-ESG', 0.05434643477201462)","('NON-ESG', 0.02937372215092182)"
Line 1433,"As COVID-19 threatens the  stability of already fragile healthcare systems globally, the need  to provide basic lifesaving care is greater than ever, especially in  low- to middle-income countries.
","('Access_And_Affordability', 0.8747920989990234)","('Critical_Incident_Risk_Management', 0.015646755695343018)","('Employee_Health_And_Safety', 0.013401222415268421)","(['Health Outcome Contribution'], 0.8747920989990234)","('NON-ESG', 0.015646755695343018)","('NON-ESG', 0.013401222415268421)"
Line 1434,"Over the past 25 years, BD has donated more  than $1.5 million in cash and products  to   Mercy Ships  to support its mission of bringing free,  safe surgical care to those in need.
","('Access_And_Affordability', 0.7883992791175842)","('Employee_Health_And_Safety', 0.05236233025789261)","('Critical_Incident_Risk_Management', 0.022463398054242134)","(['Health Outcome Contribution'], 0.7883992791175842)","('NON-ESG', 0.05236233025789261)","('NON-ESG', 0.022463398054242134)"
Line 1435,"To celebrate our 25th  anniversary of supporting Mercy Ships,  BD committed $1 million  ($750,000 in cash and $250,000 in products) over three years   (FY 2020 to FY 2022)  to help Mercy Ships double its surgical and  training capacity via the Global Mercy ™, a new ship that will  primarily serve patients in Africa.
","('Access_And_Affordability', 0.7265320420265198)","('Critical_Incident_Risk_Management', 0.044649723917245865)","('Employee_Health_And_Safety', 0.039245087653398514)","(['Health Outcome Contribution'], 0.7265320420265198)","('NON-ESG', 0.044649723917245865)","('NON-ESG', 0.039245087653398514)"
Line 1436,"BD committed $500,000 in cash and products  over two years  to the RCI University of Medicine  and Health Science, Ireland , to support the launch  of the KidSURG initiative, a pediatric surgical network that seeks  to expand surgical access to 8 million children in Malawi.Eliminating maternal and neonatal tetanus worldwide Expanding healthcare access globally Access Innovation Efficiency Empowerment Governance For more than a decade, BD has partnered with international relief agencies, including the American Red Cross, Direct Relief,  AmeriCares, MAP International, CMMB, and Heart to Heart International to deploy product donations and cash support quickly  and efficiently to the people and communities who need them most, both for the management of chronic disease and during  times of disaster.
","('Access_And_Affordability', 0.8884446024894714)","('Employee_Health_And_Safety', 0.012641103006899357)","('Product_Quality_And_Safety', 0.010946349240839481)","(['Health Outcome Contribution'], 0.8884446024894714)","('NON-ESG', 0.012641103006899357)","('NON-ESG', 0.010946349240839481)"
Line 1437,"BD committed $500,000 in cash and products  over two years  to the RCI University of Medicine  and Health Science, Ireland , to support the launch  of the KidSURG initiative, a pediatric surgical network that seeks  to expand surgical access to 8 million children in Malawi.Eliminating maternal and neonatal tetanus worldwide Expanding healthcare access globally Access Innovation Efficiency Empowerment Governance For more than a decade, BD has partnered with international relief agencies, including the American Red Cross, Direct Relief,  AmeriCares, MAP International, CMMB, and Heart to Heart International to deploy product donations and cash support quickly  and efficiently to the people and communities who need them most, both for the management of chronic disease and during  times of disaster.
","('Critical_Incident_Risk_Management', 0.9583593010902405)","('Employee_Health_And_Safety', 0.006361974403262138)","('Access_And_Affordability', 0.005449716467410326)","(['Risk & Crisis Management'], 0.9583593010902405)","('NON-ESG', 0.006361974403262138)","('NON-ESG', 0.005449716467410326)"
Line 1438,"Disaster response and strategic product donation * Includes $540,000 for COVID-19 emergency relief.
","('Critical_Incident_Risk_Management', 0.9757426381111145)","('Employee_Health_And_Safety', 0.002414802787825465)","('Air_Quality', 0.002243771217763424)","(['Risk & Crisis Management'], 0.9757426381111145)","('NON-ESG', 0.002414802787825465)","('NON-ESG', 0.002243771217763424)"
Line 1439,"† In response to the COVID-19 pandemic.
","('Physical_Impacts_Of_Climate_Change', 0.31378331780433655)","('Systemic_Risk_Management', 0.10509423166513443)","('Critical_Incident_Risk_Management', 0.08841895312070847)","('NON-ESG', 0.31378331780433655)","('NON-ESG', 0.10509423166513443)","('NON-ESG', 0.08841895312070847)"
Line 1440,"Of that $2.8 million, $540,000 was donated by BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4560694098472595)","('Access_And_Affordability', 0.10718614608049393)","('Ecological_Impacts', 0.07098352909088135)","('NON-ESG', 0.4560694098472595)","('NON-ESG', 0.10718614608049393)","('NON-ESG', 0.07098352909088135)"
Line 1441,"‡ $2.5 million reflects the combined COVID-19 philanthropic donations made by BD and the BD Foundation in FY 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7927901744842529)","('Access_And_Affordability', 0.024684907868504524)","('Ecological_Impacts', 0.020849592983722687)","(['Corporate Governance'], 0.7927901744842529)","('NON-ESG', 0.024684907868504524)","('NON-ESG', 0.020849592983722687)"
Line 1442,"Our philanthropic response to COVID-19 ($540,000)  is reported in the category “Other” in the BD Cash Contributions chart on page 107.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6907378435134888)","('Human_Rights_And_Community_Relations', 0.03168106824159622)","('Business_Ethics', 0.03145669773221016)","(['Corporate Governance'], 0.6907378435134888)","('NON-ESG', 0.03168106824159622)","('NON-ESG', 0.03145669773221016)"
Line 1443,"More detail regarding BD and the BD Foundation’s philanthropic response to the  COVID-19 pandemic is included on page 20 of this report.Our total FY 2020 product  donations worldwide were valued at   $12.6 millionFrom FY 2016 to FY 2020, our product   donations worldwide were valued at   $53.5 million From 2015 to 2020, BD issued $6.7 million * in cash donations to support our nonprofit partners in building the resiliency of  communities worldwide as they have worked to recover from some of the most significant disasters of the decade.
","('Business_Model_Resilience', 0.4947035014629364)","('Product_Design_And_Lifecycle_Management', 0.2306520789861679)","('Customer_Welfare', 0.029975038021802902)","('NON-ESG', 0.4947035014629364)","('NON-ESG', 0.2306520789861679)","('NON-ESG', 0.029975038021802902)"
Line 1444,"More detail regarding BD and the BD Foundation’s philanthropic response to the  COVID-19 pandemic is included on page 20 of this report.Our total FY 2020 product  donations worldwide were valued at   $12.6 millionFrom FY 2016 to FY 2020, our product   donations worldwide were valued at   $53.5 million From 2015 to 2020, BD issued $6.7 million * in cash donations to support our nonprofit partners in building the resiliency of  communities worldwide as they have worked to recover from some of the most significant disasters of the decade.
","('Critical_Incident_Risk_Management', 0.7363928556442261)","('Physical_Impacts_Of_Climate_Change', 0.1375362128019333)","('Systemic_Risk_Management', 0.020532414317131042)","(['Risk & Crisis Management'], 0.7363928556442261)","('NON-ESG', 0.1375362128019333)","('NON-ESG', 0.020532414317131042)"
Line 1445,"2020 2015 2017 2018 2019$250,Hurricane Joaquin $25,U.S. wildfires $80,Nepal earthquake$250,Hurricane Maria $50,Ebola response in  Democratic Republic   of Congo$25,Kerala floods$200,Hurricane Florence$300,California wildfires $100,Hurricane Dorian$25,Australian bushfires$50,Puerto Rico  earthquake $160,Hurricane Laura,  Hurricane Sally,   U.S. wildfires$2,800,Pandemic response†,‡ Access Innovation Efficiency Empowerment Governance Helping eradicate polio… In 2018, BD donated 20 million auto-disable  syringes, valued at $1 million, to Rotary  International, a nonprofit organization dedicated  to tackling the world’s most pressing humanitarian  challenges, in support of the Global Polio Eradication Initiative.
","('Physical_Impacts_Of_Climate_Change', 0.4626436233520508)","('Critical_Incident_Risk_Management', 0.342981219291687)","('Air_Quality', 0.02439558319747448)","('NON-ESG', 0.4626436233520508)","('NON-ESG', 0.342981219291687)","('NON-ESG', 0.02439558319747448)"
Line 1446,"2020 2015 2017 2018 2019$250,Hurricane Joaquin $25,U.S. wildfires $80,Nepal earthquake$250,Hurricane Maria $50,Ebola response in  Democratic Republic   of Congo$25,Kerala floods$200,Hurricane Florence$300,California wildfires $100,Hurricane Dorian$25,Australian bushfires$50,Puerto Rico  earthquake $160,Hurricane Laura,  Hurricane Sally,   U.S. wildfires$2,800,Pandemic response†,‡ Access Innovation Efficiency Empowerment Governance Helping eradicate polio… In 2018, BD donated 20 million auto-disable  syringes, valued at $1 million, to Rotary  International, a nonprofit organization dedicated  to tackling the world’s most pressing humanitarian  challenges, in support of the Global Polio Eradication Initiative.
","('Critical_Incident_Risk_Management', 0.5003507137298584)","('Physical_Impacts_Of_Climate_Change', 0.15028561651706696)","('Human_Rights_And_Community_Relations', 0.06479556113481522)","(['Risk & Crisis Management'], 0.5003507137298584)","('NON-ESG', 0.15028561651706696)","('NON-ESG', 0.06479556113481522)"
Line 1447,"More than six decades prior, in 1954, BD donated 1 million of  the first sterile disposable syringes for the Salk polio vaccine  field trials in the U.S., which inoculated nearly 1 million school  children known as “Polio Pioneers.”Helping children learn to manage type 1 diabetes… Since 2011, BD has donated nearly $2.4 million  worth of syringes to 10,000 children with type 1  diabetes in 20 under-resourced countries through  Direct Relief and the Life for a Child program.
","('Access_And_Affordability', 0.3195086121559143)","('Employee_Health_And_Safety', 0.26477351784706116)","('Product_Quality_And_Safety', 0.0842173621058464)","('NON-ESG', 0.3195086121559143)","('NON-ESG', 0.26477351784706116)","('NON-ESG', 0.0842173621058464)"
Line 1448,"Since 2015, BD has donated $3.5 million in insulin  syringes, pen needles, swabs and lancets to 200+  summer camps for children with type 1 diabetes    via Direct Relief.Increasing the strategic nature of product donation BD plans to expand this approach to virtual volunteerism in  2021 and beyond.
","('Access_And_Affordability', 0.6907853484153748)","('Employee_Health_And_Safety', 0.0817856714129448)","('Customer_Welfare', 0.027535004541277885)","(['Health Outcome Contribution'], 0.6907853484153748)","('NON-ESG', 0.0817856714129448)","('NON-ESG', 0.027535004541277885)"
Line 1449,"We are also creating new virtual volunteerism  partnerships with Operation Smile and the National Association  of Free Clinics.From 2015–2020, BD significantly evolved its approach to medical product donation.
","('Product_Design_And_Lifecycle_Management', 0.16851936280727386)","('Management_Of_Legal_And_Regulatory_Framework', 0.108488067984581)","('Customer_Welfare', 0.10585261136293411)","('NON-ESG', 0.16851936280727386)","('NON-ESG', 0.108488067984581)","('NON-ESG', 0.10585261136293411)"
Line 1450,"First, by aligning with our sustainability  commitment to reduce waste and by making a concerted effort to ensure that an increasing percentage of product overruns and  other non-saleable products were targeted for donation to communities in need.
","('Product_Design_And_Lifecycle_Management', 0.904169499874115)","('Product_Quality_And_Safety', 0.018578099086880684)","('Waste_And_Hazardous_Materials_Management', 0.017675824463367462)","(['Product Stewardship'], 0.904169499874115)","('NON-ESG', 0.018578099086880684)","('NON-ESG', 0.017675824463367462)"
Line 1451,"And second, by strategically partnering with  nonprofit organizations to direct more of our product donations to programs that help combat humanitarian challenges and help  patients better manage chronic conditions.
","('Access_And_Affordability', 0.539948582649231)","('Product_Quality_And_Safety', 0.08388088643550873)","('Customer_Welfare', 0.05914092808961868)","(['Health Outcome Contribution'], 0.539948582649231)","('NON-ESG', 0.08388088643550873)","('NON-ESG', 0.05914092808961868)"
Line 1452,"Key examples of our strategic product donations over the past six years include: 2020 performance highlights BD encourages associates from around the world to join together to serve their local communities through volunteerism—with the  goal of bringing our values to life, while making a meaningful difference in the communities where we live and work.
","('Human_Rights_And_Community_Relations', 0.5157909989356995)","('Employee_Health_And_Safety', 0.126015767455101)","('Access_And_Affordability', 0.1094723641872406)","(['Community Relations'], 0.5157909989356995)","('NON-ESG', 0.126015767455101)","('NON-ESG', 0.1094723641872406)"
Line 1453,"BD Volunteer Service Trip Program Having celebrated its 15th year in 2020, the BD Volunteer  Service Trip (VST) Program sends teams of BD associates to  low-resource countries to help strengthen local health systems  through training, education, laboratory services and  construction projects.
","('Employee_Health_And_Safety', 0.5088780522346497)","('Access_And_Affordability', 0.1657632440328598)","('Human_Rights_And_Community_Relations', 0.10008591413497925)","(['Operational Eco-Efficiency'], 0.5088780522346497)","('NON-ESG', 0.1657632440328598)","('NON-ESG', 0.10008591413497925)"
Line 1454,"This program enables BD associates to  share their knowledge and expertise, enabling them to live the  company Purpose of advancing the world of health ™.
","('Employee_Engagement_Inclusion_And_Diversity', 0.4737507700920105)","('Business_Model_Resilience', 0.08110462874174118)","('Access_And_Affordability', 0.08098859339952469)","('NON-ESG', 0.4737507700920105)","('NON-ESG', 0.08110462874174118)","('NON-ESG', 0.08098859339952469)"
Line 1455,"The onset  of COVID-19 in 2020 made it impossible for BD volunteers to  participate in inter-country travel.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2147856056690216)","('Employee_Engagement_Inclusion_And_Diversity', 0.14031574130058289)","('Access_And_Affordability', 0.08693838119506836)","('NON-ESG', 0.2147856056690216)","('NON-ESG', 0.14031574130058289)","('NON-ESG', 0.08693838119506836)"
Line 1456,"In response, BD developed  new virtual skills-based volunteer opportunities to keep  associates engaged to maintain our culture of service.
","('Employee_Engagement_Inclusion_And_Diversity', 0.546640157699585)","('Employee_Health_And_Safety', 0.24735040962696075)","('Human_Rights_And_Community_Relations', 0.031082507222890854)","(['Human Capital Development'], 0.546640157699585)","('NON-ESG', 0.24735040962696075)","('NON-ESG', 0.031082507222890854)"
Line 1457,"During 2020, BD virtual volunteers: • Delivered COVID-19 infection prevention  training to healthcare workers in partnership  with Heart to Heart International • Helped community health centers expand  access to healthcare via telehealth technology,  together with the National Association of  Community Health Centers and Pyxera  Global .
","('Employee_Health_And_Safety', 0.5932250022888184)","('Access_And_Affordability', 0.1581846922636032)","('Product_Quality_And_Safety', 0.03909973055124283)","(['Operational Eco-Efficiency'], 0.5932250022888184)","('NON-ESG', 0.1581846922636032)","('NON-ESG', 0.03909973055124283)"
Line 1458,"2020 goal Drive social impact and associate engagement through volunteer programs Access Innovation Efficiency Empowerment Governance These global awards celebrate the outstanding and creative  volunteer service of BD associates and retirees.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3020343482494354)","('Access_And_Affordability', 0.21486304700374603)","('Human_Rights_And_Community_Relations', 0.1002582460641861)","('NON-ESG', 0.3020343482494354)","('NON-ESG', 0.21486304700374603)","('NON-ESG', 0.1002582460641861)"
Line 1459,"In 2020, BD  awarded grants totaling $80,000 to 13 nonprofit organizations around the world, recognizing the community service of   13 associates from six countries.
","('Human_Rights_And_Community_Relations', 0.49549099802970886)","('Access_And_Affordability', 0.2487540990114212)","('Management_Of_Legal_And_Regulatory_Framework', 0.04646185040473938)","('NON-ESG', 0.49549099802970886)","('NON-ESG', 0.2487540990114212)","('NON-ESG', 0.04646185040473938)"
Line 1460,"Since 2013, in recognition of the   Dr. Martin Luther King, Jr. Day of Service,   BD associates from more than a dozen locations  across the United States have joined together to  pack shelf-stable meals for Rise Against Hunger, to be delivered to hungry  and food-insecure people around the world.
","('Access_And_Affordability', 0.2671920359134674)","('Customer_Welfare', 0.21088066697120667)","('Selling_Practices_And_Product_Labeling', 0.08372607082128525)","('NON-ESG', 0.2671920359134674)","('NON-ESG', 0.21088066697120667)","('NON-ESG', 0.08372607082128525)"
Line 1461,"In 2020, BD volunteers  reached their ambitious goal and packed their one millionth meal for Rise  Against Hunger.BD Volunteer Service Trips by the numbers 15 years  of  volunteer service trips262  BD volunteers From 89  BD  sites, globally33  country locations Henry P .
","('Access_And_Affordability', 0.5181624889373779)","('Employee_Health_And_Safety', 0.09561710804700851)","('Human_Rights_And_Community_Relations', 0.08495228737592697)","(['Health Outcome Contribution'], 0.5181624889373779)","('NON-ESG', 0.09561710804700851)","('NON-ESG', 0.08495228737592697)"
Line 1462,"Becton Volunteer Impact Awards Dr. Martin Luther King, Jr. Day of Service In 2020, BD collaborated with the Planet Water  Foundation to celebrate World Water Day for the  third consecutive year.
","('Water_And_Wastewater_Management', 0.9178355932235718)","('Human_Rights_And_Community_Relations', 0.00998795498162508)","('Ecological_Impacts', 0.009486665017902851)","(['Operational Eco-Efficiency'], 0.9178355932235718)","('NON-ESG', 0.00998795498162508)","('NON-ESG', 0.009486665017902851)"
Line 1463,"While COVID-19 kept BD from  deploying BD volunteers to participate, BD funding  enabled Planet Water to install two AquaTower  systems, including 12 handwashing points that provided clean, safe drinking  water to 3,600 children and community members in Aguascalientes, Mexico.
","('Water_And_Wastewater_Management', 0.9644358158111572)","('Energy_Management', 0.004352433141320944)","('Waste_And_Hazardous_Materials_Management', 0.002279282081872225)","(['Operational Eco-Efficiency'], 0.9644358158111572)","('NON-ESG', 0.004352433141320944)","('NON-ESG', 0.002279282081872225)"
Line 1464,"Since 2018, BD funding has empowered 33 BD volunteers to bring clean water  to up to 12,600 children and community members in five countries through  the installation of seven AquaTower systems.
","('Water_And_Wastewater_Management', 0.9348236322402954)","('Energy_Management', 0.008154492825269699)","('Human_Rights_And_Community_Relations', 0.007629298605024815)","(['Operational Eco-Efficiency'], 0.9348236322402954)","('NON-ESG', 0.008154492825269699)","('NON-ESG', 0.007629298605024815)"
Line 1465,"World Water Day BD matches charitable donations to eligible nonprofit  organizations, up to $5,000 per associate, per year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7087349891662598)","('Access_And_Affordability', 0.04089619591832161)","('Water_And_Wastewater_Management', 0.029026640579104424)","(['Corporate Governance'], 0.7087349891662598)","('NON-ESG', 0.04089619591832161)","('NON-ESG', 0.029026640579104424)"
Line 1466,"In FY 2020,  BD matched 26,000 donations to eligible 501(c)(3) organizations, for a total investment of $1.8 million.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6329668760299683)","('Ecological_Impacts', 0.03313594311475754)","('Business_Ethics', 0.033093102276325226)","(['Corporate Governance'], 0.6329668760299683)","('NON-ESG', 0.03313594311475754)","('NON-ESG', 0.033093102276325226)"
Line 1467,"From FY 2015 to FY 2020,  BD matched more than $8.8 million in associate donations.BD Matching Gift Program Awards, recognitions and affiliations Corporate recognition FTSE4 Good Index since FORTUNE ’s 2020 World’s Most Admired Companies List FORTUNE ’s 2020 Change the World list Newsweek ’s America’s Most Responsible Companies List Innovation Top 100 Global Innovator–Clarivate Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment One of the best companies in Brazil (Brazil)  Best Companies to Work for in Brazil–Health Sector (Brazil)  Top Employer 2021 (Africa)  Top Employer 2021 (China)  2021 Goodness award (China)  PRC 70 Years Healthcare Special Contribution Enterprise Award (China)  2020 Outstanding Contribution Award to Anti-Epidemic (China) Best Places to Work for LGBTQ Equality-The Human Rights Campaign Foundation 2021 Gender-Equality Index (GEI)–Bloomberg  Best Places to Work for Women in 2020–Great Place to Work (Argentina) BD, Franklin Lakes, NJ 07417, U.S. bd.comBD, the BD Logo, AccuCath Ace, Advancing the world of health, Alaris, AllPoints, Arctic Sun, AutoGuard, BD Helping Build Healthy Communities,  Caterpillar, Cato, ChloraPrep, ChloraShield, CLiC, COR, Covera, EleVation, FACSCelesta, FACSDuet, FACSLyric, FACSMelody, FACSymphony, FlowSmart,  HealthSight, Horizon Brilliant, Insyte, Intelliport, Intevia, Intima II Plus, Kiestra, LifeStent, Lutonix, MAX, MedMined, Nano, Onclarity, OptiBuild,  OptiFix, Pegasus Plus, PhaSeal, Phoenix, PowerMidline, Precise, Provena, PureWick, PurPrep, Pyxis, Rhapsody, Rowa, SupplyStation, Synapsys, Totalys,  UltraSafe Plus, UltraTouch, Vacutainer, Venflon, Venovo, Veritor and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates.
","('Management_Of_Legal_And_Regulatory_Framework', 0.22243060171604156)","('Product_Design_And_Lifecycle_Management', 0.17057549953460693)","('Business_Model_Resilience', 0.1231205090880394)","('NON-ESG', 0.22243060171604156)","('NON-ESG', 0.17057549953460693)","('NON-ESG', 0.1231205090880394)"
Line 1468,"From FY 2015 to FY 2020,  BD matched more than $8.8 million in associate donations.BD Matching Gift Program Awards, recognitions and affiliations Corporate recognition FTSE4 Good Index since FORTUNE ’s 2020 World’s Most Admired Companies List FORTUNE ’s 2020 Change the World list Newsweek ’s America’s Most Responsible Companies List Innovation Top 100 Global Innovator–Clarivate Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment One of the best companies in Brazil (Brazil)  Best Companies to Work for in Brazil–Health Sector (Brazil)  Top Employer 2021 (Africa)  Top Employer 2021 (China)  2021 Goodness award (China)  PRC 70 Years Healthcare Special Contribution Enterprise Award (China)  2020 Outstanding Contribution Award to Anti-Epidemic (China) Best Places to Work for LGBTQ Equality-The Human Rights Campaign Foundation 2021 Gender-Equality Index (GEI)–Bloomberg  Best Places to Work for Women in 2020–Great Place to Work (Argentina) BD, Franklin Lakes, NJ 07417, U.S. bd.comBD, the BD Logo, AccuCath Ace, Advancing the world of health, Alaris, AllPoints, Arctic Sun, AutoGuard, BD Helping Build Healthy Communities,  Caterpillar, Cato, ChloraPrep, ChloraShield, CLiC, COR, Covera, EleVation, FACSCelesta, FACSDuet, FACSLyric, FACSMelody, FACSymphony, FlowSmart,  HealthSight, Horizon Brilliant, Insyte, Intelliport, Intevia, Intima II Plus, Kiestra, LifeStent, Lutonix, MAX, MedMined, Nano, Onclarity, OptiBuild,  OptiFix, Pegasus Plus, PhaSeal, Phoenix, PowerMidline, Precise, Provena, PureWick, PurPrep, Pyxis, Rhapsody, Rowa, SupplyStation, Synapsys, Totalys,  UltraSafe Plus, UltraTouch, Vacutainer, Venflon, Venovo, Veritor and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3513110876083374)","('Human_Rights_And_Community_Relations', 0.29986822605133057)","('Labor_Practices', 0.12391743808984756)","('NON-ESG', 0.3513110876083374)","('NON-ESG', 0.29986822605133057)","('NON-ESG', 0.12391743808984756)"
Line 1469,"From FY 2015 to FY 2020,  BD matched more than $8.8 million in associate donations.BD Matching Gift Program Awards, recognitions and affiliations Corporate recognition FTSE4 Good Index since FORTUNE ’s 2020 World’s Most Admired Companies List FORTUNE ’s 2020 Change the World list Newsweek ’s America’s Most Responsible Companies List Innovation Top 100 Global Innovator–Clarivate Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment One of the best companies in Brazil (Brazil)  Best Companies to Work for in Brazil–Health Sector (Brazil)  Top Employer 2021 (Africa)  Top Employer 2021 (China)  2021 Goodness award (China)  PRC 70 Years Healthcare Special Contribution Enterprise Award (China)  2020 Outstanding Contribution Award to Anti-Epidemic (China) Best Places to Work for LGBTQ Equality-The Human Rights Campaign Foundation 2021 Gender-Equality Index (GEI)–Bloomberg  Best Places to Work for Women in 2020–Great Place to Work (Argentina) BD, Franklin Lakes, NJ 07417, U.S. bd.comBD, the BD Logo, AccuCath Ace, Advancing the world of health, Alaris, AllPoints, Arctic Sun, AutoGuard, BD Helping Build Healthy Communities,  Caterpillar, Cato, ChloraPrep, ChloraShield, CLiC, COR, Covera, EleVation, FACSCelesta, FACSDuet, FACSLyric, FACSMelody, FACSymphony, FlowSmart,  HealthSight, Horizon Brilliant, Insyte, Intelliport, Intevia, Intima II Plus, Kiestra, LifeStent, Lutonix, MAX, MedMined, Nano, Onclarity, OptiBuild,  OptiFix, Pegasus Plus, PhaSeal, Phoenix, PowerMidline, Precise, Provena, PureWick, PurPrep, Pyxis, Rhapsody, Rowa, SupplyStation, Synapsys, Totalys,  UltraSafe Plus, UltraTouch, Vacutainer, Venflon, Venovo, Veritor and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates.
","('Access_And_Affordability', 0.3407234251499176)","('Customer_Welfare', 0.0882900059223175)","('Product_Design_And_Lifecycle_Management', 0.07451203465461731)","('NON-ESG', 0.3407234251499176)","('NON-ESG', 0.0882900059223175)","('NON-ESG', 0.07451203465461731)"
Line 1470,"From FY 2015 to FY 2020,  BD matched more than $8.8 million in associate donations.BD Matching Gift Program Awards, recognitions and affiliations Corporate recognition FTSE4 Good Index since FORTUNE ’s 2020 World’s Most Admired Companies List FORTUNE ’s 2020 Change the World list Newsweek ’s America’s Most Responsible Companies List Innovation Top 100 Global Innovator–Clarivate Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment One of the best companies in Brazil (Brazil)  Best Companies to Work for in Brazil–Health Sector (Brazil)  Top Employer 2021 (Africa)  Top Employer 2021 (China)  2021 Goodness award (China)  PRC 70 Years Healthcare Special Contribution Enterprise Award (China)  2020 Outstanding Contribution Award to Anti-Epidemic (China) Best Places to Work for LGBTQ Equality-The Human Rights Campaign Foundation 2021 Gender-Equality Index (GEI)–Bloomberg  Best Places to Work for Women in 2020–Great Place to Work (Argentina) BD, Franklin Lakes, NJ 07417, U.S. bd.comBD, the BD Logo, AccuCath Ace, Advancing the world of health, Alaris, AllPoints, Arctic Sun, AutoGuard, BD Helping Build Healthy Communities,  Caterpillar, Cato, ChloraPrep, ChloraShield, CLiC, COR, Covera, EleVation, FACSCelesta, FACSDuet, FACSLyric, FACSMelody, FACSymphony, FlowSmart,  HealthSight, Horizon Brilliant, Insyte, Intelliport, Intevia, Intima II Plus, Kiestra, LifeStent, Lutonix, MAX, MedMined, Nano, Onclarity, OptiBuild,  OptiFix, Pegasus Plus, PhaSeal, Phoenix, PowerMidline, Precise, Provena, PureWick, PurPrep, Pyxis, Rhapsody, Rowa, SupplyStation, Synapsys, Totalys,  UltraSafe Plus, UltraTouch, Vacutainer, Venflon, Venovo, Veritor and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates.
","('Competitive_Behavior', 0.1841518133878708)","('Customer_Privacy', 0.09467360377311707)","('Product_Design_And_Lifecycle_Management', 0.0750521868467331)","('NON-ESG', 0.1841518133878708)","('NON-ESG', 0.09467360377311707)","('NON-ESG', 0.0750521868467331)"
Line 1471,"All  other trademarks are the property of their respective owners.
","('Customer_Privacy', 0.36981719732284546)","('Competitive_Behavior', 0.16144846379756927)","('Business_Ethics', 0.05697965994477272)","('NON-ESG', 0.36981719732284546)","('NON-ESG', 0.16144846379756927)","('NON-ESG', 0.05697965994477272)"
Line 1472,"© 2021 BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4544510245323181)","('Business_Ethics', 0.06317559629678726)","('Access_And_Affordability', 0.053981635719537735)","('NON-ESG', 0.4544510245323181)","('NON-ESG', 0.06317559629678726)","('NON-ESG', 0.053981635719537735)"
Line 1473,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 1474,"5848 (06/21)To find out more about sustainability at BD or to provide feedback on our reporting,   please contact  BD_Sustainability_ Office@bd.com Cautionary Statement Regarding Forward-Looking Statements This report contains certain forward-looking statements within the meaning of the federal securities laws.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9127686023712158)","('Business_Model_Resilience', 0.009054942987859249)","('Director_Removal', 0.00782549288123846)","(['Corporate Governance'], 0.9127686023712158)","('NON-ESG', 0.009054942987859249)","('NON-ESG', 0.00782549288123846)"
Line 1475,"Forward-looking statements involve risks  and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.
","('Systemic_Risk_Management', 0.5975109338760376)","('Management_Of_Legal_And_Regulatory_Framework', 0.09766247123479843)","('Competitive_Behavior', 0.07838613539934158)","(['Risk & Crisis Management'], 0.5975109338760376)","('NON-ESG', 0.09766247123479843)","('NON-ESG', 0.07838613539934158)"
Line 1476,"Forward-looking  statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “may,” “anticipate,” estimate,” “target,” and  other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance and strategy  for growth, future product development, regulatory approvals, competitive position and expenditures.
","('Competitive_Behavior', 0.5988046526908875)","('Business_Model_Resilience', 0.11847036331892014)","('Management_Of_Legal_And_Regulatory_Framework', 0.11342744529247284)","(['Business Ethics'], 0.5988046526908875)","('NON-ESG', 0.11847036331892014)","('NON-ESG', 0.11342744529247284)"
Line 1477,"Forward-looking statements are, and will be,  based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only  as of their dates.
","('Business_Model_Resilience', 0.792125940322876)","('Systemic_Risk_Management', 0.034694425761699677)","('Physical_Impacts_Of_Climate_Change', 0.030613752081990242)","(['Codes of Business Conduct'], 0.792125940322876)","('NON-ESG', 0.034694425761699677)","('NON-ESG', 0.030613752081990242)"
Line 1478,"Many of these risks and uncertainties are beyond the company’s control, including without limitation, challenges relating to  economic, competitive, governmental, and technological factors affecting our operations, markets, and products, and other factors listed in our  2020 Annual Report on Form 10-K and other filings with the SEC.
","('Systemic_Risk_Management', 0.7841492891311646)","('Competitive_Behavior', 0.09599427878856659)","('Business_Model_Resilience', 0.03208724781870842)","(['Risk & Crisis Management'], 0.7841492891311646)","('NON-ESG', 0.09599427878856659)","('NON-ESG', 0.03208724781870842)"
Line 1479,"BD expressly disclaims any undertaking to update or revise any forward-looking  statements set forth herein to reflect events or circumstances after the date hereof, except as required by applicable law or regulation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9607481360435486)","('Director_Removal', 0.004097465891391039)","('Physical_Impacts_Of_Climate_Change', 0.0028608893044292927)","(['Corporate Governance'], 0.9607481360435486)","('NON-ESG', 0.004097465891391039)","('NON-ESG', 0.0028608893044292927)"
